{"Title": ["3 Biotech Stocks I\u2019d Buy Right Now", "7 U.S. Stocks to Buy on Renewed Coronavirus Weakness", "Key U.S. medical group adds steroids to COVID-19 treatment guidelines", "SPECIAL REPORT-As world approaches 10 million coronavirus cases, doctors see hope in new treatments, lessons learned", "South Korea backs remdesivir for COVID-19, urges caution with dexamethasone", "EU Experts Recommend Approval of Gilead's COVID-19 Drug", "Egypt's Eva Pharma begins producing COVID-19 drug Remdesivir", "Interesting GILD Put And Call Options For August 7th", "3 Biotech Stocks I\u2019d Buy Right Now", "Gilead's remdesivir endorsed as first COVID-19 treatment in Europe", "EU drug regulator endorses Gilead's remdesivir as COVID-19 treatment", "Is Wall Street Wrong About Mesoblast?", "A Certain Type of Investor Should Buy LOW Stock at Current Levels", "Egypt's Rameda gets requests to export COVID-19 drug -CEO", "U.S. group raises pricing recommendation for Gilead's remdesivir in COVID-19", "Drug pricing review group raises recommended price for Gilead's remdesivir", "5 of the Best Pharmaceutical Stocks to Buy Right Now", "India's Hetero prices experimental COVID-19 drug remdesivir at $71 per 100 mg vial", "10 Stocks Riding on the Covid-19 Recovery", "Gilead Sciences Bets $275 Million on an Oncology Start-Up", "Gilead to buy 49.9% stake in cancer drug developer Pionyr for $275 mln", "Gilead Sciences To Acquire 49.9% Stake In Pionyr Immunotherapeutics For $275 Mln - Quick Facts", "Gilead to buy 49.9% stake in cancer drug developer Pionyr for $275 mln", "India's Cipla to price remdesivir version for COVID-19 under $66", "Why Is Everyone Talking About Bristol Myers Squibb Stock?", "Meet the Pharma Company That Just Had a Bigger IPO Than Moderna's", "MYOV To Report SPIRIT 1 Data, EVLO Joins COVID-19 Drug Race, NVTA Loosens Purse Strings", "Gilead targets remdesivir supply for 2 mln COVID-19 patients by year-end", "Gilead to Test an Inhaled Version of Remdesivir", "Gilead To Trial Inhaled Version Of Remdesivir On Covid-19 Patients", "Gilead plans to produce 2 million remdesivir courses by 2020 end", "Gilead to test inhaled version of remdesivir on COVID-19 patients in August", "Better Coronavirus Stock: Gilead Sciences vs. Sorrento Therapeutics", "Does Gilead Have a Cure for the Coronavirus?", "What's the Outlook for Gilead Sciences?", "Is Hydroxychloroquine a Cure for COVID-19?", "The 3 Best Coronavirus Stocks to Buy for Long-Term Investors", "Novartis halts malaria drug trial against COVID-19 amid participant shortfall", "Notable Friday Option Activity: GILD, CRY, NOC", "U.S. hospitals in hard hit regions step up use of steroids on sickest COVID-19 patients", "India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug", "Is Eli Lilly Stock a Buy?", "Is GlaxoSmithKline a Great Dividend Stock?", "U.S. hospitals in hard hit regions step up use of steroids on sickest patients", "Roche's Rheumatoid Arthritis Drug Actemra Fails to Help COVID-19 Patients With Pneumonia", "Notable ETF Outflow Detected - IVE, C, WFC, GILD", "Better Buy: Gilead Sciences vs. Biogen", "Roche rheumatoid arthritis drug fails to help COVID-19 patients in Italian study", "Research Indicates Blood Type Could Influence COVID-19 Severity", "As Biogen Stock Struggles, Look Elsewhere for Biotech Exposure", "2 Pros, 2 Cons for Buying AIM ImmunoTech", "Is Dexamethasone the Best Treatment for COVID-19?", "Better Coronavirus Stock: Regeneron or Gilead Sciences?", "AstraZeneca's Potential Vaccine Likely To Protect Against Covid-19 For A Year : Report", "7 Cash Stocks to Invest in As Markets Turn Negative", "Early Shareholders Can Win If iBio Gets a Vaccine Contract", "Gilead to enroll pediatric patients for late-stage remdesivir study", "Is Now Still a Good Time to Buy Gilead Sciences (GILD) Stock? Oppenheimer Says \u2018Yes\u2019", "Eli Lilly starts trial of rheumatoid arthritis drug in COVID-19 patients", "Why Is Everyone Talking About Gilead Sciences Stock?", "Better Buy: Moderna vs. Gilead Sciences", "Should Sorrento Therapeutics Be Your Next Coronavirus Buy?", "Could Gilead Sciences Have an HIV Cure Waiting in the Wings?", "Where Will AbbVie Be in 5 Years?", "Israel approves remdesivir drug for COVID-19 treatment", "India's Zydus Cadila to make Gilead's potential COVID-19 drug remdesivir", "India's Zydus Cadila signs pact with Gilead to make remdesivir", "Kite To Manufacture CAR T Cell Therapies In Europe - Quick Facts", "American Airlines Stock Surely Will Be Back After Yesterday\u2019s Beating", "Is Adaptimmune Therapeutics a Buy?", "Inovio Still a Hot Coronavirus Vaccine Supplier", "Regeneron Begins Human Trials of a Potential COVID-19 Treatment", "Dr. Reddy's Laboratories Enters Licensing Deal With Gilead Sciences For Remdesivir", "U.S. FDA Commissioner says agency seeks fast review of COVID-19 products", "Gilead Merger Unlikely at This Point, Says 5-Star Analyst", "Study: Remdesivir Prevented Lung Damage In Monkeys Infected With COVID-19", "Is Aprea Therapeutics Stock a Buy?", "GILD Named A Top Socially Responsible Dividend Stock", "Singapore approves remdesivir drug for emergency COVID-19 treatment", "Singapore approves Gilead's remdesivir for COVID-19 treatment", "Better Buy: bluebird bio vs. Gilead Sciences", "Aggressive Investors Can Do Much Better Than Merck Stock", "Ex-Dividend Reminder: SpartanNash, STERIS and Gilead Sciences", "AstraZeneca's Acquisition of Gilead Would Create a COVID-19 Colossus -- but Don't Bet on Seeing It Happen", "Gilead's remdesivir slows disease progression in monkeys with COVID-19", "Gilead's remdesivir slows progression of COVID-19 in monkeys - study", "BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Chesapeake Energy, Ideanomics", "BUZZ-U.S. STOCKS ON THE MOVE-Sino-Global Shipping, Michaels Companies, Applied DNA", "What Would a Merger Mean for Gilead? Top Analyst Weighs In", "Wall Street set to rise on swift economic rebound hopes", "Breakingviews - AstraZeneca M&A puzzle sends shareholder warning", "BUZZ-U.S. STOCKS ON THE MOVE-Gilead, Cisco", "U.S. stock futures rise on optimism over economic revival", "AstraZeneca In Informal Talks With Gilead For Potential Merger: Report", "London's FTSE 100 falls as AstraZeneca drops on megamerger report", "EU watchdog aims for speedy approval of remdesivir as COVID-19 treatment", "AstraZeneca shares down 2% after report it approached Gilead over tie-up", "London's FTSE 100 opens lower as AstraZeneca weighs", "European shares pull back from 3-month highs after rally", "AstraZeneca Proposes a Merger With Gilead Sciences", "AstraZeneca contacted Gilead over potential megamerger -Bloomberg News", "Could Gilead's COVID-19 Drug Make $7 Billion Per Year?", "Fujifilm says COVID-19 drug research may drag on into July", "European stock rally takes step back as tech, healthcare drag", "Noteworthy Thursday Option Activity: GILD, NSSC, LB", "Co-Diagnostics Could Be a Prudent Coronavirus Play", "Is Remdesivir a Disappointment?", "Better Buy: Bristol Myers Squibb vs. Gilead Sciences", "Lyft Looks Poised to Rally Over the Next Few Months", "Biotech Stocks: Buy This, Not That", "Air Travel\u2019s Comeback Looks Poised to Lift GE Stock", "What Are the Implications of Gilead\u2019s Increased Focus on Oncology? 5-Star Analyst Weights In", "Roche test receives FDA emergency use approval for COVID-19 patients", "Wait for More Clarity Before Buying Gilead Stock, Says Analyst", "BUZZ-U.S. STOCKS ON THE MOVE-Warner Music, Boeing, Pliant Therapeutics", "BUZZ-U.S. STOCKS ON THE MOVE-Glu Mobile, Boeing, American Eagle", "Gilead's remdesivir could see $7 bln in annual sales on stockpiling boost \u2013 analyst", "BUZZ-U.S. STOCKS ON THE MOVE-Coty, Zoom Video, OpGen, Campbell Soup", "Eli Lilly Leaps Past Regeneron's COVID-19 Treatment Candidate", "Gilead Sciences : Filgotinib Shows Sustained Efficacy In Studies On Rheumatoid Arthritis", "S.Korea approves import of anti-viral drug remdesivir for coronavirus treatment", "AbbVie Will Be in Big Trouble When Its Patent Cliff Arrives", "Tuesday Sector Laggards: Healthcare, Technology & Communications", "India approves emergency use of remdesivir to treat COVID-19 patients", "Better Coronavirus Stock: Gilead Sciences or Novavax?", "Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions", "India approves emergency use of remdesivir to treat COVID-19 patients", "Abbvie Stock is Offering Investors an Oil Yield Without Oil\u2019s Risk", "S.Korea approves import of anti-viral drug remdesivir for coronavirus treatment", "Why Carnival, Royal Caribbean, and Norwegian Cruise Line Stocks Rose Today", "Wall Street closes higher as recovery signs soothe protest, pandemic worries", "Health Care Sector Update for 06/01/2020: ABIO,EBS,GILD,OCGN", "Wall Street closes higher as recovery signs soothe protest, pandemic worries", "U.S. stocks gain as signs of recovery offset protests, economic worries", "NTLA Gains On Amended REGN Deal, GILD Reports SIMPLE Results, MYOV On Watch, NVUS Slumps", "Gold edges lower as economies open up", "Health Care Sector Update for 06/01/2020: EBS,GILD,OCGN", "Wall St gains as recovery hopes overshadow U.S. protests", "Vir Biotechnology Is Bucking The Biotech COVID-19 Trends, And Stands To Win", "Stock Alert: Gilead Down 4% On Remdesivir Trial Data", "Wall St flat as recovery hopes offset U.S. protests, China tensions", "BUZZ-U.S. STOCKS ON THE MOVE-Gilead, Virgin Galactic, General Electric", "BUZZ-U.S. STOCKS ON THE MOVE-Coty, Tesla, Zoom Video, Zynga", "Wall St rises as recovery hopes offset U.S. protests, China tensions", "TQQQ, CHTR, GILD, QCOM: Large Outflows Detected at ETF", "Gilead Reports Positive Late-Stage Study Results for Remdesivir in Patients With Moderate COVID-19", "Nasdaq 100 Movers: GILD, ZM", "Gilead says remdesivir helped moderate COVID-19 patients improve", "Gilead Reports Encouraging Data From Remdesivir 5-day Treatment Course", "Gilead says remdesivir helped moderate COVID-19 patients improve", "3 Biotech Quick Picks to Invest $5,000 This Week", "Gilead Gets a Boost From Positive Coronavirus Research", "EXCLUSIVE-Russia to roll out its first approved COVID-19 drug next week", "INSIGHT-Scientists hunt pandemic hotspots in race to test vaccines", "How One Hedge Fund Billionaire Is Battling to Bring Down Drug Prices in America", "The Week That Was: MRK Enters COVID Space, GSK's 1Bln Dose Target, Roche, GILD Team Up For REMDACTA", "7 U.S. Stocks to Buy on Coronavirus Weakness", "Here's Why Arcus Biosciences Stock Gained as Much as 15.9% Today", "Gilead trades that made millions on COVID-19 drug news raise eyebrows", "Gilead Gets a Boost From Positive Coronavirus Research", "EXCLUSIVE-Russia to roll out its first approved COVID-19 drug next week", "S.Korea seeks to import anti-viral remdesivir as new coronavirus cases emerge", "July 10th Options Now Available For Gilead Sciences (GILD)", "Don't Waste Your Money on Penny Stocks; These 3 Are Better Buys", "Coronavirus 2020: Where to Invest $500 Right Now", "Roche mixes Actemra with Gilead's remdesivir in COVID-19 trial", "At The ASCO: ONCY, IMV, CRDF, GILD, TAK\u2026", "PHAS To Begin COVID-19 Drug Trial In June, MRSN Hits New High, LJPC Plunges, RCUS On Watch", "Roche to study remdesivir/Actemra cocktail against severe COVID-19 pneumonia", "Gilead\u2019s Remdesivir May Be a Coronavirus Silver Bullet \u2014 But It\u2019s Already Baked in the Stock Price", "Gilead study shows shorter 5-day course of remdesivir works as well as 10-day one", "Here's Why Arcus Biosciences Is Losing Ground Today", "Gilead Sciences Signs $2 Billion Partnership with Arcus Biosciences", "AstraZeneca tests diabetes drug for COVID-19 despite risk seen by doctors", "Genentech Initiates Phase III Trial Of Actemra Plus Remdesivir On Severe COVID-19 Pneumonia", "Gilead, Arcus Biosciences Ink 10-year Deal To Co-develop Cancer Immunotherapies", "10 Stocks to Buy as They Ride a Coronavirus Tailwind", "BUZZ-U.S. STOCKS ON THE MOVE-IZEA Worldwide, Diffusion Pharma, DouYu International", "WHO expects hydroxychloroquine safety findings by mid-June", "Lilly, Junshi Biosciences plan to start human trials of COVID-19 antibody in Q2", "BUZZ-U.S. STOCKS ON THE MOVE-LATAM Airlines, Tuesday Morning, Novavax", "Merck leaps into COVID-19 development fray with vaccine, drug deals", "BUZZ-U.S. STOCKS ON THE MOVE-StoneCo, Tuesday Morning, Zynerba Pharma", "Merck leaps into COVID-19 development fray with vaccine, drug deals", "Britain to provide anti-viral drug remdesivir to some COVID-19 patients", "3 Large-Cap Coronavirus Stocks Still Worth Buying", "Mixed Results for Gilead Sciences' COVID-19 Treatment", "Better Coronavirus Stock: Gilead Sciences or Vir Biotechnology?", "Peer-reviewed data shows Gilead's drug helps COVID-19 recovery time", "Peer-reviewed data shows Gilead's drug effective against COVID-19 -NIH", "BUZZ-U.S. STOCKS ON THE MOVE-Novavax, Tuesday Morning, HPE", "Before You Buy Gilead Sciences Stock, Read This", "Gilead Stock Is Worth Owning With or Without a Coronavirus Cure", "U.S. doctors call for remdesivir data to guide coronavirus treatment", "Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib Results", "How a Coronavirus Vaccine Might Move the Stock Market", "The Virus Vaccine Race is Fueling Moderna Stock to New Highs", "ATRA Abuzz, ATOS' COVID-19 Med Effective, INO And VXRT On Track", "Remdesivir Can\u2019t Cure Covid, But Good Luck Telling Gilead Stock", "Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals", "Gilead-Galapagos's drug meets main goals of ulcerative colitis study", "Health Care Sector Update for 05/20/2020: HOTH,ALDX,GILD,INO,BDX", "Noteworthy Wednesday Option Activity: GILD, ILMN, ATVI", "Health Care Sector Update for 05/20/2020: ALDX,GILD,INO,BDX", "Notable ETF Outflow Detected - DGRO, CMCSA, TXN, GILD", "Why the Next Month Will Determine the Rest of the Year for Gilead's Stock", "Gilead Still Holds the Winning Hand, Says 5-Star Analyst", "How The Parts Add Up: SCIU Targets $33", "Where Will Adaptimmune Be in 5 Years?", "BUZZ-U.S. STOCKS ON THE MOVE-Oasis Midstream, L Brands, Diffusion Pharma", "Nasdaq 100 Movers: GILD, EXPE", "GSK's long-acting injection beats Truvada in HIV prevention trial", "Remdesivir close to EU's initial authorisation as COVID-19 treatment", "GSK's long-acting injection beats Truvada in HIV prevention trial", "GlaxoSmithKline, Pfizer, and Shionogi's HIV Prevention Candidate Outperforms Gilead's Truvada", "Why Gilead's Remdesivir Might Not Be the Mega-Moneymaker Some Think It Will Be", "Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences", "Could Veeva Systems Be a Millionaire-Maker Stock?", "Gilead to end coronavirus drug trials, adding to access worry -researchers", "Pakistan's Ferozsons to begin producing COVID-19 drug remdesivir", "Buy Good News Gilead Stock Before Other Investors Catch On", "Part of Gilead's coronavirus drug donation allocated to Japan", "Is Gilead Sciences a Great Dividend Stock?", "Health groups ask India to rescind Gilead's patents for COVID-19 drug remdesivir", "2 Recession-Proof Healthcare Stocks to Buy in 2020", "Health groups ask India to rescind Gilead's patents for COVID-19 drug remdesivir", "Japan says drugmaker Gilead's COVID-19 treatment remdesivir now in use in hospitals", "Takeda says coronavirus treatment trial using recovered patients' blood could start in July", "U.S. accuses China-linked hackers of stealing coronavirus research", "Gilead's Remdesivir Isn't Enough to Drive Its Stock Higher", "France says any Sanofi COVID-19 vaccine for the world, no favourites", "U.S. accuses China-linked hackers of stealing coronavirus research", "Where Will Gilead Sciences Be in 1 Year?", "U.S. stock futures climb ahead of Fed Chair Powell's address", "Is AbbVie a Buy Now That the Allergan Deal Is Done?", "Gilead Stock Still Looks Poised to Prove the Bears Wrong", "A tale of two Japanese drugs in tests to fight COVID-19", "Gilead Strikes Deal With Mylan to Supply Remdesivir Internationally", "Gilead In Deal With 5 Cos. To Make And Sell Remdesivir In 127 Countries", "9 Enduring Stocks That You Shouldn\u2019t Sell in May", "EMA recommends expanding compassionate use of Gilead's COVID-19 drug", "EMA recommends expanding compassionate use of Gilead's COVID-19 drug", "The Government Will Distribute Gilead's Remdesivir. This Could Be Bad News for Investors", "MOAT, NOW, PFE, GILD: ETF Inflow Alert", "A COVID-19 Strategy: Invest in Companies That Are Doing Good", "Gilead's Remdesivir Supply Won't Meet U.S. Need, Analyst Says", "India's Jubilant signs licensing deal for Gilead's potential COVID-19 drug", "Despite Challenges, GE Is a Long-Term Winner", "3 Top Biotech Stocks to Buy in May", "What Investors Are Missing About Gilead Sciences", "U.S. to allow states to distribute Gilead's remdesivir to fight COVID-19", "The Dow Rose 455 Points Because Job Losses Can't Get Any Worse", "NIH begins study of remdesivir with anti-inflammatory drug to treat COVID-19", "NIH begins study of remdesivir with anti-inflammatory drug to treat COVID-19", "Co-Diagnostics Is a Smart Way to Play Coronavirus Testing", "Is Gilead Sciences Stock a Buy?", "U.S. Doctors want details on federal distribution of Gilead coronavirus drug", "Doctors want details on federal distribution of Gilead coronavirus drug", "June 26th Options Now Available For Gilead Sciences (GILD)", "The Best Thing Happening During These \u2018Worst of Times\u2019", "From Gilead To AstraZeneca, Investors Should Watch These Biotech Giants Right Now", "Japan approves Gilead Sciences' remdesivir as COVID-19 drug", "EXCLUSIVE-Iran-linked hackers recently targeted coronavirus drugmaker Gilead -sources", "Will Gilead price its coronavirus drug for public good or company profit?", "How Will Double-Digit Unemployment Affect Your Stock Portfolio?", "4 Safe Stocks That Can Make You Rich in This Economy", "Inovio Pharmaceuticals Is Hurting From Remdesivir but It\u2019s Still Standing", "Israel Reports a \"Breakthrough\" Coronavirus Antibody Treatment", "Co-Diagnostics Is Becoming More Relevant", "EXPLAINER-Who can make Gilead's coronavirus drug, licence free?", "Japan approves Gilead Sciences' remdesivir as COVID-19 drug", "Gilead Sciences Plans to Expand Global Supply of Remdesivir", "Gilead in talks to expand global supply of COVID-19 drug remdesivir", "Gilead in talks to expand global supply of COVID-19 drug remdesivir", "How Can The Stock Market Soar With Rising Unemployment?", "Regeneron Says Its COVID-19 Combo Treatment Could Be Ready for People This Fall", "The Trends are Mostly Friendly for Moderna Stock Investors", "Gilead Sciences Is a Strong Buy Despite What Its Detractors Might Say", "Is This Coronavirus Drug Authorization Really Good News for Gilead?", "EXCLUSIVE-Bangladesh's Beximco to begin producing COVID-19 drug remdesivir-COO", "Could This Under-the-Radar Biotech Piggyback on Gilead's Remdesivir Success?", "The Dow Rose 26 Points Because an Oil Rebound Lifted Stocks", "Apps cannot replace \"boots-on-the-ground\" in virus fight - WHO", "Earnings Preview: Is SQ Stock a Buy Before Wednesday?", "BUZZ-U.S. STOCKS ON THE MOVE-Airlines, banks, insurers, oil stocks", "BUZZ-U.S. STOCKS ON THE MOVE-Airlines, banks, insurers, PG&E", "Finding a Coronavirus Cure: 5 Companies Making Moves", "JPMorgan\u2019s Bullish Stance on Gilead Sciences (GILD) Stock Comes to an End", "What Might Gilead's Covid-19 Drug Cost, $10 or $4,500?", "Forget Gilead, These 2 Pharma Dividends Pay up to 10%", "Vir, Alnylam identify COVID-19 therapy candidate, plan human trials by year end", "Despite Gains, Threat, Gilead Is Still Attractive", "Here\u2019s Why It\u2019s Not Too Late to Load Up on Moderna Stock", "European stock futures drop as U.S., China spar over virus origin", "The 3 Best Stocks to Buy in May", "Gold gains as rising U.S.-China tensions dent risk sentiment", "5 Top Coronavirus Stocks to Buy in May", "Japan aims to fast-track review of anti-viral drug remdesivir", "What Should Investors Make Of Conflicting Results Surrounding Gilead's Remdesivir?", "Gilead's Remdesivir Becomes 1st Drug Allowed For Emergency Use For COVID-19", "FDA Authorizes Gilead's Remdesivir for COVID-19", "Why Foot Locker, Callaway Golf, and Newell Brands Plunged 10% Early Friday", "Foreigners remain net sellers of Japan stocks for 11th straight week", "FDA Allows Emergency Use of Gilead's Covid-19 Drug", "U.S. FDA authorizes remdesivir drug as emergency treatment for COVID-19", "Trump: FDA authorizes Remdesivir drug for COVID-19", "Gilead Aims to Get Its Potential COVID-19 Drug to as Many Patients as Possible", "BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Medigus, Aemetis", "Daily Dividend Report: AAPL,GILD,GLW,TRP,WWD", "BUZZ-U.S. STOCKS ON THE MOVE-Medigus Ltd, Western Digital Corp, Aemetis Inc", "U.S. FDA authorizes remdesivir drug as emergency treatment for COVID-19", "Coronavirus trial drug remdesivir's maker aims for wide distribution -Gilead CEO", "Coronavirus trial drug Redesivir's maker hopes for swift FDA approval -interview", "3 Big Stories in Gilead Sciences' Q1 Results", "Inovio Is in a Race to Develop a COVID-19 Vaccine, but Can It Possibly Win?", "What Does Remdesivir's Promising Study Mean for Gilead's Stock?", "Gilead Sciences Inc (GILD) Q1 2020 Earnings Call Transcript", "7 U.S. Stocks to Buy on Coronavirus Weakness", "Gilead Stock Drops on Wave of Downgrades", "Gilead Beats Earnings Estimates, but the Stock Falls", "Gilead aims to expand remdesivir output for COVID-19, posts flat 1st-qtr results", "GLOBAL MARKETS-Global equities dip at end of best month since '09", "Gilead Sciences Inc. Q1 adjusted earnings of $1.68 per share", "Yields fall, two-year note touches lowest level since 2011", "GLOBAL MARKETS-Equities dip but remain on pace for best month on record", "Is Gilead Sciences Stock a Buy Right Now? This Is What You Need to Know", "Notable Thursday Option Activity: MDB, CASA, GILD", "U.S. FDA moving with 'lightning speed' on Gilead's COVID-19 drug - Bloomberg", "GLOBAL MARKETS-Global equities dip; remain on pace for best month on record", "Gilead Awaits FDA Approval on Remdesivir to Treat Covid-19", "PayPal Is the Elixir We Need in This Awful Earnings Season", "Wall St set to slide at open after jobless claims data", "Daily Markets: Nearly 1 In 5 Have Lost Their Jobs in Just 6 Weeks", "Gilead (GILD) 1st Quarter Earnings: What to Expect", "IBB, GILD, VRTX, BIIB: ETF Inflow Alert", "3 Big Stock Charts for Thursday: Gilead Sciences, Boeing, and Nio", "Dow, S&P 500 futures dip at end of strong month; jobless data awaited", "Have $3,000 to Invest? Here Are 3 Top Coronavirus Stocks to Buy Right Now.", "Moderna Stock Is Near Highs, But Faces Risk", "Gilead Sciences Q1 20 Earnings Conference Call At 4:30 PM ET", "Indian stocks log best month since 2009, track global cheer on virus drug hopes", "European Stocks Pause After Big Asia and Wall Street Rally", "Dow, S&P 500 futures dip at end of strong month; jobless data eyed", "London stocks hit by Shell's historic dividend cut", "EMERGING MARKETS-Stocks extend gains, Hungary outperforms on reopening plans", "China stocks log best month in five on virus drug trial, policy hopes", "London stocks rise on optimism around virus drug, upbeat earnings", "Tokyo shares end near 8-week high, track Wall Street gains on virus drug hopes", "Glenmark to conduct trials in India for potential COVID-19 drug", "EM ASIA FX-Indonesian rupiah jumps about 3% on higher bond inflows expectation", "GLOBAL MARKETS-Stocks head for best month on record ahead of ECB", "GLOBAL MARKETS-Stocks rally on treatment hopes, currencies await ECB", "China stocks touch seven-week high on coronavirus treatment, policy hopes", "GLOBAL MARKETS-Stocks rally on treatment hopes, currencies await ECB", "GLOBAL MARKETS-Asian stocks set to track U.S. gains as virus treatment hopes lift confidence", "Why Discover Financial Stock Jumped 15% Today", "Why Discover Financial Stock Jumped 15%Today", "The Dow Surged 532 Points Because We're Closer to a Covid-19 Drug", "Indian shares soar on COVID-19 drug hopes, set for best month since 2009", "GLOBAL MARKETS-Stocks rally on treatment hopes, currencies await ECB", "China stocks touch seven-week high on coronavirus treatment, policy hopes", "Wall Street rallies on promising coronavirus drug", "Why Novavax Stock Slumped Today", "GLOBAL MARKETS-Shares jump on coronavirus treatment hopes, oil soars", "EMERGING MARKETS-Latam shares, FX rally as hopes of COVID-19 drug lifts sentiment", "This News Has Foot Locker Stock Running Higher Today", "Breakingviews - Corona Capital: U.S. GDP, Gilead\u2019s drug, Spotify", "Dow Jones Today: Vaccine Hopes Overcame Contracting GDP", "Dow, Oil Close With Strong Wins", "U.S. stocks rally on coronavirus drug hopes", "Restaurant Stocks Soar Wednesday on Positive COVID-19 Developments", "Why Hotel Stocks Are Surging Today", "What Lies Ahead for Vaccine Development and INO Stock in May?", "Here's Why Visa, Mastercard, and American Express Are Higher on Wednesday", "FOREX-Dollar drops as Fed repeats vow to support economy", "BUZZ-U.S. STOCKS ON THE MOVE-Capricor Therapeutics, Liberty Oilfield, Blue Apron", "COVID-19 complication seen in children is \"rare\", WHO says", "Buy Gilead Stock Because Remdesivir Is a Covid-19 Game-Changer", "Stock Market News: Mastercard Charges Ahead; Alphabet Spells Ad Success", "Gold falls as equities drift higher ahead of Fed statement", "Wall St jumps on coronavirus drug hopes; Fed decision awaited", "BUZZ-U.S. STOCKS ON THE MOVE-Liberty Oilfield, MRC Global, Capricor Therapeutics", "Wall Street jumps on coronavirus drug hopes; Fed in focus", "BUZZ-U.S. STOCKS ON THE MOVE-Capricor Therapeutics, Liberty Oilfield, Blue Apron", "COVID-19 complication seen in children is \"rare\", WHO says", "Buy Gilead Stock Because Remdesivir Is a Covid-19 Game-Changer", "Yields down ahead of Fed meeting wrap-up", "Dollar drops as Coronavirus treatment hopes boosts risk sentiment", "Wall Street jumps on hopes of potential coronavirus drug", "BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Spotify, Blue Apron", "Stock Alert: Gilead Sciences Up 4% On Positive Data On COVID-19 Drug", "Gilead Sciences Records Positive Data From 10-day Covid-19 Trial Of Remdesivir", "Gilead says remdesivir shows improvement in COVID-19 patients when used early", "US STOCKS SNAPSHOT-Futures jump after Gilead's COVID-19 drug meets main goal", "Gilead's remdesivir meets main goal of trial in COVID-19 patients", "Better Buy: Cara Therapeutics vs. Sangamo Therapeutics", "The Cure for Profitably in Buying Gilead Sciences", "European shares rise on COVID-19 drug hopes, upbeat outlook from corporates", "Wall St set to jump at open on hopes of potential coronavirus drug", "10 Stocks to Buy for an Aging Population", "The AbbVie Buyout is Not a Sure Thing for Allergan Stock Investors", "BUZZ-U.S. STOCKS ON THE MOVE-Regeneron, Zoom Video, U.S. oil companies, Apple, U.S. insurers", "Pfizer Stock Is Much More Than Just a Coronavirus Play", "BUZZ-U.S. STOCKS ON THE MOVE-Kohl's, tanker operators, oil and gas companies, U.S. casinos", "BUZZ-U.S. STOCKS ON THE MOVE-Tanker operators, oil and gas companies, Caterpillar", "Don\u2019t Let Negative Data Dissuade You from Gilead Sciences", "Gilead Sciences' (GILD) Remdesivir Sparks Market Hope With Trial Success", "Here's What to Expect With Gilead Sciences' Q1 Earnings Update", "ANALYSIS-Investors bet on testing, treatments for restart of U.S. economy", "Moderna Scores Huge Grant, Leads Charge Toward Coronavirus Vaccine", "ANALYSIS-Investors bet on testing, treatments for restart of U.S. economy", "Why Is the Stock Market Hanging Its Hopes on Gilead's Remdesivir?", "While Big Pharma Tanked, Gilead Sciences and Regeneron Soared", "Gilead Sciences Disputes Claim That Remdesivir Failed in a COVID-19 Trial", "Besides Remdesivir, These 2 COVID-19 Treatments Could Have Promise", "EXCLUSIVE-Trial of Gilead's potential coronavirus treatment running ahead of schedule -researcher", "EXCLUSIVE-Trial of Gilead's potential coronavirus treatment running ahead of schedule -researcher", "GLOBAL MARKETS-Stocks struggle with muddled government pandemic response", "Why Remdesivir Clinical Studies Will Lift Gilead Sciences", "3 Top Stocks Under $5 to Buy Now", "GLOBAL MARKETS-Global equities edge higher as oil continues rebound", "The Coronavirus Makes iBio Finally Relevant", "EXCLUSIVE-Trial of Gilead's potential coronavirus treatment running ahead of schedule -researcher", "EXCLUSIVE-Trial of Gilead's potential coronavirus treatment running ahead of schedule -researcher", "EXCLUSIVE-Trial of Gilead's potential coronavirus treatment running ahead of schedule -researcher", "GLOBAL MARKETS-Stocks fall on worries over EU stimulus details, coronavirus drug", "FTSE 100 tracks global mood lower as retail sales sink", "European shares slide as pandemic jitters return", "EM ASIA FX-Currencies ease on lockdown extensions, coronavirus drug report", "Sanofi confirms targets, strong demand for pain killers lifts Q1", "European shares slide as EU stimulus fails to impress", "SE Asia Stocks-Most slide on lockdown extension in parts of region, weak global data", "GLOBAL MARKETS-Asian shares fall on coronavirus drug, economic damage concerns", "GLOBAL MARKETS-Asian stocks poised to rise after Wall Street gains slip away", "Gilead Sciences Rebuts Report Claiming Covid-19 Drug Remdesivir Trial Failed", "5 Top Stock Trades for Friday: GILD, INO, LVS, DPZ, LLY", "Stock Market Wrap-Up: Why Zoom and Royal Caribbean Shares Jumped Today", "Gilead's Remdesivir Reportedly Flopped in Chinese COVID-19 Study", "GLOBAL MARKETS-Asian stocks fall, Europe set to follow on doubts over coronavirus drug", "S&P 500 slips after report on coronavirus drug trial", "S&P 500 slips after report on coronavirus drug trial", "WHO to launch initiative to share COVID-19 drugs, tests and vaccines-statement", "Wall Street trims gains after report on coronavirus drug trial", "Buy the Dip in Gilead Stock Because Remdesivir May Not Be a Flop", "BUZZ-U.S. STOCKS ON THE MOVE-Sleep Number, Crocs, Cassava Sciences", "7 Safe Stocks to Buy on the Coronavirus Dip", "Jobs Data, Treatment Buzz Keep Stock Gains in Check", "Notable Thursday Option Activity: COF, GILD, WYNN", "Wall Street pares gains on report of potential coronavirus drug failing trial", "Gilead's coronavirus drug flops in first trial - FT", "First Week of GILD July 17th Options Trading", "BUZZ-U.S. STOCKS ON THE MOVE-Expedia Group, Crocs, Enzo Biochem", "BUZZ-U.S. STOCKS ON THE MOVE-Immunomedics, Helix Energy, Sleep Number Corp", "BUZZ-U.S. STOCKS ON THE MOVE-Aytu BioScience, QEP Resources, Immunomedics", "Wall St rises on hopes worst for labor market is over", "Better Buy: AbbVie vs. Gilead Sciences", "Foreigners remain net sellers of Japan stocks for 10th week", "How Banks Have Prepared for a Slowdown", "Artificial Intelligence and Drug Discovery: The Companies Leading The Way", "The 10 Best Dividend Stocks for 2020", "Does British American Tobacco's COVID-19 Vaccine Make It a Buy?", "Gilead Sciences Races to Manufacture Remdesivir, but Chemistry Has Speed Limits", "Is It Too Late to Buy Gilead Sciences?", "3 Great Reasons to Buy Gilead Sciences Stock", "Gilead, ONKo-innate Announce Research Collaboration For Cancer Therapy", "Gilead Sciences: Possible COVID-19 Treatment Already Priced in the Stock, Says Analyst", "Why These COVID-19 Vaccine Stocks Soared Today", "Alexion Pharmaceuticals to Initiate Phase 3 Study for Ultomiris as a Potential Coronavirus Treatment", "There's More to Gilead Sciences' Remdesivir Data Than Meets the Eye", "BUZZ-U.S. STOCKS ON THE MOVE-Co-Diagnostics, Xeris Pharma, Cyclacel Pharma", "4 Reasons Why Chesapeake Energy Stock Can Survive", "Gilead Sciences Reaches Analyst Target Price", "Stock market gains alongside economic pain; some worry about over-optimism", "Novartis, U.S. drug regulator agree to malaria drug trial against COVID-19", "Novartis, U.S. regulators agree to malaria drug trial against COVID-19", "Stock market gains alongside economic pain; some worry about over-optimism", "If You Invested $1,000 in Gilead Sciences' IPO, This Is How Much Money You'd Have Now", "2 Best Stocks to Buy Now", "Notable ETF Inflow Detected - VYM, GILD, CME, USB", "Why Restaurant Stocks Jumped Today", "EMERGING MARKETS-Mexican peso rises on stimulus, Latam FX ends week in losses", "Wall Street gains on Boeing surge and coronavirus drug hopes", "4 Top Stock Trades for Monday: BA, MRNA, SLB, KSU", "GLOBAL MARKETS-Stocks rally as investors take heart on U.S. economic reopening plan", "Wall Street gains on Boeing surge, coronavirus drug hopes", "Health Care Sector Update for 04/17/2020: GENE,GILD,WORX", "Can Gilead Sciences\u2019 Coronavirus Gains Continue?", "Gilead Stock Isn\u2019t Worth Chasing Now Despite Recent Remdesivir Success", "Why Shares of AMC, Cinemark, Live Nation, and Planet Fitness Popped Today", "Health Care Sector Update for 04/17/2020: GENE,GILD,WORX", "Wall St climbs on Boeing, Trump's reopening plan", "Whether or Not Gilead Sciences Produces a Successful COVID-19 Therapeutic, It's a Bargain", "BUZZ-U.S. STOCKS ON THE MOVE-Netflix, Cutera, Moderna", "Gilead's shares rise on report of experimental drug's promise in COVID-19", "Wall Street gains on Boeing news, Trump's reopening plan", "BUZZ-U.S. STOCKS ON THE MOVE-Schlumberger, Biohaven Pharmaceutical, Spirit AeroSystems", "Wall St gains on Boeing, Trump's restart plan", "Here's Why JPMorgan Chase and Other Bank Stocks Are Up on Friday", "Stock Market News: Coronavirus Hopes Boost These 2 Stocks", "Boeing, Trump's restart plan boost Wall Street", "EMERGING MARKETS-Latam FX topped by Chile's peso, but eyes weekly losses", "Gilead's Remdesivir Shows Promise Against COVID-19 in Sneak Peek at Clinical Trial Data", "GLOBAL MARKETS-Stocks race toward second weekly gain", "BUZZ-U.S. STOCKS ON THE MOVE-Schlumberger, Biohaven Pharmaceutical, Spirit AeroSystems", "Wall St gains on Boeing, Trump's restart plan", "Here's Why JPMorgan Chase and Other Bank Stocks Are Up on Friday", "Boeing, lockdown easing hopes set to lift Wall Street", "Institutional investors tell Big Pharma to cooperate on coronavirus", "BUZZ-U.S. STOCKS ON THE MOVE-Pulmatrix, Cutera, Moderna, Spirit AeroSystems", "Nasdaq 100 Movers: CTXS, GILD", "GLOBAL MARKETS-Super-charged stocks race towards second weekly gain", "Daily Markets: Investors Cheer Gilead Results and Reopening Roadmap", "U.S. stocks futures jump on Trump's restart plan, coronavirus drug hopes", "Don't Waste Your Money on Penny Stocks, These 2 Stocks Are Better Buys", "US STOCKS-Futures jump on Trump's restart plan, coronavirus drug hopes", "UK shares surge on signs of U.S. restart, Rio Tinto results", "GLOBAL MARKETS-Super-charged stocks race toward second best week ever", "Coronavirus Drug Results Send Gilead Sciences Stock Flying; JPMorgan Weighs In", "Lonza focuses on coronavirus projects as epidemic brings in new business", "South African rand stronger at end of torrid week", "GLOBAL MARKETS-Asian stocks rise as re-open of U.S economy offsets China GDP slump", "Nikkei scales 6-week high on hopes for virus treatment, U.S. plan to reopen", "Hopes for virus treatment, U.S. reopening snuff out dollar rally", "Dollar slips as hopes for virus treatment prop up risk appetite", "Dollar wobbles as fresh hopes for virus treatment prop up risk appetite", "EMERGING MARKETS-Equities buoyed by U.S. optimism as currencies dip", "GLOBAL MARKETS-Asian stocks set to rise as markets brace for China GDP data", "U.S. stock futures jump late following data on potential virus treatment, Trump guidelines", "Gilead surges after report suggests COVID-19 patients responding to remdesivir", "Gilead Sciences Drug Shows Promising Results In Covid-19 Patients; Stock Up 14%", "Why Gilead Sciences Stock Is on Fire Today", "Report: Gilead Is Considering Taking a Stake in Arcus Biosciences", "Is Exelixis a Buy?", "Report says COVID-19 patients respond to Gilead's remdesivir, shares surge", "Gilead Sciences\u2019 Remdesivir Data Release Brings Much Needed Relief for Patients and Investors", "Health Care Sector Update for 04/16/2020: SNGX, GILD, RCUS, RAD, JNJ, PFE, ABT, MRK, AMGN", "AstraZeneca to Test Blood Cancer Drug for COVID-19 Treatment", "Chinese Researchers Suspend Trial of Experimental Coronavirus Treatment", "BUZZ-U.S. STOCKS ON THE MOVE-U.S. oil stocks, retailers, restaurants, BofA, J.C. Penny, IBM, Gilead, LyondellBasell", "Buying Gilead Sciences Stock Means Buying Into Political Risk", "Initial Coronavirus Treatment Trials Look Good for Gilead Stock", "Why Arcus Biosciences Stock Is Skyrocketing Today", "Gilead Sciences\u2019 Remdesivir Data Release Brings Much Needed Relief for Patients and Investors", "Three Reasons to Consider Buying Regeneron Stock", "How Good Is Gilead's Latest News for Coronavirus Drug Remdesivir?", "AMRN Chugs Along, ATHX To Initiate Pivotal COVID-19 Trial, WORX Soars 550%", "Health Care Sector Update for 04/13/2020: PSTI,WORX,GILD,CANF", "Reasons for hope: the drugs, tests and tactics that may conquer coronavirus", "Health Care Sector Update for 04/13/2020: WORX,GILD,CANF", "Gilead Stock Could Get a Lift From a Coronavirus Treatment", "BUZZ-U.S. STOCKS ON THE MOVE-Amazon.com, Netflix, Royal Caribbean Cruises, Sabre Corp, Pluristem Therapeutics", "Wall Street Week Ahead-Health, tech, staples could shine through earnings gloom", "Wall Street set to dip as focus turns to earnings", "Health Care Sector Update for 04/13/2020: CANF, CTSO, GILD, JNJ, PFE, ABT, MRK, AMGN", "BUZZ-U.S. STOCKS ON THE MOVE-Carnival Corp, Gilead Sciencs, Pluristem Therapeutics, Dropbox, Scworx, Quintana Energy", "US STOCKS-Futures fall as focus turns to corporate earnings", "3 Top Biotech Stocks to Buy in April", "BUZZ-U.S. STOCKS ON THE MOVE-Netflix, Amazon.com, Dish Network, GE, AMC Entertainment, Aurora Cannabis", "Eli Lilly Starts Clinical Trial for Potential COVID-19 Treatment", "Early Look at Gilead Sciences' Experimental Coronavirus Treatment Disappoints", "5 Biotech Stocks Winning the Coronavirus Race", "Bristol-Myers' win in U.S. patent case against Gilead boosted to $1.2 bln", "Health Care Sector Update for 04/09/2020: BIOC,BHC,BHC.TO,RTIX,GILD", "Health Care Sector Update for 04/09/2020: BHC,BHC.TO,RTIX,GILD", "GILD May 29th Options Begin Trading", "Is Galapagos Stock a Buy?", "Gilead Canada Submits SNDS To Health Canada For Descovy - Quick Facts", "Why Forty Seven Stock Skyrocketed 64.5% in March", "Good News for Remdesivir Is Good News for Gilead Sciences Stock", "Better Coronavirus Stock: Emergent BioSolutions vs. Gilead Sciences", "Novavax to start human trial for novel coronavirus vaccine", "GRAPHIC-Wall St volatility raises fears of another selloff", "Investors await data on coronavirus drugs as market rally builds", "Nasdaq 100 Movers: CTXS, UAL", "BUZZ-U.S. STOCKS ON THE MOVE-Activision Blizzard, Gilead Sciences, Royal Caribbean, Kohl's", "Is Inovio Pharmaceuticals a Good Buy on Coronavirus Potential?", "BUZZ-U.S. STOCKS ON THE MOVE-Royal Caribbean, Kohl's, Gilead Sciences, Electronic Arts", "BUZZ-U.S. STOCKS ON THE MOVE-Roadrunner Transportation, Gannett Co, Liminal BioSciences", "Gilead Unit Completes Acquisition Of Forty Seven - Quick Facts", "BUZZ-U.S. STOCKS ON THE MOVE-Roadrunner Transportation, Trevi Therapeutics, Gannett Co", "Here Are All the Companies Working on COVID-19 Vaccines, Treatments, and Testing", "Tuesday Sector Laggards: Utilities, Healthcare", "Gilead Sciences Pins Its Hopes on Remdesivir", "Doctors embrace drug touted by Trump for COVID-19, without hard evidence it works", "Monday Sector Laggards: Healthcare, Energy", "Coronavirus Fighter Gilead Sciences Might Be Expensive, but It\u2019s Still Worth Owning", "BUZZ-U.S. STOCKS ON THE MOVE-Gilead Sciences, Wayfair, Immunomedics, Akers Bioscience", "GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln", "BUZZ-U.S. STOCKS ON THE MOVE-Carnival Corp, Capri Holdings, Kohl's, Immunomedics", "My Top Biotech Stocks to Buy in the Market Crash", "Gilead Sciences Pins Its Hopes on Remdesivir", "It\u2019s Tough to Admit, but Our New Normal Might Justify Buying IBIO Stock", "Gilead To Donate 1.5 Mln Doses Of Investigational COVID-19 Drug Remdesivir", "GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln", "BUZZ-U.S. STOCKS ON THE MOVE-Borr Drillng, Millendo Therapeutics, Menlo Therapeutics, Immunomedics Inc", "BUZZ-U.S. STOCKS ON THE MOVE-Crescent Point Energy, Millendo Therapeutics, Menlo Therapeutics", "Gilead, Second Genome Enter Four-year Strategic Collaboration - Quick Facts", "BUZZ-U.S. STOCKS ON THE MOVE-Kohl's, Carnival Corp, Akers Bioscience, Immunomedics", "The 5 Best Coronavirus Stocks To Buy Right Now", "Should You Buy Gilead Sciences Stock Right Now?", "Yes, the Stock Market Will Probably Go Lower. Here's Why You Should Invest Anyway.", "3 Coronavirus Stocks That Could Lead the Market to Recovery", "Should You Buy Forty Seven Before Gilead Sciences' Acquisition Closes?", "Is the End of Quarter Market Run-Up Just Wall Street Dressing the Window?", "Why Gilead Sciences Is the Hottest Stock to Buy Today", "Gilead Has Treated More Than 1,700 COVID-19 Patients With Remdesivir", "Gilead Sciences\u2019 Coronavirus Treatment Has Big-Time Potential", "EMA Recommends Remdesivir for Treatment of COVID-19 Under Compassionate-Use Rules", "EMA recommends compassionate use of Gilead's remdesivir for COVID-19", "Why Gilead Sciences Shares Rose 7.79% in March", "Better Buy: Gilead Sciences vs. Biogen", "GILD May 22nd Options Begin Trading", "GILD Stock Remains a Smart Play Now and in the Future", "Noteworthy Friday Option Activity: MTSI, GILD, WYNN", "Better Coronavirus Stock: Abbott Labs vs. Gilead Sciences", "My Top Pharma Stocks to Buy in the Market Crash", "Is iBio Stock Worth the Risk as Coronavirus Continues to Spread?", "5 Hot Stocks for 2020 That Are Soaring While the Market Plunges", "Gilead\u2019s Cash and the Coronavirus Make GILD Stock Look Cheap", "Look For Better Buys Than Coronavirus Play INO Stock", "4 Reasons Drug Stocks Are a Buy Right Now", "Top 3 Healthcare Stocks to Buy Right Now", "Gilead Expands Access To Investigational Anti-coronavirus Drug", "Gilead Sciences Expands Access to Experimental COVID-19 Treatment", "3 Coronavirus-Proof Dividend Stocks That Are Perfect for Retirees", "2 Biotech Stocks in the Hunt for New Coronavirus Drugs; Oppenheimer Weighs In", "The 3 Most Resilient Stocks in the Bear Market Today", "First Week of GILD November 20th Options Trading", "Noteworthy ETF Outflows: RSP, REGN, GILD, AMD", "Is It Time To Buy Stocks Or Is The Market Heading Even Lower?", "For Gilead, Its Coronavirus Treatment Is Icing on the Cake", "3 Things to Know if Chloroquine Wins the COVID-19 Treatment Race", "7 U.S. Stocks to Buy on Coronavirus Weakness", "This PR Nightmare for GILD Stock Will Eventually Fade", "May 8th Options Now Available For Gilead Sciences (GILD)", "Better Coronavirus Stock: Gilead Sciences vs. Moderna", "1 Safe-Haven Stock for the Near Term", "Nasdaq 100 Movers: EXPE, GILD", "A COVID-19 Immunity Test Is on the Way", "Gilead Asks the FDA to Rescind Orphan Drug Designation for Remdesivir as a Treatment for COVID-19", "Health Care Sector Update for 03/25/2020: GILD,ASTC,VTGN,ALLK", "How Are Market Caps Doing in a Downturn", "Moderna CEO Says a Coronavirus Vaccine Could Be Available in Emergencies This Fall", "Wednesday Sector Laggards: Technology & Communications, Healthcare", "5 Stocks to Buy in the Coronavirus Bear Market", "GILD Seeks To Revoke Coveted Status, ELOX Pauses Trial, PRQR On Watch", "Coronavirus Drugs Already in the Pipeline", "10 Stocks to Buy as They Ride a Coronavirus Tailwind", "Top-Notch Vaccine Technology Makes iBio Stock a Smart Bet", "Inovio Could Be a Bargain Using Probability Analysis", "3 Biotech Stocks Fighting the Coronavirus; Here\u2019s What to Expect", "Top Pharma Stocks Under $5", "Why Consider These 2 Stocks When Markets Are Crashing?", "4 Reasons Biotech Stocks Are a Buy Right Now", "Gilead Sciences Stops Accepting Emergency-Use Applications for Remdesivir", "Don\u2019t Forget About Stocks to Buy During the Coronavirus Crisis", "3 Things To Watch In The Coronavirus Bear Market This Week", "Coronavirus Crisis: 3 Biotech Stocks to Buy Right Now", "All the Drugs Proving Anecdotally Effective Against COVID-19, and the Companies That Make Them", "Nonprofit Group Starts Multiple COVID-19 Clinical Studies", "Gilead\u2019s Coronavirus Vaccine Candidate Shows Promise, Says Cowen", "Gilead Stock Flies High With a Potential Coronavirus Treatment", "3 of the Strongest Stocks to Buy", "These 4 Top Stocks Are Bear-Market Tested", "Is It Too Late to Buy Coronavirus Biotech Stocks?", "Mylan Ramps Up Production of Hydroxychloroquine as a Potential COVID-19 Treatment", "China Reports No New Coronavirus Outbreaks, First Time Since Outbreak Began", "Remdesivir, Other Positive Catalysts Should Lift Gilead Stock", "Coronavirus-Fighting Tech Makes iBio Stock an Interesting Play", "Trump\u2019s Coronavirus News Conference on Thursday: 3 Key Things That Investors Should Know", "Noteworthy ETF Inflows: ESGU, NEE, ADBE, GILD", "Big Pharma's Fight Against the Coronavirus Pandemic: Good News and Bad News", "Better Coronavirus Stock: Gilead Sciences or Regeneron Pharmaceuticals?", "Trump Signs Coronavirus Relief Bill Into Law", "Bayer Is Donating Its Malaria Drug That Could Help Coronavirus Patients In The U.S.", "Will COVID-19 Derail New Drugs?", "Why Is Everyone Talking About Gilead Sciences?", "Japanese-Developed Flu Drug Avigan Seems Effective Against COVID-19", "Noteworthy ETF Inflows: ESGU, NEE, ADBE, GILD", "Big Pharma's Fight Against the Coronavirus Pandemic: Good News and Bad News", "3 Cloud Computing Stocks That Are Winning From the Coronavirus", "Coronavirus Correction: 3 Must-Own Dividend Stocks", "Will Your Elective Surgery Be Delayed by Coronavirus?", "European Medicines Agency Offers Free Advice for Drugmakers Working on Coronavirus Treatments", "As the Coronavirus Worsens, INO Stock Gets More Interesting", "How to Survive the Economic Fallout from COVID-19", "Can This American Biotech Company Save the Global Economy?", "Why This Coronavirus Stock Will Keep Growing Long After the Outbreak is Over", "When Will the Coronavirus Market Crash Be Over? Watch These 3 Stocks", "Early Results Dampen Outlook for Experimental COVID-19 Treatment", "Eli Lilly Joins the Hunt for a Coronavirus Treatment", "The 12 Best Low-Volatility Stocks of the Market Crash", "Why iBio Pharma Stock Is Not for Timid Investors Despite Great Potential", "7 Biotech Stocks to Buy and Hold in 2020", "10 Health and Pharmaceutical Companies Fighting the Coronavirus", "CDC: Gilead Sciences' Remdesivir Is Being Used to Treat Coronavirus Patients", "World Health Organization: Coronavirus Disease COVID-19 Now a Pandemic", "Nasdaq 100 Movers: WDC, NTES", "S&P 500 Movers: WCG, DXC", "Will Moderna Make a Fortune Off Its Coronavirus Vaccine?", "Better Coronavirus Stock: Gilead Sciences vs. Inovio Pharmaceuticals", "CDC Releases List of Conditions That Increase the Risk of Severe Coronavirus Illness", "FDA Postpones All Foreign Inspections Over Coronavirus", "The Gates Foundation and Friends Launch COVID-19 Treatment Accelerator", "COVID-19 Nearing Pandemic Level, WHO Warns", "IBB, GILD, VRTX, BIIB: Large Outflows Detected at ETF", "Nasdaq 100 Movers: GILD, TSLA", "S&P 500 Movers: WCG, APA", "AbbVie to Test HIV Drug as a Potential Coronavirus Treatment", "5 Biotech Stocks to Buy for a Strong Growth Prognosis", "3 Profitable Healthcare Stocks That Are Trouncing the Market During the Coronavirus Correction", "GILD Stock Looks Poised for a Serious Coronavirus Bump", "CDC Says Coronavirus Spread to Continue Into 2021", "Study Warns Number of U.S. COVID-19 Cases Much Higher Than Reported", "CDC Advises Americans to Postpone Cruises", "Is Inovio Pharmaceuticals Stock the Cure for Your Portfolio?", "7 Big Pharma Companies Trump Asked to Fight the Coronavirus Outbreak", "How to Be Greedy When Others Are Fearful", "Will Gilead Sciences Make a Fortune Off Its Coronavirus Drug?", "GILD Crosses Above Average Analyst Target", "Better Buy: Amgen vs. Gilead Sciences", "Gilead Sciences Could Be the First to Beat the Coronavirus", "Coronavirus Market Correction: Where to Invest $1,000 Right Now", "3 Stocks That Are Actually Up Because of the Coronavirus", "FDA Warns Companies Selling Fraudulent COVID-19 Products", "Is There a Cure for the SARS-CoV-2 Coronavirus?", "Amid the Coronavirus Frenzy, Novavax Remains a Risky Bet", "EPA Releases List of Disinfectants to Protect Against Coronavirus", "3 Top U.S. Stocks to Watch in March", "Here's My Top Stock to Buy in March", "Congress Approves $8.3 Billion Coronavirus Funding Bill", "Inovio Pharmaceuticals Rapidly Becoming The Premier Coronavirus Play", "4 Top Stock Trades for Monday: AMD, WMT, CRM, GILD", "Nasdaq 100 Movers: AAL, NTES", "Is Inovio Stock a Buy on Coronavirus Cure Potential?", "Up 2000% on Coronavirus Worries, CODX Stock Is a Short-Term Buy", "3 Biotech Stocks That Are Coronavirus Safe Havens", "Is Inovio Stock Still a Buy After Its Massive 150% Leap This Year?", "Moderna CEO Says Its Coronavirus Vaccine Will Be Affordable", "China Approves a Treatment for COVID-19 Complications", "Is iShares Nasdaq Biotechnology Index Fund a Buy?", "Why It\u2019s Probably Safe to Start Buying AMD Stock on Weakness", "Is Gilead Sciences the Best Buy in the Coronavirus Sell-Off?", "Why Forty Seven Stock Soared 57% in February", "Buy Regeneron Stock for Coronavirus 2.0 and Beyond", "Barrick Gold Isn\u2019t the Best Hedge Against the Coronavirus", "Trump Considering Expanded Travel Ban in Effort to Slow the Spread of Coronavirus", "Trump Administration Considers Reimbursing Hospitals to Treat Uninsured Coronavirus Patients", "Wednesday's ETF with Unusual Volume: MDIV", "Inovio Has Potential Beyond Its Speculative Coronavirus Vaccine", "Nasdaq 100 Movers: ADSK, TSLA", "Nasdaq CEO Says Capital Is Part of Curing the Coronavirus", "Dow Jones Recovers 1,300 Points Despite Increase in U.S. Coronavirus Deaths", "Health Care Sector Update for 03/02/2020: CODX,FTSV,GILD,APDN,UMRX", "Health Care Sector Update for 03/02/2020: APDN,FTSV,GILD,UMRX", "Now Is the Time to Buy the Dip in Amazon Stock for the Long Term", "Kids May Be the Hidden Carriers of COVID-19", "Why Gilead Sciences, Forty Seven, and Trillium Therapeutics Are Moving Higher Today", "Health Care Sector Update for 03/02/2020: FTSV, GILD, KPTI, CODX, JNJ, PFE, ABT, MRK, AMGN", "3 Top Biotech Stocks to Buy in March", "Daily Markets: Investors Hoping Central Banks Will Relieve Coronavirus Pressures", "Forty Seven's Stock Surges As Gilead Sciences To Buy Company In $4.9 Bln Deal", "Biotech Stocks Facing FDA Decision In March 2020", "2 Biotech Stocks Winning the Coronavirus Race", "Gilead Sciences Acquiring Cancer-Focused Biotech Forty Seven for $4.9 Billion", "Better Buy: Gilead Sciences vs. Pfizer", "7 Stocks to Buy as a Hedge Against The Coronavirus Threat", "All the Stocks I'm Selling If the Coronavirus Keeps Spreading", "FDA Approves Coronavirus Tests in Academic Laboratories Across U.S.", "Coronavirus: Emerging Numbers Provide Reasons for Calm", "Investors Endure Wild Ride in This Biotech Taking on COVID-19", "Here's Why Hype Around Companies Working on Coronavirus Treatments Is Overblown", "2 Stocks That Can Help You Protect Your Wealth From a Coronavirus Pandemic", "Better Buy: Gilead Sciences vs. Pfizer", "7 Stocks to Buy as a Hedge Against The Coronavirus Threat", "Gilead Sciences (GILD) Shares Cross 4% Yield Mark", "Gilead Reportedly in Talks to Acquire Cancer Biotech Forty Seven", "Health Care Sector Update for 02/28/2020: ALT,FTSV,GILD,CLSN", "Traders Are Treating Inovio Like 2018\u2019s Pot Stock Stars", "Stock Alert: Forty Seven Surges 30%", "3 Small-Caps That Are Soaring Because of Coronavirus Panic", "Health Care Sector Update for 02/28/2020: FTSV, GILD, SGMO, BHVN, JNJ, PFE, ABT, MRK, AMGN", "How Gilead Sciences Is Driving Forty Seven and Trillium Therapeutics Higher Today", "This Under-the-Radar Stock Is the Biggest Winner From the Coronavirus Outbreak", "Noteworthy Thursday Option Activity: SAIA, GILD, MA", "April 9th Options Now Available For Gilead Sciences (GILD)", "Wait for Tesla Stock to Drop Below $700 on Coronavirus Fears", "Nasdaq 100 Movers: AAL, GILD", "Forty Seven (FTSV) Soars On Reports Of Takeover Interest", "Stock Alert: GILD Gains After Initiating Phase 3 Studies For COVID-19 Treatment", "Momentum Stocks Benefitting From Coronavirus", "Why Inovio Pharmaceuticals, Gilead Sciences, Moderna, and Novavax Are All Jumping Today", "Fighting The Deadly Coronavirus", "Buy Microsoft Stock On The Dip Over Coronavirus", "Gilead Sciences Initiates Late-Stage Testing of Its Promising Coronavirus Drug", "Airport Screeners Are Likely Missing 2 Out of 3 COVID-19 Carriers, Researchers Warn", "S&P 500 Movers: FLIR, PWR", "Novavax to Begin Clinical Testing of Coronavirus Vaccine by Late Spring", "Noteworthy ETF Inflows: IBB, GILD, VRTX, BIIB", "7 Safe Stocks to Buy on the Coronavirus Dip", "Gilead\u2019s Coronavirus Drug Could Propel GILD Stock Much Higher", "Should You Buy Inovio Pharmaceuticals Stock Right Now?", "Meet the Company That Just Might Prevent a Global Recession", "U.S. Health Official Warns: COVID-19 Will Hit the United States", "Resilience to Coronavirus Concern Is a Bullish Sign for Alibaba Stock", "NIO Stock Will Sustain Momentum in 2020 Despite Coronavirus Concerns", "Nasdaq 100 Movers: GILD, REGN", "8 of the Best Stocks to Buy for ESG Investors", "Is It Too Late to Buy High-Flying Galapagos?", "11 Best Stocks to Ride Out the Coronavirus Outbreak", "Moderna's New COVID-19 Vaccine Ready for Human Trials; Stock Up 15%", "Health Care Sector Update for 02/24/2020: NGM,UTHR,GILD,EPZM", "U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment", "Health Care Sector Update for 02/24/2020: UTHR,GILD,EPZM", "Stock Market News: Berkshire Sinks Despite Buffett Optimism; Gilead Rises on Coronavirus Hopes", "Nasdaq 100 Movers: AAL, GILD", "S&P 500 Movers: AAL, GILD", "3 Dividend Stocks That Raised Their Payouts in February", "Is Gilead Sciences Stock a Buy?", "A Plan to Use Blockchain to Stop Counterfeit Drugs Moves Forward", "Gilead Antiviral Drug Shows the Most Potential for COVID-19, Says WHO Official", "Health Care Sector Update for 02/24/2020: UTHR,GILD,EPZM", "Why Wells Fargo Stock Looks Poised to Rebound", "3 Contrarian Stocks to Buy Now for Absolute Returns", "Where Will Gilead Sciences Be in 10 Years?", "Report: Gilead Struggling to Find Subjects for COVID-19 Drug Trial", "Johnson & Johnson Expands Pact With U.S. Government to Seek a Treatment for COVID-19", "2 Reasons to Be Optimistic About Gilead Sciences\u2019 Future", "Nasdaq 100 Movers: ALGN, BMRN", "Notable Thursday Option Activity: STX, UNP, GILD", "Why Wells Fargo Stock Looks Poised to Rebound", "3 Contrarian Stocks to Buy Now for Absolute Returns", "Where Will Gilead Sciences Be in 10 Years?", "3 High-Yielding U.S. Pharmaceutical Companies to Consider", "S&P 500 Analyst Moves: GILD", "White House Claims Other Countries Are \"Free-Riding\" on U.S. Drug Development", "IBB, GILD, VRTX, BIIB: ETF Outflow Alert", "Is Viking Therapeutics' Stock a Buy?", "Moderna Will Rebound, But Wait for a Dip Lower to Buy Shares", "The FDA Has a Plan to Deal With the Coronavirus", "Better Buy: AbbVie vs. Gilead Sciences", "Pandemic Fears Not Enough to Buy Inovio Stock", "Gilead Sciences Looks Ready to Outpace AbbVie", "Better Buy: bluebird bio vs. Gilead Sciences", "Inovio\u2019s Surge on a Coronavirus Vaccine Was Just Speculation", "Coronavirus Gets an Official Name From the WHO", "Johnson & Johnson Is Racing Against Time to Develop the First Coronavirus Vaccine", "Is Gilead Sciences an Acquisition Target?", "3 Pros and 3 Cons For INO Stock Amid Chinese Coronavirus Outbreak", "FDA Grants a Priority Review To Gilead Sciences' Cancer Therapy", "Monday's ETF with Unusual Volume: PJP", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Johnson & Johnson Announces Partnership With U.S. government to Accelerate Coronavirus Vaccine Development", "FDA Grants Priority Review For Kite's KTE-X19 BLA - Quick Facts", "1 Big Question to Ask Yourself Before Buying Gilead Sciences Stock", "Gilead Sciences: Still on the Path to Recovery", "Health Officials Say U.S. Coronavirus Vaccine is Making Good Progress", "4 Internet Stocks to Buy That Are Surging Higher", "3 Big Stock Charts for Friday: Barrick Gold, Gilead Sciences, and Cloudflare", "Multiple Positive Catalysts Make JD.com Stock Worth Buying", "Could These 5 Stocks Benefit From the Coronavirus Outbreak?", "FDA Grants Priority Review For Kite's KTE-X19 BLA - Quick Facts", "1 Big Question to Ask Yourself Before Buying Gilead Sciences Stock", "Gilead Sciences: Still on the Path to Recovery", "Notable Wednesday Option Activity: IBM, MSFT, GILD", "Daily Dividend Report: MMM, GILD, CG, PSX, SYK", "Gilead Sciences: Patience Required", "3 Important Things to Know About Gilead Sciences' Q4 Results", "Health Care Sector Update for 02/05/2020: VVUS,CERN,AIMT,GILD", "FDA Approves Emergency Use of Coronavirus Test", "FDA Approves Emergency Use of Coronavirus Test", "Gilead Sciences Q4 Profit Misses Estimates", "Gilead Announces Q4 Financial Results, Misses EPS Target", "Gilead Sciences Inc. Q4 adjusted earnings Miss Estimates", "Gilead Sciences Q4 19 Earnings Conference Call At 4:30 PM ET", "Here's a Better Reason to Buy Gilead Sciences Stock Than a Possible Coronavirus Treatment", "Gilead Sciences Inc (GILD) Q4 2019 Earnings Call Transcript", "FDA Approves Emergency Use of Coronavirus Test", "Gilead's Ebola Drug Shows Positive Signs in Treating Coronavirus", "Here's Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today", "GILD Crosses Above Key Moving Average Level", "S&P 500 Movers: WCG, GILD", "Why Gilead Sciences Stock Is Up 13% Today", "Momentum Stocks To Watch: Gilead Sciences Inc. (GILD)", "Where Will Vertex Pharmaceuticals Be in 10 Years?", "Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences", "Noteworthy ETF Outflows: IBB, GILD, VRTX, BIIB", "Near a 7-Year Low, Is Gilead Sciences a Buy?", "Why Novavax Shares Are Jumping Again Today", "5 Biotech Stocks to Watch With the Coronavirus Scare", "3 Big Drugmakers Are Taking On the Coronavirus", "Better Buy: Vertex Pharmaceuticals vs. Galapagos", "An Emboldened Bristol-Myers Squibb Wants $1.5 Billion From Gilead Sciences", "Better Buy: Amgen vs. Gilead Sciences", "Gilead Considering Ebola Drug as Potential Coronavirus Treatment", "2 Dividend-Paying Biotech Stocks Worth Owning in 2020", "Where Will Intercept Pharmaceuticals Be in 5 Years?", "2 Small-Cap Biotech Stocks to Watch in 2020", "Which Big Biotech Has the Safer Dividend -- Amgen or Gilead Sciences?", "PJP's Underlying Holdings Could Mean 14% Gain Potential", "Notable Monday Option Activity: AIMT, NKE, GILD", "Gilead Sciences To Present At J.P. Morgan Conference; Webcast At 12:30 PM ET", "IBB, GILD, VRTX, BIIB: Large Inflows Detected at ETF", "Gilead Invests In Kyverna Therapeutics, Enters License Agreement - Quick Facts", "Better Buy: Biogen vs. Gilead Sciences", "7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Better Buy: Gilead Sciences vs. Biogen", "IBB, GILD, VRTX, BIIB: ETF Outflow Alert", "Biotech's Most Volatile Binary Events for Q1", "Vascepa\u2019s Future Looks Rosy, But It Could Still Be Fishy for Amarin Stock", "Notable Two Hundred Day Moving Average Cross - GILD", "3 Big Pharma Stocks That Pay Big Dividends", "3 Dividend Stocks to Buy for 2020", "Gilead Sciences Licenses Portfolio Of HIV Antibodies From Rockefeller", "Interesting GILD Put And Call Options For August 2020", "Gilead's Japan Unit In Deal With Eisai To Co-Promote RA Drug Filgotinib", "Did Cellectis Just Provide a Glimpse of the Future of Cellular Medicine?", "iShares Russell 1000 Value ETF Experiences Big Outflow", "20 High-Yield Dividend Stocks to Buy in 2020", "How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition", "Health Care Sector Update for 12/20/2019: GILD,TXG,BIO,NLNK,MRK,ABEO", "Better Buy: Editas Medicine vs. CRISPR Therapeutics", "2 Must-Own Dividend Growth Stocks in 2020", "5 Biotech Stocks to Buy for a Strong Growth Prognosis", "7 Biotech Stocks to Buy and Hold in 2020", "Drugs That Missed Key Goals In Phase III Trials", "Amarin\u2019s Vascepa Approval Seems Fishy for Patients and AMRN Investors", "Is Amarin a $20 Billion Stock?", "Gilead: Phase 2 ATLAS Data Shows Consistent Improvements In Liver Histology", "Noteworthy Friday Option Activity: GILD, MET, PYPL", "Bristol-Myers Wins $752 Mln In US Patent Case Against Gilead Sciences", "IBB, GILD, VRTX, ILMN: ETF Outflow Alert", "GILD's KTE-X19 To Face FDA, NTEC Drops As NVS Walks Away, KZIA On Watch", "Noteworthy Wednesday Option Activity: GILD, GKOS, DERM", "GILD Named A Top Socially Responsible Dividend Stock", "Ex-Dividend Reminder: El Paso Electric, Conmed and Gilead Sciences", "APTO On The Move, PLX To Effect Reverse Split, SCYX Plunges", "Better Buy: Gilead Sciences vs. Amgen", "Thursday Sector Laggards: Energy, Healthcare", "IBB, GILD, VRTX, ILMN: Large Outflows Detected at ETF", "Better Buy: Editas Medicine or Sangamo Therapeutics?", "5 Top Stock Trades for Tuesday: NVDA, TSLA, GILD", "Does Amarin Have a Dark Horse Suitor?", "Better Buy: AbbVie vs. GlaxoSmithKline", "3 Dividend Stocks to Buy on Sale", "No CRISPR Required: This Forgotten Gene Editing Stock Is Up 50% in 5 Weeks", "January 2020 Options Now Available For Gilead Sciences (GILD)", "3 Recovering Healthcare Stocks to Buy That Already Escaped Flu Season", "Notable Thursday Option Activity: GILD, GEO, TTWO", "Gilead Sciences (GILD) Shares Cross 4% Yield Mark", "3 Big Stock Charts for Thursday: Gilead Sciences, DocuSign and Western Digital", "These Superior Dividend Stocks Are Found in Some Odd Industries", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales", "US Files Complaint Against Gilead Sciences For Patent Infringement", "Is The Future Finally Looking Up For Gilead Sciences?", "Here's Why Galapagos Stock Rose 20.5% in October", "Up 19.2%, Is Viking Therapeutics Stock Still a Buy?", "These 3 European Biotechs Can Help Recession-Proof Your Portfolio", "GILD Crosses Above Key Moving Average Level", "Noteworthy ETF Outflows: IBB, CELG, GILD, VRTX", "Will Its HIV Lineup Save Gilead Sciences?", "3 Reasons CRISPR Therapeutics Stock Can Reach Record Highs Again", "The 3 Best Sectors for Long-Term Earnings", "Can New Drugs Help Gilead Sciences Rebound?", "IBB, CELG, GILD, ILMN: ETF Outflow Alert", "Better Buy: Abbott Laboratories vs. Novo Nordisk", "5 Top Healthcare ETFs", "4 Top Stock Trades for Monday: TSLA, GILD, GLD, VZ", "Notable Friday Option Activity: GILD, AMED, TGT", "Daily Dividend Report: VFC, BRO, COG, GRC, GILD", "5 Biotech Stocks to Buy for a Strong Growth Prognosis", "What's Behind Gilead Sciences' Lackluster Q3 Earnings Results", "Gilead Sciences Inc (GILD) Q3 2019 Earnings Call Transcript", "Gilead Sciences Inc. Q3 adjusted earnings Beat Estimates", "Interesting GILD Put And Call Options For December 6th", "Noteworthy Tuesday Option Activity: GILD, APLS, MAT", "Gilead Sciences Q3 Revenue Is Flat, and R&D Hits Earnings", "Gilead Sciences Names Andrew Dickinson CFO - Quick Facts", "3 Top Healthcare Dividend Stocks That Are Great Picks for Retirees", "Better Buy: Gilead Sciences vs. Johnson & Johnson", "Health Care Sector Update for 10/11/2019: ACRS, GERN, GILD, GLPG, JNJ, PFE, ABT, MRK, AMGN", "MITO Empowered, FPRX Cuts Another 70 Jobs, Second Death In Legionnaires Outbreak", "Notable Thursday Option Activity: ABBV, GILD, SWKS", "Better Buy: Biogen vs. Gilead Sciences", "TQQQ, COST, CHTR, GILD: ETF Outflow Alert", "3 Companies To Watch For At November\u2019s Society for Immunotherapy of Cancer Meeting", "Gilead Announces NDA Submission For Filgotinib In Japan - Quick Facts", "Noteworthy ETF Outflows: IBB, CELG, GILD, ILMN", "FDA Approves Descovy, Second Drug To Prevent HIV Infection", "Forget Vertex Pharmaceuticals; CRISPR Therapeutics Is a Better Biotech Growth Stock", "Better Buy: Gilead Sciences vs. Pfizer", "Biotech Stocks Facing FDA Decision In October 2019", "3 Big Pharma Companies Driving Price Inflation", "Notable Thursday Option Activity: CALM, GILD, EPAY", "OEF, GILD, AXP, MS: ETF Outflow Alert", "OEF, GILD, AXP, MS: ETF Outflow Alert", "3 Big Stock Charts for Tuesday: Baker Hughes, Gilead Sciences and Jefferies Financial Group", "Meet the Revolutionary New Diabetes Drug You've Probably Never Heard Of", "Better Buy: Vertex Pharmaceuticals vs. Galapagos", "Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences", "Is GlaxoSmithKline a Buy?", "An Investor's Guide to Disrupting Drugmakers", "PBE, GILD, ALXN, INCY: Large Outflows Detected at ETF", "Is iShares Nasdaq Biotechnology Index Fund a Buy?", "Better Buy: Celgene vs. Gilead Sciences", "Interesting GILD Put And Call Options For November 1st", "Notable Wednesday Option Activity: AXDX, GILD, MDB", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for September 12, 2019", "3 Biotechs With the Biggest Cash Stockpiles", "Ex-Dividend Reminder: Gilead Sciences, Conmed and Crown Castle International", "Gilead Sciences Breaks Above 200-Day Moving Average - Bullish for GILD", "IVE, COST, MDLZ, GILD: ETF Outflow Alert", "Sum Up The Parts: ESGL Could Be Worth $35", "'Serving on a Board Made Me a Better CFO'", "3 High-Yield Dividend Stocks to Buy on Sale", "Better Buy: Gilead Sciences vs. Biogen", "4 Key Questions for Gilead Sciences' New CEO", "Noteworthy ETF Outflows: IBB, GILD, CELG, VRTX", "3 Big Stock Charts for Monday: Intuit, Gilead Sciences and Nike", "5 Top ESG Stocks on RBC Capital's 'Best Ideas' List", "VTV, GE, MO, GILD: ETF Outflow Alert", "3 Big Stock Charts for Monday: Xilinx, News Corp and Gilead Sciences", "3 Embarrassingly Cheap Dividend Stocks", "Fidelity National Information Services Achieves #72 Analyst Rank, Surpassing Gilead Sciences", "Notable Wednesday Option Activity: JNJ, GILD, GLNG", "Gilead Sciences a Top 25 Dividend Giant With 3.94% Yield", "DERM On Watchlist, FDA Panel Nod For GILD, So Long, CVRS And AVDR", "Notable Tuesday Option Activity: GILD, EVRI, PLT", "GILD Crosses Above 4% Yield Territory", "Notable ETF Outflow Detected - IBB, GILD, CELG, ILMN", "Here's Why Galapagos NV Rose 34.5% in July", "2 Small-Cap Stocks That Could Make You Rich", "Analysts Anticipate SUSA To Hit $133", "Gilead Sciences Reports Improving Revenue in the 2nd Quarter", "After Hours: Apple, Mastercard, and Gilead Sciences Report Earnings", "Gilead Sciences Inc. Q2 adjusted earnings Beat Estimates", "Noteworthy Tuesday Option Activity: GRMN, GILD, MCD", "Gilead (GILD) 2nd Quarter Earnings: What to Expect", "Gilead Sciences Q2 19 Earnings Conference Call At 4:30 PM ET", "Marijuana Stock Cann('t)Trust, and What's Behind Gilead's Latest Megadeal", "Are Amgen and Gilead Sciences Better Buys After Second-Quarter Earnings?", "Weekly Market Preview: Six Stocks To Watch For the Coming Week (BYND, GILD, AAPL, AMD, QCOM, SQ)", "3 'Perfect 10' Biotech Companies to Buy", "Health Care Sector Update for 07/24/2019: GILD,GHDX,EFII,EW,SGEN", "5 Biotech Stocks to Buy for a Strong Growth Prognosis", "8 More Big Pharma Events in 2019 You Don't Want to Miss", "Friday Sector Laggards: Utilities, Healthcare", "Notable ETF Inflow Detected - IBB, GILD, CELG, VRTX", "Biotech Stocks Facing FDA Decision In August 2019", "3 Top Healthcare Stocks to Buy Right Now", "The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On", "Gilead's Galapagos Deal: What It Means for Investors", "3 Soaring Biotech Stocks With More Fuel in the Tank", "What Happened in the Stock Market Today", "Nasdaq Today: Bitcoin & Libra; What\u2019s Broadcom Doing?", "Health Care Sector Update for 07/15/2019: CAPR,GLPG,GILD,OMCL,TEVA", "Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis", "Galapagos Deal: GLPG Stock Rockets Higher on Gilead Stake", "Health Care Sector Update for 07/15/2019: GLPG,GILD,OMCL,TEVA", "GILD Crosses Above Key Moving Average Level", "Nasdaq 100 Movers: SYMC, GILD", "Health Care Sector Update for 07/15/2019: CAPR, GLPG, GILD, NTGN, JNJ, PFE, ABT, MRK, AMGN", "Why Galapagos NV Stock Is Soaring Today", "IBB, GILD, CELG, ILMN: Large Outflows Detected at ETF", "Monday Sector Leaders: Utilities, Healthcare", "We Did The Math OVLU Can Go To $30", "Are Natural Killer Cells the Next Big Thing in Immunotherapy?", "VTI, C, GE, GILD: ETF Inflow Alert", "After Hours: Sarin Scare at Facebook, Gilead to Make Arthritis Drug Submission Soon", "First Week of February 2020 Options Trading For Gilead Sciences (GILD)", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "The 10 Biggest Biotech Stocks", "August 23rd Options Now Available For Gilead Sciences (GILD)", "3 Large-Cap Biotech Stocks to Buy for Massive Gains", "GILD Crosses Above Key Moving Average Level", "3 Big Stock Charts for Tuesday: McKesson, Dish Network and Gilead Sciences", "3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal", "5 Top Stock Trades for Tuesday: FB, NFLX, GILD, TSLA", "Notable ETF Outflow Detected - IBB, GILD, BIIB, VRTX", "Better Buy: Aurora Cannabis vs. Gilead Sciences", "3 Drugs Under FDA Review With Blockbuster Potential", "Notable Wednesday Option Activity: EXAS, GILD, PSTG", "Is the Newest Gene Editing Stock a Buy?", "Is Gilead Sciences Worth the Wait?", "How The Pieces Add Up: RNDV Targets $25", "Vanguard Total World Stock ETF Experiences Big Outflow", "3 Cancer Stocks Given a Lift by Amgen", "Kite And Humanigen Collaborate To Conduct Clinical Study On Relapsed/DLBCL", "3 Top Dividend Stocks to Buy in June", "Noteworthy Tuesday Option Activity: UAL, GILD, HP", "Nasdaq 100 Movers: MYL, AMD", "10 Top Pot Stocks to Buy", "IBB, CELG, GILD, AMGN: ETF Inflow Alert", "3 Top Biotech Stocks to Buy Right Now", "Better Buy: Vertex Pharmaceuticals vs. Galapagos", "Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences", "5 Top Stock Trades for Wednesday: GILD, NVDA, AMD", "IBB, GILD, CELG, BIIB: ETF Outflow Alert", "Is It Finally Time to Buy Gilead Sciences?", "Goldfinch Bio Partners With Gilead Sciences - Quick Facts", "Where Will Gilead Sciences Spend Its Cash?", "Analysts Expect VOOV To Hit $124", "5 Things You Can Expect for Gilead Sciences With Its New CEO at the Helm", "VTV, MO, GILD, AXP: ETF Inflow Alert", "Who Had the Better Quarter: Gilead Sciences or Amgen?", "Gilead Sciences Returns to Growth in the First Quarter", "Gilead Sciences Inc (GILD) Q1 2019 Earnings Call Transcript", "Daily Dividend Report: EOG, GILD, DUK, ECL, ICE", "Gilead Sciences Inc. Q1 adjusted earnings Beat Estimates", "June 14th Options Now Available For Gilead Sciences (GILD)", "Better Buy: Vertex Pharmaceuticals vs. Galapagos", "Gilead (GILD) 1st Quarter Earnings: What to Expect", "Has Gilead Sciences Turned the Corner?", "3 Things You Can Expect in Gilead Sciences' Q1 Earnings Update", "Will Gilead Stock Get A Needed Boost From This Week\u2019s Earnings Report?", "2 Reasons Gilead Sciences' NASH Program Could Bounce Back", "How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life", "Notable ETF Inflow Detected - IBB, CELG, GILD, BIIB", "2 Best Biotech Buyout Plays", "5 Top Stock Trades for Tuesday: TSLA, TWTR, TTD, O", "Gilead Sciences Q1 19 Earnings Conference Call At 4:30 PM ET", "Noteworthy Thursday Option Activity: GM, GILD, ICPT", "Noteworthy Thursday Option Activity: GM, GILD, ICPT", "Noteworthy ETF Inflows: VLUE, GM, GILD, EXC", "Is TG Therapeutics a Buy?", "Why Amgen Stock Could Break Out to New Highs", "Gilead teams up with insitro for experimental NASH treatments", "Gilead Sciences Enters Strategic Collaboration With Insitro - Quick Facts", "Top Gene-Sequencing Stocks for 2019", "Gilead Sciences (GILD) Gains As Market Dips: What You Should Know", "Gilead to Collaborate with Novo Nordisk for NASH Treatment", "Better Buy: Gilead Sciences vs. Biogen", "Better Buy: Amgen vs. Gilead Sciences", "Novo Nordisk and Gilead team up to test fatty liver disease treatment", "Noteworthy Thursday Option Activity: ADSK, GILD, HUM", "Noteworthy Thursday Option Activity: ADSK, GILD, HUM", "Interesting GILD Put Options For May 31st", "3 Dividend Stocks Perfect for Retirees", "Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know", "Gilead Files sNDA for Label Expansion of HIV Therapy Descovy", "Where Will Gilead Sciences Be in 5 Years?", "Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences", "Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences", "IBB, GILD, CELG, VRTX: Large Outflows Detected at ETF", "Why Galapagos NV Stock Bolted Higher in March", "3 Dividend Stocks Perfect for Retirees", "Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know", "Health Care Sector Update for 03/29/2019: GLPG,GILD,FTSV,SEEL,AZN,AZN.L", "Why Galapagos Stock Is Crushing It Today", "Shares in Galapagos jump 15 pct after arthritis drug results", "Why BlackBerry, Galapagos, and Progress Software Jumped Today", "Health Care Sector Update for 03/29/2019: GLPG,GILD,FTSV,SEEL,AZN,AZN.L", "2 Incredibly Cheap Pharma Stocks to Buy Now", "3 Top Dividend Stocks to Add to Your Watchlist", "Gilead Sciences (GILD) Gains As Market Dips: What You Should Know", "Why 1 Top Analyst Thinks Gilead Sciences Will Soar More Than 25%", "iShares Nasdaq Biotechnology ETF Experiences Big Inflow", "Biogen Stock Fell Too Far on Unfortunate News", "Conatus (CNAT) Declines on Failure of NASH Fibrosis Study", "Does Recent AbbVie Stock Weakness Make It A Buy? 3 Pros, 3 Cons", "ARDS On The Move, GLPG Reports Positive Data, PRTO Plunges On PATENCY-2 Results", "YETI, Gilead, Dick's, FedEx and Amazon highlighted as Zacks Bull and Bear of the Day", "Bear of the Day: Gilead Sciences (GILD)", "After Hours Most Active for Mar 18, 2019 : ELAN, LLY, BAC, MRK, HPQ, WMB, QCOM, GILD, CMCSA, PEP, EBAY, ATVI", "Better Buy: Amgen vs. Gilead Sciences", "Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up", "IBB, CELG, BIIB, GILD: Large Inflows Detected at ETF", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for March 14, 2019", "Gilead Sciences (GILD) Gains As Market Dips: What You Should Know", "YETI, Gilead, Dick's, FedEx and Amazon highlighted as Zacks Bull and Bear of the Day", "Don\u2019t Abandon Gilead Stock After Weak Q4 Results", "Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy", "2 Biotech Stocks With Major Incoming Catalysts", "Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy", "World's second man cleared of AIDS virus invigorates quest for cure", "Why Is Gilead (GILD) Down 4.9% Since Last Earnings Report?", "Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know", "Gilead Sciences (GILD) Shares Cross 4% Yield Mark", "Why Sangamo Therapeutics Lost 22.9% of Its Value in February", "Sum Up The Pieces: QQXT Could Be Worth $58", "Eli Lilly seeks to quell drug price anger with cheaper insulin", "After Hours Most Active for Mar 4, 2019 : LTHM, LLY, ATVI, BAC, S, OHI, GE, GILD, CMCSA, IMGN, AAPL, SGMS", "The 3 Oldest Members of Biotech's Billion-Burned Club", "Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus", "3 Big Pharmas Trying to Pop the Rebate Bubble", "Is Viking Therapeutics a Buy?", "Better Buy: bluebird bio vs. Gilead Sciences", "2 Frustrating Flops, Plus Welcome to the Wrinkle Wars", "The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis", "What Pharma Investors Need to Know About Pfizer's Latest Disaster", "Intercept Pharmaceuticals Investors Strap In for a Wild Ride", "Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More", "Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended", "Intercept's fatty liver drug meets late-stage main goal, shares soar", "Tuesday's ETF with Unusual Volume: PBE", "Better Buy: Celgene vs. Gilead Sciences", "U.S. Medicare plans to track CAR-T cancer therapy outcomes", "Should You Buy Viking Therapeutics After Gilead Drug Failure?", "Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings", "Celgene vs. Gilead Stock: What\u2019s the Better Biotech Buy?", "Intercept Reports Positive Top-Line Data for NASH, Shares Up", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 14, 2019", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for February 14, 2019", "Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars", "Nasdaq 100 Movers: GILD, EA", "Health Care Sector Update for 02/12/2019: KMDA, GILD, MDGS, JNJ, PFE, MRK, ABT, AMGN", "Better Buy: Gilead Sciences vs. Pfizer", "Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails", "Noteworthy ETF Outflows: XLV, JNJ, GILD, CVS", "5 Must-See Stock Charts for Wednesday: GILD, NFLX, EA", "Here's Why Viking Therapeutics Rose as Much as 13.9% Today", "Health Care Sector Update for 02/12/2019: GILD,KMDA,OHI", "Notable Tuesday Option Activity: EA, GILD, NKE", "Gilead Sciences Stock Slides Lower on NASH Drug Failure", "Gilead misses key goal in NASH liver disease trial, shares sink", "Why Gilead Sciences Stock Perked Up in January", "Health Care Sector Update for 02/12/2019: JAZZ,GILD,KMDA,OHI", "Why Agenus Inc. Stock Took Flight in January", "The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO", "Amgen a Top Socially Responsible Dividend Stock With 3.1% Yield (AMGN)", "Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink", "Wednesday Sector Leaders: Healthcare, Technology & Communications", "Nasdaq 100 Movers: GILD, JD", "Health Care Sector Update for 02/05/2019: OPGN, CNC, GILD, JNJ, PFE, ABT, MRK, AMGN", "Is Intercept Pharmaceuticals a Buy?", "UnitedHealth, MercadoLibre, Alphabet and Gilead highlighted as Zacks Bull and Bear of the Day", "Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat", "Is Gilead Sciences a Bad News Buy?", "Gilead Sciences' HCV Albatross Weighs on Its Results Yet Again", "Stock Market Today: Alphabet Grows While Gilead Sciences Shrinks", "5 Top Stock Trades for Wednesday: GOOGL, GILD, EL, BA", "Daily Dividend Report: GILD, EXC, AVB, CHD, UTX", "7 Key Things You Need to Know From Gilead Sciences' Q4 Earnings Update", "UnitedHealth, MercadoLibre, Alphabet and Gilead highlighted as Zacks Bull and Bear of the Day", "Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat", "Is Gilead Sciences a Bad News Buy?", "Gilead Sciences' HCV Albatross Weighs on Its Results Yet Again", "Gilead Sciences Earnings: GILD Stock Dips on Q4 EPS Miss, Revenue Beat", "Gilead 4th-qtr profit misses Wall Street estimate, shares fall", "Alphabet (GOOGL) Outperforms Estimates, Gilead (GILD) Mixed", "5 of the Best Biotech Stocks to Buy Now", "Gilead fourth-quarter profit misses Wall Street estimate, shares fall", "Notable Monday Option Activity: BABY, GILD, VRNT", "After-Hours Earnings Report for February 4, 2019 : GOOGL, GILD, AVB, HIG, ITUB, ARE, STX, QGEN, AIV, KRC, LEG, OLN", "Novartis's cancer therapy wins UK backing after initial lymphoma snub", "3 Top Large-Cap Stocks to Buy in February", "Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?", "A Cure for Cancer Next Year? The Stock Market Says Don't Believe the Hype", "Gilead Sciences (GILD) Misses Q4 Earnings Estimates", "Avalon GloboCare Stock Is an Expensive Mystery", "Nasdaq 100 Movers: AMD, PCAR", "The Biggest Biotech Binary Event in 2019 Is Just Around the Corner", "Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for", "iShares U.S. Healthcare ETF Experiences Big Inflow", "Does Johnson & Johnson's Grim Outlook Spell Trouble for Big Pharma Stocks?", "3 Upcoming Readouts for Gilead Sciences You Don't Want to Miss", "Gilead Sciences (GILD) Gains But Lags Market: What You Should Know", "3 Top Healthcare Stocks to Buy in January", "7 Stupidly Cheap Stocks to Buy Now", "After Hours Most Active for Jan 22, 2019 : GRPN, QQQ, INTC, XEL, GILD, AMD", "Better Buy: Biogen vs. Gilead Sciences", "Notable Friday Option Activity: WYNN, GS, GILD", "Why Gilead Sciences Stock Sank by 12.7% in 2018", "Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon", "Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know", "Will Dividend Stocks be the Hot Stocks of 2019?", "Here's Why Verastem Tumbled 34.1% in December", "Value Added: 7 Top Stocks for 2019", "Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus", "7 Things to Expect for Gilead Sciences in 2019", "Japan Okays Approves Gilead Sciences' Epclusa", "Why Agenus Stock Is Spiking Today", "1 Chart That Shows Why Celgene Has Been Bought Out and Gilead Hasn't (Yet)", "Gilead (GILD) Collaborates With Yuhan for NASH Candidates", "Gilead Sciences (GILD) Gains But Lags Market: What You Should Know", "After Hours Most Active for Jan 7, 2019 : CMCSA, ABEV, BAC, AMAT, GILD, FDC, MSFT, CTL, SYMC, QQQ, EXC, EMR", "2019 J.P. Morgan Healthcare Conference Roundup", "Better Buy: Gilead Sciences vs. Amgen", "Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?", "Gilead Sciences To Present At J.P. Morgan Conference; Webcast At 12:30 PM ET", "3 Pharma Stocks Revving for Growth", "Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know", "Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018", "3 Biotech Stocks That Are Too Cheap to Ignore", "Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal", "Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III", "Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder", "3 Biopharma Stocks to Buy for Their Robust Dividend Yields", "2 Beaten-Down Biotech Stocks That Look Like Bargains Now", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead", "Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer", "Why Agenus Stock Is Soaring Today", "Wall Street Sees Cautiously Higher Open After Fed Move", "US Futures Inch Higher After Fed Move", "Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija", "3 Top Healthcare Stocks to Buy in December", "Gilead Partners with Scholar Rock for Fibrotic Disease Drugs", "Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint", "Forget bluebird bio, Amgen Is a Better Biotech Stock", "Gilead Sciences, Scholar Collaborate On Novel Therapies For Fibrotic Diseases", "Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer", "What Happened With CAR-T Stocks in 2018", "Bristol-Myers to Sell French Consumer Health Unit for $1.6B", "3 Biotechs With Potential Blockbusters Near the Finish Line", "Evofem Shares Up as Birth Control Gel Succeeds in Phase III", "Why Dova Pharmaceuticals Is Nosediving Today", "Gilead Sciences (GILD) Stock Moves -0.69%: What You Should Know", "Validea's Top Five Healthcare Stocks Based On Benjamin Graham - 12/16/2018", "2 Sets of Disasters Biotech Will Pay For in 2019", "3 Biotechs Gilead Sciences Could Buy in March", "Bristol-Myers' Label Expansion of Sprycel Gets CHMP Nod", "AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals", "The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis", "Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals", "Gilead Sciences a Top Socially Responsible Dividend Stock With 3.4% Yield (GILD)", "Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for December 13, 2018", "Notable Wednesday Option Activity: NDSN, GILD, TLRD", "Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus", "Ex-Dividend Reminder: New Jersey Resources, Conmed and Gilead Sciences", "4 Biotech Stocks Investors Can Add to Their Portfolio in 2019", "Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO", "Roche's Tecentriq Gets FDA Approval for First-Line NSCLC", "Don\u2019t Punish Gilead Stock for Doing Its Job", "Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know", "Why CRSP Stock Has Added Layers of Risk", "The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen", "Ex-Dividend Reminder: New Jersey Resources, Conmed and Gilead Sciences", "4 Biotech Stocks Investors Can Add to Their Portfolio in 2019", "Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO", "Roche's Tecentriq Gets FDA Approval for First-Line NSCLC", "Don\u2019t Punish Gilead Stock for Doing Its Job", "Shire's Takhzyro Gets European Nod for Hereditary Angioedema", "FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate", "Did Gilead Sciences Make an $11 Billion Blunder?", "VLUE, GM, MU, GILD: ETF Outflow Alert", "Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis", "How Google Is Helping Make Advances In Medical Technology", "Catalyst's Firdapse Receives FDA Approval for Rare Disease", "How The Parts Add Up: RNDV Targets $24", "Merck (MRK) Receives Approval for 2 HIV Medicines in EU", "Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know", "Novartis (NVS) Receives EC Approval for Neulasta Biosimilar", "Pfizer's Epilepsy Drug Lyrica Gets Pediatric Exclusivity", "Celgene & Bluebird's CAR T Therapy Study Completes Enrollment", "5 Biotech Stocks to Scoop Up for Big Dividends", "Eyenovia Initiates Phase III Study for Mydriasis Candidate", "Bayer's TRK Inhibitor Gets FDA Nod for Advanced Solid Tumors", "Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial", "Aileron Inks Collaboration Deal With Pfizer for Cancer Combo", "Bristol-Myers' Opdivo-Yervoy Combo Fails in Lung Cancer Trial", "Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth", "After Hours Most Active for Nov 26, 2018 : CTL, GE, QQQ, RF, TEVA, HAL, BAC, INTC, AAPL, GILD, XEL, STLD", "Better Buy: Gilead Sciences vs. Celgene", "Novartis Gets Approval for Gene Therapy Luxturna in Europe", "Biotech Stock Roundup: GILD's Drug Wins Nod in China, Arena Up On Licensing Deal", "Nasdaq 100 Movers: TSLA, ADSK", "Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate", "Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint", "Gilead's Vemlidy Gets Approval in China for HBV Infection", "Tesaro Stock Sinks in Aftermath of Sale Rumors", "Amgen's Blincyto Gets Positive CHMP Opinion for Line Extension", "Novartis (NVS) Gets FDA Nod for Label Expansion of Promacta", "Validea's Top Five Healthcare Stocks Based On Benjamin Graham - 11/18/2018", "IBB, GILD, CELG, ILMN: ETF Outflow Alert", "Should Value Investors Consider Gilead (GILD) Stock Now?", "Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes", "Acorda Down More Than 30% in the Past 3 Months: Here's Why", "Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for November 15, 2018", "Roche's Tecentriq Gets Priority Review for Breast Cancer", "Amarin's Vascepa Cuts Heart Risk in Outcomes Test, Stock Down", "Medicines Company (MDCO) Q3 Loss Widens, Inclisiran in Focus", "Bristol-Myers' Opdivo Receives Positive CHMP Opinion for RCC", "Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?", "Arena Pharmaceuticals (ARNA) Beats on Q3 Earnings and Sales", "Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat", "PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up", "Prothena (PRTA) Reports Narrower-Than-Expected Loss in Q3", "Validea Benjamin Graham Strategy Daily Upgrade Report - 11/8/2018", "Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction", "Cronos (CRON) to Report Q3 Earnings: What's in the Offing?", "Pacira (PCRX) Q3 Earnings and Revenues Surpass Estimates", "Why Gilead Sciences, Inc. Stock Broke Down in October", "Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down", "3 Top Biotech Stocks With P/Es Below 14", "Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates", "Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates", "bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for November 08, 2018", "Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock", "Acorda (ACOR) Q3 Earnings Top Estimates, Ampyra Sales View Up", "3 Big Stock Charts for Thursday: Walmart, Prologis and Incyte", "The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals", "Intercept (ICPT) Gains on Earnings and Revenue Beat in Q3", "Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag", "SPTM, TXN, GILD, LMT: Large Inflows Detected at ETF", "Radius Health (RDUS) Posts Narrower-Than-Expected Q3 Loss", "Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock", "Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal", "Better Buy: Celgene Corporation vs. Gilead Sciences", "Can the Strong Economy Save the Stock Market?", "7 Rising Healthcare Stocks to Consider", "Analysts See 18% Upside For The Holdings of JKF", "The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers (Revised)", "Nasdaq 100 Movers: EA, NFLX", "Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2", "AbbVie Takes Aim at Vertex Pharmaceuticals Incorporated", "Where Will Gilead Sciences, Inc. Be in 5 Years?", "Daily Dividend Report: MAC, COG, GILD, AGN, DUK", "Gilead (GILD) Beats on Q3 Earnings & Sales, Updates View", "Gilead Sciences' 3rd Quarter: Good News Gets Better, Bad News Gets Worse", "Gilead Sciences Stock Is Back to Base \u2014 Go Long", "Gilead Sciences (GILD) Gains As Market Dips: What You Should Know", "Vertex (VRTX) Q3 Earnings and Revenues Surpass Estimates", "Bristol-Myers (BMY) Beats on Q3 Earnings, Raises EPS View", "Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up", "New Batch of Q3 Earnings: AMZN, GOOGL, INTC & More", "Earnings Reaction History: Gilead Sciences Inc., 58.3% Follow-Through Indicator, 4.5% Sensitive", "After-Hours Earnings Report for October 25, 2018 : AMZN, GOOGL, INTC, GILD, SYK, FTV, DFS, DLR, RSG, CERN, FE, BMRN", "Investors Are Underestimating Gilead Sciences Stock", "Gilead Sciences Inc (GILD) Q3 2018 Earnings Conference Call Transcript", "3 Top Healthcare Stocks to Buy Right Now", "Noteworthy Wednesday Option Activity: GILD, WING, VEEV", "Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook", "The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers", "Why CASI Pharmaceuticals Inc. Is Rocketing Higher Today", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Will Gilead (GILD) HIV Sales Offset HCV Sales Decline in Q3?", "Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG", "3 Top Healthcare Stocks to Buy Right Now", "Noteworthy Wednesday Option Activity: GILD, WING, VEEV", "Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook", "Gilead Sciences Breaks Above 200-Day Moving Average - Bullish for GILD", "Can This Tiny Biotech Revolutionize a $35 Billion Market?", "Notable Tuesday Option Activity: GS, CMG, GILD", "2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better", "Can UnitedHealth Group and Johnson & Johnson Continue Their Winning Ways?", "Is Sangamo Therapeutics Inc. a Buy?", "Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know", "Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status", "The 5 Best Dividend Stocks to Buy, Hands Down", "Better Buy: Crispr Therapeutics AG vs. Editas", "Gilead Announces Positive Data From Ongoing Biktarvy Study", "Gilead Sciences (GILD) Stock Moves -0.24%: What You Should Know", "IBB, GILD, BIIB, CELG: Large Inflows Detected at ETF", "Notable ETF Outflow Detected - IBB, GILD, BIIB, CELG", "J&J's Phase III Data Shows Switch to its HIV Drug Beneficial", "Better Buy: Gilead Sciences, Inc. vs. Pfizer", "Noteworthy Thursday Option Activity: CBLK, GILD, AMTD", "7 Healthcare Stocks to Buy Right Now", "Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs", "Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors", "Merck Reports Positive Efficacy Data from Phase III HIV Study", "Notable ETF Outflow Detected - IBB, GILD, BIIB, CELG", "5 Reasons to Buy Gilead Stock Today", "Better Buy: Vertex Pharmaceuticals Incorporated vs. Galapagos NV", "Alexion (ALXN) to Acquire Biotech Syntimmune for $1.2 Billion", "Look Under The Hood: SPYV Has 11% Upside", "Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch", "IBB, BIIB, GILD, CELG: ETF Inflow Alert", "5 Top Healthcare Mutual Funds to Buy in October", "Gilead Sciences' Latest Tactic? Go Generic", "Gilead Sciences (GILD) Gains As Market Dips: What You Should Know", "Notable Wednesday Option Activity: ISRG, CELG, GILD", "Gilead Is Undercutting Its Own Drugs: Here's Why", "5 Biotech Stocks to Play the Sector\u2019s Next Big Trend: NASH", "Gilead (GILD) to Launch Generics for Leading HCV Treatments", "3 Ways to Unpack Some Hidden Treasure in Tesaro Stock", "Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars", "CHMP Reconfirms Negative Opinion for Sarepta's Exondys", "3 Top Biotech Stocks to Buy Right Now", "How Do Drugs Compete Against Each Other?", "FDA Confirms Positive Safety Profile of Acadia's Nuplazid", "Is iShares Nasdaq Biotechnology ETF a Buy?", "Molecular Templates Surges 50%, Inks Cancer Deal With Takeda", "The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences", "Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx", "Ultragenyx's Shares Surge More Than 80% in the Year So Far", "Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success", "Viking Therapeutics Liver Candidate Passes Test, Shares Soar", "Dr. Reddy's (RDY) Presence in Generics Market Remains Strong", "Is Gilead (GILD) a Suitable Stock for Value Investors Now?", "Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know", "Theravance, Mylan Report Positive Data on COPD Drug Yupelri", "Exelixis' Partner Ipsen Gets Approval for Cabometyx in Canada", "Is Galapagos NV a Buy Now?", "After Hours Most Active for Sep 18, 2018 : F, T, ABEV, SYMC, QQQ, MO, NLY, INTC, GILD, FE, FOXA, GRPN", "Viking Therapeutics and Madrigal Pharmaceuticals Are Racing to the Finish Line in NASH", "Should Value Investors Pick Gilead Sciences (GILD) Stock?", "Why Gilead Stock Is a Sleepy Giant Waiting to Break Out", "Validea's Top Five Healthcare Stocks Based On Benjamin Graham - 9/16/2018", "IBB, BIIB, GILD, CELG: Large Outflows Detected at ETF", "Agenus Receives Milestone Payment of $5 Million from Incyte", "A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis", "Gilead Inks Gene Editing Collaboration Deal for HBV Infection", "Company News For Sep 13, 2018", "Better Buy: Gilead Sciences, Inc. vs. Biogen", "What's Next for Gilead Sciences After Its Latest Clinical Success", "Here's Why Galapagos NV Is Skyrocketing 18.3% Today", "Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars", "Unity (UBX) Catches Eye: Stock Jumps 8.8%", "Merck's Antibacterial Drug Succeeds in Label Expansion Study", "Regeneron/Sanofi's sBLA for Praluent to be Reviewed by FDA", "3 Top Stocks for Investing in Pharma's Next $35 Billion Market", "Incyte, Foundation Medicine Partner for Companion Diagnostics", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for September 13, 2018", "Gilead Sciences Reports Market-Moving News", "Why Altria Group, Galapagos, and Laredo Petroleum Jumped Today", "Nasdaq 100 Movers: MXIM, GILD", "Endocyte Announces FDA's Acceptance of Trial Endpoint Change", "Ex-Dividend Reminder: El Paso Electric, DTE Energy and Gilead Sciences", "Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth", "The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE", "Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know", "Shire's ADHD Portfolio Remains Strong Amid Competition", "Inovio Initiates Dosing in Phase I/IIa Study on MERS Vaccine", "Gilead's Rheumatoid Arthritis Drug Successful in Phase III", "Noteworthy Friday Option Activity: UBNT, ROKU, GILD", "Arrowhead Stock Is Not Done Rallying After Its 38% Jump", "ProQR Up More Than 120% on Favorable Eye Disorder Study Data", "Puma Biotech Gets EU Nod for Breast Cancer Drug Nerlynx", "IBB, GILD, CELG, REGN: Large Outflows Detected at ETF", "3 Top Big Pharma Stocks to Buy Now", "bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy", "Top Research Reports for Abbott, Gilead & FedEx", "MannKind Stock Up on Licensing Deal With United Therapeutics", "Horizon Pharma Completes Enrollment in Eye Disease Study", "Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout", "Inovio (INO) Initiates Phase I Study on Hepatitis C Vaccine", "Is Now a Good Time to Buy Gilead Sciences?", "Alnylam's Shares Up as Onpattro Gets FDA and EU Approvals", "Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)", "Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint", "MannKind Stock Up on Licensing Deal With United Therapeutics", "Horizon Pharma Completes Enrollment in Eye Disease Study", "Vertex Inks Deal With Genomics to Make Serious Disease Drugs", "Bayer's (BAYRY) Jivi Gets FDA Approval to Treat Hemophilia A", "Alnylam Gets European Nod for First-Ever RNAi Therapeutic", "Merck (MRK) Receives FDA Approval for Two HIV Medicines", "Bristol-Myers' Sprycel Seeks Label Expansion in the U.S.", "AstraZeneca's Lupus Drug Misses Primary Endpoint in Study", "Ultragenyx to File NDA for LC-FAOD Candidate on Existing Data", "Gilead Sciences (GILD) Gains As Market Dips: What You Should Know", "Gilead Sciences (GILD) Gains As Market Dips: What You Should Know", "Affimed (AFMD) Surges on Collaboration Contract with Roche (revised)", "Bausch (BHC) Resubmits NDA for Duobrii for Plaque Psoriasis", "Affimed (AFMD) Surges On Collaboration Contract With Roche", "Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA", "5 Enticing Dividend Stocks Primed for Long-Term Growth", "Time to Take Some Profits in Sarepta Therapeutics Stock", "Amgen Files for Once-Weekly Regimen for Myeloma Drug Kyprolis", "Gilead's CAR-T Therapy Yescarta Gets Approval in Europe", "3 Top Healthcare Stocks to Buy This Week", "Ultragenyx's Rare Disease Drug Mepsevii Gets EU Approval", "Bayer's Blood Thinner Xarelto Fails in Line Extension Studies", "Play The Future of Gene Therapy With These 5 Biotech Stocks", "3 Top Healthcare Stocks to Buy Right Now", "Novartis' CAR-T Therapy Kymriah Gets Approval in Europe", "Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events", "Bausch (BHC) Gets FDA Approval for Altreno for Acne Vulgaris", "Why Is Gilead (GILD) Down 6.2% Since Last Earnings Report?", "Shire's Takhzyro Gets FDA Nod for Hereditary Angioedema", "Roche (RHHBY) Gets FDA Approval for Cobas EFGR Mutation Test", "3 Big Drug Stocks With Big Cash Stockpiles: Should You Spend Your Cash Buying Them?", "Notable ETF Outflow Detected - IBB, BIIB, GILD, CELG", "Novartis' CAR-T Therapy Kymriah Gets Approval in Europe", "Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events", "Bausch (BHC) Gets FDA Approval for Altreno for Acne Vulgaris", "Pacira (PCRX) Rides High on Robust Exparel Performance", "Allergan Falls on FDA's Rejection of Uterine Fibroids Drug", "Infinity Focuses on Developing IPI-549 for Solid Tumors", "AbbVie Posts Positive Data on Elagolix for Uterine Fibroids", "Exact Sciences Inks Cologuard Co-Promotion Deal With Pfizer", "4 Biotech Stocks Investors Can Bet on Post Solid Q2 Earnings", "Mallinckrodt's Stannsoporfin Gets Complete Response Letter", "The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed", "Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC", "8 Undervalued Biotech Stocks to Watch", "Alnylam Completes Enrollment in Phase III Givosiran Study", "Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin", "Time for Jackson Hole: Global Week Ahead", "Is Viking Therapeutics, Inc. a Buy?", "Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?", "Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?", "Regeneron, Teva Announce Positive Data on Osteoarthritis Drug", "Zacks Value Trader Highlights: Sony, Carrizo Oil & Gas, Intel, United Rentals and Gilead", "Bristol-Myers' Opdivo Gets FDA Nod for Small Cell Lung Cancer", "Notable Friday Option Activity: ADBE, FB, GILD", "Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study", "Lessons from a Legendary Value Investor", "Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children", "Should Gilead Be Worried About This New Monthly HIV Medication?", "GILD Makes Notable Cross Below Critical Moving Average", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 16, 2018", "Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study", "Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit", "Shire, Shionogi File NDA for Intuniv for Adults in Japan", "Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech", "Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic", "Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold", "Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales", "Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for August 16, 2018", "Biotech ETFs in Focus on String of Q2 Earnings Beat", "Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag", "PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y", "Is Crispr Therapeutics Stock Grossly Overvalued?", "Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well", "Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise", "Noteworthy Thursday Option Activity: PRGO, OXY, GILD", "GILD a Top 25 Dividend Giant With $5.23B Held By ETFs", "Inovio (INO) Q2 Loss Narrows, Revenues Surpass Estimates", "AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss", "Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2", "VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y", "Better Buy: Gilead Sciences, Inc. vs. Amgen Inc.", "Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus", "Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges", "Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates", "Radius (RDUS) Q2 Loss Narrower Than Expected, Tymlos Sales Up", "Alnylam's (ALNY) Q2 Loss Wider Than Expected, Sales Beat", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Q2 Scorecard & Research Reports for Gilead, American Tower & Others", "bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss", "Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates", "Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers", "3 Top Biotech Stocks to Buy in August", "Ultragenyx (RARE) Posts Narrower-than-Expected Loss in Q2", "Epizyme (EPZM) Q2 Loss Narrows, Shares Crash 24% on Setbacks", "5 Cheap PEG Stocks Suitable for GARP Investors", "Zoetis (ZTS) Beats on Q2 Earnings & Sales, Updates '18 View", "The 5 Best Dividend Stocks to Buy, Hands Down", "Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2", "Endocyte (ECYT) Posts Narrower-Than-Expected Loss in Q2", "Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM", "Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss", "Better Buy: Biogen Inc. vs. Gilead Sciences, Inc.", "Is Gilead Sciences' Sudden Change in Leadership a Good Thing?", "3 Cheap Big Pharma Dividend Stocks That You Can Buy Now and Hold for Years", "iShares Nasdaq Biotechnology ETF Experiences Big Inflow", "Forget Gilead Sciences' CEO Departure -- This Was the Biotech's Big News", "After Hours Most Active for Jul 27, 2018 : QQQ, WFC, CSCO, MS, DB, NOK, CZR, MO, KO, GILD, SOXX, SYMC", "Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit", "Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan", "AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up", "Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up", "Microsoft, H&R Block, Facebook, Qualcomm and Gilead highlighted as Zacks Bull and Bear of the Day", "Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit", "CEO Departure at Gilead Sciences Upstages Good Second-Quarter Results", "Daily Dividend Report: SCHW, MCK, CVX, CMCSA, GILD", "2 Reasons the Market Frowned After AbbVie's Blowout Q2 -- and 1 Reason It Should Be Excited", "Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug", "Facebook Misses 1st Time in 11 Quarters; Plus GILD, QCOM", "Gilead Sciences (GILD) Q2 Earnings and Revenues Surpass Estimates", "Notable Wednesday Option Activity: GRPN, GILD, SPWR", "After-Hours Earnings Report for July 25, 2018 : FB, V, PYPL, GILD, QCOM, SU, MDLZ, LVS, VRTX, F, NOW, ALGN", "Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?", "Is a Beat in Store for Keryx (KERX) This Earnings Season?", "Thursday's ETF with Unusual Volume: FBT", "Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug", "Facebook Misses 1st Time in 11 Quarters; Plus GILD, QCOM", "Gilead Sciences (GILD) Q2 Earnings and Revenues Surpass Estimates", "Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?", "Why I Finally Sold my Gilead Sciences Stock Position", "3 Key Things to Watch in Gilead Sciences' Q2 Earnings Report", "4 Biotech Bets to Watch as Industry Rebounds in a Month", "Is a Beat in Store for Alexion (ALXN) This Earnings Season?", "Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?", "Noteworthy ETF Outflows: IBB, BIIB, GILD, AMGN", "5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates", "J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod", "4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit?", "Validea's Top Five Healthcare Stocks Based On Benjamin Graham - 7/15/2018", "3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018", "3 Top Healthcare Stocks to Buy in July", "If You're Thinking About Buying Gilead Sciences Stock, Now's the Time to Do It", "Noteworthy ETF Inflows: IBB, GILD, AMGN, BIIB", "3 Huge Biotech Winners in 2018 (So Far)", "Gilead Sciences (GILD) Shares Cross 3% Yield Mark", "The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna", "Trade of the Day: Gilead Sciences (GILD)", "Is Invesco Zacks Multi-Asset Income ETF (CVY) a Hot ETF Right Now?", "3 Biotech Stocks With Big News Coming in NASH", "Bullish Two Hundred Day Moving Average Cross - GILD", "Biotech ETFs Surge on Biogen's Positive Drug Trial Result", "Why Biotech Stocks Rallied on Biogen's Alzheimer's Test", "Noteworthy Friday Option Activity: GILD, OMC, ADSK", "Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More", "IBB, GILD, AMGN, BIIB: Large Outflows Detected at ETF", "Is Gilead Sciences a Great Stock for Value Investors?", "Top Research Reports for Mastercard, Gilead & Goldman Sachs", "Novartis to Spin-Off Alcon as Separate Trading Company", "4 Biotech Stocks to Bet on in the Second Half of 2018", "Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod", "Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection", "After Hours Most Active for Jun 26, 2018 : PFE, F, QQQ, MSFT, FLNT, ON, BWP, TEVA, GILD, T, INTC, MDT", "IBB, GILD, BIIB, CELG: ETF Inflow Alert", "Health Care Sector Update for 06/25/2018: DRIO, SYBX, GILD", "Gilead's (GILD) CAR T Therapy Gets Positive CHMP Opinion", "Health Care Sector Update for 06/25/2018: DRIO,VLRX,GILD,SYBX", "Health Care Sector Update for 06/25/2018: VLRX,GILD,SYBX", "2 High-Flying Biotech Stocks With Even More Room to Grow", "CRISPR Science and Stocks: Knowing Enough to Invest", "3 Great Reasons to Buy Gilead Sciences", "Novartis Announces Positive Data on CAR-T Therapy, Kymriah", "Validea's Top Five Healthcare Stocks Based On Benjamin Graham - 6/17/2018", "We Did The Math QQXT Can Go To $58", "Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant", "NASH Space in Focus as Galmed (GLMD) Posts Positive Data", "Galmed (GLMD) Soars on Positive NASH Data on Aramchol", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for June 14, 2018", "Drug Stocks: The Next Hot Industry or Value Traps?", "Noteworthy Wednesday Option Activity: ANET, TPX, GILD", "1 Under-the-Radar Dividend Growth Stock to Buy Right Now", "After Hours Most Active for Jun 12, 2018 : CMCSA, F, EDR, MU, KNX, WMB, GE, MGM, AMAT, INTC, GILD, AGNC", "JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space", "Gilead Sciences a Top Socially Responsible Dividend Stock With 3.2% Yield (GILD)", "Should You Stick With Gilead Sciences?", "iShares Nasdaq Biotechnology ETF Experiences Big Inflow", "Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO", "2 Cheap Dividend Stocks You Can Buy Right Now", "Ex-Dividend Reminder: Chesapeake Utilities, Gilead Sciences and Owens & Minor", "After Hours Most Active for Jun 12, 2018 : CMCSA, F, EDR, MU, KNX, WMB, GE, MGM, AMAT, INTC, GILD, AGNC", "Has the Gilead Sciences Buy Argument Collapsed?", "Better Know Biotech: 2 Stocks You've Got to Know About", "Madrigal's NASH Study Data Encouraging, Stock Skyrockets", "5 Top Stocks to Buy in June", "Here's Why Madrigal Pharmaceuticals Is Skyrocketing Today", "Gilead Collaborates with Hookipa for HBV and HIV Therapies", "Gilead & Galapagos Announce Positive Data on Filgotinib", "2018 ASCO Conference Roundup", "Why Is Gilead Sciences (GILD) Down 7.2% Since Its Last Earnings Report?", "ASCO Conference Preview: Here's What Biotech Investors Need to Watch", "Read This Before You Buy Immuno-Oncology Stocks", "Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod", "3 Top Value Stocks to Buy Now", "Is GlaxoSmithKline plc Stock a Buy?", "Noteworthy ETF Outflows: XLV, GILD, TMO, CVS", "bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA", "We Did The Math MGV Can Go To $86", "Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval", "3 Biotechs on the FDA's Naughty List That Should Be on Investors' Buy Lists", "Should The FDA Be Shaming Drug Companies? Financial Advisors' Daily Digest", "XLV, MRK, AMGN, GILD: ETF Inflow Alert", "3 Healthcare Stocks That Are Undeniably Dirt Cheap Right Now", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 16, 2018", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for May 11, 2018", "Why Bristol-Myers Squibb Stock Crashed in April", "3 Stocks That Turned $10,000 Into $1 Million", "Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag", "The Zacks Analyst Blog Highlights: BP, Gilead, Enterprise Products and Colgate", "After Hours Most Active for May 7, 2018 : CMCSA, QQQ, GILD, MU, FNSR, CRZO", "3 High-Yield Stocks With Virtual Monopolies", "Celgene (CELG) Q1 Earnings & Sales Beat on Revlimid Strength", "5 Value Stocks to Book Gains Using Price-to-Book Ratio", "Is Gilead Sciences Stock Finally a Bargain?", "Notable Friday Option Activity: GILD, EXEL, RIG", "Gilead Sciences, Inc. Stock Will Recover\u2026 Eventually", "Did Gilead Sciences Make a Big Mistake?", "Company News for May 3, 2018", "Top Stock Reports for BP, Gilead, Enterprise Products & Colgate", "Earnings Season Is Keeping the Markets Wobbly", "5 Reasons You Shouldn't Worry About Gilead Sciences' Ugly Q1 Results", "Relative Strength Alert For Gilead Sciences", "Nasdaq 100 Movers: GILD, AAPL", "The Zacks Analyst Blog Highlights: Apple, Snap, Gilead and T-Mobile U.S.", "Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1", "Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV", "Thursday\u2019s Vital Data: Snap Inc (SNAP), Gilead Sciences, Inc. (GILD) and Weatherford International plc (WFT)", "Market Close Report: NASDAQ Composite index closes at 7,100.90 down -29.80 points", "Why Molson Coors, Gilead Sciences, and Yum China Holdings Slumped Today", "5 Top Stock Trades for Thursday Morning", "XLV, MRK, AMGN, GILD: Large Outflows Detected at ETF", "Gilead Sciences, Inc. (GILD) Q1 2018 Earnings Conference Call Transcript", "Gilead Sciences, Inc. Stock Declined After Earnings Miss", "Better Buy: Biogen Inc. vs. Gilead Sciences Inc.", "Gilead Sciences' First-Quarter Twist: Weak HIV Sales", "Market Close Report: NASDAQ Composite index closes at 7,100.90 down -29.80 points", "Why Molson Coors, Gilead Sciences, and Yum China Holdings Slumped Today", "Earnings Reaction History: Gilead Sciences Inc., 54.5% Follow-Through Indicator, 4.3% Sensitive", "Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings?", "What's in Store for ImmunoGen (IMGN) This Earnings Season?", "Will Agenus (AGEN) Disappoint Investors This Earnings Season?", "Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More", "Apple (AAPL) iPhone Sales Off the Mark, Shares Up; Also SNAP, GILD & TMUS", "Gilead (GILD) Shares Slip on Earnings Miss, Revenues Down Over 20%", "After-Hours Earnings Report for May 1, 2018 : AAPL, GILD, SU, MDLZ, APC, ALL, FISV, OKE, CXO, EIX, DVN, VRSK", "3 Things You Need to Know About AbbVie's Monster Q1 Earnings", "Health Care Sector Update for 04/27/2018: ACAD,GILD,HRC,SNY", "HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?", "Health Care Sector Update for 04/27/2018: SNY,GILD,HRC", "Gilead (GILD) 1st Quarter Earnings: What to Expect", "What to Expect With Gilead Sciences Inc.'s Q1 Earnings Results", "What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?", "What's in the Offing for Keryx (KERX) This Earnings Season?", "Better Buy: Celgene Corporation vs. Gilead Sciences", "An Eye On Biotech - Today's Editors' Picks", "Notable Thursday Option Activity: MAR, GILD, ABBV", "Interesting GILD Put And Call Options For July 20th", "Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid", "Is Bellicum Pharmaceuticals, Inc. a Buy?", "Is a Beat in Store for Vertex (VRTX) This Earnings Season?", "3 Bargain Stocks You Can Buy Right Now", "Your Guide to Investing in Zinc-Finger (ZFN) Gene Editing", "Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?", "Analysts Expect 14% Gains Ahead For SPYG", "Is a Beat in Store for Alexion (ALXN) This Earnings Season?", "Stocks Drop as 10-Year Yield Touches 3%", "Better Buy: Gilead Sciences, Inc. (GILD) vs. Pfizer (PFE)", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "The Zacks Analyst Blog Highlights: IBM, McDonald's, Gilead, Phillips 66 and Lam Research", "4 Beaten-Down Funds Set to Soar (with dividends up to 10.9%)", "Health Care Sector Update for 04/19/2018: NVS, DHR, ALGN, GILD, 4503.T", "Health Care Sector Update for 04/19/2018: AGN,SHPG,GILD,NVS,DHR", "Top Research Reports for IBM, McDonald's & Gilead", "See Which Of The Latest 13F Filers Holds Gilead Sciences", "Big Biotech ETF Can Bounce Back", "Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics", "Gilead (GILD) Presents Encouraging Data on NASH Therapies", "Validea's Top Five Healthcare Stocks Based On Benjamin Graham - 4/15/2018", "Bristol-Myers Collaborates With Harvard Fibrosis Network", "3 Top Healthcare Stocks to Buy in April", "IBB, GILD, BIIB, VRTX: ETF Outflow Alert", "Health Care Sector Update for 04/19/2018: GILD,NVS,DHR", "Why One Drug Flop Tanked Incyte's Stock", "This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous", "Is Gilead Sciences, Inc. (GILD) a Buy?", "Biotech Fire Sale: 2 Top Stocks to Buy Next Week", "4 Top Stocks for Investing in Pharma's Next $35 Billion Market", "Is Cellectis SA Stock a Buy Now?", "Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?", "Alexion (ALXN) to Acquire Wilson Therapeutics for $855M", "Which Big Pharma CEOs Least Deserved Their Big Pay Increases?", "The Zacks Analyst Blog Highlights: United Technologies, Medtronic, Gilead, Hewlett Packard and Yum! Brands", "Top Stock Reports for United Technologies, Medtronic & Gilead", "Better Buy: Celgene Corporation vs. Gilead Sciences", "Celgene Loses 17.8% in 3 Months: Time to Reshuffle Portfolio?", "Is Gilead Sciences a Beaten-Up Biotech Stock to Buy?", "5 Biotech Stocks With Amazing Pipelines", "Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale", "Which Big Pharma CEOs Least Deserved Their Big Pay Increases?", "The Zacks Analyst Blog Highlights: United Technologies, Medtronic, Gilead, Hewlett Packard and Yum! Brands", "Stemline Therapeutics Inc Stock Investors Are Betting, Not Investing", "Gilead Sciences (GILD) Shares Cross 3% Yield Mark", "Better Buy: Amgen Inc. vs. Gilead Sciences, Inc.", "Notable Two Hundred Day Moving Average Cross - GILD", "3 Blockbuster Drug Launches to Watch In 2018", "Despite Struggles Celgene Corporation Stock Is Still A Buy", "Validea's Top Five Healthcare Stocks Based On David Dreman - 3/18/2018", "Gilead Sciences' $14 Billion-Per-Year Threat", "3 Revolutionary Cancer Treatments", "5 Must-See Quotes From AbbVie's Management", "3 Reasons CRISPR Stocks Could Keep Soaring", "Is Gilead Sciences (GILD) a Great Stock for Value Investors?", "Why It's So Dang Hard to Value Biotech Deals", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for March 15, 2018", "Bull of the Day: Regeneron (REGN)", "Notable Wednesday Option Activity: DDD, GILD, HD", "Is Gilead Sciences Trying to Put Itself Out of Business?", "3 Biotech Stocks With Rising Earnings Estimates Post Q4", "The 1 Big Risk That Every Drugmaker Fears", "How Pricing Can Be Vital to a Drugmaker's Profitability", "IBB, AMGN, GILD, REGN: ETF Outflow Alert", "After Hours Most Active for Mar 12, 2018 : PFE, QCOM, F, CBS, BAC, QQQ, CELG, HST, SOHU, GE, CTSH, GILD", "Here's What Lifted Sangamo Therapeutics Inc. in February", "The Revolutionary New HIV Drug You've Probably Never Heard Of", "How Biopharmas Battle for Billions", "Gilead Sciences (GILD) Down 3.4% Since Earnings Report: Can It Rebound?", "2 Cheap Growth Stocks to Buy Right Now", "Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta", "How Drugmakers Approach Efficacy Is the Key to Success", "Gilead Announces Positive Data on New HIV Therapy Biktarvy", "Notable Tuesday Option Activity: GILD, LE, PYPL", "Here's Why Crispr Therapeutics AG Jumped Again in February", "Here\u2019s Why Gilead Sciences' Jump Into Gene Editing Is Important", "The Zacks Analyst Blog Highlights: Gilead, BNY Mellon, State Street, Alliant Energy and Dillard's", "Gilead Sciences' History Points to Future Success", "Intangibles Hold the Key to Valeant Pharmaceuticals Intl Inc Stock", "Noteworthy ETF Outflows: IWB, AMGN, GILD, UTX", "Biotech ETFs Head to Head: XBI vs. IBB.", "Health Care Sector Update for 02/28/2018: HTBX, SGYP, CODX, GILD", "Health Care Sector Update for 02/28/2018: GILD,SGYP,CPH.TO,HTBX,CODX", "Top Analyst Reports for Gilead, BNY Mellon & State Street", "Biotech Stock Round Up: Celgene Suffers Setback, Gilead Teams Up with Sangamo", "SPDR Portfolio S&P 500 Growth ETF Experiences Big Inflow", "Gilead Sciences: The Oncology Company?", "Apple's Cure for Soaring Costs? Tech-Savvy Healthcare Clinics", "Why Sangamo Therapeutics Rocketed Higher Today", "Health Care Sector Update for 02/22/2018: SGMO, GILD, CLVS, NVO, NVS, BKD", "5 Drugs That Are Critical for Gilead Sciences' Future", "Health Care Sector Update for 02/22/2018: CLVS,SGMO,GILD,BKD", "Health Care Sector Update for 02/22/2018: CLVS,SGMO,GILD,BKD", "Is AbbVie or Gilead Sciences Stock a Better Buy?", "Validea's Top Five Healthcare Stocks Based On Benjamin Graham - 2/18/2018", "How Gilead Sciences Is Betting Big on Gene Editing", "Why Sangamo Therapeutics Rocketed Higher Today", "Health Care Sector Update for 02/22/2018: SGMO, GILD, CLVS, NVO, NVS, BKD", "5 Drugs That Are Critical for Gilead Sciences' Future", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for February 15, 2018", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 14, 2018", "Intercept Starts OCA Trial for NASH Patients With Cirrhosis", "How Huge Is the Latest HIV Drug Approval for Gilead Sciences?", "How Celgene Hopes to Cash In on CAR-T", "Better Buy: Pfizer Inc. vs. GlaxoSmithKline plc", "3 ETFs to Watch on Biotech Earnings", "Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study", "Glaxo (GSK) Earnings and Revenues Surpass Estimates in Q4", "FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up", "Here's What Gilead Sciences Just Said About Its Future", "Is Gilead Sciences, Inc. Stock Still a Solid Value Play?", "Why Biotech Stocks Soared in Trump's First Year in Office", "Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre", "The Zacks Analyst Blog Highlights: Walt Disney, Chipotle, Snap and Gilead Sciences", "Gilead Sciences Inc. Delivers Deja Vu in the Fourth Quarter", "Daily Dividend Report: GILD, CTSH, ICE, APC, GLW", "5 Things Gilead Sciences' Management Just Said That You Need to Know", "Gilead (GILD) 4th Quarter Earnings: What to Expect", "Gilead Sciences Inc. (GILD) Q4 2017 Earnings Conference Call Transcript", "Why Crispr Therapeutics AG Stock Bolted Higher in January", "New Quarterly Earnings Results for DIS, CMG, SNAP and More", "Gilead (GILD) Posts Earnings Beat, Total Product Sales See YoY Decline", "Earnings Reaction History: Gilead Sciences Inc., 63.6% Follow-Through Indicator, 4.4% Sensitive", "After-Hours Earnings Report for February 6, 2018 : DIS, GILD, APC, PXD, CERN, MCHP, MKL, PAA, AKAM, UDR, JKHY, ATO", "Noteworthy Monday Option Activity: CMI, MU, GILD", "3 Headwinds in Q4 Earnings Results That Make Merck a Mediocre Stock", "What to Expect With Gilead Sciences' Q4 Results", "Gilead Sciences, Inc. (GILD) Shares Slide on Weak Outlook", "3 Top Biotherapeutics Stocks to Buy Now", "Will Gilead (GILD) Disappoint Investors in Q4 Earnings?", "Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February", "GILD Crosses Above Average Analyst Target", "3 Big Biotech Stocks With Major Catalysts on the Way", "Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?", "3 Top Biotherapeutics Stocks to Buy Now", "Will Gilead (GILD) Disappoint Investors in Q4 Earnings?", "Gilead Sciences, Take-Two Interactive Hit Buys After Vertex Breakout", "Monday Sector Leaders: Consumer Products, Healthcare", "3 Small Biotechs That Big Drugmakers Are Probably Drooling Over", "Is It Finally Safe to Buy Gilead Sciences Stock? 1 Analyst Thinks So", "Why This Biopharma 'Behemoth' Could Soon Become Acquisitive", "After Hours Most Active for Jan 30, 2018 : ETP, MSFT, ETE, FE, EPD, MRK, T, CSCO, INTC, QQQ, GILD, FB", "5 Biotech and Pharmaceutical Stocks Going Bonkers", "Notable Friday Option Activity: SBUX, GILD, ITW", "Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid", "Will 2018 Be Bellicum Pharmaceuticals, Inc.'s Best Year Yet?", "Celgene Reverses In Fourth Quarter As Otezla Sales Rebound", "Bluebird Up on Buyout Speculation After Celgene/Juno Deal", "Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion", "Don\u2019t Chase AbbVie Inc Stock After Its Huge Earnings Win", "Celgene's $9 Billion Buyout of Juno: Is It a Good Deal for Investors?", "3 Stocks the World's Best Investors Are Buying Right Now", "Noteworthy ETF Outflows: IWB, AMGN, GILD, ABT", "What to Expect From Amgen, Inc. in 2018", "Better Buy: GlaxoSmithKline plc vs. Eli Lilly", "Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.", "The Zacks Analyst Blog Highlights: Apple, JPMorgan, AbbVie, Gilead and Simon Property Group", "Analysts More Bullish On Celgene-Juno, But Sales Outlook Nags", "The Top 10 Value Stocks in the S&P 500", "Merck & Co., Inc. Stock Could Still Soar Another 10% From Here", "3 Top-Ranked Drug Stocks That Are Broker Favorites", "Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA", "No Reason To Rush Into Juno Therapeutics Inc Stock After This Big Pop", "3 Top-Ranked Drug Stocks that are Broker Favorites", "Healthcare: Is Celgene Going to Buy Juno Therapeutics?", "Gilead Collaborates with Pfizer for Yescarta Combo Study", "Juno Hits 52-Week High on Celgene's Rumored Buyout Interest", "Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense", "Why Juno Therapeutics Stock Is Soaring Today", "What's Juno Therapeutics Worth to Celgene?", "Is Celgene (CELG) Looking to Take Over Juno Therapeutics?", "Is Gilead Sciences, Inc. a Buy in 2018?", "Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News", "Top Research Reports for Apple, JPMorgan & AbbVie", "Noteworthy Tuesday Option Activity: GILD, WDC, BMY", "10 Value Stocks to Buy for 2018 and Beyond", "XLV, MRK, AMGN, GILD: ETF Outflow Alert", "2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better", "3 Reasons Dividend-Monster Pfizer Inc. Could Explode Higher", "Can Biotech Keep Last Year's Momentum Alive in 2018?", "Big Pharma CEOs Speak About Impact of Tax Reform on M&A", "Juno Therapeutics Stock Rockets On Report That Celgene Is In Buyout Talks", "Valeant Pharmaceuticals Intl Inc Stock Is Worth the Risk", "Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus", "3 Top Healthcare Stocks to Buy in January", "5 Ways Gilead Sciences Plans to Return to Growth", "Galapagos Reports Topline Data From Osteoarthritis Study", "Celgene to Acquire Impact Biomedicines to Boost Pipeline", "5 Biggest New Drugs of 2018 -- and How You Can Profit From Their Makers", "7 Must-See Numbers from AbbVie's J. P. Morgan Presentation", "Dynavax To Launch Hepatitis B Vaccine \u2014 Is An Acquisition Coming?", "Biotech: The Tide Is Turning", "Noteworthy Friday Option Activity: GILD, AVXS, UAA", "Why Juno Therapeutics Stock Cooled Off in December", "XLV, AMGN, GILD, LLY: Large Outflows Detected at ETF", "18 Reasons I Like Biotech Stocks in 2018", "Why This Is the Perfect Level to Buy Celgene Corporation Stock", "Why 2017 Was a Year to Remember for Gilead Sciences, Inc.", "Dynavax To Launch Hepatitis B Vaccine \u2014 Is An Acquisition Coming?", "Biotech: The Tide Is Turning", "Noteworthy Friday Option Activity: GILD, AVXS, UAA", "Why Juno Therapeutics Stock Cooled Off in December", "XLV, AMGN, GILD, LLY: Large Outflows Detected at ETF", "Intercept (ICPT) Stock Loses Sheen in 2017: What Lies Ahead?", "Celgene (CELG) in Troubled Waters in '17: What Does 2018 Hold?", "Generalists On Biotech Sidelines As Tax Reform Sweeps The U.S.", "3 Biotech and Pharma Stocks with FDA Catalysts this January", "4 Biotech Stocks Ready to Crush the Market in 2018", "Notable Wednesday Option Activity: RL, WBA, GILD", "Q&A: Vertex Chief Talks About Company's 'Transformational Year'", "Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb", "Gilead: Maybe 2018 Won't Be Its Year Either", "Why Gilead Sciences Stock Should Be Avoided in 2018", "5 of the Best-Performing Biotech Stocks of 2017", "Noteworthy ETF Outflows: XLV, GILD, LLY, BIIB", "4 Biotech Stocks Ready to Crush the Market in 2018", "3 Questions Keeping Juno Therapeutics' Investors Up at Night", "Why These Biotech Stocks Could Be Taken Over In 2018", "After Hours Most Active for Dec 18, 2017 : EPD, GM, INTC, BP, ETE, QQQ, LC, AAPL, MPLX, GILD, CMCSA, AKAM", "Why No Large-Cap Biotech Franchise Is Safe From Threats In 2018", "Interesting GILD Put And Call Options For August 2018", "3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2018", "Biotechs: Not So 'Darn Scary' After All", "Biotechs: Not So 'Darn Scary' After All - An SA Marketplace Roundtable", "3 Questions Keeping Juno Therapeutics' Investors Up at Night", "Notable Friday Option Activity: INTC, LMT, GILD", "Thursday\u2019s Vital Data: JD.com Inc(ADR) (JD), Time Warner Inc. (TWX) and Gilead Sciences, Inc. (GILD)", "3 Top Stocks That Are Cash Cows", "Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs", "Ex-Dividend Reminder: Conmed, Merck and Gilead Sciences", "Bluebird's Shares Jump on Strong Data for CAR-T Therapy", "ASH 2017: CAR-T Wallops Blood Cancer", "Juno Reports Additional Data on CAR-T Therapy, Shares Drop", "Jim Simons: Pioneer Quant Manager", "Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for December 14, 2017", "3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise", "Health Care Sector Update for 12/11/2017: VSTM, MRK, IONS, GILD, IMGN, JUNO, CELG, REGN, BIVV", "Gilead (GILD) Posts Updated Data on CAR-T Therapy Yescarta", "Novartis Reports Updated Results from Kymriah's JULIET Study", "What's Causing Juno Therapeutics Shares to Tumble 11.9% Today", "Is Gilead Sciences, Inc. a Buy?", "Is Now the Perfect Time to Buy Juno Therapeutics Stock?", "Company News For Dec 11, 2017", "Why Biotech Stocks May Wait A While Before Feeling The Love", "Gilead Sciences to Acquire Cell Design Labs for $567 Million", "Noteworthy Friday Option Activity: UAL, GILD, ABBV", "Notable Two Hundred Day Moving Average Cross - GILD", "Notable ETF Inflow Detected - VLUE, GILD, F, NSC", "Why Gilead Could Have 'Greatest' Ever In HIV Drug Launches", "Can Drug/Biotech M&A Rebound Next Year After Bleak 2017?", "You'll Be Stunned by How Many Cancer Immunotherapies Are Being Developed", "5 Top Biotech Stocks to Buy Now", "Gilead & 3 Other Drug Stocks in Focus this World AIDS Day", "Glaxo Begins Phase III Study on Injection to Prevent HIV", "10 Blockbuster Drugs of the Future for Big Pharma Stocks", "Better Buy: Ziopharm Oncology Inc. vs. Celldex Therapeutics, Inc.", "Morning Movers: Sears Soars on Earnings; Kroger Gains", "No. 1-Ranked Medical Stock Tests Support In New Base", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 12/6/2017", "Does Gilead's Kite Acquisition Offer A New Buying Opportunity?", "Gilead Sciences Stock Upgraded: This Is the Power of Free", "Notable ETF Inflow Detected - QUAL, BLK, MMC, GILD", "3 Dividend Stocks With Better Yields Than McDonald's", "How Will U.S. Tax Reform Impact Pharma/Biotech Industry?", "Health Care Sector Update for 11/28/2017: COOL,PZRX,PETX, MDT,GILD,PFE", "Glaxo, Pfizer's ViiV Healthcare Begins HIV Drug Combo Study", "5 Biotech and Pharma Stocks with FDA Catalysts this December", "Sphera Funds Management Ltd. Buys Cellcom Israel, Allergan PLC, Teva Pharmaceutical Industries, ...", "Hedge Funds Are Snapping Up These 3 \u2018Strong Buy\u2019 Stocks", "Biotech Poised for Growth: 3 Healthy Fund Choices", "J&J & Glaxo's Jucala Approval Puts Spotlight on HIV Space", "CAR-T Therapy Space 2017 Progress Report", "J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen", "The 1 Thing Missing From Gilead Sciences' 2018 Priority List", "Gilead (GILD) Down 7.9% Since Earnings Report: Can It Rebound?", "Sphera Funds Management Ltd. Buys Cellcom Israel, Allergan PLC, Teva Pharmaceutical Industries, ...", "Hedge Funds Are Snapping Up These 3 \u2018Strong Buy\u2019 Stocks", "Better Buy: Biogen Inc. vs. Gilead Sciences", "Celgene CAR-T Therapy Gets Breakthrough Therapy Designation", "Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3", "Summit Street Capital Management, LLC Buys Fluor Corp, Hawaiian Holdings Inc, Kulicke & ...", "Biotech Industry: Small Innovators Outflank Big Caps As Blockbuster Drug Patent Cliff Looms", "United Therapeutics PAH Drug's Exclusivity Period Extended", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for November 16, 2017", "Gilead Sciences Inc (GILD) President and CEO John F Milligan Sold $16 million of Shares", "GILD Makes Notable Cross Below Critical Moving Average", "Temasek Holdings (private) Ltd Buys Visa Inc, Virtu Financial Inc, Ctrip. ...", "Biotechs Sell Off In Droves \u2014 Are Investors Seeking Mergers?", "7 Life Science Stocks to Buy Today", "What Investors Need to Know About Investing in Low PE Stocks", "Hampstead Capital LLP Buys Merck Inc, American International Group Inc, Pioneer Natural ...", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for November 16, 2017", "Gilead Sciences Inc (GILD) President and CEO John F Milligan Sold $16 million of Shares", "GILD Makes Notable Cross Below Critical Moving Average", "Sphera Funds Management Ltd. Buys Cellcom Israel, Allergan PLC, Teva Pharmaceutical Industries, ...", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for November 09, 2017", "3 Stocks Changing the Future of Healthcare", "3 ETFs to Watch on Biotech Earnings", "3 Top Biotech Stocks for 2018", "Notable Friday Option Activity: ICPT, GILD, CLVS", "You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018", "5 Biotech and Pharma Stocks with Key FDA Catalysts this November", "Sharp Drop Celgene Corporation Stock May Have Just Created an Entry Point", "Notable Thursday Option Activity: VMC, GILD, MIC", "What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October?", "3 Things You'll Want to Closely Watch in CVS Health's Q3 Results", "How Blood-Disease Data Sent These 2 Biotech Stocks Flying", "Can Juno Therapeutics Outmaneuver Its CAR-T Competitors?", "See Which Of The Latest 13F Filers Holds Gilead Sciences", "The Zacks Analyst Blog Highlights: JPMorgan Chase, Gilead, ConocoPhillips, General Electric and Walgreens", "Ionis Down Big on Analyst Miss", "iShares Edge MSCI USA Value Factor ETF Experiences Big Inflow", "What's in the Cards for PFE, INCY and ACOR in Q3 Earnings?", "Why Juno Therapeutics Shares Are Going Up 21.2% Today", "How Blood-Disease Data Sent These 2 Biotech Stocks Flying", "How Celgene, Gilead's Pricing Woes Continue To Haunt Biotech Stocks", "Top Research Reports for JPMorgan Chase, Gilead & ConocoPhillips", "Gilead Sciences, Inc. (GILD) Stock Isn\u2019t Worth It Here", "5 Things You Need to Know From Gilead Sciences' Q3 Update", "3 ETFs to Watch on Biotech Earnings", "Validea Benjamin Graham Strategy Daily Upgrade Report - 10/28/2017", "Nasdaq 100 Movers: JBHT, SHPG", "Dow Stock Merck, AbbVie Top Earnings Views, Light On Sales", "3 Stocks to Watch on Friday: Baidu Inc (ADR) (BIDU), Gilead Sciences, Inc. (GILD) and Mattel, Inc. (MAT)", "Daily Dividend Report: SPG, PFG, GILD, AGN, ITW", "Gilead Sciences, Inc. Stock Is a Buy When It Seems Like It Shouldn\u2019t Be", "Gilead Sciences, Inc. Stock Looks Good Regardless of Quarterly Earnings Report", "Gilead Sciences Inc. Still Singing the HCV Blues in the 3rd Quarter", "Gilead (GILD) Q3 Earnings and Revenues Sink", "Gilead (GILD) Down on Weak HCV Sales Despite Q3 Earnings Beat", "Dow Stock Merck, AbbVie Top Earnings Views, Light On Sales", "5 Biotech Stocks That Are Getting Battered Too Hard for Comfort", "Earnings Reaction History: Gilead Sciences Inc., 66.7% Follow-Through Indicator, 4.8% Sensitive", "After-Hours Earnings Report for October 26, 2017 : MSFT, AMZN, GOOGL, INTC, GILD, BIDU, CB, SYK, WDC, FTV, CERN, EXPE", "Is a Beat in Store for Agenus (AGEN) This Earnings Season?", "Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season?", "Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod", "RSI Alert: Gilead Sciences Now Oversold", "Is a Beat in Store for Alexion (ALXN) This Earnings Season?", "Better Buy: Gilead Sciences, Inc. vs. Amgen", "3 Healthcare Value Stocks", "Why Agenus Inc. Stock Briefly Popped Today", "Is Gilead (GILD) Poised for a Beat This Earnings Season?", "Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider", "3 Gene Therapy Stocks That Could Make You Rich", "Noteworthy Wednesday Option Activity: GILD, WYN, ORLY", "Is a Beat in Store for Alexion (ALXN) This Earnings Season?", "Better Buy: Gilead Sciences, Inc. vs. Amgen", "3 Healthcare Value Stocks", "Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval", "Gilead Sciences Shows Rising Relative Price Performance; Still Shy Of Key Threshold", "Sellers Come Into Nasdaq As Apple Lags; Another IPO Soars", "iShares Edge MSCI USA Value Factor ETF Experiences Big Inflow", "3 Things You Should Expect in Gilead Sciences' Q3 Results", "IBD's No. 1 Group Under Pressure; These 6 Key Earnings Loom; S&P 500 Futures", "What's in Store for BioMarin (BMRN) This Earnings Season?", "Celgene Could Be the Best CAR-T Stock to Buy, Not Gilead Sciences", "Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval", "S&P 500 Futures: These 5 Top Stocks Are Big Overnight Movers", "Top Stock Reports for IBM, Celgene and Procter & Gamble", "Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen", "Nasdaq 100 Movers: CTRP, ADBE", "Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics", "IBD Biotech Innovator Awards", "Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field", "Notable Monday Option Activity: TGTX, GILD, RT", "Trump Likely To Sign Executive Order On Drug Pricing 'Any Day'", "Exane Asset Management Buys AT&T Inc, Verizon Communications Inc, CNH Industrial NV, Sells ...", "It\u2019s Time to Start Buying Beaten-Up Gilead Sciences, Inc. (GILD) Stock", "Where to Find Value in Healthcare Stocks", "Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy", "3 Healthcare Value Stocks", "Why These Biotech Players Look Poised To Crush Earnings Views", "ANTIPODES PARTNERS Ltd Buys KT Corp, Michael Kors Holdings, Oracle Corp, Sells Dynegy Inc, ...", "This No. 1-Ranked Medical Stock Is Breaking Out With Q3 Earnings Due", "Non-Alcoholic Steatohepatitis 2017 Progress Update", "5 Game-Changing Cancer Drug Innovations Being Developed Right Now", "Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study", "Going Long Pfizer Inc. (PFE) Stock Is an Easy Pill to Swallow", "$50,000 Per Year in Prescription Drugs? You Likely Know Someone Who Used at Least That Much", "Horan Capital Management Buys TJX Inc, Chipotle Mexican Grill Inc, Nike Inc, Sells Berkshire ...", "Healthcare: Are These the Best Dividend Stocks to Buy Now?", "Bitcoin vs. Biotech: Which Is the Smarter Investment?", "AbbVie's Fast Becoming a Top Stock to Buy Now", "This Dirt-Cheap Biotech Stock Is a Bargain to Buy", "Is AbbVie the Best Dividend Stock in Healthcare?", "Intercept Dives Along With Ocaliva Prescriptions On FDA Warning", "5 Stocks the Bull Market Left Behind", "Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now?", "Here's What's Has Happened in the HCV Space Lately", "5 Undervalued Stocks With Free Cash Flow to Burn", "FXH, ALNY, ALGN, GILD: Large Inflows Detected at ETF", "Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation", "Here's Why Juno Therapeutics Stock May Still Be Worth Buying", "Intercept Dives Along With Ocaliva Prescriptions On FDA Warning", "5 Stocks the Bull Market Left Behind", "Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now?", "Good News and Bad News for Gilead Sciences: Which Carries More Weight?", "Here's Why Bluebird Bio (BLUE) Stock Is Falling Today", "Better Buy: Gilead Sciences, Inc. vs. Pfizer", "Merck Drops Two HCV Combination Programs Amid Competition", "5 ETF Picks for October", "Best Buy: Johnson & Johnson, Pfizer, or Gilead Sciences?", "Keep Riding the GoPro Inc (GPRO) Stock Wave!", "Go Long Costco Wholesale Corporation (COST) Stock for Big-Time Gains", "Gilead Sciences, Inc. (GILD) Stock Got Its Mojo Back", "How Will Trump\u2019s Proposed Tax Reform Impact Drug Companies?", "Novartis Could Acquire This Biotech \u2014 Why A Deal Is 'Very Logical'", "Gilead (GILD) Gets Approval for HCV Drug Sovaldi in China", "4 Biotech Stocks (and 1 ETF) to Buy As They Bolt Higher", "Why Gilead Sciences, Pier 1 Imports, and PetMed Express Slumped Today", "Market Close Report: NASDAQ Composite index closes at 6,453.45 up .19 points", "Gilead Tumbles On Report HIV-Drug Whistleblower Case Reopened", "Noteworthy Thursday Option Activity: GILD, BMY, XOM", "Indexes Mixed, Apple And Gilead Down; Here Is The Threat To Autohome Stock", "Biotechs Beating The Market, But Are They In Buy Range?", "Biotech Stocks To Watch And Pharma Industry News", "Vertex Pharmaceuticals: The Gilead Sciences of Cystic Fibrosis?", "If Familiarity Breeds Contempt, What Do Debt And Complacency Breed?", "Noteworthy ETF Outflows: FTA, GPS, GILD, LEA", "Kite Pharma Triples So Far in 2017: What's Driving the Rally?", "Biotech Stock Roundup: Amgen Reiterates 2017 Outlook, Intercept Hit by Ocaliva Safety Issues", "FDA Chief Gottlieb Addresses Opioids, Cancer, New Therapies", "3 Sector-Specific Trades to Start the Week Off Right", "First Week of May 2018 Options Trading For Gilead Sciences (GILD)", "Intercept (ICPT) Provides Safety Guidelines For Ocaliva", "3 Big Biotech Stocks to Buy This Fall", "Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy?", "Oddly, Juno Therapeutics Is Jumping 11.3% Today", "Gilead's (GILD) Epclusa Receives Label Expansion in Canada", "Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade", "3 Biotech Stocks With Major Catalysts Incoming", "4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid", "Why Is Cash-Rich Gilead Sciences, Inc. Borrowing $3 Billion?", "3 Big Biotech Stocks to Buy This Fall", "Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy?", "3 Biotech Stocks That Are Just Getting Started", "Notable ETF Inflow Detected - MOAT, GILD, GWRE, VFC", "3 Value Stocks for Smart Investors", "Why Bellicum Pharmaceuticals Stock Is Rising Today", "3 Great Income Stocks That Could Double Their Dividends", "Should Value Investors Consider Gilead Sciences (GILD) Stock?", "3 Reasons Why Gilead Sciences Stock Is a Buy Now", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 9/15/2017", "3 Dividend Healthcare Stocks", "CAR-T Therapy FDA Approved - Slingshot Insights' Idea Of The Month", "Nasdaq 100 Movers: HSIC, CTRP", "Options Traders Expect Huge Moves in Gilead Sciences (GILD) Stock", "4 Biotech Stocks That Show Promise on Sustainable Growth", "After Gilead Sciences, More Biotech M&A?", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for September 14, 2017", "3 Biotech Stocks That Have Already Quadrupled in 2017", "Is the Sell-Off of Intercept Pharmaceuticals Stock Overblown?", "Gilead Sciences, Inc.'s Best Investment of 2017 (Hint: It Wasn't Kite Pharmaceuticals)", "Ex-Dividend Reminder: Gilead Sciences, Hill-Rom Holdings and Owens & Minor", "The Zacks Analyst Blog Highlights: Gilead, Oracle, Morgan Stanley, Expedia and Kroger", "3 Stocks for Future Millionaires", "3 Pharma/Biotech Sector Bargains for a Healthy Portfolio", "5 Tough Questions for Gilead Sciences About the Kite Pharma Acquisition", "Top Stock Reports for Gilead, Oracle & Morgan Stanley", "The Move in SPDR S&P Biotech (ETF) (XBI) ETF Is Coming \u2014 Get on Board", "Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors", "CAR-T Mania: Could Juno Therapeutics Get Acquired Next?", "Noteworthy ETF Outflows: ITOT, GILD, SLB, CVS", "GILD Crosses Above Average Analyst Target", "5 Top-Ranked Biotech Stocks to Buy Right Now", "After Hours Most Active for Sep 8, 2017 : KNX, AAPL, IUSG, IUSV, QQQ, VIPS, ITUB, CHK, GILD, JBLU, T, XOM", "4 Biotech Stocks to Improve Your Portfolio\u2019s Health", "5 Things You'll Want to Know From Celgene Corporation's Latest Presentation", "5 Things Gilead Sciences' Management Just Said That You'll Want to Know", "Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus", "Are These Healthcare Stocks Top Takeover Targets?", "Are You Buying Gilead Sciences, Inc. for the Wrong Reason?", "Top Ranked Income Stocks to Buy for September 8th", "After Hours Most Active for Sep 8, 2017 : KNX, AAPL, IUSG, IUSV, QQQ, VIPS, ITUB, CHK, GILD, JBLU, T, XOM", "Why Kite Pharma Soared 64.8% in August", "The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Activision Blizzard, Intuit, Alexion Pharmaceuticals and Gilead Sciences", "Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better", "Biotech Stocks Back in Favor: Will the Rally Continue?", "Why Juno Therapeutics Shares Vaulted 46% Higher in August", "Buy These 5 Large Caps on Extraordinary ROI Potential", "Mallinckrodt Down as District Court Invalidates Inomax Patents", "Here's What Lifted bluebird bio Inc. Stock 40% Higher in August", "Here's the Best Dividend Stock in Big Pharma", "Why Gilead Sciences Shares Soared 10.6% in August", "3 Biotech Stocks That Skyrocketed This Week", "Gilead Buys Kite, the Future of CAR-T, and A Visit to the New Whole Foods", "Friday\u2019s Vital Data: Apple Inc. (AAPL), Advanced Micro Devices, Inc. (AMD) and Gilead Sciences, Inc. (GILD)", "4 Biotech Stocks to Improve Your Portfolio's Health", "5 Winning Stocks to Beat September Blues", "Valeant (VRX) Continues to Lose Ground: Can It Bounce Back?", "Gilead Sciences\u2019 Oncology M&A Strategy Explained", "You Reached Retirement: 3 Stocks to Consider Today", "Wonder Why Gilead Sciences Bought Kite Pharma? Here\u2019s the Answer!", "Thursday's ETF with Unusual Volume: BBH", "Novartis (NVS) CAR-T Therapy Kymriah Receives FDA Approval", "3 Reasons Gilead Sciences Jumped to Buy Kite Pharma", "5 Winning Stocks to Beat September Blues", "Valeant (VRX) Continues to Lose Ground: Can It Bounce Back?", "Gilead Sciences\u2019 Oncology M&A Strategy Explained", "You Reached Retirement: 3 Stocks to Consider Today", "Could Gilead Sciences Stock Skyrocket 25%? 1 Analyst Thinks So", "Wednesday's ETF with Unusual Volume: PKW", "Zacks.com featured highlights Broadcom, CBRE Group, Sandvik, Applied Materials and Gilead Sciences", "Stock Market News For August 31, 2017", "Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences", "Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update", "After Hours Most Active for Aug 31, 2017 : DOW, DD, SBAC, BAC, QQQ, MSFT, TEVA, PFE, GE, AMAT, GILD, INTC", "Why bluebird bio Inc Continued Its March Higher Again Today", "5 Biotech Stocks That Are Breaking Higher", "Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap", "Amgen Presents New Repatha Analysis from FOURIER Study", "Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal", "The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG", "Can Gilead Sciences Squeeze $12 Billion From Kite Pharma?", "5 Top ROE Stocks to Buy as Hurricane Harvey Wreaks Havoc", "Here's What Else Gilead Sciences Gets by Buying Kite Pharma", "Indecision Won't Kill You, But It Will Take Your Money", "Get Ready for More Acquisitions by Gilead Sciences", "Gilead to Fly High with Kite Pharma Acquisition for $11.9B", "Gilead Sciences, Inc. (GILD) Stock Still Has Room to Grow", "Company News For August 29, 2017", "Midday Update: Sectors Split As Hurricane Harvey's Impact Spreads Through Wall Street", "Gilead Sciences to Buy Kite Pharma for $11.9 Billion: Is It Enough to Move the Needle?", "3 Reasons to Applaud Gilead Sciences' Acquisition of Kite Pharma", "Stock Futures Perk Up Despite Potential Economic Damage From Hurricane", "Health Care Sector Update for 08/28/2017: JNJ, PFE, ABT, MRK, AMGN, KITE, GILD, AVEO, NVS", "Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition", "Pre-Market Most Active for Aug 28, 2017 : KITE, WFM, GILD, JUNO, TVIX, MYCC, QQQ, FCAU, BHP, Q, DB, BABA", "Roche's Gazyva Gets Priority Review for Follicular Lymphoma", "AstraZeneca's Faslodex Gets FDA Nod in First-Line Setting", "Close Update: Shares Mixed As Hurricane Batters Energy Sector, Underpins Construction, Home Improvement Stocks", "Novartis Announces Positive Data on Cardiovascular Drug", "Why Thor Industries, IXYS Corporation, and Kite Pharma Jumped Today", "Mid-Afternoon Market Update: IXYS Surges On Acquisition News; Uni-Pixel Shares Plunge", "Morning Movers: Gilead Jumps on Kite Acquisition; Expedia Drops as CEO Leaves for Uber", "Why Did Kite Pharma (KITE) Stock Skyrocket Today?", "Gilead's Plan? Cash In on CAR-T", "Why I Love AbbVie Inc.", "Novartis (NVS) Receives EC Approval for Breast Cancer Drug", "Will Endo (ENDP) Continue to Disappoint Investors in 2017?", "Why I'm Hanging On to a Loser", "Roche (RHHBY) Hemophilia A Drug Granted Priority Review", "Why bluebird bio Inc and Juno Therapeutics Inc Shot Higher Today", "Pfizer's Ibrance in First-Line Combo Breast Cancer Study", "Are Glaxo's Successful New Drugs Enough to Drive Growth?", "3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences", "Noteworthy ETF Outflows: FXH, ALGN, CNC, GILD", "Alkermes Initiates Rolling Submission of Depression Drug", "4 Biotech Stocks to Add to your Portfolio Post Q2 Earnings", "Alexion's (ALXN) Soliris' Label Expansion Approved in Europe", "Top Ranked Income Stocks to Buy for August 24th", "Monday's ETF with Unusual Volume: BBH", "AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada", "Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada", "Pfizer's (PFE) Besponsa Gets FDA Nod with a Boxed Warning", "Mylan Finalizes Settlement Agreement with DOJ for $465M", "Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?", "3 Value Stocks for Retirees", "3 Value Stocks for Smart Investors", "Sterneck Capital Management, LLC Buys CorEnergy Infrastructure Trust Inc, Chicago Bridge & ...", "Biotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Review", "Regeneron's (REGN) RSV Drug Suptavumab Fails NURSERY Trial", "Chiron Investment Management, LLC Buys iShares iBoxx $ Investment Grade Corporate Bond, Gilead ...", "Zacks.com featured highlights: Coca-Cola FEMSA, Banco Bilbao Vizcaya Argentaria, Lantheus Holdings, Gilead Sciences and Lam Research", "Mallinckrodt (MNK) Looks Strong on Acthar, Generics Weak", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for August 16, 2017", "Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)", "Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review", "3 Healthcare Stocks That Are Looking Cheap Right Now", "5 Discounted PEG Stocks for GARP Investors", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 15, 2017", "Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?", "iShares Edge MSCI USA Value Factor ETF Experiences Big Inflow", "Forget Teva (TEVA), Buy These 4 Drug Stocks Instead", "Zacks.com featured highlights: Broadcom Limited, CBRE Group, Sandvik AB, Applied Materials and Gilead Sciences", "Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review", "3 Healthcare Stocks That Are Looking Cheap Right Now", "5 Discounted PEG Stocks for GARP Investors", "After Hours Most Active for Aug 9, 2017 : VG, ABEV, GGB, T, COR, QQQ, BRCD, MOMO, ODP, ADP, NEE, GILD", "Validea David Dreman Strategy Daily Upgrade Report - 8/9/2017", "Valeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View", "Mylan (MYL) Misses on Q2 Earnings & Sales, Lowers View", "Markets Remain Choppy on Continuing Conflicts: 5 Top Picks", "Pioneer Investments Buys Citigroup, Berkshire, Gilead", "Mallinckrodt (MNK) Tops Q2 Earnings, Generics Segment Weak", "Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More", "These 3 Biotechs Just Crushed Analyst Expectations", "Top Ranked Momentum Stocks to Buy for August 7th", "10 Reasons Cancer Drugs Usually Cost $100,000 or More a Year", "Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?", "Forget Bayer, Buy These 3 Drug Stocks Instead", "Infinity (INFI) Q2 Loss Wider than Expected, View Intact", "Radius (RDUS) Q2 Loss Wider than Expected on Higher Expenses", "Domini Social Investments LLC Buys First Solar Inc, SunPower Corp, Sells Sunrun Inc, Fitbit Inc", "ITOT, MDT, GILD, SLB: Large Inflows Detected at ETF", "Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock? 3 Pros, 3 Cons", "Regeneron (REGN) Beats on Q2 Earnings & Sales, Raises View", "3 \u201cStrong Buy\u201d High-Yield Dividend Stocks", "Celgene vs. Gilead Sciences: Who Reported Better Earnings?", "Top Ranked Income Stocks to Buy for August 2nd", "Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote", "3 ETFs to Watch Out for on Biotech Earnings", "Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2", "Gilead Sciences a Top 25 Dividend Giant With 2.74% Yield (GILD)", "General American Investors Co Inc Buys Oracle Corp, NOW Inc, eBay Inc, Sells Imax Corp, ...", "5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You", "Aerie (AERI) Reports Narrower-Than-Expected Loss in Q2", "4 Drug Stocks in Focus this World Hepatitis Day", "Gilead Sciences, Inc. (GILD) Stock Has Tremendous Potential Even Post-Rally", "Whoops! Twitter Inc (TWTR) Stock Tanks as User Growth Vanishes", "Score Hot Profits on a Netflix, Inc. (NFLX) Stock Cooldown", "3 Stocks to Watch on Thursday: Buffalo Wild Wings (BWLD), Gilead Sciences, Inc. (GILD) and PayPal Holdings Inc (PYPL)", "Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up", "Validea Benjamin Graham Strategy Daily Upgrade Report - 7/27/2017", "United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top", "VOO, MDT, GILD, BMY: Large Outflows Detected at ETF", "Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug", "Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense", "Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales", "Gilead (GILD) Shares Pop on Q2 Earnings and Revenue Beats", "Earnings Reaction History: Gilead Sciences Inc., 72.7% Follow-Through Indicator, 5.1% Sensitive", "After-Hours Earnings Report for July 26, 2017 : FB, GILD, PYPL, SU, LVS, VRTX, PSA, LRCX, EW, DFS, ABX, NOW", "Daily Dividend Report: SU, MCK, SYF, CVX, CMCSA, GILD, UNP", "Will Radius Health (RDUS) Disappoint this Earnings Season?", "Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season?", "3 Dividend Stocks That Thrive in Bear Markets", "Gilead Sciences, Inc. (GILD) Stock Is a 2-for-1 Deal", "Is a Beat in Store for Agenus (AGEN) this Earnings Season?", "3 Things You Can Expect in Gilead Sciences' Q2 Update", "Better Buy: Celgene Corporation vs. Gilead Sciences, Inc.", "Can Intercept (ICPT) Beat Estimates this Earnings Season?", "What to Expect from Keryx (KERX) this Earnings Season?", "What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings?", "HCA Healthcare (HCA) Q2 Earnings: Will it Beat Estimates?", "Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?", "Warren Buffett's Net Worth Would Be $100 Billion Right Now if Not for This", "Better Buy: Valeant Pharmaceuticals International, Inc. vs. Gilead Sciences", "Is a Beat in the Cards for Vertex (VRTX) in Q2 Earnings?", "Better Buy: AbbVie Inc. vs. Johnson & Johnson", "Is a Beat in Store for Alexion (ALXN) this Earnings Season?", "Is Gilead (GILD) Poised for a Beat This Earnings Season?", "Health Care Sector Update for 07/20/2017: SBPH,GILD,SRPT,CFRX", "Exane Asset Management Buys Monsanto Co, Biogen Inc, Qiagen NV, Sells Citigroup Inc, W R Grace, ...", "Gilead's HCV Portfolio Receives a Boost With Vosevi Approval", "Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs", "Why Vertex Pharmaceuticals Incorporated Stock Is Soaring Today", "Notable Thursday Option Activity: GILD, GS, ATHN", "5 Big Pharma Stocks With the Best Drug Pipelines", "5 Ways Gilead Sciences Could Spend Its Cash Hoard", "Health Care Sector Update for 07/18/2017: GILD,CAPR,IMUC", "VLUE, WMT, GILD, NSC: ETF Outflow Alert", "These 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition", "Will the Drug Pricing Executive Order Help Big Pharma?", "Gilead (GILD) Application for HIV Drug Validated in EU", "Agree To Purchase Gilead Sciences At $40, Earn 2.5% Using Options", "Gilead (GILD) Application for HIV Drug Validated in EU", "The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire", "3 Dividend Stocks That Are Minting Money", "3 Value Stocks for Discriminating Investors", "5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings", "How Biogen Inc. Makes Most of Its Money", "5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates", "The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals", "Gilead (GILD) Application for HIV Drug Validated in EU", "The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire", "3 Dividend Stocks That Are Minting Money", "Top Stock Reports for Wells Fargo, Broadcom & Gilead", "How Shrewd of a Dealmaker Is Gilead Sciences? Just Look at Its Last 7 Acquisitions", "Will Gilead's Dividend Keep Climbing?", "What's Behind Gilead Sciences, Inc.'s 9.5% Rally in June", "Biotech Stock Roundup: Arena Shoots Up on Study Data, CELG Inks Immuno-Oncology Deal", "GILD Dividend Yield Pushes Past 3%", "Chevron Corporation (CVX) Is Stabilizing \u2014 Fill Up", "Bank on Gilead Sciences, Inc. (GILD) Stock Getting Its Mojo Back", "Galapagos-Gilead Begin Phase II Study on Uveitis Candidate", "3 Top High-Yield Pharmaceutical Stocks to Buy Now", "3 Reasons Why Gilead Sciences Shouldn't Buy Vertex Pharmaceuticals", "3 Charts That Show Why to Buy Gilead Sciences Stock Now", "3 Hot Biotech Stocks Ready for the Sector\u2019s Next Breakout", "3 Big Stock Charts for Thursday: Merck & Co., Inc. (MRK), Gilead Sciences, Inc. (GILD) and Valeant Pharmaceuticals Intl Inc (VRX)", "Trade of the Day: Gilead Sciences, Inc. (GILD)", "Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod", "Biotechs Soared In June; Japan, Small Caps Also Outperformed", "Notable ETF Inflow Detected - VHT, GILD, LLY, AGN", "FBT's Underlying Holdings Could Mean 11% Gain Potential", "Gilead's (GILD) HCV Drug Application Accepted in the EU", "Which Of These June Winners Show Strength Amid Market Weakness?", "3 Big Stock Charts for Thursday: Merck & Co., Inc. (MRK), Gilead Sciences, Inc. (GILD) and Valeant Pharmaceuticals Intl Inc (VRX)", "Trade of the Day: Gilead Sciences, Inc. (GILD)", "Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod", "Biotechs Soared In June; Japan, Small Caps Also Outperformed", "Nasdaq 100 Movers: CA, REGN", "Market Close Report: NASDAQ Composite index closes at 6,236.69 up 2.74 points", "Thursday Sector Leaders: Healthcare, Energy", "AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU", "2 Pharma Buyout Targets That May Surprise You", "How We Earn $5,300 In Dividends From A $10,000 Investment (VZ, PSX, GILD)", "2 Top Biotech Stocks to Buy on Sale", "ProShares UltraPro QQQ Experiences Big Inflow", "Why This Billionaire Just Bought Gilead Sciences, Synergy, and Valeant Stock", "Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada", "Why Tesaro Inc. Stock Briefly Dipped Today", "Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt", "How to Find the Best Value Stocks", "3 Beaten-Down Stocks Ready to Bounce Back", "Will These Cutting-Edge Cancer Killers Reignite The Biotech Rally?", "3 Stocks With Better Dividends Than CVS Health Corporation", "Epizyme Provides Positive Interim Data on EZH2 Inhibitor", "Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug", "Notable Monday Option Activity: AMG, TRIP, GILD", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for June 14, 2017", "3 Dividend Stocks to Buy on Sale", "Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen", "Notable Monday Option Activity: GE, GILD, ADBE", "Noteworthy ETF Outflows: OEF, BA, GILD, USB", "Ex-Dividend Reminder: Analogic, Gilead Sciences and Hill-Rom Holdings", "3 Beaten-Up Biotech Stocks: Are They Bargains?", "New Data Shows TG Therapeutics Could Be Onto Something Big", "The 3 Best Value Stocks You Can Buy Right Now", "Gilead Sciences, Inc.: The Bear Case From a Bull", "Why GlaxoSmithKline Stock Had a Breakout May", "What Traders Can Learn From Professional Horse Betting", "The Best Hep C Drug Stock to Buy in 2017", "The Zacks Analyst Blog Highlights: Gilead, BP, Dow Chemical, America Movil and MetLife", "Spring Bank Pharmaceuticals' Hepatitis B Results in Context", "GILD Named A Top Socially Responsible Dividend Stock", "Why Gilead Sciences Stock Slumped in May", "3 Value Stocks Perfect for Retirement", "3 Stocks Baby Boomers Are Buying That Millennials Aren't", "3 Great Dividend Stocks to Buy That You Might Not Know Are Dividend Stocks", "3 Dividend Stocks for Daring Investors", "3 History-Making Stocks", "Notable ETF Inflow Detected - IVW, SBUX, QCOM, GILD", "Top Stock Reports for Gilead, BP & Dow Chemical", "Noteworthy Thursday Option Activity: TUP, RH, GILD", "Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose", "Gilead Single Tablet Regiment for HIV Good in Phase III", "Better Buy: Biogen Inc. vs. Gilead Sciences Inc.", "Intercept's (ICPT) Liver Drug Ocaliva Approved in Canada", "Meet the Cancer Therapy that Could Become the Second Best-Selling Drug in the World by Year's End", "7 Things You Didn't Know About Gilead Sciences, Inc.", "Why Is Gilead Sciences (GILD) Down 3.5% Since the Last Earnings Report?", "These Are the 10 Lowest P/E Stocks Today", "3 Value Stocks for Daring Investors", "Federal Reserve Reluctant to Let Go", "Is The Worst Behind Gilead Sciences?", "3 Reasons Gilead Sciences, Inc. Is a Better Dividend Stock Than Amgen, Inc.", "Inovio Pharmaceuticals Stock Soars on Encouraging HIV Vaccine Readout", "Valeant and Gilead: Beaten Down Bargains or Truly Terrible?", "1 Underdog Stock I'm Watching", "Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose", "Woodford Investment Management LLP Buys Gilead Sciences Inc, Bioverativ Inc, Biogen Inc, Sells ...", "Zacks Value Investor Highlights: Avis Budget Group, General Motors, Gilead Sciences, LGI Homes and Micron", "Gilead Sciences Enters Oversold Territory", "A Doomed Trump Presidency Would Be a Terrifying Development for Pharmaceutical Stocks", "Alcentra Capital: Selling Stock Or Selling Out?", "Value Stock or Value Trap?", "Investing Podcast Highlights: Tech Stocks, Trump, REITs, Retail Earnings, and More!", "VYM, BMY, GILD, QCOM: ETF Inflow Alert", "Want to Get in on Biotech? Check Out These 3 Stocks", "3 Best Dividend Stocks in Biotech", "Stocks That Fell to 3-Year Lows in the Week of May 12", "Better Buy: Gilead Sciences, Inc. vs. Amgen Inc.", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 15, 2017", "Why Gilead Sciences is the 'Top Dividend Stock of the Nasdaq 100' With 3.1% Yield (GILD)", "3 Dividend Stocks You Haven't Thought Of", "3 Top Biotech Stocks For May", "Better Buy: GlaxoSmithKline vs. Johnson & Johnson", "Why Gilead Sciences Stock Lagged Behind Other Biotechs in April", "I Still Can't Believe Gilead Sciences, Inc. Spent $14.8 Billion on Shareholder Rewards", "3 Stocks That Generate Tons of Cash", "Here's Why Diplomat Pharmacy Inc. Is Rising Today", "ProShares UltraPro S&P500 Experiences Big Outflow", "Charles Brandes Invests in Health Care in 1st Quarter", "Better Buy: Gilead Sciences, Inc. vs. Johnson & Johnson", "Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Beat", "Top Research Reports for Today: GILD, DOW, MET & More", "A Big, New Threat to Gilead Sciences Is Coming", "Notable Wednesday Option Activity: GRA, AERI, GILD", "How to Trade Gilead Sciences, Inc. (GILD) Stock After Its Q1 Miss", "Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates", "The Zacks Analyst Blog Highlights: Gilead, Dow Chemical, MetLife, Tesla and Emerson Electric", "Amazon: Love The Company, Hate The Stock Price", "Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus", "After Gilead Earnings, Buy These Biotech Stocks", "Gilead Sciences' 5-Point Plan to Turn Things Around", "Daily Dividend Report: AAPL, PEP, EXPD, MAN, WIN, GILD, SYK", "Walt Disney Co (DIS) Stock Cracks, And It Could Get Worse", "Gilead Sciences Inc.'s Revenue and Earnings Continue to Fall on Declining HCV Sales", "Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update", "Gilead (GILD) Misses Q1 Earnings and Revenue Estimates, Stock Drops", "This Week's Must See Earnings Charts", "Earnings Reaction History: Gilead Sciences Inc., 72.7% Follow-Through Indicator, 4.9% Sensitive", "After-Hours Earnings Report for May 2, 2017 : AAPL, GILD, MDLZ, APC, ALL, DVN, VRSK, DVA, OKE, OKS, AKAM, WGP", "Geron (GERN) Q1 Earnings: What's in Store for the Stock?", "Apple, Facebook and Gilead Sciences are part of Zacks Earnings Preview", "3 Big Drugmakers That Could Make Billions Under Trump's Tax Plan", "Apple Sells Fewer iPhones, Gilead Misses Sales", "What's in Store for Zoetis (ZTS) Stock This Earnings Season?", "What to Expect from Endocyte (ECYT) Stock for Q1 Earnings?", "Spot Trading L.L.C Buys Walt Disney Co, Johnson & Johnson, Mastercard, Sells SPDR S&P ...", "Gilead Sciences, Inc. (GILD) Stock Still Looks Sick", "3 Things to Watch With Gilead Sciences, Inc. Q1 Results", "IUSG, GILD, QCOM, TWX: ETF Inflow Alert", "Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up", "Radius Health (RDUS) Q1 Earnings: What's in Store?", "General American Investors Co Inc Buys Ensco PLC, Johnson Controls International PLC, Liberty ...", "Is Intercept (ICPT) Poised for a Beat This Earnings Season?", "What to Expect from Keryx (KERX) Stock This Earnings Season?", "Regeneron (REGN) to Post Q1 Earnings: What's in the Cards?", "The Tech Sector's Strong Earnings Power", "BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?", "United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss", "Why Gilead (GILD) Might Surprise This Earnings Season", "What's in Store for Merck (MRK) this Earnings Season?", "Pfizer (PFE) Q1 Earnings: Will it Pull Off a Surprise?", "What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?", "Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug", "Extreme Leverage? Extreme Valuations? Big-Time Short Sellers Must Be Thinking About It", "After Hours Most Active for Apr 26, 2017 : BAC, QQQ, NRG, MPW, GE, PFE, GM, MCHI, GILD, SIRI, MU, MSFT", "What to Expect from Prothena (PRTA) This Earnings Season?", "1 Dividend Stock That Could Double Your Money", "Jerome Dodson Keeps Buying McKesson, Axalta, Pentair", "Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?", "Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?", "Noteworthy Tuesday Option Activity: ETSY, GILD, UAL", "Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store?", "What's in Store for Agenus (AGEN) this Earnings Season?", "Celgene (CELG) to Post Q1 Earnings: What's in the Cards?", "3 Stocks Could Double Their Dividends -- But Shouldn't", "Jerome Dodson Keeps Buying McKesson, Axalta, Pentair", "Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?", "Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?", "Noteworthy Tuesday Option Activity: ETSY, GILD, UAL", "Amgen (AMGN) to Report Q1 Earnings: Will it Beat Again?", "Alexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise?", "10 Reasons Merck Could Be the World's Most Perfect Stock", "Better Buy: Gilead Sciences vs. Celgene", "Should Gilead Sciences Be Worried About Allergan?", "Why Now Is Not the Time to Buy Valeant Pharmaceuticals", "Health Care Sector Update for 04/20/2017: GILD,IMNP,SKLN", "Peek Under The Hood: IYH Has 11% Upside", "Looking for a Smart Way to Use Your Tax Refund? Buy These 3 Stocks", "Here's The Real Reason Gilead Sciences Is So Incredibly Cheap", "Did Pharma & Biotech M&As Pick Pace in Q1?", "3 Reasons Gilead Sciences Is a Better Dividend Stock Than Johnson & Johnson", "Health Care Sector Update for 04/21/2017: GILD,AUPH,XBIT", "Novartis (NVS) Q1 Earnings: Will the Stock Disappoint?", "VOO, BMY, GILD, AGN: Large Inflows Detected at ETF", "Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback", "ANTIPODES PARTNERS Ltd Buys United States Natural Gas Fund LP, Gilead Sciences, Baidu", "3 Fire-Sale Stocks: Will They Bounce Back or Burn You?", "Noteworthy Tuesday Option Activity: GILD, AGN, BA", "Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion", "The 3 Best HIV Drug Stocks to Buy in 2017", "Would Gilead Sciences Make This Staggeringly Audacious Move?", "Can This Fallen Biotech Be Revived?", "Gilead Sciences: The Bull, the Bear and the Fence-Sitter", "KMG Chemicals, Gilead Sciences, STMicroelectronics NV, Lockheed Martin and AeroVironment highlighted as Zacks Bull and Bear of the Day", "Bear of the Day: Gilead Sciences (GILD)", "3 Big Drugmakers Most Likely to Buy Incyte", "Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion", "The 3 Best HIV Drug Stocks to Buy in 2017", "Would Gilead Sciences Make This Staggeringly Audacious Move?", "Can This Fallen Biotech Be Revived?", "Gilead Sciences: The Bull, the Bear and the Fence-Sitter", "KMG Chemicals, Gilead Sciences, STMicroelectronics NV, Lockheed Martin and AeroVironment highlighted as Zacks Bull and Bear of the Day", "Bear of the Day: Gilead Sciences (GILD)", "3 Big Drugmakers Most Likely to Buy Incyte", "Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug", "Gilead (GILD) Up 4.3% Since Earnings Report: Can It Continue?", "Health Care Sector Update for 04/05/2017: SRPT,GILD,NEOT,UNIS", "Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study", "3 Drugmakers With Boatloads of Cash to Spend", "3 Least Risky Biotech Stocks on the Market", "6 Reasons Gilead Sciences Could Be the World's Most Perfect Stock", "IVW, HD, CMCSA, GILD: Large Inflows Detected at ETF", "Better Buy: Celgene Corporation vs. Gilead Sciences", "3 Top Dividend Stocks Selling for a Discount This Spring", "The Best-Case Scenario for Gilead Sciences, Inc.", "Why Teva Pharmaceutical Industries Ltd (ADR) Stock Has Staying Power", "Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen", "Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results", "These 2 Stocks Are Ridiculously Cheap", "Is Valeant Pharmaceuticals Intl Inc (VRX) Stock Worth the Risk?", "Biotech Bull Making a Comeback", "Mylan Receives Tentative Approval from FDA for HIV Therapy", "Why Biotech Stock Gilead (GILD) Could Be a Value Trap", "Look Under The Hood: BBH Has 12% Upside", "3 Stocks That Are Ridiculously Cheap Right Now", "3 Drug Stocks With Some of the Highest Profit Margins", "My 3 Worst-Performing Stocks -- and Why I Still Own Them", "Is Valeant Pharmaceuticals Intl Inc (VRX) Stock Worth the Risk?", "Biotech Bull Making a Comeback", "Mylan Receives Tentative Approval from FDA for HIV Therapy", "3 Reasons Why Gilead Sciences Will Buy Incyte -- and 1 Reason Why It Won't", "Forget Gilead, Buy These Small-Cap Biotech Stocks Instead", "The Beginning of a Stock Portfolio Experiment", "Noteworthy Friday Option Activity: VRTX, GILD, HD", "Sarepta's DMD Drug Launch Slow; What's in Store for 2017?", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for March 14, 2017", "3 Healthcare Stocks That Are Looking Cheap", "Which Biotech Is the Best Dividend Stock?", "Ex-Dividend Reminder: Gilead Sciences, T Rowe Price Group and Redwood Trust", "North Tide Capital, Llc Buys Impax Laboratories, Allergan PLC, Accuray, Sells Community Health ...", "AbbVie Stock Upgraded: What You Need to Know", "3 Underdog Stocks We're Watching Closely", "Will Gilead Sciences Net a $270 Million Windfall?", "Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal", "Notable ETF Inflow Detected - IYH, GILD, AGN, BIIB", "Here's Why the Best Is Yet to Come for Gilead Sciences, Inc.", "Is This the Right Time to Invest in Biotech Stocks?", "North Tide Capital, Llc Buys Impax Laboratories, Allergan PLC, Accuray, Sells Community Health ...", "3 Biotech Stocks You Don't Have to Babysit", "I Was Wrong About Gilead Sciences", "Should You Buy General Motors Company (GM) Stock? 3 Pros, 3 Cons", "2 Reasons Behind Sarepta Therapeutics Inc.'s 6.9% February Jump", "Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International", "Biotech ETF (BBH) Hits New 52-Week High", "North Tide Capital, Llc Buys Impax Laboratories, Allergan PLC, Accuray, Sells Community Health ...", "After Hours Most Active for Mar 2, 2017 : FTR, V, GE, FIG, XRX, HST, LOW, GILD, DISCA, YHOO, QCOM, CMCSA", "Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow", "How Are Drug Prices Determined?", "Should You Buy General Motors Company (GM) Stock? 3 Pros, 3 Cons", "Jerome Dodson Adds to 9 Positions in 4th Quarter", "Better Buy: Biogen Inc. vs. Gilead Sciences Inc.", "North Tide Capital, Llc Buys Impax Laboratories, Allergan PLC, Accuray, Sells Community Health ...", "3 Top Healthcare Stocks to Buy Now", "Numeric Investors Llc Buys Gilead Sciences, Microsoft, Baxter International, Sells Facebook, ...", "Carl Icahn Takes Aim at Bristol-Myers Squibb", "These 3 Big Pharma Stocks Are Ridiculously Cheap", "VOO, GILD, HON, UNP: Large Inflows Detected at ETF", "3 Incredibly Cheap Biotech Stocks", "United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss", "3 Beaten-Up Dividend Stocks: Are They Bargains?", "Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising", "North Tide Capital, Llc Buys Impax Laboratories, Allergan PLC, Accuray, Sells Community Health ...", "3 Stocks That Are Ridiculously Cheap Right Now", "3 Things Gilead Sciences' CEO Just Said That You'll Want to Know", "Gilead Sciences, Inc. (GILD) Stock Has Caught a Cold", "Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead", "7 Ultra-Cheap Value Stocks to Buy Now", "Why Gilead Sciences Is a Buy", "Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.", "Thanks, Martin Shkreli, for the Dumbest Advice Ever on Drug Pricing", "Who Could Buy Bristol-Myers Squibb?", "3 Things Gilead Sciences' CEO Just Said That You'll Want to Know", "Gilead Sciences, Inc. (GILD) Stock Has Caught a Cold", "Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead", "7 Ultra-Cheap Value Stocks to Buy Now", "Why Gilead Sciences Is a Buy", "Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More", "Investors Are Betting Big Against Intercept Pharmaceuticals. Are They Wrong?", "Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data", "Could A Blockbuster Cannabis Drug Be On The Way? (GILD, GWPH)", "The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics", "Tuesday\u2019s Vital Data: Tesla Inc (TSLA), Gilead Sciences, Inc. (GILD) and Microsoft Corporation (MSFT)", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for February 15, 2017", "North Tide Capital, Llc Buys Impax Laboratories, Allergan PLC, Accuray, Sells Community Health ...", "Why I Just Bought More Shares of Gilead Sciences, Inc.", "Two Sigma Advisers, Llc Buys Cisco Systems, Medtronic PLC, Oracle, Sells Amazon. ...", "Gilead (GILD) Announces Data on Combination Therapy for HIV", "Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More", "Forget Gilead, Buy These 5 Biotech Stocks Instead", "Notable Monday Option Activity: GS, GILD, DE", "Better Buy: Illumina or Gilead Sciences?", "Is Gilead Sciences Getting Ready for a Massive Acquisition?", "Gilead Sciences, Fossil Reach 3-Year Low Prices", "3 Stocks We're Watching in the First Quarter", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 13, 2017", "Biotech ETFs Powered by Q4 Earnings", "Don't Panic: Gilead Sciences Really Isn't a Value Trap", "Thursday's ETF with Unusual Volume: LRGF", "Nasdaq 100 Movers: MCHP, VIAB", "Zacks Market Edge Highlights: Health Care SPDR ETF, iShares NASDAQ Biotechnology ETF, Acadia, Aetna and Gilead", "Thursday\u2019s Vital Data: Apple Inc. (AAPL), Gilead Sciences, Inc. (GILD) and Advanced Micro Devices, Inc. (AMD)", "Why Intercept Pharmaceuticals' Latest News Caused the Stock to Jump", "Holowesko Partners Ltd. Buys Wells Fargo, Gilead Sciences, PulteGroup, Sells Citizens Financial ...", "Gilead Sciences, Inc. (GILD) Stock Tumbles on Dismal Guidance", "3 Big Stock Charts for Wednesday: Gilead Sciences, Inc. (GILD), AK Steel Holding Corporation (AKS) and Sysco Corporation (SYY)", "Gilead Sciences Just Lost $9 Billion in Market Value -- Here's Why", "Nasdaq 100 Movers: AKAM, MCHP", "S&P 500 Movers: AKAM, MCHP", "Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints", "GILD's Strong Dividend History Helps it Reach 'Top Dividend Stock of the Nasdaq 100'", "Pre-Market Most Active for Feb 8, 2017 : PE, GILD, AMC, TWTR, FCAU, BAC, TVIX, RIO, QQQ, CTSH, MCHP, GMLP", "Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib", "Why Gilead Sciences, Zillow Group, and Parsley Energy Slumped Today", "Why Gilead Sciences, Inc. (GILD), Zillow Group, Inc. (Z) and Akamai Technologies, Inc. (AKAM) Are 3 of Today\u2019s Worst Stocks", "5 Things Gilead Sciences' Management Said as Its Stock Slumped", "Why Gilead Sciences Stock Slumped Today", "Daily Dividend Report: MMM, GILD, ALK, TWX, SYK, PSX, IR, RCL, CLX", "Gilead Sciences Just Shocked Investors, And It Wasn't Good", "3 Attractive Income Stocks Whose Dividends Could Double", "Gilead Sciences Inc. Reports Q4 Earnings Decline and Worsening Outlook for 2017", "Gilead Sciences Posts Q4 Earnings Beat, Slumps on Weak Guidance", "After Hours Most Active for Feb 7, 2017 : BAC, FCX, GILD, SCOR, GE, MSFT, QQQ, TEVA, HBAN, T, TWLO, MTCH", "Spot Trading L.L.C Buys Gilead Sciences, Allergan PLC, Bristol-Myers Squibb Company, Sells SPDR ...", "After-Hours Earnings Report for February 7, 2017 : DIS, GILD, MDLZ, PXD, ORLY, MCHP, PAA, AKAM, ATO, CPT, JKHY, DEI", "VLUE, GM, WMT, GILD: ETF Inflow Alert", "3 Healthcare Tickers That Will Return Profits in 3 Months", "Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More", "3 Crucial Questions Gilead Sciences Should Answer Tuesday", "Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?", "8 Value Stocks to Buy In The S&P 500", "3 Dividend Stocks With the Biggest Revenue Growth Over the Past 10 Years", "These 3 Biotech Stocks Are Ridiculously Cheap", "Earnings Reaction History: Gilead Sciences Inc., 63.6% Follow-Through Indicator, 4.0% Sensitive", "Gilead Sciences a Top 25 Dividend Giant With 2.63% Yield (GILD)", "This Was, Unquestionably, the Most Disappointing Drug Launch of 2016", "3 Critical Things to Watch in Gilead Sciences' Q4 Results", "Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline", "Why You're Right to Invest in Gilead Sciences Stock", "The Single Most Important Number for Gilead Sciences", "3 Companies Putting the Squeeze on Bristol-Myers Squibb", "15 Best Short-Term Stock Investments", "3 Healthcare Stocks to Buy Despite Trump\u2019s Bluster", "3 Reasons Gilead Sciences Inc. Stock Could Rise", "3 Top Stocks You Can Buy on Sale", "Forget Incyte: Gilead Sciences Would Be Better Off Buying This Company", "Biotech Stock Roundup: Synergy Drug Gets FDA Nod, AbbVie, GILD HCV Drugs under EU Review", "3 Top Biotech Stocks to Buy Now", "Notable Wednesday Option Activity: MTB, CMA, GILD", "3 Most Unbelievably Undervalued Biotech Stocks", "Better Buy: Biogen Inc. vs. Gilead Sciences Inc.", "Gilead Sciences Stock: What Could Go Wrong?", "Can Q4 Earnings Revitalize Healthcare ETFs?", "Has Gilead Sciences' Cash Cow Finally Hit Bottom?", "Is Gilead Sciences, Inc. (GILD) Stock Great for Value Investors?", "Gilead (GILD) HCV Therapy Application Validated in Europe", "Incyte Has Insight Into Market With Potential Blockbuster Drugs", "3 Biotech Stocks to Buy and Hold Stress-Free", "Better Buy: Biogen Inc. vs. Gilead Sciences Inc.", "Gilead Sciences Stock: What Could Go Wrong?", "Is Gilead Sciences (GILD) a Great Stock for Value Investors?", "The Zacks Analyst Blog Highlights: Gilead Sciences, Las Vegas Sands, Illinois Tool Works, Pfizer and Lockheed Martin", "Are You Undervaluing These 3 Biopharmas' Pipelines?", "Noteworthy ETF Inflows: VLUE, GM, GILD, F", "Cabot-Wellington, LLC Buys iShares Core MSCI EAFE, Vanguard Total Stock Market, Sells iShares ...", "These 3 Healthcare Stocks Are Ridiculously Cheap", "Value Investing 2017: 3 Stocks to Put on Your Radar", "Agree To Buy Gilead Sciences At $55, Earn 4.4% Using Options", "3 Bargain Stocks to Buy Now", "Notable Tuesday Option Activity: GILD, Q, AXP", "Is Donald Trump Big Pharma's Worst Nightmare?", "Should Investors Bet on Gilead Sciences Version 3.0?", "4 Top Biotech Mutual Funds for 2017", "Stock Market News for January 12, 2017", "Is the Options Market Predicting a Spike in Gilead Sciences (GILD) Stock?", "Gilead (GILD) HBV Drug Vemlidy Receives European Approval", "Waverton Investment Management Ltd Buys Wells Fargo & Co, US Bancorp, Baidu Inc, Sells ...", "This Stumbling Biotech Stock Still Has a Lot of Promise", "Should You Buy Amgen Inc. (AMGN) Stock? 3 Pros, 3 Cons", "Stock Market Roundup Jan. 11: Health Sector Lower on Trump \"Murder\" Comment", "Donald Trump Just Leveled Drug Companies With These 4 Words", "Why Ariad Pharmaceuticals Stock Soared Today", "Top Biotech Resolutions for 2017", "Notable ETF Outflow Detected - TQQQ, AMGN, KHC, GILD", "The Zacks Analyst Blog Highlights: Gilead Sciences, Pepsi, United Parcel Services, Twitter and Stanley Black & Decker", "2017 J.P. Morgan Healthcare Conference Roundup", "The 10 Worst Stocks in the Nasdaq in 2016", "4 Things Gilead Sciences' CEO Says to Expect in 2017", "Is This the Solution to Gilead Sciences' Woes?", "What If You Considered Gilead Sciences a Start-Up?", "Biotech Investing: 3 Bold Predictions for 2017", "Noteworthy Friday Option Activity: APC, KITE, GILD", "5 Stocks to Buy for Enterprise Investors", "Why Gilead Sciences Lost a Staggering 29.2% In 2016", "Gilead Sciences Must Answer to Investors After a Disappointing 2016", "Gilead Sciences Inc.'s Biggest Failure in 2016", "Kempner Capital Management Inc. Buys XL Group Ltd, Teva Pharmaceutical Industries Ltd, Gilead ...", "Is Biogen Playing With Fire?", "Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year", "Biotech Stocks: What to Watch in 2017", "United Therapeutics' PAH Suite Bodes Well, Competition Rife", "2 Incredibly Cheap Dividend Stocks", "Will 2017 Be Gilead Sciences Inc.'s Worst Year Yet?", "3 Great Income Stocks That Could Double Their Dividends", "Stock Market News for January 04, 2017", "Noteworthy ETF Outflows: TQQQ, AMGN, KHC, GILD", "Will 2017 Be Gilead Sciences Inc.'s Worst Year Yet?", "10 Best Stocks for Retirement Investors", "Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug", "5 Steps To Buying Biotech Stocks", "Health Care Sector Update for 12/21/2016: ALXN,GILD,MRUS,INCY,MACK", "Forget Gilead Sciences Inc.: These 3 Stocks Are Better Buys", "The Most Likely Incyte Acquisition Deal for 2017?", "Nasdaq 100 Movers: GILD, TRIP", "Gilead Sciences Has Bought Back $10 Billion of Stock in 2016. Should Investors Be Happy?", "3 Incredibly Cheap Biotech Stocks", "Could Gilead Sciences' Game-Changing HIV Pill Solve Its Growth Problem?", "The 12 Greatest Medical Breakthroughs of 2016", "The Most Expensive Drugs of 2016", "3 Small Biotech Stocks That Big Biotechs Like", "2 Great Stocks You Can Buy on Sale", "Is This Gilead Sciences' Biggest Mistake in 2016?", "Gilead to Pay Merck $2.5B in HCV Patent Dispute, Stock Falls", "Why AbbVie Inc (ABBV) Stock Is Still a Long-Term Winner", "Gilead Sciences' Year Officially Becomes Superbad", "Gilead Sciences Inc.'s Best Moves in 2016", "How Risky Is Gilead Sciences Inc.?", "XLV, AMGN, ABBV, GILD: ETF Outflow Alert", "Could These 2 Small Biotechs Beat Allergan and Gilead Sciences?", "Is This Gilead Sciences' Biggest Mistake in 2016?", "Gilead to Pay Merck $2.5B in HCV Patent Dispute, Stock Falls", "Why AbbVie Inc (ABBV) Stock Is Still a Long-Term Winner", "3 Top Biotech Stocks to Buy on Sale", "Better Buy: Gilead Sciences Inc. vs. Amgen Inc.", "3 Cheap Healthcare Stocks You Can Buy Right Now", "The Zacks Analyst Blog Highlights: Gilead Sciences, Medtronic, NVIDIA, Accenture and Simon Property", "Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data", "Trade Valeant Pharmaceuticals Intl Inc (VRX) Stock for Free Profits", "How Gilead Sciences Inc. Could Pay You $30,000 a Year in Retirement", "After Hours Most Active for Dec 9, 2016 : V, PBCT, HPE, IFGL, FOSL, PCAR, CAT, BAC, MT, SXL, MSFT, GILD", "Top Research Reports for NVIDIA, Medtronic & Gilead Sciences", "Noteworthy ETF Inflows: XLV, MRK, AMGN, GILD", "Gilead Sciences Inc.'s Worst Moves in 2016", "Gilead Sciences, Inc.'s $10 Billion Mistake", "3 Biotech Buybacks With the Biggest Bang for the Buck", "Trade of the Day: Gilead Sciences, Inc. (GILD) Stock Looks Like a Bargain", "5 Things Gilead Sciences' CEO Just Said That You Need to Know", "\u2014\u2018 Questions With Gabriele Grego", "J&J (JNJ) Reportedly Approaches Actelion for Acquisition", "The Worst Growth Dividend Stocks of 2016", "3 Inexpensive Top Stocks You've Overlooked This Fall", "Galapagos (GLPG) Filgotinib in Phase III for Crohn's Disease", "The 10 Best Healthcare Stocks to Buy for 2017", "Trade of the Day: Gilead Sciences, Inc. (GILD) Stock Looks Like a Bargain", "5 Things Gilead Sciences' CEO Just Said That You Need to Know", "\u2014\u2018 Questions With Gabriele Grego", "Attention, Biotech Investors: Black Friday Is Already Here", "The No. 1 Healthcare Concern Americans Want Donald Trump to Fix -- and It's Not Obamacare", "5 Most Expensive Medicare Drugs -- and Which Companies Are Getting Rich From Them", "3 Embarrassingly Cheap Dividend Stocks", "When Will Gilead Sciences' Unlucky Streak End?", "Gilead Reports Phase III Myelofibrosis Data on Momelotinib", "3 Beaten-Down Biotech Stocks to Buy for Huge Gains", "Bad News for Gilead Sciences Is Good News for Incyte", "Biotech Stock Roundup: Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved", "3 Potential Acquisition Targets for Gilead Sciences, Inc.", "3 Biotech ETFs for Decades of Big Returns", "4 Biotech Stocks to Buy After Clinton\u2019s Defeat", "Does Gilead Sciences Pass Warren Buffett's Test?", "Merck's Triple Combination HCV Therapy Positive in Phase III", "Gilead (GILD) HBV Drug Vemlidy Gets Positive CHMP Opinion", "Should Biopharma Companies Buy Innovation?", "3 Drugmakers That Probably Have Lower Tax Rates Than You Do", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for November 14, 2016", "Drug Stocks' Q3 Earnings to Watch on Nov 14: ARGS, AST", "XLV, JNJ, GILD, BIIB: ETF Inflow Alert", "These 3 Stocks Are Undeniably Cheap", "Peek Into Drug Stocks' Q3 Earnings on Nov 11: XBIT & REPH", "How a Donald Trump Presidency Could Affect Biotech Stocks", "Is a Donald Trump Presidency a Black Swan Event for Pharma Stocks?", "Drug Stocks Q3 Earnings Roster for Nov 10: AVXS, GBT & BPMC", "Biotech Stock Roundup: Ionis Soars on Spinraza Data, Regeneron's Q3 Results Mixed", "Better Buy: Gilead Sciences Inc. vs. Pfizer Inc.", "The Zacks Analyst Blog Highlights: ExxonMobil, Gilead, Duke Energy, NVIDIA and Monster Beverage", "5 Top Biotech Stocks to Buy on Trump Victory", "Why Gilead Sciences Shares Fell 7% in October", "Biotech ETFs Slumping on Q3 Results", "Top Research Reports for Exxon, Duke & Gilead", "Zacks Industry Outlook Highlights: Amgen, Vertex, Valeant Pharmaceuticals International, Mylan N.V. and Gilead Sciences", "3 Best Healthcare Stocks to Buy Now", "2 Reasons Why the iShares NASDAQ Biotechnology Index (ETF) Tumbled 11% in October", "3 Best Biotech Stocks of the 21st Century (So Far)", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for November 09, 2016", "Drug Stocks Earnings Roster for Nov 7: HZNP, ACAD & More", "After Hours Most Active for Nov 4, 2016 : GLW, BAC, BHI, AKS, EVDY, GE, MSFT, CTSH, TXN, AAPL, QCOM, GILD", "Friday's ETF with Unusual Volume: BBH", "Noteworthy ETF Inflows: VUG, PM, ORCL, GILD", "Company News for November 03, 2016", "Drug Stocks to Watch for Earnings on Nov 4; REGN & More", "Thursday\u2019s Vital Data: Facebook Inc (FB), Alibaba Group Holdings Ltd (BABA) and Gilead Sciences, Inc. (GILD)", "The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies", "5 Things Gilead Sciences' Management Said After Its Earnings Plummet", "Why Celgene Corp Is a Better Buy Than Gilead Sciences", "Gilead (GILD) Misses Q3 Earnings Estimates, Retains View", "3 Stocks to Watch on Wednesday: Square Inc (SQ), Gilead Sciences, Inc. (GILD) and Electronic Arts Inc. (EA)", "Gilead Sciences Inc. Hepatitis C Sales Sink Again in Q3", "Drug Stocks Q3 Earnings Roster for Nov 3; ICPT, EXEL, AKRX", "Gilead's Q3 Bombshell: No More Hepatitis C R&D", "Biotech Stock Roundup: Amgen Down on Enbrel Sales, Regeneron's Sarilumab Faces Delay", "AbbVie's Stock Is Suffering From a Lack of Diversification", "Why We're Right to Invest in Gilead Sciences Stock", "Gilead (GILD) Misses Q3 Earnings, Reiterates 2016 Guidance", "After Hours Most Active for Nov 1, 2016 : YUMC, QCP, AA, GES, BAC, CSCO, PFE, AAPL, INTC, MENT, MSFT, GILD", "The 3 Best Stocks to Buy Before Nov. 8", "Earnings Reaction History: Gilead Sciences Inc., 60.0% Follow-Through Indicator, 4.2% Sensitive", "After-Hours Earnings Report for November 1, 2016 : GILD, PXD, EIX, EA, ILMN, DVN, CERN, ES, FLT, NBL, SBAC, VRSK", "Daily Dividend Report: EL, ROK, HII, CDW, GILD", "These Companies Make Millions Per Employee \u2014 And Yield Up To 13%", "$40 Billion Opportunity: 3 Biotechs Poised to Dominate", "Genetic Stocks to Watch for Earnings on Nov 1: GILD & More", "Your Two Minute Earnings Preview for Gilead (GILD) Stock", "9 Shiny New Dividend Stocks You Can Trust in the Long Run", "Unfazed by FDA Warning, Gilead Sciences' Stock Could Be Turning a Corner", "3 Things AbbVie's Management Said While Its Stock Got Hammered", "The Best Options Trade for Gilead Sciences (GILD) Earnings", "These Companies Make Millions Per Employee \u2014 And Yield Up To 13%", "$40 Billion Opportunity: 3 Biotechs Poised to Dominate", "Genetic Stocks to Watch for Earnings on Nov 1: GILD & More", "Your Two Minute Earnings Preview for Gilead (GILD) Stock", "Global Blood Therapeutics: Incredible Value At This Price", "Biotech Stock Roundup: Clinical Holds Hit Inovio & Aduro, Vertex Q3 Results Miss Estimates", "Make Valeant Pharmaceuticals Intl Inc (VRX) Stock Pay YOU", "3 Key Questions for Gilead Sciences, Inc. in Q3", "IVW, DIS, MA, GILD: ETF Inflow Alert", "4 Top Drug Stocks That Can Be Purchased on the Cheap This Fall", "Healthcare ETFs: Gain or Pain Ahead in Q3 Earnings?", "Best And Worst Biotech ETFs Of 2016 Tell A Tale About This Industry", "Nothing Can Stop Merck & Co., Inc. (MRK) Stock Now", "Better Buy: Pfizer Inc. vs. GlaxoSmithKline plc", "Gilead Sciences (GILD) Q3 Earnings: Stock to Disappoint?", "41 Billion Reasons Why Gilead Sciences Might Need New Management", "Better Buy: Biogen Inc. vs. Gilead Sciences, Inc.", "3 Top Bargain Stocks to Buy Today", "Notable ETF Inflow Detected - IVW, DIS, GILD, MA", "3 Top Stocks to Buy for Your Grandchildren's Benefit", "Any Bank Stocks You Can Trust?", "ContraVir Pharmaceuticals Stock Jumps on Positive Results From Hepatitis B-Drug Trial", "Gilead Sciences: Is the Bar Set Low Enough for a Beat?", "Gilead Sciences, Inc. Is More Than an HCV Play (GILD)", "Merck's New Products and Solid Pipeline As Growth Drivers", "7 Stocks the 2016 Presidential Candidates Have Called Out By Name", "Will Gilead Sciences Inc. Set Its Sights on Incyte?", "After Hours Most Active for Oct 10, 2016 : MU, PG, QQQ, TWTR, FB, YHOO, QCOM, CPN, GILD, KO, OLN, MTG", "The Big Reason You Shouldn't Give Up on Big-Cap Biotech", "Steven Cohen Increases Position in Dynavax", "3 Stocks to Watch on Wednesday: Barracuda Networks Inc (CUDA), Blackhawk Network Holdings Inc (HAWK) and Delta Air Lines, Inc. (DAL)", "Biotech Stock Roundup: Summit Soars on Sarepta Deal, Regeneron Presents Data", "FDA Issues Warning on Hepatitis C Drugs", "How To YieldBoost GILD To 8.2% Using Options", "Nope, Gilead Sciences Won\u2019t Get Bought out", "Nasdaq 100 Movers: NTAP, CTSH", "Gilead Sciences' Pain Is Celgene's Gain", "7 Stocks That Could Be Bought Next", "Gilead Sciences Should Absolutely Not Split", "Hey Gilead, It's Time to Start Looking Over Your Shoulder in Hepatitis C", "Nonalcoholic Steatohepatitis: What's The Market Opportunity And Who Are The Major Players?", "Nonalcoholic Steatohepatitis (NASH): What's The Market Opportunity And Who Are The Major Players?", "Biotech Stock Roundup: Amgen's Kyprolis Disappoints, Array Up on Cancer Data", "XLV, AMGN, MDT, GILD: ETF Inflow Alert", "Nasdaq 100 Movers: GILD, NCLH", "5 Safe Stocks to Buy Today", "3 Healthcare Stocks That Could Raise Their Dividends", "Why Cash Is King for Biotech Stocks", "Tuesday's ETF with Unusual Volume: IWY", "The Zacks Analyst Blog Highlights: Deutsche Bank, Apple, Therapeutics, Allergan and Gilead Sciences", "Is This Tiny Company the Best Pharmacy Stock to Buy?", "3 Dirt-Cheap Dividend Stocks You Can Buy Right Now", "The Cheapest Stocks in Biotech", "The Pros and Cons of Buying Gilead Sciences Stock", "Market Close Report: NASDAQ Composite index closes at 5,305.71 up 48.22 points", "Is Galectin The Next Takeover Target for the Biotech World?", "Gilead Sciences Inc.'s Biggest Win in 2016 So Far", "Stock Market News for September 21, 2016", "Trade of the Day: iShares Nasdaq Biotechnology Index (ETF) (IBB) Is Turning Things Around", "Allergan Buys NASH Therapy Maker Tobira at Huge Premium", "How Safe Is Gilead Sciences Inc. and Its Dividend?", "After Hours Most Active for Sep 20, 2016 : GILD, HPQ, QQQ, CSCO, SYMC, INTC, YHOO, VZ, HES, EVHC, BAC, POT", "Gilead to Stop GS-5745 Development for Ulcerative Colitis", "After Hours Most Active for Sep 20, 2016 : GILD, HPQ, QQQ, CSCO, SYMC, INTC, VZ, YHOO, HES, EVHC, POT, PG", "Noteworthy ETF Outflows: XLV, MDT, GILD, ABBV", "How Risky Is Gilead Sciences Inc.?", "5 Undervalued Stocks to Buy for Enterprising Value Investors", "The Zacks Analyst Blog Highlights: TOTAL, Oracle and Gilead Sciences", "New Oracle, Gilead Sciences & TOTAL Research Reports", "Biotech Stock Roundup: Horizon-Raptor Acquisition Deal, Geron Down on Pipeline News", "Market Close Report: NASDAQ Composite index closes at 5,241.35 up 6.32 points", "After Hours Most Active for Sep 20, 2016 : GILD, HPQ, QQQ, CSCO, SYMC, INTC, VZ, YHOO, HES, EVHC, POT, PG", "Noteworthy ETF Outflows: XLV, MDT, GILD, ABBV", "How Risky Is Gilead Sciences Inc.?", "5 Undervalued Stocks to Buy for Enterprising Value Investors", "The Zacks Analyst Blog Highlights: TOTAL, Oracle and Gilead Sciences", "New Oracle, Gilead Sciences & TOTAL Research Reports", "Buy Gilead Sciences for a 42% Profit? What You Need to Know", "You'll Never Guess Which Pharma Could Knock Gilead Sciences Off Its HIV Throne", "Two Things You Must Understand About Biotech Investing", "The Perfect Defensive Stock For This \u2018Joyless\u2019 Bull Market (JNJ)", "Hillary Clinton's New Prescription Drug Proposal Takes Aim at Valeant Pharmaceuticals and Mylan", "7 Good Stocks to Buy While They Are Down", "Better Buy: Biogen Inc. vs. Gilead Sciences", "2 Stocks With Better Dividends Than CVS Health Corporation", "Zeke Ashton Invests in \u2013\u2026 New Holdings", "This Could Save Medicare at Least $16 Billion a Year, but the Agency Is Barred From Doing It", "Two Things You Must Understand About Biotech Investing", "The Perfect Defensive Stock For This \u2018Joyless\u2019 Bull Market (JNJ)", "Hillary Clinton's New Prescription Drug Proposal Takes Aim at Valeant Pharmaceuticals and Mylan", "7 Good Stocks to Buy While They Are Down", "Better Buy: Biogen Inc. vs. Gilead Sciences", "2 Stocks With Better Dividends Than CVS Health Corporation", "Zeke Ashton Invests in \u2013\u2026 New Holdings", "Forget Gilead Sciences Inc.: These 3 Stocks Are Better Buys", "7 Deeply Underloved Blue-Chip Stocks to Buy Now", "Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved", "Noteworthy Thursday Option Activity: MRK, GPS, GILD", "3 Beaten-Up Biotech Stocks: Are They Bargains?", "There\u2019s More to Johnson & Johnson (JNJ) Than Meets the Eye", "2 Clinical-Stage Biotech Stocks to Buy", "Looking Beyond Hepatitis C: Here's How Gilead Could Make Another $10 Billion Annually", "Gilead Sciences Becomes Oversold", "7 Deeply Underloved Blue-Chip Stocks to Buy Now", "Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved", "Noteworthy Thursday Option Activity: MRK, GPS, GILD", "3 Beaten-Up Biotech Stocks: Are They Bargains?", "3 Top Stocks to Buy for Your Children", "6 More Pharma Companies Selling Overpriced Drugs", "Mylan NV (MYL): Stop Rewarding Big Pharma Greed!", "Monday's ETF with Unusual Volume: PBE", "Noteworthy ETF Outflows: TQQQ, AMGN, KHC, GILD", "Nasdaq 100 Movers: GILD, TMUS", "Why Gilead Sciences, Inc. (GILD), Valeant Pharmaceuticals Intl Inc (VRX) and Core-Mark Holding Company, Inc. (CORE) Are 3 of Today\u2019s Worst Stocks", "Billionaire George Soros' Fund Dumped These 3 Biotech Holdings. Should You?", "Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review", "Gilead (GILD) Truvada Gets EU Approval for Label Expansion", "Galapagos (GLPG) Advances RA Drug Filgotinib to Phase III", "Stock Market News for August 25, 2016", "3 Reasons Gilead Sciences Inc. Stock Could Fall", "After Hours Most Active for Aug 25, 2016 : ENS, MSFT, BAC, CLF, LMT, WNC, QQQ, WLL, FITB, GILD, URBN, EA", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for August 25, 2016", "Why You Should (and Shouldn't) Buy Gilead Sciences, Inc.", "Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review", "Noteworthy ETF Outflows: TQQQ, GILD, QCOM, CELG", "3 Cheap Stocks for Rookie Investors to Start With", "3 Cheap Healthcare Stocks Paying Dividends Now", "4 Top Biotech Stocks That Can Be Purchased on the Cheap This Summer", "7 Battered Biotech Stocks to Buy", "These 3 Hated Dividend Stocks Look Like Buys", "Could Gilead Sciences Face an Unexpected $10 Billion Tax Bill?", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 15, 2016", "The Implied Analyst 12-Month Target For QQXT", "Gilead Sciences, Inc.: A Breakdown Looms for GILD Stock", "Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data", "ETFs to Watch as Nasdaq Hits All-Time High", "Noteworthy ETF Outflows: OEF, GILD, AGN, CELG", "Licensing Agreements Drive Ligand Pharmaceuticals Inc. 13% Higher in July", "Are Gilead Sciences' Best Days Behind It?", "Ligand (LGND) Q2 Earnings Decline Y/Y, Maintains View", "After Hours Most Active for Aug 5, 2016 : AAPL, BAC, MSFT, QQQ, GILD, FCX, NVDA, VZ, AAL, MRK, GM, PFE", "Drug Stocks' Earnings to Watch on Aug 5: PETX, DVAX & More", "Gilead Sciences Inc. Stock in 3 Charts", "Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More", "Celgene Corporation: Why CELG Stock Could Top $200/Share", "Rapidly Rising Prescription Drug Costs Could Put Medicare on Life Support", "12 Big Pharma Stats That Will Blow You Away", "What Awaits ACUR & Other Drug Stocks this Earnings Season?", "QUAL, GILD, MMM, PEG: ETF Outflow Alert", "The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene", "The 1 Big Bright Spot in Gilead Sciences' Otherwise Dismal Quarter", "Research Reports for Facebook, DuPont, Gilead & Others", "Express Scripts (ESRX) Posts In-Line Earnings, Lags Revenues (Revised)", "The Drug-Price War Just Took a Big New Twist", "Wednesday\u2019s Vital Data: Apple Inc. (AAPL), Twitter Inc (TWTR) and Gilead Sciences, Inc. (GILD)", "Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure", "Tuesday's ETF with Unusual Volume: DLN", "Tuesday's ETF Movers: XME, BBH", "2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK", "iShares Silver Trust (ETF): A Golden Opportunity Beckons in SLV", "Gilead Sciences, Inc. (GILD): Catch This Falling Knife NOW", "S&P 500 Movers: CNC, TXN", "Nasdaq 100 Movers: GILD, TXN", "Gilead (GILD) Beats on Q2 Earnings, Cuts 2016 Sales View", "The Zacks Analyst Blog Highlights: Texas Instruments, Gilead Sciences and Las Vegas Sands", "3 Big Stock Charts for Tuesday: AbbVie Inc (ABBV), Gilead Sciences, Inc. (GILD) and Sprint Corp (S)", "3 Key Takeaways Following Gilead Sciences' Second-Quarter Conference Call", "iShares Silver Trust (ETF): A Golden Opportunity Beckons in SLV", "3 Stocks to Watch on Tuesday: Express Scripts Holding Company (ESRX), Las Vegas Sands Corp. (LVS) and Gilead Sciences, Inc. (GILD)", "Jerome Dodson Comments on Gilead", "After GILD Earnings, Which Biomed Stock is Best Right Now?", "Why Gilead Sciences, Inc. (GILD), Mobileye NV (MBLY) and Under Armour Inc (UA) Are 3 of Today\u2019s Worst Stocks", "Harvoni Sales Declines Hurt Gilead Sciences Inc. in Q2", "Daily Dividend Report: IBM, GILD, COST, AEP, EXC, ETN, FIS", "Express Scripts (ESRX) Tops Q2 Earnings, Lags Revenues", "Pre-Market Most Active for Jul 26, 2016 : SIRI, RDS/B, MBLY, AZN, FCX, NFLX, MCD, S, GILD, XIV, TXN, AAPL", "Q2 Earnings After the Bell Monday: TXN, GILD, LVS", "Gilead (GILD) Stock Falls on Sales Miss and Lower 2016 Revenues Guidance", "This Week Could Decide Whether Biotech ETFs' Rally Sizzles Or Fizzles", "Why Gilead Sciences, Inc. (GILD), Netflix, Inc. (NFLX) and Sprint Corp (S) Are 3 of Today\u2019s Best Stocks", "After Hours Most Active for Jul 25, 2016 : GE, GILD, MDLZ, AA, AAPL, PFE, BAC, MSFT, AER, QQQ, FOXA, XOM", "Biotech Earnings Battle: Gilead (GILD) vs. Amgen (AMGN)", "7 Key Figures From Gilead Sciences' Q2 Earnings", "Earnings Reaction History: Gilead Sciences Inc., 60.0% Follow-Through Indicator, 3.9% Sensitive", "3 Stocks That Turned $10,000 Into $1 Million", "5 Reasons Biotech Stocks Are Smart Investments", "I Just Bought These 4 Fast-Growing Biotech Stocks", "Medical Stocks Reporting Early Next Week: GILD, LLY & More", "Can GoPro (GPRO) Spring a Surprise this Earnings Season?", "Gilead Sciences, Inc.: 2 GILD Stock Trades for Earnings", "After-Hours Earnings Report for July 25, 2016 : GILD, TXN, CNI, ESRX, LVS, AVB, CE, BRX, CDNS, RE, WRB, ACC", "Biogen (BIIB) Stock Up on Q2 Earnings Beat, Raised Outlook", "Express Scripts (ESRX) Q2 Earnings: Stock to Disappoint?", "Eli Lilly (LLY) May Beat Q2 Earnings: Will the Stock Gain?", "Gilead (GILD) Stock Likely to Beat This Earnings Season", "What's in Store for TransUnion (TRU) This Earnings Season?", "3 Healthcare ETFs to Buy as JNJ Beats Q2 Earnings", "Will Honeywell (HON) Pull a Surprise this Earnings Season?", "3 Enormously Important Things You Won't See in Gilead Sciences' Q2 Results", "Biogen (BIIB) Stock Up on Q2 Earnings Beat, Raised Outlook", "Express Scripts (ESRX) Q2 Earnings: Stock to Disappoint?", "Eli Lilly (LLY) May Beat Q2 Earnings: Will the Stock Gain?", "Gilead (GILD) Stock Likely to Beat This Earnings Season", "What's in Store for TransUnion (TRU) This Earnings Season?", "3 Healthcare ETFs to Buy as JNJ Beats Q2 Earnings", "5 Stocks with High ROE to Buy as Earnings Bells Chime", "Zacks.com featured highlights: Altria Group, Priceline Group, Zoetis, Gilead Sciences and Citrix Systems", "3 Biotech Stocks to Buy and Hold", "5 Best Stocks For Value Investors This Week", "Earnings Estimates for These 3 Biotech Giants Should Be Heading Lower -- Here's Why", "Is This Gilead Sciences' Most Underappreciated Drug Candidate?", "Abbott Labs (ABT) Q2 Earnings: Will the Stock Surprise?", "TE Connectivity (TEL) Q3 Earnings: What's in the Cards?", "Roche's Gazyva Fails in Phase III B-cell Lymphoma Study", "4 Top Stocks on Sale This Summer", "Novartis (NVS) Likely to Beat Q2 Earnings: Stock to Gain?", "Will UnitedHealth (UNH) Continue to Beat on Earnings in Q2?", "Gilead's HCV Drug Epclusa Gets Regulatory Nod in Canada", "Biogen (BIIB) Q2 Earnings: Will the Stock Disappoint?", "J&J (JNJ) May Beat Q2 Earnings: Will the Stock Gain?", "How Much Do Stock Prices Matter in Biotech?", "The Zacks Analyst Blog Highlights: Juno, Amgen, AbbVie, Gilead and CytRx", "4 Rock-Solid, Cheap Biotech Stocks", "Why Investors Are Underestimating Gilead Sciences", "Biotech Stock Roundup: Juno In and Out of Clinical Hold, Amgen Biosimilar Gets Panel Backing", "Gilead Sciences' Latest Approval Is a Big Deal", "Ligand (LGND) Signs Deal with Gilead for OmniAb Technology", "Gilead's Pan-Genotypic HCV Drug Epclusa Gains EU Approval", "3 Stocks With 50% More Post-Brexit Upside (BP, GSK, RBS)", "Implied RDVY Analyst Target Price: $23", "3 Dividend Aristocrats to Avoid", "Like Conscious Capitalism? You'll Love These 3 Stocks", "Attention Investors: The P/E Ratio Revisited", "Health Care Select Sector SPDR Fund Experiences Big Outflow", "Stock Market News for July 07, 2016", "Non-GAAP Earnings Aren't The Solution", "Agree To Purchase Gilead Sciences At $47.50, Earn 4.4% Using Options", "These 3 Biotech Stocks Are Ridiculously Cheap Now", "Top 7 Research Reports for July 11, 2016", "Gilead Sciences Stock Is Stupid Cheap", "The Big Loser After Gilead's Latest Approval May Not Be Who You Think (Hint: It's not AbbVie, Inc.)", "3 Issues That Every Healthcare Investor Should Consider", "10 Biotech And Specialty Pharma Bargains - Do You Have The Guts To Speculate?", "Health Insurers: a Surprising Key to Drugmakers' Sucess", "The Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma", "3 Dividend Growth Stocks to Buy in July", "How Gilead's New Hepatitis C Virus Combination Stacks Up to the Competition", "How Much Will the Elections Affect Healthcare Stocks?", "3 Biotech Stocks to Buy on Sale Right Now", "Top 6 Research Reports for June 29, 2016", "Biotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold", "Why Is Gilead Sciences (GILD) Stock Gaining Today?", "This Leading Indicator Suggests the Stock Market May Be on the Precipice of Tumbling", "The FDA Unsurprisingly Approves Gilead's New Hepatitis C Drug. Now What?", "141 Reasons to Love Biotech Stocks", "GILD Stock: FDA Greenlights Gilead Sciences, Inc. Hep-C Drug Epclusa", "Instant Analysis: Gilead Sciences Wins an Important FDA Approval", "Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?", "When Will Gilead Sciences, Celgene, and CVS Health Hit $100 Again?", "Can Gilead Sciences Rebound in the Second Half of 2016?", "3 Biotech Stocks to Buy Now for the Long Haul", "The iShares NASDAQ Biotechnology Index (IBB): Biotech Stocks Are Pushing for Recovery", "Why Gilead Sciences, Inc. (GILD), Bank of America Corp (BAC) and Facebook Inc (FB) Are 3 of Today\u2019s Best Stocks", "The 3 Most Important Data Releases and FDA Decisions in the Second Half of 2016", "Corporate Share Buybacks Rise to Record Level in First Quarter", "Noteworthy ETF Outflows: XLV, UNH, BMY, GILD", "Can These Upstarts Knock Gilead Sciences Off Its Perch?", "Gilead Presents Favorable Preliminary Bictegravir HIV Data", "New Strong Sell Stocks for June 21st", "These 5 Biotech Stocks Are Ridiculously Cheap", "Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU", "The 3 Most Important Data Releases and FDA Decisions in the Second Half of 2016", "2 Biotech Stocks That Could Raise Their Dividends -- and 1 That Won't", "New Strong Sell Stocks for June 17th", "ABBV Named A Top Socially Responsible Dividend Stock", "3 Reasons Gilead Sciences Is a Buy", "Noteworthy ETF Inflows: XLV, UNH, BMY, GILD", "Why Achillion Pharmaceuticals Is Down Big in 2016", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for June 14, 2016", "Dividend Stocks Retirees Can Buy", "My Favorite Clinical-Stage Biotech Stocks to Buy", "3 Stocks That Are Ridiculously Cheap Right Now", "Why Galapagos NV Shares Soared 30.5% in May", "Acadia Pharmaceuticals Inc.: 7 Companies That Could Buy ACAD", "Legal Dispute Puts Ionis Pharmaceuticals' Payday on Hold", "3 Biotech Stocks to Buy If the Market Crashes", "3 Cheap Biotech Stocks You Can Buy Now", "After Hours Most Active for Jun 6, 2016 : BAX, AMAT, WPX, SPLS, BABA, S, CSCO, STJ, GILD, PHM, TVIX, CMCSA", "7 Stocks to Buy in June", "Forget Biogen: These 3 Stocks Are Better Buys", "Is AbbVie's Stock Too Risky?", "GuruFocus Best Idea Contest \u2014\u2026\u20136: Who Is Beating the Market", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for June 02, 2016", "Noteworthy ETF Inflows: XLV, UNH, BMY, GILD", "3 Perfect Stocks for Baby Boomers in Their 50s to Consider Buying", "Gilead's (GILD) New HCV Drug Epclusa Wins CHMP Backing", "5 Dividend Stocks to Buy in June", "10 Biotech Stocks With Symptoms of Strong Growth", "Notable ETF Inflow Detected - XLV, UNH, BMY, GILD", "Interested in Medivation? Take a Number!", "3 Retirement Stocks to Buy in June", "Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News", "Billionaires Are Bailing on Gilead Sciences -- Should You, Too?", "3 Stocks the Market Loves to Hate, but You Should Love", "After Hours Most Active for May 25, 2016 : FCX, YHOO, ETE, QQQ, JPM, SYMC, MCD, DOW, WFC, INTC, GILD, AAPL", "Galapagos' RA Drug Filgotinib to Enter Phase III in 3Q16", "Notable Tuesday Option Activity: CYTR, GILD, CKEC", "Your 2016 Guide to Investing in Gilead Sciences Stock", "Gilead Sciences, Inc. (GILD): Grab This Bargain While You Can", "Better Buy: Gilead Sciences Inc. vs. Johnson & Johnson", "Friday's ETF with Unusual Volume: PBE", "These 4 Value Stocks Are Collectively Generating $114 Billion in Free Cash Flow a Year", "Low Volatility ETFs For The Impatient Investor Are Latest Hot Trend", "Biotech Stocks Show Signs Of Revival, But Beware Of Side Effects", "XLV, UNH, GILD, AMGN: ETF Outflow Alert", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 13, 2016", "Noteworthy ETF Outflows: XLV, UNH, GILD, AMGN", "Billionaire George Soros' Fund Bought These Stocks: Should You?", "Biotech Giant Gilead Sciences Goes on Sale", "Drug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for May 11, 2016", "Walt Disney Co (DIS) Stock: Short the Short-Term", "Should You Buy Or Sell Gilead (GILD) Stock? 3 Pros, 3 Cons", "Drug Stocks' Earnings Previews: FGEN, IRWD, ENTA, FLML", "7 Figures That Sum Up Merck & Co.'s First Quarter", "Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY", "Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More", "Health Care Select Sector SPDR Fund Experiences Big Inflow", "3 Dirt-Cheap Biotech Stocks To Buy", "Better Buy: Gilead Sciences vs. Biogen", "Biotech Stock Roundup: Amgen Impresses, Gilead Disappoints in Q1, Biogen to Spin Off Hemophilia", "This New Stock Market Trend Is Catching Investors By Surprise (but It Shouldn't)", "Mallinckrodt (MNK) Tops Q2 Earnings and Sales, Ups View", "The Zacks Analyst Blog Highlights: Amgen, Gilead, Celgene, Medivation and Biogen", "Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More", "Health Care Select Sector SPDR Fund Experiences Big Inflow", "3 Dirt-Cheap Biotech Stocks To Buy", "Better Buy: Gilead Sciences vs. Biogen", "What Sent Medivation, Inc.'s Shares Soaring 25.1% In April", "5 Data Points Wall Street Is Anxiously Awaiting in Merck's Q1 Report", "SurModics (SRDX) Beats Q2 Earnings & Revenues Estimates", "Alnylam (ALNY) Reports Wider-than-Expected Loss in Q1", "Novo Nordisk (NVO) Beats on Q1 Earnings, Retains Outlook", "ImmunoGen (IMGN) Posts Wider-than-Expected Q3 Loss", "Stock Market News for May 02, 2016", "Biotech ETFs Sink on Mixed Q1 Results", "Shire (SHPG) Tops Q1 Earnings, Baxalta Buyout Set for June", "Trade of the Day: IBB Breaking Down", "Good News: Gilead Sciences Discounted Its Drugs Again", "Aduro (ADRO) Q1 Loss Wider than Expected, Revenues Fall", "3 Key Pipeline Developments for Gilead Investors to Watch", "RPT: U.S. Stocks Slump, Led by Healthcare and Technology", "Chevron Corporation Continues Chasing a Moving Target in Oil (CVX)", "Gilead Sciences, Inc. Reports Disappointing Q1 Harvoni Sales", "3 Drug Stocks Reporting Early Next Week: PFE, MYL, MNK", "2 Bullish Bets for Alibaba Group Holding Ltd (BABA)", "The Zacks Analyst Blog Highlights: Broadcom, Kellogg, Altria Group, Gilead Sciences and Braskem", "Does Healthcare\u2019s Past Predict its Future?", "3 Megatrends Powering the Growth Machine at Facebook Inc (FB)", "The Motley Fool\u2019s 10 Best Stock Calls of the Last 10 Years", "3 Stocks to Watch on Friday: Amgen, Inc. (AMGN), Gilead Sciences, Inc. (GILD) and TiVo, Inc. (TIVO)", "Why Gilead Sciences, Inc. (GILD), Stericycle Inc (SRCL) and Western Digital Corp (WDC) Are 3 of Today\u2019s Worst Stocks", "Close Update: U.S. Stocks Head for Weekly Loss Amid Apple's Woes", "U.S. Stocks Head for Weekly Loss Amid Apple's Woes", "Daily Dividend Report: GILD, PFG, OXY, PX, K, HCN, PAYX", "Gilead (GILD) Lags Q1 Earnings & Revenues, '16 View Intact", "3 Megatrends Powering the Growth Machine at Facebook Inc (FB)", "The Motley Fool\u2019s 10 Best Stock Calls of the Last 10 Years", "3 Stocks to Watch on Friday: Amgen, Inc. (AMGN), Gilead Sciences, Inc. (GILD) and TiVo, Inc. (TIVO)", "Why Gilead Sciences, Inc. (GILD), Stericycle Inc (SRCL) and Western Digital Corp (WDC) Are 3 of Today\u2019s Worst Stocks", "Close Update: U.S. Stocks Head for Weekly Loss Amid Apple's Woes", "Q1 Earnings Reports Continue the Deluge: AMZN, GILD, AMGN", "Gilead Sciences (GILD) Stock Slumps on Q1 Earnings, Revenue Miss", "Friday's ETF Movers: GDX, BBH", "RPT - Mid-Day Update: U.S. Stocks Decline, Led by Technology and Healthcare Sectors After Weak Earnings", "The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead", "AbbVie (ABBV) Beats on 1Q Earnings, Lowers View on Deal", "Sanofi's Bid for Medivation Is Too Low", "Earnings Reaction History: Gilead Sciences Inc., 50.0% Follow-Through Indicator, 3.3% Sensitive", "After-Hours Earnings Report for April 28, 2016 : AMZN, GILD, AMGN, BIDU, HIG, RSG, EXPE, ESS, BMRN, LNKD, SWKS, DLR", "4 Biotech Stocks Reporting on Apr 28: AMGN, GILD, ALXN, CELG", "Amazon.com, Inc. (AMZN): Q1 Earnings Answer Investors\u2019 Prayers", "Aegerion (AEGR): Can the Stock Surprise in Q1 Earnings?", "Aerie (AERI): Can the Stock Pull a Surprise in Q1 Earnings?", "Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News", "Biotech Stock Gilead (GILD) Likely to Beat in Q1 Earnings", "UCB (UCBJF) Posts Q1 Results, Reiterates 2016 Guidance", "Health Care Select Sector SPDR Fund Experiences Big Inflow", "Henry Schein (HSIC) Q1 Earnings: Can the Stock Surprise?", "Why Gilead Sciences (GILD) Might Surprise This Earnings Season", "Aegerion (AEGR): Can the Stock Surprise in Q1 Earnings?", "Aerie (AERI): Can the Stock Pull a Surprise in Q1 Earnings?", "Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News", "Myriad Genetics (MYGN) Q3 Earnings: A Beat in the Cards?", "Perrigo's CEO Resigns, Trims 2016 Outlook, Stock Tumbles", "Healthcare Q1 Earnings Look Solid: ETFs to Benefit", "Will Ametek (AME) Earnings Surpass Estimates in Q1?", "Will CVS Health (CVS) Earnings Surprise Estimates in Q1?", "Amgen (AMGN) May Beat Q1 Earnings: Will the Stock Gain?", "Can Arrowhead Do For Hep B What Gilead Sciences Did For Hep C?", "5 Biotech Stocks to Bet on This Earnings Season", "87% of Americans Want Medicare to Have This Power, but the Federal Government Disagrees", "Are These 3 Biotechs Destined to Be Bought Out?", "3 Things to Watch in Gilead Sciences, Inc.'s First-Quarter Results", "What's in Store for Keryx (KERX) this Earnings Season?", "Texas Instruments (TXN) Q1 Earnings: What Lies in Store?", "Will Thermo Fisher (TMO) Exceed Q1 Earnings Expectations?", "Will GNC Holdings' (GNC) Q1 Earnings Surprise Investors?", "3 Stocks to Buy in a Crashing Market", "GILD Makes Bullish Cross Above Critical Moving Average", "What Awaits Edwards Lifesciences (EW) in Q1 Earnings?", "Zimmer Biomet (ZBH) Q1 Earnings: A Beat in the Cards?", "The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen", "Express Scripts (ESRX) Q1 Earnings: Stock to Disappoint?", "5 Stocks That Could Hike Their Dividends 20%", "Epizyme (EPZM) Q1 Earnings: Can the Stock Surprise?", "Healthcare ETFs to Buy on Blockbuster J&J Q1 Results", "Biotech Stock Roundup: Medivation Buyout Rumors Resurface, Synta Up on Merger Deal", "3 Biotech Stocks That Could Endure Hillary Clinton", "Biogen (BIIB) Tops on Q1 Earnings, Slight Revenue Miss", "The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen", "Express Scripts (ESRX) Q1 Earnings: Stock to Disappoint?", "5 Stocks That Could Hike Their Dividends 20%", "Epizyme (EPZM) Q1 Earnings: Can the Stock Surprise?", "Healthcare ETFs to Buy on Blockbuster J&J Q1 Results", "Top 4 Sales Growth Stocks", "The Big Downside to Better Medicine? Higher Prices", "Don't Let the Day's News Drive Your Investing", "Better Buy: Gilead Sciences Inc. vs. Celgene Corporation", "Why Regulus Therapeutics Is Slumping 14% Today", "Friday's ETF with Unusual Volume: IYH", "AbbVie Reveals Positive Data on Combination HCV Therapy", "Merck Offers Positive Data from Comparative Trial on Zepatier", "SPDR S&P 500 Growth ETF Experiences Big Inflow", "Better Buy: Inovio Pharmaceuticals or Arrowhead Research Corp.?", "The 1 Stock You've Been Overlooking for Your Roth IRA", "Horizon Pharma Plunges on Bleak Q1 and 1H16 Guidance", "Nasdaq 100 Movers: STX, JD", "CorMedix (CRMD) Worth Watching: Stock Soars 19.9%", "How ROE Can Ensure Big Gains While Picking Cash-Rich Stocks", "Clovis Drops, FDA Panel Seeks More Data on Rociletinib", "AbbVie's Venclexta Notches FDA Win, But Investors Might Want To Temper Enthusiasm", "3 Biotech Stocks to Buy in April", "3 Momentum Stocks To Buy Now", "Weekly CEO Sells Highlight: Gilead Sciences, Boston Scientific, Sonic, HealthEquity", "After Nearly 39 Million Deaths, a Cure for HIV Could Be Just 3 Years Away", "Edwards Lifesciences Corp: EW Stock Is at the Heart of Innovation", "The Zacks Analyst Blog Highlights: 3M, Canadian Pacific Railway, Edison International, CGI Group and Gilead Sciences", "After Hours Most Active for Apr 8, 2016 : RIG, CIT, GE, SYMC, ESRX, INTC, GLW, PFE, GILD, CSCO, BRCD, WMT", "3M (MMM): A Likely Winner Among Losers This Earnings Season?", "3 Big Pharma Stocks to Buy, 3 to Avoid", "The Zacks Analyst Blog Highlights: Gilead, Regeneron, Medivation and Intercept", "Gilead (GILD) is a Cheap Growth Stock Worth Buying Now", "Notable ETF Outflow Detected - IWB, GILD, AMGN, SBUX", "5 Dividend Stocks Starting a Multi-Decade Bull Market", "The Zacks Analyst Blog Highlights: Edwards Lifesciences, PRA Health Sciences, Gilead Sciences, AMAG Pharmaceuticals and Horizon Pharma", "Biotech Stock Roundup: Gilead's HIV Drug Approved, Regeneron Up on Positive Data", "4 Great Stocks to Ride the IBB Rebound", "Ignore Exelixis, Inc.: Here Are 3 Better Stocks", "Forget Regeneron Pharmaceuticals, Inc.: These 2 Stocks Are Better Buys", "Gilead Descovy Wins FDA Nod, To Buy Nimbus Liver Program", "Why Is Gilead Sciences (GILD) A Zacks Rank #1 Stock Right Now?", "Gilead Sciences, Inc. (GILD) Buys Nimbus Therapeutics Subsidiary for $1.2B", "Commit To Buy Gilead Sciences At $47.50, Earn 3.6% Using Options", "3 Biotech Stocks on the Verge of an Overdue Run (AMGN, GILD, REGN)", "Better Buy: Gilead Sciences Inc. vs. Biogen Inc.", "Nasdaq 100 Movers: ENDP, EBAY", "Forget Regeneron Pharmaceuticals, Inc.: These 2 Stocks Are Better Buys", "Gilead Descovy Wins FDA Nod, To Buy Nimbus Liver Program", "Why Is Gilead Sciences (GILD) A Zacks Rank #1 Stock Right Now?", "Gilead Sciences, Inc. (GILD) Buys Nimbus Therapeutics Subsidiary for $1.2B", "Commit To Buy Gilead Sciences At $47.50, Earn 3.6% Using Options", "3 Biotech Stocks on the Verge of an Overdue Run (AMGN, GILD, REGN)", "3 Stocks We're Watching in the Second Quarter", "Buying These 2 Drug Developers Would Make a Lot of Sense for Johnson & Johnson", "After Hours Most Active for Mar 31, 2016 : BAC, VG, GE, MSFT, GILD, QQQ, GRUB, FCX, PFE, AAPL, CSCO, INTC", "Health Care Sector Update for 03/31/2016: MDVN,AZN,GILD,AMGN,SNY,GNVA,LIFE", "3 Biotech Stocks That Make the Grade for Investors", "4 Value Stocks to Buy Now", "5 Value Stocks to Buy Now", "Markets Reverse Earlier Declines as Consumer, Tech Stocks Lead Gains But Falling Oil Price, Yellen Speech Limits Advance", "5 Large Cap Stocks with P/Es Below 15: A Must Buy?", "The Zacks Analyst Blog Highlights: Accenture, Broadcom, Gilead Sciences, ULTA Salon, Cosmetics & Fragrance, and NetEase", "3 Biotech Stocks You Don't Have to Babysit", "Close Update: Wall Street Gives Yellen's Speech Thumbs-Up", "Health Care Sector Update for 03/29/2016: NVTA,CTRV,BPMX", "Health Care Sector Update for 03/29/2016: PBYI,CTRV,GILD,BPMX", "Gilead to Pay $200 Million to Merck for HCV Patent Dispute", "Nasdaq 100 Movers: MU, MAR", "Noteworthy ETF Inflows: ITOT, AAPL, CVX, GILD", "A Snapshot of the 6 Cheapest Megacap Stocks", "Buy These 5 Large Caps for Incredible ROI Potential", "Patent Payoff? Merck's and Ionis Pharmaceuticals' Take Could Be Tiny", "AbbVie Inc.'s Big Win Over Gilead Sciences Wasn't in Hepatitis C", "After Hours Most Active for Mar 24, 2016 : BXLT, SPN, GE, QQQ, MSFT, SAN, AES, JD, PFE, QCOM, ATML, GILD", "Gilead & Biogen's Patent Woes, Amgen Scores Win in Patent Litigation", "An Attempt to Value Valeant Just for Fun", "The Zacks Analyst Blog Highlights: Gilead, Amgen, Regeneron, Ionis and Biogen", "Pre-Market Most Active for Mar 23, 2016 : MIK, ASX, HNT, VRX, CNC, NKE, TVIX, SDRL, HMIN, IONS, GILD, QQQ", "Gilead Sciences' Cancer Folly", "Why Freeport-McMoRan Inc (FCX), Gilead Sciences, Inc. (GILD) and Tesla Motors Inc (TSLA) Are 3 of Today\u2019s Worst Stocks", "Eli Lilly and Co: Can LLY Stock Get Healthy Again?", "Stock Market News for March 22, 2012", "Gilead and 4 Other Buy Stocks in the Biotech Industry", "Gilead Sciences, Inc.: GILD Could Squeeze the Bears From Here", "The Surprising Winner in Merck's Patent War With Gilead Sciences", "3 Large-Cap Stocks With the Highest Net Profit Margins", "Forget CVS Health Corp.: Here Are 2 Better Dividend Stocks", "Do You Own Any Of These Top Sector Funds?", "Gilead, Expedia Are Greatly Undervalued", "The Zacks Analyst Blog Highlights: GW Pharma, Orexigen, Gilead and Regeneron", "Biotech Stock Roundup: GW Pharma Soars on Epidiolex Data, Gilead's Zydelig in Trouble?", "Stock Market News for March 16, 2016", "XLV, GILD, AGN, ABT: Large Outflows Detected at ETF", "Why Investors Should Sell These Biotech Stocks & Buy Gilead Instead", "The Zacks Analyst Blog Highlights: Celgene, Gilead Sciences and Logitech International", "Better To Short Biotech ETF Or To Invest In Inverse Counterpart?", "4 Large Caps to Navigate an Erratic Market", "Gilead's Zydelig under EU Review amid Safety Concerns", "Biotech Investing Guide: 3 Stocks to Buy and 3 to Avoid", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for March 14, 2016", "The Zacks Analyst Blog Highlights: Koninklijke Ahold N.V., Gilead Sciences, HCA Holdings and Tyson Foods", "AbbVie Inc (ABBV) Is About to Steamroll the Competition", "Sucampo Beats Earnings & Revenues on Strong Amitiza Sales", "Merck KGaA's Q4 Earnings Down Y/Y, Offers 2016 Outlook", "Is U.S. Demand for New Hepatitis C Drugs About to Explode?", "3 Value Stocks Near 52-Week Lows Worth Buying", "3 Stocks to Hold Forever", "Celldex Advised to Discontinue Phase III Study on Rintega", "3 Stocks We Like More Than Johnson & Johnson", "Can Conatus (CNAT) Surprise Estimates in Q4 Earnings?", "Better Buy: Celgene Corporation vs. Gilead Sciences", "The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Gilead Sciences, Biogen, Amgen and Regeneron Pharmaceuticals", "After Hours Most Active for Mar 7, 2016 : NJR, SDRL, FTSM, CLF, MOS, HBI, V, AMAT, BJRI, MSFT, GILD, QQQ", "Last Month's Best Healthcare ETF", "What Does Trump's Healthcare Plan Mean for Investors?", "Gilead Sciences, Inc.: Short the Looming Value Trap in GILD Stock", "The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is a Buy, But Not for Long", "The Zacks Analyst Blog Highlights: Gilead, Amgen, Baxalta, PTC Therapeutics and Cara Therapeutics", "Biotech Stock Roundup: Gilead HIV Drug Approved, Baxalta in Immuno-Oncology Deal", "The Zacks Analyst Blog Highlights: Petrobras, Korea Electric Power, Taiwan's Chungwa Telecom, Gilead Sciences and Celgene", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for March 02, 2016", "Forget Eli Lilly and Co: Here Are 2 Better Dividend Stocks", "Worry More or Worry Less? Global Week Ahead", "2 Drug Stocks To Buy For Safe Dividends And 20% Gains", "After Hours Most Active for Mar 4, 2016 : UDR, HR, MU, AIG, GILD, IBN, QQQ, JPM, CMI, AAPL, VIP, MSFT", "Geron Q4 Loss In-Line with Estimates, Imetelstat in Focus", "United Therapeutics Tops on 4Q Revenues, Earnings Up Y/Y", "Noteworthy ETF Inflows: XLV, PFE, GILD, AGN", "How to Find Ethical Investments in the Pharmaceutical Industry", "A Look Back at 2 Successful Biotech Buyouts", "Do Sky-High Drug Prices Turn Biotech Companies Into Bad Guys?", "Better Buy: Gilead Sciences Inc. vs. Amgen Inc.", "Should This Data Worry Gilead Sciences Inc.'s Investors?", "The Simple Way I Search for the Next Hit Stock", "Is This the Company Gilead Sciences Should Fear Most? (Hint: It's Not Merck or AbbVie)", "5 Ways to Spot Awe-Inspiring Growth Stocks", "Agios' (AGIO) Q4 Loss Wider than Expected, Pipeline in Focus", "Can Biotech Stocks Bounce Back?", "The Zacks Analyst Blog Highlights: Incyte, Intercept Pharma, Gilead, Aegerion and Clovis", "Forget AbbVie Inc.: Here Are 2 Better Dividend Stocks", "Is Big Pharma Evil?", "The Simple Way I Search for the Next Hit Stock", "Is This the Company Gilead Sciences Should Fear Most? (Hint: It's Not Merck or AbbVie)", "5 Ways to Spot Awe-Inspiring Growth Stocks", "Biotech Stock Roundup: Incyte Down on Jakafi Update, Is Intercept a Buyout Target?", "Express Scripts Tops Earnings in Q4, Misses on Revenues", "Pre-Market Most Active for Feb 17, 2016 : ASX, BAC, KMI, NJ, GRPN, RGLS, MFG, NOK, AAPL, TVIX, XIV, GILD", "3 Quotes Show Gilead Sciences' New CEO Is Ready to Deal", "4 Funds to Buy on Healthy Medical Sector Earnings", "Gilead's HCV Drug Harvoni Approved in Two More Indications", "Noteworthy ETF Inflows: QUAL, MSFT, AAPL, GILD", "Intercept Pharmaceuticals (ICPT) Soars on Buyout Rumors", "Novartis Acquires Rights to Biosimilar of Remicade from Pfizer", "7 Words That Could Have Biotech and Big Pharma Very Worried", "Zoetis Tops Q4 Earnings and Revenues, Updates Guidance", "Gilead Sciences Wants to Make Being a Shareholder Worth It", "Bouncing Biotech? Here Are 3 Stocks to Buy", "Acorda Q4 Earnings Decline Y/Y, Ampyra & Pipeline in Focus", "These 7 Single-Digit P/E Stocks Could Collectively Deliver $600 Billion in Free Cash Flow by 2020", "Why Intercept Pharmaceuticals Inc is Skyrocketing Today", "Novartis Filing for Neulasta Biosimilar Accepted in the EU", "Achillion Begins Study on First Complement Factor D Inhibitor", "Genomic Health Q4 Loss Wider than Expected, Revenues Up", "GW Pharmaceuticals Up on Narrower-than-Expected Q1 Loss", "Shire Tops Q4 Earnings, Baxalta Buyout & Lifitegrast in Focus", "Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 11, 2016", "Pfizer's Biosimilar of Remicade Recommended for Approval", "CTI BioPharma's Myelofibrosis Drug on Full Clinical Hold", "Gilead Sciences Inc.'s Outlook For 2016: What Investors Need to Know", "3 Biotech Stocks to Buy in a Market Crash", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for February 10, 2016", "Roche to Stop Study on Lung Cancer Drug Alecensa Early", "Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 11, 2016", "Pfizer's Biosimilar of Remicade Recommended for Approval", "CTI BioPharma's Myelofibrosis Drug on Full Clinical Hold", "Gilead Sciences Inc.'s Outlook For 2016: What Investors Need to Know", "3 Biotech Stocks to Buy in a Market Crash", "1 Company Gilead Sciences Should Consider Buying Right Now", "Curing Hepatitis C: How Gilead Sciences Plans to Beat Merck", "5 Stocks We're Buying Again", "Gilead Sciences 2016 Guidance: Sandbagging Wall Street Again?", "The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Intrexon and NewLink", "Why Did Biotech Fall Off a Cliff in January?", "4 Can't-Miss Numbers From GlaxoSmithKline's Fourth-Quarter Results", "Why Achillion Pharmaceuticals Shares Crashed 37% in January", "Qiagen Q4 Earnings Miss, Molecular Diagnostics Disappoints", "Noteworthy ETF Outflows: XLV, GILD, AGN, MDT", "5 Stocks We're Buying Again", "The Zacks Analyst Blog Highlights: Gilead Sciences, Mylan, United Therapeutics and INSYS Therapeutics", "The Zacks Analyst Blog Highlights: Darden Restaurants, KLA-Tencor, Motorola Solutions, Gilead Sciences and NVIDIA", "The Zacks Analyst Blog Highlights: Yahoo, Chipotle, Gilead Sciences and Match Group", "Gilead (GILD) Beats Q4 Earnings Estimates, Gives 2016 View", "Market Close Report: NASDAQ Composite index closes at 4,504.24 down -12.71 points", "International Growth Propels Gilead Sciences Inc.'s Solid Q4 Results", "Forget Gilead Sciences: These Stocks Doubled Last Year", "Instant Analysis: Gilead Sciences Raises Its Dividend 10%", "Myriad Genetics Tops Q2 Earnings; myRisk Conversion Over", "Why Gilead Sciences Shares Tumbled 18% in January", "Start the New Year off Right with 3 Best Biotech Stocks", "4 Top-Ranked Biotech Stocks on Sale", "5 Top-Rated S&P 500 Dividend Stocks to Buy in February", "Gilead's Stock is on Sale: Should You Buy?", "Gilead Sciences (GILD) Beats Earnings and Revenue Estimates", "After Hours Most Active for Feb 2, 2016 : FCAU, QQQ, MRVL, HPE, MSFT, GILD, T, DFT, AAPL, FUEL, AKR, GE", "How to Benefit from Daily Trading Order Flow", "Abbott Labs to Boost Diagnostics Business with Alere Buyout", "Will Qorvo (QRVO) Miss Q3 Earnings on Expected Low Sales?", "What's in Store for Stericycle (SRCL) this Earnings?", "Earnings Reaction History: Gilead Sciences Inc., 50.0% Follow-Through Indicator, 3.1% Sensitive", "Pfizer Beats on Q4 Earnings, Revenues, Outlook Disappoints", "Gilead Sciences (GILD) Beats Earnings and Revenue Estimates", "After Hours Most Active for Feb 2, 2016 : FCAU, QQQ, MRVL, HPE, MSFT, GILD, T, DFT, AAPL, FUEL, AKR, GE", "How to Benefit from Daily Trading Order Flow", "Abbott Labs to Boost Diagnostics Business with Alere Buyout", "3 Biotech Stocks You Don't Have to Babysit", "Will Mallinckrodt (MNK) Earnings Disappoint Investors in Q1?", "Can Microchip (MCHP) Keep the Earnings Streak Alive in Q3?", "After-Hours Earnings Report for February 2, 2016 : GILD, EQR, YHOO, ILMN, FISV, EW, CMG, KIM, UDR, CHRW, DOX, ATO", "Is Alexion (ALXN) Likely to Disappoint this Earnings Season?", "GW Pharmaceuticals (GWPH): What Awaits in Q1 Earnings?", "Is Illumina (ILMN) Poised to Beat Earnings Estimates in Q4?", "Johnson & Johnson Wants Investors to Ignore Falling Hepatitis C Drug Sales", "3 Surprisingly Controversial Stocks in Donald Trump's Portfolio", "Here's Why Johnson & Johnson's Sales Fell Last Year", "What's in Store for Nivalis (NVLS) this Earnings Season?", "Can GlaxoSmithKline (GSK) Q4 Earnings Surprise Estimates?", "Instant Analysis: Can Merck Make Waves In the Crowded Hepatitis C Space?", "Merck's Hepatitis C Doublet Wins FDA Approval and Unveils Its Secret Weapon", "Should You Buy Gilead Sciences (GILD) Ahead of Earnings?", "Amgen Tops on Q4 Earnings & Revenues, Ups 2016 Outlook", "Pre-Market Most Active for Jan 29, 2016 : CBX, GILD, TAP, TVIX, UBS, MSFT, INO, QQQ, BAC, FB, NOK, XRX", "Merck's HCV Drug Zepatier Gets FDA Nod; Sets Lower Price", "Bristol-Myers' Daklinza-Sovaldi Label Expanded in the EU", "Can Gilead (GILD) Keep the Earnings Streak Alive in Q4?", "Instant Analysis: Can Merck Make Waves In the Crowded Hepatitis C Space?", "Merck's Hepatitis C Doublet Wins FDA Approval and Unveils Its Secret Weapon", "Should You Buy Gilead Sciences (GILD) Ahead of Earnings?", "Amgen Tops on Q4 Earnings & Revenues, Ups 2016 Outlook", "Roche's (RHHBY) Earnings Miss Estimates, Revenues Beat", "Edwards Lifesciences (EW) Likely to Top Earnings Again in Q4", "AbbVie Posts In-Line Earnings, Maintains 2016 Outlook", "Johnson & Johnson's Results Include a Healthy Dose of Asterisks", "Abbott Labs (ABT) Beats on Q4 Earnings, Lags on Revenues", "XLV, PFE, GILD, AGN: Large Inflows Detected at ETF", "Celgene Misses on Q4 Earnings, Reiterates 2016 Guidance", "Gilead Sciences (GILD) Looks Cheap at these Levels", "Bristol-Myers Beats on Q4 Earnings, Provides 2016 Guidance", "Vertex (VRTX) Posts Narrower 4Q Loss, Maintains Outlook", "3 Things to Watch in Gilead Sciences' Q4 Results", "Can Baxter (BAX) Pull a Surprise this Earnings Season?", "ImmunoGen (IMGN) Q2 Earnings Preview: What to Expect?", "Will Alibaba Group (BABA) Beat Earnings Estimates in Q3?", "Biogen Tops on Q4 Earnings by a Wide Margin, Provides View", "Will 2016 Be BioMarin Pharmaceutical's Best Year Yet?", "Will AbbVie (ABBV) Keep the Earnings Streak Alive in Q4?", "Will Currency Volatility Keep Hurting Abbott's (ABT) Earnings?", "Will Myriad Genetics Q2 Earnings (MYGN) Surprise Investors?", "5 Mouthwatering Stocks on Sale Now", "ImmunoGen (IMGN) Q2 Earnings Preview: What to Expect?", "Will Alibaba Group (BABA) Beat Earnings Estimates in Q3?", "Biogen Tops on Q4 Earnings by a Wide Margin, Provides View", "Will 2016 Be BioMarin Pharmaceutical's Best Year Yet?", "J&J's Q4 Results Mixed with Earnings Beat, Revenue Miss", "The Zacks Analyst Blog Highlights: Gilead Sciences, Horizon Pharma, NXP Semiconductor and TDK", "Celgene (CELG) to Report Q4 Earnings: What to Expect?", "Will Thermo Fisher (TMO) Surprise Q4 Earnings Expectations?", "Will Currency and Generics Hit J&J's (JNJ) Q4 Earnings?", "Oil Short Covering Isn't A Share Price Bottom - Global Week Ahead", "Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks", "The Stock Sell-Off: What Should You Do Now?", "Will Biogen (BIIB) Beat 4Q Earnings on MS Franchise Sales?", "After Hours Most Active for Jan 25, 2016 : BAC, FCAU, QQQ, HLF, MSFT, SCHW, HPE, SIRI, AAPL, HES, GILD, CSCO", "Will Higher Expenses Hurt Vertex's (VRTX) 4Q Earnings?", "Will Mead Johnson (MJN) Q4 Earnings Let Down Investors?", "See Which Of The Latest 13F Filers Holds Gilead Sciences", "Why Q4 Earnings Beat is Dicey at Quest Diagnostics (DGX)", "Will Zimmer Biomet (ZBH) Beat Earnings Again in Q4?", "What to Expect from Lam Research's (LRCX) Q2 Earnings?", "What's in Store for Texas Instruments' (TXN) Q4 Earnings?", "Gilead Takes a Page Out of Celgene's Playbook", "What's in Store for Teradyne (TER) this Earnings Season?", "Will Bristol-Myers (BMY) Beat Q4 Earnings Expectations?", "What's in Store for Corning (GLW) This Earnings Season?", "5 Dividend Stocks to Buy in January", "Zacks Investment Ideas feature highlights: Gilead Sciences, Qorvo, Essex Property Trust and Facebook", "Merrimack Reports Positive Onivyde Data in Pancreatic Cancer", "Dynavax, AstraZeneca Amend Deal for Asthma Candidate", "The Weekly Play: Sell Calls on This Sector (IBB)", "3 Slides That Perfectly Sum Up Where AbbVie Is Headed Next", "Cleveland BioLabs Gets Orphan Status for Entolimod in EU", "What's in Store for Corning (GLW) This Earnings Season?", "5 Dividend Stocks to Buy in January", "Zacks Investment Ideas feature highlights: Gilead Sciences, Qorvo, Essex Property Trust and Facebook", "The Zacks Analyst Blog Highlights: Amazon.com, Delta Air Lines, Gilead Sciences, Citrix Systems and Motorola Solutions", "The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Cytokinetics and Bristol-Myers Squibb", "3 Stocks We're Watching in the First Quarter", "Will ResMed (RMD) Surprise Earnings Estimates in Q2?", "4 Biotech Stocks Looking Good this Earnings Season", "5 Strong Growth S&P 500 Stocks to Buy on the Sell-off", "Gilead Sciences' Galapagos Deal Advances It Toward a Multibillion-Dollar Market", "5 Good Stocks to Buy While They Are Cheap", "Why Galapagos NV's Shares Bolted Higher in 2015", "Pluristem (PSTI) Gets FDA Approval for Phase I PLX-R18 Trial", "Gilead Sciences Takes 2 Steps Forward and 1 Step Back", "AbbVie's Management Just Made Some Pretty Bold Predictions", "3 Slides Suggesting Gilead Sciences May Be Unstoppable", "Noteworthy ETF Outflows: XLV, PFE, GILD, BMY", "3 Things You Absolutely Must Know About Merck", "The Zacks Analyst Blog Highlights: Gilead, Horizon Pharma, AVEO Pharmaceuticals, Achillion Pharmaceuticals and Inovio Pharmaceuticals", "Invest in San Francisco with These 3 Stocks!", "Aegerion Provides Preliminary Sales View & Pipeline Updates", "Celldex Therapeutics Drops 10% as Biotech Heads South", "Gilead Seeks Approval for Tenofovir Alafenamide for HBV", "3 Slides Suggesting Gilead Sciences May Be Unstoppable", "5 Biotech Stocks Ready to Crush the Market in 2016", "1 George Soros Quote to Keep in Mind in 2016", "5 Commonly Prescribed Drugs With Six-Digit Annual Price Tags", "3 Healthcare Stocks to Buy on Sale", "AbbVie's Viekira Pak sNDA Accepted with Priority Review", "Vertex (VRTX) Gives 2016 View, Orkambi View to Come Later", "The Zacks Analyst Blog Highlights: Gilead, MannKind, VIVUS and Baxalta", "Company News for January 06, 2016", "Biotech Stock Roundup: MannKind Tanks on Deal Termination, Speedy Review for Gilead Drug", "Gilead Up on Encouraging Data on Tenofovir Alafenamide", "Gilead's (GILD) HCV Drug Gets Priority Review Status in U.S.", "How to Pick an Undervalued Stock Before It Picks Up Steam", "Why the Dow Jones Industrial Average Is Falling Today", "Buy Gilead (GILD) for Deep-Rooted Growth in 2016", "3 Stocks To Buy In A Market Crash", "What Does 2016 Hold for Biotech Stocks?", "What Makes a Stock \"Cheap\"?", "Why Did Gilead Sciences, Inc. Take on a Mountain of Debt?", "Can Gilead Sciences Score With AbbVie's Dropped Ball?", "Drugmaker Returns on R&D Are Shrinking", "Irony of Ironies: Gilead Sciences Is Licensing AbbVie's Rejected Drug", "XLV, PFE, GILD, BMY: Large Outflows Detected at ETF", "Enzon Pharmaceuticals, Inc. (ENZN) Ex-Dividend Date Scheduled for December 30, 2015", "5 Play-It-Safe Stocks for 2016", "What Happened in Biotech in 2015?", "The Worst Johnson & Johnson Headlines in 2015", "3 New Drugs Ready to Explode in 2016", "Biotech Industry Could Offer Early Profit in 2016", "The Zacks Analyst Blog Highlights: Actelion, Amgen, Gilead, AbbVie and BioMarin", "The Zacks Analyst Blog Highlights: OFS Capital, Carnival, Navios Maritime Acquisition, Sibanye Gold and Gilead Sciences", "Noteworthy ETF Inflows: XLV, JNJ, GILD, BMY", "Don't Sell Gilead Sciences; Try This Instead", "Biotech Stock Roundup: KaloBios Removes CEO Shkreli, Actelion PAH Drug Approved", "After Hours Most Active for Dec 22, 2015 : BK, PFE, ETE, MU, AAPL, GILD, ABEV, NKE, QQQ, YHOO, HPE, UBNT", "Is Merck & Co. About to Derail Gilead Sciences?", "After Hours Most Active for Dec 21, 2015 : HST, GM, AAPL, EMC, C, CSCO, KR, PFE, QCOM, FB, XIV, GILD", "This Revolutionary FDA Approval Showcases an Important Trend", "The Best Merck & Co. Inc. Headlines in 2015", "Ackman, Sequoia Stock Valeant Changes Course", "Gilead (GILD) Collaborates with Galapagos for Filgotinib", "U.S. Stock Futures Extend Post-Fed Gains", "Instant Analysis: Amgen Cranks Dividend 27% Higher", "Is There Any Value Left in Healthcare? This Top Investing Firm Seems to Think Not", "Amgen Returns More to Shareholders, Hikes Dividend by 27%", "IUSG, GILD, BMY, MCD: ETF Inflow Alert", "7 Best Cheap Stocks to Buy for 2016", "Ackman, Sequoia Stock Valeant Changes Course", "Gilead (GILD) Collaborates with Galapagos for Filgotinib", "U.S. Stock Futures Extend Post-Fed Gains", "The Average American Spends This Much on Prescription Drugs Each Year", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for December 14, 2015", "Balance Sheet Brawl: Pfizer Vs. Bristol-Myers Squibb", "Will This Study Finally Catapult Gilead Sciences Into a Cancer Powerhouse?", "GlaxoSmithKline plc's Best Drug in 2015", "The 3 Most Important Drugs in Gilead Sciences' Pipeline", "Gilead's HCV Drug's Regulatory Application Validated in EU", "Bristol-Myers/AbbVie Report Long-Term Data on Empliciti", "The Zacks Analyst Blog Highlights: Repros Therapeutics, AbbVie, Amgen, XOMA and Gilead", "AbbVie's NDA for Once-Daily Viekira Pak Accepted by FDA", "After Hours Most Active for Dec 3, 2015 : PAH, QQQ, MDLZ, HPE, PFE, FCX, AAPL, WEN, BAC, ORCL, GILD, CSCO", "Why Achillion Pharmaceuticals Shot 30% Higher in November", "Gilead Reveals Encouraging Data on Leukemia Drug Zydelig", "The 3 Most Important Drugs in Gilead Sciences' Pipeline", "Gilead's HCV Drug's Regulatory Application Validated in EU", "Bristol-Myers/AbbVie Report Long-Term Data on Empliciti", "Biotech Stock Roundup: Repros Tanks on CRL, AbbVie Multiple Myeloma Drug Approved", "Stock Market News for December 01, 2015", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for December 02, 2015", "Curing the World: A Shout Out to Healthcare Innovators", "John Rogers Comments on Gilead Sciences Inc.", "There's a 0.0000000000028% Chance This Drug Doesn't Work", "The Most Important Message From Charlie Sheen's Recent HIV Admission", "3 Healthcare Stocks With Massive Buyback Programs", "The Zacks Analyst Blog Highlights: BioMarin, Amgen, Vertex, Gilead, Biogen and Repros", "5 Dividend Stocks to Buy in December", "Giving Thanks, Healthcare Style", "Gilead Sciences Grabs 4 Regulatory Wins -- but Does It Matter?", "Where Will Gilead Sciences Be in 10 Years?", "There's a 0.0000000000028% Chance This Drug Doesn't Work", "Gilead's (GILD) Cocktail HIV Drug Genvoya Approved in EU", "5 Cheap Health Care Stocks that Promise Healthy Returns", "Zacks Industry Outlook Highlights: Valeant, Pfizer, Allergan, AbbVie and Gilead", "Healthcare's Greatest Dividend Stocks", "Biogen's (BIIB) Biosimilar of Pfizer's Enbrel Gets CHMP Nod", "Can Merck & Co. Take Down Gilead Sciences?", "Biotech Stock Roundup: KaloBios Soars as Shkreli Steps In, FDA Panel Not Convinced about BioMarin Drug", "The Zacks Analyst Blog Highlights: Gilead Sciences, Mylan, Indivior, OmniComm Systems and Air Methods", "Gilead's (GILD) Cocktail HIV Drug Genvoya Approved in EU", "5 Cheap Health Care Stocks that Promise Healthy Returns", "Zacks Industry Outlook Highlights: Valeant, Pfizer, Allergan, AbbVie and Gilead", "This Just In: Upgrades and Downgrades", "GILD Makes Bullish Cross Above Critical Moving Average", "Vertex's (VRTX) Orkambi Approved in EU for Cystic Fibrosis", "3 Biotech Stocks You Don't Have to Babysit", "Gilead's Leukemia Study Unblinded Early on Positive Data", "Bristol-Myers' Opdivo Gets Priority Review from the FDA", "Better Dividend Stock: Gilead Sciences Inc. vs. Teva Pharmaceutical Industries", "AbbVie Reports Encouraging Data on HCV Drug Viekira Pak", "5 Drugs That Are the Face of Prescription Drug Reform", "Tyco Q4 Earnings In Line with Estimates, Revenues Lag", "Biotech Stock Roundup: Clovis Plunges, Label Expansion for Gilead's Harvoni", "Hepatitis C Treatment in 2016: Will Gilead Sciences or AbbVie Win?", "Gilead's (GILD) HCV Drug Harvoni's Label Expanded in U.S.", "IWF, AAPL, GILD, CMCSA: ETF Inflow Alert", "The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem", "A Trio of Catalysts Lift Merck Higher in October", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for November 12, 2015", "5 Biotech Stocks with Good Growth Prospects", "5 Stocks Generating Incredible Return on Assets", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for November 10, 2015", "Three Rules for Options Trading Success", "What Does 2016 Hold for This Closely-Watched Biotech ETF?", "5 Picks on Strongest Jobs Gains of 2015", "Biotech Sees Better-than-Expected Earnings: ETFs in Focus", "Marijuana and Hepatitis C: What to Watch in 2016", "Gilead's (GILD) Cocktail HIV Drug Genvoya Gets FDA Nod", "The Zacks Analyst Blog Highlights: Fiserv, Gilead Sciences, American Eagle Outfitters, BJ's Restaurants and Lennar", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for November 10, 2015", "Does AbbVie's Viekira Pak Warning Land Express Scripts in the Penalty Box?", "Gilead's Sovaldi in Focus on Bradyarrhythmia Concerns", "Biotech Stock Roundup: AbbVie's Humira Remains Strong, Shire to Buy Dyax", "5 Exciting Biotech Stocks to Buy on November Upswing", "Vanguard Growth ETF Experiences Big Inflow", "ViiV Healthcare Attacking, but Gilead Prepares to Strike Back", "Gilead and 2 Biotech Picks Value Investors Will Love", "Make Gilead part of your biotech portfolio", "Which Dividends Would Be Safest If Drug Prices Were Slashed Tomorrow?", "What's in Store for Conatus (CNAT) this Earnings Season?", "5 Best Dividend Stocks To Buy In November", "10 Stocks with 10% Plus Gains in October", "Gilead Sciences Is Shrugging Off Its Competitors", "Health Care Sector Update for 10/30/2015: GILD, SGEN", "Zoetis Tops Q3 Earnings, Ups 2015 Bottom-Line Guidance", "Will AbbVie (ABBV) Surprise on Earnings Again in Q3?", "Daily Dividend Report: AFL, SXI, AAPL, WFC, GILD, MET, ICE, GWW, CHD", "Commit To Purchase Gilead Sciences At $60, Earn 5.1% Using Options", "Biotech Stock Roundup: Biogen Tops Estimates, FDA Approves Alexion's Strensiq", "Gilead (GILD) Beats on Q3 Earnings, HCV Drugs Lose Shine", "This Company's 31-Year Adjusted EPS Growth Streak Will Likely End in 2015", "Top-Rated Stock Picks and Most-Read Stories at Nasdaq.com: October 18 - 24", "Another Strong Quarter for Gilead Sciences, Inc.", "Here's Why Wall Street May Be Dead Wrong About AbbVie", "Gilead Sciences (GILD) Stock Rising On Q3 Earnings and Revenue Estimates", "After Hours Most Active for Oct 27, 2015 : TWTR, AAPL, GE, ABX, QQQ, MSFT, CSCO, PPS, NRG, HCC, GILD, FB", "Earnings Reaction History: Gilead Sciences Inc., 44.4% Follow-Through Indicator, 3.2% Sensitive", "After-Hours Earnings Report for October 27, 2015 : AAPL, GILD, ESRX, CNI, APC, AFL, FISV, EIX, TWTR, VRSK, AKAM, MAC", "Specialty Drug Classes That Are Costing Consumers an Arm and a Leg", "AbbVie Slumps, FDA Issues Warning Related to 2 HCV Drugs", "VUG, AAPL, GILD, DHR: ETF Inflow Alert", "Gilead Sciences (GILD) Jumps: Stock Adds 5.8% in Session", "What's in Store for Gilead (GILD) this Earnings Season?", "Shares of AbbVie Inc Plummeted Today. Here's Why.", "Achillion, J&J's HCV Combo Drug Phase IIa Study Started", "Bullish Two Hundred Day Moving Average Cross - GILD", "Stock Market News for October 21, 2015", "Battle Royale: Gilead Sciences Inc vs Celgene Corporation", "See Which Of The Latest 13F Filers Holds Gilead Sciences", "Gilead Sciences (GILD) Jumps: Stock Adds 5.8% in Session", "What's in Store for Gilead (GILD) this Earnings Season?", "Gilead Sciences: Stagnation Directly Ahead?", "The 5 Best Bargains in the Stock Market", "Bristol-Myers' (BMY) Daklinza Gets NICE Recommendation", "Breaking Down Biotech's Bloodbath: Which Companies to Buy", "3 Big Questions for Gilead Sciences Inc. in Q3", "Stock Market News for October 20, 2015", "Johnson & Johnson Tells Gilead Sciences \"Game On\"", "Noteworthy ETF Inflows: QUAL, AAPL, GILD, COST", "Gilead Sciences: Stagnation Directly Ahead?", "The 5 Best Bargains in the Stock Market", "Bristol-Myers' (BMY) Daklinza Gets NICE Recommendation", "Breaking Down Biotech's Bloodbath: Which Companies to Buy", "3 Beaten-Down Biotech Stocks to Buy Now", "Build Your Long-Term Investment Portfolio", "Stock Market News for October 08, 2015", "Gilead Is About to Disappoint Investors -- but for All the Right Reasons", "3 Pharma Stocks With Big Margins of Safety", "Stock Market News for October 07, 2015", "Biotech's Bloodbath Is Ridiculous; Here's Why", "Bristol-Myers Gets Priority Review for HCV Drug Daklinza", "2 Reasons Gilead Sciences Suffered Through a Rough September", "3 Biotech Stocks That Have Been Unfairly Beaten Down", "Merck's (MRK) All-Oral Ribavirin-Free HCV Data Published", "Notable Tuesday Option Activity: GILD, HP, T", "Why AbbVie Inc.'s Shares Slumped 13% in September", "ContraVir Soars 150% as New HBV Drug is 60x More Active than Gilead's Viread", "3 Biotech Bargains to Buy", "Tweet This Hillary: Pros See Biotech ETFs As A Buy", "Health Care Sector Update for 10/07/2015: CTRV,AVXL,ADPT", "Health Care Sector Update for 10/05/2015: ONCE,CTRV,SIEN", "Health Care Sector Update for 10/05/2015: ATRC,CTRV,GILD,SIEN", "5 Stocks We Bought Recently", "iShares MSCI USA Quality Factor ETF Experiences Big Inflow", "Stock Market News for October 01, 2015", "The Zacks Analyst Blog Highlights: Regeneron, Vertex, Gilead, Biogen and Celgene", "3 Companies That Could Beat Apple to a $1 Trillion Valuation", "Gilead's Letairis Gets FDA Nod in Combination with Adcirca", "Biotech Stock Roundup: Pricing Concerns Hit Biotech Stocks, EU Nod for Regeneron's Praluent", "Buy 3 Compelling Biotech Stocks at Bargain Prices", "Is Gilead Sciences' Dominance in Hepatitis C Unstoppable?", "John Buckingham's Interview With Barron's", "Charlie Munger's Six Filters for Investing Successfully", "Regeneron/Sanofi's PCSK9 Inhibitor Praluent Approved in EU", "Genomic Health Posts Positive Breast Cancer Trial Results", "Stock Market News for September 30, 2015", "Stock Market News for September 25, 2015", "KemPharm (KMPH) Updates on Abuse-Deterrent Opioid Drug", "Aduro (ADRO) to Acquire BioNovion in Cash and Stock Deal", "Bellerophon Presents Positive Interim Data on INOpulse", "Friday's ETF with Unusual Volume: XBI", "Myriad Genetics Posts Positive Data on Oncology Tests", "The Zacks Analyst Blog Highlights: Juno, Amgen, Gilead, Intra-Cellular and TRACONThe Zacks Analyst Blog Highlights: Juno, Amgen, Gilead, Intra-Cellular and TRACON", "The Best-Selling Drugs in the World By 2020", "Conatus Reports Promising Phase II Data on Emricasan", "Amgen, Allergan's Biosimilar of Avastin Tops Phase III Study", "PDL BioPharma Concludes Financing Agreement with Avinger", "Myriad Genetics: Study Results Impress, Currency Woes Stay", "Biotech Stock Roundup: Clinton's Tweet Shakes Biotech Stocks, Amgen In Pipeline-Boosting Deals", "Zacks.com featured expert Kevin Matras highlights: Cal-Maine Foods, Express, Tesoro, Build-A-Bear Workshop and Gilead Sciences", "$24.7 Billion Says Gilead Is Up to Something", "Orexigen Receives $22M Milestone Payment for Contrave", "ANI Pharmaceuticals (ANIP) Falls: Stock Goes Down 15.8%", "Strength Seen in Vascular Biogenics (VBLT): Stock Up 22%", "KYTHERA Files IND Application for Male Hair Loss Treatment", "Heron's (HRTX) Post-Operative Pain Candidate Encourages", "AcelRx's Pain Treatment Drug Zalviso Approved in Europe", "Weekly Insider Sells Highlight: Flowers Foods, Gilead Sciences, Cigna, HanesBrands", "Pfizer's Xeljanz Tops Phase III Ulcerative Colitis Studies", "Horizon Pharma (HZNP) in Focus: Stock Plunges 12%", "ANI Pharmaceuticals (ANIP) Falls: Stock Goes Down 15.8%", "Strength Seen in Vascular Biogenics (VBLT): Stock Up 22%", "PEG Ratio vs. the P/E Ratio", "10 Super-High-Growth Stocks to Buy Now", "Dicerna Pharmaceuticals (DRNA) Rises: Stock Gains 7.8%", "The Zacks Analyst Blog Highlights: Medivation, Gilead Sciences, Regeneron Pharmaceuticals and Anthera Pharmaceuticals", "Organovo Holdings (ONVO) In Focus: Stock Jumps 6.7%", "Inovio Gets Grant for Ebola Drugs, Regeneron Inks Deal", "Flex Pharma (FLKS) in Focus; Stock Tumbles 8.9%", "Here's Why Gilead Sciences Is a Buy (Hint: It's Not Hepatitis C)", "To Test or Retest?", "Amgen's Kyprolis Label Expansion Under Priority Review", "Trevena Hits a 52-Week High on Positive Phase II Data", "GILD Crosses Below Key Moving Average Level", "TRACON Skyrockets on Positive Choriocarcinoma Study Data", "GenVec (GNVC) Shows Strength: Stock Moves Up 18.7%", "Neogenomics Hits a 52-Week High on Cancer-Testing Deal", "3 Triple-Digit Biotech Stocks That Are Worth Every Penny", "Notable ETF Inflow Detected - XLV, JNJ, GILD, MRK", "Yellen Doesn't Raise Rates: 4 Biotech Stocks to Buy", "Allergan/Gedeon's Vraylar Gets FDA Nod for Mental Disorders", "Friday's ETF with Unusual Volume: XBI", "3 Biotech Stocks That Can Upgrade Your Portfolio", "BioDelivery Up, Opioid Dependence Treatments in Focus", "Neogenomics Hits a 52-Week High on Cancer-Testing Deal", "3 Triple-Digit Biotech Stocks That Are Worth Every Penny", "Notable ETF Inflow Detected - XLV, JNJ, GILD, MRK", "Novo Nordisk's Victoza Fares Better than Sanofi's Lyxumia", "Intra-Cellular Up on Positive Data from Schizophrenia Study", "XenoPort Hits 52-Week Low on Preliminary Psoriasis Data", "Bristol-Myers Up, Opdivo Gets Breakthrough Therapy Status", "Inovio Presents Positive Data on Cervical Neoplasia Drug", "Intra-Cellular Therapies (ITCI) Jumps: Stock Rises 86.9%", "Could These 2 Biopharmas Be the Real Apples of Gilead Sciences' Eye?", "Aerie Reported Positive Phase III Data on Rhopressa", "Novo Nordisk's Victoza Fares Better than Sanofi's Lyxumia", "Intra-Cellular Up on Positive Data from Schizophrenia Study", "Baxalta Seeks FDA Nod for Primary Immunodeficiency Disorder", "Top Weekly Insider Sells Highlights", "Illumina in Partnership with Memorial Sloan to Develop ctDNA", "Trevena (TRVN) Catches Eye: Stock Adds 15.5% in Session", "Raptor Pharmaceuticals (RPTP) in Focus: Stock Plunges 37.5%", "Did Gilead Sciences Just Commit a Cardinal Sin?", "Medivation Upgraded to Strong Buy, Perfect for Your Portfolio", "AbbVie Seeks FDA Approval for Imbruvica's Label Expansion", "Raptor Crushed by Liver Disease Data, Hits 52-Week Low", "Company News for September 14, 2015", "Biotech Poised to Rebound: 5 Growth Picks", "Which Biotech Blue-Chip Stock Is the Best Buy?", "Collegium's Xtampza Supported for Approval by FDA Panels", "Sanofi's (SNY) LixiLan Positive in Phase III Diabetes Study", "Better Buy: Biogen vs. Gilead Sciences", "Will Kite (KITE) Get Orphan Status Again in EU for KTE-C19?", "4 Ways to Protect Yourself From a Biotech Meltdown", "Weekly CFO Sells Highlight: Gilead Sciences, DexCom, and Palo Alto Networks", "Seattle Genetics (SGEN) Catches Eye: Stock Moves Up 8.3%", "Which Biotech Blue-Chip Stock Is the Best Buy?", "Why is Gilead (GILD) Raising a Whopping $10 Billion?", "Health Care Sector Update for 09/11/2015: AKBA,BIIB,GILD,ARWR,NWBO", "Revance's Botulinum Toxin Type A Gel in Phase II Study", "Aduro-Incyte in Clinical Trial Agreement for Ovarian Cancer", "Genomic Health: Test Volume Impresses, Margin Woes Persist", "Noteworthy ETF Outflows: XLV, JNJ, GILD, MRK", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for September 14, 2015", "VBI Vaccines (VBIV) Worth a Look: Stock Adds 8% in Session", "Clovis Oncology (CLVS) Jumps: Stock Adds 13.8% in Session", "VIVUS (VVUS) in Focus: Stock Moves 12.5% Higher in Session", "Marinus' End-of-Phase II Meeting Positive for Ganaxolone", "Protalix's Phase I/II Fabry Disease Study Interim Data Positive", "Integra Faces Multiple Headwinds, SeaSpine Spin-off Strong", "Notable Thursday Option Activity: BRCM, CVC, GILD", "Biogen (BIIB) in Autoimmune Disease Deal Worth Up To $544M", "VBI Vaccines (VBIV) Worth a Look: Stock Adds 8% in Session", "Clovis Oncology (CLVS) Jumps: Stock Adds 13.8% in Session", "Immunomedics (IMMU) Worth Watching: Stock Rises 8.4%", "Does Achillion's 13% Slump in August Make It a Bargain?", "Impax Hayward Facility Gets FDA Clearance, Shares Rise", "BioDelivery Up on Striking Deal with TennCare for Bunavail", "Theravance, Glaxo SUMMIT Study Misses Primary Endpoint", "EPI, SYG: Big ETF Inflows", "Bursting Biotechs -- Are These Stocks Buys?", "Healthcare Boom a Bubble? 4 Stocks to Buy Anyway", "Perigon Wealth Management's Largest Buys in Second Quarter", "Bristol-Myers' Opdivo Encourages in Lung Cancer Study", "Is Another Amendment of QLT-InSite Vision Deal Coming Up?", "Whipsaw the Market Right Back with These Three Tech Investing Plays", "Alexion's Kanuma FDA Action Date Delayed by Three Months", "Alnylam to Speed Up Development for Primary Hyperoxaluria", "AstraZeneca, Starpharma Ink Drug Delivery Technology Deal", "4 Low-Volatility Stocks to Sail Through Market Mayhem", "Value Stocks: 2 to Buy, 1 to Avoid", "Roche's Hemophilia A Drug Gets Breakthrough Status in U.S.", "Allergan (AGN) to Buy Eye Care Device Company AqueSys", "AstraZeneca's Brilinta Gains FDA Nod for Label Expansion", "Dicerna Files IND Application for Primary Hyperoxaluria Drug", "5 Low-Risk Stocks for Dividend Investors", "AstraZeneca Ties Up for FluMist, CAZ-AVI Scores; Shares Up", "Nektar Receives $40M Milestone Payment from AstraZeneca", "The Zacks Analyst Blog Highlights: Google, Gilead Sciences, Regeneron Pharmaceuticals, Intuitive Surgical and Amazon.com", "Gilead Sciences' 11% Drop in August Could Make It a Steal", "Incyte & Hengrui to Develop Anti-PD-1 Monoclonal Antibody", "Notable ETF Outflow Detected - XLV, GILD, AGN, AMGN", "4 Google-Beating Stocks that Still Hold Promise", "3 Biotech Stocks to Buy in the Middle of a Turbulent Market", "Biotech Stock Roundup: Amgen in the News, ARIAD a Takeover Target?", "Meet The Manager Of A Top Performing Mutual Fund", "AstraZeneca Strikes Deal with Valeant for Psoriasis Drug", "Illumina Acquires GenoLogics, Boosts Genomic Sequencing", "Stock Market News for September 01, 2015", "Cytori Therapeutics (CYTX) in Focus: Stock Rises 15%", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for September 02, 2015", "Strength Seen in Trevena (TRVN): Stock Surges 51.5%", "5 Top Stocks to Buy in September", "Intercept's (ICPT) OCA Under Priority Review in the U.S.", "Amicus (FOLD) Signs Agreement to Acquire Scioderm", "Trevena's Postoperative Pain Drug Positive in Phase IIb Study", "Sanofi Teams Up with Google Life Sciences for Diabetes", "Allergan Buys Naurex, Boosts Mental Health Portfolio", "ARIAD Skyrockets More than 40% Following Buyout Rumors", "BIND Therapeutics (BIND) Rises: Stock Adds 5.4% in Session", "Alnylam Presents Positive Data on PCSK9 Synthesis Inhibitor", "4 Not-Too-Scary Ways to Make Money on Biotech Stocks", "Pfizer (PFE) Gains on Label Expansion Efforts for Ibrance", "Exelixis Up on Swiss Approval of Advanced Melanoma Drug", "Eli Lilly's (LLY) Diabetes Drug Synjardy Gets U.S. Approval", "12 Attractive Fast-Growing Dividend Growth Stocks For High Total Return", "Celldex (CLDX) Shows Strength: Stock Adds 8.2% in Session", "Applied Genetic Meets Enrolment Milestone in XLRS Study", "What Makes CoLucid Pharmaceuticals (CLCD) a Strong Sell?", "J&J to Sell Sugar Substitute Splenda to Heartland Food", "Novartis' (NVS) Promacta Label Further Expanded in U.S.", "Eli Lilly's Alimta Patent Upheld by U.S. District Court", "Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review", "Bouncing Biotech? 3 Stocks To Buy", "XLV, GILD, AGN, AMGN: Large Outflows Detected at ETF", "Acorda Therapeutics (ACOR) Jumps: Stock Moves 8.3% Higher", "Epizyme (EPZM) Shows Strength: Stock Adds 9.6% in Session", "4 Notable Stocks Still Green After Late Tuesday Sell-Off", "Nasdaq Slips into Correction: 4 Stocks Stand Tall", "Medivation to Gain Global Rights to BioMarin's Talazoparib", "AstraZeneca, Peregrine Team Up for Immuno-Oncology Study", "Stock Futures Plunge: 4 Value Stocks Brokers Love Right Now", "6 Things You Should Know About a Stock Market Correction", "The Zacks Analyst Blog Highlights: Gilead Sciences, DSW, Cardtronics and CECO Environmental", "Raptor Pharmaceuticals (RPTP) in Focus: Stock Adds 5.8%", "Seres (MCRB) Up on Orphan Drug Status for Lead Candidate", "Alkermes' (ALKS) Aristada Review Date Postponed by FDA", "Bad News for Hepatitis C Patients: Your Treatment Costs May Be Higher Than Expected", "Friday's ETF with Unusual Volume: PJP", "Argos Therapeutics (ARGS) Jumps: Stock Moves Up 12%", "Falling Earnings Estimates Signal Weakness Ahead for Alexion Pharmaceuticals (ALXN)", "Arena Pharmaceuticals (ARNA) Rises: Stock Adds 5.7% in Session", "Vascular (VBLT) Starts Patient Dosing in Glioblastoma Study", "Raptor (RPTP) to Buy Quinsair, Boost Rare Disease Portfolio", "Notable Two Hundred Day Moving Average Cross - GILD", "Is Valeant's (VRX) $1B Buy of Addyi Maker a Prudent Move?", "Gilead's EU Regulatory Application for HIV Drug Validated", "Why Eli Lilly (LLY) was a Bright Spot in the Market on Thursday", "Weakness Seen in TrovaGene (TROV) Estimates: Should You Stay Away?", "Did AbbVie Just Make an Incredibly Brilliant Decision?", "Vascular (VBLT) Starts Patient Dosing in Glioblastoma Study", "Raptor (RPTP) to Buy Quinsair, Boost Rare Disease Portfolio", "Notable Two Hundred Day Moving Average Cross - GILD", "BioMarin's Drisapersen Gets Rare Pediatric Disease Status", "Illumina (ILMN) Creates Helix to Encourage Genomics Startups", "Insys Files CP; Dronabinol Oral Solution under FDA Review", "Merck's Keytruda under FDA Review for First-Line Melanoma", "Bellerophon Therapeutics (BLPH) Jumps: Stock Rises 15.8%", "3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever", "Achillion Pharmaceuticals (ACHN) Jumps: Stock Gains 16.7%", "Kite Pharma Provides Update, Death Not Related to KTE-C19", "BioLineRx Up on Phase IIb Study Initiation on Leukemia Drug", "Myriad Genetics: myRisk Offers Strength, Currency Woes Linger", "Genomic Health Prostate Cancer Test Wins Medicare Coverage", "iShares Core S&P 500 ETF Experiences Big Inflow", "Walgreens Boots Plans to Eliminate 370 Employees to Cut Cost", "3 Numbers Show Why Gilead Sciences Inc. Is in a Great Position Today", "What Falling Estimates & Price Mean for bluebird bio (BLUE)", "Why ACADIA Pharmaceuticals (ACAD) Could Be Positioned for a Slump", "John Buckingham Buys 10 New Stakes in Second Quarter", "Emergent BioSolutions Gets $44M CDC Contract for VIGIV", "AMGN vs. GILD: The Battle of the Large Cap Biotech Stock", "Better Dividend Stock: Gilead Sciences Inc. vs. Amgen Inc.", "Myriad: Medicare Coverage for Prolaris Prostrate Cancer Test", "Integra's Acquisitions to Buoy Growth in '15, Currency Woes Stay", "BioDelivery's New Onsolis Formulation Gains FDA Approval", "Juno Therapeutics Posts In-Line 2Q Loss, Pipeline in Focus", "Myriad Genetics (MYGN) Jumps: Stock Moves 6.8% Higher", "Should You Get Rid of Five Prime Therapeutics (FPRX) Now?", "Is Gilead Sciences Biotech's Biggest Bargain?", "Integra Closes TEI Buyout to Grow in Regenerative Wound Care", "Teva's Chorea in Huntington Disease Treatment under Review", "Myriad Genetics Posts In-Line Earnings in Q4, Margins Suffer", "Enzon Pharmaceuticals, Inc. (ENZN) Ex-Dividend Date Scheduled for August 13, 2015", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for August 13, 2015", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 13, 2015", "Should You Get Rid of ANI Pharmaceuticals (ANIP) Now?", "Clovis Oncology Strikes Deal with Roche for Rociletinib", "AbbVie/Roche's Leukemia Drug Hits Phase II Primary Endpoint", "Pluristem (PSTI) Provides Update on PLX-PAD Cells in Japan", "BioScrip's Strategic Plans Offer Hope, Margin Concerns Stay", "Kite Pharma 2Q Loss Wider Than Expected, Pipeline in Focus - Analyst Blog", "Repros Incurs Narrower Y/Y Loss in Q2, Pipeline in Focus - Analyst Blog", "Celldex Q2 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog", "BioDelivery Incurs Wider Loss in Q2, Revenues Fall Y/Y - Analyst Blog", "TrovaGene Q2 Loss Widens on Higher Expenses, Shares Fall - Analyst Blog", "Stocks & ETFs to Reflect Top Sales Growth", "Sanofi Inks Deals, Diabetes and Immuno-Oncology in Focus - Analyst Blog", "3 Biotech Stocks to Buy in August", "Did Gilead Sciences Just Give Wall Street a Huge Head Fake?", "iShares Core S&P 500 ETF Experiences Big Inflow", "Top Biotech Stocks to Buy on Sale", "What Does the Social Media Crowd Think About Gilead Sciences (GILD) Stock? - Tale of the Tape", "Sarepta Posts Narrower-than-Expected Loss in Q2, Shares Up - Analyst Blog", "Gilead Sciences Stock: 3 Reasons Why It Is a Top Choice for Growth Investors - Tale of the Tape", "Geron Q2 Loss Narrower-than-Expected, Imetelstat in Focus - Analyst Blog", "Arena Pharmaceuticals 2Q Loss Narrower-Than-Expected - Analyst Blog", "Ronald Muhlenkamp Makes Small Changes in Composition of His Top 10 Stakes", "Jazz Pharmaceuticals Misses on Q2 Earnings, Affirms View - Analyst Blog", "Osiris Therapeutics' Q2 Earnings & Revenues Grow Y/Y - Analyst Blog", "Allergan's (AGN) 2Q Earnings & Revenues Shoot Up Y/Y - Analyst Blog", "What Company Will Be Fastest Growing Big-Cap Biotech?", "Genomic Health Q2 Loss Wider than Expected; Tests Ramp Up - Analyst Blog", "The Zacks Analyst Blog Highlights: BJ's Restaurants, Gilead Sciences, Scorpio Tankers and Teekay Tankers - Press Releases", "Mixed Biotech Earnings put These ETFs in Focus - ETF News And Commentary", "Integra Tops Earnings & Revenues, Guides Low on Spine Sale - Analyst Blog", "4 Stocks Set to Crush Their 52-Week Highs Soon - Analyst Blog", "What's in Store for Conatus (CNAT) This Earnings Season? - Analyst Blog", "5 Can't-Miss Quotes From Gilead Sciences Management", "Notable ETF Outflow Detected - XLV, GILD, AGN, BMY", "Top-Rated Stock Picks and Most-Read Stories at Nasdaq.com: July 26 - August 1", "Gilead's Hepatitis C Dominance Unchecked By AbbVie", "A Pharma ETF Focused On Quality, Fast-Growing Stocks", "Even With Recent Declines, Investors Still Love Biotech ETFs", "YieldBoost Gilead Sciences From 0.4% To 5.4% Using Options", "Stock Market News for July 29, 2015 - Market News", "Amp Up Your Portfolio With These Biotech Stocks", "Gilead (GILD) Beats on Q2 Earnings, Raises 2015 Outlook - Analyst Blog", "Stock Market News for July 30, 2015 - Market News", "Gilead's Hepatitis C Dominance Unchecked By AbbVie", "Daily Dividend Report: MPC, HLT, CG, XOM, WFC, GILD, AMGN, SYK, PX, BDX", "Great Stocks for Baby Boomers", "EWG, DWAQ: Big ETF Inflows", "The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Merck, Achillion Pharmaceuticals and Express Scripts - Press Releases", "Are These 2 Big Pharmas Really Buyout Candidates?", "3 Big Biotech Buybacks That Investors Should Love", "Lithia Motors, Qualcomm, Twitter, Gilead and Facebook highlighted as Zacks Bull and Bear of the Day - Press Releases", "Gilead Sciences Inc. Posts Q2 Results, Able to Beat Earnings, Revenue Estimates - Stocks in the News", "Gilead Sciences Inc. Q2 Earnings: Harvoni Delivers Again", "After Hours Most Active for Jul 28, 2015 : TWTR, SIG, JD, PRXL, ACWI, T, ABEV, MRK, BAC, GILD, UTIW, FB", "Earnings Reaction History: Gilead Sciences Inc., 55.6% Follow-Through Indicator, 3.5% Sensitive", "After-Hours Earnings Report for July 28, 2015 : GILD, ESRX, APC, EQR, AFL, TWTR, EW, AKAM, VRSK, CTXS, KIM, CHRW", "Stock Market News for July 27, 2015 - Market News", "3 Stocks for Retirees to Buy", "Twitter Q2 Earnings Turns After-hours Rollercoaster - Analyst Blog", "Gilead Sciences Inc. Posts Q2 Results, Able to Beat Earnings, Revenue Estimates - Stocks in the News", "Gilead Sciences Inc. Q2 Earnings: Harvoni Delivers Again", "After Hours Most Active for Jul 28, 2015 : TWTR, SIG, JD, PRXL, ACWI, T, ABEV, MRK, BAC, GILD, UTIW, FB", "Earnings Reaction History: Gilead Sciences Inc., 55.6% Follow-Through Indicator, 3.5% Sensitive", "After-Hours Earnings Report for July 28, 2015 : GILD, ESRX, APC, EQR, AFL, TWTR, EW, AKAM, VRSK, CTXS, KIM, CHRW", "Gilead Sciences' Next Big Move May Not Be What You're Thinking", "Gilead (GILD) Presents Encouraging Data on HIV Candidate - Analyst Blog", "4 Stocks to Fight the Virus on World Hepatitis Day - Analyst Blog", "The Best Deals in Value Stocks", "Bristol-Myers' HIV-1 Drug Evotaz Gets European Approval - Analyst Blog", "8 Biotech Stocks to Buy", "Manager Of Hot New Biotech ETFs Explains The Strategy", "Are Gilead Sciences, Inc.'s Expectations Too High for This Drug?", "Stock Market News for July 14, 2015 - Market News", "3 Biotech Stocks That Could Soon Rocket Higher", "Top-Rated Stock Picks and Most-Read Stories at Nasdaq.com: July 12 - 18", "The Best Deals in Value Stocks", "Bristol-Myers' HIV-1 Drug Evotaz Gets European Approval - Analyst Blog", "8 Biotech Stocks to Buy", "Manager Of Hot New Biotech ETFs Explains The Strategy", "Are Gilead Sciences, Inc.'s Expectations Too High for This Drug?", "3 Stocks to Buy in a Market Crash", "Biotech Stock Roundup: Vertex CF Drug Approved, Biogen Strikes Deal for Gene Therapy - Analyst Blog", "Midyear Report Card: Grading My Biotech Predictions for 2015", "iShares Russell 1000 ETF Experiences Big Inflow", "5 Drugs That Investors May Be Undervaluing", "S&P 500 Analyst Moves: GILD", "Gilead's (GILD) HCV Drug Harvoni Gets Approval in Japan - Analyst Blog", "Gilead Sciences Spent $125 Million to Get This Drug on the Market 4 Months Early", "The Competitive Advantage of the Best Biotech Stocks", "Noteworthy ETF Inflows: IWB, DIS, GILD, AMZN", "Are Biotechs In A Bubble?", "Express Scripts Reports Public Exchange Pharmacy Trends - Analyst Blog", "Stock Market News for July 01, 2015 - Market News", "What Is Beyond Vision-Loss Blockbuster For Regeneron?", "Stock Market News for June 30, 2015 - Market News", "Juno-Celgene in Immunotherapy Deal, Initial Deal Value $1B - Analyst Blog", "Gilead Sciences (GILD): An Ideal Buy the Dip Candidate", "Celldex's Rintega Phase III Study Recommended to Continue - Analyst Blog", "Gilead Submits Marketing Application for HIV Drug to FDA - Analyst Blog", "BioMarin's NDA for DMD Drug Drisapersen Accepted by FDA - Analyst Blog", "Intercept Pharmaceuticals Files for OCA in U.S. and Europe - Analyst Blog", "Integra to Acquire TEI, Expand in Regenerative Wound Care - Analyst Blog", "3 Stocks to Buy if Biotech Crashes", "Better Dividend Stock: AbbVie or Johnson & Johnson?", "Biogen/Sobi's Hemophilia B Drug Alprolix under EU Review - Analyst Blog", "BioMarin DMD Drug Drisapersen Validated for EU Review - Analyst Blog", "Sarepta Files Eteplirsen NDA, Secures $40M Debt Financing - Analyst Blog", "Eli Lilly Wins Alimta Patent Lawsuit in the UK, Shares Up - Analyst Blog", "Glaxo, Pfizer Meningitis B Vaccines Get ACIP's Category B - Analyst Blog", "Agios Doses First Patient with AG-881 in Early-Stage Study - Analyst Blog", "Transition Therapeutics Tanks on Alzheimer's Disease Data - Analyst Blog", "Genomic's Oncotype DCIS Score Betters Treatment Guidance - Analyst Blog", "Macrocure (MCUR) Falls: Stock Goes Down 10% - Tale of the Tape", "Alnylam Reports Encouraging New Data on Hemophilia Drug - Analyst Blog", "Can Cambrex Keep Profits Healthy On Gilead Pact?", "Eli Lilly Wins Alimta Patent Lawsuit in the UK, Shares Up - Analyst Blog", "Stock Market News for June 23, 2015 - Market News", "Kite Pharma and Bluebird Tie Up for HPV Cancer Targets - Analyst Blog", "Can a Growth Stock Also Be a Value Stock?", "Pfizer to Buy Two Meningitis Vaccines from Glaxo for $130M - Analyst Blog", "The Medicines Co. Antiplatelet Drug Kengreal Wins FDA Nod - Analyst Blog", "Synergy Pharmaceuticals' Plecanatide in 2nd IBS-C study - Analyst Blog", "Isis Pharmaceuticals Up on Spinal Muscular Atrophy Data - Analyst Blog", "ProShares Releases 2 New Leveraged Biotech ETFs", "Epizyme Lead Candidate Effective in Ongoing Cancer Study - Analyst Blog", "Bristol-Myers' (BMY) Melanoma Drug Opdivo Gets EU Nod - Analyst Blog", "Gilead Patent for Sovaldi Rejected in China, Shares Down - Analyst Blog", "Where Can Mega-Drug Stock Gilead Sciences Go Now?", "Did China Just Crush Gilead Sciences' Dreams?", "Vical's Genital Herpes Vaccine Fails in Phase I/II Study - Analyst Blog", "Stock Market News for June 19, 2015 - Market News", "BioMarin Pharmaceutical Surges on Price Target Increase - Analyst Blog", "Qiagen, Hitachi High-Technologies Ink Molecular Testing Deal - Analyst Blog", "Nasdaq Composite's New High Built On Solid Growth", "Masimo (MASI) Upped to Strong Buy on a Slew of Positives - Analyst Blog", "Better Buy: Gilead Sciences Inc. or Celgene Corporation?", "Lion Biotechnologies (LBIO) Falls: Stock Goes Down 9.1% - Tale of the Tape", "The Best Return on Equity in Biotech", "Eli Lilly Reports Data on Migraine Drug; Inks Oncology Deals - Analyst Blog", "Synergy Pharmaceuticals Soars on Constipation Drug Data - Analyst Blog", "Qiagen's New Genetic Fingerprint Kits to Aid DNA Analysis - Analyst Blog", "Biotech ETFs Hit New 2015 Highs", "The Ensign Group Hits 52-Week High, Acquisitions Hold Key - Analyst Blog", "3 Good Stocks to Buy for Their Earnings Growth", "5 Healthcare Stocks for Dividend Lovers", "KYTHERA Soars on $2.1 Billion Buyout Offer from Allergan - Analyst Blog", "Acorda Gains on Positive Parkinson's Disease Study Data - Analyst Blog", "Genomic Health Liquid Biopsy Test Fit for Bladder Cancer - Analyst Blog", "Shire to Make Milestone Payment to ArmaGen for AGT-182 - Analyst Blog", "RedHill Biopharma Surges on Encouraging Data on RHB-105 - Analyst Blog", "United Therapeutics Faces Patent Challenge for Tyvaso - Analyst Blog", "Sanofi Starts Dosing in Phase I/II Study on Olipudase Alfa - Analyst Blog", "bluebird bio Reports Encouraging Data on Thalassemia Drug - Analyst Blog", "Teva Announces Positive Results on Tardive Dyskinesia Drug - Analyst Blog", "Acorda Gains on Positive Parkinson's Disease Study Data - Analyst Blog", "iShares U.S. Healthcare ETF Experiences Big Outflow", "Stock Market News for June 15, 2015 - Market News", "Agios Reports New Data on Hematologic Malignancy Drugs - Analyst Blog", "AstraZeneca Presents Phase III Data on Gout Drug Lesinurad - Analyst Blog", "Celgene Presents Positive SPRINT Study Data on Revlimid - Analyst Blog", "Alnylam Reveals Positive Initial Data on RNAi Drug ALN-CC5 - Analyst Blog", "Roche's Diagnostic Test with Pfizer Approved by FDA - Analyst Blog", "Novartis Presents Data on Leukemia, Dermatology Drugs - Analyst Blog", "Gilead Sciences' Next Growth Market", "Novartis' (NVS) Promacta's Label Expansion Approved in U.S. - Analyst Blog", "Pfizer's Pristiq Fails in First Phase III Pediatric Study - Analyst Blog", "Isis Pharmaceuticals Up on Positive Data on ISIS-SMNRx - Analyst Blog", "3 Things AbbVie Inc.'s Management Wants You to Know", "Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for June 12, 2015", "ARIAD (ARIA) Presents Favorable Long-Term Data on Iclusig - Analyst Blog", "After Hours Most Active for Jun 11, 2015 : QRVO, TWTR, WETF, QCOM, LO, GM, FOXA, GILD, AA, RAI, QQQ, AMH", "Bayer (BAYRY) Up on Deal to Sell Diabetes Care Business - Analyst Blog", "Agios Gets Orphan Drug Designation from FDA for AG-120 - Analyst Blog", "Illumina Partners in China to Develop NGS Diagnostic Solution - Analyst Blog", "7 Things to Know About Gilead Sciences - Stocks in the News", "TrovaGene Hits 52-Week High, PCM Continues to Impress - Analyst Blog", "Roche's Actemra Gets Breakthrough Therapy Designation - Analyst Blog", "Novartis Reports Data on Cosentyx for Ankylosing Spondylitis - Analyst Blog", "Celgene and Lycera Collaborate, Acquisition Option Included - Analyst Blog", "Seattle Genetics-Unum Therapeutics Tie Up for Cancer Drugs - Analyst Blog", "Roche to Develop Diagnostic Test for Cardiovascular Disease - Analyst Blog", "Jazz Pharmaceuticals' Sleep Disorder Drug Enters Phase III - Analyst Blog", "Renaissance Technologies: Here\u2019s What this Huge Hedge Fund Company Has Been Buying", "10 Most Profitable Businesses in San Francisco", "Intrexon, Fibrocell Announce Positive Pre-Clinical Data - Analyst Blog", "Regeneron/Sanofi's Praluent Gets Positive FDA Panel Vote - Analyst Blog", "Chimerix Enrolls for Trial on Cytomegalovirus Infection Drug - Analyst Blog", "Repros' Enclomiphene to Face FDA Advisory Panel in November - Analyst Blog", "BioMarin Seeks EU Approval for DMD Drug Drisapersen - Analyst Blog", "Horizon Pharma (HNZP) Starts Phase III Study on Actimmune - Analyst Blog", "Regeneron/Sanofi's PCSK9 Drug Praluent Set for FDA Panel - Analyst Blog", "Gilead Sciences (GILD) Stock: Moving Average Crossover Alert - Tale of the Tape", "Eli Lilly (LLY) Presents Encouraging Data on Diabetes Drugs - Analyst Blog", "Amgen's Repatha Briefing Document Gives Mixed Review - Analyst Blog", "After Hours Most Active for Jun 8, 2015 : PFE, CMCSA, FTR, BAC, HTZ, CX, VSH, QQQ, GNW, HBAN, GILD, QVCA", "Bio-Techne to Buy Cliniqa, Boost Clinical Controls Portfolio - Analyst Blog", "Are Biotech Stocks Really Overvalued?", "Problems With Obamacare That Could Prove Difficult to Fix", "Bad News for Obamacare: Insurance Rates Could Rise By Double-Digits in 2016", "Is Gilead Sciences Inc.'s Moat Filling Up With Sand?", "5 Stocks to Buy for June", "Sanofi (SNY) Presents Data from Extension Studies on Toujeo - Analyst Blog", "Retrophin's Neurodegenerative Drug Gets Fast Track Status - Analyst Blog", "Ardelyx Regains Product Portfolio Rights from AstraZeneca - Analyst Blog", "bluebird Amends Collaboration Agreement with Celgene - Analyst Blog", "CVS Health-HHS to Endorse Preventive Health Services Online - Analyst Blog", "Merge's New Cloud-based Mobile App to Aid Clinical Research - Analyst Blog", "Biotech Stock Roundup: ImmunoGen Soars on ASCO Data, Amgen Collaborates with Roche - Analyst Blog", "Zacks.com featured expert Kevin Matras highlights: Gilead Sciences, Goodyear Tire, Kraton, Aecom and Teekay Tankers - Press Releases", "AbbVie Reports Positive Results on Oncology Drug Imbruvica - Analyst Blog", "Ultragenyx KRN23 Positive in Children, to be Studied in Adults - Analyst Blog", "3 Bargain Stocks to Beat the Market", "Why Gilead Sciences, Inc. Catapulted Higher in May", "Merck's Keytruda under Priority Review for Lung Cancer - Analyst Blog", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for June 03, 2015", "Celldex Glioblastoma Vaccine Hits Phase II Primary Endpoint - Analyst Blog", "Roche Collaborates with Amgen for Immuno-Oncology - Analyst Blog", "Ligand Pharmaceuticals Updates Viking IPO, Ups 2015 View - Analyst Blog", "Bristol-Myers Slumps: BMY Falls 6.6% in Session - Tale of the Tape", "Are Celgene Corp.'s Shares About to Get Hammered?", "Why I'm Buying Gilead Sciences Stock", "Your Best Investing Questions", "Gilead Reveals Encouraging Data from Leukemia Study - Analyst Blog", "Bristol-Myers' Opdivo Superior to Standard-of-Care Therapies - Analyst Blog", "AbbVie Presents Positive Data from Multiple Studies at ASCO - Analyst Blog", "Novartis Presents Data on Leukemia & Lung Cancer Drugs - Analyst Blog", "Why AbbVie, Inc. Is a Better Long-Term Buy Than Gilead Sciences, Inc.", "Stocks To Watch in Biotech", "Investing for Beginners: How to Start in Biotech", "Leading Health Insurers in These 4 States Just Proposed 25% to 52% Premium Price Hikes", "3 Best of Breed Biotech Stocks", "Time to Take Profits in Gilead Sciences Inc. Stock?", "Teva Settles Provigil Drug Delay Charge with FTC for $1.2B - Analyst Blog", "A Stock Market Bubble In Healthcare Stocks?", "Is CVS Health (CVS) Worth Adding to Your Portfolio Now? - Analyst Blog", "Gilead's New HIV Combination Drug under Review in the EU - Analyst Blog", "Gilead's Sustainable Competitive Advantage", "IWF, GILD, V, CMCSA: Large Inflows Detected at ETF", "Undervalued Stocks in Biotech Worth Buying", "Actavis' Viberzi Gets FDA Nod for Irritable Bowel Syndrome - Analyst Blog", "Qiagen Launches Clinical Insight Bioinformatics Platform - Analyst Blog", "Pacira-FDA Meet for Exparel's Nerve Block Label Expansion - Analyst Blog", "Is CVS Health (CVS) Worth Adding to Your Portfolio Now? - Analyst Blog", "Retrophin Soars on $245M Priority Review Voucher Sale - Analyst Blog", "Synageva BioPharma Files for Kanuma's Approval in Japan - Analyst Blog", "Genomic's Prostate Cancer Test Recommended by Palmetto - Analyst Blog", "The 7 Best ETFs to Buy for June", "Merck/J&J Get CHMP Backing for Simponi's Expanded Use - Analyst Blog", "Health Care Sector Update for 05/27/2015: GBIM,GILD,GBSN,NURO", "Valeant Pharmaceuticals Gets FDA Nod for Xifaxan for IBS-D - Analyst Blog", "GlobeImmune-Gilead's Hepatitis B Drug Fails in Phase II - Analyst Blog", "Retrophin Soars on $245M Priority Review Voucher Sale - Analyst Blog", "Synageva BioPharma Files for Kanuma's Approval in Japan - Analyst Blog", "Pharmacyclics' Imbruvica Gets CHMP's Nod for Full Approval - Analyst Blog", "Merck's (MRK) Keytruda a Step Closer to European Approval - Analyst Blog", "Amgen's PCSK9 Inhibitor a Step Closer to EU Approval - Analyst Blog", "The Best Business Model in Biotech", "Alnylam (ALNY) Begins Phase I Study on Liver Disease Drug - Analyst Blog", "Aegerion's Juxtapid Successful in Phase III Japanese Study - Analyst Blog", "Actavis to Continue Selling Namenda IR under Court Ruling - Analyst Blog", "Pop! 3 To Buy If Biotech Stocks Burst", "Novartis Announces Positive Data on Oncology Drug Afinitor - Analyst Blog", "Kite Pharma Starts Dosing in Phase I/II Study on KTE-C19 - Analyst Blog", "Should You Get Rid of CytRx Corporation (CYTR) Now? - Tale of the Tape", "MannKind, Front and Center: The Best Product Doesn\u2019t Always Equal the Best Stock", "Bristol-Myers' Opdivo Gets Positive Opinion from CHMP - Analyst Blog", "AstraZeneca, Amgen End Psoriasis Drug Brodalumab Deal - Analyst Blog", "Warren Buffett's Portfolio: 3 Biotech Stocks the Oracle of Omaha Could Love", "Healthcare Investment Opportunities for the Long Term", "Why Achillion Pharmaceuticals, Inc. Shares Are Collapsing", "IWF, GILD, V, SLB: Large Inflows Detected at ETF", "SWOT Analysis of Gilead Sciences Inc. Stock", "Zacks.com featured expert Kevin Matras highlights: Outerwall, Gilead Sciences, Lionbridge Technologies, Silicon Motion Technology and Wabash National - Press Releases", "Following Hepatitis C, This Could Be the Next Disease Researchers Cure", "How Celgene Stock Is Breaking All the Rules", "Johnson & Johnson Takes On Gilead Sciences in Hep C... Again", "Intercept Pharmaceuticals Reveals Phase III OCA Study Plan - Analyst Blog", "Achillion and Johnson & Johnson in $1.1B HCV Tie-Up - Analyst Blog", "Stock Market News for May 19, 2015 - Market News", "Merck KGaA Q1 Earnings Fall Y/Y, 2015 Sales View Retained - Analyst Blog", "Eleven Biotherapeutics (EBIO) in Focus: Stock Tanks 69.2% - Tale of the Tape", "Intercept Pharmaceuticals (ICPT) in Focus: Stock Tanks 16.1% - Tale of the Tape", "How Celgene Stock Is Breaking All the Rules", "Johnson & Johnson Takes On Gilead Sciences in Hep C... Again", "Theravance Biopharma Posts Positive Data on Velusetrag - Analyst Blog", "Genomic Health's Loss Lingers, Profits Expected in 4Q15 - Analyst Blog", "XBiotech's Xilonix Recommended for Colorectal Cancer Study - Analyst Blog", "Lannett (LCI) Signs Deal to Acquire Silarx Pharmaceuticals - Analyst Blog", "Celgene/Accelreon's Luspatercept Granted Fast Track Status - Analyst Blog", "Endo to Acquire Par Pharma for $8.05B, Shares Down - Analyst Blog", "Kite Pharma Narrows Q1 Loss, Misses Estimates; Gives View - Analyst Blog", "This Experimental Drug Could Finally Cure HIV", "Gilead Sciences (GILD) Stock: 3 Reasons Why It Is a Top Choice for Growth Investors - Tale of the Tape", "3 Types of Risks Facing Biotech Stocks", "The Best Blue Chips to Own Forever", "Alnylam Files Clinical Trial Application for ALN-AAT - Analyst Blog", "Why Achillion Pharmaceuticals, Inc. Shares Soared Today", "AbbVie's Humira Gets FDA Orphan Status for Skin Disease - Analyst Blog", "Is Gilead Sciences Its Own Worst Enemy?", "Could an HIV/AIDS Vaccine Be a Reality By the End of the Decade?", "Could This Tiny Biotech Be on Gilead Sciences\u2019 M&A Radar?", "Prestige Brands Holdings Beats on Q4 Earnings, Revenues - Analyst Blog", "Amgen Announces Positive Results on Migraine Candidate - Analyst Blog", "Endo/BioDelivery Reveal Encouraging Data on Pain Drug - Analyst Blog", "Agenus (AGEN) Provides Update on its Brain Cancer Vaccine - Analyst Blog", "3 Safe Investments in Biotech (Relatively Speaking)", "Teva Presents Encouraging Data from Chronic Migraine Study - Analyst Blog", "Eli Lilly, Sanford-Burnham Ink Deal for Immunotherapies - Analyst Blog", "Emergent BioSolutions, Glaxo Initiate Ebola Vaccine Study - Analyst Blog", "Sanofi (SNY) Exercises Celiac Disease Program Option - Analyst Blog", "Roche Reports Encouraging Data on Lung Cancer Drugs - Analyst Blog", "RXi (RXII) Q1 Loss Wider-Than-Expected, Pipeline in Focus - Analyst Blog", "Vertex Pharmaceuticals' Orkambi Wins FDA Panel Backing - Analyst Blog", "Corcept Therapeutics' Korlym Positive in Breast Cancer Study - Analyst Blog", "Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog", "Zacks.com featured expert Kevin Matras highlights: Gilead Sciences, Citigroup and Barclays - Press Releases", "McKesson Beats on Q4 Earnings & Revenues, Guides Strong - Analyst Blog", "Why ANI Pharmaceuticals (ANIP) Could Be Positioned for a Slump - Tale of the Tape", "Falling Earnings Estimates Signal Weakness Ahead for Compugen (CGEN) - Tale of the Tape", "Retail Sector in the Spotlight - Earnings Outlook", "Retail Sector in the Spotlight - Earnings Trends", "Perrigo (PRGO) Buys Patheon's Mexican Business for $34M - Analyst Blog", "Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog", "TrovaGene (TROV) in Focus: Stock Rises 7.1% - Tale of the Tape", "Inovio Narrows Q1 Loss Y/Y, Misses Earnings Estimates - Analyst Blog", "Arena Pharmaceuticals 1Q Loss Narrower-Than-Expected - Analyst Blog", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for May 13, 2015", "Forget Gilead Sciences, Inc. -- This Tiny Biotech Offers A Much Richer Opportunity", "Orexigen Slumps as New Contrave Data Comes to Light - Analyst Blog", "Fluidigm Q1 Revenues Lower than Expected, Stock Down - Analyst Blog", "ETFs in Focus on Impressive Q1 Biotech Earnings - ETF News And Commentary", "IWB, MRK, GILD, V: Large Inflows Detected at ETF", "Actavis Tops 1Q Earnings by Wide Margin, Provides Outlook - Analyst Blog", "Osiris Therapeutics Q1 Earnings & Revenues Grow Y/Y - Analyst Blog", "Bio-Techne Lags on Q3 Earnings, Revenues; Expenses Rise - Analyst Blog", "Seattle Genetics (SGEN) in Focus: Stock Up 8.1% - Tale of the Tape", "Johnson & Johnson's Invega Sustenna sNDA Suffers Setback - Analyst Blog", "Novartis' Zykadia Approved in the EU for Lung Cancer - Analyst Blog", "Endo (ENDP) Beats on Q1 Earnings, 2015 Guidance Upped - Analyst Blog", "Myriad Genetics Q3 Test Growth Impresses Yet Revenues Fall - Analyst Blog", "NxStage Medical Loss Narrower than Expected, Revenues Up - Analyst Blog", "The Best And Worst ETFs Of The Week Amid Biotech Rebound", "A Stock Market Bubble in Biotech Stocks?", "MannKind's (MNKD) Q1 Loss In Line with Expectation - Analyst Blog", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 12, 2015", "Novartis' Zykadia Approved in the EU for Lung Cancer - Analyst Blog", "Endo (ENDP) Beats on Q1 Earnings, 2015 Guidance Upped - Analyst Blog", "Emergent BioSolutions (EBS) Loss Wider than Expectations - Analyst Blog", "Sarepta Posts Wider-than-Expected Loss, Eteplirsen in Focus - Analyst Blog", "Medivation (MDVN) Misses on Q1 Earnings, Revenues - Analyst Blog", "Corcept Therapeutics Reports Wider Q1 Loss, Revenue Miss - Analyst Blog", "Alnylam's Q1 Loss Narrower than Expected, Confirms Guidance - Analyst Blog", "Big Pharma Giant AbbVie Inc. Took Off in April -- Here's Why", "10 Most Profitable Companies in Healthcare", "After Hours Most Active for May 7, 2015 : VALE/P, VALE, RIG, EMC, GILD, MSFT, AAPL, PFE, CX, ODP, MRVL, QQQ", "Alexion to Buy Synageva for $8.4B: Alexion Down, Synageva Up - Analyst Blog", "Glaxo's (GSK) Q1 Earnings Fall Y/Y; Gives Five-Year View - Analyst Blog", "Standout Sectors of Q1 Earnings Season - Earnings Trends", "Standout Sectors of Q1 Earnings Season - Earnings Outlook", "Qiagen Q1 Earnings in Line; Revenues Miss the Mark - Analyst Blog", "Top-Rated Stock Picks and Most-Read Stories at Nasdaq.com: April 26 to May 2, 2015", "Beyond Pharma: 3 Healthcare Choices - Analyst Blog", "Is This Why the Street Keeps Doubting Gilead Sciences, Inc.?", "Conatus Pharmaceuticals (CNAT): What's Up this Earnings? - Analyst Blog", "Stock Market News for May 04, 2015 - Market News", "How These 2 Industries Helped Save the Stock Market This Earnings Season", "Biotech's Blue Chip Stocks", "Sucampo Posts In-Line First-Quarter Earnings, Revenue Miss - Analyst Blog", "Midday Update: Wall Street Mostly Ignores Weak Manufacturing Data, Starts May in Buying Mood Buy", "QUAL, GILD, V, MA: ETF Outflow Alert", "Gilead Tops Q1 Earnings Estimates, 2015 Outlook Revised - Analyst Blog", "Gilead Sciences, Inc. Earnings: Hepatitis C Market by the Numbers", "Daily Dividend Report: LM, KO, GILD, AIG, VFC, PAYX", "Agree To Buy Gilead Sciences At $70, Earn 5.4% Using Options", "The Zacks Analyst Blog Highlights: Amgen, Celladon, Biogen, Celgene and Gilead - Press Releases", "Bristol-Myers Squibb Outpaces AbbVie in Hepatitis C", "Q1 Earnings Scorecard - The Dollar Impact - Earnings Outlook", "After Hours Most Active for Apr 30, 2015 : LNKD, QQQ, MSFT, GILD, AAPL, LOW, HD, NVAX, CY, NRZ, BAC, GE", "Earnings Reaction History: Gilead Sciences Inc., 55.6% Follow-Through Indicator, 3.7% Sensitive", "After-Hours Earnings Report for April 30, 2015 : GILD, V, AIG, PSA, LNKD, BMRN, SWKS, FLT, EMN, EXPE, WU, FMX", "What's Behind Vertex Pharmaceuticals Incorporated's Disappointing Q1", "Bristol-Myers Squibb Crushes First-Quarter Earnings: Here's Why", "3 Things to Watch with Gilead Sciences Inc.'s Q1 Earnings", "Gilead Sciences Inc. Reaps a Big Q1 Harvest From Harvoni", "Q1 Earnings Scorecard - The Dollar Impact - Earnings Outlook", "10 Most Profitable Businesses in Biotech", "Gilead and Bristol-Myers Reveal Positive Data on HCV Drugs - Analyst Blog", "Will Express Scripts (ESRX) Disappoint Earnings in Q1? - Analyst Blog", "Biotech Bubble Bursting? 3 Stocks I Want to Buy", "Why Healthcare is the Best Sector For Your Money", "Can You Guess Which State Won't Pay for Hepatitis C Drugs?", "Will Gilead (GILD) Miss Q1 Earnings on Weak HCV Sales? - Analyst Blog", "Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog", "AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog", "Is Amgen Inc.'s Dividend Sustainable?", "Gilead (GILD) Announces Encouraging Data on its HCV Drugs - Analyst Blog", "Notable ETF Outflow Detected - XLV, GILD, UNH, ESRX", "The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Geron, Johnson & Johnson and Anthera Pharmaceuticals - Press Releases", "Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys - Analyst Blog", "4 Nasdaq Stocks at All-Time Highs - Analyst Blog", "3 Biotech Stocks That Could Be Developing Billion Dollar Drugs", "How to Invest Money in Biotech", "What Could Possibly Go Wrong With Gilead Sciences Inc. Stock?", "3 Drug Stocks Leading the Charge Against Infectious Diseases", "Gilead Sciences (GILD) Shares Cross Below 200 DMA", "Johnson & Johnson's Earnings: The Good, The Bad and The Ugly", "The Best Stock to Invest in Hep C", "Forget Gilead (GILD), Buy These Impressive Biotech Stocks Instead - Analyst Blog", "3 Biotech Stocks Under $10 with Amazing Growth Prospects - Analyst Blog", "XLV, MRK, GILD, UNH: ETF Outflow Alert", "J.P. Morgan, Bank of America, Gilead Sciences and Actavis are part of Zacks Earnings Preview: - Press Releases", "Q1 Earnings Season Ramps Up - Earnings Preview", "3 Stocks You Absolutely Must Watch This Earnings Season", "The 3 Best Stocks to Invest in Biotechnology", "The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases", "AbbVie's HCV Treatment Granted Priority Review in Japan - Analyst Blog", "Merck's HCV Combo Drug Gets Two Breakthrough Status - Analyst Blog", "Gilead Submits Regulatory Application for HIV Drug in U.S. - Analyst Blog", "Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blog", "The One Biotech Stock That Looks Like a Bargain These Days", "Notable ETF Inflow Detected - XLV, MRK, GILD, UNH", "Actavis in Patent Infringement Lawsuit for Gilead's Letairis - Analyst Blog", "After Hours Most Active for Apr 6, 2015 : WIN, O, IGT, DEI, CNO, SIRI, KKR, KO, QQQ, CSCO, FOXA, GILD", "After Hours Most Active for Apr 9, 2015 : MU, EPD, PBR, CX, SFUN, QQQ, WIN, MDCO, SCTY, GILD, SXL, AA", "Merck's HCV Combo Drug Gets Two Breakthrough Status - Analyst Blog", "5 Big Losers if the Supreme Court Strikes Down Federal Obamacare Subsidies", "Following Gilead Sciences, Inc., Which Biotech Will Pay a Dividend Next?", "The Safest Biotech Bet on the Market", "Is AbbVie Inc. Stock About to Crash?", "Q1 Earnings Season is Spotlight as Alcoa (AA) Reports Results - Earnings Preview", "Zacks Earnings Trends Highlights: Bank of America, Gilead Sciences and Apple - Press Releases", "3 Events That Could Sink the Biotech Sector This Year", "After Hours Most Active for Apr 1, 2015 : AA, MU, PFE, ACWI, MYL, JNJ, MRK, AVIV, QQQ, PAGP, THRM, GILD", "Post-UNH Deal, Spotlight on Pharmacy Benefit Stocks - Analyst Blog", "What to Look for This Earnings Season - Earnings Outlook", "What to Look for This Earnings Season - Earnings Trends", "The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex - Press Releases", "3 Triple-Digit Stocks With Upside Potential of At Least 40%", "3 Best Dividend Stocks for 2015", "Should Gilead Sciences, Inc. Be Worried By Achillion Pharmaceuticals?", "The Best Dividend-Paying Healthcare Stocks", "The Biggest Red Flag for Biotech Investors", "Could These Experimental Drugs Eclipse Harvoni's Historic Launch?", "Investors Might Want To Stay Away From This Biotech ETF", "Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog", "iShares S&P 100 ETF Experiences Big Outflow", "Stock Market News for March 26, 2015 - Market News", "Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?", "The Best Dividend-Paying Healthcare Stocks", "The Biggest Red Flag for Biotech Investors", "Company News for March 24, 2015 - Corporate Summary", "Pre-Market Most Active for Mar 23, 2015 : STO, GSK, GILD, AAPL, VRTX, IMGN, RDS/B, QQQ, FB, RDS/A, SDRL, NVS", "Better Dividend Stock: AbbVie or Gilead Sciences, Inc.?", "After Hours Most Active for Mar 23, 2015 : BAC, OPK, CSCO, GE, QQQ, ZTS, OCN, MSFT, GILD, MDLZ, AAPL, WFC", "Previewing the Q1 Earnings Season - Video Blog", "The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press Releases", "Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst Blog", "Drug Spending Is Soaring: 3 Takeaways You Can't Miss", "1 Biotech Stock You Can Buy and Hold for the Next 20 Years", "Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Analyst Blog", "Why I'm Not Giving Up on This Tiny Biotech Stock (Yet)", "Bristol-Myers Squibb Co. Is Back in the Hepatitis C Race", "3 Stocks Benefiting From Jaw-Dropping Growth in Specialty Drug Spending", "3 Things You Need to Know About Achillion Pharmaceuticals Inc.", "3 Biotech Stocks Wall Street Loves", "Should Gilead Sciences Inc.\u2019s Slowing Growth Concern Investors?", "Is This Number the Scariest Healthcare Statistic Out There?", "Bristol-Myers Seeks Daclatasvir Approval in the U.S. - Analyst Blog", "Biotech Stock Roundup: AbbVie to Buy Pharmacyclics, FDA Approves First Biosimilar - Analyst Blog", "Express Scripts Issues Report on Prescription Drug Spending - Analyst Blog", "In Case You Missed It, Gilead Sciences, Inc.\u2019s \u201cBad\u201d News Is Actually Great", "S&P 500 Analyst Moves: GILD", "Forget Gilead Sciences (GILD), Buy These Biotech Stocks Instead - Stocks in the News", "After Hours Most Active for Mar 5, 2015 : EMC, BAC, GRMN, RIO, GE, QQQ, KLAC, MU, DNR, MS, GILD, AAPL", "Bristol-Myers' Drug Shows Impressive Data, Inks Deal - Analyst Blog", "Top-Rated Stock Picks and Most-Read Stories at Nasdaq.com: Feb. 22-28, 2015", "Pioneer Fundamental Growth Fund: Why Is It Revving Up?", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for March 03, 2015", "Gilead's (GILD) HIV Drug Positive in 2 Phase III Studies - Analyst Blog", "IYH, PFE, MRK, GILD: ETF Inflow Alert", "3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year", "Why Don't These Winning Stocks Pay Dividends?", "This Breakthrough Study May Allow Researchers to Tackle the Root Cause of Heart Disease", "Noteworthy ETF Inflows: IYH, MRK, GILD, AMGN", "Biotech Head-to-Head: Gilead vs. Celgene", "These Pharmaceutical Stocks Let You Tap into a $402 Billion Trend", "Why Pharmacyclics, Inc. Soared Higher Today", "Billionaire George Soros Just Dumped These 3 Dividend Stocks", "3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year", "Why Don't These Winning Stocks Pay Dividends?", "3 Stocks Pre-Retirees Can Buy and Hold for the Next 20 Years", "3 Biotech Stocks I'd Love to Stash Away in My Portfolio Forever", "Did Researchers Just Discover a Cure for HIV/AIDS?", "3 Tiny Biotech Stocks That I'm Paying Attention to in 2015", "Gilead Insider buys 10,000 shares", "Billions on the Line in the Next Drug Pricing War", "XLV, PFE, MRK, GILD: Large Inflows Detected at ETF", "11.7 Billion Reasons Gilead Sciences, Inc. Should Keep Winning", "Is Gilead Sciences Inc. Stock Cheap Now?", "Not Too Late to Ride on Q4 Earnings: 3 Biotech Picks - Earnings ESP", "Surprise! We Still Need Drugmakers to Develop Revolutionary Hepatitis C Drugs", "Tiger Management's Julian Robertson Buys Apple, Netflix, Illumina, Sells Alibaba, EBay, MasTec", "Could This Be The Biggest Advance in Hepatitis C since Gilead Sciences' Sovaldi?", "Will Express Scripts (ESRX) Beat Q4 Earnings Estimates? - Analyst Blog", "Obamacare Could Soon Make These Stocks Soar", "Was Gilead Sciences Inc.'s Dividend a Good Idea?", "3 Biotech Stocks I Love", "1 Number Shows Why Gilead Sciences, Inc. Shareholders Should Be Thrilled Right Now", "In Case You Missed It, There's a New Fastest Growing Drug in the World", "1 Sentence That Tells You Everything You Need to Know About Each of These 10 Big Pharma Earnings Rep", "5 Things CVS Health's Management Wants You to Know", "1 George Soros Quote Every Investor Should Read Right Now", "Obamacare Could Soon Make These Stocks Soar", "Was Gilead Sciences Inc.'s Dividend a Good Idea?", "OEF, GILD, C, DIS: ETF Outflow Alert", "Gilead Sciences Shares Rise Amid Insider Buy, Conference Presentation Broadcast - Stocks in the News", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for February 11, 2015", "Why Shares of Regulus Therapeutics Inc. Crashed", "Forget Gilead Sciences: Here Are 3 Better Biotech Stocks", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 10, 2015", "Achillion Soars on 6 Week HCV Cure When Used with Gilead's Sofosbuvir - Stocks in the News", "Dividend Investing News: GM, GILD, and 29 More Increases", "What's Bad For Gilead Sciences and Merck Is a Good Sign for Patients", "5 Key Findings After 1 Full Year of Obamacare", "Can You Guess the Stock Putting Gilead Sciences to Shame? (Hint: It's Not AbbVie)", "3 Things You Ought to Know About Gilead's Tumble", "Why Shares of Achillion Pharmaceuticals, Inc. Soared", "Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs - ETF News And Commentary", "Why Achillion Pharmaceuticals, Inc. Stock Is Crashing Today", "Biotech Stock Roundup: Biogen Impresses with 4Q Results, Gilead & AbbVie HCV Drugs in Focus - Analyst Blog", "Why Gilead Sciences Shares Crashed Today", "AbbVie Inc. Earnings: After a Strong Year, Eyes Shift to 2015", "Nasdaq 100 Movers: GILD, CTSH", "S&P 500 Movers: RL, SJM", "Can Gilead Boost HCV Sales with Health Service Deals? - Analyst Blog", "Pre-Market Most Active for Feb 4, 2015 : ODP, SPLS, PBR, VIV, GILD, GM, GSK, PHG, AZN, TVIX, PEGI, QQQ", "Gilead Tops Q4 Earnings Estimates, 2015 Outlook Disappoints - Analyst Blog", "Dow Jones Ends Choppy Trading Session with 6-Point Gain", "Merck & Co., Inc. Earnings: 1 Sentence That Changed Everything", "IYH, GILD, AMGN, ABBV: ETF Outflow Alert", "Gilead Sciences, Inc. Earnings: We'll Make Up for It in Volume", "Gilead Sciences Beats Q4 Earnings Estimates, GILD Falls on Revenue Outlook - Stocks in the News", "Surprise! Gilead Sciences Inc. to Pay a Dividend", "What's Behind Gilead Sciences' Strong Q4 but Weak 2015 Outlook?", "After Hours Most Active for Feb 3, 2015 : FNFG, COST, GILD, QQQ, BK, AAXJ, DIS, COP, BAC, ESRX, STT, ALLY^A", "Earnings Reaction History: Gilead Sciences Inc., 44.4% Follow-Through Indicator, 3.0% Sensitive", "After-Hours Earnings Report for February 3, 2015 : GILD, DIS, EQR, AFL, CMG, FISV, WYNN, EW, ITUB, CHRW, UNM, AJG", "3 Things to Watch With Gilead Sciences, Inc. Q4 Results", "Why Gilead Sciences, Inc. Shares Roared Higher By 11% in January", "Will Gilead (GILD) Miss Q4 Earnings on Low HCV Drug Sales? - Analyst Blog", "Should You Buy AbbVie Inc. Stock on This Dip?", "Can Biotech Duplicate Its 2014 Performance, or Is It Time to Jump Ship?", "Gilead Sciences' Future in 3 Simple Slides", "3 Biotech Giants That Shouldn't Pay a Dividend", "AbbVie (ABBV) Tops 4Q Earnings Estimates, Affirms View - Tale of the Tape", "Is AbbVie (ABBV) Set to Beat 4Q Earnings on Humira Sales? - Analyst Blog", "Cancer biotech Kolltan Pharmaceuticals withdraws $86 million IPO", "This Telling Figure Insinuates Big Pharma Could Be in Big Trouble", "Should You Buy Gilead Sciences (GILD) Stock Ahead of Earnings? - Stocks in the News", "Can Biotech Duplicate Its 2014 Performance, or Is It Time to Jump Ship?", "IWF, GILD, PEP, ORCL: Large Outflows Detected at ETF", "Why Johnson & Johnson's Stock Could Crater in 2015", "Biotech Stock Roundup: EU Approvals for AbbVie & Celgene Drugs, CytRx Partial Clinical Hold Lifted - Analyst Blog", "Healthcare ETFs in Focus on Mixed JNJ Results - ETF News And Commentary", "After Hours Most Active for Jan 20, 2015 : BAC, PFE, EMC, AAPL, QQQ, NFLX, FCX, INTC, JPM, IBM, GILD, MACK", "Johnson & Johnson Overcomes Threats from Competitors, Delivers Solid Quarterly Results", "Gilead Includes Pan-Genotypic Agent in HCV Licensing Deals - Analyst Blog", "Is 1 Drug Really Outselling Legalized Marijuana?", "3 Big Pharma Stocks With More Free Cash Flow Than Gilead Sciences Inc.", "Understanding Stock Dilution -- and Why You Should Care About It", "Will Organovo Holdings Inc. be Bought Out in 2015?", "QUAL, GILD, HD, ORCL: ETF Inflow Alert", "3 Stocks to Buy When the Market Crashes", "How Much Could AbbVie Inc. Make Selling Its Hepatitis C Drug This Year?", "AbbVie Gains EU Approval for Hepatitis C Virus Treatment - Analyst Blog", "Nasdaq 100 Movers: GILD, CELG", "Did Gilead Sciences' Sales Soar in Q4?", "Why Pharmacyclics Inc. Skyrocketed Higher Today", "1 Big Loser in the Slugfest Between AbbVie and Gilead Sciences", "Which Big Biotech Will Soar in 2015?", "Is Celgene Corporation a Takeover Target in 2015?", "Better Healthcare Buy: Big or Little Biotechs", "Gilead Sciences, Inc. Is No Longer Just an HIV Company", "3 Ways Gilead Sciences, Inc. Could Still Be in Big Trouble", "Should AbbVie Inc. Or Gilead Sciences Buy These Tiny Biotech Stocks?", "The Dark Secret in the AbbVie-Gilead Sciences Hepatitis C Drug War", "Did Gilead Sciences Just Buy Its Next Blockbuster Drug?", "Is Gilead Sciences Inc. Now a Takeover Target?", "Why Medivation Inc. Stock Sank 14% in December", "1 Amazing Chart Shows Why Gilead Sciences, Inc.'s Stock Still Belongs in Your Portfolio", "5 Predictions for Biotechnology Stocks in 2015", "VV, C, GILD, PEP: ETF Inflow Alert", "3 Biotech Stocks That Could Trounce Gilead Sciences, Inc. in 2015", "Enzon Pharmaceuticals, Inc. (ENZN) Ex-Dividend Date Scheduled for January 08, 2015", "The Biggest Surprise in the Battle Between AbbVie and Gilead Sciences", "Gilead to Purchase Liver Disease Program from Phenex - Analyst Blog", "Prospects For 2014's Best and Worst Performing Sectors", "Why Gilead Sciences, Inc. Stock Plunged as Much as 14% in December", "Gilead Sciences, Inc. Fires Back at AbbVie Inc.", "VV, C, GILD, PEP: ETF Inflow Alert", "The 3 Underlying Reasons Why Gilead Sciences, Inc. Could Remain Wildly Successful", "How 1 Tiny Hepatitis C Drug Developer Trounced Gilead Sciences, Inc. in 2014", "Interesting GILD Put And Call Options For February 2015", "These 3 Biotechs Are Looking at a Happy New Year", "3 Biotech Stocks That Soared Past Gilead in 2014 - Analyst Blog", "Start the New Year Off Right With the 3 Best Biotech Stocks", "Growth Stocks 2015: 3 Companies With Room to Run", "DoctoRx Positions For 2015: I Have Cut Back On My Exposure To All Biotech Substantially", "Gilead/J&J Expand TAF-based HIV Drugs Related Agreement - Analyst Blog", "Nasdaq 100 Movers: REGN, GILD", "IBB, GILD, REGN, BMRN: Large Inflows Detected at ETF", "Health Care Sector Update for 12/29/2014: POZN, AEZS, GILD", "Pre-Market Most Active for Dec 29, 2014 : RIO, TVIX, ALU, FCAU, GILD, XIV, JUNO, AAPL, PBR, BAC, GPRO, MTW", "Is Gilead Sciences, Inc. a Value Stock Following Its Tumble?", "3 Cheap Dividend Stocks You Can Buy Right Now", "Mid-Afternoon Market Update: Crude Oil Slides 3%; Gilead Sciences Shares Spike Higher", "Should AbbVie Inc. and Gilead Sciences, Inc. Fear This Biotech Instead of Each Other?", "Pharma Stocks Could Be in Deep Trouble in 2015. Here's Why.", "3 Stocks Poised for Eye-Popping Gains in 2015", "S&P 500 Movers: EQT, GILD", "Nasdaq 100 Movers: VIP, GILD", "Stock Market News for December 26, 2014 - Market News", "Gilead Sciences, Inc. Can't Do It Alone", "Mid-Afternoon Market Update: Crude Oil Slides 3%; Gilead Sciences Shares Spike Higher", "Nasdaq 100 Movers: VIP, CELG", "Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen Plunges on Data - Analyst Blog", "The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)", "Pre-Market Most Active for Dec 24, 2014 : RIG, GPRO, SNN, ARCP, FB, SMFG, ACHN, BAC, FCAU, TVIX, CRH, GILD", "Biotech Booms Amid Pre-Christmas Snoozefest", "Could Express Scripts Holding Company's Gilead Gamble Backfire?", "After Gilead Sciences, Is it Time to Sell Biotech Stocks? - Analyst Blog", "Pre-Market Most Active for Dec 26, 2014 : GPRO, FB, TVIX, BAC, GILD, QQQ, PBR, VALE, RAD, AAPL, BABA, AUY", "Gilead Falls on AbbVie and Express Scripts Deal: 3 Biotech ETFs to Watch - ETF News And Commentary", "What the World's Biggest Hedge Fund Has Been Selling", "Express Scripts Hates Gilead Sciences, Loves AbbVie", "Top-Rated Stock Picks and Most-Read Stories of the Week of December 15 for Nasdaq.com", "AbbVie Inc. Throws First Punch in Hep C Price War With Gilead Sciences, Inc.", "Gilead Sciences Slumps: GILD Tumbles 14.3% in Session - Tale of the Tape", "Midday Update: Stocks Extending Winning Streak To A Fifth Day Following Strong GDP, Consumer Spending Data", "Pre-Market Most Active for Dec 23, 2014 : ALU, VALE/P, NQ, RAD, RIG, GPRO, ARIA, BAC, JRJC, QQQ, GILD, TVIX", "Achillion Gains on Positive Results from its HCV Candidates - Analyst Blog", "Express Scripts (ESRX) Picks AbbVie's Hepatitis C Drug - Analyst Blog", "Why Achillion Pharmaceuticals Shares Collapsed by 25% Today", "S&P 500 Movers: GILD, LM", "Nasdaq 100 Movers: GILD, VIP", "Mid-Morning Market Update: Markets Open Higher; Caesars Entertainment To Buy Caesars Acquisition", "Gilead Sciences Vs. AbbVie: Surprise! Sovaldi Still Matters", "U.S. Stocks Set to Mostly Continue Post-Fed Rally in Light Holiday Trading; Chicago Fed Activity Index Surges", "Pre-Market Most Active for Dec 22, 2014 : ACHN, GILD, CHL, TVIX, ABBV, FB, RAD, ALU, PBR, ALLY, XIV, QQQ", "U.S. Stock Futures Gain In Pre-Christmas Rally", "Could Gilead Sciences, Inc. Be a Top Stock in 2015?", "AbbVie's All-Oral, Interferon-Free HCV Treatment Approved - Analyst Blog", "Why Gilead Sciences Shares Tumbled Today", "Gilead/Ono Pharmaceutical Ink Deal for Blood Cancer Drug - Analyst Blog", "Is the Price Still Right for Gilead Sciences?", "Monday's ETF Movers: EEM, BBH", "These Biotech Stocks Are Growing Even Faster Than Gilead Sciences", "Gilead Sciences, Inc. Gets Some Competition (but Not Really)", "3 Pharma Giants Growing Significantly Faster Than Pfizer, Inc.", "United Therapeutics Lung Drug Keeps Going And Going", "Noteworthy ETF Outflows: OEF, GILD, GOOG, PM", "Pfizer, Inc. Invests in Growth... Literally", "Week Ahead Market Report: December 22, 2014", "The 3 Most Exceptional CEOs of 2014", "3 Healthcare Stocks to Watch in 2015", "Could the World's Top-Selling Drug Be Toppled?", "Why I'm Not Short Gilead Sciences, Inc.", "Can These Top Dividend-Paying Stocks Soar in 2015?", "Why Gilead Sciences and AbbVie Care About This Tiny Company", "Cheap Stocks for 2015: The Best Buys in Healthcare", "Which Biotech Will Become the Next Gilead Sciences, Inc.?", "The 3 Most Exceptional CEOs of 2014", "3 Healthcare Stocks to Watch in 2015", "Could the World's Top-Selling Drug Be Toppled?", "Why I'm Not Short Gilead Sciences, Inc.", "Can These Top Dividend-Paying Stocks Soar in 2015?", "3 Top Large-Cap Biotech Stocks for 2015", "3 Reasons Gilead Sciences Could Soar in 2015", "The Smartest Financial Decision I Ever Made", "25 Best Stocks for 2015", "3 Cheap Growth Stocks You Can Buy Right Now", "1 Big FDA Decision I'm Watching This Month", "Why Biotech Stocks Don't Pay Dividends", "Johnson & Johnson Bought Alios for Hepatitis C", "The Most Important FDA Decision We're Watching This Month", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for December 03, 2014", "Gilead Sciences, Inc. Beats Another Threat", "Mylan, Gilead Ink Deal for TAF-based HIV Drugs - Analyst Blog", "Nasdaq 100 Movers: VIP, GILD", "3 Healthcare Stocks to Hold Forever", "Bristol-Myers Squibb Co's Hep C Drug Denied; Gilead Sciences Inc. Smiling (for Now)", "5 Drug Classes Where Prescription Spending Could Grow the Quickest", "Johnson & Johnson's Rezolsta Approved in the EU for HIV-1 - Analyst Blog", "Should Gilead Sciences, Inc. Pay a Dividend?", "Why Gilead Sciences, Inc. Stock Lost 10% in November", "Why You Shouldn't Bet Against Gilead Sciences (GILD) Stock - Tale of the Tape", "3 Biotech Growth Stocks You Can Buy Right Now", "AbbVie Takes Aim at Gilead Sciences", "Gilead Sciences Inc. Just Paid $125 Million for Something It Can't Use for a Year", "AbbVie's HCV Cocktail Treatment Closer to EU Approval - Analyst Blog", "Can Partnering To Fight Hepatitis C Pay At Enanta?", "3 Biotech Stocks That Could Soar Even Higher", "3 Simple Reasons Doctors May Stick With Gilead Sciences Instead of AbbVie", "Why You Shouldn't Bet Against Gilead Sciences (GILD) Stock - Tale of the Tape", "3 Biotech Growth Stocks You Can Buy Right Now", "AbbVie Takes Aim at Gilead Sciences", "Gilead to Buy Knight Therapeutics' Priority Review Voucher - Analyst Blog", "Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog", "Stock Market News for November 19, 2014 - Market News", "Nasdaq 100 Movers: TSLA, SPLS", "Get Your Wallet Out: Global Drug Spending is About to Hit a Dubious Milestone", "This May Be the Fastest Growing Big Biotech Stock Next Year (Hint: It's Not Gilead Sciences)", "Notable ETF Inflow Detected - VTI, BAC, GILD, INTC", "Biotech's 3 Most Influential CEOs", "Gilead to Buy Knight Therapeutics' Priority Review Voucher - Analyst Blog", "Biotech: And Yet We've Just Begun...", "Tiger Management's Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, ...", "Nasdaq 100 Movers: NTAP, VIAB", "Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015", "3 Stocks the Smartest Investors Are Buying Right Now", "Incyte Building Blockbuster Drug One Disease At A Time", "Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog", "Notable ETF Inflow Detected - XLV, MRK, GILD, UNH", "Stock Market News for November 11, 2014 - Market News", "Gilead Sciences Inc. Breathes a Sigh of Relief -- Hepatitis C Patients, Not So Much", "Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog", "Why Gilead Sciences (GILD) Isn't Done Growing Earnings Yet - Tale of the Tape", "Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog", "This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success", "Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog", "3 Drugs That Make Gilead Sciences' Harvoni Look Cheap", "Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog", "5 Prescription Drugs Selling Like Hot Cakes", "3 Biotech Stocks to Watch in November", "Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog", "Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.", "Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog", "Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig", "5 Things AbbVie Inc.'s Management Wants You to Know", "Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October", "ETF Outlook: First Trust Amex Biotech Index Fund ETF (FBT)", "Is This Trend Making Gilead Sciences, Inc. Worry?", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for November 10, 2014", "Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog", "Novo Nordisk's Earnings Rise in Q3, 2014 Outlook Narrowed - Analyst Blog", "Noteworthy ETF Inflows: XLV, GILD, MRK, UNH", "2 More Gilead Sciences, Inc. Blockbusters You Ought to Know About", "5 Staggering Statistics About the Fastest Growing Drug in the World", "5 Things Bristol-Myers Squibb Co.'s Management Wants You to Know", "Why You Shouldn't Worry About Gilead Sciences, Inc.", "Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for November 06, 2014", "Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog", "In the news: Facebook earnings, AT&T facing a lawsuit over throttling and more", "Amgen Beats Earnings Estimates, What's Next for AMGN? - Stocks in the News", "Gilead (GILD) Posts Weak Earnings; Stock Falls 4% After-Hours - Stocks in the News", "3 Ways You'll Know Gilead Sciences, Inc. Stock Is Still On Track", "What to Make of Gilead Sciences Inc.'s Third-Quarter Earnings Miss", "After Hours Most Active for Oct 28, 2014 : FB, QQQ, BAC, JNJ, BSBR, EMC, AAPL, SAN, KMI, GPOR, YHOO, GILD", "5 Things McKesson Corporation's Management Wants You to Know", "Will Marijuana-Based Pharmaceuticals Make Drugs More Affordable?", "IYH, GILD, ABT, AGN: Large Inflows Detected at ETF", "A safe route into the biotech sector", "Stock of the Week: Gilead Sciences (GILD)", "3 Biotech Stocks Growing Faster Than Gilead Sciences Inc.", "Merck & Co., Inc. Earnings: Patent Losses and Competition Weigh on Sales", "How Gilead Sciences Inc. Isn't Gouging Hepatitis C Patients, in 1 Simple Infographic", "After-Hours Earnings Report for October 28, 2014 : FB, GILD, ESRX, MCK, APC, AFL, VRTX, EQR, AMP, WDC, MAR, EIX", "Bristol-Myers Squibb Co's Third-Quarter Earnings Beat the Street", "Stocks Trade Higher Ahead of News-Heavy Weekend", "Friday's ETF with Unusual Volume: BBH", "Will Gilead (GILD) Miss Earnings on High Operating Costs? - Analyst Blog", "Is Johnson & Johnson's Worst Nightmare Becoming Reality?", "Gilead's Hep C Dream Drug Faces Demanding Investors", "Why Regulus Therapeutics Inc. Stock More Than Doubled", "5 Things Johnson & Johnson's Management Wants You to Know", "3 Drugs Critical to Johnson & Johnson's Future", "What Johnson & Johnson Can Tell Us about Gilead Sciences, inc. Stock", "3 Stocks I'll Buy if the Market Crashes", "This Drug Could Outsell Medical Marijuana", "180 Million People Have This Disease, Yet Few Are Aware of It", "Could This Game-Changing Drug Deliver $10 Billion in Sales Within Its First Year?", "IYH, GILD, TMO, COV: Large Outflows Detected at ETF", "5 Best Biotech Stocks to Buy Now", "3 Drugs Critical to Johnson & Johnson's Future", "What Johnson & Johnson Can Tell Us about Gilead Sciences, inc. Stock", "Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog", "Should Gilead Sciences, inc. Fear Incoming Competition?", "Healthcare ETFs in Focus on JNJ Earnings Beat - ETF News And Commentary", "S&P 500 Movers: GILD, CCI", "Will Sagging Scripts Dent Gilead Sciences, Inc. Earnings?", "Gilead Sciences president and COO sells 146,895 shares", "Gilead Sciences, inc. Stock's Green Light Sparks Offensive", "Gilead's All-Oral Combo HCV Drug Harvoni Cleared by FDA - Analyst Blog", "Gilead Sciences Inc. Gets First Hepatitis C Cocktail Drug Approved", "Bristol-Myers Co Regroups; Hepatitis C Fight With Gilead Sciences Not Over", "iShares U.S. Healthcare ETF Experiences Big Inflow", "3 Stocks to Buy if the Market Crashes", "Nasdaq 100 Movers: GILD, SYMC", "After Hours Most Active for Oct 9, 2014 : SIRI, SVU, BNDX, BRK/B, BAC, SYF, COG, CS, QQQ, AAPL, MSFT, GILD", "Bristol-Myers Tells Gilead Sciences, Inc. \"You Win\"", "ETF Outlook: Health Care Select Sector SPDR ETF (XLV)", "Biotech Stock Roundup: Sunesis Tanks on Study Results, Chimerix Up on Ebola Update - Analyst Blog", "Bristol-Myers Gives Up on US Approval of 2-Drug HCV Combo - Analyst Blog", "After Hours Most Active for Oct 8, 2014 : AA, REXX, QQQ, CS, GPS, CX, ABB, KMI, ZNGA, GILD, SIRI, MSFT", "The Most Important Number You Need to Know Before Buying Gilead Sciences Inc. Stock", "Can Arrowhead Research Corp. Stock Recover from Its Horrendous Drop?", "After Hours Most Active for Oct 6, 2014 : ITUB, BAC, CX, PUK, HSBC, FTR, JDSU, HBAN, BID, GILD, SYMC, FITB", "Gilead Sciences' Other Important New Drug", "Gilead Sciences, Inc. Got 2 Drugs Approved, and Didn't Bother to Tell Anyone", "Better Dividend Stock: Merck & Co. Inc. or Bristol-Myers Squibb Co.?", "The Biggest Threat Facing Johnson & Johnson", "MannKind Receives $150 Million Upfront Payment from Sanofi - Analyst Blog", "Regeneron-Sanofi's Dupilumab Meets All Endpoints - Analyst Blog", "Johnson & Johnson Takes Aim at Gilead Sciences, inc.", "Progenics/Salix's Relistor Label Expanded in the U.S. - Analyst Blog", "AbbVie's (ABBV) Humira Gains Yet Another FDA Approval - Analyst Blog", "AVEO-Biodesix Reveal Lung Cancer Study Exploratory Data - Analyst Blog", "Did Achillion Pharmaceuticals, Inc. Get Left Out in the M&A Cold?", "Round 2 of Gilead Sciences, Inc.'s Offensive Begins", "#PreMarket Primer: Wednesday, October 1: First Case Of Ebola In The US Confirmed", "Seattle Genetics-Takeda Reveal Impressive Adcetris Data - Analyst Blog", "Top Fund Buys: Chipotle, Allergan, Jazz, Gilead", "Ambit Biosciences (AMBI) Soars: Stock Adds 87.1% - Tale of the Tape", "Immunomedics (IMMU) Jumps: Stock Adds 9.1% is Session - Tale of the Tape", "Gilead Sciences, Inc. Stock's Stunning New Opportunity", "Raptor Pharmaceuticals (RPTP) Crumbles: Stock Falls by 7.2% - Tale of the Tape", "CorMedix Files IND Application for Neutrolin in the US - Analyst Blog", "AMAG Up on Roughly $1B deal with Lumara to Widen Portfolio - Analyst Blog", "Regado Trims Workforce, Revamps Strategy on Trial Halt - Analyst Blog", "Machines Rule, Bears Drool - Video Blog", "Gilead Sciences, Inc. Takes Aim at Bristol-Myers Squibb", "Bristol-Myers' Opdivo Under Review in US, EU for Cancer Treatment - Analyst Blog", "Alimera/pSivida's Iluvien Receives FDA Approval for DME - Analyst Blog", "Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog", "Gilead's HCV Combo Drug Harvoni Secures CHMP Backing - Analyst Blog", "Nektar/AstraZeneca's Moventig a Step Closer to EU Approval - Analyst Blog", "What This Huge George Soros Mistake Can Teach You", "Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% - Tale of the Tape", "Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% - Tale of the Tape", "The 5 Best Biotech Stocks in 2014...so far", "Celldex (CLDX) Up on Pilot Study Initiation on CDX-301 - Analyst Blog", "Alnylam Starts New Study on Cardiac Amyloidosis Patients - Analyst Blog", "MannKind and Sanofi Complete Afrezza Collaboration Deal - Analyst Blog", "Gilead's HIV Drugs Tybost and Vitekta Get FDA Clearance - Analyst Blog", "Myriad Genetics Poised on Strong myRisk, Overseas Results - Analyst Blog", "Merrimack Pharmaceuticals (MACK) Soars: Stock Adds 7.4% is Session - Tale of the Tape", "ETF Outlook: S&P Health Care Select SPDR ETF (XLV)", "This Switch Could Make Gilead Sciences, Inc. Stock Billions", "The Best Biotech Stock for Your Growth Portfolio", "Seattle Genetics' Adcetris Positive in Durability Analysis - Analyst Blog", "Acorda Skyrockets on $525M Civitas Therapeutics Deal - Analyst Blog", "Gilead Scores with TAF-based HIV Regimen, Shares Up - Analyst Blog", "Genomic Health Upbeat on Strong International Performance - Analyst Blog", "Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog", "ETF Outlook: S&P Health Care Select SPDR ETF (XLV)", "The Next Blue Chip Stocks: Gilead Sciences, Inc.", "Novavax's Influenza Vaccine Study Shows Adjuvant Efficiency - Analyst Blog", "Gilead (GILD) Seeks Japanese Approval for HCV Combo Drug - Analyst Blog", "Celgene's Otezla Label Expanded to Include Plaque Psoriasis - Analyst Blog", "Emergent BioSolutions Initiates Pivotal Study on BioThrax - Analyst Blog", "IWF, IBM, VZ, GILD: Large Inflows Detected at ETF", "Acceleron Pharma (XLRN) Jumps: Stock Rises 12.8% - Tale of the Tape", "Amgen Files Blinatumomab Marketing Application in U.S. - Analyst Blog", "AstraZeneca Posts Positive Data on its Type II Diabetes Drug - Analyst Blog", "Bayer/Regeneron Successfully Expand Eylea Label in Japan - Analyst Blog", "Integra Freedom Wrist's Commercial Availability Falls Flat - Analyst Blog", "Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher - Tale of the Tape", "Cytori Therapeutics (CYTX) Jumps: Stock Rises 6.4% - Tale of the Tape", "Vertex Pharmaceuticals (VRTX) Jumps: Stock Rises 6.6% - Tale of the Tape", "OncoMed Pharmaceuticals (OMED) Jumps: Stock Up 5.4% - Tale of the Tape", "Isis Pharmaceuticals Up on $4M Milestone Payment - Analyst Blog", "Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer - Analyst Blog", "Flexion Continues to Fall Post Clinical Hold on FX006 - Analyst Blog", "Surprising Silver Lining for Gilead Sciences, inc. Stock", "Dividend Aristocrats: Time to Buy AbbVie Inc Stock?", "5 Things Gilead Sciences, Inc. Management Wants You to Know", "VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape", "Glaxo Fined Roughly $484M in China Bribery Probe - Analyst Blog", "VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog", "Bristol-Myers' (BMY) Yervoy Label Expanded in Canada - Analyst Blog", "Spectrum Pharmaceuticals Out-Licenses Products in China - Analyst Blog", "Bayer to Shed MaterialScience Business, Shares Rise - Analyst Blog", "Eli Lilly's Trulicity Approved by FDA for Type II Diabetes - Analyst Blog", "Is Merck KGaA on Track with its \"Fit for 2018\" Program? - Analyst Blog", "Sector Update: Health-Care Shares Lower in Pre-Market Trade", "Is It Time to Buy Dividend Stock Bristol-Myers Squibb Co?", "ImmunoCellular Therapeutics (IMUC) Jumps: Stock Up 9% - Tale of the Tape", "Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% - Tale of the Tape", "Repros Therapeutics (RPRX) Crumbles: Stock Falls by 10.5% - Tale of the Tape", "Gilead Sciences, inc. Stock's Incoming Game Changer", "3 Best Stocks for Investing in Biotech", "Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies - Analyst Blog", "Gilead Science stumbles, but stays on its feet", "Alnylam (ALNY) to File Clinical Trial Application for ALN-CC5 - Analyst Blog", "Gilead Down on Weak Simtuzumab Data and Sovaldi News - Analyst Blog", "3 Hot Ways to Play the Biotechnology Bonanza", "Sector Update: Health-Care Shares Mixed Pre-Market", "Sector Update: Health Care", "Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog", "Shire's Vyvanse Accepted for FDA Review for Binge Eating - Analyst Blog", "Bayer/Orion Progress with Prostate Cancer Drug ODM-201 - Analyst Blog", "Regeneron Gets Breakthrough Therapy Status for Eylea - Analyst Blog", "Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog", "AstraZeneca and Eli Lilly Collaborate for Alzheimer's Drug - Analyst Blog", "Synthetic Biologics' SYN-005 Gets Orphan Drug Designation - Analyst Blog", "Gilead (GILD) Slips on Generic Sovaldi Licensing Deals - Analyst Blog", "Is Illumina (ILMN) a Buy on Solid Q2, Strategic Road Map? - Analyst Blog", "UCB-Amgen Reveals Positive Data on Romosozumab for PMO - Analyst Blog", "AstraZeneca's Constipation Drug Movantik Gets FDA Nod - Analyst Blog", "Sector Update: Health Care", "NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote - Analyst Blog", "Alnylam Expands Pipeline with Preeclampsia Drug ALN-AGT - Analyst Blog", "Novartis Presents Positive Data on Lucentis and Jetrea - Analyst Blog", "Abbott Labs Presents Positive One-Year Data on Absorb - Analyst Blog", "S&P 500 Movers: GILD, TAP", "Eli Lilly's Cyramza Scores in Colorectal Cancer Study - Analyst Blog", "Genomic Health Reveals Positive Oncotype DX Test Results - Analyst Blog", "3 Reasons McKesson Corporation's Stock Could Rise", "#PreMarket Primer: Friday, September 12: US Allies Vague About Participation In Syrian Airstrikes", "Will Allergan's Board Be Revamped to Aid Valeant Buyout? - Analyst Blog", "Abbott Labs (ABT) to Repurchase Shares for $3B - Analyst Blog", "Biogen Reports Positive Two-Year Data on MS Drug Plegridy - Analyst Blog", "Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog", "Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog", "Momenta Gains on Purchase of Autoimmune Antibodies - Analyst Blog", "Medivation Eyes Blockbuster As Cancer Drug Gets An OK", "Mylan to Acquire U.S. Rights to Arixtra for up to $300M - Analyst Blog", "Why Gilead Sciences Stock Is Up 40% in 2014", "Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary", "Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog", "Medivation-Astellas' Xtandi's Label Expanded by FDA - Analyst Blog", "Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog", "Stemline Therapeutics (STML) in Focus: Stock Up 12.3% - Tale of the Tape", "PDL BioPharma Sees Higher-than-Expected Revenues in Q3 - Analyst Blog", "Spectrum Pharmaceuticals to Advance Neutropenia Drug - Analyst Blog", "Auxilium Pharmaceuticals to Restructure, Cut Jobs by 30% - Analyst Blog", "Emergent BioSolutions Wins $29M Anthrax Vaccine Deal - Analyst Blog", "Myriad Genetics Posts Encouraging myPath Melanoma Data - Analyst Blog", "ERBA Diagnostics (ERB) in Focus: Stock Up 7% - Tale of the Tape", "Glaxo (GSK) Updates on Asthma Candidate Mepolizumab - Analyst Blog", "Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog", "Hospira Down on Legal Blow; Court Allows Generic Precedex - Analyst Blog", "ZIOPHARM Oncology (ZIOP) in Focus: Stock Rises 10.4% - Tale of the Tape", "Keryx Biopharmaceuticals (KERX) Crumbles: Stock Falls by 5.5% - Tale of the Tape", "BioDelivery Sciences (BDSI) Jumps: Stock Rises 8.9% - Tale of the Tape", "Stock of the Week: Express Scripts (ESRX)", "AstraZeneca Presents Unfavorable Benralizumab Study Data - Analyst Blog", "OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog", "Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog", "Novartis (NVS) Presents Positive Data on Ultibro Breezhaler - Analyst Blog", "Bayer/Regeneron Looking for Eylea Label Expansion in Japan - Analyst Blog", "Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog", "Gilead Down on Likely Sovaldi Generic Deal in Poor Nations - Analyst Blog", "Is a Cheap Hepatitis C Cure About to Go Global?", "Keryx Falls after Ferric Citrate's Approval with Warnings - Analyst Blog", "OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog", "Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog", "XOMA Corporation (XOMA) Jumps: Stock Rises 6.2% - Tale of the Tape", "Mallinckrodt's Pain Therapy Hits Phase III Primary Endpoint - Analyst Blog", "Celgene's Revlimid Impresses in Phase III NDMM Study - Analyst Blog", "Abbott Labs' FreeStyle Libre Flash Glucose Gets CE Mark - Analyst Blog", "Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 9.6% - Tale of the Tape", "Nasdaq 100 Movers: GILD, VRTX", "iShares Russell 1000 Growth ETF Experiences Big Inflow", "3 Reasons Bristol-Myers Squibb's Stock Could Fall", "J&J Ebola Vaccine Gets Funding, Development to Pick Pace - Analyst Blog", "Bristol-Myers Returns Clazakizumab Rights, Alder Sinks - Analyst Blog", "Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor - Analyst Blog", "Alder Biopharmaceuticals Slumps: ALDR Tanks 13.2% in Session - Tale of the Tape", "Exact Sciences Corp. (EXAS) in Focus: Stock Rises 6.3% - Tale of the Tape", "Infinity Pharma (INFI) Shares Skyrocket on Cancer Drug Partnership - Stocks in the News", "Sanofi Reports Positive Phase III Data on Dengue Vaccine - Analyst Blog", "Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead", "New Managers Revive Thrivent Large Cap Growth Fund", "Arena Pharmaceuticals' APD811 Gets Orphan Drug Status - Analyst Blog", "Bayer Discloses Encouraging Data on Anticoagulant Xarelto - Analyst Blog", "ETF Insider: Q&A with Kevin Kelly of Recon Capital Partners", "Roche's Cobas 6800/8800 Testing Systems Launched - Analyst Blog", "Ambit Biosciences (AMBI) Jumps: Stock Up 6.6% - Tale of the Tape", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for September 03, 2014", "Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog", "AstraZeneca Reports Data on Brilinta from ATLANTIC Study - Analyst Blog", "Bayer/Johnson & Johnson to Expand Xarelto Label Further - Analyst Blog", "United Therapeutics Soars on Remodulin Patent Case Win - Analyst Blog", "Novartis Releases Positive Data on LCZ696 for Heart Failure - Analyst Blog", "Biotechnology, Oil And Brazil ETFs To Watch This Week", "BioCryst's Ebola Candidate Moving to Efficacy Study Soon - Analyst Blog", "3 Simple Ways to Invest Like George Soros", "Protalix BioTherapeutics, Inc. (PLX) Jumps: Stock Adds 8.3% in Session - Tale of the Tape", "Why Gilead Sciences (GILD) Could Be Positioned for a Surge? - Tale of the Tape", "OncoMed Pharmaceuticals (OMED) in Focus: Stock Up 9.9% - Tale of the Tape", "Regeneron Pharmaceuticals' Pipeline Progress Raises Costs - Analyst Blog", "Pfizer's C. Difficile Vaccine Gets Fast Track Status - Analyst Blog", "Prestige Brands to Sell Bonine for Insight Acquisition - Analyst Blog", "Isis Pharmaceuticals Starts Phase III Study on ISIS-APOCIIIRx - Analyst Blog", "Momenta-Sandoz's Generic Copaxone Accepted for Review by FDA - Analyst Blog", "Guggenheim S&P 500 Equal Weight ETF Experiences Big Inflow", "Bristol-Myers Squibb's Daklinza Threatens Johnson & Johnson More Than Gilead Sciences", "Has Gilead Sciences, Inc.'s Star Drug Already Peaked?", "Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance - Analyst Blog", "Intellipharmaceutics' Oxycodone Program to Prevent Overdose - Analyst Blog", "Protalix/Pfizer's Elelyso Approved in Pediatric Patients - Analyst Blog", "Aegerion Resolves FDA's Warning on Juxtapid, Lifts Overhang - Analyst Blog", "MediciNova Rises on FDA's Nod on MN-166 Study Initiation - Analyst Blog", "Allergan Seeks Court Order to Stop Valeant, Affiliates - Analyst Blog", "Q2 Earnings Season in Rearview Mirror - Earnings Trends", "Q2 Earnings Season in Rearview Mirror - Earnings Outlook", "BioTime's AST-OPC1 Cleared by FDA for Phase I/IIa Study - Analyst Blog", "RedHill Expands ERADICATE Study on RHB-105 for H. pylori - Analyst Blog", "Is It Time to Buy AbbVie Stock?", "Amicus Therapeutics Hits 52-Week High on Migalastat Data - Analyst Blog", "3 Reasons Pfizer Inc.'s Stock Could Fall", "Isis Pharmaceuticals, Inc. (ISIS) Surges: Stock Moves 10.8% Higher - Tale of the Tape", "Celldex Therapeutics (CLDX) Worth Watching: Stock Rises 9.1% - Tale of the Tape", "#PreMarket Primer: Wednesday, August 27: Israel And Hamas To Resume Peace Talks In Cairo", "Nasdaq 100 Movers: GILD, TSCO", "Repros Reports Encouraging Late-Stage Data on Androxal - Analyst Blog", "Gilead (GILD) Shares March Higher, Can It Continue? - Tale of the Tape", "TrovaGene (TROV) Jumps: Stock Rises 9.2% - Tale of the Tape", "InterMune (ITMN) Worth Watching: Stock Rises 35.4% - Tale of the Tape", "Alkermes Gains on Aripiprazole Lauroxil NDA Submission - Analyst Blog", "Kite Pharma Drug Fares Well in Non-Hodgkin's Lymphoma Study - Analyst Blog", "#PreMarket Primer: Tuesday, August 26: US Gathers Intelligence In Syria", "Cardiome Pharma Signs Agreement with Eurolab for Brinavess - Analyst Blog", "Should Gilead Sciences, inc. Fear This New Competitor Drug?", "S&P 500 Movers: STZ, GILD", "Nasdaq 100 Movers: INTU, GILD", "OncoMed Pharmaceuticals (OMED) in Focus: Stock Rises 5.1% - Tale of the Tape", "Cubist Pharmaceuticals' Antibiotic Accepted for EU Review - Analyst Blog", "More Biotech Mergers: Roche to Acquire InterMune (ITMN) - Stocks in the News", "3 Reasons Johnson & Johnson's Stock Could Fall", "Regado Slumps on Permanent Termination of Revolixys Study - Analyst Blog", "VIVUS Acquires Certain Topamax Related Patents from J&J - Analyst Blog", "S&P 500 Movers: STZ, GILD", "Nasdaq 100 Movers: INTU, GILD", "OncoMed Pharmaceuticals (OMED) in Focus: Stock Rises 5.1% - Tale of the Tape", "Cubist Pharmaceuticals' Antibiotic Accepted for EU Review - Analyst Blog", "More Biotech Mergers: Roche to Acquire InterMune (ITMN) - Stocks in the News", "VTI, MRK, KO, GILD: Large Inflows Detected at ETF", "Repros Therapeutics (RPRX) Shows Strength: Stock Rises 5% - Tale of the Tape", "Why Gilead Sciences (GILD) Could Beat Earnings Estimates Again - Tale of the Tape", "Discovery Laboratories (DSCO) Worth Watching: Stock Up 6.9% - Tale of the Tape", "Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog", "Achillion Attains 52-Week High on ACH-3102 Patent Protection - Analyst Blog", "Amicus Therapeutics (FOLD) Soars on Fabry Drug Trial Results - Analyst Blog", "Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate - Analyst Blog", "3 Reasons Gilead Science, Inc.\u2019s Stock Could Rise", "Gilead (GILD) Hits 52-Week High Thanks to Sovaldi - Analyst Blog", "Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog", "Record Earnings & Stronger Growth in Q2 - Earnings Trends", "Record Earnings & Stronger Growth in Q2 - Earnings Outlook", "Oncothyreon (ONTY) Slumps, Tecemotide Fails Phase I/II Study - Analyst Blog", "PDL BioPharma Misses on Q2 Earnings due to Higher Expenses - Analyst Blog", "Celladon Corp. (CLDN) Jumps: Stock Adds 11.3% in Session - Tale of the Tape", "Will Roche (RHHBY) Buy the Remaining Stake in Chugai? - Analyst Blog", "Hospira Sues FDA on Generic Precedex Approval, Shares Down - Analyst Blog", "After Hours Most Active for Aug 19, 2014 : BAC, XOM, AAPL, QQQ, MET, MSFT, NOK, CAT, BBD, MDLZ, GILD, ACHN", "Pfizer Submits Palbociclib Marketing Application to the FDA - Analyst Blog", "Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog", "Techne Corporation (TECH) Ex-Dividend Date Scheduled for August 19, 2014", "#PreMarket Primer: Monday, August 18: Jackson Hole Draws Market Attention", "Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data - Analyst Blog", "Should Achillion Pharma (ACHN) Be In Your Portfolio Now? - Stocks in the News", "Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 - Analyst Blog", "Array BioPharma Falls Despite Narrower-than-Expected Q4 Loss - Analyst Blog", "Closing Update: Nasdaq Closes Higher in Afternoon Rebound But Dow, S&P 500 Finish in the Red on Russia-Ukraine Worries", "A Double Dose of Good News for Gilead Sciences, Inc.", "Sector Update: Health Care Stocks Turn Mixed at Close; Achillion Pharma Spikes After Hep C Drug Candidate Performs Well in Phase II Testing", "Sector Update: Health Care", "Why Achillion Pharmaceuticals, Inc. Stock Soared", "Gilead Sciences (GILD): Plenty Of Room To Run", "Gilead Scores Legal Victory Over Roche for Sovaldi, Shares Up - Analyst Blog", "After Hours Most Active for Aug 14, 2014 : JCP, CIE, KMI, QQQ, GFI, ULTI, SIRI, KING, CAT, PTEN, GILD, GLUU", "Strong Earnings Season Winding Down - Earnings Trends", "Strong Earnings Season Winding Down - Earnings Outlook", "Should Gilead Sciences (GILD) Be in Your Portfolio? - Stocks in the News", "IWF, KO, GILD, ORCL: Large Inflows Detected at ETF", "Intercept Pharmaceuticals Posts Earnings, Pipeline in Focus - Analyst Blog", "ETF Outlook: SPDR S&P Biotech ETF (XBI)", "Amgen's FOCUS Study on Multiple Myeloma Drug Kyprolis Fails - Analyst Blog", "Dendreon Down on Default Risk, Reports Narrower Q2 Loss - Analyst Blog", "BioDelivery Sciences Q2 Loss Narrows, Up on Solid Revenues - Analyst Blog", "Spectrum Pharmaceuticals (SPPI) Posts Strong Earnings in Q2 - Analyst Blog", "MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog", "Anacor's Q2 Loss Narrower than Expected, Kerydin in Focus - Analyst Blog", "OvaScience (OVAS) Shows Strength: Stock Up 7% - Tale of the Tape", "Five Prime Therapeutics (FPRX) Jumps: Stock Adds 10.3% in Session - Tale of the Tape", "Bull of the Day: Gilead Sciences (GILD) - Bull of the Day", "After Hours Most Active for Aug 12, 2014 : KING, QQQ, RAD, XRX, NVDA, TD, KMI, CAT, EA, GILD, MSFT, MRVL", "Tekmira Shares Continue to Rise in the Search for Ebola Cure - Analyst Blog", "What is Your Stock's Earnings Yield? - Screen of the Week", "Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog", "Alnylam's Q2 Loss Wider-than-Expected, Pipeline in Focus - Analyst Blog", "Medivation Jumps on Q2 Earnings Beat, Outlook Encourages - Analyst Blog", "Emergent BioSolutions Misses on Earnings, Ups Revenue View - Analyst Blog", "Regeneron's Eye Drug Eylea Cleared in the EU for DME - Analyst Blog", "MannKind Enters into a Global Deal with Sanofi for Afrezza - Analyst Blog", "After Hours Most Active for Aug 11, 2014 : KMI, QQQ, MU, SQNM, GILD, NUAN, AMKR", "Tekmira Pharma Soars on FDA Announcement over Ebola Drug - Analyst Blog", "Market Strategy: Play Energy & IT - Analyst Blog", "#PreMarket Primer: Thursday, August 7: Russia Set To Release A List Of Banned Goods", "Q3 Earnings Estimates Not Falling As Much - Earnings Trends", "Achillion Pharmaceuticals Up on Narrower-than-Expected Loss - Analyst Blog", "XLV, MRK, GILD, UNH: Large Outflows Detected at ETF", "Can the Earnings Rebound be Sustained? - Earnings Trends", "Can the Earnings Rebound be Sustained? - Earnings Outlook", "Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog", "Merck, J&J, Baxter Provide Healthy Dividend Stream", "#PreMarket Primer: Monday, July 28: Tension Between U.S. And Israel On The Rise", "Biotech ETF Price Swings May Signal Need For Caution", "Q3 Earnings Estimates Not Falling As Much - Earnings Outlook", "XLV, MRK, GILD, UNH: Large Outflows Detected at ETF", "Can the Earnings Rebound be Sustained? - Earnings Trends", "Can the Earnings Rebound be Sustained? - Earnings Outlook", "Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog", "Merck, J&J, Baxter Provide Healthy Dividend Stream", "Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog", "Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog", "Will Gilead (GILD) Earnings Disappoint in Q2 as Costs Rise? - Analyst Blog", "Biogen Shares Rebound As Street Has A Change Of Heart", "Nasdaq 100 Movers: NVDA, AVGO", "Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog", "Hefty Price Tag of Gilead's Sovaldi Questioned Again - Analyst Blog", "Sector Update: Health Care Stocks Ending Mixed; Achillion Pharmaceutical Easing From M&A-Fueled Afternoon Rally", "Sector Update: Health Care", "After-Hours Earnings Report for July 23, 2014 : T, FB, QCOM, GILD, CCI, ILMN, AVB, WFT, NXPI, ORLY, TRIP, CA", "Bristol-Myers Gains Japanese Approval for HCV Combo Drug - Analyst Blog", "Alexion Pharma Looks To Life Beyond Its Blockbuster", "Merck, Gilead Lead Race To Eradicate Hepatitis C", "Nasdaq 100 Movers: PAYX, LMCA", "Biotech Stock Roundup: Vertex Jumps on Phase III Data, MannKind Scores FDA Approval - Analyst Blog", "IYH, PFE, GILD, ABT: Large Inflows Detected at ETF", "Gilead Seeks Japanese Approval for Sovaldi - Analyst Blog", "Gilead Sciences August 29th Options Begin Trading", "RegeneRx and Lee's Pharmaceutical Dry Eye Drug Progresses - Analyst Blog", "Cubist Gains FDA Approval for Sivextro - Analyst Blog", "Novo Nordisk Reveals Positive Data on Victoza 3 mg - Analyst Blog", "Alkermes plc (ALKS) Jumps: Stock Rises 5.7% - Tale of the Tape", "Strength Seen in Cara Therapeutics Inc. (CARA) as Stock Rallies 19.60% - Tale of the Tape", "Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights - Analyst Blog", "Celgene Rises on Yet Another Stock Split - Analyst Blog", "Strength Seen in Vertex Pharmaceuticals Incorporated (VRTX) as Stock Shoots 40.41% - Tale of the Tape", "AstraZeneca's Naloxegol Data Published - Analyst Blog", "OncoMed's OMP-54F28 on Partial Clinical Hold - Analyst Blog", "Merge Healthcare: Updated Research Report - Analyst Blog", "Illumina: Updated Research Report - Analyst Blog", "Alkermes' Aripiprazole Lauroxil Looks Promising - Analyst Blog", "Ultragenyx Pharmaceutical (RARE) Jumps: Stock Up 6.5% - Tale of the Tape", "Insmed Incorporated (INSM) Catches Eye: Stock Surges 42.6% - Tale of the Tape", "Cubist Gets Priority Review from FDA for Antibiotic Candidate - Analyst Blog", "Acorda Therapeutics (ACOR) in Focus: Stock Moves 7.8% Higher - Tale of the Tape", "Applied Genetic Technologies (AGTC) Jumps: Stock Up 6.1% - Tale of the Tape", "Intra-Cellular Therapies, Inc. (ITCI) in Focus: Stock Rises 8.74% - Tale of the Tape", "Protalix Drug in Phase IIa Study for Gaucher Disease - Analyst Blog", "BioLineRx to Commence BL-8040 Study - Analyst Blog", "Valeant Launches Hostile Bid for Allergan - Analyst Blog", "Vertex Pharmaceuticals-Johnson & Johnson Collaborate on Flu Drug - Analyst Blog", "Protalix (PLX) in Focus: Stock Adds 6.5% in Session - Tale of the Tape", "Acorda Therapeutics (ACOR) in Focus: Stock Moves 7.8% Higher - Tale of the Tape", "Applied Genetic Technologies (AGTC) Jumps: Stock Up 6.1% - Tale of the Tape", "Intra-Cellular Therapies, Inc. (ITCI) in Focus: Stock Rises 8.74% - Tale of the Tape", "AVEO Pharmaceuticals (AVEO) Catches Eye: Stock Up 11.4% - Tale of the Tape", "Merck KGaA-Ono Pharma Deal Ends - Analyst Blog", "Orexigen (OREX) in Focus: Stock Moves 7.5% Higher - Tale of the Tape", "Sequenom Inc. (SQNM) Soars: Stock Rises 9.2% - Tale of the Tape", "Insmed Soars on Arikayce's Breakthrough Designation - Analyst Blog", "Strength Seen in bluebird bio, Inc. (BLUE) as Stock Shoots up 32.08% - Tale of the Tape", "J&J's Velcade in Focus at the European Hematology Association - Analyst Blog", "Vertex Pharmaceuticals Crumbles on Analyst Worries - Analyst Blog", "Novartis Submits Bexsero to FDA for Marketing Approval - Analyst Blog", "Glaxo's Promacta Holds Promise - Analyst Blog", "Ligand Pharma's LGD-6972 Positive in Phase I Study - Analyst Blog", "Valeant Receives FDA's Clearance for Restylane - Analyst Blog", "Achillion Pharmaceuticals (ACHN) Jumps: Stock Up 20.9% - Tale of the Tape", "Gilead's HCV Combination Therapy Data Looks Promising - Analyst Blog", "What Falling Estimates & Price Mean for Rexahn Pharmaceuticals (RNN) - Tale of the Tape", "Sector Update: Shares Mixed Pre-Market; Gilead Lifts on Phase 3 Results for Hepatitis C Treatment", "Sector Update: Healthcare", "Actelion's Selexipag Meets Primary Endpoint - Analyst Blog", "Celgene's Vidaza Disappoints in Phase III Study - Analyst Blog", "OncoMed's OMP-18R5 On Clinical Hold, Shares Down - Analyst Blog", "Celgene's Pomalyst Data at European Hematology Association Shows Promise - Analyst Blog", "Karyopharm Therapeutics Skyrockets on Drug Trial News - Analyst Blog", "Novo Nordisk's Victoza 3 mg Positive in Phase III - Analyst Blog", "Sanofi's Diabetes Portfolio in Focus at American Diabetes Association Sessions - Analyst Blog", "Integra LifeSciences, Premier Ink 3-Year Purchase Deal - Analyst Blog", "AbbVie Gets Priority Review from FDA for HCV Treatment - Analyst Blog", "Bristol-Myers Suffers a Legal Setback - Analyst Blog", "BIND Therapeutics (BIND) Soars: Stock Up 6.8% - Tale of the Tape", "Agios Presents Data on AG-221 - Analyst Blog", "Karyopharm Therapeutics Skyrockets on Drug Trial News - Analyst Blog", "AstraZeneca Boosts Pipeline with $232 Million Synairgen Deal - Analyst Blog", "Relief for Nektar after AADPAC Voting - Analyst Blog", "Sanofi/ Regeneron Present Postive Data on Sarilumab - Analyst Blog", "J&J, ViiV Healthcare Tie Up for Single-Tablet HIV Treatment - Analyst Blog", "Vertex Pharmaceuticals' New Kalydeco Data Out - Analyst Blog", "Sunesis Pharmaceuticals (SNSS) Soars: Stock Adds 8% in Session - Tale of the Tape", "Avanir Gains - AVP-825 Hits Phase III Primary Endpoint - Analyst Blog", "Auxilium Pharma Launches Authorized Generic Testim - Analyst Blog", "Roche's HPV Test Approved in Canada - Analyst Blog", "Encouraging Long-Term Data on Celgene's Otezla - Analyst Blog", "Geron Corp. (GERN) Soars: Stock Up 10.6% - Tale of the Tape", "Vital Therapies (VTL) Catches Eye: Stock Surges 20.7% - Tale of the Tape", "Orexigen Therapeutics (OREX) in Focus: Stock Tumbles 14.7% - Tale of the Tape", "Geron Gains as FDA Lifts Partial Hold on Imetelstat Study - Analyst Blog", "Avanir Gains - AVP-825 Hits Phase III Primary Endpoint - Analyst Blog", "Auxilium Pharma Launches Authorized Generic Testim - Analyst Blog", "Orexigen Slumps as Obesity Drug Approval Delayed - Analyst Blog", "Eli Lilly's Cyramza Misses Primary Goal in Liver Cancer Study - Analyst Blog", "Amgen-AstraZeneca Psoriatic Arthritis Drug Shows Improvement - Analyst Blog", "Genomic Health's Oncotype DX Redefines Breast Cancer Therapy - Analyst Blog", "Allergan Rejects Valeant's Proposal Yet Again - Analyst Blog", "BioDelivery Sciences International (BDSI) Jumps: Stock Up 14.1% - Tale of the Tape", "Achillion Pharmaceuticals (ACHN) in Focus: Stock Falls 6.4% - Tale of the Tape", "Achillion Surges Two Days in a Row, HCV in Focus - Analyst Blog", "Alkermes Progresses with its Late Stage Candidate - Analyst Blog", "Centene Dodges Bullets In Changing Medicaid Landscape", "Merck KGaA/Auxogyn's Eeva System Gets FDA Clearance - Analyst Blog", "NPS Pharma's Natpara Likely to be Reviewed in September - Analyst Blog", "Oragenics (OGEN) in Focus: Stock Adds 6% in Session - Tale of the Tape", "Strength Seen in Receptos, Inc. (RCPT) as Stock Shoots up 36.78% - Tale of the Tape", "Why Puma Biotechnology (PBYI) Could Be Positioned for a Slump - Tale of the Tape", "Idenix Pharmaceuticals (IDIX) Soars: Stock Rises 229.1% - Tale of the Tape", "AVEO Pharmaceuticals, Inc. (AVEO) in Focus: Stock Rises 7.8% - Tale of the Tape", "Pharmacyclics' Imbruvica Under FDA Priority Review - Analyst Blog", "Immunomedics' IMMU-132 Gets Orphan Drug Status - Analyst Blog", "Isis Pharma Earns Milestone Payment on Study Initiation - Analyst Blog", "Strength Seen in Inovio (INO): Stock Rises 9.4% - Tale of the Tape", "Achillion Pharmaceuticals (ACHN) in Focus: Stock Rises 47.6% - Tale of the Tape", "Closing the Books on Q1 Earnings Season - Earnings Trends", "Integra Lifesciences Down to Sell on Poor Q1 Segment Show - Analyst Blog", "Idenix Skyrockets on Merck Acquisition Deal, Focus on HCV - Analyst Blog", "Mid-Morning Market Update: Markets Edge Higher; Tyson Wins Bidding Battle To Buy Hillshire Brands For $63/Share", "Dendreon's CEO Departs at Critical Juncture - Analyst Blog", "Novavax (NVAX) Crumbles: Stock Tumbles by 7.7% - Tale of the Tape", "Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock Rises 5.71% - Tale of the Tape", "Pre-Market Most Active for Jun 9, 2014 : HSH, IDIX, WU, ACHN, AAPL, FDO, RIO, YELP, DG, FB, MNKD, GILD", "Pipeline Progress at Momenta - Analyst Blog", "GW Pharma Gets Fast-Track Designation for Epidiolex - Analyst Blog", "BioDelivery Sciences' Bunavail Gets FDA Nod - Analyst Blog", "Orexigen's Upcoming Pipeline Catalyst - Analyst Blog", "Fibrocell Science (FCSC) in Focus: Stock Rises 14.4% - Tale of the Tape", "Pipeline Progress at GlaxoSmithKline - Analyst Blog", "Celldex Therapeutics (CLDX) Soars: Stock Adds 12.6% in Session - Tale of the Tape", "Clovis Oncology (CLVS) Jumps: Stock Rises 6.2% - Tale of the Tape", "MannKind Hits 52-Week High - Analyst Blog", "Curis Re-Initiates Dosing for CUDC-427 - Analyst Blog", "Alkermes' Pipeline Holds Promise - Analyst Blog", "Affymetrix, BioDiscovery Launch Cancer Research Software - Analyst Blog", "Biogen's Eloctate Approved in the U.S. - Analyst Blog", "MannKind Corp. (MNKD) Soars: Stock Adds 10.8% in Session - Tale of the Tape", "Vanda Up on EU News - Analyst Blog", "Roche's Ventana Collaborates with AstraZeneca's MedImmune - Analyst Blog", "Halozyme Study Clinical Hold Lifted by FDA - Analyst Blog", "Bristol-Myers Focuses on India - Analyst Blog", "Positive Data on Vertex Pharma's Kalydeco - Analyst Blog", "Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO - Analyst Blog", "Stock Market News for June 05, 2014 - Market News", "MannKind Corp. (MNKD) Soars: Stock Adds 10.8% in Session - Tale of the Tape", "Data on Incyte's Jakafi - Analyst Blog", "Data on Bristol-Myers' Yervoy - Analyst Blog", "Puma Biotech Crashes on PB272 Study News - Analyst Blog", "Myriad Genetics Posts Key myPath Melanoma Data - Analyst Blog", "Valeant Relentless on Acquiring Allergan - Analyst Blog", "Encouraging Data on Pharmacyclics/J&J Drug - Analyst Blog", "Incyte Gains on Positive Jakafi Data - Analyst Blog", "Stock Market News for June 02, 2014 - Market News", "Retrophin (RTRX) Jumps: Stock Adds 13.5% in Session - Tale of the Tape", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for June 03, 2014", "Allergan Inc. (AGN) in Focus: Stock Rises 5.65% - Tale of the Tape", "Merck Presents Positive Trial Results For Cancer Drug", "Roche Acquires Genia Technologies - Analyst Blog", "Myriad Genetics to Unveil BRACAnalysis, HRD Data - Analyst Blog", "NPS Pharma on Shire's Radar? - Analyst Blog", "Update on Bayer's Xarelto - Analyst Blog", "Oncothyreon Collaborates with Celldex - Analyst Blog", "Valeant Ups Offer for Allergan - Analyst Blog", "Intercept's Obeticholic Acid Gets Fast Track Status - Analyst Blog", "BioMarin's Pipeline Advances - Analyst Blog", "Orexigen (OREX) in Focus: Stock Moves 6.1% Higher - Tale of the Tape", "Xenoport, Inc. (XNPT) Soars: Stock Up 5.9% - Tale of the Tape", "Amicus Therapeutics (FOLD) Soars: Stock Up 10% - Tale of the Tape", "GTX Inc. (GTXI) Soars: Stock Up 9.7% - Tale of the Tape", "Array BioPharma Collaborates with Biogen - Analyst Blog", "Verastem (VSTM) in Focus: Stock Adds 14% in Session - Tale of the Tape", "Isis Pharmaceuticals, Inc. (ISIS) in Focus: Stock Rises 9.21% - Tale of the Tape", "InterMune Resubmits Esbriet NDA - Analyst Blog", "Incyte Joins Forces with Bristol-Myers - Analyst Blog", "Valeant Selling Product Rights to Nestle - Analyst Blog", "KaloBios Pharmaceuticals (KBIO) Worth Watching: Stock Up 5.3% - Tale of the Tape", "Pfizer Pulls Out of AstraZeneca Deal - Analyst Blog", "Ambit Biosciences (AMBI) in Focus: Stock Jumps 10.0% - Tale of the Tape", "Amgen's Vectibix Label Expanded - Analyst Blog", "CHMP Negative on Novartis' RLX030 - Analyst Blog", "CHMP Positive on Roche's Gazyvaro - Analyst Blog", "Durata Therapeutics' Skin Drug Gets FDA Nod - Analyst Blog", "PTC Therapeutics Up on Positive CHMP Opinion - Analyst Blog", "AbbVie Up on HCV Filing in Canada - Analyst Blog", "Nasdaq 100 Movers: GILD, VIP", "Stock Market News for May 23, 2014 - Market News", "Pipeline Progress at RedHill Biopharma - Analyst Blog", "ZIOPHARM Presents Encouraging Data - Analyst Blog", "Update on Celsion's ThermoDox - Analyst Blog", "Sarepta to Acquire Manufacturing Facility - Analyst Blog", "Celgene Gains Slightly on Management Changes - Analyst Blog", "S&P 500 Movers: GILD, HPQ", "Clovis Gets Breakthrough Therapy Designation - Analyst Blog", "Data on Insmed's Arikayce - Analyst Blog", "Another Weak Earnings Season Coming to an End - Earnings Outlook", "Another Weak Earnings Season Coming to an End - Earnings Trends", "Gilead's GS-5806 Encourages - Analyst Blog", "Celgene Inks Licensing Deal with AADi - Analyst Blog", "Insmed (INSM) in Focus: Stock Moves 6.7% Higher - Tale of the Tape", "Isis Pharma Gains on Mid-Stage Data - Analyst Blog", "Clovis Gets Breakthrough Therapy Designation - Analyst Blog", "Data on Insmed's Arikayce - Analyst Blog", "Another Weak Earnings Season Coming to an End - Earnings Outlook", "Dendreon Up on Provenge Data - Analyst Blog", "AbbVie's Humira Gets Orphan Drug Designation - Analyst Blog", "Myriad Genetics Unveils Positive Prolaris Data - Analyst Blog", "Sector Update: Healthcare", "Glaxo-Genmab's Arzerra Disappoints - Analyst Blog", "InterMune Up on Esbriet Data Presentation - Analyst Blog", "AstraZeneca Rejects Pfizer's Final Offer - Analyst Blog", "Ligand-AstraZeneca Collaborate - Analyst Blog", "Shire Meets FDA for Lifitegrast - Analyst Blog", "After Hours Most Active for May 19, 2014 : MTCN, CAM, MSFT, MO, NXPI, JNJ, ARCP, FITB, DTV, GILD", "XenoPort - Reckitt Benckiser Pharma Collaborate - Analyst Blog", "InterMune (ITMN) Jumps: Stock Moves 13.4% Higher - Tale of the Tape", "Clovis Oncology, Inc. (CLVS) in Focus: Stock Surges 16 % - Tale of the Tape", "Data on Novo Nordisk's NovoEight - Analyst Blog", "Update on Glaxo's Darapladib - Analyst Blog", "Novartis Settles Gleevec Patent Litigation - Analyst Blog", "Progenics' Q1 Loss Narrows - Analyst Blog", "Arena Slides on Wider Q1 Loss, Misses Ests - Analyst Blog", "Incyte to Collaborate with AstraZeneca - Analyst Blog", "Rexahn Pharmaceuticals (RNN) Jumps: Stock Surges 19.2% - Tale of the Tape", "Q1 Earnings Season Coming to an End - Earnings Outlook", "Q1 Earnings Season Coming to an End - Earnings Trends", "Athersys Reports Wider-than-Expected Q1 Loss - Analyst Blog", "Oragenics (OGEN) Catches Eye: Stock Rises 9.7% - Tale of the Tape", "Halozyme Therapeutics, Inc. (HALO) in Focus: Stock Up 6.9% - Tale of the Tape", "XenoPort's Q1 Loss Narrows - Analyst Blog", "PDL BioPharma Misses on Q1 Earnings - Analyst Blog", "Celldex Gains on Bristol-Myers Squibb Deal - Analyst Blog", "Halozyme's Q1 Loss Widens - Analyst Blog", "Osiris Therapeutics Q1 Loss Narrower-Than-Expected - Analyst Blog", "Tesaro, Inc. (TSRO) Looks Strong as Stock Rallies 21% - Tale of the Tape", "Shire to Acquire Lumena - Analyst Blog", "Insys in Focus on Subsys Worries - Analyst Blog", "Gilead Shows More Pipeline Progress - Analyst Blog", "Loss Widens at Achillion - Analyst Blog", "Repros' Q1 Loss In Line with Expectations - Analyst Blog", "RadNet Touches New 52-Week High - Analyst Blog", "Dendreon Falls on Q1 Loss - Analyst Blog", "Strength Seen in Medivation (MDVN): Stock Up 8.5% - Tale of the Tape", "Spectrum Pharma Up on Q1 Earnings - Analyst Blog", "Illumina Upgraded to Strong Buy - Analyst Blog", "Amgen-AstraZeneca Psoriasis Drug Scores - Analyst Blog", "Mallinckrodt Earnings Beat, Shares Dip on Low Revs - Analyst Blog", "Medivation Q1 Loss Wider Than Expected - Analyst Blog", "Earnings Up at Jazz Pharma, Guidance Reiterated - Analyst Blog", "XOMA Posts Wider Q1 Loss - Analyst Blog", "Anacor Reports Wider-than-Expected Q1 Loss - Analyst Blog", "Salix Q1 Earnings Boosted by Santarus Acquisition - Analyst Blog", "Avanir Loss In Line with Ests, Revs Up - Analyst Blog", "J&J /Gilead HCV Combo Drug Filed - Analyst Blog", "Wider-Than-expected Loss at NPS Pharma, Shares Down - Analyst Blog", "Medivation Q1 Loss Wider Than Expected - Analyst Blog", "Narrower-than-Expected Loss at Momenta - Analyst Blog", "Split Update Overshadows Wider Q1 Loss at Theravance - Analyst Blog", "IYH, GILD, BMY, ABBV: ETF Outflow Alert", "Wider-than-Expected Loss at Aegerion - Analyst Blog", "Dynavax Reports In Line Q1 Results - Analyst Blog", "Myriad Genetics Drops despite Earnings, Revs Beat; Ups View - Analyst Blog", "Marginal Earnings Beat at Zoetis, View Maintained - Analyst Blog", "Techne Corporation (TECH) Ex-Dividend Date Scheduled for May 07, 2014", "Endocyte, Inc. (ECYT) in Focus: Stock Rises 5.6% - Tale of the Tape", "Regeneron Inks Ophthalmology Deal - Analyst Blog", "Vical Narrows Q1 Loss - Analyst Blog", "Nasdaq 100 Movers: WYNN, GILD", "Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog", "Wider-than-Expected Loss at Pacira, Revs Up - Analyst Blog", "Vertex Down on Wider-than-Expected Loss - Analyst Blog", "InterMune Up on Narrower-than-Expected Q1 Loss - Analyst Blog", "Celldex's Q1 Loss Widens - Analyst Blog", "Pfizer Tops on Q1 Earnings, Generics Hit Revs - Analyst Blog", "Idenix's Q1 Loss Widens - Analyst Blog", "Geron Reports In-Line Q1 Loss - Analyst Blog", "AstraZeneca Rejects Pfizer's Latest Offer - Analyst Blog", "Earnings Beat at Pharmacyclics, Guidance Pulls Down Stock - Analyst Blog", "Bull of the Day: Gilead Sciences (GILD) - Bull of the Day", "Novo Nordisk Beats Earnings Ests, Misses Revs - Analyst Blog", "Wider-than-Expected Q1 Loss at Incyte - Analyst Blog", "Can the Rally in Gilead (GILD) Shares Continue? - Tale of the Tape", "Earnings Estimates Moving Higher for Gilead (GILD): Time to Buy? - Tale of the Tape", "Loss at BioMarin Narrower Than Expected - Analyst Blog", "Shire Beats on Earnings in Q1 - Analyst Blog", "Endocyte Shares Sink on DSMB Recommendation - Analyst Blog", "3 Biotech Beats this Earnings Season - Earnings ESP", "Wider-than-expected Loss at Alkermes, Revenues Slip - Analyst Blog", "OncoGenex Posts Wider Loss, Beats Revenues - Analyst Blog", "Synageva's Q1 Loss Narrower than Expected - Analyst Blog", "Merck (MRK) Earnings Beat Puts Healthcare ETFs in Focus - ETF News And Commentary", "United Therapeutics Gains on Q1 Earnings - Analyst Blog", "Q2 Earnings Estimates Coming Down - Earnings Outlook", "Affymetrix Q1 Earnings Beat Ests by a Penny - Analyst Blog", "3 Biotech Beats this Earnings Season - Earnings ESP", "Wider-than-expected Loss at Alkermes, Revenues Slip - Analyst Blog", "OncoGenex's Custirsen Misses Primary Endpoint - Analyst Blog", "Can Affymetrix (AFFX) Surprise This Earnings Season? - Analyst Blog", "Hyperion Set to Acquire Andromeda - Analyst Blog", "3 Pharma Mutual Funds Beating the S&P 500 - Best of Funds", "AbbVie Beats on Q1 Earnings, Humira Soars - Analyst Blog", "Q2 Earnings Estimates Coming Down - Earnings Trends", "Alexion Posts Strong Earnings in Q1 - Analyst Blog", "Strong Q1 Earnings at Gilead on Stellar Sovaldi Sales - Analyst Blog", "Nasdaq 100 Movers: ISRG, GILD", "Cubist Pharma Posts Weak Earnings on Soft Cubicin Sales - Analyst Blog", "Stock Market News for April 23, 2014 - Market News", "Amgen's Q1 Earnings Decline Y/Y - Analyst Blog", "US Futures Mixed Amid Earnings Deluge; Apple, Facebook Set to Report After Close", "Earnings from Gilead and Amgen Put These ETFs in Focus - ETF News And Commentary", "US Futures Edge Lower Amid Mixed Earnings Bag, Markets Eye Apple, Facebook After Close", "An Improving, But Still Weak Earnings Picture - Earnings Trends", "An Improving, But Still Weak Earnings Picture - Earnings Outlook", "AbbVie Files for HCV Combination Therapy in U.S. - Analyst Blog", "Biogen's Q1 Earnings Soar Y/Y on Tecfidera Sales - Analyst Blog", "Keep an Eye on these 3 Biotech Stocks - Earnings ESP", "Synageva Heading For Big Disappointment", "Pre-Market Most Active for Apr 23, 2014 : VZ, MDLZ, DOW, GILD, ING, FB, T, EMC, JNPR, EBAY, VOD, AKAM", "After-Hours Earnings Report for April 22, 2014 : T, GILD, AMGN, CNI, YUM, DFS, ILMN, ISRG, VMW, FTI, JNPR, BCR", "Will Gilead (GILD) Beat Q1 Earnings? - Analyst Blog", "After Hours Most Active for Apr 21, 2014 : BAC, C, NFLX, GS^I, AGN, FB, AMD, PT, QQQ, MSFT, GILD, WEN", "Weekly CFO Sells Highlight: AthenaHealth Inc, Gilead Sciences Inc, JPMorgan Chase & Co.", "Noteworthy ETF Outflows: VHT, GILD, MDT, ESRX", "Has A Streamlined FDA Raised The Value Of Drug Stocks?", "S&P 500 Movers: NEM, TRIP", "After Hours Most Active for Apr 22, 2014 : CX, BTU, QQQ, CMCSA, T, GILD, AMX, INTC, C, AGN, HBAN, CREE", "Gilead Bucks Biotech Trend Thanks to Sovaldi News - Analyst Blog", "Pre-Market Most Active for Apr 14, 2014 : C, ING, BAC, FB, QQQ, ALU, TVIX, BCS, NBG, XIV, ASML, GILD", "Hard-to-Cure Patients May Benefit from Merck's HCV Drug - Analyst Blog", "Positive Data on AbbVie's HCV Program - Analyst Blog", "Encouraging Data from Bristol-Myers - Analyst Blog", "Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% - Tale of the Tape", "Sector Update: Healthcare Shares Lower in Pre-Market Trade", "Bristol-Myers Seeks Approval for HIV Combo Drug - Analyst Blog", "Encouraging Results on Gilead's Sovaldi - Analyst Blog", "3 Pharma Mutual Funds Beating the S&P 500 - Best of Funds", "Sector Update: Healthcare", "Sector Update: Healthcare Mixed in Late Session; Gilead Sciences Turns Higher", "3 Top-Ranked Biotech Stocks on the Rebound - Analyst Blog", "After Hours Most Active for Apr 10, 2014 : CWH^D, HBAN, QQQ, MSFT, GE, VZ, EMC, MO, D, LRCX, FB, GILD", "Gilead Announces Encouraging Sovaldi Data - Analyst Blog", "Sector Update: Healthcare", "VUG, GILD, HD, AXP: Large Inflows Detected at ETF", "Nasdaq 100 Movers: MYL, BIDU", "FDA Target Date for Gilead's HCV Candidate - Analyst Blog", "Encouraging Results from Pfizer's Palbociclib - Analyst Blog", "Pipeline Update from Idenix - Analyst Blog", "FDA News Lifts Dyax Slightly - Analyst Blog", "Amgen's Oncology Candidate Disappoints - Analyst Blog", "Merck Up on Encouraging HCV Data - Analyst Blog", "VUG, GILD, HD, AXP: Large Inflows Detected at ETF", "Nasdaq 100 Movers: MYL, BIDU", "Stock Market News for April 01, 2014 - Market News", "Ultragenyx (RARE) Jumps: Stock Rises 7.0% - Tale of the Tape", "Momenta Pharmaceuticals Slumps: MNTA Falls 16.9% in Session - Tale of the Tape", "Biotechnology Shares Rebound 2.4% on Monday, But Still on Track to End March Lower", "Pre-Market Most Active for Mar 31, 2014 : RIO, BBRY, QQQ, BAC, NOK, FB, GILD, TVIX, TWTR, MNKD, MT, ALSN", "The Medicines Co's Fibrocaps Under U.S. Review - Analyst Blog", "Gilead Sciences Now #33 Largest Company, Surpassing Visa", "Any Survivors from the Biotech ETF Meltdown? - ETF News And Commentary", "FDA Nod for Biogen's Alprolix - Analyst Blog", "Sector Update: Healthcare", "Nasdaq 100 Movers: GILD, CTSH", "Gilead's HCV Candidate Under Review in the EU - Analyst Blog", "Glaxo Presents Darapladib Data - Analyst Blog", "Gilead Sciences Breaks Below 200-Day Moving Average - Notable for GILD", "Update on Glaxo's Mekinist-Tafinlar - Analyst Blog", "Moderate Gains for Healthcare Stocks; Gilead Sciences Slips After Reported Sales Dip for HCV Drug", "Glaxo's Eperzan Approved in EU - Analyst Blog", "Insmed Down on Disappointing Arikayce Results - Analyst Blog", "Retrophin (RTRX) Catches Eye: Stock Moves 7.9% Higher - Tale of the Tape", "Positive Data on Halozyme Candidate - Analyst Blog", "Dow 30 Stock Roundup: Pfizer Gains, Crimea, Biotech Stocks Drag Markets - Analyst Blog", "Gilead Sciences Breaks Below 200-Day Moving Average - Notable for GILD", "Update on Glaxo's Mekinist-Tafinlar - Analyst Blog", "Gilead (GILD) is now in Oversold Territory - Tale of the Tape", "Gilead Down on Sovaldi Price Issue - Analyst Blog", "Are Biotech Stocks Oversold? - Analyst Blog", "Closing Update: Stocks Decline on Below-Consensus Manufacturing Index, Biotech Selling Blitz", "Pfizer Gains Slightly on Xalkori Data - Analyst Blog", "Update on Celgene's Product Portfolio - Analyst Blog", "Biotech Continues Friday Sell-Off On Drug Pricing Concerns", "Healthcare Stocks Undercut Earlier Market Advance; Gilead Sciences Sinks After Congress Questions Drug Price", "Sector Update: Healthcare", "Favorable Data for Myriad Genetics - Analyst Blog", "Nasdaq 100 Movers: GILD, AKAM", "S&P 500 Movers: SYMC, EXC", "Health Care Select Sector SPDR Fund Experiences Big Inflow", "Palatin Technologies (PTN) Worth Watching: Stock Soars 15.6% - Tale of the Tape", "Why ANI Pharmaceuticals (ANIP) Has a Bright Short-Term Future? - Tale of the Tape", "Stock Market News for March 19, 2014 - Market News", "Strength Seen in GTX (GTXI): Stock Moves 8.8% Higher - Tale of the Tape", "Idenix Files Lawsuit vs. Gilead Again - Analyst Blog", "After Hours Most Active for Mar 19, 2014 : BTU, JPM, QQQ, WFC, BPO, STAG, MET, GILD, HZNP, ADSK, CSCO, MSFT", "Prothena Surges on Clinical Data Hopes - Analyst Blog", "Biogen Faces Delay in FDA Action Date - Analyst Blog", "Narrower-Than-Expected Loss at Relypsa - Analyst Blog", "Actelion's Tracleer Misses Primary Endpoint - Analyst Blog", "Repros Provides Proellex Update - Analyst Blog", "Intercept Sees Weakness in Earnings Result - Analyst Blog", "Amgen Scores Again with PCSK9 Inhibitor - Analyst Blog", "Biogen to be added to S&P100 - Analyst Blog", "Medivation-Astellas Seek Xtandi Label Expansion - Analyst Blog", "Novartis' Bexsero Recommended in Australia - Analyst Blog", "S&P 500 Movers: CELG, COH", "Raptor Pharma Posts Wider-Than-Expected Q4 Loss - Analyst Blog", "Anacor Reports Narrower Q4 Loss - Analyst Blog", "Narrower-than-Expected Q4 Loss at Repros - Analyst Blog", "Vanda Pharmaceuticals (VNDA) Soars: Stock Adds 9.6% in Session - Tale of the Tape", "Sector Update: Health Care", "Actelion's Update on Asahi Litigation - Analyst Blog", "Novartis' Bexsero Recommended in Australia - Analyst Blog", "Bright Outlook at Bayer - Analyst Blog", "Unfavorable Ruling for Pfizer - Analyst Blog", "Wider Q4 Loss at Keryx - Analyst Blog", "Geron Plunges on FDA Clinical Hold - Analyst Blog", "Sanofi, UCB Ink Deal - Analyst Blog", "Phase I Data on Rexahn's Supinoxin - Analyst Blog", "Sector Update: Health-Care Shares Mixed Pre-Market; Idenix File Patent-Infringement Suit Vs. Gilead", "Is Gilead Sciences (GILD) a Great Growth Stock? - Tale of the Tape", "Focus on Regulus' Pipeline - Analyst Blog", "Alexion Lifts 2014 View, Shares Up - Analyst Blog", "OEF, GILD, HD, UTX: ETF Inflow Alert", "Salesforce (CRM) & MacroGenics (MGNX): The Relative Value of Potential", "Additional Positive Data on Omeros Treatment - Analyst Blog", "NewLink Genetics' Shares Sink - Analyst Blog", "Chelsea Therapeutics Posts Wider Q4 Loss - Analyst Blog", "Alcobra Gains IND Clearance for MDX - Analyst Blog", "Friday's ETF with Unusual Volume: IBB", "Pipeline Progress at Bristol-Myers - Analyst Blog", "Oncothyreon (ONTY) Jumps: Stock Moves 9.9% Higher - Tale of the Tape", "Rigel Rises on Narrower Q4 Loss - Analyst Blog", "Osiris Misses on Q4 Earnings - Analyst Blog", "Biogen-Eisai Ink Alzheimer's Deal - Analyst Blog", "Sangamo Biosciences (SGMO) Worth Watching: Stock Surges 17.1% - Tale of the Tape", "Dynavax Receives Milestone Payments from AstraZeneca - Analyst Blog", "Pipeline Setback Overshadows XOMA's Q4 - Analyst Blog", "Narrower-than-Expected Q4 Loss at GTx - Analyst Blog", "Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher - Tale of the Tape", "Acorda Therapeutics (ACOR) Jumps: Stock Rises 7.5% - Tale of the Tape", "Theravance to Split in Q2 - Analyst Blog", "Celldex Posts Narrower-Than-Expected Loss in Q4 - Analyst Blog", "Update on Alexion's Soliris - Analyst Blog", "Narrower-than-Expected Loss at Dendreon Drives Shares Up - Analyst Blog", "AbbVie HCV Combination Therapy Data Looks Good - Analyst Blog", "Isis Pharma Slips on Wider-Than-Expected Q4 Loss - Analyst Blog", "Are These Biotechs Part of Your Portfolio? - Analyst Blog", "EU Review for The Medicines Co.'s Oritavancin - Analyst Blog", "Actelion Gains on QIDP and Fast Track Status - Analyst Blog", "Update on Anacor's AN2728 - Analyst Blog", "Synageva 4Q Loss Narrower-than-Expected Loss - Analyst Blog", "Earnings Decline YoY at Alkermes - Analyst Blog", "Noteworthy ETF Inflows: IBB, BIIB, GILD, AMGN", "Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for March 03, 2014", "bluebird bio (BLUE) Zooms: Stock Up 7.2% - Tale of the Tape", "Mylan Beats on Q4 Earnings & Revenues - Analyst Blog", "No Looking Back for Regeneron's Eylea - Analyst Blog", "Biogen Keeps Momentum Going With MS Drug Tecfidera", "Earnings Decline YoY at Alkermes - Analyst Blog", "Noteworthy ETF Inflows: IBB, BIIB, GILD, AMGN", "Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for March 03, 2014", "Stock Market News for February 12, 2014 - Market News", "IBB, GILD, BIIB, AMGN: Large Inflows Detected at ETF", "Gilead Seeks U.S. Approval - Analyst Blog", "FDA Designation for Bristol-Myers Candidate - Analyst Blog", "Pharmacyclics Attains 52-Week High - Analyst Blog", "S&P 500 Analyst Moves: GILD", "BioMarin Rises on Favorable CHMP Opinion - Analyst Blog", "Will Gilead (GILD) Disappoint This Earnings Season? - Analyst Blog", "3 Reasons For Biotech Stock Advance To Continue", "Weekly CFO Sells Highlight: Google Inc, Forest Laboratories Inc, Facebook Inc, Gilead Sciences Inc.", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 11, 2014", "CHMP Positive on Bayer's Riociguat - Analyst Blog", "Pre-Market Most Active for Jan 22, 2014 : PBR/A, VALE, AMD, BBD, CX, COH, NUAN, BBRY, FB, GILD, GRPN, TSLA", "After Hours Most Active for Jan 22, 2014 : EBAY, QQQ, NFLX, BAC, EXEL, AVP, AA, FCX, COLE, MSFT, XOM, GILD", "European Approval for Gilead Drug - Analyst Blog", "Weekly CFO Sells Highlight: Gilead Sciences Inc., Micron Technology Inc., Adobe Systems Inc.", "Bayer's Adempas Gets Japanese Approval - Analyst Blog", "Stocks 2014: Investing For Growth - The Power And Protection Of High Compounding Earnings Growth - Part 2", "Idenix to Raise Funds, Shares up - Analyst Blog", "Can Biotech Repeat in 2014?", "Stock Market News for January 10, 2014 - Corporate Summary", "Bullish on Gilead - Analyst Blog", "Gilead Sciences Inc. (GILD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report", "Weekly CFO Sells Highlight: Facebook Inc., Google Inc., Verisk Analytics Inc., Gilead Sciences Inc.", "Update on RedHill Biopharma's Pipeline - Analyst Blog", "Genomic Health Remains Neutral - Analyst Blog", "Standard Review for Gilead's Oncology Candidate - Analyst Blog", "Can Biotech Repeat in 2014?", "Stock Market News for December 19, 2013 - Market News", "Positive Data on Gilead's Sovaldi - Analyst Blog", "Gilead's Sovaldi Holds Promise - Analyst Blog", "Label of Gilead's Complera Expanded - Analyst Blog", "After Hours Most Active for Dec 16, 2013 : JPM, BAC, BRY, QQQ, MSFT, GILD, PFE, GM, EMC, INTC, CSCO, MU", "Buzz on the Street: Naughty Bears May Keep Santa Away", "Dynavax Submits Response to EMA - Analyst Blog", "Enzon Pharmaceuticals, Inc. (ENZN) Ex-Dividend Date Scheduled for December 24, 2013", "Stock Market News for December 19, 2013 - Market News", "Are Biotech ETFs Back on Track? - ETF News And Commentary", "Update on Gilead's Legal Troubles - Analyst Blog", "Biotech Stock Roundup: CBST Hits 52-Week High, OREX Lights Up - Analyst Blog", "Medidata, CaesarStone Among New Buys Of Top Funds", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for December 03, 2013", "Gilead's Pipeline Encourages - Analyst Blog", "Pre-Market Most Active for Dec 9, 2013 : GIVN, SYY, INFI, NOK, ALU, JCP, GILD, AAXJ, FB, BAC, CRNT, NJ", "FDA Clears Gilead's Sovaldi - Analyst Blog", "Are Biotech ETFs Back on Track? - ETF News And Commentary", "Gilead Soars on Positive CHMP Opinion - Analyst Blog", "Stock Market News for November 25, 2013 - Market News", "Glaxo Shares Rise on Tivicay News - Analyst Blog", "Recent Cloud IPO Veeva Systems Scores In Health Biz", "A safe way to win with biotech growth", "Gilead Sciences can fix what's ailing your portfolio", "3 Invesco Funds Delivering Great Returns (revised) - Analyst Blog", "Sector Update: Biotech Select Index Achieves All-Time High; UBS Reportedly Positive", "Gilead Soars on Positive CHMP Opinion - Analyst Blog", "Bristol-Myers Seeks Japanese Approval - Analyst Blog", "Antiviral Franchise Powers Earnings Beat at Gilead - Analyst Blog", "After-Hours Earnings Report for October 29, 2013 : GILD, BIDU, AFL, LNKD, AMP, VRTX, BXP, EIX, FISV, RRC, WU, KIM", "Dendreon (DNDN) in Focus: Stock Moves 9.7% Higher - Tale of the Tape", "Glaxo Seeks EU Approval for HIV Drug - Analyst Blog", "Positive CHMP Opinion for Actelion's Opsumit - Analyst Blog", "Top Ranked Biotech ETF in Focus: BBH - ETF News And Commentary", "After Hours Most Active for Oct 24, 2013 : ZNGA, MSFT, CSCO, ABV, AMZN, GILD, BAC, QQQ, KO, CRM, TSM, OZM", "Inside Biotech ETFs: Can the Run Continue? - ETF News And Commentary", "United Therapeutics Aims For A Cardiovascular Drug OK", "Actelion's Opsumit Cleared in the U.S. - Analyst Blog", "Will Gilead (GILD) Disappoint in Q3? - Analyst Blog", "Glaxo Seeks EU Approval for HIV Drug - Analyst Blog", "Bayer's Adempas Cleared in the U.S. - Analyst Blog", "J&J Gains Marginally on HCV Deal - Analyst Blog", "Weekly CFO Sells Highlight: FWLT, DOOR, NKE, MGAM, GILD", "After Hours Most Active for Oct 7, 2013 : AAT, MU, QCOM, AMD, GILD, QQQ, AAXJ, RENN, FOXA, XOM, PBR/A, MLU", "Playing Momentum With ETFs (PDP, PIE, MTUM)", "After Hours Most Active for Oct 18, 2013 : QQQ, RVBD, BAC, SID, ELN, MSFT, RF, GE, CBSH, KMI, CSCO, GILD", "Gilead Back to Neutral - Analyst Blog", "Health Care Stocks Gurus Investors Are Buying Ahead of Obamacare", "Update on Gilead's Portfolio - Analyst Blog", "Threats of a Government Shutdown Weigh on the Dow, S&P 500", "Pipeline Progress at Agios Pharma - Analyst Blog", "Pipeline Progress at BioMarin - Analyst Blog", "Good News for Perrigo's Generic Unit - Analyst Blog", "Bayer Cardiovascular Suite Progresses - Analyst Blog", "Sativex Pricing Agreement for GW Pharma - Analyst Blog", "Japanese Approval for Theravance/Glaxo Drug - Analyst Blog", "Pipeline Progress at Alexion - Analyst Blog", "Sarepta Therapeutics (SRPT) Worth Considering: Stock Surges 18.0% - Analyst Blog", "Data on Cytori's Cell Therapy - Analyst Blog", "Pipeline Progress at Omeros - Analyst Blog", "CHMP Positive on GSK/THRX candidate - Analyst Blog", "IART Accomplishes Shoulder Implant - Analyst Blog", "Data on KaloBios' KB001 Published - Analyst Blog", "Positive Data on Pacira's Exparel - Analyst Blog", "Actelion Acquires Ceptaris - Analyst Blog", "Sangamo Prices Shares - Analyst Blog", "Biogen Upped to Outperform - Analyst Blog", "BioCryst, NIAID Collaborate for BCX4430 - Analyst Blog", "Protalix Raises Funds - Analyst Blog", "Strength Seen in Isis Pharmaceuticals (ISIS): Stock Soars 14.1% - Analyst Blog", "Still Neutral on Perrigo - Analyst Blog", "U.S. Patent Allowance for BioLineRx' BL-8020 - Analyst Blog", "Pipeline Update from BioMarin - Analyst Blog", "Kythera Biopharmaceuticals (KYTH) in Focus: Stock Surges 25.1% - Analyst Blog", "Clovis Oncology (CLVS) Surges: Stock Gains 7.3% in Session - Analyst Blog", "Encouraging Data on Kythera's ATX-101 - Analyst Blog", "EU Approval for Raptor Pharma's Procysbi - Analyst Blog", "Coronado Biosciences' TSO in Phase II study - Analyst Blog", "Pipeline Progress at Gilead - Analyst Blog", "New Patents for Insmed's Arikace - Analyst Blog", "New Phase I data on Omeros' OMS824 - Analyst Blog", "United Therapeutics NDA Accepted - Analyst Blog", "Good News for Perrigo - Analyst Blog", "Zacks #1 Rank Additions for Friday - Tale of the Tape", "Protalix Prices Notes - Analyst Blog", "Encouraging News for Alexion - Analyst Blog", "Biotech Alexion: A Giant In The Tiny Orphan Market", "Gilead Seeks FDA Approval for Idelalisib - Analyst Blog", "Positive Results on Ventrus' Candidate, Shares Up - Analyst Blog", "Data on Actelion's Opsumit - Analyst Blog", "Some New ETFs Off To Impressive Starts", "Biogen-Amicus in Parkinson's Deal - Analyst Blog", "Lannett Beats Q4 Earnings Estimates - Analyst Blog", "Data from Alexion's Soliris Study - Analyst Blog", "Catalyst Pharma Raises Funds - Analyst Blog", "Biogen-Isis Team Up Again - Analyst Blog", "Rigel Pharma Trims Workforce - Analyst Blog", "Cubist Pharma Prices Senior Notes - Analyst Blog", "Data on Biodel's BIOD-123 - Analyst Blog", "Encouraging Data on Oncolytics' Reolysin - Analyst Blog", "Orphan Status for BioLineRx' Candidate - Analyst Blog", "Encouraging Data on Xenoport's XP23829 - Analyst Blog", "Target Date for Endo Health's Aveed - Analyst Blog", "Illumina Inks Supply Deal in NIPT - Analyst Blog", "FDA Expands Celgene's Abraxane Label - Analyst Blog", "Pipeline Progress at AstraZeneca - Analyst Blog", "Bayer Looking to Expand in Russia - Analyst Blog", "Data on Pomalyst Published - Analyst Blog", "FDA Licensure for Merck Facility - Analyst Blog", "Zacks #1 Rank Additions for Monday - Tale of the Tape", "Amgen/Cytokinetics Drug Misses Primary Endpoint - Analyst Blog", "Encouraging News from THRX's TD-4208 - Analyst Blog", "Data on MDCO's Cangrelor - Analyst Blog", "New U.S. Patent for BiolineRx's BL-8040 - Analyst Blog", "Pipeline Progress at Tetraphase - Analyst Blog", "Good News for Chelsea Therapeutics - Analyst Blog", "Priority Review for Takeda Candidate - Analyst Blog", "Bull of the Day: Gilead Sciences (GILD) - Bull of the Day", "Gilead Sciences: A Biotech Powerhouse", "Sanofi Unveils Bond Issue Pricing - Analyst Blog", "Spectrum Pharma Launches Marqibo - Analyst Blog", "Data Presented on Eliquis - Analyst Blog", "Interim Phase II Data on Isis Candidate - Analyst Blog", "Additional Funds for Galectin - Analyst Blog", "Aradigm, Grifols Collaborate - Analyst Blog", "European Approval for Glaxo's Tafinlar - Analyst Blog", "Affymetrix Upped to Outperform - Analyst Blog", "PCYC's Ibrutinib Under FDA Review - Analyst Blog", "Voluntary Recall at Cubist Pharma - Analyst Blog", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for September 03, 2013", "Data on Actelion's Opsumit Published - Analyst Blog", "Swissmedic Negative on Apricus' Vitaros - Analyst Blog", "Opko Acquires Prolor Biotech - Analyst Blog", "Sanofi's Aubagio Gets EU Nod - Analyst Blog", "Merrimack Progresses With MM-398 - Analyst Blog", "Topline Data on Astex Candidate - Analyst Blog", "Sanofi Reports Positive Vaccine Data - Analyst Blog", "Good News for Regeneron on Eylea - Analyst Blog", "Orexigen Provides Contrave Update - Analyst Blog", "Pharmacyclics' Ibrutinib Data Published - Analyst Blog", "Akorn to Buy Hi-Tech Pharma - Analyst Blog", "Endo Health Eyeing Generic Company, Shares up - Analyst Blog", "Rigel Down on Phase II Setback - Analyst Blog", "Actelion Inches Close to Ceptaris - Analyst Blog", "Amgen to Acquire Onyx Pharma - Analyst Blog", "XOMA Raises Funds - Analyst Blog", "Horizon Pharma Settles with Par Pharma - Analyst Blog", "Pipeline Setback for Glaxo - Analyst Blog", "After Hours Most Active for Aug 26, 2013 : JCP, FTK, QQQ, HCBK, GILD, ONXX, BAC, MSFT, CDNS, RF, CAT, AMD", "Sanofi Initiates Vaccine Study in Canada - Analyst Blog", "Cytokinetics' Tirasemtiv Data Published - Analyst Blog", "Pound For Pound, Are Biotechs Still Worth Their Salt?", "Merrimack Study Data Published - Analyst Blog", "Omnicell Held at Neutral - Analyst Blog", "Good News for RedHill Biopharma - Analyst Blog", "Positive Results from Fibrocell Science - Analyst Blog", "Epizyme Wins Orphan Drug Status - Analyst Blog", "Vical Cuts Jobs, Shifts Focus - Analyst Blog", "Voluntary Recall at Alexion - Analyst Blog", "XOMA Prices Offering - Analyst Blog", "Pipeline Setback for GTx - Analyst Blog", "After Hours Most Active for Aug 21, 2013 : HPQ, LIFE, MSFT, GMCR, GILD, GE, TWC, PHM, QQQ, XOM, VNDA, EMC", "Boston Scientific Upgraded to Buy - Analyst Blog", "Medtronic Posts In-Line Q1 Earnings, Misses Revs - Analyst Blog", "Japanese Reimbursement for EW Valve - Analyst Blog", "LIFE Remains at Neutral - Analyst Blog", "Voluntary Recall at Alexion - Analyst Blog", "XOMA Prices Offering - Analyst Blog", "New Reagent Kits from Illumina - Analyst Blog", "Narrower-than-Expected Loss at Athersys - Analyst Blog", "Update on Chelsea's Northera - Analyst Blog", "Glaxo's Tyverb Gets EU Approval - Analyst Blog", "Gilead: A Buying Opportunity - Analyst Blog", "Apricus' Loss Narrows Y/Y - Analyst Blog", "Wider-than-Expected Loss at Biodel - Analyst Blog", "Glaxo's Tivicay Gets Approval - Analyst Blog", "After Hours Most Active for Aug 16, 2013 : BAC, SNV, QQQ, QCOM, PGR, SE, RSG, FE, VRTX, DELL, GILD, CA", "Integra Receives Go-Ahead in N.J. - Analyst Blog", "Progenics' Loss Narrows Y/Y - Analyst Blog", "Earnings Beat at Perrigo in Q4, Sales Dip - Analyst Blog", "Sizing Up Jackson Hole - Analyst Blog", "ENDP to Offload Anatomical Pathology Unit - Analyst Blog", "Myriad Outstrips Q4 and FY Earnings Estimates - Analyst Blog", "Wider Y/Y Loss at Ariad - Analyst Blog", "Major Setback for Vical - Analyst Blog", "Impax Surpasses Earnings Estimates - Analyst Blog", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 14, 2013", "Techne Corporation (TECH) Ex-Dividend Date Scheduled for August 14, 2013", "BioDelivery Sciences Posts Loss Y/Y - Analyst Blog", "Glaxo Seeks Vaccine Approval - Analyst Blog", "Bristol-Myers Downgraded to Underperform - Analyst Blog", "FDA Panel to Review THRX/GSK Candidate - Analyst Blog", "Glaxo Seeks Votrient Label Expansion in EU - Analyst Blog", "Jazz Pharma Posts Higher Earnings & Revs - Analyst Blog", "Wider-than-Expected Loss at Spectrum Pharma - Analyst Blog", "After Hours Most Active for Aug 8, 2013 : BAC, QQQ, MACK, ONNN, CTL, GILD, DNDN, FIG, TSM, WMGI, RAX, KEY", "Narrower Q2 Loss at Geron - Analyst Blog", "Affymetrix Rise on Turnaround 2Q Earnings - Analyst Blog", "Rigel Pharma Narrows Q2 Loss - Analyst Blog", "Endo Health Beats on Earnings & Revs. in Q2 - Analyst Blog", "Sanofi's Vaccine Progresses - Analyst Blog", "Earnings Beat at Regeneron in Q2 - Analyst Blog", "Zoetis Reports In-Line Earnings in Q2 - Analyst Blog", "Anika Soars on Strong Q2 Results - Analyst Blog", "Affymetrix Rolls Out Advanced Assay - Analyst Blog", "Earnings Beat at AstraZeneca in 2Q - Analyst Blog", "Earnings Increase at Bayer in 2Q - Analyst Blog", "PCYC Reports Earnings in Q2, Revs Surge - Analyst Blog", "Earnings Beat at Hospira in 2Q, Sales In Line - Analyst Blog", "Amgen Beats on Earnings & Revs in Q2 - Analyst Blog", "Cubist Pharma Announces Acquisition Deals - Analyst Blog", "Zacks #1 Rank Additions for Tuesday - Tale of the Tape", "Affymetrix Sees Earnings After Two Years - Analyst Blog", "Can the Recent Uptrend Continue for Gilead Sciences, Inc. (GILD)? - Tale of the Tape", "After Hours Most Active for Jul 29, 2013 : ELN, PFE, HLF, QQQ, HAL, ZTS, CAT, MU, FB, GILD, AGNC, PDLI", "After-Hours Earnings Report for July 25, 2013 : AMZN, GILD, SBUX, MCK, CB, CERN, NEM, RSG, PFG, KLAC, BMRN, CBG", "Biogen Idec Inc. (BIIB): Today's Most Compelling Stock Buy", "After Hours Most Active for Jul 8, 2013 : S, NLSN, INTC, FB, ORCL, NOK, AA, CSCO, MSFT, GILD, IGT, JNPR", "Gilead Retained at Neutral - Analyst Blog", "Gilead Presents Idelalisib Data - Analyst Blog", "Best Stocks: Isis, Gilead, Celgene, and Regeneron Take Over the Top Ranks", "3 Impressive Biotech ETFs Crushing the Market - ETF News And Commentary", "Priority Review for Gilead Drug - Analyst Blog", "Enzon Pharmaceuticals, Inc. (ENZN) Ex-Dividend Date Scheduled for June 05, 2013", "Stock Market News for June 3, 2013 - Market News", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for June 03, 2013", "Pre-Market Most Active for May 22, 2013 : NTAP, PFE, NMR, RDS/A, RDS/B, NOK, SNE, PGTI, IRWD, GILD, VOD, ZNGA", "Gilead's Sofosbuvir under European Review - Analyst Blog", "Market Close Report: NASDAQ Composite index closes at 3,452.13 up 28.57 points", "3 Impressive Biotech ETFs Crushing the Market - ETF News And Commentary", "Priority Review for Gilead Drug - Analyst Blog", "Enzon Pharmaceuticals, Inc. (ENZN) Ex-Dividend Date Scheduled for June 05, 2013", "Stock Market News for June 3, 2013 - Market News", "Techne Corporation (TECH) Ex-Dividend Date Scheduled for May 08, 2013", "The Markets Now: Dow, S&P Hit New Highs on Employment Report", "Gilead Misses on Earnings, Sales in 1Q - Analyst Blog", "Pre-Market Most Active for May 20, 2013 : WCRX, RDS/B, YHOO, ACT, BAC, BP, AU, NBG, GILD, ASML, WBSN, ZNGA", "After-Hours Earnings Report for May 2, 2013 : GILD, AIG, CNQ, LNKD, MYL, WFT, FLR, XL, TDC, MHK, MCHP, CPT", "The Markets Now: Stocks Climb Higher After ECB Rate Cut, Jobless Claims Report", "Double Setback for Gilead - Analyst Blog", "A Look Ahead: This Week's ETFs to Watch", "After Hours Most Active for Apr 26, 2013 : STX, CMCSA, BAC, NTAP, VZ, QQQ, GILD, INTC, APC, GE, AXP, PFE", "Buzz on the Street: Apple Earnings, a Hijacked AP, and the Telltale VIX Make for One Wacky Week", "Is the Biotech Sector Still a Market Leader? - Real Time Insight", "Benzinga Market Primer: Thursday, May 2", "Will Eli Lilly Beat Earnings in 1Q? - Analyst Blog", "Forest Labs Likely to Miss 4Q Earnings - Analyst Blog", "Biogen: Will it Miss Earnings Again? - Analyst Blog", "Will Amgen Beat Earnings? - Analyst Blog", "Bristol-Myers Likely to Report In Line Earnings - Analyst Blog", "Vertex News Lifts Biotech ETFs", "Waters 1Q Earnings Expected to Miss - Analyst Blog", "Gilead Reports Encouraging HCV Data - Analyst Blog", "Will Eli Lilly Beat Earnings in 1Q? - Analyst Blog", "Forest Labs Likely to Miss 4Q Earnings - Analyst Blog", "Biogen: Will it Miss Earnings Again? - Analyst Blog", "Will Amgen Beat Earnings? - Analyst Blog", "Data on ArQule's ARQ 092 - Analyst Blog", "Gilead Seeks FDA Approval - Analyst Blog", "Priority Review for Bayer's Riociguat - Analyst Blog", "After Hours Most Active for Apr 19, 2013 : PBR/A, CRM, PPL, DOW, GILD, MS, QQQ, EMC, DTV, DNDN, SQNM, YHOO", "Generics: The Way Forward in India? - Analyst Blog", "Pharma & Biotech Stock Outlook - Apr 2013 - Zacks Analyst Interviews", "Pharma & Biotech Stock Outlook - Apr 2013 - Industry Outlook", "Gilead's HCV Study to Continue - Analyst Blog", "After Hours Most Active for Apr 1, 2013 : BAC, FCX, QQQ, CPNO, PNG, INTC, VCSH, HUM, GILD, MS, VCIT, AER", "WEEKLY CFO SELLS HIGHLIGHT: ANIK, GILD, PETM, NKE, ADBE", "Balanced View on Gilead Sciences - Analyst Blog", "Weekly CEO Sells Highlight: Activision Blizzard, Nielsen Holdings NV, Gilead Sciences, Autodesk", "Market Close Report: NASDAQ Composite index closes at 3,256.52 up 4.04 points", "After Hours Most Active for Mar 26, 2013 : TWX, HAL, RF, WFC, HPQ, NEM, MDLZ, QCOM, INTC, ORCL, QQQ, GILD", "Mid-Morning Market Update: Markets Rise On Cyprus Deal, Dollar General Posts Higher Profit", "Gilead's Stribild Backed by CHMP - Analyst Blog", "Mid-Afternoon Market Update: VrinetX Falls as Veeco Continues to Boost", "Mid-Day Market Update: Markets Turn Red, Apollo Group Surges On Upbeat Results", "Pre-Market Most Active for Mar 14, 2013 : BBRY, VOD, SLCA, BAC, ETFC, GILD, NOK, QQQ, TSM, SD, ERIC, MT", "Setback for Idenix Pharma - Analyst Blog", "Gilead Hits 52-Week High - Analyst Blog", "Encouraging Data Presented by Gilead - Analyst Blog", "Gilead Puts Biotech ETFs in Focus - ETF News And Commentary", "Good News for Gilead's HIV Pipeline - Analyst Blog", "PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for March 01, 2013", "Gilead and Teva Bury the Hatchet - Analyst Blog", "March Action Date for UTHR Candidate - Analyst Blog", "After Hours Most Active for Mar 14, 2013 : BAC, QQQ, RCL, V, JPM, ULTA, GE, C, CSCO, MSFT, GILD, INTC", "Gilead Hits 52-Week High - Analyst Blog", "Encouraging Data Presented by Gilead - Analyst Blog", "Gilead Closes YM Biosciences Buyout - Analyst Blog", "After Hours Most Active for Feb 11, 2013 : BAC, FB, GILD, UAL, TTWO, FE, WFR, AMGN, TLM, ATVI, KORS, SQNM", "Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 11, 2013", "Gilead Beats Estimates in 4Q - Analyst Blog", "After-Hours Earnings Report for February 4, 2013 : GILD, APC, YUM, BIDU, GGP, BAP, LIFE, HIG, EW, AXS, LEG, SWI", "Gilead Presents Positive HCV Data - Analyst Blog", "MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook", "MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews", "Safest Way to Play Biotech - Cook`s Kitchen", "Gilead's HIV Candidate Advances - Analyst Blog", "One Biotech Stock Investors are Unfairly Ignoring", "The Smart Money Loves These 10 Stocks", "Update on HCV Pipeline from Gilead - Analyst Blog", "MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook", "This Stock Could be Perfect for the \"Dividend Decade\"", "Roche's Tamiflu Label Expanded - Analyst Blog", "Actelion Drug Accepted for Review - Analyst Blog", "Gilead to Buy YM BioSciences - Analyst Blog", "Gilead Plans to Split Stock 2-for-1 - Analyst Blog", "Pharma & Biotech Stock Outlook - Dec 2012 - Industry Outlook", "Pharma & Biotech Stock Outlook - Dec 2012 - Zacks Analyst Interviews", "After Hours Most Active for Jan 9, 2013 : QQQ, BAC, HPQ, SIRI, NLY, NOK, ARCT, KEY, GILD, PPG, TROW, FB", "This Stock Could be Perfect for the \"Dividend Decade\"", "Roche's Tamiflu Label Expanded - Analyst Blog", "Actelion Drug Accepted for Review - Analyst Blog", "Gilead to Buy YM BioSciences - Analyst Blog", "Actelion Drug to be Reviewed in EU - Analyst Blog", "Weekly Top Insider Sells? AAPL, GILD, BMRN, and PCLN", "Pharma & Biotech Stock Outlook - Dec 2012 - Industry Outlook", "Biotech ETFs: A Fiscal Cliff Safe Haven? - ETF News And Commentary", "Gilead Presents Encouraging Data - Analyst Blog", "Abbott's Phase III Plans for HCV - Analyst Blog", "Mid-Day Market Update: Markets Slow Their Rally; JC Penney Spikes Lower", "Mid-Morning Market Update: Markets Continue Cautious Rally; Jefferies Acquired by Leucadia", "Pre-Market Most Active for Nov 12, 2012 : TIE, UN, BAC, GILD, MT, CLVS, FB, JEF, GRPN, DCM, NKTR, QQQ", "Gilead Sciences And Celgene Liven Up Biotech ETFs", "Steven Cohen's SAC Capital Advisors Q3 Updates: Buys Fossil, Fastenal Company and C.R. Bard", "After Hours Most Active for Nov 12, 2012 : MET, PGR, QQQ, PRU, GILD, EVER, CIM, MSFT, C, QCOM, NVDA, INTC", "Mid-Afternoon Market Update: Markets Near Flat; J.C. Penney Falling Further", "After Hours Most Active for Nov 8, 2012 : PDLI, QQQ, AVP, ETP, PFE, GRPN, MRK, BAC, SD, NVDA, GILD, MSFT", "Edward Owens' Vanguard Health Care Fund Does More Shedding Than Adding in Third Quarter", "Actelion Files NDA for Macitentan - Analyst Blog", "Pre-Market Most Active for Oct 24, 2012 : FB, SIRI, EMC, BAC, QQQ, GILD, DOW, ZNGA, MM, BP, SEH, AMRN", "S&P Likes a Trio of Biotech ETFs", "Market Close Report: NASDAQ Composite index closes at 2,904.26 down -.61 points", "Actelion Beats; Maintains View - Analyst Blog", "Arena Pharma Initiates PAH Study - Analyst Blog", "After Hours Most Active for Oct 11, 2012 : QQQ, AMD, BAC, ETP, LOPE, CLWR, S, WCRX, SAN, GILD, PPL, MSFT", "Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)", "Mixed Results from Vertex Studies - Analyst Blog", "Weekly CFO Sells Highlight: ASGN, COF, AKRX, MCRS, GILD, ROP, PLL", "Cost Cutting at Actelion - Analyst Blog", "Gilead Beats Zacks Estimates - Analyst Blog", "Pharma & Biotech Stock Outlook - Aug. 2012 - Industry Outlook", "Pharma & Biotech Stock Outlook - Aug. 2012 - Industry Outlook", "Pharma & Biotech Stock Outlook - Aug. 2012 - Zacks Analyst Interviews", "Pre-Market Most Active for Aug 2, 2012 : KCG, NOK, BAC, GILD, SIRI, CAJ, GMCR, FSLR, NAV, QQQ, IDIX, BMY", "Top-Performing Funds Latch On To Biotech And Discount Retail Stocks", "Gilead Beats Zacks Estimates - Analyst Blog", "Balanced View on Gilead - Analyst Blog", "Gilead's Stribild Gets FDA Nod - Analyst Blog", "Earnings Preview: Celgene - Analyst Blog", "FDA Nod for Gilead's Truvada - Analyst Blog", "FDA Nod for Gilead's Truvada - Analyst Blog", "Gilead Seeks FDA OK for Cobicistat - Analyst Blog", "Gilead Seeks FDA Approval - Analyst Blog", "EMA Validates Gilead's Drug - Analyst Blog", "Biotechs In Motion As New Drug Pipeline Brims", "FDA Nod for Merck Drug Label Update - Analyst Blog", "Gilead Drug Up for European Review - Analyst Blog", "The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb - Press Releases", "Good News for Gilead - Analyst Blog", "After Hours Most Active for May 4, 2012 : QQQ, BAC, STD, STJ, NEM, GILD, GGC, TOT, SPPI, MSFT, FNFG, INTC", "Higher Costs Hurt Gilead - Analyst Blog", "Pharma & Biotech Stock Outlook - April 2012 - Industry Outlook", "Weekly CEO Sells Highlight: Widepoint Corp, Gilead Sciences, Primoris Services, and Riverbed Tech.", "FDA Nod for Merck Drug Label Update - Analyst Blog", "Gilead Drug Up for European Review - Analyst Blog", "Pre-Market Most Active for Apr 19, 2012 : BAC, HGSI, GILD, MS, CVI, QQQ, NOK, EBAY, TOT, EMC, VOD, AAPL", "After Hours Most Active for Apr 5, 2012 : QQQ, FTR, DDD, STD, BAC, EXC, GILD, CSCO, TLEO, MDAS, SYK, MSFT", "Vertex' HCV-HIV Treatment Impresses - Analyst Blog", "3 Nasdaq Stocks for Active Investors", "Largest option buying in equities so far", "Celgene Misses, Reaffirms - Analyst Blog", "Action Date for UTHR Candidate - Analyst Blog", "Gilead's HCV Drug Suffers Setback - Analyst Blog", "Gilead Remains Neutral - Analyst Blog", "Weak Revenues Pull Down Actelion - Analyst Blog", "Generic Challenge for UTHR's Remodulin - Analyst Blog", "Company News for February 6, 2012 - Corporate Summary", "Gilead Misses EPS Ests, Sales Up - Analyst Blog", "Actelion Gets Auxilium Drug Rights - Analyst Blog", "The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Inhibitex, Vertex Pharmaceuticals and Merck - Press Releases", "Gilead Clinches Pharmasset Buy - Analyst Blog", "The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, Inhibitex, Gilead Sciences and Pharmasset - Press Releases", "BMY Kicks Off 2012 Pharma Deals - Analyst Blog", "Take a Look at My \"Cheat Sheet\" of Undervalued Stocks", "Pharma & Biotech Stock Review & Outlook - Zacks Analyst Interviews", "Pharma & Biotech Stock Review & Outlook - Industry Outlook", "The Best Way to Invest in Biotech Stocks", "Fate on Gilead Quad Set for Aug '12 - Analyst Blog", "Pharma & Biotech Stock Review & Outlook - Industry Outlook", "Gilead's Candidate under EMA Review - Analyst Blog", "Gilead Presents Elvitegravir Data - Analyst Blog", "The Zacks Analyst Blog Highlights: AutoZone, Johnson & Johnson, Bristol-Myers Squibb, Gilead Sciences and Pharmasset - Press Releases", "Spotlight on Hepatitis-C Market - Analyst Blog", "Gilead Delivers Once Again - Analyst Blog", "EU Nod for UTHR's Remodulin IV - Analyst Blog", "The Zacks Analyst Blog Highlights: Gilead Sciences, Pharmasset, Nasdaq Biotechnology ETF, InterMune and Dendreon - Press Releases", "Gilead to Buy Pharmasset for $11B - Analyst Blog", "Mid-Day Update: Stocks Plunge on Expected Super Committee Failure; Home Sales Rise", "Biotech Investing Lessons: GILD Buys VRUS - Tactical Trading", "\"Super-Committee\" Anything But - Analyst Blog", "Ahead of Wall Street - November 21, 2011 - Ahead of Wall Street", "Gilead's Eviplera Cleared in EU - Analyst Blog", "Debt Supercycle: Are These Leveraged Companies in Trouble?", "5 More \"Forever\" Stocks on Sale", "Stocks Rally at Mid-Day on Lower Jobless Claims; Cisco's Upbeat Earnings, Guidance", "Mid-Day Update: Stocks Rally as Weekly Jobless Claims Drop; Gold Backs Off Record", "25 Undervalued Stocks With Great Management Teams", "European Market May Open its Doors to This Biotech", "Stocks Near Flat Ahead of Christmas Holiday Weekend; Deal News Provides Some Support", "Gilead Steady at Neutral - Analyst Blog", "Three Sectors and Four Stocks to Consider - Despite the Macro Uncertainty", "The Perfect Technical Trade for This Market", "Using ETFs to Mimic Mutual Fund Ideas", "6 Hazardous Stocks to Sell Now", "11 Health Care Stocks to Sell", "Opening View: Can the SPX Hold Above 1,100?", "11 Famous Health Care Stocks to Sell", "Mid-Day Update: Stocks Mixed as Economic Data Begets Choppy Holiday Trading", "Bullish roll-out in U.S. Steel (NYSE: X), call spread seller in Gilead (NASDAQ: GILD)", "40 Million People Need This Life-Saving Drug", "An Easy Way to Find Winning Stocks", "Indicators Show Market is Dangerously Overbought"], "Elapsed Time": ["1 DAY AGO", "1 DAY AGO", "2 DAYS AGO", "2 DAYS AGO", "2 DAYS AGO", "3 DAYS AGO", "3 DAYS AGO", "3 DAYS AGO", "1 DAY AGO", "3 DAYS AGO", "3 DAYS AGO", "3 DAYS AGO", "3 DAYS AGO", "3 DAYS AGO", "4 DAYS AGO", "4 DAYS AGO", "3 DAYS AGO", "4 DAYS AGO", "4 DAYS AGO", "4 DAYS AGO", "5 DAYS AGO", "5 DAYS AGO", "5 DAYS AGO", "5 DAYS AGO", "4 DAYS AGO", "5 DAYS AGO", "5 DAYS AGO", "6 DAYS AGO", "6 DAYS AGO", "6 DAYS AGO", "6 DAYS AGO", "6 DAYS AGO", "5 DAYS AGO", "JUN 21, 2020", "JUN 21, 2020", "JUN 20, 2020", "JUN 20, 2020", "JUN 19, 2020", "JUN 19, 2020", "JUN 19, 2020", "JUN 21, 2020", "JUN 19, 2020", "JUN 19, 2020", "JUN 19, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 17, 2020", "JUN 19, 2020", "JUN 17, 2020", "JUN 17, 2020", "JUN 17, 2020", "JUN 17, 2020", "JUN 16, 2020", "JUN 16, 2020", "JUN 16, 2020", "JUN 17, 2020", "JUN 15, 2020", "JUN 15, 2020", "JUN 14, 2020", "JUN 14, 2020", "JUN 14, 2020", "JUN 14, 2020", "JUN 13, 2020", "JUN 16, 2020", "JUN 12, 2020", "JUN 12, 2020", "JUN 12, 2020", "JUN 12, 2020", "JUN 12, 2020", "JUN 11, 2020", "JUN 11, 2020", "JUN 13, 2020", "JUN 10, 2020", "JUN 10, 2020", "JUN 10, 2020", "JUN 10, 2020", "JUN 10, 2020", "JUN 10, 2020", "JUN 10, 2020", "JUN 11, 2020", "JUN 9, 2020", "JUN 9, 2020", "JUN 9, 2020", "JUN 9, 2020", "JUN 9, 2020", "JUN 8, 2020", "JUN 8, 2020", "JUN 9, 2020", "JUN 8, 2020", "JUN 8, 2020", "JUN 8, 2020", "JUN 8, 2020", "JUN 8, 2020", "JUN 8, 2020", "JUN 8, 2020", "JUN 8, 2020", "JUN 8, 2020", "JUN 8, 2020", "JUN 7, 2020", "JUN 7, 2020", "JUN 7, 2020", "JUN 7, 2020", "JUN 8, 2020", "JUN 4, 2020", "JUN 4, 2020", "JUN 4, 2020", "JUN 4, 2020", "JUN 4, 2020", "JUN 4, 2020", "JUN 4, 2020", "JUN 4, 2020", "JUN 4, 2020", "JUN 3, 2020", "JUN 3, 2020", "JUN 3, 2020", "JUN 3, 2020", "JUN 3, 2020", "JUN 3, 2020", "JUN 4, 2020", "JUN 2, 2020", "JUN 2, 2020", "JUN 2, 2020", "JUN 2, 2020", "JUN 2, 2020", "JUN 2, 2020", "JUN 2, 2020", "JUN 3, 2020", "JUN 2, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 2, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "MAY 31, 2020", "MAY 30, 2020", "MAY 29, 2020", "MAY 29, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "MAY 29, 2020", "MAY 28, 2020", "MAY 28, 2020", "MAY 28, 2020", "MAY 28, 2020", "MAY 29, 2020", "MAY 28, 2020", "MAY 28, 2020", "MAY 27, 2020", "MAY 27, 2020", "MAY 27, 2020", "MAY 27, 2020", "MAY 27, 2020", "MAY 28, 2020", "MAY 27, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 27, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 24, 2020", "MAY 23, 2020", "MAY 23, 2020", "MAY 22, 2020", "MAY 22, 2020", "MAY 26, 2020", "MAY 22, 2020", "MAY 22, 2020", "MAY 21, 2020", "MAY 21, 2020", "MAY 21, 2020", "MAY 21, 2020", "MAY 21, 2020", "MAY 22, 2020", "MAY 20, 2020", "MAY 20, 2020", "MAY 20, 2020", "MAY 20, 2020", "MAY 20, 2020", "MAY 20, 2020", "MAY 20, 2020", "MAY 20, 2020", "MAY 19, 2020", "MAY 19, 2020", "MAY 18, 2020", "MAY 18, 2020", "MAY 18, 2020", "MAY 18, 2020", "MAY 18, 2020", "MAY 19, 2020", "MAY 17, 2020", "MAY 16, 2020", "MAY 16, 2020", "MAY 15, 2020", "MAY 15, 2020", "MAY 14, 2020", "MAY 14, 2020", "MAY 17, 2020", "MAY 14, 2020", "MAY 14, 2020", "MAY 14, 2020", "MAY 14, 2020", "MAY 13, 2020", "MAY 13, 2020", "MAY 13, 2020", "MAY 14, 2020", "MAY 13, 2020", "MAY 13, 2020", "MAY 13, 2020", "MAY 13, 2020", "MAY 13, 2020", "MAY 12, 2020", "MAY 12, 2020", "MAY 13, 2020", "MAY 12, 2020", "MAY 11, 2020", "MAY 11, 2020", "MAY 11, 2020", "MAY 11, 2020", "MAY 11, 2020", "MAY 11, 2020", "MAY 12, 2020", "MAY 11, 2020", "MAY 10, 2020", "MAY 10, 2020", "MAY 9, 2020", "MAY 8, 2020", "MAY 8, 2020", "MAY 8, 2020", "MAY 11, 2020", "MAY 8, 2020", "MAY 7, 2020", "MAY 7, 2020", "MAY 7, 2020", "MAY 7, 2020", "MAY 7, 2020", "MAY 7, 2020", "MAY 8, 2020", "MAY 6, 2020", "MAY 6, 2020", "MAY 6, 2020", "MAY 6, 2020", "MAY 6, 2020", "MAY 6, 2020", "MAY 6, 2020", "MAY 7, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 6, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 5, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 4, 2020", "MAY 3, 2020", "MAY 2, 2020", "MAY 2, 2020", "MAY 2, 2020", "MAY 1, 2020", "MAY 1, 2020", "MAY 1, 2020", "MAY 4, 2020", "MAY 1, 2020", "MAY 1, 2020", "MAY 1, 2020", "MAY 1, 2020", "MAY 1, 2020", "MAY 1, 2020", "MAY 1, 2020", "MAY 1, 2020", "MAY 1, 2020", "MAY 1, 2020", "MAY 1, 2020", "MAY 1, 2020", "MAY 1, 2020", "MAY 1, 2020", "APR 30, 2020", "MAY 1, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 28, 2020", "APR 28, 2020", "APR 27, 2020", "APR 27, 2020", "APR 27, 2020", "APR 27, 2020", "APR 27, 2020", "APR 28, 2020", "APR 27, 2020", "APR 27, 2020", "APR 27, 2020", "APR 26, 2020", "APR 26, 2020", "APR 25, 2020", "APR 24, 2020", "APR 27, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 24, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 24, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 23, 2020", "APR 22, 2020", "APR 22, 2020", "APR 22, 2020", "APR 22, 2020", "APR 22, 2020", "APR 23, 2020", "APR 22, 2020", "APR 21, 2020", "APR 20, 2020", "APR 20, 2020", "APR 20, 2020", "APR 20, 2020", "APR 20, 2020", "APR 22, 2020", "APR 20, 2020", "APR 20, 2020", "APR 20, 2020", "APR 20, 2020", "APR 19, 2020", "APR 19, 2020", "APR 19, 2020", "APR 20, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 19, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 16, 2020", "APR 16, 2020", "APR 17, 2020", "APR 16, 2020", "APR 16, 2020", "APR 16, 2020", "APR 16, 2020", "APR 16, 2020", "APR 16, 2020", "APR 16, 2020", "APR 16, 2020", "APR 16, 2020", "APR 16, 2020", "APR 15, 2020", "APR 15, 2020", "APR 15, 2020", "APR 15, 2020", "APR 15, 2020", "APR 16, 2020", "APR 16, 2020", "APR 14, 2020", "APR 14, 2020", "APR 13, 2020", "APR 13, 2020", "APR 13, 2020", "APR 13, 2020", "APR 15, 2020", "APR 13, 2020", "APR 13, 2020", "APR 13, 2020", "APR 13, 2020", "APR 13, 2020", "APR 13, 2020", "APR 12, 2020", "APR 13, 2020", "APR 11, 2020", "APR 11, 2020", "APR 11, 2020", "APR 9, 2020", "APR 9, 2020", "APR 9, 2020", "APR 9, 2020", "APR 12, 2020", "APR 9, 2020", "APR 8, 2020", "APR 8, 2020", "APR 8, 2020", "APR 8, 2020", "APR 7, 2020", "APR 7, 2020", "APR 9, 2020", "APR 7, 2020", "APR 7, 2020", "APR 7, 2020", "APR 7, 2020", "APR 7, 2020", "APR 7, 2020", "APR 7, 2020", "APR 7, 2020", "APR 7, 2020", "APR 6, 2020", "APR 6, 2020", "APR 6, 2020", "APR 6, 2020", "APR 6, 2020", "APR 6, 2020", "APR 7, 2020", "APR 7, 2020", "APR 6, 2020", "APR 6, 2020", "APR 6, 2020", "APR 6, 2020", "APR 6, 2020", "APR 6, 2020", "APR 6, 2020", "APR 5, 2020", "APR 5, 2020", "APR 5, 2020", "APR 5, 2020", "APR 4, 2020", "APR 4, 2020", "APR 4, 2020", "APR 5, 2020", "APR 3, 2020", "APR 3, 2020", "APR 3, 2020", "APR 3, 2020", "APR 3, 2020", "APR 2, 2020", "APR 2, 2020", "APR 3, 2020", "APR 2, 2020", "APR 2, 2020", "MAR 31, 2020", "MAR 31, 2020", "MAR 31, 2020", "MAR 30, 2020", "MAR 30, 2020", "APR 2, 2020", "MAR 30, 2020", "MAR 29, 2020", "MAR 29, 2020", "MAR 29, 2020", "MAR 28, 2020", "MAR 27, 2020", "MAR 27, 2020", "MAR 30, 2020", "MAR 27, 2020", "MAR 27, 2020", "MAR 26, 2020", "MAR 26, 2020", "MAR 26, 2020", "MAR 26, 2020", "MAR 26, 2020", "MAR 27, 2020", "MAR 25, 2020", "MAR 25, 2020", "MAR 25, 2020", "MAR 25, 2020", "MAR 25, 2020", "MAR 25, 2020", "MAR 25, 2020", "MAR 26, 2020", "MAR 25, 2020", "MAR 24, 2020", "MAR 24, 2020", "MAR 24, 2020", "MAR 24, 2020", "MAR 24, 2020", "MAR 24, 2020", "MAR 25, 2020", "MAR 23, 2020", "MAR 23, 2020", "MAR 23, 2020", "MAR 22, 2020", "MAR 21, 2020", "MAR 21, 2020", "MAR 20, 2020", "MAR 23, 2020", "MAR 20, 2020", "MAR 20, 2020", "MAR 20, 2020", "MAR 19, 2020", "MAR 19, 2020", "MAR 19, 2020", "MAR 19, 2020", "MAR 20, 2020", "MAR 19, 2020", "MAR 19, 2020", "MAR 19, 2020", "MAR 18, 2020", "MAR 18, 2020", "MAR 18, 2020", "MAR 18, 2020", "MAR 19, 2020", "MAR 19, 2020", "MAR 19, 2020", "MAR 17, 2020", "MAR 17, 2020", "MAR 16, 2020", "MAR 16, 2020", "MAR 16, 2020", "MAR 18, 2020", "MAR 16, 2020", "MAR 15, 2020", "MAR 15, 2020", "MAR 14, 2020", "MAR 13, 2020", "MAR 13, 2020", "MAR 12, 2020", "MAR 16, 2020", "MAR 12, 2020", "MAR 11, 2020", "MAR 11, 2020", "MAR 11, 2020", "MAR 11, 2020", "MAR 11, 2020", "MAR 11, 2020", "MAR 12, 2020", "MAR 10, 2020", "MAR 10, 2020", "MAR 10, 2020", "MAR 10, 2020", "MAR 10, 2020", "MAR 10, 2020", "MAR 10, 2020", "MAR 11, 2020", "MAR 10, 2020", "MAR 10, 2020", "MAR 9, 2020", "MAR 9, 2020", "MAR 9, 2020", "MAR 9, 2020", "MAR 10, 2020", "MAR 9, 2020", "MAR 9, 2020", "MAR 9, 2020", "MAR 9, 2020", "MAR 8, 2020", "MAR 8, 2020", "MAR 8, 2020", "MAR 9, 2020", "MAR 6, 2020", "MAR 6, 2020", "MAR 6, 2020", "MAR 6, 2020", "MAR 6, 2020", "MAR 5, 2020", "MAR 5, 2020", "MAR 6, 2020", "MAR 5, 2020", "MAR 5, 2020", "MAR 5, 2020", "MAR 5, 2020", "MAR 5, 2020", "MAR 4, 2020", "MAR 4, 2020", "MAR 5, 2020", "MAR 4, 2020", "MAR 4, 2020", "MAR 4, 2020", "MAR 4, 2020", "MAR 4, 2020", "MAR 3, 2020", "MAR 3, 2020", "MAR 4, 2020", "MAR 3, 2020", "MAR 3, 2020", "MAR 3, 2020", "MAR 2, 2020", "MAR 2, 2020", "MAR 2, 2020", "MAR 2, 2020", "MAR 3, 2020", "MAR 2, 2020", "MAR 2, 2020", "MAR 2, 2020", "MAR 2, 2020", "MAR 2, 2020", "MAR 2, 2020", "MAR 1, 2020", "MAR 2, 2020", "MAR 1, 2020", "MAR 1, 2020", "MAR 1, 2020", "FEB 29, 2020", "FEB 29, 2020", "FEB 29, 2020", "FEB 29, 2020", "MAR 1, 2020", "MAR 1, 2020", "FEB 28, 2020", "FEB 28, 2020", "FEB 28, 2020", "FEB 28, 2020", "FEB 28, 2020", "FEB 28, 2020", "FEB 28, 2020", "FEB 28, 2020", "FEB 28, 2020", "FEB 28, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 28, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 26, 2020", "FEB 26, 2020", "FEB 27, 2020", "FEB 26, 2020", "FEB 26, 2020", "FEB 26, 2020", "FEB 26, 2020", "FEB 26, 2020", "FEB 26, 2020", "FEB 25, 2020", "FEB 26, 2020", "FEB 25, 2020", "FEB 25, 2020", "FEB 25, 2020", "FEB 25, 2020", "FEB 25, 2020", "FEB 24, 2020", "FEB 24, 2020", "FEB 25, 2020", "FEB 24, 2020", "FEB 24, 2020", "FEB 24, 2020", "FEB 24, 2020", "FEB 22, 2020", "FEB 22, 2020", "FEB 21, 2020", "FEB 24, 2020", "FEB 24, 2020", "FEB 20, 2020", "FEB 19, 2020", "FEB 19, 2020", "FEB 18, 2020", "FEB 18, 2020", "FEB 18, 2020", "FEB 21, 2020", "FEB 20, 2020", "FEB 20, 2020", "FEB 19, 2020", "FEB 19, 2020", "FEB 15, 2020", "FEB 14, 2020", "FEB 13, 2020", "FEB 18, 2020", "FEB 18, 2020", "FEB 18, 2020", "FEB 17, 2020", "FEB 16, 2020", "FEB 12, 2020", "FEB 12, 2020", "FEB 12, 2020", "FEB 13, 2020", "FEB 11, 2020", "FEB 11, 2020", "FEB 11, 2020", "FEB 10, 2020", "FEB 10, 2020", "FEB 10, 2020", "FEB 10, 2020", "FEB 11, 2020", "FEB 10, 2020", "FEB 9, 2020", "FEB 8, 2020", "FEB 7, 2020", "FEB 7, 2020", "FEB 7, 2020", "FEB 6, 2020", "FEB 10, 2020", "FEB 10, 2020", "FEB 9, 2020", "FEB 5, 2020", "FEB 5, 2020", "FEB 5, 2020", "FEB 5, 2020", "FEB 5, 2020", "FEB 5, 2020", "FEB 4, 2020", "FEB 4, 2020", "FEB 4, 2020", "FEB 4, 2020", "FEB 4, 2020", "FEB 4, 2020", "FEB 4, 2020", "FEB 4, 2020", "FEB 4, 2020", "FEB 3, 2020", "FEB 3, 2020", "FEB 3, 2020", "FEB 3, 2020", "FEB 3, 2020", "FEB 4, 2020", "FEB 2, 2020", "JAN 30, 2020", "JAN 29, 2020", "JAN 29, 2020", "JAN 27, 2020", "JAN 26, 2020", "FEB 3, 2020", "JAN 25, 2020", "JAN 24, 2020", "JAN 24, 2020", "JAN 23, 2020", "JAN 23, 2020", "JAN 23, 2020", "JAN 23, 2020", "JAN 26, 2020", "JAN 14, 2020", "JAN 13, 2020", "JAN 13, 2020", "JAN 13, 2020", "JAN 13, 2020", "JAN 11, 2020", "JAN 10, 2020", "JAN 21, 2020", "JAN 5, 2020", "JAN 3, 2020", "JAN 3, 2020", "DEC 31, 2019", "DEC 30, 2019", "DEC 30, 2019", "DEC 29, 2019", "JAN 9, 2020", "DEC 24, 2019", "DEC 24, 2019", "DEC 23, 2019", "DEC 23, 2019", "DEC 22, 2019", "DEC 21, 2019", "DEC 20, 2019", "DEC 27, 2019", "DEC 19, 2019", "DEC 18, 2019", "DEC 17, 2019", "DEC 17, 2019", "DEC 16, 2019", "DEC 16, 2019", "DEC 16, 2019", "DEC 20, 2019", "DEC 14, 2019", "DEC 13, 2019", "DEC 11, 2019", "DEC 11, 2019", "DEC 11, 2019", "DEC 10, 2019", "DEC 10, 2019", "DEC 15, 2019", "DEC 5, 2019", "NOV 27, 2019", "NOV 26, 2019", "NOV 25, 2019", "NOV 24, 2019", "NOV 24, 2019", "NOV 24, 2019", "DEC 9, 2019", "NOV 21, 2019", "NOV 20, 2019", "NOV 14, 2019", "NOV 14, 2019", "NOV 14, 2019", "NOV 13, 2019", "NOV 12, 2019", "NOV 22, 2019", "NOV 8, 2019", "NOV 8, 2019", "NOV 7, 2019", "NOV 6, 2019", "NOV 6, 2019", "NOV 5, 2019", "NOV 4, 2019", "NOV 11, 2019", "OCT 30, 2019", "OCT 29, 2019", "OCT 29, 2019", "OCT 28, 2019", "OCT 27, 2019", "OCT 26, 2019", "OCT 25, 2019", "NOV 1, 2019", "OCT 25, 2019", "OCT 25, 2019", "OCT 25, 2019", "OCT 24, 2019", "OCT 24, 2019", "OCT 24, 2019", "OCT 22, 2019", "OCT 25, 2019", "OCT 15, 2019", "OCT 13, 2019", "OCT 12, 2019", "OCT 11, 2019", "OCT 11, 2019", "OCT 10, 2019", "OCT 10, 2019", "OCT 15, 2019", "OCT 9, 2019", "OCT 8, 2019", "OCT 7, 2019", "OCT 4, 2019", "OCT 2, 2019", "SEP 29, 2019", "SEP 27, 2019", "OCT 10, 2019", "SEP 26, 2019", "SEP 25, 2019", "SEP 25, 2019", "SEP 24, 2019", "SEP 23, 2019", "SEP 22, 2019", "SEP 21, 2019", "SEP 27, 2019", "SEP 18, 2019", "SEP 17, 2019", "SEP 15, 2019", "SEP 14, 2019", "SEP 12, 2019", "SEP 11, 2019", "SEP 11, 2019", "SEP 20, 2019", "SEP 10, 2019", "SEP 9, 2019", "SEP 9, 2019", "SEP 9, 2019", "SEP 4, 2019", "SEP 1, 2019", "SEP 1, 2019", "SEP 11, 2019", "AUG 28, 2019", "AUG 26, 2019", "AUG 19, 2019", "AUG 16, 2019", "AUG 12, 2019", "AUG 11, 2019", "AUG 8, 2019", "AUG 28, 2019", "AUG 8, 2019", "AUG 8, 2019", "AUG 6, 2019", "AUG 6, 2019", "AUG 6, 2019", "AUG 5, 2019", "AUG 1, 2019", "AUG 8, 2019", "JUL 31, 2019", "JUL 30, 2019", "JUL 30, 2019", "JUL 30, 2019", "JUL 30, 2019", "JUL 30, 2019", "JUL 29, 2019", "JUL 31, 2019", "JUL 28, 2019", "JUL 25, 2019", "JUL 24, 2019", "JUL 23, 2019", "JUL 20, 2019", "JUL 19, 2019", "JUL 19, 2019", "JUL 29, 2019", "JUL 18, 2019", "JUL 17, 2019", "JUL 17, 2019", "JUL 16, 2019", "JUL 15, 2019", "JUL 15, 2019", "JUL 15, 2019", "JUL 19, 2019", "JUL 15, 2019", "JUL 15, 2019", "JUL 15, 2019", "JUL 15, 2019", "JUL 15, 2019", "JUL 15, 2019", "JUL 11, 2019", "JUL 15, 2019", "JUL 8, 2019", "JUL 8, 2019", "JUL 3, 2019", "JUL 1, 2019", "JUN 27, 2019", "JUN 25, 2019", "JUN 25, 2019", "JUL 8, 2019", "JUN 19, 2019", "JUN 18, 2019", "JUN 18, 2019", "JUN 18, 2019", "JUN 17, 2019", "JUN 17, 2019", "JUN 16, 2019", "JUN 20, 2019", "JUN 12, 2019", "JUN 11, 2019", "JUN 9, 2019", "JUN 6, 2019", "JUN 5, 2019", "JUN 4, 2019", "MAY 31, 2019", "JUN 14, 2019", "MAY 28, 2019", "MAY 28, 2019", "MAY 28, 2019", "MAY 23, 2019", "MAY 23, 2019", "MAY 19, 2019", "MAY 19, 2019", "MAY 28, 2019", "MAY 15, 2019", "MAY 12, 2019", "MAY 8, 2019", "MAY 7, 2019", "MAY 6, 2019", "MAY 5, 2019", "MAY 3, 2019", "MAY 17, 2019", "MAY 3, 2019", "MAY 3, 2019", "MAY 2, 2019", "MAY 2, 2019", "MAY 2, 2019", "MAY 2, 2019", "MAY 2, 2019", "MAY 3, 2019", "MAY 1, 2019", "APR 30, 2019", "APR 27, 2019", "APR 27, 2019", "APR 25, 2019", "APR 23, 2019", "APR 22, 2019", "MAY 2, 2019", "APR 18, 2019", "APR 18, 2019", "APR 17, 2019", "APR 16, 2019", "APR 16, 2019", "APR 16, 2019", "APR 16, 2019", "APR 19, 2019", "APR 15, 2019", "APR 15, 2019", "APR 14, 2019", "APR 13, 2019", "APR 12, 2019", "APR 11, 2019", "APR 11, 2019", "APR 15, 2019", "APR 9, 2019", "APR 8, 2019", "APR 8, 2019", "APR 7, 2019", "APR 2, 2019", "APR 2, 2019", "APR 1, 2019", "APR 9, 2019", "APR 9, 2019", "APR 8, 2019", "MAR 29, 2019", "MAR 29, 2019", "MAR 29, 2019", "MAR 29, 2019", "MAR 29, 2019", "APR 1, 2019", "MAR 27, 2019", "MAR 25, 2019", "MAR 24, 2019", "MAR 22, 2019", "MAR 22, 2019", "MAR 22, 2019", "MAR 21, 2019", "MAR 28, 2019", "MAR 18, 2019", "MAR 18, 2019", "MAR 18, 2019", "MAR 17, 2019", "MAR 14, 2019", "MAR 14, 2019", "MAR 13, 2019", "MAR 19, 2019", "MAR 9, 2019", "MAR 8, 2019", "MAR 8, 2019", "MAR 7, 2019", "MAR 7, 2019", "MAR 6, 2019", "MAR 6, 2019", "MAR 13, 2019", "MAR 6, 2019", "MAR 4, 2019", "MAR 4, 2019", "MAR 4, 2019", "MAR 4, 2019", "MAR 3, 2019", "MAR 1, 2019", "MAR 6, 2019", "FEB 27, 2019", "FEB 23, 2019", "FEB 21, 2019", "FEB 21, 2019", "FEB 21, 2019", "FEB 20, 2019", "FEB 20, 2019", "MAR 1, 2019", "FEB 19, 2019", "FEB 19, 2019", "FEB 17, 2019", "FEB 15, 2019", "FEB 14, 2019", "FEB 14, 2019", "FEB 13, 2019", "FEB 20, 2019", "FEB 13, 2019", "FEB 13, 2019", "FEB 13, 2019", "FEB 12, 2019", "FEB 12, 2019", "FEB 12, 2019", "FEB 12, 2019", "FEB 13, 2019", "FEB 12, 2019", "FEB 12, 2019", "FEB 12, 2019", "FEB 12, 2019", "FEB 12, 2019", "FEB 11, 2019", "FEB 10, 2019", "FEB 12, 2019", "FEB 8, 2019", "FEB 7, 2019", "FEB 6, 2019", "FEB 6, 2019", "FEB 6, 2019", "FEB 5, 2019", "FEB 5, 2019", "FEB 10, 2019", "FEB 5, 2019", "FEB 5, 2019", "FEB 5, 2019", "FEB 5, 2019", "FEB 5, 2019", "FEB 5, 2019", "FEB 5, 2019", "FEB 5, 2019", "FEB 5, 2019", "FEB 5, 2019", "FEB 5, 2019", "FEB 4, 2019", "FEB 4, 2019", "FEB 4, 2019", "FEB 4, 2019", "FEB 4, 2019", "FEB 4, 2019", "FEB 4, 2019", "FEB 4, 2019", "FEB 1, 2019", "JAN 31, 2019", "JAN 31, 2019", "JAN 30, 2019", "FEB 4, 2019", "JAN 29, 2019", "JAN 29, 2019", "JAN 29, 2019", "JAN 28, 2019", "JAN 24, 2019", "JAN 24, 2019", "JAN 23, 2019", "JAN 30, 2019", "JAN 23, 2019", "JAN 22, 2019", "JAN 22, 2019", "JAN 19, 2019", "JAN 18, 2019", "JAN 17, 2019", "JAN 17, 2019", "JAN 23, 2019", "JAN 16, 2019", "JAN 11, 2019", "JAN 9, 2019", "JAN 9, 2019", "JAN 8, 2019", "JAN 8, 2019", "JAN 7, 2019", "JAN 17, 2019", "JAN 7, 2019", "JAN 7, 2019", "JAN 7, 2019", "JAN 6, 2019", "JAN 6, 2019", "JAN 4, 2019", "JAN 7, 2019", "JAN 2, 2019", "DEC 28, 2018", "DEC 28, 2018", "DEC 26, 2018", "DEC 26, 2018", "DEC 24, 2018", "DEC 24, 2018", "JAN 3, 2019", "DEC 23, 2018", "DEC 21, 2018", "DEC 21, 2018", "DEC 21, 2018", "DEC 20, 2018", "DEC 20, 2018", "DEC 20, 2018", "DEC 24, 2018", "DEC 20, 2018", "DEC 20, 2018", "DEC 19, 2018", "DEC 19, 2018", "DEC 19, 2018", "DEC 18, 2018", "DEC 18, 2018", "DEC 20, 2018", "DEC 18, 2018", "DEC 18, 2018", "DEC 17, 2018", "DEC 17, 2018", "DEC 16, 2018", "DEC 16, 2018", "DEC 15, 2018", "DEC 18, 2018", "DEC 14, 2018", "DEC 13, 2018", "DEC 13, 2018", "DEC 13, 2018", "DEC 12, 2018", "DEC 12, 2018", "DEC 12, 2018", "DEC 14, 2018", "DEC 11, 2018", "DEC 11, 2018", "DEC 11, 2018", "DEC 10, 2018", "DEC 10, 2018", "DEC 10, 2018", "DEC 10, 2018", "DEC 12, 2018", "DEC 11, 2018", "DEC 11, 2018", "DEC 11, 2018", "DEC 10, 2018", "DEC 10, 2018", "DEC 3, 2018", "DEC 3, 2018", "DEC 9, 2018", "DEC 7, 2018", "DEC 7, 2018", "NOV 29, 2018", "NOV 29, 2018", "NOV 29, 2018", "NOV 29, 2018", "DEC 3, 2018", "NOV 28, 2018", "NOV 28, 2018", "NOV 28, 2018", "NOV 27, 2018", "NOV 27, 2018", "NOV 27, 2018", "NOV 27, 2018", "NOV 28, 2018", "NOV 27, 2018", "NOV 26, 2018", "NOV 26, 2018", "NOV 25, 2018", "NOV 23, 2018", "NOV 21, 2018", "NOV 21, 2018", "NOV 27, 2018", "NOV 20, 2018", "NOV 20, 2018", "NOV 19, 2018", "NOV 19, 2018", "NOV 19, 2018", "NOV 18, 2018", "NOV 16, 2018", "NOV 21, 2018", "NOV 15, 2018", "NOV 15, 2018", "NOV 14, 2018", "NOV 14, 2018", "NOV 14, 2018", "NOV 13, 2018", "NOV 12, 2018", "NOV 16, 2018", "NOV 12, 2018", "NOV 9, 2018", "NOV 9, 2018", "NOV 8, 2018", "NOV 8, 2018", "NOV 8, 2018", "NOV 8, 2018", "NOV 12, 2018", "NOV 5, 2018", "NOV 5, 2018", "NOV 5, 2018", "NOV 3, 2018", "NOV 2, 2018", "NOV 2, 2018", "NOV 2, 2018", "NOV 7, 2018", "NOV 2, 2018", "NOV 1, 2018", "NOV 1, 2018", "NOV 1, 2018", "NOV 1, 2018", "OCT 31, 2018", "OCT 31, 2018", "NOV 2, 2018", "NOV 2, 2018", "OCT 31, 2018", "OCT 30, 2018", "OCT 30, 2018", "OCT 29, 2018", "OCT 29, 2018", "OCT 29, 2018", "OCT 31, 2018", "OCT 29, 2018", "OCT 27, 2018", "OCT 27, 2018", "OCT 26, 2018", "OCT 26, 2018", "OCT 26, 2018", "OCT 26, 2018", "OCT 29, 2018", "OCT 25, 2018", "OCT 25, 2018", "OCT 25, 2018", "OCT 25, 2018", "OCT 25, 2018", "OCT 25, 2018", "OCT 24, 2018", "OCT 26, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 23, 2018", "OCT 23, 2018", "OCT 23, 2018", "OCT 22, 2018", "OCT 22, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 23, 2018", "OCT 16, 2018", "OCT 16, 2018", "OCT 16, 2018", "OCT 15, 2018", "OCT 18, 2018", "OCT 18, 2018", "OCT 18, 2018", "OCT 10, 2018", "OCT 10, 2018", "OCT 9, 2018", "OCT 5, 2018", "OCT 5, 2018", "OCT 12, 2018", "OCT 4, 2018", "OCT 4, 2018", "OCT 4, 2018", "OCT 4, 2018", "OCT 4, 2018", "OCT 3, 2018", "OCT 3, 2018", "OCT 5, 2018", "OCT 2, 2018", "OCT 1, 2018", "SEP 28, 2018", "SEP 27, 2018", "SEP 27, 2018", "SEP 27, 2018", "SEP 26, 2018", "OCT 2, 2018", "SEP 26, 2018", "SEP 26, 2018", "SEP 26, 2018", "SEP 26, 2018", "SEP 26, 2018", "SEP 25, 2018", "SEP 24, 2018", "SEP 26, 2018", "SEP 24, 2018", "SEP 23, 2018", "SEP 21, 2018", "SEP 21, 2018", "SEP 21, 2018", "SEP 20, 2018", "SEP 20, 2018", "SEP 24, 2018", "SEP 20, 2018", "SEP 19, 2018", "SEP 19, 2018", "SEP 19, 2018", "SEP 19, 2018", "SEP 19, 2018", "SEP 18, 2018", "SEP 20, 2018", "SEP 18, 2018", "SEP 18, 2018", "SEP 18, 2018", "SEP 17, 2018", "SEP 17, 2018", "SEP 16, 2018", "SEP 14, 2018", "SEP 18, 2018", "SEP 14, 2018", "SEP 13, 2018", "SEP 13, 2018", "SEP 13, 2018", "SEP 13, 2018", "SEP 12, 2018", "SEP 12, 2018", "SEP 14, 2018", "SEP 12, 2018", "SEP 12, 2018", "SEP 12, 2018", "SEP 12, 2018", "SEP 12, 2018", "SEP 12, 2018", "SEP 12, 2018", "SEP 12, 2018", "SEP 11, 2018", "SEP 11, 2018", "SEP 10, 2018", "SEP 10, 2018", "SEP 10, 2018", "SEP 10, 2018", "SEP 7, 2018", "SEP 12, 2018", "SEP 7, 2018", "SEP 7, 2018", "SEP 6, 2018", "SEP 6, 2018", "SEP 6, 2018", "SEP 6, 2018", "SEP 6, 2018", "SEP 7, 2018", "SEP 5, 2018", "SEP 5, 2018", "SEP 5, 2018", "SEP 4, 2018", "SEP 4, 2018", "SEP 4, 2018", "SEP 4, 2018", "SEP 6, 2018", "SEP 5, 2018", "SEP 5, 2018", "AUG 31, 2018", "AUG 31, 2018", "AUG 31, 2018", "AUG 31, 2018", "AUG 31, 2018", "SEP 3, 2018", "AUG 30, 2018", "AUG 30, 2018", "AUG 30, 2018", "AUG 30, 2018", "AUG 30, 2018", "AUG 29, 2018", "AUG 29, 2018", "AUG 31, 2018", "AUG 29, 2018", "AUG 28, 2018", "AUG 28, 2018", "AUG 28, 2018", "AUG 28, 2018", "AUG 28, 2018", "AUG 27, 2018", "AUG 29, 2018", "AUG 27, 2018", "AUG 27, 2018", "AUG 27, 2018", "AUG 24, 2018", "AUG 24, 2018", "AUG 24, 2018", "AUG 24, 2018", "AUG 27, 2018", "AUG 27, 2018", "AUG 27, 2018", "AUG 27, 2018", "AUG 22, 2018", "AUG 22, 2018", "AUG 22, 2018", "AUG 23, 2018", "AUG 23, 2018", "AUG 23, 2018", "AUG 23, 2018", "AUG 21, 2018", "AUG 21, 2018", "AUG 20, 2018", "AUG 22, 2018", "AUG 20, 2018", "AUG 20, 2018", "AUG 19, 2018", "AUG 17, 2018", "AUG 17, 2018", "AUG 17, 2018", "AUG 17, 2018", "AUG 20, 2018", "AUG 17, 2018", "AUG 16, 2018", "AUG 16, 2018", "AUG 16, 2018", "AUG 16, 2018", "AUG 15, 2018", "AUG 15, 2018", "AUG 17, 2018", "AUG 14, 2018", "AUG 13, 2018", "AUG 13, 2018", "AUG 13, 2018", "AUG 13, 2018", "AUG 10, 2018", "AUG 10, 2018", "AUG 15, 2018", "AUG 10, 2018", "AUG 9, 2018", "AUG 9, 2018", "AUG 9, 2018", "AUG 9, 2018", "AUG 9, 2018", "AUG 9, 2018", "AUG 10, 2018", "AUG 8, 2018", "AUG 8, 2018", "AUG 8, 2018", "AUG 8, 2018", "AUG 8, 2018", "AUG 8, 2018", "AUG 8, 2018", "AUG 8, 2018", "AUG 7, 2018", "AUG 6, 2018", "AUG 6, 2018", "AUG 6, 2018", "AUG 3, 2018", "AUG 3, 2018", "AUG 3, 2018", "AUG 8, 2018", "AUG 3, 2018", "AUG 3, 2018", "AUG 2, 2018", "AUG 2, 2018", "AUG 2, 2018", "AUG 1, 2018", "AUG 1, 2018", "AUG 3, 2018", "JUL 31, 2018", "JUL 31, 2018", "JUL 30, 2018", "JUL 29, 2018", "JUL 27, 2018", "JUL 27, 2018", "JUL 27, 2018", "AUG 1, 2018", "JUL 26, 2018", "JUL 26, 2018", "JUL 26, 2018", "JUL 26, 2018", "JUL 26, 2018", "JUL 26, 2018", "JUL 26, 2018", "JUL 27, 2018", "JUL 25, 2018", "JUL 25, 2018", "JUL 25, 2018", "JUL 25, 2018", "JUL 25, 2018", "JUL 24, 2018", "JUL 24, 2018", "JUL 26, 2018", "JUL 25, 2018", "JUL 25, 2018", "JUL 25, 2018", "JUL 23, 2018", "JUL 23, 2018", "JUL 22, 2018", "JUL 20, 2018", "JUL 23, 2018", "JUL 20, 2018", "JUL 19, 2018", "JUL 19, 2018", "JUL 18, 2018", "JUL 16, 2018", "JUL 15, 2018", "JUL 15, 2018", "JUL 20, 2018", "JUL 12, 2018", "JUL 11, 2018", "JUL 11, 2018", "JUL 11, 2018", "JUL 10, 2018", "JUL 10, 2018", "JUL 10, 2018", "JUL 14, 2018", "JUL 9, 2018", "JUL 9, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 5, 2018", "JUL 3, 2018", "JUL 3, 2018", "JUL 9, 2018", "JUL 2, 2018", "JUN 29, 2018", "JUN 27, 2018", "JUN 26, 2018", "JUN 26, 2018", "JUN 25, 2018", "JUN 25, 2018", "JUL 2, 2018", "JUN 25, 2018", "JUN 25, 2018", "JUN 20, 2018", "JUN 20, 2018", "JUN 19, 2018", "JUN 18, 2018", "JUN 17, 2018", "JUN 25, 2018", "JUN 15, 2018", "JUN 14, 2018", "JUN 13, 2018", "JUN 13, 2018", "JUN 13, 2018", "JUN 13, 2018", "JUN 17, 2018", "JUN 12, 2018", "JUN 11, 2018", "JUN 11, 2018", "JUN 7, 2018", "JUN 6, 2018", "JUN 6, 2018", "JUN 6, 2018", "JUN 12, 2018", "JUN 12, 2018", "JUN 1, 2018", "JUN 1, 2018", "JUN 1, 2018", "JUN 1, 2018", "MAY 31, 2018", "JUN 6, 2018", "MAY 31, 2018", "MAY 31, 2018", "MAY 31, 2018", "MAY 31, 2018", "MAY 30, 2018", "MAY 30, 2018", "MAY 29, 2018", "MAY 31, 2018", "MAY 25, 2018", "MAY 24, 2018", "MAY 23, 2018", "MAY 22, 2018", "MAY 22, 2018", "MAY 21, 2018", "MAY 17, 2018", "MAY 27, 2018", "MAY 15, 2018", "MAY 10, 2018", "MAY 9, 2018", "MAY 9, 2018", "MAY 8, 2018", "MAY 7, 2018", "MAY 7, 2018", "MAY 17, 2018", "MAY 4, 2018", "MAY 4, 2018", "MAY 4, 2018", "MAY 4, 2018", "MAY 4, 2018", "MAY 3, 2018", "MAY 3, 2018", "MAY 4, 2018", "MAY 3, 2018", "MAY 3, 2018", "MAY 2, 2018", "MAY 2, 2018", "MAY 2, 2018", "MAY 2, 2018", "MAY 2, 2018", "MAY 3, 2018", "MAY 2, 2018", "MAY 2, 2018", "MAY 2, 2018", "MAY 1, 2018", "MAY 1, 2018", "MAY 1, 2018", "MAY 1, 2018", "MAY 2, 2018", "MAY 2, 2018", "MAY 2, 2018", "MAY 1, 2018", "APR 30, 2018", "APR 30, 2018", "APR 30, 2018", "APR 30, 2018", "MAY 1, 2018", "MAY 1, 2018", "MAY 1, 2018", "APR 27, 2018", "APR 27, 2018", "APR 27, 2018", "APR 27, 2018", "APR 30, 2018", "APR 29, 2018", "APR 26, 2018", "APR 26, 2018", "APR 26, 2018", "APR 26, 2018", "APR 26, 2018", "APR 25, 2018", "APR 26, 2018", "APR 24, 2018", "APR 24, 2018", "APR 24, 2018", "APR 24, 2018", "APR 23, 2018", "APR 23, 2018", "APR 23, 2018", "APR 25, 2018", "APR 22, 2018", "APR 20, 2018", "APR 20, 2018", "APR 19, 2018", "APR 19, 2018", "APR 19, 2018", "APR 19, 2018", "APR 23, 2018", "APR 18, 2018", "APR 18, 2018", "APR 16, 2018", "APR 15, 2018", "APR 13, 2018", "APR 13, 2018", "APR 12, 2018", "APR 19, 2018", "APR 12, 2018", "APR 11, 2018", "APR 11, 2018", "APR 8, 2018", "APR 8, 2018", "APR 7, 2018", "APR 6, 2018", "APR 12, 2018", "APR 4, 2018", "APR 3, 2018", "APR 2, 2018", "MAR 30, 2018", "MAR 28, 2018", "MAR 27, 2018", "MAR 27, 2018", "APR 4, 2018", "APR 4, 2018", "APR 3, 2018", "MAR 23, 2018", "MAR 22, 2018", "MAR 21, 2018", "MAR 21, 2018", "MAR 26, 2018", "MAR 19, 2018", "MAR 18, 2018", "MAR 18, 2018", "MAR 17, 2018", "MAR 16, 2018", "MAR 16, 2018", "MAR 15, 2018", "MAR 21, 2018", "MAR 14, 2018", "MAR 14, 2018", "MAR 14, 2018", "MAR 14, 2018", "MAR 13, 2018", "MAR 12, 2018", "MAR 12, 2018", "MAR 14, 2018", "MAR 12, 2018", "MAR 11, 2018", "MAR 11, 2018", "MAR 10, 2018", "MAR 8, 2018", "MAR 8, 2018", "MAR 8, 2018", "MAR 12, 2018", "MAR 6, 2018", "MAR 6, 2018", "MAR 4, 2018", "MAR 2, 2018", "MAR 1, 2018", "MAR 1, 2018", "MAR 1, 2018", "MAR 6, 2018", "MAR 1, 2018", "FEB 28, 2018", "FEB 28, 2018", "FEB 28, 2018", "FEB 28, 2018", "FEB 26, 2018", "FEB 26, 2018", "MAR 1, 2018", "FEB 22, 2018", "FEB 22, 2018", "FEB 22, 2018", "FEB 22, 2018", "FEB 22, 2018", "FEB 19, 2018", "FEB 18, 2018", "FEB 23, 2018", "FEB 22, 2018", "FEB 22, 2018", "FEB 22, 2018", "FEB 14, 2018", "FEB 13, 2018", "FEB 13, 2018", "FEB 12, 2018", "FEB 17, 2018", "FEB 11, 2018", "FEB 10, 2018", "FEB 9, 2018", "FEB 8, 2018", "FEB 8, 2018", "FEB 8, 2018", "FEB 8, 2018", "FEB 11, 2018", "FEB 7, 2018", "FEB 7, 2018", "FEB 7, 2018", "FEB 7, 2018", "FEB 7, 2018", "FEB 6, 2018", "FEB 6, 2018", "FEB 8, 2018", "FEB 6, 2018", "FEB 6, 2018", "FEB 6, 2018", "FEB 6, 2018", "FEB 5, 2018", "FEB 4, 2018", "FEB 4, 2018", "FEB 6, 2018", "FEB 2, 2018", "FEB 1, 2018", "FEB 1, 2018", "JAN 31, 2018", "JAN 31, 2018", "JAN 30, 2018", "JAN 30, 2018", "FEB 2, 2018", "FEB 2, 2018", "JAN 29, 2018", "JAN 29, 2018", "JAN 29, 2018", "JAN 28, 2018", "JAN 26, 2018", "JAN 26, 2018", "JAN 30, 2018", "JAN 26, 2018", "JAN 26, 2018", "JAN 25, 2018", "JAN 25, 2018", "JAN 25, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 26, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 21, 2018", "JAN 21, 2018", "JAN 21, 2018", "JAN 19, 2018", "JAN 23, 2018", "JAN 19, 2018", "JAN 18, 2018", "JAN 18, 2018", "JAN 18, 2018", "JAN 18, 2018", "JAN 18, 2018", "JAN 18, 2018", "JAN 19, 2018", "JAN 18, 2018", "JAN 17, 2018", "JAN 17, 2018", "JAN 17, 2018", "JAN 17, 2018", "JAN 17, 2018", "JAN 17, 2018", "JAN 18, 2018", "JAN 16, 2018", "JAN 12, 2018", "JAN 12, 2018", "JAN 12, 2018", "JAN 12, 2018", "JAN 11, 2018", "JAN 11, 2018", "JAN 16, 2018", "JAN 11, 2018", "JAN 10, 2018", "JAN 9, 2018", "JAN 9, 2018", "JAN 8, 2018", "JAN 8, 2018", "JAN 7, 2018", "JAN 11, 2018", "JAN 5, 2018", "JAN 5, 2018", "JAN 5, 2018", "JAN 4, 2018", "JAN 4, 2018", "JAN 4, 2018", "JAN 3, 2018", "JAN 5, 2018", "JAN 5, 2018", "JAN 5, 2018", "JAN 5, 2018", "JAN 4, 2018", "JAN 4, 2018", "DEC 29, 2017", "DEC 29, 2017", "JAN 3, 2018", "JAN 2, 2018", "DEC 27, 2017", "DEC 27, 2017", "DEC 22, 2017", "DEC 22, 2017", "DEC 21, 2017", "DEC 29, 2017", "DEC 28, 2017", "DEC 27, 2017", "DEC 27, 2017", "DEC 19, 2017", "DEC 19, 2017", "DEC 18, 2017", "DEC 18, 2017", "DEC 20, 2017", "DEC 20, 2017", "DEC 20, 2017", "DEC 20, 2017", "DEC 19, 2017", "DEC 15, 2017", "DEC 14, 2017", "DEC 17, 2017", "DEC 13, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 11, 2017", "DEC 13, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 10, 2017", "DEC 10, 2017", "DEC 11, 2017", "DEC 8, 2017", "DEC 8, 2017", "DEC 8, 2017", "DEC 7, 2017", "DEC 7, 2017", "DEC 6, 2017", "DEC 6, 2017", "DEC 10, 2017", "DEC 3, 2017", "DEC 1, 2017", "DEC 1, 2017", "NOV 30, 2017", "NOV 30, 2017", "NOV 30, 2017", "NOV 30, 2017", "DEC 6, 2017", "NOV 30, 2017", "NOV 30, 2017", "NOV 29, 2017", "NOV 29, 2017", "NOV 29, 2017", "NOV 28, 2017", "NOV 28, 2017", "NOV 30, 2017", "NOV 27, 2017", "NOV 27, 2017", "NOV 24, 2017", "NOV 24, 2017", "NOV 24, 2017", "NOV 22, 2017", "NOV 21, 2017", "NOV 28, 2017", "NOV 27, 2017", "NOV 27, 2017", "NOV 18, 2017", "NOV 17, 2017", "NOV 17, 2017", "NOV 16, 2017", "NOV 16, 2017", "NOV 21, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 14, 2017", "NOV 14, 2017", "NOV 14, 2017", "NOV 14, 2017", "NOV 13, 2017", "NOV 16, 2017", "NOV 15, 2017", "NOV 15, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 8, 2017", "NOV 6, 2017", "NOV 6, 2017", "NOV 12, 2017", "NOV 10, 2017", "NOV 9, 2017", "NOV 2, 2017", "NOV 2, 2017", "NOV 2, 2017", "NOV 2, 2017", "NOV 4, 2017", "NOV 1, 2017", "NOV 1, 2017", "NOV 1, 2017", "OCT 31, 2017", "OCT 31, 2017", "OCT 30, 2017", "OCT 30, 2017", "NOV 2, 2017", "NOV 1, 2017", "OCT 30, 2017", "OCT 30, 2017", "OCT 29, 2017", "OCT 29, 2017", "OCT 29, 2017", "OCT 28, 2017", "OCT 30, 2017", "OCT 27, 2017", "OCT 27, 2017", "OCT 27, 2017", "OCT 27, 2017", "OCT 26, 2017", "OCT 26, 2017", "OCT 26, 2017", "OCT 27, 2017", "OCT 26, 2017", "OCT 26, 2017", "OCT 26, 2017", "OCT 26, 2017", "OCT 25, 2017", "OCT 25, 2017", "OCT 25, 2017", "OCT 26, 2017", "OCT 24, 2017", "OCT 24, 2017", "OCT 24, 2017", "OCT 23, 2017", "OCT 23, 2017", "OCT 23, 2017", "OCT 23, 2017", "OCT 25, 2017", "OCT 24, 2017", "OCT 24, 2017", "OCT 24, 2017", "OCT 20, 2017", "OCT 20, 2017", "OCT 19, 2017", "OCT 19, 2017", "OCT 23, 2017", "OCT 23, 2017", "OCT 23, 2017", "OCT 20, 2017", "OCT 20, 2017", "OCT 18, 2017", "OCT 18, 2017", "OCT 17, 2017", "OCT 19, 2017", "OCT 17, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 13, 2017", "OCT 13, 2017", "OCT 17, 2017", "OCT 13, 2017", "OCT 13, 2017", "OCT 13, 2017", "OCT 12, 2017", "OCT 12, 2017", "OCT 12, 2017", "OCT 12, 2017", "OCT 13, 2017", "OCT 10, 2017", "OCT 10, 2017", "OCT 10, 2017", "OCT 10, 2017", "OCT 8, 2017", "OCT 8, 2017", "OCT 7, 2017", "OCT 11, 2017", "OCT 6, 2017", "OCT 6, 2017", "OCT 6, 2017", "OCT 6, 2017", "OCT 5, 2017", "OCT 4, 2017", "OCT 4, 2017", "OCT 7, 2017", "OCT 6, 2017", "OCT 6, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 2, 2017", "OCT 2, 2017", "OCT 2, 2017", "OCT 4, 2017", "OCT 1, 2017", "SEP 29, 2017", "SEP 29, 2017", "SEP 29, 2017", "SEP 29, 2017", "SEP 28, 2017", "SEP 28, 2017", "OCT 2, 2017", "SEP 28, 2017", "SEP 28, 2017", "SEP 28, 2017", "SEP 28, 2017", "SEP 28, 2017", "SEP 28, 2017", "SEP 28, 2017", "SEP 28, 2017", "SEP 27, 2017", "SEP 26, 2017", "SEP 26, 2017", "SEP 26, 2017", "SEP 26, 2017", "SEP 25, 2017", "SEP 25, 2017", "SEP 27, 2017", "SEP 22, 2017", "SEP 22, 2017", "SEP 22, 2017", "SEP 22, 2017", "SEP 21, 2017", "SEP 21, 2017", "SEP 21, 2017", "SEP 22, 2017", "SEP 22, 2017", "SEP 22, 2017", "SEP 18, 2017", "SEP 18, 2017", "SEP 18, 2017", "SEP 18, 2017", "SEP 17, 2017", "SEP 19, 2017", "SEP 15, 2017", "SEP 15, 2017", "SEP 15, 2017", "SEP 14, 2017", "SEP 14, 2017", "SEP 14, 2017", "SEP 14, 2017", "SEP 15, 2017", "SEP 13, 2017", "SEP 13, 2017", "SEP 13, 2017", "SEP 13, 2017", "SEP 12, 2017", "SEP 12, 2017", "SEP 12, 2017", "SEP 13, 2017", "SEP 11, 2017", "SEP 11, 2017", "SEP 11, 2017", "SEP 10, 2017", "SEP 10, 2017", "SEP 8, 2017", "SEP 8, 2017", "SEP 11, 2017", "SEP 8, 2017", "SEP 8, 2017", "SEP 7, 2017", "SEP 7, 2017", "SEP 7, 2017", "SEP 7, 2017", "SEP 7, 2017", "SEP 8, 2017", "SEP 8, 2017", "SEP 6, 2017", "SEP 5, 2017", "SEP 5, 2017", "SEP 5, 2017", "SEP 5, 2017", "SEP 6, 2017", "SEP 6, 2017", "SEP 6, 2017", "SEP 3, 2017", "SEP 3, 2017", "SEP 2, 2017", "SEP 1, 2017", "SEP 1, 2017", "SEP 5, 2017", "SEP 1, 2017", "SEP 1, 2017", "SEP 1, 2017", "SEP 1, 2017", "SEP 1, 2017", "AUG 31, 2017", "AUG 31, 2017", "SEP 1, 2017", "SEP 1, 2017", "SEP 1, 2017", "SEP 1, 2017", "SEP 1, 2017", "AUG 31, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 31, 2017", "AUG 31, 2017", "AUG 31, 2017", "AUG 31, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 29, 2017", "AUG 30, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 29, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 27, 2017", "AUG 25, 2017", "AUG 25, 2017", "AUG 24, 2017", "AUG 24, 2017", "AUG 28, 2017", "AUG 23, 2017", "AUG 23, 2017", "AUG 23, 2017", "AUG 22, 2017", "AUG 22, 2017", "AUG 22, 2017", "AUG 22, 2017", "AUG 24, 2017", "AUG 21, 2017", "AUG 18, 2017", "AUG 18, 2017", "AUG 18, 2017", "AUG 18, 2017", "AUG 17, 2017", "AUG 17, 2017", "AUG 21, 2017", "AUG 16, 2017", "AUG 16, 2017", "AUG 16, 2017", "AUG 15, 2017", "AUG 15, 2017", "AUG 15, 2017", "AUG 15, 2017", "AUG 16, 2017", "AUG 14, 2017", "AUG 14, 2017", "AUG 14, 2017", "AUG 14, 2017", "AUG 13, 2017", "AUG 11, 2017", "AUG 11, 2017", "AUG 14, 2017", "AUG 14, 2017", "AUG 14, 2017", "AUG 14, 2017", "AUG 9, 2017", "AUG 9, 2017", "AUG 9, 2017", "AUG 9, 2017", "AUG 11, 2017", "AUG 8, 2017", "AUG 8, 2017", "AUG 7, 2017", "AUG 7, 2017", "AUG 7, 2017", "AUG 6, 2017", "AUG 5, 2017", "AUG 8, 2017", "AUG 4, 2017", "AUG 4, 2017", "AUG 4, 2017", "AUG 3, 2017", "AUG 3, 2017", "AUG 3, 2017", "AUG 3, 2017", "AUG 4, 2017", "AUG 2, 2017", "AUG 2, 2017", "AUG 1, 2017", "AUG 1, 2017", "AUG 1, 2017", "AUG 1, 2017", "JUL 31, 2017", "AUG 2, 2017", "JUL 28, 2017", "JUL 27, 2017", "JUL 27, 2017", "JUL 27, 2017", "JUL 27, 2017", "JUL 27, 2017", "JUL 27, 2017", "JUL 28, 2017", "JUL 26, 2017", "JUL 26, 2017", "JUL 26, 2017", "JUL 26, 2017", "JUL 26, 2017", "JUL 26, 2017", "JUL 26, 2017", "JUL 27, 2017", "JUL 25, 2017", "JUL 25, 2017", "JUL 25, 2017", "JUL 24, 2017", "JUL 24, 2017", "JUL 24, 2017", "JUL 22, 2017", "JUL 25, 2017", "JUL 21, 2017", "JUL 21, 2017", "JUL 21, 2017", "JUL 21, 2017", "JUL 21, 2017", "JUL 21, 2017", "JUL 21, 2017", "JUL 22, 2017", "JUL 20, 2017", "JUL 20, 2017", "JUL 20, 2017", "JUL 19, 2017", "JUL 19, 2017", "JUL 19, 2017", "JUL 19, 2017", "JUL 20, 2017", "JUL 18, 2017", "JUL 18, 2017", "JUL 18, 2017", "JUL 17, 2017", "JUL 16, 2017", "JUL 16, 2017", "JUL 15, 2017", "JUL 18, 2017", "JUL 14, 2017", "JUL 13, 2017", "JUL 13, 2017", "JUL 13, 2017", "JUL 13, 2017", "JUL 13, 2017", "JUL 13, 2017", "JUL 14, 2017", "JUL 14, 2017", "JUL 13, 2017", "JUL 13, 2017", "JUL 10, 2017", "JUL 9, 2017", "JUL 7, 2017", "JUL 7, 2017", "JUL 12, 2017", "JUL 6, 2017", "JUL 5, 2017", "JUL 5, 2017", "JUL 5, 2017", "JUL 3, 2017", "JUL 3, 2017", "JUL 2, 2017", "JUL 6, 2017", "JUN 29, 2017", "JUN 29, 2017", "JUN 29, 2017", "JUN 29, 2017", "JUN 28, 2017", "JUN 28, 2017", "JUN 27, 2017", "JUN 30, 2017", "JUN 29, 2017", "JUN 29, 2017", "JUN 29, 2017", "JUN 29, 2017", "JUN 22, 2017", "JUN 22, 2017", "JUN 22, 2017", "JUN 27, 2017", "JUN 27, 2017", "JUN 26, 2017", "JUN 24, 2017", "JUN 20, 2017", "JUN 20, 2017", "JUN 20, 2017", "JUN 19, 2017", "JUN 21, 2017", "JUN 21, 2017", "JUN 16, 2017", "JUN 15, 2017", "JUN 15, 2017", "JUN 15, 2017", "JUN 15, 2017", "JUN 19, 2017", "JUN 13, 2017", "JUN 13, 2017", "JUN 13, 2017", "JUN 12, 2017", "JUN 12, 2017", "JUN 12, 2017", "JUN 12, 2017", "JUN 15, 2017", "JUN 9, 2017", "JUN 9, 2017", "JUN 9, 2017", "JUN 9, 2017", "JUN 8, 2017", "JUN 7, 2017", "JUN 7, 2017", "JUN 12, 2017", "JUN 6, 2017", "JUN 6, 2017", "JUN 5, 2017", "JUN 4, 2017", "JUN 4, 2017", "JUN 3, 2017", "JUN 2, 2017", "JUN 6, 2017", "JUN 1, 2017", "MAY 31, 2017", "MAY 31, 2017", "MAY 31, 2017", "MAY 29, 2017", "MAY 29, 2017", "MAY 28, 2017", "JUN 2, 2017", "MAY 26, 2017", "MAY 26, 2017", "MAY 25, 2017", "MAY 24, 2017", "MAY 24, 2017", "MAY 24, 2017", "MAY 23, 2017", "MAY 26, 2017", "MAY 22, 2017", "MAY 22, 2017", "MAY 19, 2017", "MAY 18, 2017", "MAY 18, 2017", "MAY 18, 2017", "MAY 17, 2017", "MAY 22, 2017", "MAY 16, 2017", "MAY 16, 2017", "MAY 16, 2017", "MAY 14, 2017", "MAY 14, 2017", "MAY 12, 2017", "MAY 12, 2017", "MAY 17, 2017", "MAY 11, 2017", "MAY 10, 2017", "MAY 10, 2017", "MAY 9, 2017", "MAY 9, 2017", "MAY 9, 2017", "MAY 8, 2017", "MAY 11, 2017", "MAY 5, 2017", "MAY 5, 2017", "MAY 5, 2017", "MAY 4, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 8, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 2, 2017", "MAY 3, 2017", "MAY 2, 2017", "MAY 2, 2017", "MAY 2, 2017", "MAY 2, 2017", "MAY 1, 2017", "MAY 1, 2017", "MAY 1, 2017", "MAY 2, 2017", "MAY 1, 2017", "MAY 1, 2017", "MAY 1, 2017", "MAY 1, 2017", "APR 30, 2017", "APR 28, 2017", "APR 28, 2017", "MAY 1, 2017", "APR 28, 2017", "APR 28, 2017", "APR 28, 2017", "APR 28, 2017", "APR 28, 2017", "APR 27, 2017", "APR 27, 2017", "APR 28, 2017", "APR 26, 2017", "APR 26, 2017", "APR 26, 2017", "APR 26, 2017", "APR 26, 2017", "APR 26, 2017", "APR 26, 2017", "APR 27, 2017", "APR 25, 2017", "APR 25, 2017", "APR 25, 2017", "APR 25, 2017", "APR 25, 2017", "APR 24, 2017", "APR 24, 2017", "APR 25, 2017", "APR 25, 2017", "APR 25, 2017", "APR 25, 2017", "APR 21, 2017", "APR 21, 2017", "APR 21, 2017", "APR 21, 2017", "APR 24, 2017", "APR 23, 2017", "APR 22, 2017", "APR 20, 2017", "APR 20, 2017", "APR 19, 2017", "APR 18, 2017", "APR 18, 2017", "APR 21, 2017", "APR 21, 2017", "APR 20, 2017", "APR 12, 2017", "APR 12, 2017", "APR 11, 2017", "APR 11, 2017", "APR 18, 2017", "APR 10, 2017", "APR 9, 2017", "APR 7, 2017", "APR 6, 2017", "APR 6, 2017", "APR 6, 2017", "APR 6, 2017", "APR 11, 2017", "APR 10, 2017", "APR 9, 2017", "APR 7, 2017", "APR 6, 2017", "APR 6, 2017", "APR 6, 2017", "APR 6, 2017", "APR 11, 2017", "APR 5, 2017", "APR 5, 2017", "APR 5, 2017", "MAR 29, 2017", "MAR 29, 2017", "MAR 28, 2017", "APR 3, 2017", "MAR 27, 2017", "MAR 27, 2017", "MAR 27, 2017", "MAR 24, 2017", "MAR 23, 2017", "MAR 22, 2017", "MAR 22, 2017", "MAR 28, 2017", "MAR 21, 2017", "MAR 21, 2017", "MAR 21, 2017", "MAR 20, 2017", "MAR 20, 2017", "MAR 20, 2017", "MAR 17, 2017", "MAR 22, 2017", "MAR 21, 2017", "MAR 21, 2017", "MAR 21, 2017", "MAR 15, 2017", "MAR 15, 2017", "MAR 15, 2017", "MAR 17, 2017", "MAR 13, 2017", "MAR 13, 2017", "MAR 12, 2017", "MAR 11, 2017", "MAR 10, 2017", "MAR 10, 2017", "MAR 10, 2017", "MAR 13, 2017", "MAR 9, 2017", "MAR 8, 2017", "MAR 7, 2017", "MAR 7, 2017", "MAR 7, 2017", "MAR 7, 2017", "MAR 7, 2017", "MAR 9, 2017", "MAR 3, 2017", "MAR 3, 2017", "MAR 2, 2017", "MAR 2, 2017", "MAR 2, 2017", "MAR 2, 2017", "MAR 1, 2017", "MAR 5, 2017", "MAR 3, 2017", "MAR 1, 2017", "FEB 27, 2017", "FEB 27, 2017", "FEB 27, 2017", "FEB 27, 2017", "MAR 1, 2017", "FEB 26, 2017", "FEB 24, 2017", "FEB 24, 2017", "FEB 23, 2017", "FEB 22, 2017", "FEB 22, 2017", "FEB 22, 2017", "FEB 26, 2017", "FEB 22, 2017", "FEB 21, 2017", "FEB 21, 2017", "FEB 21, 2017", "FEB 19, 2017", "FEB 18, 2017", "FEB 17, 2017", "FEB 22, 2017", "FEB 22, 2017", "FEB 21, 2017", "FEB 21, 2017", "FEB 21, 2017", "FEB 19, 2017", "FEB 15, 2017", "FEB 17, 2017", "FEB 15, 2017", "FEB 14, 2017", "FEB 14, 2017", "FEB 14, 2017", "FEB 14, 2017", "FEB 14, 2017", "FEB 14, 2017", "FEB 15, 2017", "FEB 14, 2017", "FEB 13, 2017", "FEB 13, 2017", "FEB 13, 2017", "FEB 13, 2017", "FEB 12, 2017", "FEB 12, 2017", "FEB 14, 2017", "FEB 10, 2017", "FEB 10, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 11, 2017", "FEB 9, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 9, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 7, 2017", "FEB 7, 2017", "FEB 7, 2017", "FEB 7, 2017", "FEB 7, 2017", "FEB 7, 2017", "FEB 7, 2017", "FEB 6, 2017", "FEB 6, 2017", "FEB 5, 2017", "FEB 3, 2017", "FEB 2, 2017", "FEB 2, 2017", "FEB 1, 2017", "FEB 7, 2017", "JAN 31, 2017", "JAN 31, 2017", "JAN 31, 2017", "JAN 30, 2017", "JAN 30, 2017", "JAN 29, 2017", "JAN 27, 2017", "JAN 31, 2017", "JAN 27, 2017", "JAN 26, 2017", "JAN 25, 2017", "JAN 25, 2017", "JAN 25, 2017", "JAN 25, 2017", "JAN 25, 2017", "JAN 27, 2017", "JAN 24, 2017", "JAN 24, 2017", "JAN 23, 2017", "JAN 23, 2017", "JAN 23, 2017", "JAN 23, 2017", "JAN 23, 2017", "JAN 24, 2017", "JAN 24, 2017", "JAN 24, 2017", "JAN 20, 2017", "JAN 20, 2017", "JAN 20, 2017", "JAN 19, 2017", "JAN 23, 2017", "JAN 18, 2017", "JAN 18, 2017", "JAN 17, 2017", "JAN 17, 2017", "JAN 17, 2017", "JAN 15, 2017", "JAN 14, 2017", "JAN 18, 2017", "JAN 12, 2017", "JAN 12, 2017", "JAN 12, 2017", "JAN 12, 2017", "JAN 11, 2017", "JAN 11, 2017", "JAN 11, 2017", "JAN 14, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 10, 2017", "JAN 7, 2017", "JAN 6, 2017", "JAN 6, 2017", "JAN 5, 2017", "JAN 5, 2017", "JAN 5, 2017", "JAN 5, 2017", "JAN 8, 2017", "JAN 4, 2017", "JAN 2, 2017", "JAN 1, 2017", "DEC 29, 2016", "DEC 28, 2016", "DEC 25, 2016", "DEC 24, 2016", "JAN 4, 2017", "DEC 22, 2016", "DEC 22, 2016", "DEC 22, 2016", "DEC 21, 2016", "DEC 21, 2016", "DEC 21, 2016", "DEC 21, 2016", "DEC 23, 2016", "DEC 20, 2016", "DEC 20, 2016", "DEC 20, 2016", "DEC 19, 2016", "DEC 18, 2016", "DEC 18, 2016", "DEC 18, 2016", "DEC 20, 2016", "DEC 16, 2016", "DEC 16, 2016", "DEC 16, 2016", "DEC 16, 2016", "DEC 15, 2016", "DEC 15, 2016", "DEC 14, 2016", "DEC 17, 2016", "DEC 16, 2016", "DEC 16, 2016", "DEC 13, 2016", "DEC 13, 2016", "DEC 13, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 14, 2016", "DEC 12, 2016", "DEC 11, 2016", "DEC 9, 2016", "DEC 9, 2016", "DEC 6, 2016", "DEC 6, 2016", "DEC 1, 2016", "DEC 12, 2016", "NOV 30, 2016", "NOV 30, 2016", "NOV 26, 2016", "NOV 25, 2016", "NOV 23, 2016", "NOV 23, 2016", "NOV 23, 2016", "DEC 1, 2016", "NOV 30, 2016", "NOV 30, 2016", "NOV 26, 2016", "NOV 21, 2016", "NOV 20, 2016", "NOV 20, 2016", "NOV 18, 2016", "NOV 23, 2016", "NOV 17, 2016", "NOV 17, 2016", "NOV 17, 2016", "NOV 16, 2016", "NOV 16, 2016", "NOV 15, 2016", "NOV 14, 2016", "NOV 17, 2016", "NOV 14, 2016", "NOV 14, 2016", "NOV 13, 2016", "NOV 13, 2016", "NOV 11, 2016", "NOV 11, 2016", "NOV 10, 2016", "NOV 14, 2016", "NOV 10, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 8, 2016", "NOV 10, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 6, 2016", "NOV 8, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 3, 2016", "NOV 3, 2016", "NOV 3, 2016", "NOV 3, 2016", "NOV 4, 2016", "NOV 3, 2016", "NOV 3, 2016", "NOV 2, 2016", "NOV 2, 2016", "NOV 2, 2016", "NOV 2, 2016", "NOV 2, 2016", "NOV 3, 2016", "NOV 1, 2016", "NOV 1, 2016", "NOV 1, 2016", "NOV 1, 2016", "NOV 1, 2016", "NOV 1, 2016", "NOV 1, 2016", "NOV 2, 2016", "OCT 31, 2016", "OCT 31, 2016", "OCT 31, 2016", "OCT 31, 2016", "OCT 31, 2016", "OCT 29, 2016", "OCT 29, 2016", "OCT 31, 2016", "OCT 31, 2016", "OCT 31, 2016", "OCT 31, 2016", "OCT 31, 2016", "OCT 26, 2016", "OCT 26, 2016", "OCT 28, 2016", "OCT 26, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 24, 2016", "OCT 21, 2016", "OCT 20, 2016", "OCT 20, 2016", "OCT 26, 2016", "OCT 19, 2016", "OCT 18, 2016", "OCT 17, 2016", "OCT 17, 2016", "OCT 17, 2016", "OCT 14, 2016", "OCT 13, 2016", "OCT 20, 2016", "OCT 12, 2016", "OCT 11, 2016", "OCT 11, 2016", "OCT 10, 2016", "OCT 10, 2016", "OCT 8, 2016", "OCT 7, 2016", "OCT 12, 2016", "OCT 5, 2016", "OCT 5, 2016", "OCT 4, 2016", "OCT 4, 2016", "OCT 3, 2016", "OCT 3, 2016", "OCT 3, 2016", "OCT 6, 2016", "SEP 30, 2016", "SEP 29, 2016", "SEP 29, 2016", "SEP 28, 2016", "SEP 27, 2016", "SEP 27, 2016", "SEP 27, 2016", "OCT 1, 2016", "SEP 27, 2016", "SEP 27, 2016", "SEP 26, 2016", "SEP 24, 2016", "SEP 24, 2016", "SEP 23, 2016", "SEP 22, 2016", "SEP 27, 2016", "SEP 22, 2016", "SEP 22, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 20, 2016", "SEP 20, 2016", "SEP 22, 2016", "SEP 20, 2016", "SEP 19, 2016", "SEP 18, 2016", "SEP 16, 2016", "SEP 15, 2016", "SEP 14, 2016", "SEP 14, 2016", "SEP 20, 2016", "SEP 20, 2016", "SEP 19, 2016", "SEP 18, 2016", "SEP 16, 2016", "SEP 15, 2016", "SEP 14, 2016", "SEP 12, 2016", "SEP 14, 2016", "SEP 11, 2016", "SEP 9, 2016", "SEP 9, 2016", "SEP 8, 2016", "SEP 8, 2016", "SEP 8, 2016", "SEP 8, 2016", "SEP 11, 2016", "SEP 11, 2016", "SEP 9, 2016", "SEP 9, 2016", "SEP 8, 2016", "SEP 8, 2016", "SEP 8, 2016", "SEP 2, 2016", "SEP 7, 2016", "SEP 1, 2016", "SEP 1, 2016", "SEP 1, 2016", "AUG 31, 2016", "AUG 30, 2016", "AUG 30, 2016", "AUG 30, 2016", "SEP 2, 2016", "SEP 1, 2016", "SEP 1, 2016", "SEP 1, 2016", "AUG 28, 2016", "AUG 26, 2016", "AUG 26, 2016", "AUG 25, 2016", "AUG 29, 2016", "AUG 29, 2016", "AUG 29, 2016", "AUG 29, 2016", "AUG 24, 2016", "AUG 24, 2016", "AUG 23, 2016", "AUG 23, 2016", "AUG 25, 2016", "AUG 25, 2016", "AUG 25, 2016", "AUG 24, 2016", "AUG 24, 2016", "AUG 24, 2016", "AUG 19, 2016", "AUG 17, 2016", "AUG 23, 2016", "AUG 16, 2016", "AUG 14, 2016", "AUG 14, 2016", "AUG 13, 2016", "AUG 12, 2016", "AUG 11, 2016", "AUG 10, 2016", "AUG 17, 2016", "AUG 9, 2016", "AUG 8, 2016", "AUG 8, 2016", "AUG 7, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 4, 2016", "AUG 9, 2016", "AUG 2, 2016", "AUG 1, 2016", "JUL 31, 2016", "JUL 31, 2016", "JUL 29, 2016", "JUL 28, 2016", "JUL 28, 2016", "AUG 3, 2016", "JUL 28, 2016", "JUL 27, 2016", "JUL 27, 2016", "JUL 27, 2016", "JUL 27, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 28, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 26, 2016", "JUL 25, 2016", "JUL 25, 2016", "JUL 25, 2016", "JUL 25, 2016", "JUL 25, 2016", "JUL 25, 2016", "JUL 25, 2016", "JUL 25, 2016", "JUL 25, 2016", "JUL 24, 2016", "JUL 24, 2016", "JUL 23, 2016", "JUL 22, 2016", "JUL 22, 2016", "JUL 21, 2016", "JUL 25, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 20, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 19, 2016", "JUL 19, 2016", "JUL 20, 2016", "JUL 19, 2016", "JUL 19, 2016", "JUL 19, 2016", "JUL 18, 2016", "JUL 18, 2016", "JUL 18, 2016", "JUL 18, 2016", "JUL 19, 2016", "JUL 15, 2016", "JUL 15, 2016", "JUL 15, 2016", "JUL 15, 2016", "JUL 15, 2016", "JUL 14, 2016", "JUL 14, 2016", "JUL 16, 2016", "JUL 13, 2016", "JUL 13, 2016", "JUL 12, 2016", "JUL 11, 2016", "JUL 11, 2016", "JUL 11, 2016", "JUL 11, 2016", "JUL 14, 2016", "JUL 10, 2016", "JUL 8, 2016", "JUL 8, 2016", "JUL 7, 2016", "JUL 7, 2016", "JUL 5, 2016", "JUL 5, 2016", "JUL 11, 2016", "JUL 4, 2016", "JUL 3, 2016", "JUL 2, 2016", "JUL 1, 2016", "JUN 30, 2016", "JUN 30, 2016", "JUN 30, 2016", "JUL 5, 2016", "JUN 29, 2016", "JUN 29, 2016", "JUN 29, 2016", "JUN 29, 2016", "JUN 28, 2016", "JUN 28, 2016", "JUN 28, 2016", "JUN 30, 2016", "JUN 28, 2016", "JUN 28, 2016", "JUN 27, 2016", "JUN 27, 2016", "JUN 25, 2016", "JUN 25, 2016", "JUN 24, 2016", "JUN 28, 2016", "JUN 23, 2016", "JUN 22, 2016", "JUN 22, 2016", "JUN 22, 2016", "JUN 21, 2016", "JUN 21, 2016", "JUN 21, 2016", "JUN 24, 2016", "JUN 23, 2016", "JUN 18, 2016", "JUN 17, 2016", "JUN 17, 2016", "JUN 17, 2016", "JUN 14, 2016", "JUN 20, 2016", "JUN 13, 2016", "JUN 12, 2016", "JUN 11, 2016", "JUN 11, 2016", "JUN 9, 2016", "JUN 8, 2016", "JUN 7, 2016", "JUN 14, 2016", "JUN 6, 2016", "JUN 6, 2016", "JUN 5, 2016", "JUN 5, 2016", "JUN 4, 2016", "JUN 4, 2016", "JUN 1, 2016", "JUN 6, 2016", "MAY 31, 2016", "MAY 31, 2016", "MAY 31, 2016", "MAY 31, 2016", "MAY 27, 2016", "MAY 27, 2016", "MAY 27, 2016", "JUN 1, 2016", "MAY 25, 2016", "MAY 25, 2016", "MAY 25, 2016", "MAY 25, 2016", "MAY 24, 2016", "MAY 23, 2016", "MAY 23, 2016", "MAY 26, 2016", "MAY 20, 2016", "MAY 20, 2016", "MAY 20, 2016", "MAY 20, 2016", "MAY 19, 2016", "MAY 12, 2016", "MAY 11, 2016", "MAY 21, 2016", "MAY 10, 2016", "MAY 10, 2016", "MAY 10, 2016", "MAY 9, 2016", "MAY 9, 2016", "MAY 6, 2016", "MAY 5, 2016", "MAY 11, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 3, 2016", "MAY 3, 2016", "MAY 5, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 3, 2016", "MAY 3, 2016", "MAY 3, 2016", "MAY 3, 2016", "MAY 2, 2016", "MAY 2, 2016", "MAY 2, 2016", "MAY 2, 2016", "MAY 2, 2016", "MAY 2, 2016", "MAY 2, 2016", "MAY 3, 2016", "APR 30, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "MAY 1, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 29, 2016", "APR 28, 2016", "APR 28, 2016", "APR 29, 2016", "APR 29, 2016", "APR 28, 2016", "APR 28, 2016", "APR 28, 2016", "APR 28, 2016", "APR 28, 2016", "APR 27, 2016", "APR 28, 2016", "APR 27, 2016", "APR 27, 2016", "APR 27, 2016", "APR 26, 2016", "APR 26, 2016", "APR 26, 2016", "APR 26, 2016", "APR 27, 2016", "APR 27, 2016", "APR 27, 2016", "APR 27, 2016", "APR 26, 2016", "APR 26, 2016", "APR 25, 2016", "APR 25, 2016", "APR 26, 2016", "APR 25, 2016", "APR 25, 2016", "APR 25, 2016", "APR 24, 2016", "APR 24, 2016", "APR 23, 2016", "APR 25, 2016", "APR 25, 2016", "APR 22, 2016", "APR 22, 2016", "APR 22, 2016", "APR 21, 2016", "APR 21, 2016", "APR 22, 2016", "APR 21, 2016", "APR 21, 2016", "APR 21, 2016", "APR 21, 2016", "APR 20, 2016", "APR 20, 2016", "APR 19, 2016", "APR 21, 2016", "APR 21, 2016", "APR 21, 2016", "APR 21, 2016", "APR 21, 2016", "APR 18, 2016", "APR 18, 2016", "APR 16, 2016", "APR 18, 2016", "APR 15, 2016", "APR 15, 2016", "APR 15, 2016", "APR 14, 2016", "APR 14, 2016", "APR 14, 2016", "APR 14, 2016", "APR 16, 2016", "APR 13, 2016", "APR 13, 2016", "APR 13, 2016", "APR 13, 2016", "APR 13, 2016", "APR 13, 2016", "APR 12, 2016", "APR 14, 2016", "APR 11, 2016", "APR 10, 2016", "APR 8, 2016", "APR 8, 2016", "APR 8, 2016", "APR 7, 2016", "APR 12, 2016", "APR 7, 2016", "APR 6, 2016", "APR 6, 2016", "APR 6, 2016", "APR 6, 2016", "APR 6, 2016", "APR 5, 2016", "APR 7, 2016", "APR 5, 2016", "APR 5, 2016", "APR 5, 2016", "APR 4, 2016", "APR 4, 2016", "APR 4, 2016", "APR 4, 2016", "APR 5, 2016", "APR 5, 2016", "APR 5, 2016", "APR 5, 2016", "APR 4, 2016", "APR 4, 2016", "APR 4, 2016", "APR 3, 2016", "MAR 31, 2016", "MAR 31, 2016", "MAR 31, 2016", "MAR 30, 2016", "MAR 30, 2016", "MAR 30, 2016", "MAR 29, 2016", "MAR 31, 2016", "MAR 29, 2016", "MAR 29, 2016", "MAR 29, 2016", "MAR 29, 2016", "MAR 29, 2016", "MAR 28, 2016", "MAR 28, 2016", "MAR 29, 2016", "MAR 28, 2016", "MAR 28, 2016", "MAR 25, 2016", "MAR 24, 2016", "MAR 24, 2016", "MAR 24, 2016", "MAR 24, 2016", "MAR 28, 2016", "MAR 23, 2016", "MAR 23, 2016", "MAR 23, 2016", "MAR 22, 2016", "MAR 22, 2016", "MAR 22, 2016", "MAR 22, 2016", "MAR 23, 2016", "MAR 21, 2016", "MAR 21, 2016", "MAR 18, 2016", "MAR 18, 2016", "MAR 17, 2016", "MAR 16, 2016", "MAR 16, 2016", "MAR 21, 2016", "MAR 15, 2016", "MAR 15, 2016", "MAR 15, 2016", "MAR 15, 2016", "MAR 14, 2016", "MAR 11, 2016", "MAR 11, 2016", "MAR 16, 2016", "MAR 10, 2016", "MAR 9, 2016", "MAR 9, 2016", "MAR 9, 2016", "MAR 8, 2016", "MAR 8, 2016", "MAR 8, 2016", "MAR 11, 2016", "MAR 7, 2016", "MAR 7, 2016", "MAR 7, 2016", "MAR 7, 2016", "MAR 5, 2016", "MAR 4, 2016", "MAR 4, 2016", "MAR 8, 2016", "MAR 3, 2016", "MAR 2, 2016", "MAR 1, 2016", "MAR 1, 2016", "MAR 1, 2016", "FEB 29, 2016", "FEB 29, 2016", "MAR 4, 2016", "FEB 26, 2016", "FEB 26, 2016", "FEB 24, 2016", "FEB 24, 2016", "FEB 22, 2016", "FEB 22, 2016", "FEB 21, 2016", "FEB 29, 2016", "FEB 20, 2016", "FEB 20, 2016", "FEB 20, 2016", "FEB 19, 2016", "FEB 19, 2016", "FEB 18, 2016", "FEB 18, 2016", "FEB 21, 2016", "FEB 20, 2016", "FEB 20, 2016", "FEB 17, 2016", "FEB 17, 2016", "FEB 17, 2016", "FEB 17, 2016", "FEB 17, 2016", "FEB 18, 2016", "FEB 17, 2016", "FEB 16, 2016", "FEB 16, 2016", "FEB 16, 2016", "FEB 16, 2016", "FEB 16, 2016", "FEB 13, 2016", "FEB 17, 2016", "FEB 12, 2016", "FEB 12, 2016", "FEB 12, 2016", "FEB 12, 2016", "FEB 12, 2016", "FEB 11, 2016", "FEB 11, 2016", "FEB 12, 2016", "FEB 10, 2016", "FEB 10, 2016", "FEB 10, 2016", "FEB 10, 2016", "FEB 10, 2016", "FEB 9, 2016", "FEB 9, 2016", "FEB 11, 2016", "FEB 10, 2016", "FEB 10, 2016", "FEB 10, 2016", "FEB 10, 2016", "FEB 10, 2016", "FEB 9, 2016", "FEB 6, 2016", "FEB 9, 2016", "FEB 5, 2016", "FEB 5, 2016", "FEB 4, 2016", "FEB 4, 2016", "FEB 4, 2016", "FEB 4, 2016", "FEB 3, 2016", "FEB 5, 2016", "FEB 5, 2016", "FEB 3, 2016", "FEB 3, 2016", "FEB 3, 2016", "FEB 3, 2016", "FEB 3, 2016", "FEB 3, 2016", "FEB 3, 2016", "FEB 3, 2016", "FEB 3, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 3, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 1, 2016", "FEB 1, 2016", "FEB 1, 2016", "FEB 1, 2016", "FEB 2, 2016", "FEB 1, 2016", "FEB 1, 2016", "FEB 1, 2016", "JAN 31, 2016", "JAN 31, 2016", "JAN 30, 2016", "JAN 29, 2016", "FEB 1, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 28, 2016", "JAN 28, 2016", "JAN 28, 2016", "JAN 28, 2016", "JAN 28, 2016", "JAN 28, 2016", "JAN 28, 2016", "JAN 29, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 28, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 27, 2016", "JAN 26, 2016", "JAN 26, 2016", "JAN 26, 2016", "JAN 26, 2016", "JAN 25, 2016", "JAN 25, 2016", "JAN 25, 2016", "JAN 25, 2016", "JAN 25, 2016", "JAN 25, 2016", "JAN 25, 2016", "JAN 26, 2016", "JAN 25, 2016", "JAN 25, 2016", "JAN 25, 2016", "JAN 25, 2016", "JAN 25, 2016", "JAN 23, 2016", "JAN 22, 2016", "JAN 25, 2016", "JAN 21, 2016", "JAN 21, 2016", "JAN 20, 2016", "JAN 20, 2016", "JAN 20, 2016", "JAN 20, 2016", "JAN 19, 2016", "JAN 22, 2016", "JAN 21, 2016", "JAN 21, 2016", "JAN 20, 2016", "JAN 18, 2016", "JAN 18, 2016", "JAN 18, 2016", "JAN 19, 2016", "JAN 15, 2016", "JAN 15, 2016", "JAN 15, 2016", "JAN 14, 2016", "JAN 14, 2016", "JAN 14, 2016", "JAN 13, 2016", "JAN 16, 2016", "JAN 12, 2016", "JAN 12, 2016", "JAN 12, 2016", "JAN 12, 2016", "JAN 12, 2016", "JAN 12, 2016", "JAN 11, 2016", "JAN 13, 2016", "JAN 12, 2016", "JAN 11, 2016", "JAN 10, 2016", "JAN 9, 2016", "JAN 9, 2016", "JAN 8, 2016", "JAN 11, 2016", "JAN 7, 2016", "JAN 6, 2016", "JAN 6, 2016", "JAN 6, 2016", "JAN 5, 2016", "JAN 5, 2016", "JAN 5, 2016", "JAN 8, 2016", "JAN 4, 2016", "JAN 3, 2016", "JAN 2, 2016", "JAN 1, 2016", "DEC 31, 2015", "DEC 30, 2015", "DEC 29, 2015", "JAN 4, 2016", "DEC 29, 2015", "DEC 28, 2015", "DEC 28, 2015", "DEC 28, 2015", "DEC 26, 2015", "DEC 24, 2015", "DEC 24, 2015", "DEC 29, 2015", "DEC 23, 2015", "DEC 23, 2015", "DEC 23, 2015", "DEC 22, 2015", "DEC 22, 2015", "DEC 21, 2015", "DEC 20, 2015", "DEC 24, 2015", "DEC 18, 2015", "DEC 18, 2015", "DEC 17, 2015", "DEC 17, 2015", "DEC 16, 2015", "DEC 16, 2015", "DEC 15, 2015", "DEC 18, 2015", "DEC 18, 2015", "DEC 18, 2015", "DEC 17, 2015", "DEC 12, 2015", "DEC 11, 2015", "DEC 11, 2015", "DEC 10, 2015", "DEC 15, 2015", "DEC 7, 2015", "DEC 7, 2015", "DEC 7, 2015", "DEC 3, 2015", "DEC 3, 2015", "DEC 3, 2015", "DEC 3, 2015", "DEC 10, 2015", "DEC 7, 2015", "DEC 7, 2015", "DEC 7, 2015", "DEC 2, 2015", "DEC 1, 2015", "DEC 1, 2015", "DEC 1, 2015", "DEC 2, 2015", "NOV 30, 2015", "NOV 28, 2015", "NOV 28, 2015", "NOV 27, 2015", "NOV 27, 2015", "NOV 27, 2015", "NOV 26, 2015", "NOV 30, 2015", "NOV 30, 2015", "NOV 24, 2015", "NOV 24, 2015", "NOV 24, 2015", "NOV 24, 2015", "NOV 23, 2015", "NOV 23, 2015", "NOV 25, 2015", "NOV 25, 2015", "NOV 24, 2015", "NOV 24, 2015", "NOV 24, 2015", "NOV 18, 2015", "NOV 18, 2015", "NOV 23, 2015", "NOV 17, 2015", "NOV 17, 2015", "NOV 17, 2015", "NOV 16, 2015", "NOV 16, 2015", "NOV 15, 2015", "NOV 13, 2015", "NOV 18, 2015", "NOV 13, 2015", "NOV 13, 2015", "NOV 11, 2015", "NOV 11, 2015", "NOV 11, 2015", "NOV 11, 2015", "NOV 10, 2015", "NOV 13, 2015", "NOV 9, 2015", "NOV 9, 2015", "NOV 9, 2015", "NOV 9, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 6, 2015", "NOV 10, 2015", "NOV 9, 2015", "NOV 5, 2015", "NOV 5, 2015", "NOV 4, 2015", "NOV 3, 2015", "NOV 3, 2015", "NOV 3, 2015", "NOV 6, 2015", "NOV 2, 2015", "NOV 2, 2015", "NOV 2, 2015", "NOV 2, 2015", "NOV 2, 2015", "OCT 31, 2015", "OCT 30, 2015", "NOV 3, 2015", "OCT 29, 2015", "OCT 28, 2015", "OCT 28, 2015", "OCT 28, 2015", "OCT 28, 2015", "OCT 28, 2015", "OCT 27, 2015", "OCT 29, 2015", "OCT 27, 2015", "OCT 27, 2015", "OCT 27, 2015", "OCT 27, 2015", "OCT 27, 2015", "OCT 24, 2015", "OCT 23, 2015", "OCT 27, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 22, 2015", "OCT 22, 2015", "OCT 22, 2015", "OCT 21, 2015", "OCT 21, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 23, 2015", "OCT 18, 2015", "OCT 18, 2015", "OCT 16, 2015", "OCT 15, 2015", "OCT 20, 2015", "OCT 20, 2015", "OCT 20, 2015", "OCT 19, 2015", "OCT 18, 2015", "OCT 18, 2015", "OCT 16, 2015", "OCT 9, 2015", "OCT 14, 2015", "OCT 9, 2015", "OCT 8, 2015", "OCT 8, 2015", "OCT 8, 2015", "OCT 7, 2015", "OCT 7, 2015", "OCT 7, 2015", "OCT 9, 2015", "OCT 6, 2015", "OCT 6, 2015", "OCT 6, 2015", "OCT 6, 2015", "OCT 5, 2015", "OCT 5, 2015", "OCT 5, 2015", "OCT 7, 2015", "OCT 5, 2015", "OCT 5, 2015", "OCT 4, 2015", "OCT 1, 2015", "OCT 1, 2015", "OCT 1, 2015", "OCT 1, 2015", "OCT 5, 2015", "SEP 30, 2015", "SEP 29, 2015", "SEP 29, 2015", "SEP 29, 2015", "SEP 28, 2015", "SEP 28, 2015", "SEP 28, 2015", "SEP 30, 2015", "SEP 25, 2015", "SEP 25, 2015", "SEP 25, 2015", "SEP 25, 2015", "SEP 25, 2015", "SEP 25, 2015", "SEP 24, 2015", "SEP 26, 2015", "SEP 24, 2015", "SEP 24, 2015", "SEP 24, 2015", "SEP 24, 2015", "SEP 23, 2015", "SEP 23, 2015", "SEP 23, 2015", "SEP 24, 2015", "SEP 23, 2015", "SEP 23, 2015", "SEP 23, 2015", "SEP 23, 2015", "SEP 23, 2015", "SEP 22, 2015", "SEP 22, 2015", "SEP 23, 2015", "SEP 23, 2015", "SEP 22, 2015", "SEP 22, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 22, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 19, 2015", "SEP 18, 2015", "SEP 18, 2015", "SEP 18, 2015", "SEP 18, 2015", "SEP 18, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 19, 2015", "SEP 17, 2015", "SEP 17, 2015", "SEP 17, 2015", "SEP 17, 2015", "SEP 17, 2015", "SEP 18, 2015", "SEP 17, 2015", "SEP 17, 2015", "SEP 17, 2015", "SEP 17, 2015", "SEP 17, 2015", "SEP 16, 2015", "SEP 15, 2015", "SEP 17, 2015", "SEP 15, 2015", "SEP 15, 2015", "SEP 15, 2015", "SEP 15, 2015", "SEP 15, 2015", "SEP 15, 2015", "SEP 14, 2015", "SEP 15, 2015", "SEP 14, 2015", "SEP 14, 2015", "SEP 14, 2015", "SEP 14, 2015", "SEP 14, 2015", "SEP 13, 2015", "SEP 13, 2015", "SEP 14, 2015", "SEP 14, 2015", "SEP 11, 2015", "SEP 11, 2015", "SEP 11, 2015", "SEP 11, 2015", "SEP 11, 2015", "SEP 10, 2015", "SEP 11, 2015", "SEP 10, 2015", "SEP 10, 2015", "SEP 10, 2015", "SEP 10, 2015", "SEP 10, 2015", "SEP 10, 2015", "SEP 10, 2015", "SEP 10, 2015", "SEP 10, 2015", "SEP 9, 2015", "SEP 9, 2015", "SEP 9, 2015", "SEP 9, 2015", "SEP 9, 2015", "SEP 9, 2015", "SEP 9, 2015", "SEP 8, 2015", "SEP 8, 2015", "SEP 8, 2015", "SEP 8, 2015", "SEP 8, 2015", "SEP 8, 2015", "SEP 7, 2015", "SEP 9, 2015", "SEP 7, 2015", "SEP 4, 2015", "SEP 4, 2015", "SEP 4, 2015", "SEP 4, 2015", "SEP 4, 2015", "SEP 4, 2015", "SEP 7, 2015", "SEP 3, 2015", "SEP 3, 2015", "SEP 3, 2015", "SEP 3, 2015", "SEP 3, 2015", "SEP 2, 2015", "SEP 2, 2015", "SEP 3, 2015", "SEP 2, 2015", "SEP 2, 2015", "SEP 2, 2015", "SEP 2, 2015", "SEP 1, 2015", "SEP 1, 2015", "SEP 1, 2015", "SEP 2, 2015", "SEP 1, 2015", "SEP 1, 2015", "SEP 1, 2015", "SEP 1, 2015", "SEP 1, 2015", "SEP 1, 2015", "AUG 31, 2015", "SEP 1, 2015", "AUG 31, 2015", "AUG 30, 2015", "AUG 28, 2015", "AUG 28, 2015", "AUG 28, 2015", "AUG 27, 2015", "AUG 26, 2015", "AUG 31, 2015", "AUG 26, 2015", "AUG 26, 2015", "AUG 26, 2015", "AUG 26, 2015", "AUG 26, 2015", "AUG 25, 2015", "AUG 25, 2015", "AUG 26, 2015", "AUG 25, 2015", "AUG 25, 2015", "AUG 25, 2015", "AUG 25, 2015", "AUG 25, 2015", "AUG 24, 2015", "AUG 24, 2015", "AUG 25, 2015", "AUG 24, 2015", "AUG 24, 2015", "AUG 24, 2015", "AUG 22, 2015", "AUG 21, 2015", "AUG 21, 2015", "AUG 21, 2015", "AUG 24, 2015", "AUG 21, 2015", "AUG 21, 2015", "AUG 21, 2015", "AUG 21, 2015", "AUG 21, 2015", "AUG 21, 2015", "AUG 20, 2015", "AUG 21, 2015", "AUG 21, 2015", "AUG 21, 2015", "AUG 21, 2015", "AUG 20, 2015", "AUG 20, 2015", "AUG 19, 2015", "AUG 19, 2015", "AUG 20, 2015", "AUG 18, 2015", "AUG 18, 2015", "AUG 18, 2015", "AUG 18, 2015", "AUG 18, 2015", "AUG 18, 2015", "AUG 17, 2015", "AUG 19, 2015", "AUG 15, 2015", "AUG 14, 2015", "AUG 14, 2015", "AUG 14, 2015", "AUG 14, 2015", "AUG 14, 2015", "AUG 17, 2015", "AUG 14, 2015", "AUG 14, 2015", "AUG 14, 2015", "AUG 13, 2015", "AUG 13, 2015", "AUG 13, 2015", "AUG 13, 2015", "AUG 14, 2015", "AUG 13, 2015", "AUG 12, 2015", "AUG 12, 2015", "AUG 12, 2015", "AUG 12, 2015", "AUG 12, 2015", "AUG 12, 2015", "AUG 13, 2015", "AUG 12, 2015", "AUG 12, 2015", "AUG 11, 2015", "AUG 11, 2015", "AUG 11, 2015", "AUG 11, 2015", "AUG 11, 2015", "AUG 12, 2015", "AUG 10, 2015", "AUG 9, 2015", "AUG 8, 2015", "AUG 7, 2015", "AUG 7, 2015", "AUG 7, 2015", "AUG 7, 2015", "AUG 11, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 5, 2015", "AUG 6, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 3, 2015", "AUG 3, 2015", "AUG 3, 2015", "AUG 1, 2015", "JUL 30, 2015", "AUG 4, 2015", "JUL 30, 2015", "JUL 30, 2015", "JUL 30, 2015", "JUL 29, 2015", "JUL 29, 2015", "JUL 29, 2015", "JUL 29, 2015", "JUL 30, 2015", "JUL 30, 2015", "JUL 29, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 29, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 27, 2015", "JUL 27, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 22, 2015", "JUL 22, 2015", "JUL 27, 2015", "JUL 21, 2015", "JUL 17, 2015", "JUL 16, 2015", "JUL 16, 2015", "JUL 15, 2015", "JUL 14, 2015", "JUL 14, 2015", "JUL 21, 2015", "JUL 21, 2015", "JUL 17, 2015", "JUL 16, 2015", "JUL 16, 2015", "JUL 15, 2015", "JUL 8, 2015", "JUL 8, 2015", "JUL 14, 2015", "JUL 13, 2015", "JUL 13, 2015", "JUL 6, 2015", "JUL 6, 2015", "JUL 6, 2015", "JUL 5, 2015", "JUL 2, 2015", "JUL 7, 2015", "JUL 2, 2015", "JUL 1, 2015", "JUL 1, 2015", "JUN 30, 2015", "JUN 30, 2015", "JUN 30, 2015", "JUN 30, 2015", "JUL 2, 2015", "JUN 30, 2015", "JUN 30, 2015", "JUN 30, 2015", "JUN 29, 2015", "JUN 29, 2015", "JUN 29, 2015", "JUN 26, 2015", "JUN 30, 2015", "JUN 26, 2015", "JUN 25, 2015", "JUN 25, 2015", "JUN 25, 2015", "JUN 25, 2015", "JUN 24, 2015", "JUN 24, 2015", "JUN 26, 2015", "JUN 26, 2015", "JUN 23, 2015", "JUN 23, 2015", "JUN 23, 2015", "JUN 23, 2015", "JUN 23, 2015", "JUN 24, 2015", "JUN 23, 2015", "JUN 23, 2015", "JUN 22, 2015", "JUN 22, 2015", "JUN 22, 2015", "JUN 22, 2015", "JUN 21, 2015", "JUN 23, 2015", "JUN 19, 2015", "JUN 19, 2015", "JUN 19, 2015", "JUN 19, 2015", "JUN 18, 2015", "JUN 18, 2015", "JUN 18, 2015", "JUN 20, 2015", "JUN 18, 2015", "JUN 18, 2015", "JUN 18, 2015", "JUN 18, 2015", "JUN 17, 2015", "JUN 17, 2015", "JUN 17, 2015", "JUN 18, 2015", "JUN 17, 2015", "JUN 17, 2015", "JUN 16, 2015", "JUN 16, 2015", "JUN 16, 2015", "JUN 16, 2015", "JUN 16, 2015", "JUN 17, 2015", "JUN 16, 2015", "JUN 15, 2015", "JUN 15, 2015", "JUN 15, 2015", "JUN 15, 2015", "JUN 15, 2015", "JUN 15, 2015", "JUN 16, 2015", "JUN 15, 2015", "JUN 14, 2015", "JUN 12, 2015", "JUN 12, 2015", "JUN 12, 2015", "JUN 11, 2015", "JUN 11, 2015", "JUN 15, 2015", "JUN 11, 2015", "JUN 11, 2015", "JUN 11, 2015", "JUN 11, 2015", "JUN 10, 2015", "JUN 10, 2015", "JUN 10, 2015", "JUN 11, 2015", "JUN 10, 2015", "JUN 9, 2015", "JUN 9, 2015", "JUN 9, 2015", "JUN 9, 2015", "JUN 9, 2015", "JUN 9, 2015", "JUN 10, 2015", "JUN 9, 2015", "JUN 9, 2015", "JUN 9, 2015", "JUN 8, 2015", "JUN 8, 2015", "JUN 8, 2015", "JUN 8, 2015", "JUN 9, 2015", "JUN 8, 2015", "JUN 8, 2015", "JUN 7, 2015", "JUN 7, 2015", "JUN 6, 2015", "JUN 6, 2015", "JUN 5, 2015", "JUN 8, 2015", "JUN 5, 2015", "JUN 4, 2015", "JUN 4, 2015", "JUN 4, 2015", "JUN 4, 2015", "JUN 3, 2015", "JUN 3, 2015", "JUN 5, 2015", "JUN 3, 2015", "JUN 2, 2015", "JUN 2, 2015", "JUN 2, 2015", "JUN 2, 2015", "JUN 2, 2015", "JUN 2, 2015", "JUN 3, 2015", "JUN 1, 2015", "JUN 1, 2015", "JUN 1, 2015", "JUN 1, 2015", "JUN 1, 2015", "JUN 1, 2015", "JUN 1, 2015", "JUN 2, 2015", "MAY 31, 2015", "MAY 31, 2015", "MAY 30, 2015", "MAY 30, 2015", "MAY 30, 2015", "MAY 30, 2015", "MAY 29, 2015", "MAY 31, 2015", "MAY 29, 2015", "MAY 29, 2015", "MAY 28, 2015", "MAY 28, 2015", "MAY 28, 2015", "MAY 28, 2015", "MAY 28, 2015", "MAY 29, 2015", "MAY 29, 2015", "MAY 28, 2015", "MAY 27, 2015", "MAY 27, 2015", "MAY 27, 2015", "MAY 27, 2015", "MAY 27, 2015", "MAY 28, 2015", "MAY 28, 2015", "MAY 28, 2015", "MAY 27, 2015", "MAY 26, 2015", "MAY 26, 2015", "MAY 25, 2015", "MAY 25, 2015", "MAY 27, 2015", "MAY 27, 2015", "MAY 26, 2015", "MAY 23, 2015", "MAY 22, 2015", "MAY 22, 2015", "MAY 22, 2015", "MAY 21, 2015", "MAY 25, 2015", "MAY 25, 2015", "MAY 24, 2015", "MAY 21, 2015", "MAY 20, 2015", "MAY 20, 2015", "MAY 20, 2015", "MAY 20, 2015", "MAY 21, 2015", "MAY 20, 2015", "MAY 20, 2015", "MAY 20, 2015", "MAY 20, 2015", "MAY 19, 2015", "MAY 19, 2015", "MAY 19, 2015", "MAY 20, 2015", "MAY 20, 2015", "MAY 20, 2015", "MAY 19, 2015", "MAY 19, 2015", "MAY 19, 2015", "MAY 19, 2015", "MAY 19, 2015", "MAY 19, 2015", "MAY 18, 2015", "MAY 18, 2015", "MAY 18, 2015", "MAY 18, 2015", "MAY 18, 2015", "MAY 18, 2015", "MAY 18, 2015", "MAY 18, 2015", "MAY 17, 2015", "MAY 16, 2015", "MAY 16, 2015", "MAY 15, 2015", "MAY 15, 2015", "MAY 15, 2015", "MAY 15, 2015", "MAY 17, 2015", "MAY 15, 2015", "MAY 15, 2015", "MAY 14, 2015", "MAY 14, 2015", "MAY 14, 2015", "MAY 14, 2015", "MAY 13, 2015", "MAY 15, 2015", "MAY 13, 2015", "MAY 13, 2015", "MAY 13, 2015", "MAY 13, 2015", "MAY 13, 2015", "MAY 13, 2015", "MAY 13, 2015", "MAY 13, 2015", "MAY 13, 2015", "MAY 12, 2015", "MAY 12, 2015", "MAY 12, 2015", "MAY 12, 2015", "MAY 12, 2015", "MAY 13, 2015", "MAY 12, 2015", "MAY 11, 2015", "MAY 11, 2015", "MAY 11, 2015", "MAY 11, 2015", "MAY 11, 2015", "MAY 11, 2015", "MAY 12, 2015", "MAY 11, 2015", "MAY 11, 2015", "MAY 11, 2015", "MAY 11, 2015", "MAY 9, 2015", "MAY 9, 2015", "MAY 8, 2015", "MAY 11, 2015", "MAY 11, 2015", "MAY 11, 2015", "MAY 8, 2015", "MAY 8, 2015", "MAY 8, 2015", "MAY 8, 2015", "MAY 8, 2015", "MAY 7, 2015", "MAY 7, 2015", "MAY 7, 2015", "MAY 7, 2015", "MAY 7, 2015", "MAY 7, 2015", "MAY 7, 2015", "MAY 7, 2015", "MAY 5, 2015", "MAY 5, 2015", "MAY 5, 2015", "MAY 5, 2015", "MAY 4, 2015", "MAY 4, 2015", "MAY 4, 2015", "MAY 7, 2015", "MAY 1, 2015", "MAY 1, 2015", "MAY 1, 2015", "MAY 1, 2015", "MAY 1, 2015", "APR 30, 2015", "APR 30, 2015", "MAY 2, 2015", "APR 30, 2015", "APR 30, 2015", "APR 30, 2015", "APR 30, 2015", "APR 29, 2015", "APR 28, 2015", "APR 28, 2015", "APR 30, 2015", "APR 30, 2015", "APR 28, 2015", "APR 27, 2015", "APR 27, 2015", "APR 27, 2015", "APR 26, 2015", "APR 26, 2015", "APR 28, 2015", "APR 24, 2015", "APR 24, 2015", "APR 23, 2015", "APR 23, 2015", "APR 22, 2015", "APR 22, 2015", "APR 22, 2015", "APR 24, 2015", "APR 19, 2015", "APR 19, 2015", "APR 18, 2015", "APR 18, 2015", "APR 17, 2015", "APR 16, 2015", "APR 16, 2015", "APR 21, 2015", "APR 15, 2015", "APR 14, 2015", "APR 14, 2015", "APR 13, 2015", "APR 13, 2015", "APR 11, 2015", "APR 9, 2015", "APR 16, 2015", "APR 9, 2015", "APR 8, 2015", "APR 8, 2015", "APR 6, 2015", "APR 6, 2015", "APR 6, 2015", "APR 6, 2015", "APR 9, 2015", "APR 9, 2015", "APR 5, 2015", "APR 4, 2015", "APR 4, 2015", "APR 2, 2015", "APR 2, 2015", "APR 1, 2015", "APR 5, 2015", "APR 1, 2015", "MAR 31, 2015", "MAR 31, 2015", "MAR 31, 2015", "MAR 30, 2015", "MAR 30, 2015", "MAR 29, 2015", "APR 1, 2015", "MAR 29, 2015", "MAR 28, 2015", "MAR 28, 2015", "MAR 27, 2015", "MAR 27, 2015", "MAR 26, 2015", "MAR 26, 2015", "MAR 29, 2015", "MAR 29, 2015", "MAR 28, 2015", "MAR 24, 2015", "MAR 23, 2015", "MAR 23, 2015", "MAR 23, 2015", "MAR 23, 2015", "MAR 26, 2015", "MAR 25, 2015", "MAR 21, 2015", "MAR 21, 2015", "MAR 18, 2015", "MAR 18, 2015", "MAR 17, 2015", "MAR 17, 2015", "MAR 22, 2015", "MAR 16, 2015", "MAR 15, 2015", "MAR 15, 2015", "MAR 13, 2015", "MAR 11, 2015", "MAR 11, 2015", "MAR 10, 2015", "MAR 17, 2015", "MAR 6, 2015", "MAR 5, 2015", "MAR 5, 2015", "MAR 4, 2015", "MAR 3, 2015", "MAR 2, 2015", "MAR 2, 2015", "MAR 9, 2015", "MAR 1, 2015", "MAR 1, 2015", "FEB 28, 2015", "FEB 27, 2015", "FEB 26, 2015", "FEB 25, 2015", "FEB 25, 2015", "MAR 1, 2015", "MAR 1, 2015", "FEB 23, 2015", "FEB 23, 2015", "FEB 22, 2015", "FEB 22, 2015", "FEB 22, 2015", "FEB 20, 2015", "FEB 24, 2015", "FEB 19, 2015", "FEB 19, 2015", "FEB 18, 2015", "FEB 17, 2015", "FEB 17, 2015", "FEB 17, 2015", "FEB 16, 2015", "FEB 20, 2015", "FEB 15, 2015", "FEB 15, 2015", "FEB 14, 2015", "FEB 14, 2015", "FEB 14, 2015", "FEB 13, 2015", "FEB 13, 2015", "FEB 15, 2015", "FEB 15, 2015", "FEB 15, 2015", "FEB 11, 2015", "FEB 11, 2015", "FEB 10, 2015", "FEB 9, 2015", "FEB 12, 2015", "FEB 9, 2015", "FEB 9, 2015", "FEB 9, 2015", "FEB 7, 2015", "FEB 7, 2015", "FEB 7, 2015", "FEB 6, 2015", "FEB 9, 2015", "FEB 6, 2015", "FEB 4, 2015", "FEB 4, 2015", "FEB 4, 2015", "FEB 4, 2015", "FEB 4, 2015", "FEB 4, 2015", "FEB 6, 2015", "FEB 4, 2015", "FEB 4, 2015", "FEB 4, 2015", "FEB 4, 2015", "FEB 3, 2015", "FEB 3, 2015", "FEB 3, 2015", "FEB 4, 2015", "FEB 3, 2015", "FEB 3, 2015", "FEB 3, 2015", "FEB 3, 2015", "FEB 2, 2015", "FEB 2, 2015", "FEB 2, 2015", "FEB 3, 2015", "FEB 1, 2015", "JAN 31, 2015", "JAN 31, 2015", "JAN 30, 2015", "JAN 28, 2015", "JAN 28, 2015", "JAN 27, 2015", "FEB 2, 2015", "JAN 24, 2015", "JAN 23, 2015", "JAN 21, 2015", "JAN 21, 2015", "JAN 21, 2015", "JAN 20, 2015", "JAN 20, 2015", "JAN 27, 2015", "JAN 19, 2015", "JAN 18, 2015", "JAN 16, 2015", "JAN 16, 2015", "JAN 15, 2015", "JAN 14, 2015", "JAN 14, 2015", "JAN 19, 2015", "JAN 13, 2015", "JAN 13, 2015", "JAN 13, 2015", "JAN 12, 2015", "JAN 12, 2015", "JAN 12, 2015", "JAN 11, 2015", "JAN 14, 2015", "JAN 11, 2015", "JAN 11, 2015", "JAN 10, 2015", "JAN 10, 2015", "JAN 9, 2015", "JAN 8, 2015", "JAN 8, 2015", "JAN 11, 2015", "JAN 7, 2015", "JAN 7, 2015", "JAN 7, 2015", "JAN 7, 2015", "JAN 7, 2015", "JAN 5, 2015", "JAN 5, 2015", "JAN 7, 2015", "JAN 7, 2015", "JAN 3, 2015", "JAN 2, 2015", "DEC 31, 2014", "DEC 31, 2014", "DEC 30, 2014", "DEC 30, 2014", "JAN 4, 2015", "DEC 30, 2014", "DEC 30, 2014", "DEC 29, 2014", "DEC 29, 2014", "DEC 29, 2014", "DEC 29, 2014", "DEC 29, 2014", "DEC 30, 2014", "DEC 29, 2014", "DEC 28, 2014", "DEC 28, 2014", "DEC 27, 2014", "DEC 26, 2014", "DEC 26, 2014", "DEC 26, 2014", "DEC 29, 2014", "DEC 29, 2014", "DEC 24, 2014", "DEC 24, 2014", "DEC 24, 2014", "DEC 24, 2014", "DEC 24, 2014", "DEC 24, 2014", "DEC 26, 2014", "DEC 26, 2014", "DEC 23, 2014", "DEC 23, 2014", "DEC 23, 2014", "DEC 23, 2014", "DEC 23, 2014", "DEC 23, 2014", "DEC 23, 2014", "DEC 23, 2014", "DEC 23, 2014", "DEC 23, 2014", "DEC 23, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 23, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 22, 2014", "DEC 21, 2014", "DEC 21, 2014", "DEC 19, 2014", "DEC 19, 2014", "DEC 17, 2014", "DEC 17, 2014", "DEC 22, 2014", "DEC 16, 2014", "DEC 15, 2014", "DEC 15, 2014", "DEC 13, 2014", "DEC 13, 2014", "DEC 11, 2014", "DEC 10, 2014", "DEC 16, 2014", "DEC 16, 2014", "DEC 15, 2014", "DEC 15, 2014", "DEC 13, 2014", "DEC 7, 2014", "DEC 6, 2014", "DEC 6, 2014", "DEC 10, 2014", "DEC 4, 2014", "DEC 4, 2014", "DEC 4, 2014", "DEC 4, 2014", "DEC 4, 2014", "DEC 2, 2014", "DEC 2, 2014", "DEC 5, 2014", "DEC 2, 2014", "DEC 1, 2014", "DEC 1, 2014", "NOV 29, 2014", "NOV 29, 2014", "NOV 27, 2014", "NOV 26, 2014", "DEC 2, 2014", "NOV 25, 2014", "NOV 25, 2014", "NOV 25, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 25, 2014", "NOV 25, 2014", "NOV 25, 2014", "NOV 20, 2014", "NOV 20, 2014", "NOV 19, 2014", "NOV 19, 2014", "NOV 19, 2014", "NOV 23, 2014", "NOV 22, 2014", "NOV 20, 2014", "NOV 20, 2014", "NOV 14, 2014", "NOV 14, 2014", "NOV 14, 2014", "NOV 13, 2014", "NOV 17, 2014", "NOV 17, 2014", "NOV 17, 2014", "NOV 12, 2014", "NOV 11, 2014", "NOV 11, 2014", "NOV 11, 2014", "NOV 11, 2014", "NOV 13, 2014", "NOV 12, 2014", "NOV 12, 2014", "NOV 12, 2014", "NOV 10, 2014", "NOV 10, 2014", "NOV 9, 2014", "NOV 8, 2014", "NOV 11, 2014", "NOV 7, 2014", "NOV 7, 2014", "NOV 7, 2014", "NOV 6, 2014", "NOV 6, 2014", "NOV 6, 2014", "NOV 5, 2014", "NOV 7, 2014", "NOV 3, 2014", "NOV 3, 2014", "NOV 3, 2014", "NOV 3, 2014", "NOV 1, 2014", "OCT 30, 2014", "OCT 30, 2014", "NOV 5, 2014", "OCT 29, 2014", "OCT 29, 2014", "OCT 28, 2014", "OCT 28, 2014", "OCT 28, 2014", "OCT 28, 2014", "OCT 28, 2014", "OCT 30, 2014", "OCT 27, 2014", "OCT 27, 2014", "OCT 27, 2014", "OCT 27, 2014", "OCT 27, 2014", "OCT 27, 2014", "OCT 26, 2014", "OCT 28, 2014", "OCT 24, 2014", "OCT 24, 2014", "OCT 24, 2014", "OCT 24, 2014", "OCT 22, 2014", "OCT 22, 2014", "OCT 22, 2014", "OCT 24, 2014", "OCT 21, 2014", "OCT 20, 2014", "OCT 20, 2014", "OCT 19, 2014", "OCT 19, 2014", "OCT 18, 2014", "OCT 17, 2014", "OCT 21, 2014", "OCT 21, 2014", "OCT 20, 2014", "OCT 15, 2014", "OCT 15, 2014", "OCT 15, 2014", "OCT 14, 2014", "OCT 17, 2014", "OCT 14, 2014", "OCT 13, 2014", "OCT 13, 2014", "OCT 10, 2014", "OCT 9, 2014", "OCT 9, 2014", "OCT 9, 2014", "OCT 14, 2014", "OCT 9, 2014", "OCT 8, 2014", "OCT 8, 2014", "OCT 8, 2014", "OCT 8, 2014", "OCT 8, 2014", "OCT 7, 2014", "OCT 9, 2014", "OCT 6, 2014", "OCT 5, 2014", "OCT 4, 2014", "OCT 4, 2014", "OCT 4, 2014", "OCT 3, 2014", "OCT 3, 2014", "OCT 6, 2014", "OCT 2, 2014", "OCT 2, 2014", "OCT 2, 2014", "OCT 1, 2014", "OCT 1, 2014", "OCT 1, 2014", "OCT 1, 2014", "OCT 2, 2014", "SEP 30, 2014", "SEP 30, 2014", "SEP 30, 2014", "SEP 30, 2014", "SEP 30, 2014", "SEP 30, 2014", "SEP 30, 2014", "OCT 1, 2014", "SEP 29, 2014", "SEP 29, 2014", "SEP 29, 2014", "SEP 29, 2014", "SEP 29, 2014", "SEP 29, 2014", "SEP 27, 2014", "SEP 29, 2014", "SEP 26, 2014", "SEP 26, 2014", "SEP 26, 2014", "SEP 26, 2014", "SEP 26, 2014", "SEP 26, 2014", "SEP 26, 2014", "SEP 26, 2014", "SEP 25, 2014", "SEP 25, 2014", "SEP 25, 2014", "SEP 25, 2014", "SEP 25, 2014", "SEP 25, 2014", "SEP 25, 2014", "SEP 26, 2014", "SEP 25, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 24, 2014", "SEP 23, 2014", "SEP 24, 2014", "SEP 23, 2014", "SEP 23, 2014", "SEP 23, 2014", "SEP 23, 2014", "SEP 22, 2014", "SEP 22, 2014", "SEP 22, 2014", "SEP 23, 2014", "SEP 22, 2014", "SEP 22, 2014", "SEP 22, 2014", "SEP 22, 2014", "SEP 19, 2014", "SEP 19, 2014", "SEP 19, 2014", "SEP 22, 2014", "SEP 19, 2014", "SEP 19, 2014", "SEP 19, 2014", "SEP 19, 2014", "SEP 19, 2014", "SEP 19, 2014", "SEP 19, 2014", "SEP 18, 2014", "SEP 18, 2014", "SEP 18, 2014", "SEP 18, 2014", "SEP 18, 2014", "SEP 18, 2014", "SEP 18, 2014", "SEP 18, 2014", "SEP 18, 2014", "SEP 18, 2014", "SEP 17, 2014", "SEP 17, 2014", "SEP 17, 2014", "SEP 17, 2014", "SEP 17, 2014", "SEP 18, 2014", "SEP 17, 2014", "SEP 17, 2014", "SEP 16, 2014", "SEP 16, 2014", "SEP 16, 2014", "SEP 16, 2014", "SEP 17, 2014", "SEP 17, 2014", "SEP 15, 2014", "SEP 15, 2014", "SEP 15, 2014", "SEP 15, 2014", "SEP 15, 2014", "SEP 15, 2014", "SEP 15, 2014", "SEP 15, 2014", "SEP 15, 2014", "SEP 12, 2014", "SEP 12, 2014", "SEP 12, 2014", "SEP 12, 2014", "SEP 15, 2014", "SEP 11, 2014", "SEP 11, 2014", "SEP 11, 2014", "SEP 11, 2014", "SEP 11, 2014", "SEP 10, 2014", "SEP 10, 2014", "SEP 11, 2014", "SEP 10, 2014", "SEP 10, 2014", "SEP 10, 2014", "SEP 10, 2014", "SEP 10, 2014", "SEP 10, 2014", "SEP 10, 2014", "SEP 10, 2014", "SEP 9, 2014", "SEP 9, 2014", "SEP 9, 2014", "SEP 8, 2014", "SEP 8, 2014", "SEP 8, 2014", "SEP 8, 2014", "SEP 9, 2014", "SEP 8, 2014", "SEP 8, 2014", "SEP 8, 2014", "SEP 8, 2014", "SEP 8, 2014", "SEP 8, 2014", "SEP 7, 2014", "SEP 8, 2014", "SEP 8, 2014", "SEP 5, 2014", "SEP 5, 2014", "SEP 5, 2014", "SEP 5, 2014", "SEP 5, 2014", "SEP 4, 2014", "SEP 5, 2014", "SEP 5, 2014", "SEP 4, 2014", "SEP 4, 2014", "SEP 3, 2014", "SEP 3, 2014", "SEP 3, 2014", "SEP 4, 2014", "SEP 3, 2014", "SEP 3, 2014", "SEP 3, 2014", "SEP 3, 2014", "SEP 3, 2014", "SEP 3, 2014", "SEP 3, 2014", "SEP 3, 2014", "SEP 2, 2014", "SEP 2, 2014", "SEP 2, 2014", "SEP 2, 2014", "SEP 2, 2014", "SEP 2, 2014", "SEP 2, 2014", "SEP 2, 2014", "SEP 2, 2014", "AUG 30, 2014", "AUG 29, 2014", "AUG 29, 2014", "AUG 29, 2014", "AUG 29, 2014", "AUG 29, 2014", "SEP 2, 2014", "AUG 29, 2014", "AUG 29, 2014", "AUG 28, 2014", "AUG 28, 2014", "AUG 28, 2014", "AUG 28, 2014", "AUG 29, 2014", "AUG 29, 2014", "AUG 28, 2014", "AUG 28, 2014", "AUG 28, 2014", "AUG 28, 2014", "AUG 28, 2014", "AUG 28, 2014", "AUG 28, 2014", "AUG 27, 2014", "AUG 27, 2014", "AUG 27, 2014", "AUG 27, 2014", "AUG 27, 2014", "AUG 27, 2014", "AUG 26, 2014", "AUG 28, 2014", "AUG 26, 2014", "AUG 26, 2014", "AUG 26, 2014", "AUG 26, 2014", "AUG 26, 2014", "AUG 26, 2014", "AUG 26, 2014", "AUG 26, 2014", "AUG 25, 2014", "AUG 25, 2014", "AUG 25, 2014", "AUG 25, 2014", "AUG 25, 2014", "AUG 25, 2014", "AUG 26, 2014", "AUG 26, 2014", "AUG 25, 2014", "AUG 25, 2014", "AUG 25, 2014", "AUG 25, 2014", "AUG 25, 2014", "AUG 21, 2014", "AUG 22, 2014", "AUG 22, 2014", "AUG 21, 2014", "AUG 21, 2014", "AUG 21, 2014", "AUG 21, 2014", "AUG 20, 2014", "AUG 20, 2014", "AUG 21, 2014", "AUG 20, 2014", "AUG 20, 2014", "AUG 20, 2014", "AUG 20, 2014", "AUG 19, 2014", "AUG 19, 2014", "AUG 19, 2014", "AUG 20, 2014", "AUG 19, 2014", "AUG 19, 2014", "AUG 19, 2014", "AUG 18, 2014", "AUG 18, 2014", "AUG 18, 2014", "AUG 18, 2014", "AUG 19, 2014", "AUG 15, 2014", "AUG 15, 2014", "AUG 15, 2014", "AUG 15, 2014", "AUG 15, 2014", "AUG 15, 2014", "AUG 14, 2014", "AUG 18, 2014", "AUG 14, 2014", "AUG 14, 2014", "AUG 14, 2014", "AUG 14, 2014", "AUG 13, 2014", "AUG 13, 2014", "AUG 13, 2014", "AUG 14, 2014", "AUG 13, 2014", "AUG 13, 2014", "AUG 12, 2014", "AUG 12, 2014", "AUG 12, 2014", "AUG 12, 2014", "AUG 12, 2014", "AUG 13, 2014", "AUG 12, 2014", "AUG 12, 2014", "AUG 12, 2014", "AUG 12, 2014", "AUG 11, 2014", "AUG 11, 2014", "AUG 11, 2014", "AUG 12, 2014", "AUG 11, 2014", "AUG 11, 2014", "AUG 11, 2014", "AUG 8, 2014", "AUG 7, 2014", "AUG 6, 2014", "AUG 11, 2014", "AUG 4, 2014", "JUL 31, 2014", "JUL 31, 2014", "JUL 30, 2014", "JUL 30, 2014", "JUL 28, 2014", "JUL 28, 2014", "AUG 6, 2014", "AUG 4, 2014", "JUL 31, 2014", "JUL 31, 2014", "JUL 30, 2014", "JUL 30, 2014", "JUL 23, 2014", "JUL 28, 2014", "JUL 22, 2014", "JUL 21, 2014", "JUL 18, 2014", "JUL 16, 2014", "JUL 14, 2014", "JUL 11, 2014", "JUL 11, 2014", "JUL 23, 2014", "JUL 8, 2014", "JUL 8, 2014", "JUL 3, 2014", "JUL 2, 2014", "JUL 2, 2014", "JUN 30, 2014", "JUN 30, 2014", "JUL 10, 2014", "JUN 23, 2014", "JUN 23, 2014", "JUN 23, 2014", "JUN 23, 2014", "JUN 23, 2014", "JUN 23, 2014", "JUN 20, 2014", "JUN 25, 2014", "JUN 20, 2014", "JUN 20, 2014", "JUN 20, 2014", "JUN 20, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 20, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 18, 2014", "JUN 18, 2014", "JUN 18, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 19, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 16, 2014", "JUN 16, 2014", "JUN 16, 2014", "JUN 16, 2014", "JUN 16, 2014", "JUN 16, 2014", "JUN 16, 2014", "JUN 17, 2014", "JUN 16, 2014", "JUN 16, 2014", "JUN 16, 2014", "JUN 16, 2014", "JUN 16, 2014", "JUN 13, 2014", "JUN 13, 2014", "JUN 16, 2014", "JUN 16, 2014", "JUN 13, 2014", "JUN 13, 2014", "JUN 13, 2014", "JUN 13, 2014", "JUN 13, 2014", "JUN 13, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 13, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 11, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 11, 2014", "JUN 11, 2014", "JUN 11, 2014", "JUN 11, 2014", "JUN 11, 2014", "JUN 11, 2014", "JUN 11, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 9, 2014", "JUN 10, 2014", "JUN 9, 2014", "JUN 9, 2014", "JUN 9, 2014", "JUN 9, 2014", "JUN 9, 2014", "JUN 9, 2014", "JUN 9, 2014", "JUN 9, 2014", "JUN 6, 2014", "JUN 6, 2014", "JUN 6, 2014", "JUN 6, 2014", "JUN 6, 2014", "JUN 6, 2014", "JUN 6, 2014", "JUN 9, 2014", "JUN 5, 2014", "JUN 5, 2014", "JUN 5, 2014", "JUN 5, 2014", "JUN 5, 2014", "JUN 5, 2014", "JUN 4, 2014", "JUN 5, 2014", "JUN 5, 2014", "JUN 3, 2014", "JUN 3, 2014", "JUN 3, 2014", "JUN 3, 2014", "JUN 3, 2014", "JUN 2, 2014", "JUN 4, 2014", "JUN 2, 2014", "JUN 2, 2014", "JUN 2, 2014", "JUN 2, 2014", "JUN 2, 2014", "JUN 2, 2014", "JUN 2, 2014", "JUN 2, 2014", "MAY 30, 2014", "MAY 30, 2014", "MAY 29, 2014", "MAY 29, 2014", "MAY 29, 2014", "MAY 29, 2014", "MAY 29, 2014", "MAY 30, 2014", "MAY 29, 2014", "MAY 29, 2014", "MAY 28, 2014", "MAY 28, 2014", "MAY 28, 2014", "MAY 28, 2014", "MAY 28, 2014", "MAY 29, 2014", "MAY 27, 2014", "MAY 27, 2014", "MAY 27, 2014", "MAY 27, 2014", "MAY 27, 2014", "MAY 27, 2014", "MAY 27, 2014", "MAY 28, 2014", "MAY 23, 2014", "MAY 23, 2014", "MAY 23, 2014", "MAY 23, 2014", "MAY 23, 2014", "MAY 23, 2014", "MAY 23, 2014", "MAY 23, 2014", "MAY 22, 2014", "MAY 22, 2014", "MAY 22, 2014", "MAY 22, 2014", "MAY 21, 2014", "MAY 21, 2014", "MAY 21, 2014", "MAY 23, 2014", "MAY 22, 2014", "MAY 22, 2014", "MAY 22, 2014", "MAY 21, 2014", "MAY 21, 2014", "MAY 21, 2014", "MAY 21, 2014", "MAY 20, 2014", "MAY 20, 2014", "MAY 19, 2014", "MAY 19, 2014", "MAY 19, 2014", "MAY 19, 2014", "MAY 16, 2014", "MAY 20, 2014", "MAY 16, 2014", "MAY 16, 2014", "MAY 16, 2014", "MAY 15, 2014", "MAY 15, 2014", "MAY 15, 2014", "MAY 15, 2014", "MAY 16, 2014", "MAY 15, 2014", "MAY 15, 2014", "MAY 14, 2014", "MAY 14, 2014", "MAY 14, 2014", "MAY 14, 2014", "MAY 13, 2014", "MAY 15, 2014", "MAY 13, 2014", "MAY 13, 2014", "MAY 13, 2014", "MAY 13, 2014", "MAY 13, 2014", "MAY 13, 2014", "MAY 12, 2014", "MAY 13, 2014", "MAY 12, 2014", "MAY 12, 2014", "MAY 12, 2014", "MAY 12, 2014", "MAY 12, 2014", "MAY 12, 2014", "MAY 12, 2014", "MAY 9, 2014", "MAY 9, 2014", "MAY 9, 2014", "MAY 9, 2014", "MAY 9, 2014", "MAY 8, 2014", "MAY 8, 2014", "MAY 9, 2014", "MAY 9, 2014", "MAY 7, 2014", "MAY 7, 2014", "MAY 7, 2014", "MAY 7, 2014", "MAY 6, 2014", "MAY 8, 2014", "MAY 6, 2014", "MAY 6, 2014", "MAY 6, 2014", "MAY 6, 2014", "MAY 6, 2014", "MAY 5, 2014", "MAY 5, 2014", "MAY 6, 2014", "MAY 5, 2014", "MAY 5, 2014", "MAY 5, 2014", "MAY 5, 2014", "MAY 5, 2014", "MAY 5, 2014", "MAY 5, 2014", "MAY 5, 2014", "MAY 5, 2014", "MAY 2, 2014", "MAY 2, 2014", "MAY 2, 2014", "MAY 2, 2014", "MAY 2, 2014", "MAY 2, 2014", "MAY 5, 2014", "MAY 1, 2014", "MAY 1, 2014", "MAY 1, 2014", "MAY 1, 2014", "MAY 1, 2014", "MAY 1, 2014", "APR 30, 2014", "MAY 2, 2014", "MAY 1, 2014", "MAY 1, 2014", "APR 29, 2014", "APR 29, 2014", "APR 29, 2014", "APR 28, 2014", "APR 25, 2014", "APR 30, 2014", "APR 24, 2014", "APR 23, 2014", "APR 23, 2014", "APR 23, 2014", "APR 23, 2014", "APR 23, 2014", "APR 23, 2014", "APR 24, 2014", "APR 23, 2014", "APR 23, 2014", "APR 23, 2014", "APR 23, 2014", "APR 23, 2014", "APR 22, 2014", "APR 22, 2014", "APR 23, 2014", "APR 22, 2014", "APR 21, 2014", "APR 21, 2014", "APR 20, 2014", "APR 17, 2014", "APR 17, 2014", "APR 15, 2014", "APR 22, 2014", "APR 14, 2014", "APR 14, 2014", "APR 14, 2014", "APR 14, 2014", "APR 11, 2014", "APR 11, 2014", "APR 11, 2014", "APR 15, 2014", "APR 11, 2014", "APR 11, 2014", "APR 11, 2014", "APR 11, 2014", "APR 10, 2014", "APR 10, 2014", "APR 10, 2014", "APR 11, 2014", "APR 9, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 7, 2014", "APR 7, 2014", "APR 10, 2014", "APR 9, 2014", "APR 8, 2014", "APR 1, 2014", "APR 1, 2014", "APR 1, 2014", "MAR 31, 2014", "MAR 31, 2014", "APR 4, 2014", "MAR 31, 2014", "MAR 31, 2014", "MAR 31, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 31, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 27, 2014", "MAR 27, 2014", "MAR 26, 2014", "MAR 26, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 24, 2014", "MAR 24, 2014", "MAR 24, 2014", "MAR 24, 2014", "MAR 26, 2014", "MAR 25, 2014", "MAR 24, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 20, 2014", "MAR 21, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 20, 2014", "MAR 19, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 19, 2014", "MAR 17, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 17, 2014", "MAR 13, 2014", "MAR 13, 2014", "MAR 13, 2014", "MAR 13, 2014", "MAR 13, 2014", "MAR 12, 2014", "MAR 12, 2014", "MAR 14, 2014", "MAR 11, 2014", "MAR 11, 2014", "MAR 11, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 12, 2014", "MAR 7, 2014", "MAR 7, 2014", "MAR 6, 2014", "MAR 6, 2014", "MAR 6, 2014", "MAR 6, 2014", "MAR 6, 2014", "MAR 7, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 4, 2014", "MAR 4, 2014", "MAR 5, 2014", "MAR 4, 2014", "MAR 4, 2014", "MAR 4, 2014", "MAR 3, 2014", "MAR 3, 2014", "MAR 3, 2014", "MAR 3, 2014", "MAR 4, 2014", "FEB 28, 2014", "FEB 28, 2014", "FEB 28, 2014", "FEB 28, 2014", "FEB 28, 2014", "FEB 27, 2014", "FEB 25, 2014", "MAR 3, 2014", "FEB 28, 2014", "FEB 28, 2014", "FEB 28, 2014", "FEB 28, 2014", "FEB 12, 2014", "FEB 11, 2014", "FEB 11, 2014", "FEB 25, 2014", "FEB 24, 2014", "FEB 24, 2014", "FEB 21, 2014", "FEB 3, 2014", "FEB 3, 2014", "FEB 2, 2014", "FEB 10, 2014", "JAN 27, 2014", "JAN 22, 2014", "JAN 22, 2014", "JAN 20, 2014", "JAN 20, 2014", "JAN 20, 2014", "JAN 16, 2014", "JAN 29, 2014", "JAN 14, 2014", "JAN 10, 2014", "JAN 2, 2014", "DEC 31, 2013", "DEC 30, 2013", "DEC 30, 2013", "DEC 27, 2013", "JAN 14, 2014", "JAN 14, 2014", "DEC 19, 2013", "DEC 19, 2013", "DEC 18, 2013", "DEC 16, 2013", "DEC 16, 2013", "DEC 13, 2013", "DEC 24, 2013", "DEC 23, 2013", "DEC 19, 2013", "DEC 4, 2013", "DEC 4, 2013", "DEC 4, 2013", "DEC 3, 2013", "DEC 2, 2013", "DEC 11, 2013", "DEC 9, 2013", "DEC 9, 2013", "NOV 25, 2013", "NOV 25, 2013", "NOV 25, 2013", "NOV 25, 2013", "NOV 22, 2013", "DEC 2, 2013", "DEC 2, 2013", "NOV 29, 2013", "NOV 25, 2013", "NOV 25, 2013", "NOV 4, 2013", "OCT 30, 2013", "OCT 29, 2013", "NOV 20, 2013", "OCT 28, 2013", "OCT 28, 2013", "OCT 24, 2013", "OCT 24, 2013", "OCT 22, 2013", "OCT 22, 2013", "OCT 21, 2013", "OCT 28, 2013", "OCT 28, 2013", "OCT 10, 2013", "OCT 10, 2013", "OCT 7, 2013", "OCT 7, 2013", "OCT 7, 2013", "OCT 18, 2013", "SEP 30, 2013", "SEP 27, 2013", "SEP 27, 2013", "SEP 27, 2013", "SEP 24, 2013", "SEP 24, 2013", "SEP 24, 2013", "OCT 3, 2013", "SEP 24, 2013", "SEP 23, 2013", "SEP 23, 2013", "SEP 23, 2013", "SEP 23, 2013", "SEP 20, 2013", "SEP 20, 2013", "SEP 24, 2013", "SEP 20, 2013", "SEP 20, 2013", "SEP 20, 2013", "SEP 19, 2013", "SEP 19, 2013", "SEP 19, 2013", "SEP 19, 2013", "SEP 20, 2013", "SEP 19, 2013", "SEP 19, 2013", "SEP 18, 2013", "SEP 18, 2013", "SEP 18, 2013", "SEP 17, 2013", "SEP 17, 2013", "SEP 19, 2013", "SEP 16, 2013", "SEP 16, 2013", "SEP 13, 2013", "SEP 13, 2013", "SEP 13, 2013", "SEP 13, 2013", "SEP 13, 2013", "SEP 16, 2013", "SEP 13, 2013", "SEP 12, 2013", "SEP 12, 2013", "SEP 12, 2013", "SEP 12, 2013", "SEP 11, 2013", "SEP 11, 2013", "SEP 13, 2013", "SEP 11, 2013", "SEP 10, 2013", "SEP 10, 2013", "SEP 10, 2013", "SEP 10, 2013", "SEP 10, 2013", "SEP 10, 2013", "SEP 11, 2013", "SEP 9, 2013", "SEP 9, 2013", "SEP 9, 2013", "SEP 9, 2013", "SEP 9, 2013", "SEP 6, 2013", "SEP 6, 2013", "SEP 9, 2013", "SEP 5, 2013", "SEP 5, 2013", "SEP 5, 2013", "SEP 5, 2013", "SEP 5, 2013", "SEP 5, 2013", "SEP 5, 2013", "SEP 6, 2013", "SEP 4, 2013", "SEP 4, 2013", "SEP 4, 2013", "SEP 3, 2013", "SEP 3, 2013", "SEP 3, 2013", "SEP 3, 2013", "SEP 4, 2013", "AUG 30, 2013", "AUG 30, 2013", "AUG 30, 2013", "AUG 30, 2013", "AUG 30, 2013", "AUG 30, 2013", "AUG 30, 2013", "SEP 3, 2013", "AUG 29, 2013", "AUG 29, 2013", "AUG 29, 2013", "AUG 29, 2013", "AUG 28, 2013", "AUG 28, 2013", "AUG 28, 2013", "AUG 29, 2013", "AUG 27, 2013", "AUG 26, 2013", "AUG 26, 2013", "AUG 26, 2013", "AUG 26, 2013", "AUG 26, 2013", "AUG 26, 2013", "AUG 27, 2013", "AUG 23, 2013", "AUG 23, 2013", "AUG 23, 2013", "AUG 23, 2013", "AUG 23, 2013", "AUG 22, 2013", "AUG 22, 2013", "AUG 23, 2013", "AUG 21, 2013", "AUG 21, 2013", "AUG 21, 2013", "AUG 21, 2013", "AUG 21, 2013", "AUG 20, 2013", "AUG 22, 2013", "AUG 21, 2013", "AUG 21, 2013", "AUG 20, 2013", "AUG 20, 2013", "AUG 19, 2013", "AUG 19, 2013", "AUG 19, 2013", "AUG 20, 2013", "AUG 16, 2013", "AUG 16, 2013", "AUG 16, 2013", "AUG 16, 2013", "AUG 16, 2013", "AUG 15, 2013", "AUG 15, 2013", "AUG 19, 2013", "AUG 14, 2013", "AUG 14, 2013", "AUG 13, 2013", "AUG 13, 2013", "AUG 13, 2013", "AUG 13, 2013", "AUG 13, 2013", "AUG 14, 2013", "AUG 12, 2013", "AUG 9, 2013", "AUG 9, 2013", "AUG 8, 2013", "AUG 8, 2013", "AUG 8, 2013", "AUG 8, 2013", "AUG 12, 2013", "AUG 7, 2013", "AUG 7, 2013", "AUG 7, 2013", "AUG 7, 2013", "AUG 6, 2013", "AUG 6, 2013", "AUG 5, 2013", "AUG 8, 2013", "AUG 2, 2013", "AUG 1, 2013", "AUG 1, 2013", "JUL 31, 2013", "JUL 31, 2013", "JUL 31, 2013", "JUL 30, 2013", "AUG 5, 2013", "JUL 29, 2013", "JUL 29, 2013", "JUL 25, 2013", "JUL 11, 2013", "JUL 8, 2013", "JUN 25, 2013", "JUN 19, 2013", "JUL 29, 2013", "JUN 11, 2013", "JUN 10, 2013", "JUN 4, 2013", "JUN 3, 2013", "MAY 31, 2013", "MAY 22, 2013", "MAY 22, 2013", "JUN 17, 2013", "JUN 11, 2013", "JUN 10, 2013", "JUN 4, 2013", "MAY 8, 2013", "MAY 7, 2013", "MAY 3, 2013", "MAY 3, 2013", "MAY 20, 2013", "MAY 2, 2013", "MAY 2, 2013", "APR 30, 2013", "APR 28, 2013", "APR 26, 2013", "APR 26, 2013", "APR 25, 2013", "MAY 2, 2013", "APR 23, 2013", "APR 22, 2013", "APR 22, 2013", "APR 22, 2013", "APR 22, 2013", "APR 19, 2013", "APR 19, 2013", "APR 24, 2013", "APR 23, 2013", "APR 22, 2013", "APR 22, 2013", "APR 22, 2013", "APR 10, 2013", "APR 9, 2013", "APR 9, 2013", "APR 19, 2013", "APR 5, 2013", "APR 4, 2013", "APR 4, 2013", "APR 1, 2013", "APR 1, 2013", "MAR 31, 2013", "MAR 28, 2013", "APR 8, 2013", "MAR 27, 2013", "MAR 26, 2013", "MAR 25, 2013", "MAR 25, 2013", "MAR 25, 2013", "MAR 25, 2013", "MAR 14, 2013", "MAR 28, 2013", "MAR 13, 2013", "MAR 12, 2013", "MAR 11, 2013", "MAR 7, 2013", "FEB 27, 2013", "FEB 21, 2013", "FEB 20, 2013", "MAR 14, 2013", "MAR 13, 2013", "FEB 11, 2013", "FEB 11, 2013", "FEB 11, 2013", "FEB 7, 2013", "FEB 5, 2013", "FEB 4, 2013", "FEB 20, 2013", "JAN 29, 2013", "JAN 29, 2013", "JAN 25, 2013", "JAN 25, 2013", "JAN 15, 2013", "JAN 14, 2013", "JAN 14, 2013", "JAN 29, 2013", "JAN 8, 2013", "DEC 24, 2012", "DEC 18, 2012", "DEC 13, 2012", "DEC 11, 2012", "DEC 6, 2012", "DEC 6, 2012", "JAN 9, 2013", "JAN 8, 2013", "DEC 24, 2012", "DEC 18, 2012", "DEC 13, 2012", "NOV 26, 2012", "NOV 19, 2012", "DEC 6, 2012", "NOV 16, 2012", "NOV 16, 2012", "NOV 14, 2012", "NOV 12, 2012", "NOV 12, 2012", "NOV 12, 2012", "NOV 12, 2012", "NOV 19, 2012", "NOV 12, 2012", "NOV 12, 2012", "NOV 8, 2012", "NOV 1, 2012", "OCT 29, 2012", "OCT 24, 2012", "OCT 24, 2012", "NOV 12, 2012", "OCT 19, 2012", "OCT 15, 2012", "OCT 11, 2012", "OCT 3, 2012", "SEP 26, 2012", "SEP 24, 2012", "SEP 11, 2012", "OCT 24, 2012", "AUG 9, 2012", "AUG 9, 2012", "AUG 9, 2012", "AUG 2, 2012", "AUG 2, 2012", "JUL 27, 2012", "SEP 7, 2012", "AUG 29, 2012", "JUL 24, 2012", "JUL 23, 2012", "JUL 23, 2012", "JUL 2, 2012", "JUN 28, 2012", "JUN 20, 2012", "JUL 27, 2012", "MAY 24, 2012", "MAY 24, 2012", "MAY 15, 2012", "MAY 14, 2012", "MAY 4, 2012", "APR 27, 2012", "APR 26, 2012", "JUN 10, 2012", "MAY 24, 2012", "MAY 24, 2012", "APR 19, 2012", "APR 5, 2012", "MAR 21, 2012", "MAR 7, 2012", "FEB 28, 2012", "APR 26, 2012", "FEB 24, 2012", "FEB 21, 2012", "FEB 17, 2012", "FEB 15, 2012", "FEB 8, 2012", "FEB 6, 2012", "FEB 3, 2012", "FEB 27, 2012", "JAN 20, 2012", "JAN 19, 2012", "JAN 10, 2012", "JAN 9, 2012", "JAN 5, 2012", "DEC 28, 2011", "DEC 28, 2011", "JAN 26, 2012", "DEC 28, 2011", "DEC 28, 2011", "DEC 21, 2011", "DEC 12, 2011", "DEC 7, 2011", "DEC 6, 2011", "DEC 6, 2011", "DEC 28, 2011", "NOV 22, 2011", "NOV 22, 2011", "NOV 21, 2011", "NOV 21, 2011", "NOV 21, 2011", "NOV 21, 2011", "NOV 29, 2011", "NOV 2, 2011", "SEP 29, 2011", "AUG 11, 2011", "AUG 11, 2011", "JAN 21, 2011", "JAN 13, 2011", "DEC 23, 2010", "NOV 17, 2011", "OCT 26, 2010", "OCT 18, 2010", "SEP 13, 2010", "AUG 6, 2010", "AUG 2, 2010", "JUL 26, 2010", "JUL 20, 2010", "DEC 23, 2010", "FEB 16, 2010", "JAN 10, 2010", "OCT 14, 2009", "APR 22, 2010"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/3-biotech-stocks-id-buy-right-now-2020-06-27", "https://www.nasdaq.com/articles/7-u.s.-stocks-to-buy-on-renewed-coronavirus-weakness-2020-06-26", "https://www.nasdaq.com/articles/key-u.s.-medical-group-adds-steroids-to-covid-19-treatment-guidelines-2020-06-26", "https://www.nasdaq.com/articles/special-report-as-world-approaches-10-million-coronavirus-cases-doctors-see-hope-in-new", "https://www.nasdaq.com/articles/south-korea-backs-remdesivir-for-covid-19-urges-caution-with-dexamethasone-2020-06-26", "https://www.nasdaq.com/articles/eu-experts-recommend-approval-of-gileads-covid-19-drug-2020-06-25", "https://www.nasdaq.com/articles/egypts-eva-pharma-begins-producing-covid-19-drug-remdesivir-2020-06-25", "https://www.nasdaq.com/articles/interesting-gild-put-and-call-options-for-august-7th-2020-06-25", "https://www.nasdaq.com/articles/3-biotech-stocks-id-buy-right-now-2020-06-27", "https://www.nasdaq.com/articles/gileads-remdesivir-endorsed-as-first-covid-19-treatment-in-europe-2020-06-25", "https://www.nasdaq.com/articles/eu-drug-regulator-endorses-gileads-remdesivir-as-covid-19-treatment-2020-06-25", "https://www.nasdaq.com/articles/is-wall-street-wrong-about-mesoblast-2020-06-25", "https://www.nasdaq.com/articles/a-certain-type-of-investor-should-buy-low-stock-at-current-levels-2020-06-25", "https://www.nasdaq.com/articles/egypts-rameda-gets-requests-to-export-covid-19-drug-ceo-2020-06-25", "https://www.nasdaq.com/articles/u.s.-group-raises-pricing-recommendation-for-gileads-remdesivir-in-covid-19-2020-06-24", "https://www.nasdaq.com/articles/drug-pricing-review-group-raises-recommended-price-for-gileads-remdesivir-2020-06-24", "https://www.nasdaq.com/articles/5-of-the-best-pharmaceutical-stocks-to-buy-right-now-2020-06-25", "https://www.nasdaq.com/articles/indias-hetero-prices-experimental-covid-19-drug-remdesivir-at-%2471-per-100-mg-vial-2020-06", "https://www.nasdaq.com/articles/10-stocks-riding-on-the-covid-19-recovery-2020-06-24", "https://www.nasdaq.com/articles/gilead-sciences-bets-%24275-million-on-an-oncology-start-up-2020-06-23", "https://www.nasdaq.com/articles/gilead-to-buy-49.9-stake-in-cancer-drug-developer-pionyr-for-%24275-mln-2020-06-23-0", "https://www.nasdaq.com/articles/gilead-sciences-to-acquire-49.9-stake-in-pionyr-immunotherapeutics-for-%24275-mln-quick", "https://www.nasdaq.com/articles/gilead-to-buy-49.9-stake-in-cancer-drug-developer-pionyr-for-%24275-mln-2020-06-23", "https://www.nasdaq.com/articles/indias-cipla-to-price-remdesivir-version-for-covid-19-under-%2466-2020-06-23", "https://www.nasdaq.com/articles/why-is-everyone-talking-about-bristol-myers-squibb-stock-2020-06-24", "https://www.nasdaq.com/articles/meet-the-pharma-company-that-just-had-a-bigger-ipo-than-modernas-2020-06-23", "https://www.nasdaq.com/articles/myov-to-report-spirit-1-data-evlo-joins-covid-19-drug-race-nvta-loosens-purse-strings-2020", "https://www.nasdaq.com/articles/gilead-targets-remdesivir-supply-for-2-mln-covid-19-patients-by-year-end-2020-06-22", "https://www.nasdaq.com/articles/gilead-to-test-an-inhaled-version-of-remdesivir-2020-06-22", "https://www.nasdaq.com/articles/gilead-to-trial-inhaled-version-of-remdesivir-on-covid-19-patients-2020-06-22", "https://www.nasdaq.com/articles/gilead-plans-to-produce-2-million-remdesivir-courses-by-2020-end-2020-06-22", "https://www.nasdaq.com/articles/gilead-to-test-inhaled-version-of-remdesivir-on-covid-19-patients-in-august-2020-06-22", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-gilead-sciences-vs.-sorrento-therapeutics-2020-06-23", "https://www.nasdaq.com/articles/does-gilead-have-a-cure-for-the-coronavirus-2020-06-21", "https://www.nasdaq.com/articles/whats-the-outlook-for-gilead-sciences-2020-06-21", "https://www.nasdaq.com/articles/is-hydroxychloroquine-a-cure-for-covid-19-2020-06-20", "https://www.nasdaq.com/articles/the-3-best-coronavirus-stocks-to-buy-for-long-term-investors-2020-06-20", "https://www.nasdaq.com/articles/novartis-halts-malaria-drug-trial-against-covid-19-amid-participant-shortfall-2020-06-19-0", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-gild-cry-noc-2020-06-19", "https://www.nasdaq.com/articles/u.s.-hospitals-in-hard-hit-regions-step-up-use-of-steroids-on-sickest-covid-19-patients", "https://www.nasdaq.com/articles/india-gives-hetero-labs-and-cipla-approval-to-make-gileads-covid-19-drug-2020-06-21", "https://www.nasdaq.com/articles/is-eli-lilly-stock-a-buy-2020-06-19", "https://www.nasdaq.com/articles/is-glaxosmithkline-a-great-dividend-stock-2020-06-19", "https://www.nasdaq.com/articles/u.s.-hospitals-in-hard-hit-regions-step-up-use-of-steroids-on-sickest-patients-2020-06-19", "https://www.nasdaq.com/articles/roches-rheumatoid-arthritis-drug-actemra-fails-to-help-covid-19-patients-with-pneumonia", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ive-c-wfc-gild-2020-06-18", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-biogen-2020-06-18", "https://www.nasdaq.com/articles/roche-rheumatoid-arthritis-drug-fails-to-help-covid-19-patients-in-italian-study-2020-06", "https://www.nasdaq.com/articles/research-indicates-blood-type-could-influence-covid-19-severity-2020-06-19", "https://www.nasdaq.com/articles/as-biogen-stock-struggles-look-elsewhere-for-biotech-exposure-2020-06-17", "https://www.nasdaq.com/articles/2-pros-2-cons-for-buying-aim-immunotech-2020-06-17", "https://www.nasdaq.com/articles/is-dexamethasone-the-best-treatment-for-covid-19-2020-06-17", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-regeneron-or-gilead-sciences-2020-06-17", "https://www.nasdaq.com/articles/astrazenecas-potential-vaccine-likely-to-protect-against-covid-19-for-a-year-%3A-report-2020", "https://www.nasdaq.com/articles/7-cash-stocks-to-invest-in-as-markets-turn-negative-2020-06-16", "https://www.nasdaq.com/articles/early-shareholders-can-win-if-ibio-gets-a-vaccine-contract-2020-06-16", "https://www.nasdaq.com/articles/gilead-to-enroll-pediatric-patients-for-late-stage-remdesivir-study-2020-06-17", "https://www.nasdaq.com/articles/is-now-still-a-good-time-to-buy-gilead-sciences-gild-stock-oppenheimer-says-yes-2020-06-15", "https://www.nasdaq.com/articles/eli-lilly-starts-trial-of-rheumatoid-arthritis-drug-in-covid-19-patients-2020-06-15", "https://www.nasdaq.com/articles/why-is-everyone-talking-about-gilead-sciences-stock-2020-06-14", "https://www.nasdaq.com/articles/better-buy%3A-moderna-vs.-gilead-sciences-2020-06-14", "https://www.nasdaq.com/articles/should-sorrento-therapeutics-be-your-next-coronavirus-buy-2020-06-14", "https://www.nasdaq.com/articles/could-gilead-sciences-have-an-hiv-cure-waiting-in-the-wings-2020-06-14", "https://www.nasdaq.com/articles/where-will-abbvie-be-in-5-years-2020-06-13", "https://www.nasdaq.com/articles/israel-approves-remdesivir-drug-for-covid-19-treatment-2020-06-16", "https://www.nasdaq.com/articles/indias-zydus-cadila-to-make-gileads-potential-covid-19-drug-remdesivir-2020-06-12", "https://www.nasdaq.com/articles/indias-zydus-cadila-signs-pact-with-gilead-to-make-remdesivir-2020-06-12", "https://www.nasdaq.com/articles/kite-to-manufacture-car-t-cell-therapies-in-europe-quick-facts-2020-06-12", "https://www.nasdaq.com/articles/american-airlines-stock-surely-will-be-back-after-yesterdays-beating-2020-06-12", "https://www.nasdaq.com/articles/is-adaptimmune-therapeutics-a-buy-2020-06-12", "https://www.nasdaq.com/articles/inovio-still-a-hot-coronavirus-vaccine-supplier-2020-06-11", "https://www.nasdaq.com/articles/regeneron-begins-human-trials-of-a-potential-covid-19-treatment-2020-06-11", "https://www.nasdaq.com/articles/dr.-reddys-laboratories-enters-licensing-deal-with-gilead-sciences-for-remdesivir-2020-06", "https://www.nasdaq.com/articles/u.s.-fda-commissioner-says-agency-seeks-fast-review-of-covid-19-products-2020-06-10", "https://www.nasdaq.com/articles/gilead-merger-unlikely-at-this-point-says-5-star-analyst-2020-06-10", "https://www.nasdaq.com/articles/study%3A-remdesivir-prevented-lung-damage-in-monkeys-infected-with-covid-19-2020-06-10", "https://www.nasdaq.com/articles/is-aprea-therapeutics-stock-a-buy-2020-06-10", "https://www.nasdaq.com/articles/gild-named-a-top-socially-responsible-dividend-stock-2020-06-10", "https://www.nasdaq.com/articles/singapore-approves-remdesivir-drug-for-emergency-covid-19-treatment-2020-06-10", "https://www.nasdaq.com/articles/singapore-approves-gileads-remdesivir-for-covid-19-treatment-2020-06-10", "https://www.nasdaq.com/articles/better-buy%3A-bluebird-bio-vs.-gilead-sciences-2020-06-11", "https://www.nasdaq.com/articles/aggressive-investors-can-do-much-better-than-merck-stock-2020-06-09", "https://www.nasdaq.com/articles/ex-dividend-reminder%3A-spartannash-steris-and-gilead-sciences-2020-06-09", "https://www.nasdaq.com/articles/astrazenecas-acquisition-of-gilead-would-create-a-covid-19-colossus-but-dont-bet-on-seeing", "https://www.nasdaq.com/articles/gileads-remdesivir-slows-disease-progression-in-monkeys-with-covid-19-2020-06-09", "https://www.nasdaq.com/articles/gileads-remdesivir-slows-progression-of-covid-19-in-monkeys-study-2020-06-09", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-boeing-chesapeake-energy-ideanomics-2020-06-08", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-sino-global-shipping-michaels-companies-applied-dna-2020-06", "https://www.nasdaq.com/articles/what-would-a-merger-mean-for-gilead-top-analyst-weighs-in-2020-06-09", "https://www.nasdaq.com/articles/wall-street-set-to-rise-on-swift-economic-rebound-hopes-2020-06-08", "https://www.nasdaq.com/articles/breakingviews-astrazeneca-ma-puzzle-sends-shareholder-warning-2020-06-08", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-gilead-cisco-2020-06-08", "https://www.nasdaq.com/articles/u.s.-stock-futures-rise-on-optimism-over-economic-revival-2020-06-08", "https://www.nasdaq.com/articles/astrazeneca-in-informal-talks-with-gilead-for-potential-merger%3A-report-2020-06-08", "https://www.nasdaq.com/articles/londons-ftse-100-falls-as-astrazeneca-drops-on-megamerger-report-2020-06-08", "https://www.nasdaq.com/articles/eu-watchdog-aims-for-speedy-approval-of-remdesivir-as-covid-19-treatment-2020-06-08", "https://www.nasdaq.com/articles/astrazeneca-shares-down-2-after-report-it-approached-gilead-over-tie-up-2020-06-08", "https://www.nasdaq.com/articles/londons-ftse-100-opens-lower-as-astrazeneca-weighs-2020-06-08", "https://www.nasdaq.com/articles/european-shares-pull-back-from-3-month-highs-after-rally-2020-06-08", "https://www.nasdaq.com/articles/astrazeneca-proposes-a-merger-with-gilead-sciences-2020-06-07", "https://www.nasdaq.com/articles/astrazeneca-contacted-gilead-over-potential-megamerger-bloomberg-news-2020-06-07", "https://www.nasdaq.com/articles/could-gileads-covid-19-drug-make-%247-billion-per-year-2020-06-07", "https://www.nasdaq.com/articles/fujifilm-says-covid-19-drug-research-may-drag-on-into-july-2020-06-07", "https://www.nasdaq.com/articles/european-stock-rally-takes-step-back-as-tech-healthcare-drag-2020-06-08", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-gild-nssc-lb-2020-06-04", "https://www.nasdaq.com/articles/co-diagnostics-could-be-a-prudent-coronavirus-play-2020-06-04", "https://www.nasdaq.com/articles/is-remdesivir-a-disappointment-2020-06-04", "https://www.nasdaq.com/articles/better-buy%3A-bristol-myers-squibb-vs.-gilead-sciences-2020-06-04", "https://www.nasdaq.com/articles/lyft-looks-poised-to-rally-over-the-next-few-months-2020-06-04", "https://www.nasdaq.com/articles/biotech-stocks%3A-buy-this-not-that-2020-06-04", "https://www.nasdaq.com/articles/air-travels-comeback-looks-poised-to-lift-ge-stock-2020-06-04", "https://www.nasdaq.com/articles/what-are-the-implications-of-gileads-increased-focus-on-oncology-5-star-analyst-weights-in", "https://www.nasdaq.com/articles/roche-test-receives-fda-emergency-use-approval-for-covid-19-patients-2020-06-04", "https://www.nasdaq.com/articles/wait-for-more-clarity-before-buying-gilead-stock-says-analyst-2020-06-03", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-warner-music-boeing-pliant-therapeutics-2020-06-03", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-glu-mobile-boeing-american-eagle-2020-06-03", "https://www.nasdaq.com/articles/gileads-remdesivir-could-see-%247-bln-in-annual-sales-on-stockpiling-boost-analyst-2020-06", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-coty-zoom-video-opgen-campbell-soup-2020-06-03", "https://www.nasdaq.com/articles/eli-lilly-leaps-past-regenerons-covid-19-treatment-candidate-2020-06-03", "https://www.nasdaq.com/articles/gilead-sciences-%3A-filgotinib-shows-sustained-efficacy-in-studies-on-rheumatoid-arthritis", "https://www.nasdaq.com/articles/s.korea-approves-import-of-anti-viral-drug-remdesivir-for-coronavirus-treatment-2020-06-02", "https://www.nasdaq.com/articles/abbvie-will-be-in-big-trouble-when-its-patent-cliff-arrives-2020-06-02", "https://www.nasdaq.com/articles/tuesday-sector-laggards%3A-healthcare-technology-communications-2020-06-02", "https://www.nasdaq.com/articles/india-approves-emergency-use-of-remdesivir-to-treat-covid-19-patients-2020-06-02-0", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-gilead-sciences-or-novavax-2020-06-02", "https://www.nasdaq.com/articles/gileads-next-step-on-coronavirus%3A-inhaled-remdesivir-other-easier-to-use-versions-2020-06", "https://www.nasdaq.com/articles/india-approves-emergency-use-of-remdesivir-to-treat-covid-19-patients-2020-06-02", "https://www.nasdaq.com/articles/abbvie-stock-is-offering-investors-an-oil-yield-without-oils-risk-2020-06-03", "https://www.nasdaq.com/articles/s.korea-approves-import-of-anti-viral-drug-remdesivir-for-coronavirus-treatment-2020-06-02", "https://www.nasdaq.com/articles/why-carnival-royal-caribbean-and-norwegian-cruise-line-stocks-rose-today-2020-06-01", "https://www.nasdaq.com/articles/wall-street-closes-higher-as-recovery-signs-soothe-protest-pandemic-worries-2020-06-01-0", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-01-2020%3A-abioebsgildocgn-2020-06-01", "https://www.nasdaq.com/articles/wall-street-closes-higher-as-recovery-signs-soothe-protest-pandemic-worries-2020-06-01", "https://www.nasdaq.com/articles/u.s.-stocks-gain-as-signs-of-recovery-offset-protests-economic-worries-2020-06-01", "https://www.nasdaq.com/articles/ntla-gains-on-amended-regn-deal-gild-reports-simple-results-myov-on-watch-nvus-slumps-2020", "https://www.nasdaq.com/articles/gold-edges-lower-as-economies-open-up-2020-06-01", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-01-2020%3A-ebsgildocgn-2020-06-01", "https://www.nasdaq.com/articles/wall-st-gains-as-recovery-hopes-overshadow-u.s.-protests-2020-06-01", "https://www.nasdaq.com/articles/vir-biotechnology-is-bucking-the-biotech-covid-19-trends-and-stands-to-win-2020-06-01", "https://www.nasdaq.com/articles/stock-alert%3A-gilead-down-4-on-remdesivir-trial-data-2020-06-01", "https://www.nasdaq.com/articles/wall-st-flat-as-recovery-hopes-offset-u.s.-protests-china-tensions-2020-06-01", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-gilead-virgin-galactic-general-electric-2020-06-01", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-coty-tesla-zoom-video-zynga-2020-06-01", "https://www.nasdaq.com/articles/wall-st-rises-as-recovery-hopes-offset-u.s.-protests-china-tensions-2020-06-01", "https://www.nasdaq.com/articles/tqqq-chtr-gild-qcom%3A-large-outflows-detected-at-etf-2020-06-01", "https://www.nasdaq.com/articles/gilead-reports-positive-late-stage-study-results-for-remdesivir-in-patients-with-moderate", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-gild-zm-2020-06-01", "https://www.nasdaq.com/articles/gilead-says-remdesivir-helped-moderate-covid-19-patients-improve-2020-06-01-0", "https://www.nasdaq.com/articles/gilead-reports-encouraging-data-from-remdesivir-5-day-treatment-course-2020-06-01", "https://www.nasdaq.com/articles/gilead-says-remdesivir-helped-moderate-covid-19-patients-improve-2020-06-01", "https://www.nasdaq.com/articles/3-biotech-quick-picks-to-invest-%245000-this-week-2020-06-01", "https://www.nasdaq.com/articles/gilead-gets-a-boost-from-positive-coronavirus-research-2020-06-01", "https://www.nasdaq.com/articles/exclusive-russia-to-roll-out-its-first-approved-covid-19-drug-next-week-2020-06-01", "https://www.nasdaq.com/articles/insight-scientists-hunt-pandemic-hotspots-in-race-to-test-vaccines-2020-06-01", "https://www.nasdaq.com/articles/how-one-hedge-fund-billionaire-is-battling-to-bring-down-drug-prices-in-america-2020-05-31", "https://www.nasdaq.com/articles/the-week-that-was%3A-mrk-enters-covid-space-gsks-1bln-dose-target-roche-gild-team-up-for", "https://www.nasdaq.com/articles/7-u.s.-stocks-to-buy-on-coronavirus-weakness-2020-05-30", "https://www.nasdaq.com/articles/heres-why-arcus-biosciences-stock-gained-as-much-as-15.9-today-2020-05-29", "https://www.nasdaq.com/articles/gilead-trades-that-made-millions-on-covid-19-drug-news-raise-eyebrows-2020-06-01", "https://www.nasdaq.com/articles/gilead-gets-a-boost-from-positive-coronavirus-research-2020-06-01", "https://www.nasdaq.com/articles/eu-regulator-promises-speedy-review-of-potential-covid-19-drug-remdesivir-2020-05-29", "https://www.nasdaq.com/articles/s.korea-seeks-to-import-anti-viral-remdesivir-as-new-coronavirus-cases-emerge-2020-05-29", "https://www.nasdaq.com/articles/july-10th-options-now-available-for-gilead-sciences-gild-2020-05-28", "https://www.nasdaq.com/articles/dont-waste-your-money-on-penny-stocks-these-3-are-better-buys-2020-05-28", "https://www.nasdaq.com/articles/coronavirus-2020%3A-where-to-invest-%24500-right-now-2020-05-28", "https://www.nasdaq.com/articles/roche-mixes-actemra-with-gileads-remdesivir-in-covid-19-trial-2020-05-28", "https://www.nasdaq.com/articles/at-the-asco%3A-oncy-imv-crdf-gild-tak...-2020-05-29", "https://www.nasdaq.com/articles/phas-to-begin-covid-19-drug-trial-in-june-mrsn-hits-new-high-ljpc-plunges-rcus-on-watch", "https://www.nasdaq.com/articles/roche-to-study-remdesivir-actemra-cocktail-against-severe-covid-19-pneumonia-2020-05-28", "https://www.nasdaq.com/articles/gileads-remdesivir-may-be-a-coronavirus-silver-bullet-but-its-already-baked-in-the-stock", "https://www.nasdaq.com/articles/gilead-study-shows-shorter-5-day-course-of-remdesivir-works-as-well-as-10-day-one-2020-05", "https://www.nasdaq.com/articles/heres-why-arcus-biosciences-is-losing-ground-today-2020-05-27", "https://www.nasdaq.com/articles/gilead-sciences-signs-%242-billion-partnership-with-arcus-biosciences-2020-05-27", "https://www.nasdaq.com/articles/astrazeneca-tests-diabetes-drug-for-covid-19-despite-risk-seen-by-doctors-2020-05-27", "https://www.nasdaq.com/articles/genentech-initiates-phase-iii-trial-of-actemra-plus-remdesivir-on-severe-covid-19", "https://www.nasdaq.com/articles/gilead-arcus-biosciences-ink-10-year-deal-to-co-develop-cancer-immunotherapies-2020-05-27", "https://www.nasdaq.com/articles/10-stocks-to-buy-as-they-ride-a-coronavirus-tailwind-2020-05-27", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-izea-worldwide-diffusion-pharma-douyu-international-2020-05", "https://www.nasdaq.com/articles/who-expects-hydroxychloroquine-safety-findings-by-mid-june-2020-05-26", "https://www.nasdaq.com/articles/lilly-junshi-biosciences-plan-to-start-human-trials-of-covid-19-antibody-in-q2-2020-05-26", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-latam-airlines-tuesday-morning-novavax-2020-05-26", "https://www.nasdaq.com/articles/merck-leaps-into-covid-19-development-fray-with-vaccine-drug-deals-2020-05-26-0", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-stoneco-tuesday-morning-zynerba-pharma-2020-05-27", "https://www.nasdaq.com/articles/merck-leaps-into-covid-19-development-fray-with-vaccine-drug-deals-2020-05-26", "https://www.nasdaq.com/articles/britain-to-provide-anti-viral-drug-remdesivir-to-some-covid-19-patients-2020-05-26", "https://www.nasdaq.com/articles/3-large-cap-coronavirus-stocks-still-worth-buying-2020-05-24", "https://www.nasdaq.com/articles/mixed-results-for-gilead-sciences-covid-19-treatment-2020-05-23", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-gilead-sciences-or-vir-biotechnology-2020-05-23", "https://www.nasdaq.com/articles/peer-reviewed-data-shows-gileads-drug-helps-covid-19-recovery-time-2020-05-22", "https://www.nasdaq.com/articles/peer-reviewed-data-shows-gileads-drug-effective-against-covid-19-nih-2020-05-22", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-novavax-tuesday-morning-hpe-2020-05-26", "https://www.nasdaq.com/articles/before-you-buy-gilead-sciences-stock-read-this-2020-05-22", "https://www.nasdaq.com/articles/gilead-stock-is-worth-owning-with-or-without-a-coronavirus-cure-2020-05-22", "https://www.nasdaq.com/articles/u.s.-doctors-call-for-remdesivir-data-to-guide-coronavirus-treatment-2020-05-21", "https://www.nasdaq.com/articles/galapagos-and-gilead-sciences-post-successful-yet-disappointing-filgotinib-results-2020-05", "https://www.nasdaq.com/articles/how-a-coronavirus-vaccine-might-move-the-stock-market-2020-05-21", "https://www.nasdaq.com/articles/the-virus-vaccine-race-is-fueling-moderna-stock-to-new-highs-2020-05-21", "https://www.nasdaq.com/articles/atra-abuzz-atos-covid-19-med-effective-ino-and-vxrt-on-track-2020-05-21", "https://www.nasdaq.com/articles/remdesivir-cant-cure-covid-but-good-luck-telling-gilead-stock-2020-05-22", "https://www.nasdaq.com/articles/higher-dose-of-gilead-galapagos-drug-meets-ulcerative-colitis-study-goals-2020-05-20", "https://www.nasdaq.com/articles/gilead-galapagoss-drug-meets-main-goals-of-ulcerative-colitis-study-2020-05-20", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-20-2020%3A-hothaldxgildinobdx-2020-05-20", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-gild-ilmn-atvi-2020-05-20", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-20-2020%3A-aldxgildinobdx-2020-05-20", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-dgro-cmcsa-txn-gild-2020-05-20", "https://www.nasdaq.com/articles/why-the-next-month-will-determine-the-rest-of-the-year-for-gileads-stock-2020-05-20", "https://www.nasdaq.com/articles/gilead-still-holds-the-winning-hand-says-5-star-analyst-2020-05-20", "https://www.nasdaq.com/articles/how-the-parts-add-up%3A-sciu-targets-%2433-2020-05-19", "https://www.nasdaq.com/articles/where-will-adaptimmune-be-in-5-years-2020-05-19", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-oasis-midstream-l-brands-diffusion-pharma-2020-05-18", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-gild-expe-2020-05-18", "https://www.nasdaq.com/articles/gsks-long-acting-injection-beats-truvada-in-hiv-prevention-trial-2020-05-18-0", "https://www.nasdaq.com/articles/remdesivir-close-to-eus-initial-authorisation-as-covid-19-treatment-2020-05-18", "https://www.nasdaq.com/articles/gsks-long-acting-injection-beats-truvada-in-hiv-prevention-trial-2020-05-18", "https://www.nasdaq.com/articles/glaxosmithkline-pfizer-and-shionogis-hiv-prevention-candidate-outperforms-gileads-truvada", "https://www.nasdaq.com/articles/why-gileads-remdesivir-might-not-be-the-mega-moneymaker-some-think-it-will-be-2020-05-17", "https://www.nasdaq.com/articles/better-buy%3A-intercept-pharmaceuticals-vs.-gilead-sciences-2020-05-16", "https://www.nasdaq.com/articles/could-veeva-systems-be-a-millionaire-maker-stock-2020-05-16", "https://www.nasdaq.com/articles/gilead-to-end-coronavirus-drug-trials-adding-to-access-worry-researchers-2020-05-15", "https://www.nasdaq.com/articles/pakistans-ferozsons-to-begin-producing-covid-19-drug-remdesivir-2020-05-15", "https://www.nasdaq.com/articles/buy-good-news-gilead-stock-before-other-investors-catch-on-2020-05-14", "https://www.nasdaq.com/articles/part-of-gileads-coronavirus-drug-donation-allocated-to-japan-2020-05-14", "https://www.nasdaq.com/articles/is-gilead-sciences-a-great-dividend-stock-2020-05-17", "https://www.nasdaq.com/articles/health-groups-ask-india-to-rescind-gileads-patents-for-covid-19-drug-remdesivir-2020-05-0", "https://www.nasdaq.com/articles/2-recession-proof-healthcare-stocks-to-buy-in-2020-2020-05-14", "https://www.nasdaq.com/articles/health-groups-ask-india-to-rescind-gileads-patents-for-covid-19-drug-remdesivir-2020-05-14", "https://www.nasdaq.com/articles/japan-says-drugmaker-gileads-covid-19-treatment-remdesivir-now-in-use-in-hospitals-2020-05", "https://www.nasdaq.com/articles/takeda-says-coronavirus-treatment-trial-using-recovered-patients-blood-could-start-in-july", "https://www.nasdaq.com/articles/u.s.-accuses-china-linked-hackers-of-stealing-coronavirus-research-2020-05-13-0", "https://www.nasdaq.com/articles/gileads-remdesivir-isnt-enough-to-drive-its-stock-higher-2020-05-13", "https://www.nasdaq.com/articles/france-says-any-sanofi-covid-19-vaccine-for-the-world-no-favourites-2020-05-14", "https://www.nasdaq.com/articles/u.s.-accuses-china-linked-hackers-of-stealing-coronavirus-research-2020-05-13", "https://www.nasdaq.com/articles/where-will-gilead-sciences-be-in-1-year-2020-05-13", "https://www.nasdaq.com/articles/u.s.-stock-futures-climb-ahead-of-fed-chair-powells-address-2020-05-13", "https://www.nasdaq.com/articles/is-abbvie-a-buy-now-that-the-allergan-deal-is-done-2020-05-13", "https://www.nasdaq.com/articles/gilead-stock-still-looks-poised-to-prove-the-bears-wrong-2020-05-13", "https://www.nasdaq.com/articles/a-tale-of-two-japanese-drugs-in-tests-to-fight-covid-19-2020-05-12", "https://www.nasdaq.com/articles/gilead-strikes-deal-with-mylan-to-supply-remdesivir-internationally-2020-05-12", "https://www.nasdaq.com/articles/gilead-in-deal-with-5-cos.-to-make-and-sell-remdesivir-in-127-countries-2020-05-13", "https://www.nasdaq.com/articles/9-enduring-stocks-that-you-shouldnt-sell-in-may-2020-05-12", "https://www.nasdaq.com/articles/ema-recommends-expanding-compassionate-use-of-gileads-covid-19-drug-2020-05-11", "https://www.nasdaq.com/articles/ema-recommends-expanding-compassionate-use-of-gileads-covid-19-drug-2020-05-11-0", "https://www.nasdaq.com/articles/the-government-will-distribute-gileads-remdesivir.-this-could-be-bad-news-for-investors", "https://www.nasdaq.com/articles/moat-now-pfe-gild%3A-etf-inflow-alert-2020-05-11", "https://www.nasdaq.com/articles/a-covid-19-strategy%3A-invest-in-companies-that-are-doing-good-2020-05-11", "https://www.nasdaq.com/articles/gileads-remdesivir-supply-wont-meet-u.s.-need-analyst-says-2020-05-11", "https://www.nasdaq.com/articles/indias-jubilant-signs-licensing-deal-for-gileads-potential-covid-19-drug-2020-05-12", "https://www.nasdaq.com/articles/despite-challenges-ge-is-a-long-term-winner-2020-05-11", "https://www.nasdaq.com/articles/3-top-biotech-stocks-to-buy-in-may-2020-05-10", "https://www.nasdaq.com/articles/what-investors-are-missing-about-gilead-sciences-2020-05-10", "https://www.nasdaq.com/articles/u.s.-to-allow-states-to-distribute-gileads-remdesivir-to-fight-covid-19-2020-05-09", "https://www.nasdaq.com/articles/the-dow-rose-455-points-because-job-losses-cant-get-any-worse-2020-05-08", "https://www.nasdaq.com/articles/nih-begins-study-of-remdesivir-with-anti-inflammatory-drug-to-treat-covid-19-2020-05-08-0", "https://www.nasdaq.com/articles/nih-begins-study-of-remdesivir-with-anti-inflammatory-drug-to-treat-covid-19-2020-05-08", "https://www.nasdaq.com/articles/co-diagnostics-is-a-smart-way-to-play-coronavirus-testing-2020-05-11", "https://www.nasdaq.com/articles/is-gilead-sciences-stock-a-buy-2020-05-08", "https://www.nasdaq.com/articles/u.s.-doctors-want-details-on-federal-distribution-of-gilead-coronavirus-drug-2020-05-07", "https://www.nasdaq.com/articles/doctors-want-details-on-federal-distribution-of-gilead-coronavirus-drug-2020-05-07", "https://www.nasdaq.com/articles/june-26th-options-now-available-for-gilead-sciences-gild-2020-05-07", "https://www.nasdaq.com/articles/the-best-thing-happening-during-these-worst-of-times-2020-05-07", "https://www.nasdaq.com/articles/from-gilead-to-astrazeneca-investors-should-watch-these-biotech-giants-right-now-2020-05", "https://www.nasdaq.com/articles/japan-approves-gilead-sciences-remdesivir-as-covid-19-drug-2020-05-07-0", "https://www.nasdaq.com/articles/exclusive-iran-linked-hackers-recently-targeted-coronavirus-drugmaker-gilead-sources-2020", "https://www.nasdaq.com/articles/will-gilead-price-its-coronavirus-drug-for-public-good-or-company-profit-2020-05-06", "https://www.nasdaq.com/articles/how-will-double-digit-unemployment-affect-your-stock-portfolio-2020-05-06", "https://www.nasdaq.com/articles/4-safe-stocks-that-can-make-you-rich-in-this-economy-2020-05-06", "https://www.nasdaq.com/articles/inovio-pharmaceuticals-is-hurting-from-remdesivir-but-its-still-standing-2020-05-06", "https://www.nasdaq.com/articles/israel-reports-a-breakthrough-coronavirus-antibody-treatment-2020-05-06", "https://www.nasdaq.com/articles/co-diagnostics-is-becoming-more-relevant-2020-05-06", "https://www.nasdaq.com/articles/explainer-who-can-make-gileads-coronavirus-drug-licence-free-2020-05-06", "https://www.nasdaq.com/articles/japan-approves-gilead-sciences-remdesivir-as-covid-19-drug-2020-05-07", "https://www.nasdaq.com/articles/gilead-sciences-plans-to-expand-global-supply-of-remdesivir-2020-05-05", "https://www.nasdaq.com/articles/gilead-in-talks-to-expand-global-supply-of-covid-19-drug-remdesivir-2020-05-05-0", "https://www.nasdaq.com/articles/gilead-in-talks-to-expand-global-supply-of-covid-19-drug-remdesivir-2020-05-05", "https://www.nasdaq.com/articles/how-can-the-stock-market-soar-with-rising-unemployment-2020-05-05", "https://www.nasdaq.com/articles/regeneron-says-its-covid-19-combo-treatment-could-be-ready-for-people-this-fall-2020-05-05", "https://www.nasdaq.com/articles/the-trends-are-mostly-friendly-for-moderna-stock-investors-2020-05-05", "https://www.nasdaq.com/articles/gilead-sciences-is-a-strong-buy-despite-what-its-detractors-might-say-2020-05-05", "https://www.nasdaq.com/articles/is-this-coronavirus-drug-authorization-really-good-news-for-gilead-2020-05-06", "https://www.nasdaq.com/articles/exclusive-bangladeshs-beximco-to-begin-producing-covid-19-drug-remdesivir-coo-2020-05-05", "https://www.nasdaq.com/articles/could-this-under-the-radar-biotech-piggyback-on-gileads-remdesivir-success-2020-05-05", "https://www.nasdaq.com/articles/the-dow-rose-26-points-because-an-oil-rebound-lifted-stocks-2020-05-04", "https://www.nasdaq.com/articles/apps-cannot-replace-boots-on-the-ground-in-virus-fight-who-2020-05-04", "https://www.nasdaq.com/articles/earnings-preview%3A-is-sq-stock-a-buy-before-wednesday-2020-05-04", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-airlines-banks-insurers-oil-stocks-2020-05-04", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-airlines-banks-insurers-pge-2020-05-04", "https://www.nasdaq.com/articles/finding-a-coronavirus-cure%3A-5-companies-making-moves-2020-05-05", "https://www.nasdaq.com/articles/jpmorgans-bullish-stance-on-gilead-sciences-gild-stock-comes-to-an-end-2020-05-04", "https://www.nasdaq.com/articles/what-might-gileads-covid-19-drug-cost-%2410-or-%244500-2020-05-04", "https://www.nasdaq.com/articles/forget-gilead-these-2-pharma-dividends-pay-up-to-10-2020-05-04", "https://www.nasdaq.com/articles/vir-alnylam-identify-covid-19-therapy-candidate-plan-human-trials-by-year-end-2020-05-04", "https://www.nasdaq.com/articles/despite-gains-threat-gilead-is-still-attractive-2020-05-04", "https://www.nasdaq.com/articles/heres-why-its-not-too-late-to-load-up-on-moderna-stock-2020-05-04", "https://www.nasdaq.com/articles/european-stock-futures-drop-as-u.s.-china-spar-over-virus-origin-2020-05-04-0", "https://www.nasdaq.com/articles/the-3-best-stocks-to-buy-in-may-2020-05-04", "https://www.nasdaq.com/articles/gold-gains-as-rising-u.s.-china-tensions-dent-risk-sentiment-2020-05-03", "https://www.nasdaq.com/articles/5-top-coronavirus-stocks-to-buy-in-may-2020-05-02", "https://www.nasdaq.com/articles/japan-aims-to-fast-track-review-of-anti-viral-drug-remdesivir-2020-05-02", "https://www.nasdaq.com/articles/what-should-investors-make-of-conflicting-results-surrounding-gileads-remdesivir-2020-05", "https://www.nasdaq.com/articles/gileads-remdesivir-becomes-1st-drug-allowed-for-emergency-use-for-covid-19-2020-05-01", "https://www.nasdaq.com/articles/fda-authorizes-gileads-remdesivir-for-covid-19-2020-05-01", "https://www.nasdaq.com/articles/why-foot-locker-callaway-golf-and-newell-brands-plunged-10-early-friday-2020-05-01", "https://www.nasdaq.com/articles/foreigners-remain-net-sellers-of-japan-stocks-for-11th-straight-week-2020-05-04", "https://www.nasdaq.com/articles/fda-allows-emergency-use-of-gileads-covid-19-drug-2020-05-01", "https://www.nasdaq.com/articles/u.s.-fda-authorizes-remdesivir-drug-as-emergency-treatment-for-covid-19-2020-05-01", "https://www.nasdaq.com/articles/trump%3A-fda-authorizes-remdesivir-drug-for-covid-19-2020-05-01", "https://www.nasdaq.com/articles/gilead-aims-to-get-its-potential-covid-19-drug-to-as-many-patients-as-possible-2020-05-01", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tesla-medigus-aemetis-2020-05-01", "https://www.nasdaq.com/articles/daily-dividend-report%3A-aaplgildglwtrpwwd-2020-05-01", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-medigus-ltd-western-digital-corp-aemetis-inc-2020-05-01", "https://www.nasdaq.com/articles/u.s.-fda-authorizes-remdesivir-drug-as-emergency-treatment-for-covid-19-2020-05-01-0", "https://www.nasdaq.com/articles/coronavirus-trial-drug-remdesivirs-maker-aims-for-wide-distribution-gilead-ceo-2020-05-01", "https://www.nasdaq.com/articles/coronavirus-trial-drug-redesivirs-maker-hopes-for-swift-fda-approval-interview-2020-05-01", "https://www.nasdaq.com/articles/3-big-stories-in-gilead-sciences-q1-results-2020-05-01", "https://www.nasdaq.com/articles/inovio-is-in-a-race-to-develop-a-covid-19-vaccine-but-can-it-possibly-win-2020-05-01", "https://www.nasdaq.com/articles/what-does-remdesivirs-promising-study-mean-for-gileads-stock-2020-05-01", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-q1-2020-earnings-call-transcript-2020-05-01", "https://www.nasdaq.com/articles/7-u.s.-stocks-to-buy-on-coronavirus-weakness-2020-04-30", "https://www.nasdaq.com/articles/gilead-stock-drops-on-wave-of-downgrades-2020-05-01", "https://www.nasdaq.com/articles/gilead-beats-earnings-estimates-but-the-stock-falls-2020-04-30", "https://www.nasdaq.com/articles/gilead-aims-to-expand-remdesivir-output-for-covid-19-posts-flat-1st-qtr-results-2020-04-30", "https://www.nasdaq.com/articles/global-markets-global-equities-dip-at-end-of-best-month-since-09-2020-04-30", "https://www.nasdaq.com/articles/gilead-sciences-inc.-q1-adjusted-earnings-of-%241.68-per-share-2020-04-30", "https://www.nasdaq.com/articles/yields-fall-two-year-note-touches-lowest-level-since-2011-2020-04-30", "https://www.nasdaq.com/articles/global-markets-equities-dip-but-remain-on-pace-for-best-month-on-record-2020-04-30", "https://www.nasdaq.com/articles/is-gilead-sciences-stock-a-buy-right-now-this-is-what-you-need-to-know-2020-04-30", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-mdb-casa-gild-2020-04-30", "https://www.nasdaq.com/articles/u.s.-fda-moving-with-lightning-speed-on-gileads-covid-19-drug-bloomberg-2020-04-30", "https://www.nasdaq.com/articles/global-markets-global-equities-dip-remain-on-pace-for-best-month-on-record-2020-04-30", "https://www.nasdaq.com/articles/gilead-awaits-fda-approval-on-remdesivir-to-treat-covid-19-2020-04-30", "https://www.nasdaq.com/articles/paypal-is-the-elixir-we-need-in-this-awful-earnings-season-2020-04-30", "https://www.nasdaq.com/articles/wall-st-set-to-slide-at-open-after-jobless-claims-data-2020-04-30", "https://www.nasdaq.com/articles/daily-markets%3A-nearly-1-in-5-have-lost-their-jobs-in-just-6-weeks-2020-04-30", "https://www.nasdaq.com/articles/gilead-gild-1st-quarter-earnings%3A-what-to-expect-2020-04-30", "https://www.nasdaq.com/articles/ibb-gild-vrtx-biib%3A-etf-inflow-alert-2020-04-30", "https://www.nasdaq.com/articles/3-big-stock-charts-for-thursday%3A-gilead-sciences-boeing-and-nio-2020-04-30", "https://www.nasdaq.com/articles/dow-sp-500-futures-dip-at-end-of-strong-month-jobless-data-awaited-2020-04-30", "https://www.nasdaq.com/articles/have-%243000-to-invest-here-are-3-top-coronavirus-stocks-to-buy-right-now.-2020-04-30", "https://www.nasdaq.com/articles/moderna-stock-is-near-highs-but-faces-risk-2020-04-30", "https://www.nasdaq.com/articles/gilead-sciences-q1-20-earnings-conference-call-at-4%3A30-pm-et-2020-04-30", "https://www.nasdaq.com/articles/indian-stocks-log-best-month-since-2009-track-global-cheer-on-virus-drug-hopes-2020-04-30", "https://www.nasdaq.com/articles/european-stocks-pause-after-big-asia-and-wall-street-rally-2020-04-30", "https://www.nasdaq.com/articles/dow-sp-500-futures-dip-at-end-of-strong-month-jobless-data-eyed-2020-04-30", "https://www.nasdaq.com/articles/london-stocks-hit-by-shells-historic-dividend-cut-2020-04-30", "https://www.nasdaq.com/articles/emerging-markets-stocks-extend-gains-hungary-outperforms-on-reopening-plans-2020-04-30", "https://www.nasdaq.com/articles/china-stocks-log-best-month-in-five-on-virus-drug-trial-policy-hopes-2020-04-30", "https://www.nasdaq.com/articles/london-stocks-rise-on-optimism-around-virus-drug-upbeat-earnings-2020-04-30", "https://www.nasdaq.com/articles/tokyo-shares-end-near-8-week-high-track-wall-street-gains-on-virus-drug-hopes-2020-04-30", "https://www.nasdaq.com/articles/glenmark-to-conduct-trials-in-india-for-potential-covid-19-drug-2020-04-30", "https://www.nasdaq.com/articles/em-asia-fx-indonesian-rupiah-jumps-about-3-on-higher-bond-inflows-expectation-2020-04-30", "https://www.nasdaq.com/articles/global-markets-stocks-head-for-best-month-on-record-ahead-of-ecb-2020-04-30", "https://www.nasdaq.com/articles/global-markets-stocks-rally-on-treatment-hopes-currencies-await-ecb-2020-04-30", "https://www.nasdaq.com/articles/china-stocks-touch-seven-week-high-on-coronavirus-treatment-policy-hopes-2020-04-30", "https://www.nasdaq.com/articles/global-markets-stocks-rally-on-treatment-hopes-currencies-await-ecb-2020-04-29", "https://www.nasdaq.com/articles/global-markets-asian-stocks-set-to-track-u.s.-gains-as-virus-treatment-hopes-lift", "https://www.nasdaq.com/articles/why-discover-financial-stock-jumped-15-today-2020-04-29", "https://www.nasdaq.com/articles/why-discover-financial-stock-jumped-15today-2020-04-29", "https://www.nasdaq.com/articles/the-dow-surged-532-points-because-were-closer-to-a-covid-19-drug-2020-04-29", "https://www.nasdaq.com/articles/indian-shares-soar-on-covid-19-drug-hopes-set-for-best-month-since-2009-2020-04-30", "https://www.nasdaq.com/articles/global-markets-stocks-rally-on-treatment-hopes-currencies-await-ecb-2020-04-30", "https://www.nasdaq.com/articles/dow-oil-close-with-strong-wins-2020-04-29", "https://www.nasdaq.com/articles/wall-street-rallies-on-promising-coronavirus-drug-2020-04-29", "https://www.nasdaq.com/articles/why-novavax-stock-slumped-today-2020-04-29", "https://www.nasdaq.com/articles/global-markets-shares-jump-on-coronavirus-treatment-hopes-oil-soars-2020-04-29", "https://www.nasdaq.com/articles/emerging-markets-latam-shares-fx-rally-as-hopes-of-covid-19-drug-lifts-sentiment-2020-04", "https://www.nasdaq.com/articles/this-news-has-foot-locker-stock-running-higher-today-2020-04-29", "https://www.nasdaq.com/articles/breakingviews-corona-capital%3A-u.s.-gdp-gileads-drug-spotify-2020-04-29", "https://www.nasdaq.com/articles/dow-jones-today%3A-vaccine-hopes-overcame-contracting-gdp-2020-04-29", "https://www.nasdaq.com/articles/american-airlines-stock-is-still-a-long-term-winner-2020-04-29", "https://www.nasdaq.com/articles/u.s.-stocks-rally-on-coronavirus-drug-hopes-2020-04-29", "https://www.nasdaq.com/articles/restaurant-stocks-soar-wednesday-on-positive-covid-19-developments-2020-04-29", "https://www.nasdaq.com/articles/why-hotel-stocks-are-surging-today-2020-04-29", "https://www.nasdaq.com/articles/what-lies-ahead-for-vaccine-development-and-ino-stock-in-may-2020-04-29", "https://www.nasdaq.com/articles/heres-why-visa-mastercard-and-american-express-are-higher-on-wednesday-2020-04-29", "https://www.nasdaq.com/articles/forex-dollar-drops-as-fed-repeats-vow-to-support-economy-2020-04-29", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-capricor-therapeutics-liberty-oilfield-blue-apron-2020-04-29", "https://www.nasdaq.com/articles/covid-19-complication-seen-in-children-is-rare-who-says-2020-04-29", "https://www.nasdaq.com/articles/buy-gilead-stock-because-remdesivir-is-a-covid-19-game-changer-2020-04-29", "https://www.nasdaq.com/articles/stock-market-news%3A-mastercard-charges-ahead-alphabet-spells-ad-success-2020-04-29", "https://www.nasdaq.com/articles/gold-falls-as-equities-drift-higher-ahead-of-fed-statement-2020-04-29", "https://www.nasdaq.com/articles/wall-st-jumps-on-coronavirus-drug-hopes-fed-decision-awaited-2020-04-29", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-liberty-oilfield-mrc-global-capricor-therapeutics-2020-04-29", "https://www.nasdaq.com/articles/wall-street-jumps-on-coronavirus-drug-hopes-fed-in-focus-2020-04-29", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-capricor-therapeutics-liberty-oilfield-blue-apron-2020-04-29", "https://www.nasdaq.com/articles/covid-19-complication-seen-in-children-is-rare-who-says-2020-04-29", "https://www.nasdaq.com/articles/what-to-expect-from-gilead-earnings-2020-04-29", "https://www.nasdaq.com/articles/yields-down-ahead-of-fed-meeting-wrap-up-2020-04-29", "https://www.nasdaq.com/articles/dollar-drops-as-coronavirus-treatment-hopes-boosts-risk-sentiment-2020-04-29", "https://www.nasdaq.com/articles/wall-street-jumps-on-hopes-of-potential-coronavirus-drug-2020-04-29", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-alphabet-spotify-blue-apron-2020-04-29", "https://www.nasdaq.com/articles/stock-alert%3A-gilead-sciences-up-4-on-positive-data-on-covid-19-drug-2020-04-29", "https://www.nasdaq.com/articles/gilead-sciences-records-positive-data-from-10-day-covid-19-trial-of-remdesivir-2020-04-29", "https://www.nasdaq.com/articles/gilead-says-remdesivir-shows-improvement-in-covid-19-patients-when-used-early-2020-04-29", "https://www.nasdaq.com/articles/us-stocks-snapshot-futures-jump-after-gileads-covid-19-drug-meets-main-goal-2020-04-29", "https://www.nasdaq.com/articles/gileads-remdesivir-meets-main-goal-of-trial-in-covid-19-patients-2020-04-29", "https://www.nasdaq.com/articles/better-buy%3A-cara-therapeutics-vs.-sangamo-therapeutics-2020-04-29", "https://www.nasdaq.com/articles/the-cure-for-profitably-in-buying-gilead-sciences-2020-04-29", "https://www.nasdaq.com/articles/european-shares-rise-on-covid-19-drug-hopes-upbeat-outlook-from-corporates-2020-04-29", "https://www.nasdaq.com/articles/wall-st-set-to-jump-at-open-on-hopes-of-potential-coronavirus-drug-2020-04-29", "https://www.nasdaq.com/articles/10-stocks-to-buy-for-an-aging-population-2020-04-28", "https://www.nasdaq.com/articles/the-abbvie-buyout-is-not-a-sure-thing-for-allergan-stock-investors-2020-04-28", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-regeneron-zoom-video-u.s.-oil-companies-apple-u.s.-insurers", "https://www.nasdaq.com/articles/pfizer-stock-is-much-more-than-just-a-coronavirus-play-2020-04-27", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-kohls-tanker-operators-oil-and-gas-companies-u.s.-casinos", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tanker-operators-oil-and-gas-companies-caterpillar-2020-04-27", "https://www.nasdaq.com/articles/dont-let-negative-data-dissuade-you-from-gilead-sciences-2020-04-27", "https://www.nasdaq.com/articles/gilead-sciences-gild-remdesivir-sparks-market-hope-with-trial-success-2020-04-29", "https://www.nasdaq.com/articles/heres-what-to-expect-with-gilead-sciences-q1-earnings-update-2020-04-27", "https://www.nasdaq.com/articles/analysis-investors-bet-on-testing-treatments-for-restart-of-u.s.-economy-2020-04-27", "https://www.nasdaq.com/articles/moderna-scores-huge-grant-leads-charge-toward-coronavirus-vaccine-2020-04-27", "https://www.nasdaq.com/articles/analysis-investors-bet-on-testing-treatments-for-restart-of-u.s.-economy-2020-04-26", "https://www.nasdaq.com/articles/why-is-the-stock-market-hanging-its-hopes-on-gileads-remdesivir-2020-04-26", "https://www.nasdaq.com/articles/while-big-pharma-tanked-gilead-sciences-and-regeneron-soared-2020-04-25", "https://www.nasdaq.com/articles/gilead-sciences-disputes-claim-that-remdesivir-failed-in-a-covid-19-trial-2020-04-24", "https://www.nasdaq.com/articles/besides-remdesivir-these-2-covid-19-treatments-could-have-promise-2020-04-27", "https://www.nasdaq.com/articles/exclusive-trial-of-gileads-potential-coronavirus-treatment-running-ahead-of-schedule-0", "https://www.nasdaq.com/articles/exclusive-trial-of-gileads-potential-coronavirus-treatment-running-ahead-of-schedule", "https://www.nasdaq.com/articles/global-markets-stocks-struggle-with-muddled-government-pandemic-response-2020-04-24", "https://www.nasdaq.com/articles/why-remdesivir-clinical-studies-will-lift-gilead-sciences-2020-04-24", "https://www.nasdaq.com/articles/3-top-stocks-under-%245-to-buy-now-2020-04-24", "https://www.nasdaq.com/articles/global-markets-global-equities-edge-higher-as-oil-continues-rebound-2020-04-24", "https://www.nasdaq.com/articles/the-coronavirus-makes-ibio-finally-relevant-2020-04-24", "https://www.nasdaq.com/articles/exclusive-trial-of-gileads-potential-coronavirus-treatment-running-ahead-of-schedule-1", "https://www.nasdaq.com/articles/exclusive-trial-of-gileads-potential-coronavirus-treatment-running-ahead-of-schedule-0", "https://www.nasdaq.com/articles/emerging-markets-set-for-weekly-losses-as-doubts-arise-over-covid-19-drug-efficacy-2020-04", "https://www.nasdaq.com/articles/global-markets-stocks-fall-on-worries-over-eu-stimulus-details-coronavirus-drug-2020-04-24", "https://www.nasdaq.com/articles/ftse-100-tracks-global-mood-lower-as-retail-sales-sink-2020-04-24", "https://www.nasdaq.com/articles/european-shares-slide-as-pandemic-jitters-return-2020-04-24", "https://www.nasdaq.com/articles/em-asia-fx-currencies-ease-on-lockdown-extensions-coronavirus-drug-report-2020-04-24", "https://www.nasdaq.com/articles/sanofi-confirms-targets-strong-demand-for-pain-killers-lifts-q1-2020-04-24", "https://www.nasdaq.com/articles/european-shares-slide-as-eu-stimulus-fails-to-impress-2020-04-24", "https://www.nasdaq.com/articles/se-asia-stocks-most-slide-on-lockdown-extension-in-parts-of-region-weak-global-data-2020", "https://www.nasdaq.com/articles/global-markets-asian-shares-fall-on-coronavirus-drug-economic-damage-concerns-2020-04-23", "https://www.nasdaq.com/articles/global-markets-asian-stocks-poised-to-rise-after-wall-street-gains-slip-away-2020-04-23", "https://www.nasdaq.com/articles/gilead-sciences-rebuts-report-claiming-covid-19-drug-remdesivir-trial-failed-2020-04-23", "https://www.nasdaq.com/articles/5-top-stock-trades-for-friday%3A-gild-ino-lvs-dpz-lly-2020-04-23", "https://www.nasdaq.com/articles/stock-market-wrap-up%3A-why-zoom-and-royal-caribbean-shares-jumped-today-2020-04-23", "https://www.nasdaq.com/articles/gileads-remdesivir-reportedly-flopped-in-chinese-covid-19-study-2020-04-23", "https://www.nasdaq.com/articles/global-markets-asian-stocks-fall-europe-set-to-follow-on-doubts-over-coronavirus-drug-2020", "https://www.nasdaq.com/articles/sp-500-slips-after-report-on-coronavirus-drug-trial-2020-04-23-0", "https://www.nasdaq.com/articles/sp-500-slips-after-report-on-coronavirus-drug-trial-2020-04-23", "https://www.nasdaq.com/articles/who-to-launch-initiative-to-share-covid-19-drugs-tests-and-vaccines-statement-2020-04-23", "https://www.nasdaq.com/articles/wall-street-trims-gains-after-report-on-coronavirus-drug-trial-2020-04-23", "https://www.nasdaq.com/articles/buy-the-dip-in-gilead-stock-because-remdesivir-may-not-be-a-flop-2020-04-23", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-sleep-number-crocs-cassava-sciences-2020-04-23", "https://www.nasdaq.com/articles/7-safe-stocks-to-buy-on-the-coronavirus-dip-2020-04-23", "https://www.nasdaq.com/articles/jobs-data-treatment-buzz-keep-stock-gains-in-check-2020-04-23", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-cof-gild-wynn-2020-04-23", "https://www.nasdaq.com/articles/wall-street-pares-gains-on-report-of-potential-coronavirus-drug-failing-trial-2020-04-23", "https://www.nasdaq.com/articles/gileads-coronavirus-drug-flops-in-first-trial-ft-2020-04-23", "https://www.nasdaq.com/articles/first-week-of-gild-july-17th-options-trading-2020-04-23", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-expedia-group-crocs-enzo-biochem-2020-04-23", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-immunomedics-helix-energy-sleep-number-corp-2020-04-23", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-aytu-bioscience-qep-resources-immunomedics-2020-04-23", "https://www.nasdaq.com/articles/wall-st-rises-on-hopes-worst-for-labor-market-is-over-2020-04-23-0", "https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-gilead-sciences-2020-04-23", "https://www.nasdaq.com/articles/foreigners-remain-net-sellers-of-japan-stocks-for-10th-week-2020-04-23", "https://www.nasdaq.com/articles/how-banks-have-prepared-for-a-slowdown-2020-04-22", "https://www.nasdaq.com/articles/artificial-intelligence-and-drug-discovery%3A-the-companies-leading-the-way-2020-04-22", "https://www.nasdaq.com/articles/the-10-best-dividend-stocks-for-2020-2020-04-22", "https://www.nasdaq.com/articles/does-british-american-tobaccos-covid-19-vaccine-make-it-a-buy-2020-04-22", "https://www.nasdaq.com/articles/gilead-sciences-races-to-manufacture-remdesivir-but-chemistry-has-speed-limits-2020-04-22", "https://www.nasdaq.com/articles/is-it-too-late-to-buy-gilead-sciences-2020-04-23", "https://www.nasdaq.com/articles/3-great-reasons-to-buy-gilead-sciences-stock-2020-04-22", "https://www.nasdaq.com/articles/gilead-onko-innate-announce-research-collaboration-for-cancer-therapy-2020-04-21", "https://www.nasdaq.com/articles/gilead-sciences%3A-possible-covid-19-treatment-already-priced-in-the-stock-says-analyst-2020", "https://www.nasdaq.com/articles/why-these-covid-19-vaccine-stocks-soared-today-2020-04-20", "https://www.nasdaq.com/articles/alexion-pharmaceuticals-to-initiate-phase-3-study-for-ultomiris-as-a-potential-coronavirus", "https://www.nasdaq.com/articles/theres-more-to-gilead-sciences-remdesivir-data-than-meets-the-eye-2020-04-20", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-co-diagnostics-xeris-pharma-cyclacel-pharma-2020-04-20", "https://www.nasdaq.com/articles/4-reasons-why-chesapeake-energy-stock-can-survive-2020-04-22", "https://www.nasdaq.com/articles/gilead-sciences-reaches-analyst-target-price-2020-04-20", "https://www.nasdaq.com/articles/stock-market-gains-alongside-economic-pain-some-worry-about-over-optimism-2020-04-20", "https://www.nasdaq.com/articles/novartis-u.s.-drug-regulator-agree-to-malaria-drug-trial-against-covid-19-2020-04-20", "https://www.nasdaq.com/articles/novartis-u.s.-regulators-agree-to-malaria-drug-trial-against-covid-19-2020-04-20", "https://www.nasdaq.com/articles/stock-market-gains-alongside-economic-pain-some-worry-about-over-optimism-2020-04-19", "https://www.nasdaq.com/articles/if-you-invested-%241000-in-gilead-sciences-ipo-this-is-how-much-money-youd-have-now-2020-04", "https://www.nasdaq.com/articles/2-best-stocks-to-buy-now-2020-04-19", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-vym-gild-cme-usb-2020-04-20", "https://www.nasdaq.com/articles/why-restaurant-stocks-jumped-today-2020-04-18", "https://www.nasdaq.com/articles/emerging-markets-mexican-peso-rises-on-stimulus-latam-fx-ends-week-in-losses-2020-04-17", "https://www.nasdaq.com/articles/wall-street-gains-on-boeing-surge-and-coronavirus-drug-hopes-2020-04-17", "https://www.nasdaq.com/articles/4-top-stock-trades-for-monday%3A-ba-mrna-slb-ksu-2020-04-17", "https://www.nasdaq.com/articles/global-markets-stocks-rally-as-investors-take-heart-on-u.s.-economic-reopening-plan-2020", "https://www.nasdaq.com/articles/wall-street-gains-on-boeing-surge-coronavirus-drug-hopes-2020-04-17-0", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-17-2020%3A-genegildworx-2020-04-17-0", "https://www.nasdaq.com/articles/can-gilead-sciences-coronavirus-gains-continue-2020-04-19", "https://www.nasdaq.com/articles/gilead-stock-isnt-worth-chasing-now-despite-recent-remdesivir-success-2020-04-17", "https://www.nasdaq.com/articles/why-shares-of-amc-cinemark-live-nation-and-planet-fitness-popped-today-2020-04-17", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-17-2020%3A-genegildworx-2020-04-17", "https://www.nasdaq.com/articles/wall-st-climbs-on-boeing-trumps-reopening-plan-2020-04-17", "https://www.nasdaq.com/articles/whether-or-not-gilead-sciences-produces-a-successful-covid-19-therapeutic-its-a-bargain", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-netflix-cutera-moderna-2020-04-17", "https://www.nasdaq.com/articles/gileads-shares-rise-on-report-of-experimental-drugs-promise-in-covid-19-2020-04-17-0", "https://www.nasdaq.com/articles/wall-street-gains-on-boeing-news-trumps-reopening-plan-2020-04-17", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-schlumberger-biohaven-pharmaceutical-spirit-aerosystems-2020", "https://www.nasdaq.com/articles/wall-st-gains-on-boeing-trumps-restart-plan-2020-04-17", "https://www.nasdaq.com/articles/heres-why-jpmorgan-chase-and-other-bank-stocks-are-up-on-friday-2020-04-17", "https://www.nasdaq.com/articles/stock-market-news%3A-coronavirus-hopes-boost-these-2-stocks-2020-04-17", "https://www.nasdaq.com/articles/boeing-trumps-restart-plan-boost-wall-street-2020-04-17", "https://www.nasdaq.com/articles/emerging-markets-latam-fx-topped-by-chiles-peso-but-eyes-weekly-losses-2020-04-17", "https://www.nasdaq.com/articles/gileads-remdesivir-shows-promise-against-covid-19-in-sneak-peek-at-clinical-trial-data", "https://www.nasdaq.com/articles/global-markets-stocks-race-toward-second-weekly-gain-2020-04-17", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-schlumberger-biohaven-pharmaceutical-spirit-aerosystems-2020", "https://www.nasdaq.com/articles/wall-st-gains-on-boeing-trumps-restart-plan-2020-04-17", "https://www.nasdaq.com/articles/heres-why-jpmorgan-chase-and-other-bank-stocks-are-up-on-friday-2020-04-17", "https://www.nasdaq.com/articles/boeing-lockdown-easing-hopes-set-to-lift-wall-street-2020-04-17", "https://www.nasdaq.com/articles/institutional-investors-tell-big-pharma-to-cooperate-on-coronavirus-2020-04-17", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-pulmatrix-cutera-moderna-spirit-aerosystems-2020-04-17", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-ctxs-gild-2020-04-17", "https://www.nasdaq.com/articles/global-markets-super-charged-stocks-race-towards-second-weekly-gain-2020-04-17", "https://www.nasdaq.com/articles/daily-markets%3A-investors-cheer-gilead-results-and-reopening-roadmap-2020-04-17", "https://www.nasdaq.com/articles/u.s.-stocks-futures-jump-on-trumps-restart-plan-coronavirus-drug-hopes-2020-04-17", "https://www.nasdaq.com/articles/dont-waste-your-money-on-penny-stocks-these-2-stocks-are-better-buys-2020-04-17", "https://www.nasdaq.com/articles/us-stocks-futures-jump-on-trumps-restart-plan-coronavirus-drug-hopes-2020-04-17", "https://www.nasdaq.com/articles/uk-shares-surge-on-signs-of-u.s.-restart-rio-tinto-results-2020-04-17", "https://www.nasdaq.com/articles/global-markets-super-charged-stocks-race-toward-second-best-week-ever-2020-04-17", "https://www.nasdaq.com/articles/coronavirus-drug-results-send-gilead-sciences-stock-flying-jpmorgan-weighs-in-2020-04-17", "https://www.nasdaq.com/articles/lonza-focuses-on-coronavirus-projects-as-epidemic-brings-in-new-business-2020-04-17", "https://www.nasdaq.com/articles/south-african-rand-stronger-at-end-of-torrid-week-2020-04-17", "https://www.nasdaq.com/articles/global-markets-asian-stocks-rise-as-re-open-of-u.s-economy-offsets-china-gdp-slump-2020-04", "https://www.nasdaq.com/articles/nikkei-scales-6-week-high-on-hopes-for-virus-treatment-u.s.-plan-to-reopen-2020-04-17", "https://www.nasdaq.com/articles/hopes-for-virus-treatment-u.s.-reopening-snuff-out-dollar-rally-2020-04-17", "https://www.nasdaq.com/articles/dollar-slips-as-hopes-for-virus-treatment-prop-up-risk-appetite-2020-04-16", "https://www.nasdaq.com/articles/dollar-wobbles-as-fresh-hopes-for-virus-treatment-prop-up-risk-appetite-2020-04-16", "https://www.nasdaq.com/articles/emerging-markets-equities-buoyed-by-u.s.-optimism-as-currencies-dip-2020-04-17", "https://www.nasdaq.com/articles/global-markets-asian-stocks-set-to-rise-as-markets-brace-for-china-gdp-data-2020-04-16", "https://www.nasdaq.com/articles/u.s.-stock-futures-jump-late-following-data-on-potential-virus-treatment-trump-guidelines", "https://www.nasdaq.com/articles/gilead-surges-after-report-suggests-covid-19-patients-responding-to-remdesivir-2020-04-16", "https://www.nasdaq.com/articles/gilead-sciences-drug-shows-promising-results-in-covid-19-patients-stock-up-14-2020-04-16", "https://www.nasdaq.com/articles/why-gilead-sciences-stock-is-on-fire-today-2020-04-16", "https://www.nasdaq.com/articles/report%3A-gilead-is-considering-taking-a-stake-in-arcus-biosciences-2020-04-16", "https://www.nasdaq.com/articles/is-exelixis-a-buy-2020-04-16", "https://www.nasdaq.com/articles/report-says-covid-19-patients-respond-to-gileads-remdesivir-shares-surge-2020-04-16", "https://www.nasdaq.com/articles/gilead-sciences-remdesivir-data-release-brings-much-needed-relief-for-patients-and", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-16-2020%3A-sngx-gild-rcus-rad-jnj-pfe-abt-mrk-amgn-2020-04", "https://www.nasdaq.com/articles/astrazeneca-to-test-blood-cancer-drug-for-covid-19-treatment-2020-04-15", "https://www.nasdaq.com/articles/chinese-researchers-suspend-trial-of-experimental-coronavirus-treatment-2020-04-15", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-u.s.-oil-stocks-retailers-restaurants-bofa-j.c.-penny-ibm", "https://www.nasdaq.com/articles/buying-gilead-sciences-stock-means-buying-into-political-risk-2020-04-15", "https://www.nasdaq.com/articles/initial-coronavirus-treatment-trials-look-good-for-gilead-stock-2020-04-15", "https://www.nasdaq.com/articles/why-arcus-biosciences-stock-is-skyrocketing-today-2020-04-16", "https://www.nasdaq.com/articles/gilead-sciences-remdesivir-data-release-brings-much-needed-relief-for-patients-and", "https://www.nasdaq.com/articles/three-reasons-to-consider-buying-regeneron-stock-2020-04-14", "https://www.nasdaq.com/articles/how-good-is-gileads-latest-news-for-coronavirus-drug-remdesivir-2020-04-14", "https://www.nasdaq.com/articles/amrn-chugs-along-athx-to-initiate-pivotal-covid-19-trial-worx-soars-550-2020-04-13", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-13-2020%3A-pstiworxgildcanf-2020-04-13", "https://www.nasdaq.com/articles/reasons-for-hope%3A-the-drugs-tests-and-tactics-that-may-conquer-coronavirus-2020-04-13", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-13-2020%3A-worxgildcanf-2020-04-13", "https://www.nasdaq.com/articles/gilead-stock-could-get-a-lift-from-a-coronavirus-treatment-2020-04-15", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-amazon.com-netflix-royal-caribbean-cruises-sabre-corp", "https://www.nasdaq.com/articles/wall-street-week-ahead-health-tech-staples-could-shine-through-earnings-gloom-2020-04-13", "https://www.nasdaq.com/articles/wall-street-set-to-dip-as-focus-turns-to-earnings-2020-04-13", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-13-2020%3A-canf-ctso-gild-jnj-pfe-abt-mrk-amgn-2020-04-13", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-carnival-corp-gilead-sciencs-pluristem-therapeutics-dropbox", "https://www.nasdaq.com/articles/us-stocks-futures-fall-as-focus-turns-to-corporate-earnings-2020-04-13", "https://www.nasdaq.com/articles/3-top-biotech-stocks-to-buy-in-april-2020-04-12", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-netflix-amazon.com-dish-network-ge-amc-entertainment-aurora", "https://www.nasdaq.com/articles/eli-lilly-starts-clinical-trial-for-potential-covid-19-treatment-2020-04-11", "https://www.nasdaq.com/articles/early-look-at-gilead-sciences-experimental-coronavirus-treatment-disappoints-2020-04-11", "https://www.nasdaq.com/articles/5-biotech-stocks-winning-the-coronavirus-race-2020-04-11", "https://www.nasdaq.com/articles/bristol-myers-win-in-u.s.-patent-case-against-gilead-boosted-to-%241.2-bln-2020-04-09", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-09-2020%3A-biocbhcbhc.tortixgild-2020-04-09", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-09-2020%3A-bhcbhc.tortixgild-2020-04-09", "https://www.nasdaq.com/articles/gild-may-29th-options-begin-trading-2020-04-09", "https://www.nasdaq.com/articles/is-galapagos-stock-a-buy-2020-04-12", "https://www.nasdaq.com/articles/gilead-canada-submits-snds-to-health-canada-for-descovy-quick-facts-2020-04-09", "https://www.nasdaq.com/articles/why-forty-seven-stock-skyrocketed-64.5-in-march-2020-04-08", "https://www.nasdaq.com/articles/good-news-for-remdesivir-is-good-news-for-gilead-sciences-stock-2020-04-08", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-emergent-biosolutions-vs.-gilead-sciences-2020-04-08", "https://www.nasdaq.com/articles/novavax-to-start-human-trial-for-novel-coronavirus-vaccine-2020-04-08", "https://www.nasdaq.com/articles/graphic-wall-st-volatility-raises-fears-of-another-selloff-2020-04-07", "https://www.nasdaq.com/articles/investors-await-data-on-coronavirus-drugs-as-market-rally-builds-2020-04-07", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-ctxs-ual-2020-04-09", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-activision-blizzard-gilead-sciences-royal-caribbean-kohls", "https://www.nasdaq.com/articles/is-inovio-pharmaceuticals-a-good-buy-on-coronavirus-potential-2020-04-07", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-royal-caribbean-kohls-gilead-sciences-electronic-arts-2020-04", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-roadrunner-transportation-gannett-co-liminal-biosciences-2020", "https://www.nasdaq.com/articles/gilead-unit-completes-acquisition-of-forty-seven-quick-facts-2020-04-07", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-roadrunner-transportation-trevi-therapeutics-gannett-co-2020", "https://www.nasdaq.com/articles/here-are-all-the-companies-working-on-covid-19-vaccines-treatments-and-testing-2020-04-07", "https://www.nasdaq.com/articles/tuesday-sector-laggards%3A-utilities-healthcare-2020-04-07", "https://www.nasdaq.com/articles/gilead-sciences-pins-its-hopes-on-remdesivir-2020-04-07", "https://www.nasdaq.com/articles/doctors-embrace-drug-touted-by-trump-for-covid-19-without-hard-evidence-it-works-2020-04", "https://www.nasdaq.com/articles/monday-sector-laggards%3A-healthcare-energy-2020-04-06", "https://www.nasdaq.com/articles/coronavirus-fighter-gilead-sciences-might-be-expensive-but-its-still-worth-owning-2020-04", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-gilead-sciences-wayfair-immunomedics-akers-bioscience-2020-04", "https://www.nasdaq.com/articles/gsk-to-partner-with-vir-for-potential-covid-19-treatments-invest-%24250-mln-2020-04-06-1", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-carnival-corp-capri-holdings-kohls-immunomedics-2020-04-06", "https://www.nasdaq.com/articles/my-top-biotech-stocks-to-buy-in-the-market-crash-2020-04-07", "https://www.nasdaq.com/articles/gilead-sciences-pins-its-hopes-on-remdesivir-2020-04-07", "https://www.nasdaq.com/articles/its-tough-to-admit-but-our-new-normal-might-justify-buying-ibio-stock-2020-04-06", "https://www.nasdaq.com/articles/gilead-to-donate-1.5-mln-doses-of-investigational-covid-19-drug-remdesivir-2020-04-06", "https://www.nasdaq.com/articles/gsk-to-partner-with-vir-for-potential-covid-19-treatments-invest-%24250-mln-2020-04-06-0", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-borr-drillng-millendo-therapeutics-menlo-therapeutics", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-crescent-point-energy-millendo-therapeutics-menlo", "https://www.nasdaq.com/articles/gilead-second-genome-enter-four-year-strategic-collaboration-quick-facts-2020-04-06", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-kohls-carnival-corp-akers-bioscience-immunomedics-2020-04-06", "https://www.nasdaq.com/articles/the-5-best-coronavirus-stocks-to-buy-right-now-2020-04-05", "https://www.nasdaq.com/articles/should-you-buy-gilead-sciences-stock-right-now-2020-04-05", "https://www.nasdaq.com/articles/yes-the-stock-market-will-probably-go-lower.-heres-why-you-should-invest-anyway.-2020-04", "https://www.nasdaq.com/articles/3-coronavirus-stocks-that-could-lead-the-market-to-recovery-2020-04-05", "https://www.nasdaq.com/articles/should-you-buy-forty-seven-before-gilead-sciences-acquisition-closes-2020-04-04", "https://www.nasdaq.com/articles/is-the-end-of-quarter-market-run-up-just-wall-street-dressing-the-window-2020-04-04", "https://www.nasdaq.com/articles/why-gilead-sciences-is-the-hottest-stock-to-buy-today-2020-04-04", "https://www.nasdaq.com/articles/gilead-has-treated-more-than-1700-covid-19-patients-with-remdesivir-2020-04-06", "https://www.nasdaq.com/articles/gilead-sciences-coronavirus-treatment-has-big-time-potential-2020-04-03", "https://www.nasdaq.com/articles/ema-recommends-remdesivir-for-treatment-of-covid-19-under-compassionate-use-rules-2020-04", "https://www.nasdaq.com/articles/ema-recommends-compassionate-use-of-gileads-remdesivir-for-covid-19-2020-04-03", "https://www.nasdaq.com/articles/why-gilead-sciences-shares-rose-7.79-in-march-2020-04-03", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-biogen-2020-04-03", "https://www.nasdaq.com/articles/gild-may-22nd-options-begin-trading-2020-04-02", "https://www.nasdaq.com/articles/gild-stock-remains-a-smart-play-now-and-in-the-future-2020-04-02", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-mtsi-gild-wynn-2020-04-03", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-abbott-labs-vs.-gilead-sciences-2020-04-02", "https://www.nasdaq.com/articles/my-top-pharma-stocks-to-buy-in-the-market-crash-2020-04-02", "https://www.nasdaq.com/articles/is-ibio-stock-worth-the-risk-as-coronavirus-continues-to-spread-2020-03-31", "https://www.nasdaq.com/articles/5-hot-stocks-for-2020-that-are-soaring-while-the-market-plunges-2020-03-31", "https://www.nasdaq.com/articles/gileads-cash-and-the-coronavirus-make-gild-stock-look-cheap-2020-03-31", "https://www.nasdaq.com/articles/look-for-better-buys-than-coronavirus-play-ino-stock-2020-03-30", "https://www.nasdaq.com/articles/4-reasons-drug-stocks-are-a-buy-right-now-2020-03-30", "https://www.nasdaq.com/articles/top-3-healthcare-stocks-to-buy-right-now-2020-04-02", "https://www.nasdaq.com/articles/gilead-expands-access-to-investigational-anti-coronavirus-drug-2020-03-30", "https://www.nasdaq.com/articles/gilead-sciences-expands-access-to-experimental-covid-19-treatment-2020-03-29", "https://www.nasdaq.com/articles/3-coronavirus-proof-dividend-stocks-that-are-perfect-for-retirees-2020-03-29", "https://www.nasdaq.com/articles/2-biotech-stocks-in-the-hunt-for-new-coronavirus-drugs-oppenheimer-weighs-in-2020-03-29", "https://www.nasdaq.com/articles/the-3-most-resilient-stocks-in-the-bear-market-today-2020-03-28", "https://www.nasdaq.com/articles/first-week-of-gild-november-20th-options-trading-2020-03-27", "https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-rsp-regn-gild-amd-2020-03-27", "https://www.nasdaq.com/articles/is-it-time-to-buy-stocks-or-is-the-market-heading-even-lower-2020-03-30", "https://www.nasdaq.com/articles/for-gilead-its-coronavirus-treatment-is-icing-on-the-cake-2020-03-27", "https://www.nasdaq.com/articles/3-things-to-know-if-chloroquine-wins-the-covid-19-treatment-race-2020-03-27", "https://www.nasdaq.com/articles/7-u.s.-stocks-to-buy-on-coronavirus-weakness-2020-03-26", "https://www.nasdaq.com/articles/this-pr-nightmare-for-gild-stock-will-eventually-fade-2020-03-26", "https://www.nasdaq.com/articles/may-8th-options-now-available-for-gilead-sciences-gild-2020-03-26", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-gilead-sciences-vs.-moderna-2020-03-26", "https://www.nasdaq.com/articles/1-safe-haven-stock-for-the-near-term-2020-03-26", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-expe-gild-2020-03-27", "https://www.nasdaq.com/articles/a-covid-19-immunity-test-is-on-the-way-2020-03-25", "https://www.nasdaq.com/articles/gilead-asks-the-fda-to-rescind-orphan-drug-designation-for-remdesivir-as-a-treatment-for", "https://www.nasdaq.com/articles/health-care-sector-update-for-03-25-2020%3A-gildastcvtgnallk-2020-03-25", "https://www.nasdaq.com/articles/how-are-market-caps-doing-in-a-downturn-2020-03-25", "https://www.nasdaq.com/articles/moderna-ceo-says-a-coronavirus-vaccine-could-be-available-in-emergencies-this-fall-2020-03", "https://www.nasdaq.com/articles/wednesday-sector-laggards%3A-technology-communications-healthcare-2020-03-25", "https://www.nasdaq.com/articles/5-stocks-to-buy-in-the-coronavirus-bear-market-2020-03-25", "https://www.nasdaq.com/articles/gild-seeks-to-revoke-coveted-status-elox-pauses-trial-prqr-on-watch-2020-03-26", "https://www.nasdaq.com/articles/coronavirus-drugs-already-in-the-pipeline-2020-03-25", "https://www.nasdaq.com/articles/10-stocks-to-buy-as-they-ride-a-coronavirus-tailwind-2020-03-24", "https://www.nasdaq.com/articles/top-notch-vaccine-technology-makes-ibio-stock-a-smart-bet-2020-03-24", "https://www.nasdaq.com/articles/inovio-could-be-a-bargain-using-probability-analysis-2020-03-24", "https://www.nasdaq.com/articles/3-biotech-stocks-fighting-the-coronavirus-heres-what-to-expect-2020-03-24", "https://www.nasdaq.com/articles/top-pharma-stocks-under-%245-2020-03-24", "https://www.nasdaq.com/articles/why-consider-these-2-stocks-when-markets-are-crashing-2020-03-24", "https://www.nasdaq.com/articles/4-reasons-biotech-stocks-are-a-buy-right-now-2020-03-25", "https://www.nasdaq.com/articles/gilead-sciences-stops-accepting-emergency-use-applications-for-remdesivir-2020-03-23", "https://www.nasdaq.com/articles/dont-forget-about-stocks-to-buy-during-the-coronavirus-crisis-2020-03-23", "https://www.nasdaq.com/articles/3-things-to-watch-in-the-coronavirus-bear-market-this-week-2020-03-23", "https://www.nasdaq.com/articles/coronavirus-crisis%3A-3-biotech-stocks-to-buy-right-now-2020-03-22", "https://www.nasdaq.com/articles/all-the-drugs-proving-anecdotally-effective-against-covid-19-and-the-companies-that-make", "https://www.nasdaq.com/articles/nonprofit-group-starts-multiple-covid-19-clinical-studies-2020-03-21", "https://www.nasdaq.com/articles/gileads-coronavirus-vaccine-candidate-shows-promise-says-cowen-2020-03-20", "https://www.nasdaq.com/articles/gilead-stock-flies-high-with-a-potential-coronavirus-treatment-2020-03-23", "https://www.nasdaq.com/articles/3-of-the-strongest-stocks-to-buy-2020-03-20", "https://www.nasdaq.com/articles/these-4-top-stocks-are-bear-market-tested-2020-03-20", "https://www.nasdaq.com/articles/is-it-too-late-to-buy-coronavirus-biotech-stocks-2020-03-20", "https://www.nasdaq.com/articles/mylan-ramps-up-production-of-hydroxychloroquine-as-a-potential-covid-19-treatment-2020-03", "https://www.nasdaq.com/articles/china-reports-no-new-coronavirus-outbreaks-first-time-since-outbreak-began-2020-03-19", "https://www.nasdaq.com/articles/remdesivir-other-positive-catalysts-should-lift-gilead-stock-2020-03-19", "https://www.nasdaq.com/articles/coronavirus-fighting-tech-makes-ibio-stock-an-interesting-play-2020-03-19", "https://www.nasdaq.com/articles/trumps-coronavirus-news-conference-on-thursday%3A-3-key-things-that-investors-should-know", "https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-esgu-nee-adbe-gild-2020-03-19", "https://www.nasdaq.com/articles/big-pharmas-fight-against-the-coronavirus-pandemic%3A-good-news-and-bad-news-2020-03-19", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-gilead-sciences-or-regeneron-pharmaceuticals-2020-03-19", "https://www.nasdaq.com/articles/trump-signs-coronavirus-relief-bill-into-law-2020-03-19", "https://www.nasdaq.com/articles/bayer-is-donating-its-malaria-drug-that-could-help-coronavirus-patients-in-the-u.s.-2020", "https://www.nasdaq.com/articles/will-covid-19-derail-new-drugs-2020-03-18", "https://www.nasdaq.com/articles/why-is-everyone-talking-about-gilead-sciences-2020-03-18", "https://www.nasdaq.com/articles/japanese-developed-flu-drug-avigan-seems-effective-against-covid-19-2020-03-19", "https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-esgu-nee-adbe-gild-2020-03-19", "https://www.nasdaq.com/articles/why-regeneron-pharmaceuticals-stock-is-bolting-higher-today-2020-03-17", "https://www.nasdaq.com/articles/3-cloud-computing-stocks-that-are-winning-from-the-coronavirus-2020-03-17", "https://www.nasdaq.com/articles/coronavirus-correction%3A-3-must-own-dividend-stocks-2020-03-17", "https://www.nasdaq.com/articles/will-your-elective-surgery-be-delayed-by-coronavirus-2020-03-17", "https://www.nasdaq.com/articles/european-medicines-agency-offers-free-advice-for-drugmakers-working-on-coronavirus", "https://www.nasdaq.com/articles/as-the-coronavirus-worsens-ino-stock-gets-more-interesting-2020-03-16", "https://www.nasdaq.com/articles/how-to-survive-the-economic-fallout-from-covid-19-2020-03-18", "https://www.nasdaq.com/articles/can-this-american-biotech-company-save-the-global-economy-2020-03-16", "https://www.nasdaq.com/articles/why-this-coronavirus-stock-will-keep-growing-long-after-the-outbreak-is-over-2020-03-15", "https://www.nasdaq.com/articles/when-will-the-coronavirus-market-crash-be-over-watch-these-3-stocks-2020-03-15", "https://www.nasdaq.com/articles/early-results-dampen-outlook-for-experimental-covid-19-treatment-2020-03-14", "https://www.nasdaq.com/articles/eli-lilly-joins-the-hunt-for-a-coronavirus-treatment-2020-03-13", "https://www.nasdaq.com/articles/the-12-best-low-volatility-stocks-of-the-market-crash-2020-03-13", "https://www.nasdaq.com/articles/why-ibio-pharma-stock-is-not-for-timid-investors-despite-great-potential-2020-03-12", "https://www.nasdaq.com/articles/7-biotech-stocks-to-buy-and-hold-in-2020-2020-03-16", "https://www.nasdaq.com/articles/10-health-and-pharmaceutical-companies-fighting-the-coronavirus-2020-03-12", "https://www.nasdaq.com/articles/cdc%3A-gilead-sciences-remdesivir-is-being-used-to-treat-coronavirus-patients-2020-03-12", "https://www.nasdaq.com/articles/world-health-organization%3A-coronavirus-disease-covid-19-now-a-pandemic-2020-03-11", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-wdc-ntes-2020-03-11", "https://www.nasdaq.com/articles/sp-500-movers%3A-wcg-dxc-2020-03-11", "https://www.nasdaq.com/articles/will-moderna-make-a-fortune-off-its-coronavirus-vaccine-2020-03-11", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-gilead-sciences-vs.-inovio-pharmaceuticals-2020-03-11", "https://www.nasdaq.com/articles/cdc-releases-list-of-conditions-that-increase-the-risk-of-severe-coronavirus-illness-2020", "https://www.nasdaq.com/articles/fda-postpones-all-foreign-inspections-over-coronavirus-2020-03-11", "https://www.nasdaq.com/articles/the-gates-foundation-and-friends-launch-covid-19-treatment-accelerator-2020-03-10", "https://www.nasdaq.com/articles/covid-19-nearing-pandemic-level-who-warns-2020-03-10", "https://www.nasdaq.com/articles/ibb-gild-vrtx-biib%3A-large-outflows-detected-at-etf-2020-03-10", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-gild-tsla-2020-03-10", "https://www.nasdaq.com/articles/sp-500-movers%3A-wcg-apa-2020-03-10", "https://www.nasdaq.com/articles/abbvie-to-test-hiv-drug-as-a-potential-coronavirus-treatment-2020-03-10", "https://www.nasdaq.com/articles/5-biotech-stocks-to-buy-for-a-strong-growth-prognosis-2020-03-11", "https://www.nasdaq.com/articles/3-profitable-healthcare-stocks-that-are-trouncing-the-market-during-the-coronavirus", "https://www.nasdaq.com/articles/gild-stock-looks-poised-for-a-serious-coronavirus-bump-2020-03-10", "https://www.nasdaq.com/articles/cdc-says-coronavirus-spread-to-continue-into-2021-2020-03-09", "https://www.nasdaq.com/articles/study-warns-number-of-u.s.-covid-19-cases-much-higher-than-reported-2020-03-09", "https://www.nasdaq.com/articles/cdc-advises-americans-to-postpone-cruises-2020-03-09", "https://www.nasdaq.com/articles/is-inovio-pharmaceuticals-stock-the-cure-for-your-portfolio-2020-03-09", "https://www.nasdaq.com/articles/7-big-pharma-companies-trump-asked-to-fight-the-coronavirus-outbreak-2020-03-10", "https://www.nasdaq.com/articles/moderna-stocks-winning-streak-seems-likely-to-end-2020-03-09", "https://www.nasdaq.com/articles/will-gilead-sciences-make-a-fortune-off-its-coronavirus-drug-2020-03-09", "https://www.nasdaq.com/articles/gild-crosses-above-average-analyst-target-2020-03-09", "https://www.nasdaq.com/articles/better-buy%3A-amgen-vs.-gilead-sciences-2020-03-09", "https://www.nasdaq.com/articles/gilead-sciences-could-be-the-first-to-beat-the-coronavirus-2020-03-08", "https://www.nasdaq.com/articles/coronavirus-market-correction%3A-where-to-invest-%241000-right-now-2020-03-08", "https://www.nasdaq.com/articles/3-stocks-that-are-actually-up-because-of-the-coronavirus-2020-03-08", "https://www.nasdaq.com/articles/fda-warns-companies-selling-fraudulent-covid-19-products-2020-03-09", "https://www.nasdaq.com/articles/is-there-a-cure-for-the-sars-cov-2-coronavirus-2020-03-06", "https://www.nasdaq.com/articles/amid-the-coronavirus-frenzy-novavax-remains-a-risky-bet-2020-03-06", "https://www.nasdaq.com/articles/epa-releases-list-of-disinfectants-to-protect-against-coronavirus-2020-03-06", "https://www.nasdaq.com/articles/3-top-u.s.-stocks-to-watch-in-march-2020-03-06", "https://www.nasdaq.com/articles/heres-my-top-stock-to-buy-in-march-2020-03-06", "https://www.nasdaq.com/articles/congress-approves-%248.3-billion-coronavirus-funding-bill-2020-03-05", "https://www.nasdaq.com/articles/inovio-pharmaceuticals-rapidly-becoming-the-premier-coronavirus-play-2020-03-05", "https://www.nasdaq.com/articles/4-top-stock-trades-for-monday%3A-amd-wmt-crm-gild-2020-03-06", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-aal-ntes-2020-03-05", "https://www.nasdaq.com/articles/is-inovio-stock-a-buy-on-coronavirus-cure-potential-2020-03-05", "https://www.nasdaq.com/articles/up-2000-on-coronavirus-worries-codx-stock-is-a-short-term-buy-2020-03-05", "https://www.nasdaq.com/articles/3-biotech-stocks-that-are-coronavirus-safe-havens-2020-03-05", "https://www.nasdaq.com/articles/is-inovio-stock-still-a-buy-after-its-massive-150-leap-this-year-2020-03-05", "https://www.nasdaq.com/articles/moderna-ceo-says-its-coronavirus-vaccine-will-be-affordable-2020-03-04", "https://www.nasdaq.com/articles/china-approves-a-treatment-for-covid-19-complications-2020-03-04", "https://www.nasdaq.com/articles/is-ishares-nasdaq-biotechnology-index-fund-a-buy-2020-03-05", "https://www.nasdaq.com/articles/why-its-probably-safe-to-start-buying-amd-stock-on-weakness-2020-03-04", "https://www.nasdaq.com/articles/is-gilead-sciences-the-best-buy-in-the-coronavirus-sell-off-2020-03-04", "https://www.nasdaq.com/articles/why-forty-seven-stock-soared-57-in-february-2020-03-04", "https://www.nasdaq.com/articles/buy-regeneron-stock-for-coronavirus-2.0-and-beyond-2020-03-04", "https://www.nasdaq.com/articles/barrick-gold-isnt-the-best-hedge-against-the-coronavirus-2020-03-04", "https://www.nasdaq.com/articles/trump-considering-expanded-travel-ban-in-effort-to-slow-the-spread-of-coronavirus-2020-03", "https://www.nasdaq.com/articles/trump-administration-considers-reimbursing-hospitals-to-treat-uninsured-coronavirus", "https://www.nasdaq.com/articles/wednesdays-etf-with-unusual-volume%3A-mdiv-2020-03-04", "https://www.nasdaq.com/articles/inovio-has-potential-beyond-its-speculative-coronavirus-vaccine-2020-03-03", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-adsk-tsla-2020-03-03", "https://www.nasdaq.com/articles/nasdaq-ceo-says-capital-is-part-of-curing-the-coronavirus-2020-03-03", "https://www.nasdaq.com/articles/dow-jones-recovers-1300-points-despite-increase-in-u.s.-coronavirus-deaths-2020-03-02", "https://www.nasdaq.com/articles/health-care-sector-update-for-03-02-2020%3A-codxftsvgildapdnumrx-2020-03-02", "https://www.nasdaq.com/articles/health-care-sector-update-for-03-02-2020%3A-apdnftsvgildumrx-2020-03-02", "https://www.nasdaq.com/articles/now-is-the-time-to-buy-the-dip-in-amazon-stock-for-the-long-term-2020-03-02", "https://www.nasdaq.com/articles/kids-may-be-the-hidden-carriers-of-covid-19-2020-03-03", "https://www.nasdaq.com/articles/why-gilead-sciences-forty-seven-and-trillium-therapeutics-are-moving-higher-today-2020-03", "https://www.nasdaq.com/articles/health-care-sector-update-for-03-02-2020%3A-ftsv-gild-kpti-codx-jnj-pfe-abt-mrk-amgn-2020-03", "https://www.nasdaq.com/articles/3-top-biotech-stocks-to-buy-in-march-2020-03-02", "https://www.nasdaq.com/articles/daily-markets%3A-investors-hoping-central-banks-will-relieve-coronavirus-pressures-2020-03", "https://www.nasdaq.com/articles/forty-sevens-stock-surges-as-gilead-sciences-to-buy-company-in-%244.9-bln-deal-2020-03-02", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-march-2020-2020-03-02", "https://www.nasdaq.com/articles/2-biotech-stocks-winning-the-coronavirus-race-2020-03-01", "https://www.nasdaq.com/articles/gilead-sciences-acquiring-cancer-focused-biotech-forty-seven-for-%244.9-billion-2020-03-02", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-pfizer-2020-03-01", "https://www.nasdaq.com/articles/7-stocks-to-buy-as-a-hedge-against-the-coronavirus-threat-2020-03-01", "https://www.nasdaq.com/articles/all-the-stocks-im-selling-if-the-coronavirus-keeps-spreading-2020-03-01", "https://www.nasdaq.com/articles/fda-approves-coronavirus-tests-in-academic-laboratories-across-u.s.-2020-03-01", "https://www.nasdaq.com/articles/coronavirus%3A-emerging-numbers-provide-reasons-for-calm-2020-02-29", "https://www.nasdaq.com/articles/investors-endure-wild-ride-in-this-biotech-taking-on-covid-19-2020-02-29", "https://www.nasdaq.com/articles/heres-why-hype-around-companies-working-on-coronavirus-treatments-is-overblown-2020-02-29", "https://www.nasdaq.com/articles/2-stocks-that-can-help-you-protect-your-wealth-from-a-coronavirus-pandemic-2020-03-01", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-pfizer-2020-03-01", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-28-2020%3A-dnlialtftsvgildclsn-2020-02-28", "https://www.nasdaq.com/articles/gilead-sciences-gild-shares-cross-4-yield-mark-2020-02-28", "https://www.nasdaq.com/articles/gilead-reportedly-in-talks-to-acquire-cancer-biotech-forty-seven-2020-02-28", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-28-2020%3A-altftsvgildclsn-2020-02-28", "https://www.nasdaq.com/articles/traders-are-treating-inovio-like-2018s-pot-stock-stars-2020-02-28", "https://www.nasdaq.com/articles/stock-alert%3A-forty-seven-surges-30-2020-02-28", "https://www.nasdaq.com/articles/3-small-caps-that-are-soaring-because-of-coronavirus-panic-2020-02-29", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-28-2020%3A-ftsv-gild-sgmo-bhvn-jnj-pfe-abt-mrk-amgn-2020-02", "https://www.nasdaq.com/articles/how-gilead-sciences-is-driving-forty-seven-and-trillium-therapeutics-higher-today-2020-02", "https://www.nasdaq.com/articles/this-under-the-radar-stock-is-the-biggest-winner-from-the-coronavirus-outbreak-2020-02-28", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-saia-gild-ma-2020-02-27", "https://www.nasdaq.com/articles/april-9th-options-now-available-for-gilead-sciences-gild-2020-02-27", "https://www.nasdaq.com/articles/wait-for-tesla-stock-to-drop-below-%24700-on-coronavirus-fears-2020-02-27", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-aal-gild-2020-02-27", "https://www.nasdaq.com/articles/forty-seven-ftsv-soars-on-reports-of-takeover-interest-2020-02-28", "https://www.nasdaq.com/articles/stock-alert%3A-gild-gains-after-initiating-phase-3-studies-for-covid-19-treatment-2020-02-27", "https://www.nasdaq.com/articles/momentum-stocks-benefitting-from-coronavirus-2020-02-27", "https://www.nasdaq.com/articles/why-inovio-pharmaceuticals-gilead-sciences-moderna-and-novavax-are-all-jumping-today-2020", "https://www.nasdaq.com/articles/fighting-the-deadly-coronavirus-2020-02-27", "https://www.nasdaq.com/articles/buy-microsoft-stock-on-the-dip-over-coronavirus-2020-02-27", "https://www.nasdaq.com/articles/gilead-sciences-initiates-late-stage-testing-of-its-promising-coronavirus-drug-2020-02-26", "https://www.nasdaq.com/articles/airport-screeners-are-likely-missing-2-out-of-3-covid-19-carriers-researchers-warn-2020-02", "https://www.nasdaq.com/articles/sp-500-movers%3A-flir-pwr-2020-02-27", "https://www.nasdaq.com/articles/novavax-to-begin-clinical-testing-of-coronavirus-vaccine-by-late-spring-2020-02-26", "https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-ibb-gild-vrtx-biib-2020-02-26", "https://www.nasdaq.com/articles/7-safe-stocks-to-buy-on-the-coronavirus-dip-2020-02-26", "https://www.nasdaq.com/articles/gileads-coronavirus-drug-could-propel-gild-stock-much-higher-2020-02-26", "https://www.nasdaq.com/articles/should-you-buy-inovio-pharmaceuticals-stock-right-now-2020-02-26", "https://www.nasdaq.com/articles/meet-the-company-that-just-might-prevent-a-global-recession-2020-02-26", "https://www.nasdaq.com/articles/u.s.-health-official-warns%3A-covid-19-will-hit-the-united-states-2020-02-25", "https://www.nasdaq.com/articles/resilience-to-coronavirus-concern-is-a-bullish-sign-for-alibaba-stock-2020-02-26", "https://www.nasdaq.com/articles/nio-stock-will-sustain-momentum-in-2020-despite-coronavirus-concerns-2020-02-25", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-gild-regn-2020-02-25", "https://www.nasdaq.com/articles/8-of-the-best-stocks-to-buy-for-esg-investors-2020-02-25", "https://www.nasdaq.com/articles/is-it-too-late-to-buy-high-flying-galapagos-2020-02-25", "https://www.nasdaq.com/articles/11-best-stocks-to-ride-out-the-coronavirus-outbreak-2020-02-25", "https://www.nasdaq.com/articles/modernas-new-covid-19-vaccine-ready-for-human-trials-stock-up-15-2020-02-25", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-24-2020%3A-ngmuthrgildepzm-2020-02-24", "https://www.nasdaq.com/articles/u.s.-health-officials-start-first-clinical-trial-with-gilead-sciences-experimental", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-24-2020%3A-uthrgildepzm-2020-02-24", "https://www.nasdaq.com/articles/stock-market-news%3A-berkshire-sinks-despite-buffett-optimism-gilead-rises-on-coronavirus", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-aal-gild-2020-02-24", "https://www.nasdaq.com/articles/sp-500-movers%3A-aal-gild-2020-02-24", "https://www.nasdaq.com/articles/3-dividend-stocks-that-raised-their-payouts-in-february-2020-02-22", "https://www.nasdaq.com/articles/is-gilead-sciences-stock-a-buy-2020-02-22", "https://www.nasdaq.com/articles/a-plan-to-use-blockchain-to-stop-counterfeit-drugs-moves-forward-2020-02-21", "https://www.nasdaq.com/articles/gilead-antiviral-drug-shows-the-most-potential-for-covid-19-says-who-official-2020-02-24", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-24-2020%3A-uthrgildepzm-2020-02-24", "https://www.nasdaq.com/articles/why-wells-fargo-stock-looks-poised-to-rebound-2020-02-20", "https://www.nasdaq.com/articles/3-contrarian-stocks-to-buy-now-for-absolute-returns-2020-02-19", "https://www.nasdaq.com/articles/where-will-gilead-sciences-be-in-10-years-2020-02-19", "https://www.nasdaq.com/articles/report%3A-gilead-struggling-to-find-subjects-for-covid-19-drug-trial-2020-02-18", "https://www.nasdaq.com/articles/johnson-johnson-expands-pact-with-u.s.-government-to-seek-a-treatment-for-covid-19-2020-02", "https://www.nasdaq.com/articles/2-reasons-to-be-optimistic-about-gilead-sciences-future-2020-02-18", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-algn-bmrn-2020-02-21", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-stx-unp-gild-2020-02-20", "https://www.nasdaq.com/articles/why-wells-fargo-stock-looks-poised-to-rebound-2020-02-20", "https://www.nasdaq.com/articles/3-contrarian-stocks-to-buy-now-for-absolute-returns-2020-02-19", "https://www.nasdaq.com/articles/where-will-gilead-sciences-be-in-10-years-2020-02-19", "https://www.nasdaq.com/articles/3-high-yielding-u.s.-pharmaceutical-companies-to-consider-2020-02-15", "https://www.nasdaq.com/articles/sp-500-analyst-moves%3A-gild-2020-02-14", "https://www.nasdaq.com/articles/white-house-claims-other-countries-are-free-riding-on-u.s.-drug-development-2020-02-13", "https://www.nasdaq.com/articles/ibb-gild-vrtx-biib%3A-etf-outflow-alert-2020-02-18", "https://www.nasdaq.com/articles/is-viking-therapeutics-stock-a-buy-2020-02-18", "https://www.nasdaq.com/articles/moderna-will-rebound-but-wait-for-a-dip-lower-to-buy-shares-2020-02-18", "https://www.nasdaq.com/articles/the-fda-has-a-plan-to-deal-with-the-coronavirus-2020-02-17", "https://www.nasdaq.com/articles/is-moderna-a-buy-2020-02-12", "https://www.nasdaq.com/articles/pandemic-fears-not-enough-to-buy-inovio-stock-2020-02-12", "https://www.nasdaq.com/articles/gilead-sciences-looks-ready-to-outpace-abbvie-2020-02-12", "https://www.nasdaq.com/articles/better-buy%3A-bluebird-bio-vs.-gilead-sciences-2020-02-12", "https://www.nasdaq.com/articles/inovios-surge-on-a-coronavirus-vaccine-was-just-speculation-2020-02-13", "https://www.nasdaq.com/articles/coronavirus-gets-an-official-name-from-the-who-2020-02-11", "https://www.nasdaq.com/articles/johnson-johnson-is-racing-against-time-to-develop-the-first-coronavirus-vaccine-2020-02-11", "https://www.nasdaq.com/articles/is-gilead-sciences-an-acquisition-target-2020-02-11", "https://www.nasdaq.com/articles/3-pros-and-3-cons-for-ino-stock-amid-chinese-coronavirus-outbreak-2020-02-10", "https://www.nasdaq.com/articles/fda-grants-a-priority-review-to-gilead-sciences-cancer-therapy-2020-02-10", "https://www.nasdaq.com/articles/mondays-etf-with-unusual-volume%3A-pjp-2020-02-10", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2020-02-10", "https://www.nasdaq.com/articles/johnson-johnson-announces-partnership-with-u.s.-government-to-accelerate-coronavirus", "https://www.nasdaq.com/articles/fda-grants-priority-review-for-kites-kte-x19-bla-quick-facts-2020-02-10", "https://www.nasdaq.com/articles/1-big-question-to-ask-yourself-before-buying-gilead-sciences-stock-2020-02-09", "https://www.nasdaq.com/articles/gilead-sciences%3A-still-on-the-path-to-recovery-2020-02-08", "https://www.nasdaq.com/articles/health-officials-say-u.s.-coronavirus-vaccine-is-making-good-progress-2020-02-08", "https://www.nasdaq.com/articles/4-internet-stocks-to-buy-that-are-surging-higher-2020-02-07", "https://www.nasdaq.com/articles/3-big-stock-charts-for-friday%3A-barrick-gold-gilead-sciences-and-cloudflare-2020-02-07", "https://www.nasdaq.com/articles/multiple-positive-catalysts-make-jd.com-stock-worth-buying-2020-02-06", "https://www.nasdaq.com/articles/could-these-5-stocks-benefit-from-the-coronavirus-outbreak-2020-02-10", "https://www.nasdaq.com/articles/fda-grants-priority-review-for-kites-kte-x19-bla-quick-facts-2020-02-10", "https://www.nasdaq.com/articles/1-big-question-to-ask-yourself-before-buying-gilead-sciences-stock-2020-02-09", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-05-2020%3A-cernaimtgild-2020-02-05", "https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-ibm-msft-gild-2020-02-05", "https://www.nasdaq.com/articles/daily-dividend-report%3A-mmm-gild-cg-psx-syk-2020-02-05", "https://www.nasdaq.com/articles/gilead-sciences%3A-patience-required-2020-02-05", "https://www.nasdaq.com/articles/3-important-things-to-know-about-gilead-sciences-q4-results-2020-02-05", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-05-2020%3A-vvuscernaimtgild-2020-02-05", "https://www.nasdaq.com/articles/fda-approves-emergency-use-of-coronavirus-test-2020-02-05", "https://www.nasdaq.com/articles/fda-approves-emergency-use-of-coronavirus-test-2020-02-05-0", "https://www.nasdaq.com/articles/gilead-sciences-q4-profit-misses-estimates-2020-02-04", "https://www.nasdaq.com/articles/gilead-announces-q4-financial-results-misses-eps-target-2020-02-04", "https://www.nasdaq.com/articles/gilead-sciences-inc.-q4-adjusted-earnings-miss-estimates-2020-02-04", "https://www.nasdaq.com/articles/gilead-sciences-q4-19-earnings-conference-call-at-4%3A30-pm-et-2020-02-04-0", "https://www.nasdaq.com/articles/heres-a-better-reason-to-buy-gilead-sciences-stock-than-a-possible-coronavirus-treatment", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-q4-2019-earnings-call-transcript-2020-02-05", "https://www.nasdaq.com/articles/fda-approves-emergency-use-of-coronavirus-test-2020-02-05", "https://www.nasdaq.com/articles/gileads-ebola-drug-shows-positive-signs-in-treating-coronavirus-2020-02-03-0", "https://www.nasdaq.com/articles/heres-why-inovio-pharmaceuticals-and-vir-biotechnology-shares-have-fallen-today-2020-02-03", "https://www.nasdaq.com/articles/gild-crosses-above-key-moving-average-level-2020-02-03", "https://www.nasdaq.com/articles/sp-500-movers%3A-wcg-gild-2020-02-03", "https://www.nasdaq.com/articles/why-gilead-sciences-stock-is-up-13-today-2020-02-03", "https://www.nasdaq.com/articles/momentum-stocks-to-watch%3A-gilead-sciences-inc.-gild-2020-02-04", "https://www.nasdaq.com/articles/where-will-vertex-pharmaceuticals-be-in-10-years-2020-02-02", "https://www.nasdaq.com/articles/better-buy%3A-intercept-pharmaceuticals-vs.-gilead-sciences-2020-01-30", "https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-ibb-gild-vrtx-biib-2020-01-29", "https://www.nasdaq.com/articles/near-a-7-year-low-is-gilead-sciences-a-buy-2020-01-29", "https://www.nasdaq.com/articles/why-novavax-shares-are-jumping-again-today-2020-01-27", "https://www.nasdaq.com/articles/5-biotech-stocks-to-watch-with-the-coronavirus-scare-2020-01-26", "https://www.nasdaq.com/articles/3-big-drugmakers-are-taking-on-the-coronavirus-2020-02-03", "https://www.nasdaq.com/articles/better-buy%3A-vertex-pharmaceuticals-vs.-galapagos-2020-01-25", "https://www.nasdaq.com/articles/an-emboldened-bristol-myers-squibb-wants-%241.5-billion-from-gilead-sciences-2020-01-24", "https://www.nasdaq.com/articles/better-buy%3A-amgen-vs.-gilead-sciences-2020-01-24", "https://www.nasdaq.com/articles/gilead-considering-ebola-drug-as-potential-coronavirus-treatment-2020-01-23", "https://www.nasdaq.com/articles/2-dividend-paying-biotech-stocks-worth-owning-in-2020-2020-01-23", "https://www.nasdaq.com/articles/where-will-intercept-pharmaceuticals-be-in-5-years-2020-01-23", "https://www.nasdaq.com/articles/2-small-cap-biotech-stocks-to-watch-in-2020-2020-01-23", "https://www.nasdaq.com/articles/which-big-biotech-has-the-safer-dividend-amgen-or-gilead-sciences-2020-01-26", "https://www.nasdaq.com/articles/pjps-underlying-holdings-could-mean-14-gain-potential-2020-01-14", "https://www.nasdaq.com/articles/notable-monday-option-activity%3A-aimt-nke-gild-2020-01-13", "https://www.nasdaq.com/articles/gilead-sciences-to-present-at-j.p.-morgan-conference-webcast-at-12%3A30-pm-et-2020-01-13", "https://www.nasdaq.com/articles/ibb-gild-vrtx-biib%3A-large-inflows-detected-at-etf-2020-01-13", "https://www.nasdaq.com/articles/gilead-invests-in-kyverna-therapeutics-enters-license-agreement-quick-facts-2020-01-13", "https://www.nasdaq.com/articles/better-buy%3A-biogen-vs.-gilead-sciences-2020-01-11", "https://www.nasdaq.com/articles/7-healthcare-stocks-to-buy-or-sell-as-pricing-pressures-mount-2020-01-10", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2020-01-21", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-biogen-2020-01-05", "https://www.nasdaq.com/articles/ibb-gild-vrtx-biib%3A-etf-outflow-alert-2020-01-03", "https://www.nasdaq.com/articles/biotechs-most-volatile-binary-events-for-q1-2020-01-03", "https://www.nasdaq.com/articles/vascepas-future-looks-rosy-but-it-could-still-be-fishy-for-amarin-stock-2019-12-31", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-gild-2019-12-30", "https://www.nasdaq.com/articles/3-big-pharma-stocks-that-pay-big-dividends-2019-12-30", "https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-for-2020-2019-12-29", "https://www.nasdaq.com/articles/gilead-sciences-licenses-portfolio-of-hiv-antibodies-from-rockefeller-2020-01-09", "https://www.nasdaq.com/articles/interesting-gild-put-and-call-options-for-august-2020-2019-12-24", "https://www.nasdaq.com/articles/gileads-japan-unit-in-deal-with-eisai-to-co-promote-ra-drug-filgotinib-2019-12-24", "https://www.nasdaq.com/articles/did-cellectis-just-provide-a-glimpse-of-the-future-of-cellular-medicine-2019-12-23", "https://www.nasdaq.com/articles/ishares-russell-1000-value-etf-experiences-big-outflow-2019-12-23", "https://www.nasdaq.com/articles/20-high-yield-dividend-stocks-to-buy-in-2020-2019-12-22", "https://www.nasdaq.com/articles/how-gilead-sciences-is-helping-fund-bristol-myers-squibbs-celgene-acquisition-2019-12-21", "https://www.nasdaq.com/articles/health-care-sector-update-for-12-20-2019%3A-gildtxgbionlnkmrkabeo-2019-12-20", "https://www.nasdaq.com/articles/better-buy%3A-editas-medicine-vs.-crispr-therapeutics-2019-12-27", "https://www.nasdaq.com/articles/2-must-own-dividend-growth-stocks-in-2020-2019-12-19", "https://www.nasdaq.com/articles/5-biotech-stocks-to-buy-for-a-strong-growth-prognosis-2019-12-18", "https://www.nasdaq.com/articles/7-biotech-stocks-to-buy-and-hold-in-2020-2019-12-17", "https://www.nasdaq.com/articles/drugs-that-missed-key-goals-in-phase-iii-trials-2019-12-17", "https://www.nasdaq.com/articles/amarins-vascepa-approval-seems-fishy-for-patients-and-amrn-investors-2019-12-16", "https://www.nasdaq.com/articles/is-amarin-a-%2420-billion-stock-2019-12-16", "https://www.nasdaq.com/articles/gilead%3A-phase-2-atlas-data-shows-consistent-improvements-in-liver-histology-2019-12-16", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-gild-met-pypl-2019-12-20", "https://www.nasdaq.com/articles/bristol-myers-wins-%24752-mln-in-us-patent-case-against-gilead-sciences-2019-12-14", "https://www.nasdaq.com/articles/ibb-gild-vrtx-ilmn%3A-etf-outflow-alert-2019-12-13", "https://www.nasdaq.com/articles/gilds-kte-x19-to-face-fda-ntec-drops-as-nvs-walks-away-kzia-on-watch-2019-12-11", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-gild-gkos-derm-2019-12-11", "https://www.nasdaq.com/articles/gild-named-a-top-socially-responsible-dividend-stock-2019-12-11", "https://www.nasdaq.com/articles/ex-dividend-reminder%3A-el-paso-electric-conmed-and-gilead-sciences-2019-12-10", "https://www.nasdaq.com/articles/apto-on-the-move-plx-to-effect-reverse-split-scyx-plunges-2019-12-10", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-amgen-2019-12-15", "https://www.nasdaq.com/articles/thursday-sector-laggards%3A-energy-healthcare-2019-12-05", "https://www.nasdaq.com/articles/ibb-gild-vrtx-ilmn%3A-large-outflows-detected-at-etf-2019-11-27", "https://www.nasdaq.com/articles/better-buy%3A-editas-medicine-or-sangamo-therapeutics-2019-11-26", "https://www.nasdaq.com/articles/5-top-stock-trades-for-tuesday%3A-nvda-tsla-gild-2019-11-25", "https://www.nasdaq.com/articles/does-amarin-have-a-dark-horse-suitor-2019-11-24", "https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-glaxosmithkline-2019-11-24", "https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-on-sale-2019-11-24", "https://www.nasdaq.com/articles/no-crispr-required%3A-this-forgotten-gene-editing-stock-is-up-50-in-5-weeks-2019-12-09", "https://www.nasdaq.com/articles/january-2020-options-now-available-for-gilead-sciences-gild-2019-11-21", "https://www.nasdaq.com/articles/3-recovering-healthcare-stocks-to-buy-that-already-escaped-flu-season-2019-11-20", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-gild-geo-ttwo-2019-11-14", "https://www.nasdaq.com/articles/gilead-sciences-gild-shares-cross-4-yield-mark-2019-11-14", "https://www.nasdaq.com/articles/3-big-stock-charts-for-thursday%3A-gilead-sciences-docusign-and-western-digital-2019-11-14", "https://www.nasdaq.com/articles/these-superior-dividend-stocks-are-found-in-some-odd-industries-2019-11-13", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2019-11-12", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-q4-results-pulled-down-by-abbvies-sinking-hcv-sales-2019-11-22", "https://www.nasdaq.com/articles/us-files-complaint-against-gilead-sciences-for-patent-infringement-2019-11-08", "https://www.nasdaq.com/articles/is-the-future-finally-looking-up-for-gilead-sciences-2019-11-08", "https://www.nasdaq.com/articles/heres-why-galapagos-stock-rose-20.5-in-october-2019-11-07", "https://www.nasdaq.com/articles/up-19.2-is-viking-therapeutics-stock-still-a-buy-2019-11-06", "https://www.nasdaq.com/articles/these-3-european-biotechs-can-help-recession-proof-your-portfolio-2019-11-06", "https://www.nasdaq.com/articles/gild-crosses-above-key-moving-average-level-2019-11-05", "https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-ibb-celg-gild-vrtx-2019-11-04", "https://www.nasdaq.com/articles/will-its-hiv-lineup-save-gilead-sciences-2019-11-11", "https://www.nasdaq.com/articles/3-reasons-crispr-therapeutics-stock-can-reach-record-highs-again-2019-10-30", "https://www.nasdaq.com/articles/the-3-best-sectors-for-long-term-earnings-2019-10-29", "https://www.nasdaq.com/articles/can-new-drugs-help-gilead-sciences-rebound-2019-10-29", "https://www.nasdaq.com/articles/ibb-celg-gild-ilmn%3A-etf-outflow-alert-2019-10-28", "https://www.nasdaq.com/articles/better-buy%3A-abbott-laboratories-vs.-novo-nordisk-2019-10-27", "https://www.nasdaq.com/articles/5-top-healthcare-etfs-2019-10-26", "https://www.nasdaq.com/articles/4-top-stock-trades-for-monday%3A-tsla-gild-gld-vz-2019-10-25", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-gild-amed-tgt-2019-11-01", "https://www.nasdaq.com/articles/daily-dividend-report%3A-vfc-bro-cog-grc-gild-2019-10-25", "https://www.nasdaq.com/articles/5-biotech-stocks-to-buy-for-a-strong-growth-prognosis-2019-10-25", "https://www.nasdaq.com/articles/whats-behind-gilead-sciences-lackluster-q3-earnings-results-2019-10-25", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-q3-2019-earnings-call-transcript-2019-10-25", "https://www.nasdaq.com/articles/gilead-sciences-inc.-q3-adjusted-earnings-beat-estimates-2019-10-24", "https://www.nasdaq.com/articles/interesting-gild-put-and-call-options-for-december-6th-2019-10-24", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-gild-apls-mat-2019-10-22", "https://www.nasdaq.com/articles/gilead-sciences-q3-revenue-is-flat-and-rd-hits-earnings-2019-10-25", "https://www.nasdaq.com/articles/gilead-sciences-names-andrew-dickinson-cfo-quick-facts-2019-10-15", "https://www.nasdaq.com/articles/3-top-healthcare-dividend-stocks-that-are-great-picks-for-retirees-2019-10-13", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-johnson-johnson-2019-10-12", "https://www.nasdaq.com/articles/health-care-sector-update-for-10-11-2019%3A-acrs-gern-gild-glpg-jnj-pfe-abt-mrk-amgn-2019-10", "https://www.nasdaq.com/articles/mito-empowered-fprx-cuts-another-70-jobs-second-death-in-legionnaires-outbreak-2019-10-11", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-abbv-gild-swks-2019-10-10", "https://www.nasdaq.com/articles/better-buy%3A-biogen-vs.-gilead-sciences-2019-10-10", "https://www.nasdaq.com/articles/tqqq-cost-chtr-gild%3A-etf-outflow-alert-2019-10-15", "https://www.nasdaq.com/articles/3-companies-to-watch-for-at-novembers-society-for-immunotherapy-of-cancer-meeting-2019-10", "https://www.nasdaq.com/articles/gilead-announces-nda-submission-for-filgotinib-in-japan-quick-facts-2019-10-08", "https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-ibb-celg-gild-ilmn-2019-10-07", "https://www.nasdaq.com/articles/fda-approves-descovy-second-drug-to-prevent-hiv-infection-2019-10-04", "https://www.nasdaq.com/articles/forget-vertex-pharmaceuticals-crispr-therapeutics-is-a-better-biotech-growth-stock-2019-10", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-pfizer-2019-09-29", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-october-2019-2019-09-27", "https://www.nasdaq.com/articles/3-big-pharma-companies-driving-price-inflation-2019-10-10", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-calm-gild-epay-2019-09-26", "https://www.nasdaq.com/articles/oef-gild-axp-ms%3A-etf-outflow-alert-2019-09-25", "https://www.nasdaq.com/articles/oef-gild-axp-ms%3A-etf-outflow-alert-2019-09-25-0", "https://www.nasdaq.com/articles/3-big-stock-charts-for-tuesday%3A-baker-hughes-gilead-sciences-and-jefferies-financial-group", "https://www.nasdaq.com/articles/meet-the-revolutionary-new-diabetes-drug-youve-probably-never-heard-of-2019-09-23", "https://www.nasdaq.com/articles/better-buy%3A-vertex-pharmaceuticals-vs.-galapagos-2019-09-22", "https://www.nasdaq.com/articles/better-buy%3A-intercept-pharmaceuticals-vs.-gilead-sciences-2019-09-21", "https://www.nasdaq.com/articles/is-glaxosmithkline-a-buy-2019-09-27", "https://www.nasdaq.com/articles/an-investors-guide-to-disrupting-drugmakers-2019-09-18", "https://www.nasdaq.com/articles/pbe-gild-alxn-incy%3A-large-outflows-detected-at-etf-2019-09-17", "https://www.nasdaq.com/articles/is-ishares-nasdaq-biotechnology-index-fund-a-buy-2019-09-15", "https://www.nasdaq.com/articles/better-buy%3A-celgene-vs.-gilead-sciences-2019-09-14", "https://www.nasdaq.com/articles/interesting-gild-put-and-call-options-for-november-1st-2019-09-12", "https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-axdx-gild-mdb-2019-09-11", "https://www.nasdaq.com/articles/gilead-sciences-inc.-gild-ex-dividend-date-scheduled-for-september-12-2019-2019-09-11", "https://www.nasdaq.com/articles/3-biotechs-with-the-biggest-cash-stockpiles-2019-09-20", "https://www.nasdaq.com/articles/ex-dividend-reminder%3A-gilead-sciences-conmed-and-crown-castle-international-2019-09-10", "https://www.nasdaq.com/articles/gilead-sciences-breaks-above-200-day-moving-average-bullish-for-gild-2019-09-09", "https://www.nasdaq.com/articles/ive-cost-mdlz-gild%3A-etf-outflow-alert-2019-09-09", "https://www.nasdaq.com/articles/sum-up-the-parts%3A-esgl-could-be-worth-%2435-2019-09-09", "https://www.nasdaq.com/articles/serving-on-a-board-made-me-a-better-cfo-2019-09-04", "https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-to-buy-on-sale-2019-09-01", "https://www.nasdaq.com/articles/better-buy%3A-gilead-sciences-vs.-biogen-2019-09-01", "https://www.nasdaq.com/articles/4-key-questions-for-gilead-sciences-new-ceo-2019-09-11", "https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-ibb-gild-celg-vrtx-2019-08-28", "https://www.nasdaq.com/articles/3-big-stock-charts-for-monday%3A-intuit-gilead-sciences-and-nike-2019-08-26", "https://www.nasdaq.com/articles/5-top-esg-stocks-on-rbc-capitals-best-ideas-list-2019-08-19", "https://www.nasdaq.com/articles/vtv-ge-mo-gild%3A-etf-outflow-alert-2019-08-16", "https://www.nasdaq.com/articles/3-big-stock-charts-for-monday%3A-xilinx-news-corp-and-gilead-sciences-2019-08-12", "https://www.nasdaq.com/articles/3-embarrassingly-cheap-dividend-stocks-2019-08-11", "https://www.nasdaq.com/articles/fidelity-national-information-services-achieves-72-analyst-rank-surpassing-gilead-sciences", "https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-jnj-gild-glng-2019-08-28", "https://www.nasdaq.com/articles/gilead-sciences-a-top-25-dividend-giant-with-3.94-yield-2019-08-08", "https://www.nasdaq.com/articles/derm-on-watchlist-fda-panel-nod-for-gild-so-long-cvrs-and-avdr-2019-08-08", "https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-gild-evri-plt-2019-08-06", "https://www.nasdaq.com/articles/gild-crosses-above-4-yield-territory-2019-08-06", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-gild-celg-ilmn-2019-08-06", "https://www.nasdaq.com/articles/heres-why-galapagos-nv-rose-34.5-in-july-2019-08-05", "https://www.nasdaq.com/articles/2-small-cap-stocks-that-could-make-you-rich-2019-08-01", "https://www.nasdaq.com/articles/analysts-anticipate-susa-to-hit-%24133-2019-08-08", "https://www.nasdaq.com/articles/gilead-sciences-reports-improving-revenue-in-the-2nd-quarter-2019-07-31", "https://www.nasdaq.com/articles/after-hours%3A-apple-mastercard-and-gilead-sciences-report-earnings-2019-07-31", "https://www.nasdaq.com/articles/gilead-sciences-inc.-q2-adjusted-earnings-beat-estimates-2019-07-30", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-grmn-gild-mcd-2019-07-30", "https://www.nasdaq.com/articles/gilead-gild-2nd-quarter-earnings%3A-what-to-expect-2019-07-30", "https://www.nasdaq.com/articles/gilead-sciences-q2-19-earnings-conference-call-at-4%3A30-pm-et-2019-07-30", "https://www.nasdaq.com/articles/marijuana-stock-cannttrust-and-whats-behind-gileads-latest-megadeal-2019-07-29", "https://www.nasdaq.com/articles/are-amgen-and-gilead-sciences-better-buys-after-second-quarter-earnings-2019-07-31", "https://www.nasdaq.com/articles/weekly-market-preview%3A-six-stocks-to-watch-for-the-coming-week-bynd-gild-aapl-amd-qcom-sq", "https://www.nasdaq.com/articles/3-perfect-10-biotech-companies-to-buy-2019-07-25", "https://www.nasdaq.com/articles/health-care-sector-update-for-07-24-2019%3A-gildghdxefiiewsgen-2019-07-24", "https://www.nasdaq.com/articles/5-biotech-stocks-to-buy-for-a-strong-growth-prognosis-2019-07-23", "https://www.nasdaq.com/articles/8-more-big-pharma-events-in-2019-you-dont-want-to-miss-2019-07-20", "https://www.nasdaq.com/articles/friday-sector-laggards%3A-utilities-healthcare-2019-07-19", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-ibb-gild-celg-vrtx-2019-07-19", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-august-2019-2019-07-29", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-to-buy-right-now-2019-07-18", "https://www.nasdaq.com/articles/the-multibillion-dollar-race-for-gene-therapy-manufacturing-is-on-2019-07-17", "https://www.nasdaq.com/articles/gileads-galapagos-deal%3A-what-it-means-for-investors-2019-07-17", "https://www.nasdaq.com/articles/3-soaring-biotech-stocks-with-more-fuel-in-the-tank-2019-07-16", "https://www.nasdaq.com/articles/what-happened-in-the-stock-market-today-2019-07-15", "https://www.nasdaq.com/articles/nasdaq-today%3A-bitcoin-libra-whats-broadcom-doing-2019-07-15", "https://www.nasdaq.com/articles/health-care-sector-update-for-07-15-2019%3A-caprglpggildomclteva-2019-07-15", "https://www.nasdaq.com/articles/gilead-licenses-respiratory-herpes-antiviral-research-programs-from-novartis-2019-07-19", "https://www.nasdaq.com/articles/galapagos-deal%3A-glpg-stock-rockets-higher-on-gilead-stake-2019-07-15", "https://www.nasdaq.com/articles/health-care-sector-update-for-07-15-2019%3A-glpggildomclteva-2019-07-15", "https://www.nasdaq.com/articles/gild-crosses-above-key-moving-average-level-2019-07-15", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-symc-gild-2019-07-15", "https://www.nasdaq.com/articles/health-care-sector-update-for-07-15-2019%3A-capr-glpg-gild-ntgn-jnj-pfe-abt-mrk-amgn-2019-07", "https://www.nasdaq.com/articles/why-galapagos-nv-stock-is-soaring-today-2019-07-15", "https://www.nasdaq.com/articles/ibb-gild-celg-ilmn%3A-large-outflows-detected-at-etf-2019-07-11", "https://www.nasdaq.com/articles/monday-sector-leaders%3A-utilities-healthcare-2019-07-15", "https://www.nasdaq.com/articles/we-did-the-math-ovlu-can-go-to-%2430-2019-07-08", "https://www.nasdaq.com/articles/are-natural-killer-cells-the-next-big-thing-in-immunotherapy-2019-07-08", "https://www.nasdaq.com/articles/vti-c-ge-gild%3A-etf-inflow-alert-2019-07-03", "https://www.nasdaq.com/articles/after-hours%3A-sarin-scare-at-facebook-gilead-to-make-arthritis-drug-submission-soon-2019-07", "https://www.nasdaq.com/articles/first-week-of-february-2020-options-trading-for-gilead-sciences-gild-2019-06-27", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2019-06-25", "https://www.nasdaq.com/articles/the-10-biggest-biotech-stocks-2019-06-25", "https://www.nasdaq.com/articles/august-23rd-options-now-available-for-gilead-sciences-gild-2019-07-08", "https://www.nasdaq.com/articles/3-large-cap-biotech-stocks-to-buy-for-massive-gains-2019-06-19", "https://www.nasdaq.com/articles/gild-crosses-above-key-moving-average-level-2019-06-18", "https://www.nasdaq.com/articles/3-big-stock-charts-for-tuesday%3A-mckesson-dish-network-and-gilead-sciences-2019-06-18", "https://www.nasdaq.com/articles/3-big-drugmakers-most-likely-to-make-acquisitions-after-pfizers-surprise-deal-2019-06-18", "https://www.nasdaq.com/articles/5-top-stock-trades-for-tuesday%3A-fb-nflx-gild-tsla-2019-06-17", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-gild-biib-vrtx-2019-06-17", "https://www.nasdaq.com/articles/better-buy%3A-aurora-cannabis-vs.-gilead-sciences-2019-06-16", "https://www.nasdaq.com/articles/3-drugs-under-fda-review-with-blockbuster-potential-2019-06-20", "https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-exas-gild-pstg-2019-06-12", "https://www.nasdaq.com/articles/newest-gene-editing-stock-buy-2019-06-11", "https://www.nasdaq.com/articles/gilead-sciences-worth-wait-2019-06-09", "https://www.nasdaq.com/articles/how-pieces-add-%3A-rndv-targets-%2425-2019-06-06", "https://www.nasdaq.com/articles/vanguard-total-world-stock-etf-experiences-big-outflow-2019-06-05", "https://www.nasdaq.com/articles/3-cancer-stocks-given-lift-amgen-2019-06-04", "https://www.nasdaq.com/articles/kite-and-humanigen-collaborate-conduct-clinical-study-relapsed/dlbcl-2019-05-31", "https://www.nasdaq.com/articles/3-top-dividend-stocks-to-buy-in-june-2019-06-14", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-ual-gild-hp-2019-05-28", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-myl-amd-2019-05-28", "https://www.nasdaq.com/articles/10-top-pot-stocks-to-buy-2019-05-28", "https://www.nasdaq.com/articles/ibb-celg-gild-amgn%3A-etf-inflow-alert-2019-05-23", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-right-now-2019-05-23", "https://www.nasdaq.com/articles/better-buy%3A-vertex-pharmaceuticals-vs.-galapagos-2019-05-19", "https://www.nasdaq.com/articles/better-buy%3A-intercept-pharmaceuticals-vs.-gilead-sciences-2019-05-19", "https://www.nasdaq.com/articles/5-top-stock-trades-wednesday%3A-gild-nvda-amd-2019-05-28", "https://www.nasdaq.com/articles/ibb-gild-celg-biib%3A-etf-outflow-alert-2019-05-15", "https://www.nasdaq.com/articles/it-finally-time-buy-gilead-sciences-2019-05-12", "https://www.nasdaq.com/articles/goldfinch-bio-partners-gilead-sciences-quick-facts-2019-05-08", "https://www.nasdaq.com/articles/where-will-gilead-sciences-spend-its-cash-2019-05-07", "https://www.nasdaq.com/articles/analysts-expect-voov-hit-124-2019-05-06", "https://www.nasdaq.com/articles/5-things-you-can-expect-gilead-sciences-its-new-ceo-helm-2019-05-05", "https://www.nasdaq.com/articles/vtv-mo-gild-axp%3A-etf-inflow-alert-2019-05-03", "https://www.nasdaq.com/articles/who-had-better-quarter%3A-gilead-sciences-or-amgen-2019-05-17", "https://www.nasdaq.com/articles/gilead-sciences-returns-growth-first-quarter-2019-05-03", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-q1-2019-earnings-call-transcript-2019-05-03", "https://www.nasdaq.com/articles/daily-dividend-report%3A-eog-gild-duk-ecl-ice-2019-05-02", "https://www.nasdaq.com/articles/gilead-sciences-inc.-q1-adjusted-earnings-beat-estimates-2019-05-02", "https://www.nasdaq.com/articles/june-14th-options-now-available-gilead-sciences-gild-2019-05-02", "https://www.nasdaq.com/articles/better-buy%3A-vertex-pharmaceuticals-vs.-galapagos-2019-05-02", "https://www.nasdaq.com/articles/gilead-gild-1st-quarter-earnings%3A-what-expect-2019-05-02", "https://www.nasdaq.com/articles/has-gilead-sciences-turned-corner-2019-05-03", "https://www.nasdaq.com/articles/3-things-you-can-expect-gilead-sciences-q1-earnings-update-2019-05-01", "https://www.nasdaq.com/articles/will-gilead-stock-get-needed-boost-weeks-earnings-report-2019-04-30", "https://www.nasdaq.com/articles/2-reasons-gilead-sciences-nash-program-could-bounce-back-2019-04-27", "https://www.nasdaq.com/articles/how-medicare-rule-change-could-bring-car-t-stocks-back-life-2019-04-27", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-ibb-celg-gild-biib-2019-04-25", "https://www.nasdaq.com/articles/2-best-biotech-buyout-plays-2019-04-23", "https://www.nasdaq.com/articles/5-top-stock-trades-tuesday-tsla-twtr-ttd-o-2019-04-22", "https://www.nasdaq.com/articles/gilead-sciences-q1-19-earnings-conference-call-4%3A30-pm-et-2019-05-02", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-gm-gild-icpt-2019-04-18", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-gm-gild-icpt-2019-04-18-0", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-vlue-gm-gild-exc-2019-04-17", "https://www.nasdaq.com/articles/tg-therapeutics-buy-2019-04-17", "https://www.nasdaq.com/articles/why-amgen-stock-could-break-out-new-highs-2019-04-16", "https://www.nasdaq.com/articles/gilead-teams-insitro-experimental-nash-treatments-2019-04-16", "https://www.nasdaq.com/articles/gilead-sciences-enters-strategic-collaboration-insitro-quick-facts-2019-04-16", "https://www.nasdaq.com/articles/top-gene-sequencing-stocks-2019-2019-04-19", "https://www.nasdaq.com/articles/gilead-sciences-gild-gains-as-market-dips%3A-what-you-should-know-2019-04-15-0", "https://www.nasdaq.com/articles/gilead-to-collaborate-with-novo-nordisk-for-nash-treatment-2019-04-15-0", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-vs-biogen-2019-04-14", "https://www.nasdaq.com/articles/better-buy-amgen-vs-gilead-sciences-2019-04-13", "https://www.nasdaq.com/articles/novo-nordisk-and-gilead-team-test-fatty-liver-disease-treatment-2019-04-12", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-adsk-gild-hum-2019-04-11", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-adsk-gild-hum-2019-04-11-0", "https://www.nasdaq.com/articles/interesting-gild-put-options-may-31st-2019-04-15", "https://www.nasdaq.com/articles/3-dividend-stocks-perfect-retirees-2019-04-09", "https://www.nasdaq.com/articles/gilead-sciences-gild-stock-sinks-as-market-gains%3A-what-you-should-know-2019-04-08-0", "https://www.nasdaq.com/articles/gilead-files-snda-for-label-expansion-of-hiv-therapy-descovy-2019-04-08-0", "https://www.nasdaq.com/articles/where-will-gilead-sciences-be-5-years-2019-04-07", "https://www.nasdaq.com/articles/better-buy-intercept-pharmaceuticals-vs-gilead-sciences-2019-04-02", "https://www.nasdaq.com/articles/better-buy-intercept-pharmaceuticals-vs-gilead-sciences-2019-04-02-0", "https://www.nasdaq.com/articles/ibb-gild-celg-vrtx-large-outflows-detected-etf-2019-04-01", "https://www.nasdaq.com/articles/why-galapagos-nv-stock-bolted-higher-march-2019-04-09", "https://www.nasdaq.com/articles/3-dividend-stocks-perfect-retirees-2019-04-09", "https://www.nasdaq.com/articles/why-blackberry-galapagos-and-progress-software-jumped-today-2019-03-29", "https://www.nasdaq.com/articles/health-care-sector-update-for-03-29-2019%3A-glpggildftsvseelaznazn.l-2019-03-29", "https://www.nasdaq.com/articles/why-galapagos-stock-crushing-it-today-2019-03-29", "https://www.nasdaq.com/articles/shares-galapagos-jump-15-pct-after-arthritis-drug-results-2019-03-29", "https://www.nasdaq.com/articles/why-blackberry-galapagos-and-progress-software-jumped-today-2019-03-29-0", "https://www.nasdaq.com/articles/health-care-sector-update-03292019-glpggildftsvseelaznaznl-2019-03-29-0", "https://www.nasdaq.com/articles/2-incredibly-cheap-pharma-stocks-buy-now-2019-04-01", "https://www.nasdaq.com/articles/3-top-dividend-stocks-add-your-watchlist-2019-03-27", "https://www.nasdaq.com/articles/gilead-sciences-gild-gains-as-market-dips%3A-what-you-should-know-2019-03-25", "https://www.nasdaq.com/articles/why-1-top-analyst-thinks-gilead-sciences-will-soar-more-25-2019-03-24", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-inflow-2019-03-22", "https://www.nasdaq.com/articles/biogen-stock-fell-too-far-unfortunate-news-2019-03-22", "https://www.nasdaq.com/articles/conatus-cnat-declines-on-failure-of-nash-fibrosis-study-2019-03-22", "https://www.nasdaq.com/articles/does-recent-abbvie-stock-weakness-make-it-buy-3-pros-3-cons-2019-03-21", "https://www.nasdaq.com/articles/ards-move-glpg-reports-positive-data-prto-plunges-patency-2-results-2019-03-29", "https://www.nasdaq.com/articles/yeti-gilead-dicks-fedex-and-amazon-highlighted-as-zacks-bull-and-bear-of-the-day-2019-03", "https://www.nasdaq.com/articles/bear-day-gilead-sciences-gild-2019-03-18", "https://www.nasdaq.com/articles/after-hours-most-active-mar-18-2019-elan-lly-bac-mrk-hpq-wmb-qcom-gild-cmcsa-pep-ebay-atvi", "https://www.nasdaq.com/articles/better-buy-amgen-vs-gilead-sciences-2019-03-17", "https://www.nasdaq.com/articles/agenus-wins-%247.5m-milestone-payment-from-gilead-stock-up-2019-03-14", "https://www.nasdaq.com/articles/ibb-celg-biib-gild-large-inflows-detected-etf-2019-03-14", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-march-14-2019-2019-03-13", "https://www.nasdaq.com/articles/gilead-sciences-gild-gains-as-market-dips%3A-what-you-should-know-2019-03-19", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-march-2019-03-09", "https://www.nasdaq.com/articles/dont-abandon-gilead-stock-after-weak-q4-results-2019-03-08", "https://www.nasdaq.com/articles/gilead-reports-positive-data-on-hiv-drugs-biktarvy-descovy-2019-03-08", "https://www.nasdaq.com/articles/2-biotech-stocks-major-incoming-catalysts-2019-03-07", "https://www.nasdaq.com/articles/gilead-reports-positive-data-on-hiv-drugs-biktarvy-descovy-2019-03-07", "https://www.nasdaq.com/articles/worlds-second-man-cleared-aids-virus-invigorates-quest-cure-2019-03-06", "https://www.nasdaq.com/articles/why-is-gilead-gild-down-4.9-since-last-earnings-report-2019-03-06", "https://www.nasdaq.com/articles/gilead-sciences-gild-outpaces-stock-market-gains%3A-what-you-should-know-2019-03-13", "https://www.nasdaq.com/articles/gilead-sciences-gild-shares-cross-4-yield-mark-2019-03-06", "https://www.nasdaq.com/articles/why-sangamo-therapeutics-lost-229-its-value-february-2019-03-04", "https://www.nasdaq.com/articles/sum-pieces-qqxt-could-be-worth-58-2019-03-04", "https://www.nasdaq.com/articles/eli-lilly-seeks-quell-drug-price-anger-cheaper-insulin-2019-03-04", "https://www.nasdaq.com/articles/after-hours-most-active-mar-4-2019-lthm-lly-atvi-bac-s-ohi-ge-gild-cmcsa-imgn-aapl-sgms", "https://www.nasdaq.com/articles/3-oldest-members-biotechs-billion-burned-club-2019-03-03", "https://www.nasdaq.com/articles/intercept-icpt-up-on-q4-revenue-beat-nash-study-in-focus-2019-03-01", "https://www.nasdaq.com/articles/3-big-pharmas-trying-pop-rebate-bubble-2019-03-06", "https://www.nasdaq.com/articles/viking-therapeutics-buy-2019-02-27", "https://www.nasdaq.com/articles/better-buy-bluebird-bio-vs-gilead-sciences-2019-02-23", "https://www.nasdaq.com/articles/2-frustrating-flops-plus-welcome-wrinkle-wars-2019-02-21", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-intercept-gilead-vertex-alkermes-and-clovis-2019-02-21", "https://www.nasdaq.com/articles/what-pharma-investors-need-know-about-pfizers-latest-disaster-2019-02-21", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-investors-strap-wild-ride-2019-02-20", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-icpt-strong-on-nash-drug-data-collaborations-more-2019-02-20", "https://www.nasdaq.com/articles/nektar-nktr-q4-earnings-beat-nktr-181-review-extended-2019-03-01", "https://www.nasdaq.com/articles/intercepts-fatty-liver-drug-meets-late-stage-main-goal-shares-soar-2019-02-19", "https://www.nasdaq.com/articles/tuesdays-etf-unusual-volume-pbe-2019-02-19", "https://www.nasdaq.com/articles/better-buy-celgene-vs-gilead-sciences-2019-02-17", "https://www.nasdaq.com/articles/us-medicare-plans-track-car-t-cancer-therapy-outcomes-2019-02-15", "https://www.nasdaq.com/articles/should-you-buy-viking-therapeutics-after-gilead-drug-failure-2019-02-14", "https://www.nasdaq.com/articles/despite-ma-spree-biotech-etfs-slide-mixed-earnings-2019-02-14", "https://www.nasdaq.com/articles/celgene-vs-gilead-stock-whats-better-biotech-buy-2019-02-13", "https://www.nasdaq.com/articles/intercept-reports-positive-top-line-data-for-nash-shares-up-2019-02-20", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-14-2019-2019-02-13", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-february-14-2019-2019-02-13", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-regeneron-impresses-in-q4-gilead-slumps-macrogenics-soars-2019-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-ea-2019-02-12", "https://www.nasdaq.com/articles/health-care-sector-update-02122019-kmda-gild-mdgs-jnj-pfe-mrk-abt-amgn-2019-02-12", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-vs-pfizer-2019-02-12", "https://www.nasdaq.com/articles/gileads-gild-late-stage-study-on-liver-disease-drug-fails-2019-02-12", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-jnj-gild-cvs-2019-02-13", "https://www.nasdaq.com/articles/5-must-see-stock-charts-wednesday-gild-nflx-ea-2019-02-12", "https://www.nasdaq.com/articles/heres-why-viking-therapeutics-rose-much-139-today-2019-02-12", "https://www.nasdaq.com/articles/health-care-sector-update-02122019-gildkmdaohi-2019-02-12", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-ea-gild-nke-2019-02-12", "https://www.nasdaq.com/articles/gilead-sciences-stock-slides-lower-nash-drug-failure-2019-02-12", "https://www.nasdaq.com/articles/gilead-misses-key-goal-nash-liver-disease-trial-shares-sink-2019-02-11", "https://www.nasdaq.com/articles/why-gilead-sciences-stock-perked-january-2019-02-10", "https://www.nasdaq.com/articles/health-care-sector-update-02122019-jazzgildkmdaohi-2019-02-12", "https://www.nasdaq.com/articles/why-agenus-inc-stock-took-flight-january-2019-02-08", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-vertex-celgene-alkermes-and-aveo-2019-02-07", "https://www.nasdaq.com/articles/amgen-top-socially-responsible-dividend-stock-31-yield-amgn-2019-02-06", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-celgene-tops-in-q4-gilead-disappoints-alks-aveo-sink-2019-02-06", "https://www.nasdaq.com/articles/wednesday-sector-leaders-healthcare-technology-communications-2019-02-06", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-jd-2019-02-05", "https://www.nasdaq.com/articles/health-care-sector-update-02052019-opgn-cnc-gild-jnj-pfe-abt-mrk-amgn-2019-02-05", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-buy-2019-02-10", "https://www.nasdaq.com/articles/unitedhealth-mercadolibre-alphabet-and-gilead-highlighted-as-zacks-bull-and-bear-of-the", "https://www.nasdaq.com/articles/gilead-gild-q4-earnings-miss-estimates-revenues-beat-2019-02-05", "https://www.nasdaq.com/articles/gilead-sciences-bad-news-buy-2019-02-05", "https://www.nasdaq.com/articles/gilead-sciences-hcv-albatross-weighs-its-results-yet-again-2019-02-05", "https://www.nasdaq.com/articles/stock-market-today-alphabet-grows-while-gilead-sciences-shrinks-2019-02-05", "https://www.nasdaq.com/articles/5-top-stock-trades-wednesday-googl-gild-el-ba-2019-02-05", "https://www.nasdaq.com/articles/daily-dividend-report-gild-exc-avb-chd-utx-2019-02-05", "https://www.nasdaq.com/articles/7-key-things-you-need-know-gilead-sciences-q4-earnings-update-2019-02-05", "https://www.nasdaq.com/articles/unitedhealth-mercadolibre-alphabet-and-gilead-highlighted-as-zacks-bull-and-bear-of-the", "https://www.nasdaq.com/articles/gilead-gild-q4-earnings-miss-estimates-revenues-beat-2019-02-05", "https://www.nasdaq.com/articles/gilead-sciences-bad-news-buy-2019-02-05", "https://www.nasdaq.com/articles/gilead-sciences-q4-18-earnings-conference-call-430-pm-et-2019-02-04", "https://www.nasdaq.com/articles/gilead-sciences-earnings-gild-stock-dips-q4-eps-miss-revenue-beat-2019-02-04", "https://www.nasdaq.com/articles/gilead-4th-qtr-profit-misses-wall-street-estimate-shares-fall-2019-02-04", "https://www.nasdaq.com/articles/alphabet-googl-outperforms-estimates-gilead-gild-mixed-2019-02-04", "https://www.nasdaq.com/articles/5-of-the-best-biotech-stocks-to-buy-now-2019-02-04", "https://www.nasdaq.com/articles/gilead-fourth-quarter-profit-misses-wall-street-estimate-shares-fall-2019-02-04", "https://www.nasdaq.com/articles/notable-monday-option-activity-baby-gild-vrnt-2019-02-04", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-4-2019-googl-gild-avb-hig-itub-are-stx-qgen-aiv-krc", "https://www.nasdaq.com/articles/novartiss-cancer-therapy-wins-uk-backing-after-initial-lymphoma-snub-2019-02-01", "https://www.nasdaq.com/articles/3-top-large-cap-stocks-buy-february-2019-01-31", "https://www.nasdaq.com/articles/will-gilead-gild-q4-earnings-disappoint-on-weak-hcv-sales-2019-01-31", "https://www.nasdaq.com/articles/cure-cancer-next-year-stock-market-says-dont-believe-hype-2019-01-30", "https://www.nasdaq.com/articles/gilead-sciences-gild-misses-q4-earnings-estimates-2019-02-04", "https://www.nasdaq.com/articles/avalon-globocare-stock-expensive-mystery-2019-01-29", "https://www.nasdaq.com/articles/nasdaq-100-movers-amd-pcar-2019-01-29", "https://www.nasdaq.com/articles/biggest-biotech-binary-event-2019-just-around-corner-2019-01-29", "https://www.nasdaq.com/articles/analysts-estimate-gilead-sciences-gild-to-report-a-decline-in-earnings%3A-what-to-look-out", "https://www.nasdaq.com/articles/ishares-us-healthcare-etf-experiences-big-inflow-2019-01-24", "https://www.nasdaq.com/articles/does-johnson-johnsons-grim-outlook-spell-trouble-big-pharma-stocks-2019-01-24", "https://www.nasdaq.com/articles/3-upcoming-readouts-gilead-sciences-you-dont-want-miss-2019-01-23", "https://www.nasdaq.com/articles/gilead-sciences-gild-gains-but-lags-market%3A-what-you-should-know-2019-01-30", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-january-2019-01-23", "https://www.nasdaq.com/articles/7-stupidly-cheap-stocks-buy-now-2019-01-22", "https://www.nasdaq.com/articles/after-hours-most-active-jan-22-2019-grpn-qqq-intc-xel-gild-amd-2019-01-22", "https://www.nasdaq.com/articles/better-buy-biogen-vs-gilead-sciences-2019-01-19", "https://www.nasdaq.com/articles/notable-friday-option-activity-wynn-gs-gild-2019-01-18", "https://www.nasdaq.com/articles/why-gilead-sciences-stock-sank-127-2018-2019-01-17", "https://www.nasdaq.com/articles/zacks-market-edge-highlights%3A-occidental-gilead-abbvie-att-and-verizon-2019-01-17", "https://www.nasdaq.com/articles/gilead-sciences-gild-stock-sinks-as-market-gains%3A-what-you-should-know-2019-01-23", "https://www.nasdaq.com/articles/will-dividend-stocks-be-hot-stocks-2019-2019-01-16", "https://www.nasdaq.com/articles/heres-why-verastem-tumbled-341-december-2019-01-11", "https://www.nasdaq.com/articles/value-added-7-top-stocks-2019-2019-01-09", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-loxo-celg-gain-j.p.-morgan-healthcare-conference-in-focus-2019-01", "https://www.nasdaq.com/articles/7-things-expect-gilead-sciences-2019-2019-01-08", "https://www.nasdaq.com/articles/japan-okays-approves-gilead-sciences-epclusa-2019-01-08", "https://www.nasdaq.com/articles/why-agenus-stock-spiking-today-2019-01-07", "https://www.nasdaq.com/articles/1-chart-shows-why-celgene-has-been-bought-out-and-gilead-hasnt-yet-2019-01-17", "https://www.nasdaq.com/articles/gilead-gild-collaborates-with-yuhan-for-nash-candidates-2019-01-07", "https://www.nasdaq.com/articles/gilead-sciences-gild-gains-but-lags-market%3A-what-you-should-know-2019-01-07", "https://www.nasdaq.com/articles/after-hours-most-active-jan-7-2019-cmcsa-abev-bac-amat-gild-fdc-msft-ctl-symc-qqq-exc-emr", "https://www.nasdaq.com/articles/2019-jp-morgan-healthcare-conference-roundup-2019-01-06", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-vs-amgen-2019-01-06", "https://www.nasdaq.com/articles/should-you-invest-invesco-dynamic-biotechnology-genome-etf-pbe-2019-01-04", "https://www.nasdaq.com/articles/gilead-sciences-present-jp-morgan-conference-webcast-1230-pm-et-2019-01-07", "https://www.nasdaq.com/articles/3-pharma-stocks-revving-for-growth-2019-01-02", "https://www.nasdaq.com/articles/gilead-sciences-gild-dips-more-than-broader-markets%3A-what-you-should-know-2018-12-28", "https://www.nasdaq.com/articles/intercept-icpt-benefits-from-ocalivas-recovery-in-2018-2018-12-28", "https://www.nasdaq.com/articles/3-biotech-stocks-are-too-cheap-ignore-2018-12-26", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alxn-acor-drugs-get-fda-nod-agen-up-on-gild-deal-2018-12-26", "https://www.nasdaq.com/articles/mallinckrodts-inhaled-xenon-gas-therapy-enters-phase-iii-2018-12-24", "https://www.nasdaq.com/articles/alexions-ultomiris-gets-early-fda-nod-for-rare-blood-disorder-2018-12-24", "https://www.nasdaq.com/articles/3-biopharma-stocks-buy-their-robust-dividend-yields-2019-01-03", "https://www.nasdaq.com/articles/2-beaten-down-biotech-stocks-look-bargains-now-2018-12-23", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2018-12-21", "https://www.nasdaq.com/articles/agenus-stock-up-23-on-immuno-oncology-deal-with-gilead-2018-12-21", "https://www.nasdaq.com/articles/novartis-nvs-offers-to-buy-french-gene-therapy-manufacturer-2018-12-21", "https://www.nasdaq.com/articles/why-agenus-stock-soaring-today-2018-12-20", "https://www.nasdaq.com/articles/wall-street-sees-cautiously-higher-open-after-fed-move-2018-12-20", "https://www.nasdaq.com/articles/us-futures-inch-higher-after-fed-move-2018-12-20", "https://www.nasdaq.com/articles/acorda-gets-fda-approval-for-parkinsons-disease-drug-inbrija-2018-12-24", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-december-2018-12-20", "https://www.nasdaq.com/articles/gilead-partners-with-scholar-rock-for-fibrotic-disease-drugs-2018-12-20", "https://www.nasdaq.com/articles/vertexs-vrtx-3rd-study-on-pain-drug-meets-primary-endpoint-2018-12-19", "https://www.nasdaq.com/articles/forget-bluebird-bio-amgen-better-biotech-stock-2018-12-19", "https://www.nasdaq.com/articles/gilead-sciences-scholar-collaborate-novel-therapies-fibrotic-diseases-2018-12-19", "https://www.nasdaq.com/articles/puma-biotechs-nerlynx-ups-survival-in-third-line-breast-cancer-2018-12-18", "https://www.nasdaq.com/articles/what-happened-car-t-stocks-2018-2018-12-18", "https://www.nasdaq.com/articles/bristol-myers-to-sell-french-consumer-health-unit-for-%241.6b-2018-12-20", "https://www.nasdaq.com/articles/3-biotechs-potential-blockbusters-near-finish-line-2018-12-18", "https://www.nasdaq.com/articles/evofem-shares-up-as-birth-control-gel-succeeds-in-phase-iii-2018-12-18", "https://www.nasdaq.com/articles/why-dova-pharmaceuticals-nosediving-today-2018-12-17", "https://www.nasdaq.com/articles/gilead-sciences-gild-stock-moves-0.69%3A-what-you-should-know-2018-12-17", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-benjamin-graham-12162018-2018-12-16", "https://www.nasdaq.com/articles/2-sets-disasters-biotech-will-pay-2019-2018-12-16", "https://www.nasdaq.com/articles/3-biotechs-gilead-sciences-could-buy-march-2018-12-15", "https://www.nasdaq.com/articles/bristol-myers-label-expansion-of-sprycel-gets-chmp-nod-2018-12-18", "https://www.nasdaq.com/articles/amag-to-acquire-ciraparantag-maker-perosphere-pharmaceuticals-2018-12-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-conatus-pharmaceuticals-biogen-ionis", "https://www.nasdaq.com/articles/bausch-bhc-bids-for-assets-of-synergy-pharmaceuticals-2018-12-13", "https://www.nasdaq.com/articles/gilead-sciences-top-socially-responsible-dividend-stock-34-yield-gild-2018-12-13", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gilead-to-get-new-ceo-biogen-in-licenses-candidate-2018-12-12", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-december-13-2018-2018-12-12", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-ndsn-gild-tlrd-2018-12-12", "https://www.nasdaq.com/articles/mylan-myl-gets-favorable-ruling-against-sanofis-lantus-2018-12-14", "https://www.nasdaq.com/articles/ex-dividend-reminder-new-jersey-resources-conmed-and-gilead-sciences-2018-12-11", "https://www.nasdaq.com/articles/4-biotech-stocks-investors-can-add-their-portfolio-2019-2018-12-11", "https://www.nasdaq.com/articles/gilead-sciences-gild-appoints-daniel-oday-as-new-ceo-2018-12-11", "https://www.nasdaq.com/articles/roches-tecentriq-gets-fda-approval-for-first-line-nsclc-2018-12-10", "https://www.nasdaq.com/articles/dont-punish-gilead-stock-doing-its-job-2018-12-10", "https://www.nasdaq.com/articles/gilead-sciences-gild-stock-sinks-as-market-gains%3A-what-you-should-know-2018-12-10", "https://www.nasdaq.com/articles/why-crsp-stock-has-added-layers-risk-2018-12-10", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-alexion-pharmaceuticals-regeneron", "https://www.nasdaq.com/articles/ex-dividend-reminder-new-jersey-resources-conmed-and-gilead-sciences-2018-12-11", "https://www.nasdaq.com/articles/4-biotech-stocks-investors-can-add-their-portfolio-2019-2018-12-11", "https://www.nasdaq.com/articles/gilead-sciences-gild-appoints-daniel-oday-as-new-ceo-2018-12-11", "https://www.nasdaq.com/articles/roches-tecentriq-gets-fda-approval-for-first-line-nsclc-2018-12-10", "https://www.nasdaq.com/articles/gilead-gild-announces-data-on-car-t-therapy-candidate-2018-12-04", "https://www.nasdaq.com/articles/shires-takhzyro-gets-european-nod-for-hereditary-angioedema-2018-12-03", "https://www.nasdaq.com/articles/fda-committee-to-review-amgens-amgn-osteoporosis-candidate-2018-12-03", "https://www.nasdaq.com/articles/did-gilead-sciences-make-11-billion-blunder-2018-12-09", "https://www.nasdaq.com/articles/vlue-gm-mu-gild-etf-outflow-alert-2018-12-07", "https://www.nasdaq.com/articles/biogen-biib-in-licenses-als-candidate-biib067-from-ionis-2018-12-07", "https://www.nasdaq.com/articles/how-google-helping-make-advances-medical-technology-2018-11-29", "https://www.nasdaq.com/articles/catalysts-firdapse-receives-fda-approval-for-rare-disease-2018-11-29", "https://www.nasdaq.com/articles/how-parts-add-rndv-targets-24-2018-11-29", "https://www.nasdaq.com/articles/merck-mrk-receives-approval-for-2-hiv-medicines-in-eu-2018-11-29", "https://www.nasdaq.com/articles/gilead-sciences-gild-stock-sinks-as-market-gains%3A-what-you-should-know-2018-12-03", "https://www.nasdaq.com/articles/novartis-nvs-receives-ec-approval-for-neulasta-biosimilar-2018-11-28", "https://www.nasdaq.com/articles/pfizers-epilepsy-drug-lyrica-gets-pediatric-exclusivity-2018-11-28", "https://www.nasdaq.com/articles/celgene-bluebirds-car-t-therapy-study-completes-enrollment-2018-11-28", "https://www.nasdaq.com/articles/5-biotech-stocks-scoop-big-dividends-2018-11-27", "https://www.nasdaq.com/articles/eyenovia-initiates-phase-iii-study-for-mydriasis-candidate-2018-11-27", "https://www.nasdaq.com/articles/bayers-trk-inhibitor-gets-fda-nod-for-advanced-solid-tumors-2018-11-27", "https://www.nasdaq.com/articles/zafgen-zfgn-plunges-as-fda-puts-hold-on-diabetes-drug-trial-2018-11-27", "https://www.nasdaq.com/articles/aileron-inks-collaboration-deal-with-pfizer-for-cancer-combo-2018-11-28", "https://www.nasdaq.com/articles/bristol-myers-opdivo-yervoy-combo-fails-in-lung-cancer-trial-2018-11-27", "https://www.nasdaq.com/articles/gileads-hiv-franchise-car-t-therapy-likely-to-propel-growth-2018-11-26", "https://www.nasdaq.com/articles/after-hours-most-active-nov-26-2018-ctl-ge-qqq-rf-teva-hal-bac-intc-aapl-gild-xel-stld", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-vs-celgene-2018-11-25", "https://www.nasdaq.com/articles/novartis-gets-approval-for-gene-therapy-luxturna-in-europe-2018-11-23", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gilds-drug-wins-nod-in-china-arena-up-on-licensing-deal-2018-11-21", "https://www.nasdaq.com/articles/nasdaq-100-movers-tsla-adsk-2018-11-21", "https://www.nasdaq.com/articles/alnylam-vir-begin-phase-i-ii-study-on-hepatitis-b-candidate-2018-11-27", "https://www.nasdaq.com/articles/emergents-ebs-zika-vaccine-candidate-meets-study-endpoint-2018-11-20", "https://www.nasdaq.com/articles/gileads-vemlidy-gets-approval-in-china-for-hbv-infection-2018-11-20", "https://www.nasdaq.com/articles/tesaro-stock-sinks-aftermath-sale-rumors-2018-11-19", "https://www.nasdaq.com/articles/amgens-blincyto-gets-positive-chmp-opinion-for-line-extension-2018-11-19", "https://www.nasdaq.com/articles/novartis-nvs-gets-fda-nod-for-label-expansion-of-promacta-2018-11-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-benjamin-graham-11182018-2018-11-18", "https://www.nasdaq.com/articles/ibb-gild-celg-ilmn-etf-outflow-alert-2018-11-16", "https://www.nasdaq.com/articles/should-value-investors-consider-gilead-gild-stock-now-2018-11-21", "https://www.nasdaq.com/articles/sangamos-shares-drop-on-rating-downgrade-pipeline-woes-2018-11-15", "https://www.nasdaq.com/articles/acorda-down-more-than-30-in-the-past-3-months%3A-heres-why-2018-11-15", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gilead-regeneron-present-data-cocrystal-pharma-surges-2018-11-14", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-november-15-2018-2018-11-14", "https://www.nasdaq.com/articles/roches-tecentriq-gets-priority-review-for-breast-cancer-2018-11-14", "https://www.nasdaq.com/articles/amarins-vascepa-cuts-heart-risk-in-outcomes-test-stock-down-2018-11-13", "https://www.nasdaq.com/articles/medicines-company-mdco-q3-loss-widens-inclisiran-in-focus-2018-11-12", "https://www.nasdaq.com/articles/bristol-myers-opdivo-receives-positive-chmp-opinion-for-rcc-2018-11-16", "https://www.nasdaq.com/articles/tilray-tlry-to-report-q3-earnings%3A-whats-in-the-cards-2018-11-12", "https://www.nasdaq.com/articles/arena-pharmaceuticals-arna-beats-on-q3-earnings-and-sales-2018-11-09", "https://www.nasdaq.com/articles/endo-endp-stock-declines-despite-q3-earnings-revenue-beat-2018-11-09", "https://www.nasdaq.com/articles/pdl-biopharma-pdli-q3-earnings-top-revenues-rise-stock-up-2018-11-08", "https://www.nasdaq.com/articles/prothena-prta-reports-narrower-than-expected-loss-in-q3-2018-11-08", "https://www.nasdaq.com/articles/validea-benjamin-graham-strategy-daily-upgrade-report-1182018-2018-11-08", "https://www.nasdaq.com/articles/aerie-aeri-q3-earnings-miss-rhopressa-gains-traction-2018-11-08", "https://www.nasdaq.com/articles/cronos-cron-to-report-q3-earnings%3A-whats-in-the-offing-2018-11-12", "https://www.nasdaq.com/articles/pacira-pcrx-q3-earnings-and-revenues-surpass-estimates-2018-11-05", "https://www.nasdaq.com/articles/why-gilead-sciences-inc-stock-broke-down-october-2018-11-05", "https://www.nasdaq.com/articles/puma-biotech-pbyi-q3-loss-narrows-nerlynx-pulls-stock-down-2018-11-05", "https://www.nasdaq.com/articles/3-top-biotech-stocks-pes-below-14-2018-11-03", "https://www.nasdaq.com/articles/emergent-ebs-q3-earnings-and-revenues-fall-shy-of-estimates-2018-11-02", "https://www.nasdaq.com/articles/conatus-cnat-q3-loss-in-line-revenues-lag-estimates-2018-11-02", "https://www.nasdaq.com/articles/bluebird-blue-q3-loss-narrower-than-expected-revenues-beat-2018-11-02", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-november-08-2018-2018-11-07", "https://www.nasdaq.com/articles/agios-agio-q3-earnings-beat-tibsovo-sales-drive-stock-2018-11-02", "https://www.nasdaq.com/articles/acorda-acor-q3-earnings-top-estimates-ampyra-sales-view-up-2018-11-01", "https://www.nasdaq.com/articles/3-big-stock-charts-for-thursday%3A-walmart-prologis-and-incyte-2018-11-01", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-amgen-vertex-pharmaceuticals-celgene", "https://www.nasdaq.com/articles/intercept-icpt-gains-on-earnings-and-revenue-beat-in-q3-2018-11-01", "https://www.nasdaq.com/articles/aduro-adro-q3-loss-narrower-than-expected-revenues-lag-2018-10-31", "https://www.nasdaq.com/articles/sptm-txn-gild-lmt-large-inflows-detected-etf-2018-10-31", "https://www.nasdaq.com/articles/radius-health-rdus-posts-narrower-than-expected-q3-loss-2018-11-02", "https://www.nasdaq.com/articles/agios-agio-q3-earnings-beat-tibsovo-sales-drive-stock-2018-11-02", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-celgene-amgen-vertex-impress-in-q3-drna-soars-on-lly-deal-2018-10", "https://www.nasdaq.com/articles/better-buy-celgene-corporation-vs-gilead-sciences-2018-10-30", "https://www.nasdaq.com/articles/can-strong-economy-save-stock-market-2018-10-30", "https://www.nasdaq.com/articles/7-rising-healthcare-stocks-consider-2018-10-29", "https://www.nasdaq.com/articles/analysts-see-18-upside-holdings-jkf-2018-10-29", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-roche-gilead-and-bristol-myers-revised-2018-10-29", "https://www.nasdaq.com/articles/nasdaq-100-movers-ea-nflx-2018-10-31", "https://www.nasdaq.com/articles/dr.-reddys-rdy-earnings-and-revenues-improve-y-y-in-q2-2018-10-29", "https://www.nasdaq.com/articles/abbvie-takes-aim-vertex-pharmaceuticals-incorporated-2018-10-27", "https://www.nasdaq.com/articles/where-will-gilead-sciences-inc-be-5-years-2018-10-27", "https://www.nasdaq.com/articles/daily-dividend-report-mac-cog-gild-agn-duk-2018-10-26", "https://www.nasdaq.com/articles/gilead-gild-beats-on-q3-earnings-sales-updates-view-2018-10-26", "https://www.nasdaq.com/articles/gilead-sciences-3rd-quarter-good-news-gets-better-bad-news-gets-worse-2018-10-26", "https://www.nasdaq.com/articles/gilead-sciences-stock-back-base-go-long-2018-10-26", "https://www.nasdaq.com/articles/gilead-sciences-gild-gains-as-market-dips%3A-what-you-should-know-2018-10-29", "https://www.nasdaq.com/articles/vertex-vrtx-q3-earnings-and-revenues-surpass-estimates-2018-10-25", "https://www.nasdaq.com/articles/bristol-myers-bmy-beats-on-q3-earnings-raises-eps-view-2018-10-25", "https://www.nasdaq.com/articles/sarepta-srpt-q3-earnings-sales-miss-exondys-51-sales-up-2018-10-25", "https://www.nasdaq.com/articles/new-batch-q3-earnings-amzn-googl-intc-more-2018-10-25", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-583-follow-through-indicator-45-sensitive", "https://www.nasdaq.com/articles/after-hours-earnings-report-october-25-2018-amzn-googl-intc-gild-syk-ftv-dfs-dlr-rsg-cern", "https://www.nasdaq.com/articles/investors-are-underestimating-gilead-sciences-stock-2018-10-24", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-q3-2018-earnings-conference-call-transcript-2018-10-26", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-right-now-2018-10-24", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-gild-wing-veev-2018-10-24", "https://www.nasdaq.com/articles/alkermes-alks-exceeds-q3-earnings-estimates-raises-outlook-2018-10-23", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-roche-gilead-and-bristol-myers-2018-10-23", "https://www.nasdaq.com/articles/why-casi-pharmaceuticals-inc-rocketing-higher-today-2018-10-23", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2018-10-22", "https://www.nasdaq.com/articles/will-gilead-gild-hiv-sales-offset-hcv-sales-decline-in-q3-2018-10-22", "https://www.nasdaq.com/articles/drug-stocks-earnings-due-on-oct-25%3A-mrk-bmy-gild-celg-2018-10-24", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-right-now-2018-10-24", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-gild-wing-veev-2018-10-24", "https://www.nasdaq.com/articles/forget-gilead-sciences-intercept-pharmaceuticals-inc-better-growth-stock-2018-10-16", "https://www.nasdaq.com/articles/gilead-sciences-breaks-above-200-day-moving-average-bullish-gild-2018-10-16", "https://www.nasdaq.com/articles/can-tiny-biotech-revolutionize-35-billion-market-2018-10-16", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-gs-cmg-gild-2018-10-16", "https://www.nasdaq.com/articles/2-pharmaceutical-stocks-buy-dividends-3-or-better-2018-10-15", "https://www.nasdaq.com/articles/can-unitedhealth-group-and-johnson-johnson-continue-their-winning-ways-2018-10-18", "https://www.nasdaq.com/articles/sangamo-therapeutics-inc-buy-2018-10-18", "https://www.nasdaq.com/articles/arbutus-abus-plunges-on-disappointing-hbv-pipeline-updates-2018-10-10", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gild-biib-present-data-vtgn-gains-on-fast-track-status-2018-10-10", "https://www.nasdaq.com/articles/5-best-dividend-stocks-buy-hands-down-2018-10-10", "https://www.nasdaq.com/articles/better-buy-crispr-therapeutics-ag-vs-editas-2018-10-09", "https://www.nasdaq.com/articles/gilead-announces-positive-data-from-ongoing-biktarvy-study-2018-10-05", "https://www.nasdaq.com/articles/gilead-sciences-gild-stock-moves-0.24%3A-what-you-should-know-2018-10-05", "https://www.nasdaq.com/articles/ibb-gild-biib-celg-large-inflows-detected-etf-2018-10-12", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-gild-biib-celg-2018-10-04", "https://www.nasdaq.com/articles/jjs-phase-iii-data-shows-switch-to-its-hiv-drug-beneficial-2018-10-04", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-pfizer-2018-10-04", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-cblk-gild-amtd-2018-10-04", "https://www.nasdaq.com/articles/7-healthcare-stocks-to-buy-right-now-2018-10-04", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alxn-on-acquisition-spree-fda-nod-for-regn-amgn-drugs-2018-10-03", "https://www.nasdaq.com/articles/gilead-hifibio-collaborate-to-develop-t-cell-receptors-2018-10-03", "https://www.nasdaq.com/articles/merck-reports-positive-efficacy-data-from-phase-iii-hiv-study-2018-10-05", "https://www.nasdaq.com/articles/3-reasons-why-buying-viking-therapeutics-dip-could-pay-big-2018-10-02", "https://www.nasdaq.com/articles/5-reasons-buy-gilead-stock-today-2018-10-01", "https://www.nasdaq.com/articles/better-buy-vertex-pharmaceuticals-incorporated-vs-galapagos-nv-2018-09-28", "https://www.nasdaq.com/articles/alexion-alxn-to-acquire-biotech-syntimmune-for-%241.2-billion-2018-09-27", "https://www.nasdaq.com/articles/look-under-hood-spyv-has-11-upside-2018-09-27", "https://www.nasdaq.com/articles/guide-crispr-stocks-latest-apple-fed-gdp-news-free-lunch-2018-09-27", "https://www.nasdaq.com/articles/ibb-biib-gild-celg-etf-inflow-alert-2018-09-26", "https://www.nasdaq.com/articles/5-top-healthcare-mutual-funds-to-buy-in-october-2018-10-02", "https://www.nasdaq.com/articles/gilead-sciences-latest-tactic-go-generic-2018-09-26", "https://www.nasdaq.com/articles/gilead-sciences-gild-gains-as-market-dips%3A-what-you-should-know-2018-09-26", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-isrg-celg-gild-2018-09-26", "https://www.nasdaq.com/articles/gilead-undercutting-its-own-drugs-heres-why-2018-09-26", "https://www.nasdaq.com/articles/5-biotech-stocks-play-sectors-next-big-trend-nash-2018-09-26", "https://www.nasdaq.com/articles/gilead-gild-to-launch-generics-for-leading-hcv-treatments-2018-09-25", "https://www.nasdaq.com/articles/3-ways-unpack-some-hidden-treasure-tesaro-stock-2018-09-24", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alxn-soliris-successful-respite-for-sarepta-amrn-soars-2018-09-26", "https://www.nasdaq.com/articles/chmp-reconfirms-negative-opinion-for-sareptas-exondys-2018-09-24", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-right-now-2018-09-23", "https://www.nasdaq.com/articles/how-do-drugs-compete-against-each-other-2018-09-21", "https://www.nasdaq.com/articles/fda-confirms-positive-safety-profile-of-acadias-nuplazid-2018-09-21", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-buy-2018-09-21", "https://www.nasdaq.com/articles/molecular-templates-surges-50-inks-cancer-deal-with-takeda-2018-09-20", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-pharmaceuticals-celgene-sanofi-and-gilead", "https://www.nasdaq.com/articles/exelixis-ipsen-receive-positive-chmp-opinion-for-cabometyx-2018-09-24", "https://www.nasdaq.com/articles/ultragenyxs-shares-surge-more-than-80-in-the-year-so-far-2018-09-20", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-celg-regn-present-data-vktx-soars-on-drugs-success-2018-09-19", "https://www.nasdaq.com/articles/viking-therapeutics-liver-candidate-passes-test-shares-soar-2018-09-19", "https://www.nasdaq.com/articles/dr.-reddys-rdy-presence-in-generics-market-remains-strong-2018-09-19", "https://www.nasdaq.com/articles/is-gilead-gild-a-suitable-stock-for-value-investors-now-2018-09-19", "https://www.nasdaq.com/articles/gilead-sciences-gild-outpaces-stock-market-gains%3A-what-you-should-know-2018-09-19", "https://www.nasdaq.com/articles/theravance-mylan-report-positive-data-on-copd-drug-yupelri-2018-09-18", "https://www.nasdaq.com/articles/exelixis-partner-ipsen-gets-approval-for-cabometyx-in-canada-2018-09-20", "https://www.nasdaq.com/articles/galapagos-nv-buy-now-2018-09-18", "https://www.nasdaq.com/articles/after-hours-most-active-sep-18-2018-f-t-abev-symc-qqq-mo-nly-intc-gild-fe-foxa-grpn-2018", "https://www.nasdaq.com/articles/viking-therapeutics-and-madrigal-pharmaceuticals-are-racing-finish-line-nash-2018-09-18", "https://www.nasdaq.com/articles/should-value-investors-pick-gilead-sciences-gild-stock-2018-09-17", "https://www.nasdaq.com/articles/why-gilead-stock-sleepy-giant-waiting-break-out-2018-09-17", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-benjamin-graham-9162018-2018-09-16", "https://www.nasdaq.com/articles/ibb-biib-gild-celg-large-outflows-detected-etf-2018-09-14", "https://www.nasdaq.com/articles/agenus-receives-milestone-payment-of-%245-million-from-incyte-2018-09-18", "https://www.nasdaq.com/articles/brawl-brewing-between-abbvie-and-gilead-sciences-arthritis-2018-09-14", "https://www.nasdaq.com/articles/gilead-inks-gene-editing-collaboration-deal-for-hbv-infection-2018-09-13", "https://www.nasdaq.com/articles/company-news-for-sep-13-2018-2018-09-13", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-biogen-2018-09-13", "https://www.nasdaq.com/articles/whats-next-gilead-sciences-after-its-latest-clinical-success-2018-09-13", "https://www.nasdaq.com/articles/heres-why-galapagos-nv-skyrocketing-183-today-2018-09-12", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gilds-arthritis-drug-successful-in-phase-iii-prqr-soars-2018-09-12", "https://www.nasdaq.com/articles/unity-ubx-catches-eye%3A-stock-jumps-8.8-2018-09-14", "https://www.nasdaq.com/articles/mercks-antibacterial-drug-succeeds-in-label-expansion-study-2018-09-12", "https://www.nasdaq.com/articles/regeneron-sanofis-sbla-for-praluent-to-be-reviewed-by-fda-2018-09-12", "https://www.nasdaq.com/articles/3-top-stocks-investing-pharmas-next-35-billion-market-2018-09-12", "https://www.nasdaq.com/articles/incyte-foundation-medicine-partner-for-companion-diagnostics-2018-09-12", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-september-13-2018-2018-09-12", "https://www.nasdaq.com/articles/gilead-sciences-reports-market-moving-news-2018-09-12", "https://www.nasdaq.com/articles/why-altria-group-galapagos-and-laredo-petroleum-jumped-today-2018-09-12", "https://www.nasdaq.com/articles/nasdaq-100-movers-mxim-gild-2018-09-12", "https://www.nasdaq.com/articles/endocyte-announces-fdas-acceptance-of-trial-endpoint-change-2018-09-11", "https://www.nasdaq.com/articles/ex-dividend-reminder-el-paso-electric-dte-energy-and-gilead-sciences-2018-09-11", "https://www.nasdaq.com/articles/inovios-early-mid-stage-vaccine-pipeline-exhibits-growth-2018-09-10", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbott-gilead-fedex-archer-daniels-and-cbre-2018-09-10", "https://www.nasdaq.com/articles/gilead-sciences-gild-outpaces-stock-market-gains%3A-what-you-should-know-2018-09-10", "https://www.nasdaq.com/articles/shires-adhd-portfolio-remains-strong-amid-competition-2018-09-10", "https://www.nasdaq.com/articles/inovio-initiates-dosing-in-phase-i-iia-study-on-mers-vaccine-2018-09-07", "https://www.nasdaq.com/articles/gileads-rheumatoid-arthritis-drug-successful-in-phase-iii-2018-09-12", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-ubnt-roku-gild-2018-09-07", "https://www.nasdaq.com/articles/arrowhead-stock-not-done-rallying-after-its-38-jump-2018-09-07", "https://www.nasdaq.com/articles/proqr-up-more-than-120-on-favorable-eye-disorder-study-data-2018-09-06", "https://www.nasdaq.com/articles/puma-biotech-gets-eu-nod-for-breast-cancer-drug-nerlynx-2018-09-06", "https://www.nasdaq.com/articles/ibb-gild-celg-regn-large-outflows-detected-etf-2018-09-06", "https://www.nasdaq.com/articles/3-top-big-pharma-stocks-buy-now-2018-09-06", "https://www.nasdaq.com/articles/bluebird-blue-reports-updated-data-on-lenti-d-gene-therapy-2018-09-06", "https://www.nasdaq.com/articles/top-research-reports-abbott-gilead-fedex-2018-09-07", "https://www.nasdaq.com/articles/mannkind-stock-up-on-licensing-deal-with-united-therapeutics-2018-09-05", "https://www.nasdaq.com/articles/horizon-pharma-completes-enrollment-in-eye-disease-study-2018-09-05", "https://www.nasdaq.com/articles/bayer-bayry-misses-on-q2-earnings-closes-monsanto-buyout-2018-09-05", "https://www.nasdaq.com/articles/inovio-ino-initiates-phase-i-study-on-hepatitis-c-vaccine-2018-09-04", "https://www.nasdaq.com/articles/now-good-time-buy-gilead-sciences-2018-09-04", "https://www.nasdaq.com/articles/alnylams-shares-up-as-onpattro-gets-fda-and-eu-approvals-2018-09-04", "https://www.nasdaq.com/articles/novo-nordisks-ozempic-lowers-risk-of-cardiovascular-events-revised-2018-09-04", "https://www.nasdaq.com/articles/gilead-galapagos-spondylitis-drug-meets-primary-endpoint-2018-09-06", "https://www.nasdaq.com/articles/mannkind-stock-up-on-licensing-deal-with-united-therapeutics-2018-09-05", "https://www.nasdaq.com/articles/glaxos-asthma-drug-gets-eu-nod-for-pediatric-population-2018-08-31", "https://www.nasdaq.com/articles/vertex-inks-deal-with-genomics-to-make-serious-disease-drugs-2018-08-31", "https://www.nasdaq.com/articles/bayers-bayry-jivi-gets-fda-approval-to-treat-hemophilia-a-2018-08-31", "https://www.nasdaq.com/articles/alnylam-gets-european-nod-for-first-ever-rnai-therapeutic-2018-08-31", "https://www.nasdaq.com/articles/merck-mrk-receives-fda-approval-for-two-hiv-medicines-2018-08-31", "https://www.nasdaq.com/articles/bristol-myers-sprycel-seeks-label-expansion-in-the-u.s.-2018-08-31", "https://www.nasdaq.com/articles/astrazenecas-lupus-drug-misses-primary-endpoint-in-study-2018-09-03", "https://www.nasdaq.com/articles/ultragenyx-to-file-nda-for-lc-faod-candidate-on-existing-data-2018-08-30", "https://www.nasdaq.com/articles/gilead-sciences-gild-gains-as-market-dips%3A-what-you-should-know-2018-08-30", "https://www.nasdaq.com/articles/gilead-sciences-gild-gains-as-market-dips%3A-what-you-should-know-2018-08-30-0", "https://www.nasdaq.com/articles/affimed-afmd-surges-on-collaboration-contract-with-roche-revised-2018-08-30", "https://www.nasdaq.com/articles/bausch-bhc-resubmits-nda-for-duobrii-for-plaque-psoriasis-2018-08-30", "https://www.nasdaq.com/articles/affimed-afmd-surges-on-collaboration-contract-with-roche-2018-08-29", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gild-gets-ec-nod-for-yescarta-amgn-submits-kyprolis-snda-2018-08-29", "https://www.nasdaq.com/articles/5-enticing-dividend-stocks-primed-long-term-growth-2018-08-31", "https://www.nasdaq.com/articles/time-to-take-some-profits-in-sarepta-therapeutics-stock-2018-08-29", "https://www.nasdaq.com/articles/amgen-files-for-once-weekly-regimen-for-myeloma-drug-kyprolis-2018-08-28", "https://www.nasdaq.com/articles/gileads-car-t-therapy-yescarta-gets-approval-in-europe-2018-08-28", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-week-2018-08-28", "https://www.nasdaq.com/articles/ultragenyxs-rare-disease-drug-mepsevii-gets-eu-approval-2018-08-28", "https://www.nasdaq.com/articles/bayers-blood-thinner-xarelto-fails-in-line-extension-studies-2018-08-28", "https://www.nasdaq.com/articles/play-the-future-of-gene-therapy-with-these-5-biotech-stocks-2018-08-27", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-right-now-2018-08-29", "https://www.nasdaq.com/articles/novartis-car-t-therapy-kymriah-gets-approval-in-europe-2018-08-27", "https://www.nasdaq.com/articles/novo-nordisks-ozempic-lowers-risk-of-cardiovascular-events-2018-08-27", "https://www.nasdaq.com/articles/bausch-bhc-gets-fda-approval-for-altreno-for-acne-vulgaris-2018-08-27", "https://www.nasdaq.com/articles/why-is-gilead-gild-down-6.2-since-last-earnings-report-2018-08-24", "https://www.nasdaq.com/articles/shires-takhzyro-gets-fda-nod-for-hereditary-angioedema-2018-08-24", "https://www.nasdaq.com/articles/roche-rhhby-gets-fda-approval-for-cobas-efgr-mutation-test-2018-08-24", "https://www.nasdaq.com/articles/3-big-drug-stocks-big-cash-stockpiles-should-you-spend-your-cash-buying-them-2018-08-24", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-biib-gild-celg-2018-08-27", "https://www.nasdaq.com/articles/novartis-car-t-therapy-kymriah-gets-approval-in-europe-2018-08-27", "https://www.nasdaq.com/articles/novo-nordisks-ozempic-lowers-risk-of-cardiovascular-events-2018-08-27", "https://www.nasdaq.com/articles/bausch-bhc-gets-fda-approval-for-altreno-for-acne-vulgaris-2018-08-27", "https://www.nasdaq.com/articles/pacira-pcrx-rides-high-on-robust-exparel-performance-2018-08-22", "https://www.nasdaq.com/articles/allergan-falls-on-fdas-rejection-of-uterine-fibroids-drug-2018-08-22", "https://www.nasdaq.com/articles/infinity-focuses-on-developing-ipi-549-for-solid-tumors-2018-08-22", "https://www.nasdaq.com/articles/abbvie-posts-positive-data-on-elagolix-for-uterine-fibroids-2018-08-23", "https://www.nasdaq.com/articles/exact-sciences-inks-cologuard-co-promotion-deal-with-pfizer-2018-08-23", "https://www.nasdaq.com/articles/4-biotech-stocks-investors-can-bet-post-solid-q2-earnings-2018-08-23", "https://www.nasdaq.com/articles/mallinckrodts-stannsoporfin-gets-complete-response-letter-2018-08-23", "https://www.nasdaq.com/articles/cost-cures-how-investing-biotech-stocks-could-soon-be-radically-changed-2018-08-21", "https://www.nasdaq.com/articles/japan-nods-to-astrazenecas-tagrisso-for-first-line-nsclc-2018-08-21", "https://www.nasdaq.com/articles/8-undervalued-biotech-stocks-to-watch-2018-08-20", "https://www.nasdaq.com/articles/alnylam-completes-enrollment-in-phase-iii-givosiran-study-2018-08-22", "https://www.nasdaq.com/articles/novo-nordisk-buys-ziylo-to-develop-glucose-responsive-insulin-2018-08-20", "https://www.nasdaq.com/articles/time-jackson-hole-global-week-ahead-2018-08-20", "https://www.nasdaq.com/articles/viking-therapeutics-inc-buy-2018-08-19", "https://www.nasdaq.com/articles/has-gilead-sciences-gild-outpaced-other-medical-stocks-this-year-2018-08-17", "https://www.nasdaq.com/articles/has-gilead-sciences-gild-outpaced-other-medical-stocks-this-year-2018-08-17-0", "https://www.nasdaq.com/articles/regeneron-teva-announce-positive-data-on-osteoarthritis-drug-2018-08-17", "https://www.nasdaq.com/articles/zacks-value-trader-highlights%3A-sony-carrizo-oil-gas-intel-united-rentals-and-gilead-2018", "https://www.nasdaq.com/articles/bristol-myers-opdivo-gets-fda-nod-for-small-cell-lung-cancer-2018-08-20", "https://www.nasdaq.com/articles/notable-friday-option-activity-adbe-fb-gild-2018-08-17", "https://www.nasdaq.com/articles/inovio-pharmaceuticals-initiates-dosing-in-hiv-vaccine-study-2018-08-16", "https://www.nasdaq.com/articles/lessons-legendary-value-investor-2018-08-16", "https://www.nasdaq.com/articles/vertexs-cystic-fibrosis-drug-gets-fda-nod-for-children-2018-08-16", "https://www.nasdaq.com/articles/should-gilead-be-worried-about-new-monthly-hiv-medication-2018-08-16", "https://www.nasdaq.com/articles/gild-makes-notable-cross-below-critical-moving-average-2018-08-15", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-august-16-2018-2018-08-15", "https://www.nasdaq.com/articles/glaxo-jjs-dual-drug-hiv-regimen-succeeds-in-phase-iii-study-2018-08-17", "https://www.nasdaq.com/articles/bayer-plunges-as-monsanto-fined-%24289m-in-roundup-lawsuit-2018-08-14", "https://www.nasdaq.com/articles/shire-shionogi-file-nda-for-intuniv-for-adults-in-japan-2018-08-13", "https://www.nasdaq.com/articles/ligand-lgnd-proposes-to-buy-u.k.s-drug-discovery-biotech-2018-08-13", "https://www.nasdaq.com/articles/alnylam-alny-gets-fda-nod-for-first-ever-rnai-therapeutic-2018-08-13", "https://www.nasdaq.com/articles/amicus-fold-gets-fda-nod-for-fabry-disease-drug-galafold-2018-08-13", "https://www.nasdaq.com/articles/puma-biotech-pbyi-q2-loss-narrows-nerlynx-drives-sales-2018-08-10", "https://www.nasdaq.com/articles/agenus-agen-q2-loss-narrower-than-expected-revenues-beat-2018-08-10", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-august-16-2018-2018-08-15", "https://www.nasdaq.com/articles/biotech-etfs-focus-string-q2-earnings-beat-2018-08-10", "https://www.nasdaq.com/articles/keryxs-kerx-loss-wider-than-expected-in-q2-sales-lag-2018-08-09", "https://www.nasdaq.com/articles/pdl-biopharma-pdli-q2-earnings-top-revenues-slump-y-y-2018-08-09", "https://www.nasdaq.com/articles/crispr-therapeutics-stock-grossly-overvalued-2018-08-09", "https://www.nasdaq.com/articles/aerie-aeri-earnings-miss-in-q2-rhopressa-performs-well-2018-08-09", "https://www.nasdaq.com/articles/horizon-pharma-hznp-q2-earnings-sales-beat-shares-rise-2018-08-09", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-prgo-oxy-gild-2018-08-09", "https://www.nasdaq.com/articles/gild-top-25-dividend-giant-523b-held-etfs-2018-08-10", "https://www.nasdaq.com/articles/inovio-ino-q2-loss-narrows-revenues-surpass-estimates-2018-08-08", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-q2-loss-in-line-revenues-miss-2018-08-08", "https://www.nasdaq.com/articles/merrimack-mack-suffers-wider-than-expected-loss-in-q2-2018-08-08", "https://www.nasdaq.com/articles/vivus-vvus-q2-loss-wider-than-expected-revenues-up-y-y-2018-08-08", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-amgen-inc-2018-08-08", "https://www.nasdaq.com/articles/prothena-prta-q2-earnings-lag-estimates-pipeline-in-focus-2018-08-08", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-regeneron-shines-blue-surges-once-plunges-2018-08-08", "https://www.nasdaq.com/articles/novo-nordisk-nvo-beats-q2-earnings-and-sales-estimates-2018-08-08", "https://www.nasdaq.com/articles/radius-rdus-q2-loss-narrower-than-expected-tymlos-sales-up-2018-08-07", "https://www.nasdaq.com/articles/alnylams-alny-q2-loss-wider-than-expected-sales-beat-2018-08-06", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2018-08-06", "https://www.nasdaq.com/articles/q2-scorecard-research-reports-gilead-american-tower-others-2018-08-06", "https://www.nasdaq.com/articles/bluebird-blue-q2-loss-wider-than-expected-revenues-miss-2018-08-03", "https://www.nasdaq.com/articles/acorda-acor-q2-earnings-and-revenues-surpass-estimates-2018-08-03", "https://www.nasdaq.com/articles/intercept-icpt-gains-on-solid-q2-results-ocaliva-recovers-2018-08-03", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-august-2018-08-08", "https://www.nasdaq.com/articles/ultragenyx-rare-posts-narrower-than-expected-loss-in-q2-2018-08-03", "https://www.nasdaq.com/articles/epizyme-epzm-q2-loss-narrows-shares-crash-24-on-setbacks-2018-08-03", "https://www.nasdaq.com/articles/5-cheap-peg-stocks-suitable-for-garp-investors-2018-08-02", "https://www.nasdaq.com/articles/zoetis-zts-beats-on-q2-earnings-sales-updates-18-view-2018-08-02", "https://www.nasdaq.com/articles/the-5-best-dividend-stocks-to-buy-hands-down-2018-08-02", "https://www.nasdaq.com/articles/shires-shpg-earnings-and-revenues-beat-estimates-in-q2-2018-08-01", "https://www.nasdaq.com/articles/endocyte-ecyt-posts-narrower-than-expected-loss-in-q2-2018-08-01", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include%3A-biogen-thermo-fisher-hca-gilead-and-qualcomm-2018", "https://www.nasdaq.com/articles/sanofis-sny-q2-earnings-surpass-estimates-sales-miss-2018-07-31", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-inc-2018-07-31", "https://www.nasdaq.com/articles/gilead-sciences-sudden-change-leadership-good-thing-2018-07-30", "https://www.nasdaq.com/articles/3-cheap-big-pharma-dividend-stocks-you-can-buy-now-and-hold-years-2018-07-29", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-inflow-2018-07-27", "https://www.nasdaq.com/articles/forget-gilead-sciences-ceo-departure-was-biotechs-big-news-2018-07-27", "https://www.nasdaq.com/articles/after-hours-most-active-jul-27-2018-qqq-wfc-csco-ms-db-nok-czr-mo-ko-gild-soxx-symc-2018", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-celgene-amgen-vertex-impress-in-q2-gileads-ceo-to-exit-2018-08-01", "https://www.nasdaq.com/articles/allergan-agn-beats-on-q2-earnings-unveils-buyback-plan-2018-07-26", "https://www.nasdaq.com/articles/astrazenecas-azn-q2-earnings-and-sales-beat-stock-up-2018-07-26", "https://www.nasdaq.com/articles/alexions-alxn-earnings-beat-estimates-in-q2-guidance-up-2018-07-26", "https://www.nasdaq.com/articles/microsoft-hr-block-facebook-qualcomm-and-gilead-highlighted-as-zacks-bull-and-bear-of-the", "https://www.nasdaq.com/articles/gilead-gild-q2-earnings-sales-beat-eclipsed-by-ceo-exit-2018-07-26", "https://www.nasdaq.com/articles/ceo-departure-gilead-sciences-upstages-good-second-quarter-results-2018-07-26", "https://www.nasdaq.com/articles/daily-dividend-report-schw-mck-cvx-cmcsa-gild-2018-07-26", "https://www.nasdaq.com/articles/2-reasons-market-frowned-after-abbvies-blowout-q2-and-1-reason-it-should-be-excited-2018", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-biogen-gains-on-q2-results-agios-gets-fda-nod-for-leukemia-drug", "https://www.nasdaq.com/articles/facebook-misses-1st-time-11-quarters-plus-gild-qcom-2018-07-25", "https://www.nasdaq.com/articles/gilead-sciences-gild-q2-earnings-and-revenues-surpass-estimates-2018-07-25", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-grpn-gild-spwr-2018-07-25", "https://www.nasdaq.com/articles/after-hours-earnings-report-july-25-2018-fb-v-pypl-gild-qcom-su-mdlz-lvs-vrtx-f-now-algn", "https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-abbvie-abbv-in-q2-earnings-2018-07-24", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-keryx-kerx-this-earnings-season-2018-07-24", "https://www.nasdaq.com/articles/thursdays-etf-unusual-volume-fbt-2018-07-26", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-biogen-gains-on-q2-results-agios-gets-fda-nod-for-leukemia-drug", "https://www.nasdaq.com/articles/facebook-misses-1st-time-11-quarters-plus-gild-qcom-2018-07-25", "https://www.nasdaq.com/articles/gilead-sciences-gild-q2-earnings-and-revenues-surpass-estimates-2018-07-25", "https://www.nasdaq.com/articles/will-strong-hiv-sales-fuel-gilead-gild-in-q2-earnings-2018-07-23", "https://www.nasdaq.com/articles/why-i-finally-sold-my-gilead-sciences-stock-position-2018-07-23", "https://www.nasdaq.com/articles/3-key-things-watch-gilead-sciences-q2-earnings-report-2018-07-22", "https://www.nasdaq.com/articles/4-biotech-bets-watch-industry-rebounds-month-2018-07-20", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-alexion-alxn-this-earnings-season-2018-07-23", "https://www.nasdaq.com/articles/will-hiv-sales-drive-gilead-gild-to-beat-in-q2-earnings-2018-07-20", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-ibb-biib-gild-amgn-2018-07-19", "https://www.nasdaq.com/articles/5-biotech-stocks-well-poised-to-beat-q2-earnings-estimates-2018-07-19", "https://www.nasdaq.com/articles/jjs-darunavir-based-single-tablet-hiv-regimen-gets-fda-nod-2018-07-18", "https://www.nasdaq.com/articles/4-biggest-hiv-drugs-2024-which-stocks-are-poised-profit-2018-07-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-benjamin-graham-7152018-2018-07-15", "https://www.nasdaq.com/articles/3-best-big-pharma-stocks-buy-2nd-half-2018-2018-07-15", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-july-2018-07-20", "https://www.nasdaq.com/articles/if-youre-thinking-about-buying-gilead-sciences-stock-nows-time-do-it-2018-07-12", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-ibb-gild-amgn-biib-2018-07-11", "https://www.nasdaq.com/articles/3-huge-biotech-winners-2018-so-far-2018-07-11", "https://www.nasdaq.com/articles/gilead-sciences-gild-shares-cross-3-yield-mark-2018-07-11", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-mastercard-gilead-goldman-sachs-pepsico-and-aetna-2018", "https://www.nasdaq.com/articles/trade-of-the-day%3A-gilead-sciences-gild-2018-07-10", "https://www.nasdaq.com/articles/is-invesco-zacks-multi-asset-income-etf-cvy-a-hot-etf-right-now-2018-07-10", "https://www.nasdaq.com/articles/3-biotech-stocks-big-news-coming-nash-2018-07-14", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-gild-2018-07-09", "https://www.nasdaq.com/articles/biotech-etfs-surge-biogens-positive-drug-trial-result-2018-07-09", "https://www.nasdaq.com/articles/why-biotech-stocks-rallied-biogens-alzheimers-test-2018-07-06", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-gild-omc-adsk-2018-07-06", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gilds-positive-chmp-nod-regulatory-updates-more-2018-07-05", "https://www.nasdaq.com/articles/ibb-gild-amgn-biib-large-outflows-detected-etf-2018-07-03", "https://www.nasdaq.com/articles/is-gilead-sciences-a-great-stock-for-value-investors-2018-07-03", "https://www.nasdaq.com/articles/top-research-reports-mastercard-gilead-goldman-sachs-2018-07-09", "https://www.nasdaq.com/articles/novartis-to-spin-off-alcon-as-separate-trading-company-2018-07-02", "https://www.nasdaq.com/articles/4-biotech-stocks-bet-second-half-2018-2018-06-29", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-pbyi-soars-mack-crashes-gilds-biktarvy-gets-ec-nod-2018-06-27", "https://www.nasdaq.com/articles/gileads-gild-biktarvy-gets-ec-nod-for-hiv-1-infection-2018-06-26", "https://www.nasdaq.com/articles/after-hours-most-active-jun-26-2018-pfe-f-qqq-msft-flnt-bwp-teva-gild-t-intc-mdt-2018-06", "https://www.nasdaq.com/articles/ibb-gild-biib-celg-etf-inflow-alert-2018-06-25", "https://www.nasdaq.com/articles/health-care-sector-update-06252018-drio-sybx-gild-2018-06-25", "https://www.nasdaq.com/articles/gileads-gild-car-t-therapy-gets-positive-chmp-opinion-2018-07-02", "https://www.nasdaq.com/articles/health-care-sector-update-06252018-driovlrxgildsybx-2018-06-25", "https://www.nasdaq.com/articles/health-care-sector-update-06252018-vlrxgildsybx-2018-06-25", "https://www.nasdaq.com/articles/2-high-flying-biotech-stocks-even-more-room-grow-2018-06-20", "https://www.nasdaq.com/articles/crispr-science-and-stocks-knowing-enough-invest-2018-06-20", "https://www.nasdaq.com/articles/3-great-reasons-buy-gilead-sciences-2018-06-19", "https://www.nasdaq.com/articles/novartis-announces-positive-data-on-car-t-therapy-kymriah-2018-06-18", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-benjamin-graham-6172018-2018-06-17", "https://www.nasdaq.com/articles/we-did-math-qqxt-can-go-58-2018-06-25", "https://www.nasdaq.com/articles/zacks-value-investor-highlights%3A-gilead-sciences-biogen-celgene-lannett-and-valeant-2018", "https://www.nasdaq.com/articles/nash-space-focus-galmed-glmd-posts-positive-data-2018-06-14", "https://www.nasdaq.com/articles/galmed-glmd-soars-on-positive-nash-data-on-aramchol-2018-06-13", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-june-14-2018-2018-06-13", "https://www.nasdaq.com/articles/drug-stocks-next-hot-industry-or-value-traps-2018-06-13", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-anet-tpx-gild-2018-06-13", "https://www.nasdaq.com/articles/1-under-radar-dividend-growth-stock-buy-right-now-2018-06-17", "https://www.nasdaq.com/articles/after-hours-most-active-jun-12-2018-cmcsa-f-edr-mu-knx-wmb-ge-mgm-amat-intc-gild-agnc-2018", "https://www.nasdaq.com/articles/jak-inhibitors-prospects-strong-4-stocks-ruling-space-2018-06-11", "https://www.nasdaq.com/articles/gilead-sciences-top-socially-responsible-dividend-stock-32-yield-gild-2018-06-11", "https://www.nasdaq.com/articles/should-you-stick-gilead-sciences-2018-06-07", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-inflow-2018-06-06", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-regeneron-celgene-amgen-impress-at-asco-2018-06-06", "https://www.nasdaq.com/articles/2-cheap-dividend-stocks-you-can-buy-right-now-2018-06-06", "https://www.nasdaq.com/articles/ex-dividend-reminder-chesapeake-utilities-gilead-sciences-and-owens-minor-2018-06-12", "https://www.nasdaq.com/articles/after-hours-most-active-jun-12-2018-cmcsa-f-edr-mu-knx-wmb-ge-mgm-amat-intc-gild-agnc-2018", "https://www.nasdaq.com/articles/has-gilead-sciences-buy-argument-collapsed-2018-06-01", "https://www.nasdaq.com/articles/better-know-biotech-2-stocks-youve-got-know-about-2018-06-01", "https://www.nasdaq.com/articles/madrigals-nash-study-data-encouraging-stock-skyrockets-2018-06-01", "https://www.nasdaq.com/articles/5-top-stocks-buy-june-2018-06-01", "https://www.nasdaq.com/articles/heres-why-madrigal-pharmaceuticals-skyrocketing-today-2018-05-31", "https://www.nasdaq.com/articles/gilead-collaborates-with-hookipa-for-hbv-and-hiv-therapies-2018-06-06", "https://www.nasdaq.com/articles/gilead-galapagos-announce-positive-data-on-filgotinib-2018-05-31", "https://www.nasdaq.com/articles/2018-asco-conference-roundup-2018-05-31", "https://www.nasdaq.com/articles/why-is-gilead-sciences-gild-down-7.2-since-its-last-earnings-report-2018-05-31", "https://www.nasdaq.com/articles/asco-conference-preview-heres-what-biotech-investors-need-watch-2018-05-31", "https://www.nasdaq.com/articles/read-you-buy-immuno-oncology-stocks-2018-05-30", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gild-epclusas-china-approval-bmrn-palynziqs-fda-nod-2018-05-30", "https://www.nasdaq.com/articles/3-top-value-stocks-buy-now-2018-05-29", "https://www.nasdaq.com/articles/glaxosmithkline-plc-stock-buy-2018-05-31", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-gild-tmo-cvs-2018-05-25", "https://www.nasdaq.com/articles/bluebirds-lenti-d-gets-breakthrough-therapy-status-from-fda-2018-05-24", "https://www.nasdaq.com/articles/we-did-math-mgv-can-go-86-2018-05-23", "https://www.nasdaq.com/articles/glaxo-and-jjs-two-drug-hiv-regimen-juluca-gets-eu-approval-2018-05-22", "https://www.nasdaq.com/articles/3-biotechs-fdas-naughty-list-should-be-investors-buy-lists-2018-05-22", "https://www.nasdaq.com/articles/should-fda-be-shaming-drug-companies-financial-advisors-daily-digest-2018-05-21", "https://www.nasdaq.com/articles/xlv-mrk-amgn-gild-etf-inflow-alert-2018-05-17", "https://www.nasdaq.com/articles/3-healthcare-stocks-are-undeniably-dirt-cheap-right-now-2018-05-27", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-may-16-2018-2018-05-15", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-may-11-2018-2018-05-10", "https://www.nasdaq.com/articles/why-bristol-myers-squibb-stock-crashed-april-2018-05-09", "https://www.nasdaq.com/articles/3-stocks-turned-10000-1-million-2018-05-09", "https://www.nasdaq.com/articles/intercept-icpt-q1-loss-narrower-than-expected-sales-lag-2018-05-08", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-bp-gilead-enterprise-products-and-colgate-2018-05-07", "https://www.nasdaq.com/articles/after-hours-most-active-may-7-2018-cmcsa-qqq-gild-mu-fnsr-crzo-2018-05-07", "https://www.nasdaq.com/articles/3-high-yield-stocks-virtual-monopolies-2018-05-17", "https://www.nasdaq.com/articles/celgene-celg-q1-earnings-sales-beat-on-revlimid-strength-2018-05-04", "https://www.nasdaq.com/articles/5-value-stocks-to-book-gains-using-price-to-book-ratio-2018-05-04", "https://www.nasdaq.com/articles/gilead-sciences-stock-finally-bargain-2018-05-04", "https://www.nasdaq.com/articles/notable-friday-option-activity-gild-exel-rig-2018-05-04", "https://www.nasdaq.com/articles/gilead-sciences-inc-stock-will-recover-eventually-2018-05-04", "https://www.nasdaq.com/articles/did-gilead-sciences-make-big-mistake-2018-05-03", "https://www.nasdaq.com/articles/company-news-for-may-3-2018-2018-05-03", "https://www.nasdaq.com/articles/top-stock-reports-bp-gilead-enterprise-products-colgate-2018-05-04", "https://www.nasdaq.com/articles/earnings-season-keeping-markets-wobbly-2018-05-03", "https://www.nasdaq.com/articles/5-reasons-you-shouldnt-worry-about-gilead-sciences-ugly-q1-results-2018-05-03", "https://www.nasdaq.com/articles/relative-strength-alert-gilead-sciences-2018-05-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-aapl-2018-05-02", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-apple-snap-gilead-and-t-mobile-u.s.-2018-05-02", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alxn-vrtx-post-solid-results-gild-disappoints-in-q1-2018-05-02", "https://www.nasdaq.com/articles/gilead-gild-q1-earnings-sales-miss-estimates-on-weak-hcv-2018-05-02", "https://www.nasdaq.com/articles/thursdays-vital-data-snap-inc-snap-gilead-sciences-inc-gild-and-weatherford-international", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-710090-down-2980-points-2018-05-02", "https://www.nasdaq.com/articles/why-molson-coors-gilead-sciences-and-yum-china-holdings-slumped-today-2018-05-02", "https://www.nasdaq.com/articles/5-top-stock-trades-thursday-morning-2018-05-02", "https://www.nasdaq.com/articles/xlv-mrk-amgn-gild-large-outflows-detected-etf-2018-05-01", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-q1-2018-earnings-conference-call-transcript-2018-05-01", "https://www.nasdaq.com/articles/gilead-sciences-inc-stock-declined-after-earnings-miss-2018-05-01", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-inc-2018-05-01", "https://www.nasdaq.com/articles/gilead-sciences-first-quarter-twist-weak-hiv-sales-2018-05-02", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-710090-down-2980-points-2018-05-02", "https://www.nasdaq.com/articles/why-molson-coors-gilead-sciences-and-yum-china-holdings-slumped-today-2018-05-02", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-545-follow-through-indicator-43-sensitive", "https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-agios-agio-in-q1-earnings-2018-04-30", "https://www.nasdaq.com/articles/whats-in-store-for-immunogen-imgn-this-earnings-season-2018-04-30", "https://www.nasdaq.com/articles/will-agenus-agen-disappoint-investors-this-earnings-season-2018-04-30", "https://www.nasdaq.com/articles/drug-stocks-q1-earnings-to-watch-on-may-1%3A-pfe-mrk-more-2018-04-30", "https://www.nasdaq.com/articles/apple-aapl-iphone-sales-mark-shares-also-snap-gild-tmus-2018-05-01", "https://www.nasdaq.com/articles/gilead-gild-shares-slip-earnings-miss-revenues-down-over-20-2018-05-01", "https://www.nasdaq.com/articles/after-hours-earnings-report-may-1-2018-aapl-gild-su-mdlz-apc-all-fisv-oke-cxo-eix-dvn-vrsk", "https://www.nasdaq.com/articles/3-things-you-need-know-about-abbvies-monster-q1-earnings-2018-04-27", "https://www.nasdaq.com/articles/health-care-sector-update-04272018-acadgildhrcsny-2018-04-27", "https://www.nasdaq.com/articles/hiv-segment-to-aid-gilead-gild-beat-q1-earnings-estimates-2018-04-27", "https://www.nasdaq.com/articles/health-care-sector-update-04272018-snygildhrc-2018-04-27", "https://www.nasdaq.com/articles/gilead-gild-1st-quarter-earnings-what-expect-2018-04-30", "https://www.nasdaq.com/articles/what-expect-gilead-sciences-incs-q1-earnings-results-2018-04-29", "https://www.nasdaq.com/articles/whats-in-the-cards-for-immune-design-imdz-in-q1-earnings-2018-04-26", "https://www.nasdaq.com/articles/whats-in-the-offing-for-keryx-kerx-this-earnings-season-2018-04-26", "https://www.nasdaq.com/articles/better-buy-celgene-corporation-vs-gilead-sciences-2018-04-26", "https://www.nasdaq.com/articles/eye-biotech-todays-editors-picks-2018-04-26", "https://www.nasdaq.com/articles/notable-thursday-option-activity-mar-gild-abbv-2018-04-26", "https://www.nasdaq.com/articles/interesting-gild-put-and-call-options-july-20th-2018-04-25", "https://www.nasdaq.com/articles/glaxo-gsk-q1-earnings-lag-shingrix-vaccines-sales-solid-2018-04-26", "https://www.nasdaq.com/articles/bellicum-pharmaceuticals-inc-buy-2018-04-24", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-vertex-vrtx-this-earnings-season-2018-04-24", "https://www.nasdaq.com/articles/3-bargain-stocks-you-can-buy-right-now-2018-04-24", "https://www.nasdaq.com/articles/your-guide-investing-zinc-finger-zfn-gene-editing-2018-04-24", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-bristol-myers-bmy-in-q1-earnings-2018-04-23", "https://www.nasdaq.com/articles/analysts-expect-14-gains-ahead-spyg-2018-04-23", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-alexion-alxn-this-earnings-season-2018-04-23", "https://www.nasdaq.com/articles/stocks-drop-10-year-yield-touches-3-2018-04-25", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-gild-vs-pfizer-pfe-2018-04-22", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2018-04-20", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-ibm-mcdonalds-gilead-phillips-66-and-lam-research-2018", "https://www.nasdaq.com/articles/4-beaten-down-funds-set-soar-dividends-109-2018-04-19", "https://www.nasdaq.com/articles/health-care-sector-update-04192018-nvs-dhr-algn-gild-4503t-2018-04-19", "https://www.nasdaq.com/articles/health-care-sector-update-04192018-agnshpggildnvsdhr-2018-04-19", "https://www.nasdaq.com/articles/top-research-reports-ibm-mcdonalds-gilead-2018-04-19", "https://www.nasdaq.com/articles/see-which-latest-13f-filers-holds-gilead-sciences-2018-04-23", "https://www.nasdaq.com/articles/big-biotech-etf-can-bounce-back-2018-04-18", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alks-up-cldx-down-alxn-to-acquire-wilson-therapeutics-2018-04-18", "https://www.nasdaq.com/articles/gilead-gild-presents-encouraging-data-on-nash-therapies-2018-04-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-benjamin-graham-4152018-2018-04-15", "https://www.nasdaq.com/articles/bristol-myers-collaborates-with-harvard-fibrosis-network-2018-04-13", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-april-2018-04-13", "https://www.nasdaq.com/articles/ibb-gild-biib-vrtx-etf-outflow-alert-2018-04-12", "https://www.nasdaq.com/articles/health-care-sector-update-04192018-gildnvsdhr-2018-04-19", "https://www.nasdaq.com/articles/why-one-drug-flop-tanked-incytes-stock-2018-04-12", "https://www.nasdaq.com/articles/little-known-company-should-have-gileads-and-celgenes-investors-nervous-2018-04-11", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-buy-2018-04-11", "https://www.nasdaq.com/articles/biotech-fire-sale-2-top-stocks-buy-next-week-2018-04-08", "https://www.nasdaq.com/articles/4-top-stocks-investing-pharmas-next-35-billion-market-2018-04-08", "https://www.nasdaq.com/articles/cellectis-sa-stock-buy-now-2018-04-07", "https://www.nasdaq.com/articles/can-been-there-biotech-entrepreneur-arie-belldegrun-do-it-yet-again-2018-04-06", "https://www.nasdaq.com/articles/alexion-alxn-to-acquire-wilson-therapeutics-for-%24855m-2018-04-12", "https://www.nasdaq.com/articles/which-big-pharma-ceos-least-deserved-their-big-pay-increases-2018-04-04", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-united-technologies-medtronic-gilead-hewlett-packard", "https://www.nasdaq.com/articles/top-stock-reports-united-technologies-medtronic-gilead-2018-04-02", "https://www.nasdaq.com/articles/better-buy-celgene-corporation-vs-gilead-sciences-2018-03-30", "https://www.nasdaq.com/articles/celgene-loses-17.8-in-3-months%3A-time-to-reshuffle-portfolio-2018-03-28", "https://www.nasdaq.com/articles/gilead-sciences-beaten-biotech-stock-buy-2018-03-27", "https://www.nasdaq.com/articles/5-biotech-stocks-amazing-pipelines-2018-03-27", "https://www.nasdaq.com/articles/pfizer-inks-new-car-t-deal-in-talks-with-pg-for-unit-sale-2018-04-04", "https://www.nasdaq.com/articles/which-big-pharma-ceos-least-deserved-their-big-pay-increases-2018-04-04", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-united-technologies-medtronic-gilead-hewlett-packard", "https://www.nasdaq.com/articles/stemline-therapeutics-inc-stock-investors-are-betting-not-investing-2018-03-23", "https://www.nasdaq.com/articles/gilead-sciences-gild-shares-cross-3-yield-mark-2018-03-22", "https://www.nasdaq.com/articles/better-buy-amgen-inc-vs-gilead-sciences-inc-2018-03-21", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-gild-2018-03-21", "https://www.nasdaq.com/articles/3-blockbuster-drug-launches-watch-2018-2018-03-26", "https://www.nasdaq.com/articles/despite-struggles-celgene-corporation-stock-still-buy-2018-03-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-david-dreman-3182018-2018-03-18", "https://www.nasdaq.com/articles/gilead-sciences-14-billion-year-threat-2018-03-18", "https://www.nasdaq.com/articles/3-revolutionary-cancer-treatments-2018-03-17", "https://www.nasdaq.com/articles/5-must-see-quotes-abbvies-management-2018-03-16", "https://www.nasdaq.com/articles/3-reasons-crispr-stocks-could-keep-soaring-2018-03-16", "https://www.nasdaq.com/articles/is-gilead-sciences-gild-a-great-stock-for-value-investors-2018-03-15", "https://www.nasdaq.com/articles/why-its-so-dang-hard-value-biotech-deals-2018-03-21", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-march-15-2018-2018-03-14", "https://www.nasdaq.com/articles/bull-day-regeneron-regn-2018-03-14", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-ddd-gild-hd-2018-03-14", "https://www.nasdaq.com/articles/gilead-sciences-trying-put-itself-out-business-2018-03-14", "https://www.nasdaq.com/articles/3-biotech-stocks-with-rising-earnings-estimates-post-q4-2018-03-13", "https://www.nasdaq.com/articles/1-big-risk-every-drugmaker-fears-2018-03-12", "https://www.nasdaq.com/articles/how-pricing-can-be-vital-drugmakers-profitability-2018-03-12", "https://www.nasdaq.com/articles/ibb-amgn-gild-regn-etf-outflow-alert-2018-03-14", "https://www.nasdaq.com/articles/after-hours-most-active-mar-12-2018-pfe-qcom-f-cbs-bac-qqq-celg-hst-sohu-ge-ctsh-gild-2018", "https://www.nasdaq.com/articles/heres-what-lifted-sangamo-therapeutics-inc-february-2018-03-11", "https://www.nasdaq.com/articles/revolutionary-new-hiv-drug-youve-probably-never-heard-2018-03-11", "https://www.nasdaq.com/articles/how-biopharmas-battle-billions-2018-03-10", "https://www.nasdaq.com/articles/gilead-sciences-gild-down-3.4-since-earnings-report%3A-can-it-rebound-2018-03-08", "https://www.nasdaq.com/articles/2-cheap-growth-stocks-buy-right-now-2018-03-08", "https://www.nasdaq.com/articles/biotech-stock-round-up%3A-regeneron-submits-sbla-biogen-to-withdraw-zinbryta-2018-03-08", "https://www.nasdaq.com/articles/how-drugmakers-approach-efficacy-key-success-2018-03-12", "https://www.nasdaq.com/articles/gilead-announces-positive-data-on-new-hiv-therapy-biktarvy-2018-03-06", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-gild-le-pypl-2018-03-06", "https://www.nasdaq.com/articles/heres-why-crispr-therapeutics-ag-jumped-again-february-2018-03-04", "https://www.nasdaq.com/articles/heres-why-gilead-sciences-jump-gene-editing-important-2018-03-02", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-bny-mellon-state-street-alliant-energy-and", "https://www.nasdaq.com/articles/gilead-sciences-history-points-future-success-2018-03-01", "https://www.nasdaq.com/articles/intangibles-hold-key-valeant-pharmaceuticals-intl-inc-stock-2018-03-01", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-iwb-amgn-gild-utx-2018-03-06", "https://www.nasdaq.com/articles/biotech-etfs-head-to-head%3A-xbi-vs.-ibb.-2018-03-01", "https://www.nasdaq.com/articles/health-care-sector-update-02282018-htbx-sgyp-codx-gild-2018-02-28", "https://www.nasdaq.com/articles/health-care-sector-update-02282018-gildsgypcphtohtbxcodx-2018-02-28", "https://www.nasdaq.com/articles/top-analyst-reports-gilead-bny-mellon-state-street-2018-02-28", "https://www.nasdaq.com/articles/biotech-stock-round-up%3A-celgene-suffers-setback-gilead-teams-up-with-sangamo-2018-02-28", "https://www.nasdaq.com/articles/spdr-portfolio-sp-500-growth-etf-experiences-big-inflow-2018-02-26", "https://www.nasdaq.com/articles/gilead-sciences-oncology-company-2018-02-26", "https://www.nasdaq.com/articles/apples-cure-soaring-costs-tech-savvy-healthcare-clinics-2018-03-01", "https://www.nasdaq.com/articles/why-sangamo-therapeutics-rocketed-higher-today-2018-02-22", "https://www.nasdaq.com/articles/health-care-sector-update-02222018-sgmo-gild-clvs-nvo-nvs-bkd-2018-02-22", "https://www.nasdaq.com/articles/5-drugs-are-critical-gilead-sciences-future-2018-02-22", "https://www.nasdaq.com/articles/health-care-sector-update-02222018-clvssgmogildbkd-2018-02-22-0", "https://www.nasdaq.com/articles/health-care-sector-update-02222018-clvssgmogildbkd-2018-02-22", "https://www.nasdaq.com/articles/abbvie-or-gilead-sciences-stock-better-buy-2018-02-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-benjamin-graham-2182018-2018-02-18", "https://www.nasdaq.com/articles/how-gilead-sciences-betting-big-gene-editing-2018-02-23", "https://www.nasdaq.com/articles/why-sangamo-therapeutics-rocketed-higher-today-2018-02-22", "https://www.nasdaq.com/articles/health-care-sector-update-02222018-sgmo-gild-clvs-nvo-nvs-bkd-2018-02-22", "https://www.nasdaq.com/articles/5-drugs-are-critical-gilead-sciences-future-2018-02-22", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-february-15-2018-2018-02-14", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-14-2018-2018-02-13", "https://www.nasdaq.com/articles/intercept-starts-oca-trial-for-nash-patients-with-cirrhosis-2018-02-13", "https://www.nasdaq.com/articles/how-huge-latest-hiv-drug-approval-gilead-sciences-2018-02-12", "https://www.nasdaq.com/articles/how-celgene-hopes-cash-car-t-2018-02-17", "https://www.nasdaq.com/articles/better-buy-pfizer-inc-vs-glaxosmithkline-plc-2018-02-11", "https://www.nasdaq.com/articles/3-etfs-to-watch-on-biotech-earnings-2018-02-10", "https://www.nasdaq.com/articles/glaxos-gsk-begins-phase-iii-hiv-two-drug-regimen-study-2018-02-09", "https://www.nasdaq.com/articles/glaxo-gsk-earnings-and-revenues-surpass-estimates-in-q4-2018-02-08", "https://www.nasdaq.com/articles/fda-approves-gilead-gild-hiv-triple-therapy-stock-up-2018-02-08", "https://www.nasdaq.com/articles/heres-what-gilead-sciences-just-said-about-its-future-2018-02-08", "https://www.nasdaq.com/articles/gilead-sciences-inc-stock-still-solid-value-play-2018-02-08", "https://www.nasdaq.com/articles/why-biotech-stocks-soared-trumps-first-year-office-2018-02-11", "https://www.nasdaq.com/articles/gilead-gild-beats-on-q4-earnings-2018-view-lacks-lustre-2018-02-07", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-walt-disney-chipotle-snap-and-gilead-sciences-2018-02", "https://www.nasdaq.com/articles/gilead-sciences-inc-delivers-deja-vu-fourth-quarter-2018-02-07", "https://www.nasdaq.com/articles/daily-dividend-report-gild-ctsh-ice-apc-glw-2018-02-07", "https://www.nasdaq.com/articles/5-things-gilead-sciences-management-just-said-you-need-know-2018-02-07", "https://www.nasdaq.com/articles/gilead-gild-4th-quarter-earnings-what-expect-2018-02-06", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-q4-2017-earnings-conference-call-transcript-2018-02-06", "https://www.nasdaq.com/articles/why-crispr-therapeutics-ag-stock-bolted-higher-january-2018-02-08", "https://www.nasdaq.com/articles/new-quarterly-earnings-results-dis-cmg-snap-and-more-2018-02-06", "https://www.nasdaq.com/articles/gilead-gild-posts-earnings-beat-total-product-sales-see-yoy-decline-2018-02-06", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-636-follow-through-indicator-44-sensitive", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-6-2018-dis-gild-apc-pxd-cern-mchp-mkl-paa-akam-udr", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-cmi-mu-gild-2018-02-05", "https://www.nasdaq.com/articles/3-headwinds-q4-earnings-results-make-merck-mediocre-stock-2018-02-04", "https://www.nasdaq.com/articles/what-expect-gilead-sciences-q4-results-2018-02-04", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-shares-slide-weak-outlook-2018-02-06", "https://www.nasdaq.com/articles/3-top-biotherapeutics-stocks-buy-now-2018-02-02", "https://www.nasdaq.com/articles/will-gilead-gild-disappoint-investors-in-q4-earnings-2018-02-01", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvie-4q-results-impress-ablynx-be-acquired-sanofi-2018-02-01", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2018-01-31", "https://www.nasdaq.com/articles/vertex-vrtx-other-drug-stocks-fda-catalysts-february-2018-01-31", "https://www.nasdaq.com/articles/gild-crosses-above-average-analyst-target-2018-01-30", "https://www.nasdaq.com/articles/3-big-biotech-stocks-major-catalysts-way-2018-01-30", "https://www.nasdaq.com/articles/gileads-gild-hcv-segment-to-decline-further-in-q4-earnings-2018-02-02", "https://www.nasdaq.com/articles/3-top-biotherapeutics-stocks-buy-now-2018-02-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-wynn-gild-2018-01-29", "https://www.nasdaq.com/articles/gilead-sciences-take-two-interactive-hit-buys-after-vertex-breakout-2018-01-29", "https://www.nasdaq.com/articles/monday-sector-leaders-consumer-products-healthcare-2018-01-29", "https://www.nasdaq.com/articles/3-small-biotechs-big-drugmakers-are-probably-drooling-over-2018-01-28", "https://www.nasdaq.com/articles/it-finally-safe-buy-gilead-sciences-stock-1-analyst-thinks-so-2018-01-26", "https://www.nasdaq.com/articles/why-biopharma-behemoth-could-soon-become-acquisitive-2018-01-26", "https://www.nasdaq.com/articles/after-hours-most-active-jan-30-2018-etp-msft-ete-fe-epd-mrk-t-csco-intc-qqq-gild-fb-2018", "https://www.nasdaq.com/articles/5-biotech-and-pharmaceutical-stocks-going-bonkers-2018-01-26", "https://www.nasdaq.com/articles/notable-friday-option-activity-sbux-gild-itw-2018-01-26", "https://www.nasdaq.com/articles/celgene-celg-q4-earnings-sales-beat-on-solid-revlimid-2018-01-25", "https://www.nasdaq.com/articles/will-2018-be-bellicum-pharmaceuticals-incs-best-year-yet-2018-01-25", "https://www.nasdaq.com/articles/celgene-reverses-fourth-quarter-otezla-sales-rebound-2018-01-25", "https://www.nasdaq.com/articles/bluebird-up-on-buyout-speculation-after-celgene-juno-deal-2018-01-23", "https://www.nasdaq.com/articles/celgene-celg-to-acquire-juno-therapeutics-for-%249-billion-2018-01-23", "https://www.nasdaq.com/articles/dont-chase-abbvie-inc-stock-after-its-huge-earnings-win-2018-01-26", "https://www.nasdaq.com/articles/celgenes-9-billion-buyout-juno-it-good-deal-investors-2018-01-22", "https://www.nasdaq.com/articles/3-stocks-worlds-best-investors-are-buying-right-now-2018-01-22", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-iwb-amgn-gild-abt-2018-01-22", "https://www.nasdaq.com/articles/what-expect-amgen-inc-2018-2018-01-21", "https://www.nasdaq.com/articles/better-buy-glaxosmithkline-plc-vs-eli-lilly-2018-01-21", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-pfizer-inc-2018-01-21", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-apple-jpmorgan-abbvie-gilead-and-simon-property-group", "https://www.nasdaq.com/articles/analysts-more-bullish-celgene-juno-sales-outlook-nags-2018-01-23", "https://www.nasdaq.com/articles/top-10-value-stocks-sp-500-2018-01-19", "https://www.nasdaq.com/articles/merck-co-inc-stock-could-still-soar-another-10-here-2018-01-18", "https://www.nasdaq.com/articles/3-top-ranked-drug-stocks-are-broker-favorites-2018-01-18-0", "https://www.nasdaq.com/articles/novartis-sbla-for-car-t-therapy-kymriah-accepted-by-fda-2018-01-18", "https://www.nasdaq.com/articles/no-reason-rush-juno-therapeutics-inc-stock-after-big-pop-2018-01-18", "https://www.nasdaq.com/articles/3-top-ranked-drug-stocks-are-broker-favorites-2018-01-18", "https://www.nasdaq.com/articles/healthcare-celgene-going-buy-juno-therapeutics-2018-01-18", "https://www.nasdaq.com/articles/gilead-collaborates-with-pfizer-for-yescarta-combo-study-2018-01-19", "https://www.nasdaq.com/articles/juno-hits-52-week-high-on-celgenes-rumored-buyout-interest-2018-01-18", "https://www.nasdaq.com/articles/why-celgenes-rumored-acquisition-juno-actually-makes-sense-2018-01-17", "https://www.nasdaq.com/articles/why-juno-therapeutics-stock-soaring-today-2018-01-17", "https://www.nasdaq.com/articles/whats-juno-therapeutics-worth-celgene-2018-01-17", "https://www.nasdaq.com/articles/is-celgene-celg-looking-to-take-over-juno-therapeutics-2018-01-17", "https://www.nasdaq.com/articles/gilead-sciences-inc-buy-2018-2018-01-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-juno-surges-acquisition-rumor-concert-down-patent-news-2018-01-17", "https://www.nasdaq.com/articles/top-research-reports-apple-jpmorgan-abbvie-2018-01-18", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-gild-wdc-bmy-2018-01-16", "https://www.nasdaq.com/articles/10-value-stocks-buy-2018-and-beyond-2018-01-12", "https://www.nasdaq.com/articles/xlv-mrk-amgn-gild-etf-outflow-alert-2018-01-12", "https://www.nasdaq.com/articles/2017-was-year-forget-gilead-sciences-inc-year-could-be-better-2018-01-12", "https://www.nasdaq.com/articles/3-reasons-dividend-monster-pfizer-inc-could-explode-higher-2018-01-12", "https://www.nasdaq.com/articles/can-biotech-keep-last-years-momentum-alive-in-2018-2018-01-11", "https://www.nasdaq.com/articles/big-pharma-ceos-speak-about-impact-of-tax-reform-on-ma-2018-01-11", "https://www.nasdaq.com/articles/juno-therapeutics-stock-rockets-report-celgene-buyout-talks-2018-01-16", "https://www.nasdaq.com/articles/valeant-pharmaceuticals-intl-inc-stock-is-worth-the-risk-2018-01-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-celgene-acquire-impact-jp-morgan-healthcare-conference-focus-2018-01", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-january-2018-01-09", "https://www.nasdaq.com/articles/5-ways-gilead-sciences-plans-return-growth-2018-01-09", "https://www.nasdaq.com/articles/galapagos-reports-topline-data-from-osteoarthritis-study-2018-01-08", "https://www.nasdaq.com/articles/celgene-to-acquire-impact-biomedicines-to-boost-pipeline-2018-01-08", "https://www.nasdaq.com/articles/5-biggest-new-drugs-2018-and-how-you-can-profit-their-makers-2018-01-07", "https://www.nasdaq.com/articles/7-must-see-numbers-abbvies-j-p-morgan-presentation-2018-01-11", "https://www.nasdaq.com/articles/dynavax-launch-hepatitis-b-vaccine-acquisition-coming-2018-01-05", "https://www.nasdaq.com/articles/biotech-tide-turning-2018-01-05", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-gild-avxs-uaa-2018-01-05", "https://www.nasdaq.com/articles/why-juno-therapeutics-stock-cooled-december-2018-01-04", "https://www.nasdaq.com/articles/xlv-amgn-gild-lly-large-outflows-detected-etf-2018-01-04", "https://www.nasdaq.com/articles/18-reasons-i-biotech-stocks-2018-2018-01-04", "https://www.nasdaq.com/articles/why-perfect-level-buy-celgene-corporation-stock-2018-01-03", "https://www.nasdaq.com/articles/why-2017-was-year-remember-gilead-sciences-inc-2018-01-05", "https://www.nasdaq.com/articles/dynavax-launch-hepatitis-b-vaccine-acquisition-coming-2018-01-05", "https://www.nasdaq.com/articles/biotech-tide-turning-2018-01-05", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-gild-avxs-uaa-2018-01-05", "https://www.nasdaq.com/articles/why-juno-therapeutics-stock-cooled-december-2018-01-04", "https://www.nasdaq.com/articles/xlv-amgn-gild-lly-large-outflows-detected-etf-2018-01-04", "https://www.nasdaq.com/articles/intercept-icpt-stock-loses-sheen-in-2017%3A-what-lies-ahead-2017-12-29", "https://www.nasdaq.com/articles/celgene-celg-in-troubled-waters-in-17%3A-what-does-2018-hold-2017-12-29", "https://www.nasdaq.com/articles/generalists-biotech-sidelines-tax-reform-sweeps-us-2018-01-03", "https://www.nasdaq.com/articles/3-biotech-and-pharma-stocks-fda-catalysts-january-2018-01-02", "https://www.nasdaq.com/articles/4-biotech-stocks-ready-to-crush-the-market-in-2018-2017-12-27", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-rl-wba-gild-2017-12-27", "https://www.nasdaq.com/articles/qa-vertex-chief-talks-about-companys-transformational-year-2017-12-22", "https://www.nasdaq.com/articles/better-buy-glaxosmithkline-plc-vs-bristol-myers-squibb-2017-12-22", "https://www.nasdaq.com/articles/gilead-maybe-2018-wont-be-its-year-either-2017-12-21", "https://www.nasdaq.com/articles/why-gilead-sciences-stock-should-be-avoided-2018-2017-12-29", "https://www.nasdaq.com/articles/5-best-performing-biotech-stocks-2017-2017-12-28", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-gild-lly-biib-2017-12-27", "https://www.nasdaq.com/articles/biotechs-not-so-darn-scary-after-all-sa-marketplace-roundtable-2017-12-20", "https://www.nasdaq.com/articles/3-questions-keeping-juno-therapeutics-investors-night-2017-12-19", "https://www.nasdaq.com/articles/why-these-biotech-stocks-could-be-taken-over-2018-2017-12-19", "https://www.nasdaq.com/articles/after-hours-most-active-dec-18-2017-epd-gm-intc-bp-ete-qqq-lc-aapl-mplx-gild-cmcsa-akam", "https://www.nasdaq.com/articles/why-no-large-cap-biotech-franchise-safe-threats-2018-2017-12-18", "https://www.nasdaq.com/articles/interesting-gild-put-and-call-options-august-2018-2017-12-20", "https://www.nasdaq.com/articles/3-pharma-biotech-pipeline-areas-keep-eye-2018-2017-12-20", "https://www.nasdaq.com/articles/biotechs-not-so-darn-scary-after-all-2017-12-20", "https://www.nasdaq.com/articles/biotechs-not-so-darn-scary-after-all-sa-marketplace-roundtable-2017-12-20", "https://www.nasdaq.com/articles/3-questions-keeping-juno-therapeutics-investors-night-2017-12-19", "https://www.nasdaq.com/articles/notable-friday-option-activity-intc-lmt-gild-2017-12-15", "https://www.nasdaq.com/articles/thursdays-vital-data-jdcom-incadr-jd-time-warner-inc-twx-and-gilead-sciences-inc-gild-2017", "https://www.nasdaq.com/articles/3-top-stocks-are-cash-cows-2017-12-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-ash-data-focus-gilead-buy-cell-design-labs-2017-12-13", "https://www.nasdaq.com/articles/ex-dividend-reminder-conmed-merck-and-gilead-sciences-2017-12-12", "https://www.nasdaq.com/articles/bluebirds-shares-jump-on-strong-data-for-car-t-therapy-2017-12-12", "https://www.nasdaq.com/articles/ash-2017-car-t-wallops-blood-cancer-2017-12-12", "https://www.nasdaq.com/articles/juno-reports-additional-data-on-car-t-therapy-shares-drop-2017-12-12", "https://www.nasdaq.com/articles/jim-simons-pioneer-quant-manager-2017-12-12", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-blue-stock-skyrocketed-today-2017-12-11", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-december-14-2017-2017-12-13", "https://www.nasdaq.com/articles/3-stocks-focus-biotech-ma-hopes-2018-rise-2017-12-11", "https://www.nasdaq.com/articles/health-care-sector-update-12112017-vstm-mrk-ions-gild-imgn-juno-celg-regn-bivv-2017-12-11", "https://www.nasdaq.com/articles/gilead-gild-posts-updated-data-on-car-t-therapy-yescarta-2017-12-11", "https://www.nasdaq.com/articles/novartis-reports-updated-results-from-kymriahs-juliet-study-2017-12-11", "https://www.nasdaq.com/articles/whats-causing-juno-therapeutics-shares-tumble-119-today-2017-12-11", "https://www.nasdaq.com/articles/gilead-sciences-inc-buy-2017-12-10", "https://www.nasdaq.com/articles/now-perfect-time-buy-juno-therapeutics-stock-2017-12-10", "https://www.nasdaq.com/articles/company-news-for-dec-11-2017-2017-12-11", "https://www.nasdaq.com/articles/why-biotech-stocks-may-wait-while-feeling-love-2017-12-08", "https://www.nasdaq.com/articles/gilead-sciences-to-acquire-cell-design-labs-for-%24567-million-2017-12-08", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-ual-gild-abbv-2017-12-08", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-gild-2017-12-07", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-vlue-gild-f-nsc-2017-12-07", "https://www.nasdaq.com/articles/why-gilead-could-have-greatest-ever-hiv-drug-launches-2017-12-06", "https://www.nasdaq.com/articles/can-drug-biotech-ma-rebound-next-year-after-bleak-2017-2017-12-06", "https://www.nasdaq.com/articles/youll-be-stunned-how-many-cancer-immunotherapies-are-being-developed-2017-12-10", "https://www.nasdaq.com/articles/5-top-biotech-stocks-buy-now-2017-12-03", "https://www.nasdaq.com/articles/gilead-3-other-drug-stocks-focus-world-aids-day-2017-12-01", "https://www.nasdaq.com/articles/glaxo-begins-phase-iii-study-on-injection-to-prevent-hiv-2017-12-01", "https://www.nasdaq.com/articles/10-blockbuster-drugs-future-big-pharma-stocks-2017-11-30", "https://www.nasdaq.com/articles/better-buy-ziopharm-oncology-inc-vs-celldex-therapeutics-inc-2017-11-30", "https://www.nasdaq.com/articles/morning-movers-sears-soars-earnings-kroger-gains-2017-11-30", "https://www.nasdaq.com/articles/no-1-ranked-medical-stock-tests-support-new-base-2017-11-30", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-1262017-2017-12-06", "https://www.nasdaq.com/articles/does-gileads-kite-acquisition-offer-new-buying-opportunity-2017-11-30", "https://www.nasdaq.com/articles/gilead-sciences-stock-upgraded-power-free-2017-11-30", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-qual-blk-mmc-gild-2017-11-29", "https://www.nasdaq.com/articles/3-dividend-stocks-better-yields-mcdonalds-2017-11-29", "https://www.nasdaq.com/articles/how-will-u.s.-tax-reform-impact-pharma-biotech-industry-2017-11-29", "https://www.nasdaq.com/articles/health-care-sector-update-11282017-coolpzrxpetx-mdtgildpfe-2017-11-28", "https://www.nasdaq.com/articles/glaxo-pfizers-viiv-healthcare-begins-hiv-drug-combo-study-2017-11-28", "https://www.nasdaq.com/articles/5-biotech-and-pharma-stocks-fda-catalysts-december-2017-11-30", "https://www.nasdaq.com/articles/sphera-funds-management-ltd-buys-cellcom-israel-allergan-plc-teva-pharmaceutical-0", "https://www.nasdaq.com/articles/hedge-funds-are-snapping-up-these-3-strong-buy-stocks-2017-11-27", "https://www.nasdaq.com/articles/biotech-poised-for-growth%3A-3-healthy-fund-choices-2017-11-24", "https://www.nasdaq.com/articles/jj-glaxos-jucala-approval-puts-spotlight-on-hiv-space-2017-11-24", "https://www.nasdaq.com/articles/car-t-therapy-space-2017-progress-report-2017-11-24", "https://www.nasdaq.com/articles/jj-glaxo-get-fda-approval-for-first-two-drug-hiv-regimen-2017-11-22", "https://www.nasdaq.com/articles/1-thing-missing-gilead-sciences-2018-priority-list-2017-11-21", "https://www.nasdaq.com/articles/gilead-gild-down-7.9-since-earnings-report%3A-can-it-rebound-2017-11-28", "https://www.nasdaq.com/articles/sphera-funds-management-ltd-buys-cellcom-israel-allergan-plc-teva-pharmaceutical-0", "https://www.nasdaq.com/articles/after-hours-most-active-nov-20-2017-acm-qqq-bac-lc-eufn-pfe-wfc-t-urbn-fitb-gild-aapl-2017", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-2017-11-18", "https://www.nasdaq.com/articles/celgene-car-t-therapy-gets-breakthrough-therapy-designation-2017-11-17", "https://www.nasdaq.com/articles/biotechs-trading-lower-in-q4-on-macro-uncertainty-tepid-q3-2017-11-17", "https://www.nasdaq.com/articles/summit-street-capital-management-llc-buys-fluor-corp-hawaiian-holdings-inc-kulicke-2017-11", "https://www.nasdaq.com/articles/biotech-industry-small-innovators-outflank-big-caps-blockbuster-drug-patent-cliff-looms", "https://www.nasdaq.com/articles/united-therapeutics-pah-drugs-exclusivity-period-extended-2017-11-21", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-november-16-2017-2017-11-15", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-president-and-ceo-john-f-milligan-sold-16-million-shares-2017-11", "https://www.nasdaq.com/articles/gild-makes-notable-cross-below-critical-moving-average-2017-11-14", "https://www.nasdaq.com/articles/temasek-holdings-private-ltd-buys-visa-inc-virtu-financial-inc-ctrip-2017-11-14", "https://www.nasdaq.com/articles/biotechs-sell-droves-are-investors-seeking-mergers-2017-11-14", "https://www.nasdaq.com/articles/7-life-science-stocks-to-buy-today-2017-11-14", "https://www.nasdaq.com/articles/what-investors-need-know-about-investing-low-pe-stocks-2017-11-13", "https://www.nasdaq.com/articles/hampstead-capital-llp-buys-merck-inc-american-international-group-inc-pioneer-natural-2017", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-november-16-2017-2017-11-15", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-president-and-ceo-john-f-milligan-sold-16-million-shares-2017-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-regeneron-delivers-strong-q3-results-cellectis-clinical-hold-lifted", "https://www.nasdaq.com/articles/sphera-funds-management-ltd-buys-cellcom-israel-allergan-plc-teva-pharmaceutical", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-november-09-2017-2017-11-08", "https://www.nasdaq.com/articles/3-stocks-changing-future-healthcare-2017-11-06", "https://www.nasdaq.com/articles/3-etfs-watch-biotech-earnings-2017-11-06", "https://www.nasdaq.com/articles/3-top-biotech-stocks-2018-2017-11-12", "https://www.nasdaq.com/articles/notable-friday-option-activity-icpt-gild-clvs-2017-11-10", "https://www.nasdaq.com/articles/youll-be-stunned-gilead-sciences-ceos-prediction-2018-2017-11-09", "https://www.nasdaq.com/articles/5-biotech-and-pharma-stocks-key-fda-catalysts-november-2017-11-02", "https://www.nasdaq.com/articles/sharp-drop-celgene-corporation-stock-may-have-just-created-entry-point-2017-11-02", "https://www.nasdaq.com/articles/notable-thursday-option-activity-vmc-gild-mic-2017-11-02", "https://www.nasdaq.com/articles/whats-behind-gilead-sciences-incs-78-billion-slide-october-2017-11-02", "https://www.nasdaq.com/articles/3-things-youll-want-closely-watch-cvs-healths-q3-results-2017-11-04", "https://www.nasdaq.com/articles/how-blood-disease-data-sent-these-2-biotech-stocks-flying-2017-11-01", "https://www.nasdaq.com/articles/can-juno-therapeutics-outmaneuver-its-car-t-competitors-2017-11-01", "https://www.nasdaq.com/articles/see-which-latest-13f-filers-holds-gilead-sciences-2017-11-01", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-jpmorgan-chase-gilead-conocophillips-general-electric", "https://www.nasdaq.com/articles/ionis-down-big-analyst-miss-2017-10-31", "https://www.nasdaq.com/articles/ishares-edge-msci-usa-value-factor-etf-experiences-big-inflow-2017-10-30", "https://www.nasdaq.com/articles/whats-in-the-cards-for-pfe-incy-and-acor-in-q3-earnings-2017-10-30", "https://www.nasdaq.com/articles/why-juno-therapeutics-shares-are-going-212-today-2017-11-02", "https://www.nasdaq.com/articles/how-blood-disease-data-sent-these-2-biotech-stocks-flying-2017-11-01", "https://www.nasdaq.com/articles/how-celgene-gileads-pricing-woes-continue-haunt-biotech-stocks-2017-10-30", "https://www.nasdaq.com/articles/top-research-reports-jpmorgan-chase-gilead-conocophillips-2017-10-30", "https://www.nasdaq.com/articles/gilead-sciences-inc.-gild-stock-isnt-worth-it-here-2017-10-29", "https://www.nasdaq.com/articles/5-things-you-need-know-gilead-sciences-q3-update-2017-10-29", "https://www.nasdaq.com/articles/3-etfs-to-watch-on-biotech-earnings-2017-10-29", "https://www.nasdaq.com/articles/validea-benjamin-graham-strategy-daily-upgrade-report-10282017-2017-10-28", "https://www.nasdaq.com/articles/nasdaq-100-movers-jbht-shpg-2017-10-30", "https://www.nasdaq.com/articles/dow-stock-merck-abbvie-top-earnings-views-light-sales-2017-10-27", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-friday%3A-baidu-inc-adr-bidu-gilead-sciences-inc.-gild-and-mattel-inc.", "https://www.nasdaq.com/articles/daily-dividend-report-spg-pfg-gild-agn-itw-2017-10-27", "https://www.nasdaq.com/articles/gilead-sciences-inc-stock-buy-when-it-seems-it-shouldnt-be-2017-10-27", "https://www.nasdaq.com/articles/gilead-sciences-inc.-stock-looks-good-regardless-of-quarterly-earnings-report-2017-10-26", "https://www.nasdaq.com/articles/gilead-sciences-inc-still-singing-hcv-blues-3rd-quarter-2017-10-26", "https://www.nasdaq.com/articles/gilead-gild-q3-earnings-and-revenues-sink-2017-10-26", "https://www.nasdaq.com/articles/gilead-gild-down-on-weak-hcv-sales-despite-q3-earnings-beat-2017-10-27", "https://www.nasdaq.com/articles/gilead-tops-sales-profit-views-misses-hep-c-shares-fall-2017-10-26", "https://www.nasdaq.com/articles/5-biotech-stocks-that-are-getting-battered-too-hard-for-comfort-2017-10-26", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-667-follow-through-indicator-48-sensitive", "https://www.nasdaq.com/articles/after-hours-earnings-report-october-26-2017-msft-amzn-googl-intc-gild-bidu-cb-syk-wdc-ftv", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-agenus-agen-this-earnings-season-2017-10-25", "https://www.nasdaq.com/articles/is-a-surprise-coming-for-gilead-sciences-gild-this-earnings-season-2017-10-25", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-tops-q3-earnings-gileads-car-t-drug-gets-fda-nod-2017-10-25", "https://www.nasdaq.com/articles/rsi-alert-gilead-sciences-now-oversold-2017-10-26", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-alexion-alxn-this-earnings-season-2017-10-24", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-amgen-2017-10-24", "https://www.nasdaq.com/articles/3-healthcare-value-stocks-2017-10-24", "https://www.nasdaq.com/articles/why-agenus-inc-stock-briefly-popped-today-2017-10-23", "https://www.nasdaq.com/articles/is-gilead-gild-poised-for-a-beat-this-earnings-season-2017-10-23", "https://www.nasdaq.com/articles/gilead-drug-approval-fuels-interest-car-t-space-3-stocks-consider-2017-10-23", "https://www.nasdaq.com/articles/3-gene-therapy-stocks-could-make-you-rich-2017-10-23", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-gild-wyn-orly-2017-10-25", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-alexion-alxn-this-earnings-season-2017-10-24", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-amgen-2017-10-24", "https://www.nasdaq.com/articles/3-healthcare-value-stocks-2017-10-24", "https://www.nasdaq.com/articles/gilead-gild-car-t-therapy-yescarta-clinches-fda-approval-2017-10-20", "https://www.nasdaq.com/articles/gilead-sciences-shows-rising-relative-price-performance-still-shy-key-threshold-2017-10-20", "https://www.nasdaq.com/articles/sellers-come-nasdaq-apple-lags-another-ipo-soars-2017-10-19", "https://www.nasdaq.com/articles/ishares-edge-msci-usa-value-factor-etf-experiences-big-inflow-2017-10-19", "https://www.nasdaq.com/articles/3-things-you-should-expect-gilead-sciences-q3-results-2017-10-23", "https://www.nasdaq.com/articles/ibds-no-1-group-under-pressure-these-6-key-earnings-loom-sp-500-futures-2017-10-23", "https://www.nasdaq.com/articles/whats-in-store-for-biomarin-bmrn-this-earnings-season-2017-10-23", "https://www.nasdaq.com/articles/celgene-could-be-best-car-t-stock-buy-not-gilead-sciences-2017-10-20", "https://www.nasdaq.com/articles/gilead-gild-car-t-therapy-yescarta-clinches-fda-approval-2017-10-20", "https://www.nasdaq.com/articles/sp-500-futures-these-5-top-stocks-are-big-overnight-movers-2017-10-18", "https://www.nasdaq.com/articles/top-stock-reports-ibm-celgene-and-procter-gamble-2017-10-18", "https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-gilead-teva-pfizer-and-amgen-2017-10-17", "https://www.nasdaq.com/articles/nasdaq-100-movers-ctrp-adbe-2017-10-19", "https://www.nasdaq.com/articles/better-buy-ziopharm-oncology-inc-vs-celldex-therapeutics-2017-10-17", "https://www.nasdaq.com/articles/ibd-biotech-innovator-awards-2017-10-16", "https://www.nasdaq.com/articles/kite-pharma-cancer-treatment-stands-out-hot-car-t-field-2017-10-16", "https://www.nasdaq.com/articles/notable-monday-option-activity-tgtx-gild-rt-2017-10-16", "https://www.nasdaq.com/articles/trump-likely-sign-executive-order-drug-pricing-any-day-2017-10-16", "https://www.nasdaq.com/articles/exane-asset-management-buys-att-inc-verizon-communications-inc-cnh-industrial-nv-sells", "https://www.nasdaq.com/articles/its-time-to-start-buying-beaten-up-gilead-sciences-inc.-gild-stock-2017-10-13", "https://www.nasdaq.com/articles/where-find-value-healthcare-stocks-2017-10-17", "https://www.nasdaq.com/articles/gilead-sciences-inc.-gild-stock-is-primed-after-kite-pharma-buy-2017-10-13", "https://www.nasdaq.com/articles/3-healthcare-value-stocks-2017-10-13", "https://www.nasdaq.com/articles/why-these-biotech-players-look-poised-crush-earnings-views-2017-10-13", "https://www.nasdaq.com/articles/antipodes-partners-ltd-buys-kt-corp-michael-kors-holdings-oracle-corp-sells-dynegy-inc", "https://www.nasdaq.com/articles/no-1-ranked-medical-stock-breaking-out-q3-earnings-due-2017-10-12", "https://www.nasdaq.com/articles/non-alcoholic-steatohepatitis-2017-progress-update-2017-10-12", "https://www.nasdaq.com/articles/5-game-changing-cancer-drug-innovations-being-developed-right-now-2017-10-12", "https://www.nasdaq.com/articles/bristol-myers-bmy-target-extend-partnership-for-nash-study-2017-10-13", "https://www.nasdaq.com/articles/going-long-pfizer-inc.-pfe-stock-is-an-easy-pill-to-swallow-2017-10-10", "https://www.nasdaq.com/articles/50000-year-prescription-drugs-you-likely-know-someone-who-used-least-much-2017-10-10", "https://www.nasdaq.com/articles/horan-capital-management-buys-tjx-inc-chipotle-mexican-grill-inc-nike-inc-sells-berkshire", "https://www.nasdaq.com/articles/healthcare-are-these-best-dividend-stocks-buy-now-2017-10-10", "https://www.nasdaq.com/articles/bitcoin-vs-biotech-which-smarter-investment-2017-10-08", "https://www.nasdaq.com/articles/abbvies-fast-becoming-top-stock-buy-now-2017-10-08", "https://www.nasdaq.com/articles/dirt-cheap-biotech-stock-bargain-buy-2017-10-07", "https://www.nasdaq.com/articles/abbvie-best-dividend-stock-healthcare-2017-10-11", "https://www.nasdaq.com/articles/intercept-dives-along-ocaliva-prescriptions-fda-warning-2017-10-06", "https://www.nasdaq.com/articles/5-stocks-bull-market-left-behind-2017-10-06", "https://www.nasdaq.com/articles/everything-going-right-abbvie-it-best-biotech-stock-buy-right-now-2017-10-06", "https://www.nasdaq.com/articles/heres-whats-has-happened-in-the-hcv-space-lately-2017-10-06", "https://www.nasdaq.com/articles/5-undervalued-stocks-free-cash-flow-burn-2017-10-05", "https://www.nasdaq.com/articles/fxh-alny-algn-gild-large-inflows-detected-etf-2017-10-04", "https://www.nasdaq.com/articles/biotech-stock-roundup-endocyte-shoots-deal-amgen-abbvie-settle-humira-litigation-2017-10", "https://www.nasdaq.com/articles/heres-why-juno-therapeutics-stock-may-still-be-worth-buying-2017-10-07", "https://www.nasdaq.com/articles/intercept-dives-along-ocaliva-prescriptions-fda-warning-2017-10-06", "https://www.nasdaq.com/articles/5-stocks-bull-market-left-behind-2017-10-06", "https://www.nasdaq.com/articles/5-best-ma-deals-2017-so-far-2017-10-03", "https://www.nasdaq.com/articles/good-news-and-bad-news-gilead-sciences-which-carries-more-weight-2017-10-03", "https://www.nasdaq.com/articles/heres-why-bluebird-bio-blue-stock-falling-today-2017-10-02", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-pfizer-2017-10-02", "https://www.nasdaq.com/articles/merck-drops-two-hcv-combination-programs-amid-competition-2017-10-02", "https://www.nasdaq.com/articles/5-etf-picks-october-2017-10-04", "https://www.nasdaq.com/articles/best-buy-johnson-johnson-pfizer-or-gilead-sciences-2017-10-01", "https://www.nasdaq.com/articles/keep-riding-the-gopro-inc-gpro-stock-wave-2017-09-29", "https://www.nasdaq.com/articles/go-long-costco-wholesale-corporation-cost-stock-for-big-time-gains-2017-09-29", "https://www.nasdaq.com/articles/gilead-sciences-inc.-gild-stock-got-its-mojo-back-2017-09-29", "https://www.nasdaq.com/articles/how-will-trumps-proposed-tax-reform-impact-drug-companies-2017-09-29", "https://www.nasdaq.com/articles/novartis-could-acquire-biotech-why-deal-very-logical-2017-09-28", "https://www.nasdaq.com/articles/gilead-gild-gets-approval-for-hcv-drug-sovaldi-in-china-2017-09-28", "https://www.nasdaq.com/articles/4-biotech-stocks-and-1-etf-to-buy-as-they-bolt-higher-2017-10-02", "https://www.nasdaq.com/articles/why-gilead-sciences-pier-1-imports-and-petmed-express-slumped-today-2017-09-28", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-645345-19-points-2017-09-28", "https://www.nasdaq.com/articles/gilead-tumbles-report-hiv-drug-whistleblower-case-reopened-2017-09-28", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-gild-bmy-xom-2017-09-28", "https://www.nasdaq.com/articles/indexes-mixed-apple-and-gilead-down-here-threat-autohome-stock-2017-09-28", "https://www.nasdaq.com/articles/biotechs-beating-market-are-they-buy-range-2017-09-28", "https://www.nasdaq.com/articles/biotech-stocks-watch-and-pharma-industry-news-2017-09-28", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-gilead-sciences-cystic-fibrosis-2017-09-28", "https://www.nasdaq.com/articles/if-familiarity-breeds-contempt-what-do-debt-and-complacency-breed-2017-09-27", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-fta-gps-gild-lea-2017-09-26", "https://www.nasdaq.com/articles/kite-pharma-triples-so-far-in-2017%3A-whats-driving-the-rally-2017-09-26", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-reiterates-2017-outlook-intercept-hit-ocaliva-safety-issues", "https://www.nasdaq.com/articles/fda-chief-gottlieb-addresses-opioids-cancer-new-therapies-2017-09-26", "https://www.nasdaq.com/articles/3-sector-specific-trades-to-start-the-week-off-right-2017-09-25", "https://www.nasdaq.com/articles/first-week-may-2018-options-trading-gilead-sciences-gild-2017-09-25", "https://www.nasdaq.com/articles/intercept-icpt-provides-safety-guidelines-for-ocaliva-2017-09-27", "https://www.nasdaq.com/articles/3-big-biotech-stocks-buy-fall-2017-09-22", "https://www.nasdaq.com/articles/juno-therapeutics-inc-juno-stock%3A-to-buy-or-not-to-buy-2017-09-22", "https://www.nasdaq.com/articles/oddly-juno-therapeutics-jumping-113-today-2017-09-22", "https://www.nasdaq.com/articles/gileads-gild-epclusa-receives-label-expansion-in-canada-2017-09-22", "https://www.nasdaq.com/articles/immunize-juno-therapeutics-inc-juno-stock-trade-2017-09-21", "https://www.nasdaq.com/articles/3-biotech-stocks-major-catalysts-incoming-2017-09-21", "https://www.nasdaq.com/articles/4-sell-ranked-biotech-stocks-with-falling-estimates-to-avoid-2017-09-21", "https://www.nasdaq.com/articles/why-cash-rich-gilead-sciences-inc-borrowing-3-billion-2017-09-22", "https://www.nasdaq.com/articles/3-big-biotech-stocks-buy-fall-2017-09-22", "https://www.nasdaq.com/articles/juno-therapeutics-inc-juno-stock%3A-to-buy-or-not-to-buy-2017-09-22", "https://www.nasdaq.com/articles/3-biotech-stocks-that-are-just-getting-started-2017-09-18", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-moat-gild-gwre-vfc-2017-09-18", "https://www.nasdaq.com/articles/3-value-stocks-smart-investors-2017-09-18", "https://www.nasdaq.com/articles/why-bellicum-pharmaceuticals-stock-rising-today-2017-09-18", "https://www.nasdaq.com/articles/3-great-income-stocks-could-double-their-dividends-2017-09-17", "https://www.nasdaq.com/articles/should-value-investors-consider-gilead-sciences-gild-stock-2017-09-19", "https://www.nasdaq.com/articles/3-reasons-why-gilead-sciences-stock-buy-now-2017-09-15", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-9152017-2017-09-15", "https://www.nasdaq.com/articles/3-dividend-healthcare-stocks-2017-09-15", "https://www.nasdaq.com/articles/car-t-therapy-fda-approved-slingshot-insights-idea-month-2017-09-14", "https://www.nasdaq.com/articles/nasdaq-100-movers-hsic-ctrp-2017-09-14", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-gilead-sciences-gild-stock-2017-09-14", "https://www.nasdaq.com/articles/4-biotech-stocks-that-show-promise-on-sustainable-growth-2017-09-14", "https://www.nasdaq.com/articles/after-gilead-sciences-more-biotech-ma-2017-09-15", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-september-14-2017-2017-09-13", "https://www.nasdaq.com/articles/3-biotech-stocks-have-already-quadrupled-2017-2017-09-13", "https://www.nasdaq.com/articles/sell-intercept-pharmaceuticals-stock-overblown-2017-09-13", "https://www.nasdaq.com/articles/gilead-sciences-incs-best-investment-2017-hint-it-wasnt-kite-pharmaceuticals-2017-09-13", "https://www.nasdaq.com/articles/ex-dividend-reminder-gilead-sciences-hill-rom-holdings-and-owens-minor-2017-09-12", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-oracle-morgan-stanley-expedia-and-kroger-2017-09", "https://www.nasdaq.com/articles/3-stocks-future-millionaires-2017-09-12", "https://www.nasdaq.com/articles/3-pharma-biotech-sector-bargains-for-a-healthy-portfolio-2017-09-13", "https://www.nasdaq.com/articles/5-tough-questions-gilead-sciences-about-kite-pharma-acquisition-2017-09-11", "https://www.nasdaq.com/articles/top-stock-reports-gilead-oracle-morgan-stanley-2017-09-11", "https://www.nasdaq.com/articles/the-move-in-spdr-sp-biotech-etf-xbi-etf-is-coming-get-on-board-2017-09-11", "https://www.nasdaq.com/articles/why-exelixis-inc-could-be-gold-mine-growth-investors-2017-09-10", "https://www.nasdaq.com/articles/car-t-mania-could-juno-therapeutics-get-acquired-next-2017-09-10", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-itot-gild-slb-cvs-2017-09-08", "https://www.nasdaq.com/articles/gild-crosses-above-average-analyst-target-2017-09-08", "https://www.nasdaq.com/articles/5-top-ranked-biotech-stocks-buy-right-now-2017-09-11", "https://www.nasdaq.com/articles/after-hours-most-active-sep-8-2017-knx-aapl-iusg-iusv-qqq-vips-itub-chk-gild-jblu-t-xom", "https://www.nasdaq.com/articles/4-biotech-stocks-to-improve-your-portfolios-health-2017-09-08", "https://www.nasdaq.com/articles/5-things-youll-want-know-celgene-corporations-latest-presentation-2017-09-07", "https://www.nasdaq.com/articles/5-things-gilead-sciences-management-just-said-youll-want-know-2017-09-07", "https://www.nasdaq.com/articles/kymriah-first-car-t-therapy-approved%3A-4-pharma-stocks-in-focus-2017-09-07", "https://www.nasdaq.com/articles/are-these-healthcare-stocks-top-takeover-targets-2017-09-07", "https://www.nasdaq.com/articles/are-you-buying-gilead-sciences-inc-wrong-reason-2017-09-07", "https://www.nasdaq.com/articles/top-ranked-income-stocks-to-buy-for-september-8th-2017-09-08", "https://www.nasdaq.com/articles/after-hours-most-active-sep-8-2017-knx-aapl-iusg-iusv-qqq-vips-itub-chk-gild-jblu-t-xom", "https://www.nasdaq.com/articles/why-kite-pharma-soared-648-august-2017-09-06", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-pharmaceuticals-activision-blizzard-intuit", "https://www.nasdaq.com/articles/gilead-sciences-couldnt-have-timed-its-splash-car-t-better-2017-09-05", "https://www.nasdaq.com/articles/biotech-stocks-back-favor-will-rally-continue-2017-09-05", "https://www.nasdaq.com/articles/why-juno-therapeutics-shares-vaulted-46-higher-august-2017-09-05", "https://www.nasdaq.com/articles/buy-these-5-large-caps-on-extraordinary-roi-potential-2017-09-06", "https://www.nasdaq.com/articles/mallinckrodt-down-as-district-court-invalidates-inomax-patents-2017-09-06", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-johnson-johnson-2017-09-03", "https://www.nasdaq.com/articles/heres-best-dividend-stock-big-pharma-2017-09-03", "https://www.nasdaq.com/articles/why-gilead-sciences-shares-soared-106-august-2017-09-03", "https://www.nasdaq.com/articles/3-biotech-stocks-skyrocketed-week-2017-09-02", "https://www.nasdaq.com/articles/gilead-buys-kite-future-car-t-and-visit-new-whole-foods-2017-09-01", "https://www.nasdaq.com/articles/fridays-vital-data%3A-apple-inc.-aapl-advanced-micro-devices-inc.-amd-and-gilead-sciences", "https://www.nasdaq.com/articles/4-biotech-stocks-to-improve-your-portfolios-health-2017-09-05", "https://www.nasdaq.com/articles/5-winning-stocks-beat-september-blues-2017-09-01", "https://www.nasdaq.com/articles/valeant-vrx-continues-to-lose-ground%3A-can-it-bounce-back-2017-09-01", "https://www.nasdaq.com/articles/gilead-sciences-oncology-ma-strategy-explained-2017-09-01", "https://www.nasdaq.com/articles/you-reached-retirement-3-stocks-consider-today-2017-09-01", "https://www.nasdaq.com/articles/wonder-why-gilead-sciences-bought-kite-pharma-heres-answer-2017-09-01", "https://www.nasdaq.com/articles/thursdays-etf-unusual-volume-bbh-2017-08-31", "https://www.nasdaq.com/articles/novartis-nvs-car-t-therapy-kymriah-receives-fda-approval-2017-08-31", "https://www.nasdaq.com/articles/3-reasons-gilead-sciences-jumped-buy-kite-pharma-2017-09-01", "https://www.nasdaq.com/articles/5-winning-stocks-beat-september-blues-2017-09-01", "https://www.nasdaq.com/articles/valeant-vrx-continues-to-lose-ground%3A-can-it-bounce-back-2017-09-01", "https://www.nasdaq.com/articles/gilead-sciences-oncology-ma-strategy-explained-2017-09-01", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-continued-its-march-higher-again-today-2017-08-31", "https://www.nasdaq.com/articles/could-gilead-sciences-stock-skyrocket-25-1-analyst-thinks-so-2017-08-31", "https://www.nasdaq.com/articles/wednesdays-etf-unusual-volume-pkw-2017-08-30", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-broadcom-cbre-group-sandvik-applied-materials-and-gilead", "https://www.nasdaq.com/articles/stock-market-news-for-august-31-2017-2017-08-31", "https://www.nasdaq.com/articles/novartis-475000-price-tag-sets-stage-price-war-gilead-sciences-2017-08-31", "https://www.nasdaq.com/articles/biotech-stock-roundup-car-t-focus-gilead-kite-deal-incyte-baricitinib-update-2017-08-31", "https://www.nasdaq.com/articles/after-hours-most-active-aug-31-2017-dow-dd-sbac-bac-qqq-msft-teva-pfe-ge-amat-gild-intc", "https://www.nasdaq.com/articles/why-analog-devices-gilead-sciences-and-universal-display-jumped-today-2017-08-30", "https://www.nasdaq.com/articles/5-biotech-stocks-that-are-breaking-higher-2017-08-30", "https://www.nasdaq.com/articles/why-novatis-475k-car-t-cancer-treatment-actually-cheap-2017-08-30", "https://www.nasdaq.com/articles/amgen-presents-new-repatha-analysis-from-fourier-study-2017-08-29", "https://www.nasdaq.com/articles/juno-bluebird-hot-acquisition-targets-after-kite-gilead-deal-2017-08-30", "https://www.nasdaq.com/articles/company-news-for-august-29-2017-2017-08-29", "https://www.nasdaq.com/articles/can-gilead-sciences-squeeze-12-billion-kite-pharma-2017-08-29", "https://www.nasdaq.com/articles/5-top-roe-stocks-buy-hurricane-harvey-wreaks-havoc-2017-08-29", "https://www.nasdaq.com/articles/heres-what-else-gilead-sciences-gets-buying-kite-pharma-2017-08-29", "https://www.nasdaq.com/articles/indecision-wont-kill-you-it-will-take-your-money-2017-08-29", "https://www.nasdaq.com/articles/get-ready-more-acquisitions-gilead-sciences-2017-08-29", "https://www.nasdaq.com/articles/gilead-to-fly-high-with-kite-pharma-acquisition-for-%2411.9b-2017-08-29", "https://www.nasdaq.com/articles/gilead-sciences-inc.-gild-stock-still-has-room-to-grow-2017-08-29", "https://www.nasdaq.com/articles/company-news-for-august-29-2017-2017-08-29", "https://www.nasdaq.com/articles/midday-update-sectors-split-hurricane-harveys-impact-spreads-through-wall-street-2017-08", "https://www.nasdaq.com/articles/gilead-sciences-buy-kite-pharma-119-billion-it-enough-move-needle-2017-08-28", "https://www.nasdaq.com/articles/3-reasons-applaud-gilead-sciences-acquisition-kite-pharma-2017-08-28", "https://www.nasdaq.com/articles/stock-futures-perk-despite-potential-economic-damage-hurricane-2017-08-28", "https://www.nasdaq.com/articles/health-care-sector-update-08282017-jnj-pfe-abt-mrk-amgn-kite-gild-aveo-nvs-2017-08-28", "https://www.nasdaq.com/articles/juno-therapeutics-juno-continues-gains-after-gilead-kite-acquisition-2017-08-29", "https://www.nasdaq.com/articles/pre-market-most-active-aug-28-2017-kite-wfm-gild-juno-tvix-mycc-qqq-fcau-bhp-q-db-baba", "https://www.nasdaq.com/articles/roches-gazyva-gets-priority-review-for-follicular-lymphoma-2017-08-28", "https://www.nasdaq.com/articles/astrazenecas-faslodex-gets-fda-nod-in-first-line-setting-2017-08-28", "https://www.nasdaq.com/articles/close-update-shares-mixed-hurricane-batters-energy-sector-underpins-construction-home", "https://www.nasdaq.com/articles/novartis-announces-positive-data-on-cardiovascular-drug-2017-08-28", "https://www.nasdaq.com/articles/why-thor-industries-ixys-corporation-and-kite-pharma-jumped-today-2017-08-28", "https://www.nasdaq.com/articles/mid-afternoon-market-update-ixys-surges-acquisition-news-uni-pixel-shares-plunge-2017-08", "https://www.nasdaq.com/articles/morning-movers-gilead-jumps-kite-acquisition-expedia-drops-ceo-leaves-uber-2017-08-28", "https://www.nasdaq.com/articles/why-did-kite-pharma-kite-stock-skyrocket-today-2017-08-28", "https://www.nasdaq.com/articles/gileads-plan-cash-car-t-2017-08-28", "https://www.nasdaq.com/articles/why-i-love-abbvie-inc-2017-08-27", "https://www.nasdaq.com/articles/novartis-nvs-receives-ec-approval-for-breast-cancer-drug-2017-08-25", "https://www.nasdaq.com/articles/will-endo-endp-continue-to-disappoint-investors-in-2017-2017-08-25", "https://www.nasdaq.com/articles/why-im-hanging-loser-2017-08-24", "https://www.nasdaq.com/articles/roche-rhhby-hemophilia-a-drug-granted-priority-review-2017-08-24", "https://www.nasdaq.com/articles/why-bluebird-bio-inc-and-juno-therapeutics-inc-shot-higher-today-2017-08-28", "https://www.nasdaq.com/articles/pfizers-ibrance-in-first-line-combo-breast-cancer-study-2017-08-23", "https://www.nasdaq.com/articles/are-glaxos-successful-new-drugs-enough-to-drive-growth-2017-08-23", "https://www.nasdaq.com/articles/3-reasons-abbvie-better-dividend-stock-gilead-sciences-2017-08-23", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-fxh-algn-cnc-gild-2017-08-22", "https://www.nasdaq.com/articles/alkermes-initiates-rolling-submission-of-depression-drug-2017-08-22", "https://www.nasdaq.com/articles/4-biotech-stocks-add-your-portfolio-post-q2-earnings-2017-08-22", "https://www.nasdaq.com/articles/alexions-alxn-soliris-label-expansion-approved-in-europe-2017-08-22", "https://www.nasdaq.com/articles/top-ranked-income-stocks-to-buy-for-august-24th-2017-08-24", "https://www.nasdaq.com/articles/mondays-etf-unusual-volume-bbh-2017-08-21", "https://www.nasdaq.com/articles/abbvies-hcv-combo-drug-mavyret-clinches-approval-in-canada-2017-08-18", "https://www.nasdaq.com/articles/gilead-gild-hcv-drug-vosevi-receives-approval-in-canada-2017-08-18", "https://www.nasdaq.com/articles/pfizers-pfe-besponsa-gets-fda-nod-with-a-boxed-warning-2017-08-18", "https://www.nasdaq.com/articles/mylan-finalizes-settlement-agreement-with-doj-for-%24465m-2017-08-18", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-best-biotech-stock-buy-2017-08-17", "https://www.nasdaq.com/articles/3-value-stocks-retirees-2017-08-17", "https://www.nasdaq.com/articles/3-value-stocks-smart-investors-2017-08-21", "https://www.nasdaq.com/articles/sterneck-capital-management-llc-buys-corenergy-infrastructure-trust-inc-chicago-bridge", "https://www.nasdaq.com/articles/biotech-stock-roundup-regeneron-drops-rsv-antibody-gilead-hiv-drug-gets-priority-review", "https://www.nasdaq.com/articles/regenerons-regn-rsv-drug-suptavumab-fails-nursery-trial-2017-08-16", "https://www.nasdaq.com/articles/chiron-investment-management-llc-buys-ishares-iboxx-investment-grade-corporate-bond-gilead", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-coca-cola-femsa-banco-bilbao-vizcaya-argentaria-lantheus", "https://www.nasdaq.com/articles/mallinckrodt-mnk-looks-strong-on-acthar-generics-weak-2017-08-15", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-august-16-2017-2017-08-15", "https://www.nasdaq.com/articles/falling-earnings-estimates-signal-weakness-ahead-for-mylan-myl-2017-08-16", "https://www.nasdaq.com/articles/gilead-gild-nda-for-hiv-combo-regimen-gets-priority-review-2017-08-14", "https://www.nasdaq.com/articles/3-healthcare-stocks-are-looking-cheap-right-now-2017-08-14", "https://www.nasdaq.com/articles/5-discounted-peg-stocks-for-garp-investors-2017-08-14", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-august-15-2017-2017-08-14", "https://www.nasdaq.com/articles/why-has-2017-been-horrible-year-so-far-biotech-acquisitions-2017-08-13", "https://www.nasdaq.com/articles/ishares-edge-msci-usa-value-factor-etf-experiences-big-inflow-2017-08-11", "https://www.nasdaq.com/articles/forget-teva-teva-buy-these-4-drug-stocks-instead-2017-08-11", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-broadcom-limited-cbre-group-sandvik-ab-applied-materials", "https://www.nasdaq.com/articles/gilead-gild-nda-for-hiv-combo-regimen-gets-priority-review-2017-08-14", "https://www.nasdaq.com/articles/3-healthcare-stocks-are-looking-cheap-right-now-2017-08-14", "https://www.nasdaq.com/articles/prothena-prta-q2-loss-narrows-as-roche-makes-%2430m-payment-2017-08-09", "https://www.nasdaq.com/articles/after-hours-most-active-aug-9-2017-vg-abev-ggb-t-cor-qqq-brcd-momo-odp-adp-nee-gild-2017", "https://www.nasdaq.com/articles/validea-david-dreman-strategy-daily-upgrade-report-892017-2017-08-09", "https://www.nasdaq.com/articles/valeant-vrx-beats-q2-earnings-sales-in-line-trims-view-2017-08-09", "https://www.nasdaq.com/articles/mylan-myl-misses-on-q2-earnings-sales-lowers-view-2017-08-09", "https://www.nasdaq.com/articles/markets-remain-choppy-continuing-conflicts-5-top-picks-2017-08-11", "https://www.nasdaq.com/articles/pioneer-investments-buys-citigroup-berkshire-gilead-2017-08-08", "https://www.nasdaq.com/articles/mallinckrodt-mnk-tops-q2-earnings-generics-segment-weak-2017-08-08", "https://www.nasdaq.com/articles/drug-stocks-q2-earnings-roster-for-aug-8%3A-acad-jazz-more-2017-08-07", "https://www.nasdaq.com/articles/these-3-biotechs-just-crushed-analyst-expectations-2017-08-07", "https://www.nasdaq.com/articles/top-ranked-momentum-stocks-to-buy-for-august-7th-2017-08-07", "https://www.nasdaq.com/articles/10-reasons-cancer-drugs-usually-cost-100000-or-more-year-2017-08-06", "https://www.nasdaq.com/articles/abbvie-about-deliver-blow-gilead-sciences-guidance-2017-08-05", "https://www.nasdaq.com/articles/forget-bayer-buy-these-3-drug-stocks-instead-2017-08-08", "https://www.nasdaq.com/articles/infinity-infi-q2-loss-wider-than-expected-view-intact-2017-08-04", "https://www.nasdaq.com/articles/radius-rdus-q2-loss-wider-than-expected-on-higher-expenses-2017-08-04", "https://www.nasdaq.com/articles/domini-social-investments-llc-buys-first-solar-inc-sunpower-corp-sells-sunrun-inc-fitbit", "https://www.nasdaq.com/articles/itot-mdt-gild-slb-large-inflows-detected-etf-2017-08-03", "https://www.nasdaq.com/articles/should-you-buy-vertex-pharmaceuticals-incorporated-vrtx-stock-3-pros-3-cons-2017-08-03", "https://www.nasdaq.com/articles/regeneron-regn-beats-on-q2-earnings-sales-raises-view-2017-08-03", "https://www.nasdaq.com/articles/3-strong-buy-high-yield-dividend-stocks-2017-08-03", "https://www.nasdaq.com/articles/celgene-vs-gilead-sciences-who-reported-better-earnings-2017-08-04", "https://www.nasdaq.com/articles/top-ranked-income-stocks-to-buy-for-august-2nd-2017-08-02", "https://www.nasdaq.com/articles/biotech-stock-roundup-q2-earnings-gilead-celg-more-dynavax-panel-vote-2017-08-02", "https://www.nasdaq.com/articles/3-etfs-to-watch-out-for-on-biotech-earnings-2017-08-01", "https://www.nasdaq.com/articles/intercept-icpt-posts-narrower-than-expected-loss-in-q2-2017-08-01", "https://www.nasdaq.com/articles/gilead-sciences-top-25-dividend-giant-274-yield-gild-2017-08-01", "https://www.nasdaq.com/articles/general-american-investors-co-inc-buys-oracle-corp-now-inc-ebay-inc-sells-imax-corp-2017", "https://www.nasdaq.com/articles/5-things-gilead-sciences-q2-earnings-numbers-didnt-tell-you-2017-07-31", "https://www.nasdaq.com/articles/aerie-aeri-reports-narrower-than-expected-loss-in-q2-2017-08-02", "https://www.nasdaq.com/articles/4-drug-stocks-focus-world-hepatitis-day-2017-07-28", "https://www.nasdaq.com/articles/gilead-sciences-inc.-gild-stock-has-tremendous-potential-even-post-rally-2017-07-27", "https://www.nasdaq.com/articles/whoops-twitter-inc-twtr-stock-tanks-as-user-growth-vanishes-2017-07-27", "https://www.nasdaq.com/articles/score-hot-profits-on-a-netflix-inc.-nflx-stock-cooldown-2017-07-27", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-thursday%3A-buffalo-wild-wings-bwld-gilead-sciences-inc.-gild-and", "https://www.nasdaq.com/articles/gilead-gild-tops-q2-earnings-revenue-estimates-stock-up-2017-07-27", "https://www.nasdaq.com/articles/validea-benjamin-graham-strategy-daily-upgrade-report-7272017-2017-07-27", "https://www.nasdaq.com/articles/united-therapeutics-uthr-incurs-loss-in-q2-sales-top-2017-07-28", "https://www.nasdaq.com/articles/voo-mdt-gild-bmy-large-outflows-detected-etf-2017-07-26", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-biogen-top-q2-estimates-update-incyte-ra-drug-2017-07-26", "https://www.nasdaq.com/articles/gilead-sciences-has-3-available-options-only-1-makes-sense-2017-07-26", "https://www.nasdaq.com/articles/gilead-sciences-inc-boosts-its-full-year-outlook-thanks-stronger-expected-hep-c-sales-2017", "https://www.nasdaq.com/articles/gilead-gild-shares-pop-q2-earnings-and-revenue-beats-2017-07-26", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-727-follow-through-indicator-51-sensitive", "https://www.nasdaq.com/articles/after-hours-earnings-report-july-26-2017-fb-gild-pypl-su-lvs-vrtx-psa-lrcx-ew-dfs-abx-now", "https://www.nasdaq.com/articles/daily-dividend-report-su-mck-syf-cvx-cmcsa-gild-unp-2017-07-27", "https://www.nasdaq.com/articles/will-radius-health-rdus-disappoint-this-earnings-season-2017-07-25", "https://www.nasdaq.com/articles/is-a-surprise-coming-for-gilead-sciences-gild-this-earnings-season-2017-07-25", "https://www.nasdaq.com/articles/3-dividend-stocks-thrive-bear-markets-2017-07-25", "https://www.nasdaq.com/articles/gilead-sciences-inc.-gild-stock-is-a-2-for-1-deal-2017-07-24", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-agenus-agen-this-earnings-season-2017-07-24", "https://www.nasdaq.com/articles/3-things-you-can-expect-gilead-sciences-q2-update-2017-07-24", "https://www.nasdaq.com/articles/better-buy-celgene-corporation-vs-gilead-sciences-inc-2017-07-22", "https://www.nasdaq.com/articles/can-intercept-icpt-beat-estimates-this-earnings-season-2017-07-25", "https://www.nasdaq.com/articles/what-to-expect-from-keryx-kerx-this-earnings-season-2017-07-21", "https://www.nasdaq.com/articles/whats-in-the-offing-for-bristol-myers-bmy-in-q2-earnings-2017-07-21", "https://www.nasdaq.com/articles/hca-healthcare-hca-q2-earnings%3A-will-it-beat-estimates-2017-07-21", "https://www.nasdaq.com/articles/amgen-amgn-to-report-q2-earnings%3A-whats-in-the-cards-2017-07-21", "https://www.nasdaq.com/articles/warren-buffetts-net-worth-would-be-100-billion-right-now-if-not-2017-07-21", "https://www.nasdaq.com/articles/better-buy-valeant-pharmaceuticals-international-inc-vs-gilead-sciences-2017-07-21", "https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-vertex-vrtx-in-q2-earnings-2017-07-21", "https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-johnson-johnson-2017-07-22", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-alexion-alxn-this-earnings-season-2017-07-20", "https://www.nasdaq.com/articles/is-gilead-gild-poised-for-a-beat-this-earnings-season-2017-07-20", "https://www.nasdaq.com/articles/health-care-sector-update-07202017-sbphgildsrptcfrx-2017-07-20", "https://www.nasdaq.com/articles/exane-asset-management-buys-monsanto-co-biogen-inc-qiagen-nv-sells-citigroup-inc-w-r-grace", "https://www.nasdaq.com/articles/gileads-hcv-portfolio-receives-a-boost-with-vosevi-approval-2017-07-19", "https://www.nasdaq.com/articles/biotech-stock-roundup-vertex-boosted-cf-data-fda-nod-gilead-puma-drugs-2017-07-19", "https://www.nasdaq.com/articles/why-vertex-pharmaceuticals-incorporated-stock-soaring-today-2017-07-19", "https://www.nasdaq.com/articles/notable-thursday-option-activity-gild-gs-athn-2017-07-20", "https://www.nasdaq.com/articles/5-big-pharma-stocks-best-drug-pipelines-2017-07-18", "https://www.nasdaq.com/articles/5-ways-gilead-sciences-could-spend-its-cash-hoard-2017-07-18", "https://www.nasdaq.com/articles/health-care-sector-update-07182017-gildcaprimuc-2017-07-18", "https://www.nasdaq.com/articles/vlue-wmt-gild-nsc-etf-outflow-alert-2017-07-17", "https://www.nasdaq.com/articles/these-3-charts-dont-lie-gilead-sciences-needs-acquisition-2017-07-16", "https://www.nasdaq.com/articles/will-drug-pricing-executive-order-help-big-pharma-2017-07-16", "https://www.nasdaq.com/articles/gilead-gild-application-for-hiv-drug-validated-in-eu-2017-07-15", "https://www.nasdaq.com/articles/agree-purchase-gilead-sciences-40-earn-25-using-options-2017-07-18", "https://www.nasdaq.com/articles/gilead-gild-application-for-hiv-drug-validated-in-eu-2017-07-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-merck-eli-lilly-celgene-gilead-sciences-and-shire-2017", "https://www.nasdaq.com/articles/3-dividend-stocks-are-minting-money-2017-07-13", "https://www.nasdaq.com/articles/3-value-stocks-discriminating-investors-2017-07-13", "https://www.nasdaq.com/articles/5-pharma-biotech-stocks-could-be-big-winners-q2-earnings-2017-07-13", "https://www.nasdaq.com/articles/how-biogen-inc-makes-most-its-money-2017-07-13", "https://www.nasdaq.com/articles/5-drug-stocks-well-poised-to-beat-q2-earnings-estimates-2017-07-13", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-merck-celgene-gilead-sciences-seattle-genetics-and", "https://www.nasdaq.com/articles/gilead-gild-application-for-hiv-drug-validated-in-eu-2017-07-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-merck-eli-lilly-celgene-gilead-sciences-and-shire-2017", "https://www.nasdaq.com/articles/3-dividend-stocks-are-minting-money-2017-07-13", "https://www.nasdaq.com/articles/top-stock-reports-wells-fargo-broadcom-gilead-2017-07-10", "https://www.nasdaq.com/articles/how-shrewd-dealmaker-gilead-sciences-just-look-its-last-7-acquisitions-2017-07-09", "https://www.nasdaq.com/articles/will-gileads-dividend-keep-climbing-2017-07-07", "https://www.nasdaq.com/articles/whats-behind-gilead-sciences-incs-95-rally-june-2017-07-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-arena-shoots-study-data-celg-inks-immuno-oncology-deal-2017-07-12", "https://www.nasdaq.com/articles/gild-dividend-yield-pushes-past-3-2017-07-06", "https://www.nasdaq.com/articles/chevron-corporation-cvx-is-stabilizing-fill-up-2017-07-05", "https://www.nasdaq.com/articles/bank-on-gilead-sciences-inc.-gild-stock-getting-its-mojo-back-2017-07-05", "https://www.nasdaq.com/articles/galapagos-gilead-begin-phase-ii-study-on-uveitis-candidate-2017-07-05", "https://www.nasdaq.com/articles/3-top-high-yield-pharmaceutical-stocks-buy-now-2017-07-03", "https://www.nasdaq.com/articles/3-reasons-why-gilead-sciences-shouldnt-buy-vertex-pharmaceuticals-2017-07-03", "https://www.nasdaq.com/articles/3-charts-show-why-buy-gilead-sciences-stock-now-2017-07-02", "https://www.nasdaq.com/articles/3-hot-biotech-stocks-ready-sectors-next-breakout-2017-07-06", "https://www.nasdaq.com/articles/3-big-stock-charts-for-thursday%3A-merck-co.-inc.-mrk-gilead-sciences-inc.-gild-and-valeant", "https://www.nasdaq.com/articles/trade-of-the-day%3A-gilead-sciences-inc.-gild-2017-06-29", "https://www.nasdaq.com/articles/biotech-stock-roundup-eu-nod-regeneron-ra-drug-portola-soars-fda-nod-2017-06-29", "https://www.nasdaq.com/articles/biotechs-soared-june-japan-small-caps-also-outperformed-2017-06-29", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-vht-gild-lly-agn-2017-06-28", "https://www.nasdaq.com/articles/fbts-underlying-holdings-could-mean-11-gain-potential-2017-06-28", "https://www.nasdaq.com/articles/gileads-gild-hcv-drug-application-accepted-in-the-eu-2017-06-27", "https://www.nasdaq.com/articles/which-these-june-winners-show-strength-amid-market-weakness-2017-06-30", "https://www.nasdaq.com/articles/3-big-stock-charts-for-thursday%3A-merck-co.-inc.-mrk-gilead-sciences-inc.-gild-and-valeant", "https://www.nasdaq.com/articles/trade-of-the-day%3A-gilead-sciences-inc.-gild-2017-06-29", "https://www.nasdaq.com/articles/biotech-stock-roundup-eu-nod-regeneron-ra-drug-portola-soars-fda-nod-2017-06-29", "https://www.nasdaq.com/articles/stock-market-news-for-june-23-2017-2017-06-23", "https://www.nasdaq.com/articles/nasdaq-100-movers-ca-regn-2017-06-22", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-623669-274-points-2017-06-22", "https://www.nasdaq.com/articles/thursday-sector-leaders-healthcare-energy-2017-06-22", "https://www.nasdaq.com/articles/abbvies-hcv-combo-drug-gets-positive-chmp-opinion-in-eu-2017-06-27", "https://www.nasdaq.com/articles/2-pharma-buyout-targets-may-surprise-you-2017-06-27", "https://www.nasdaq.com/articles/how-we-earn-%245300-in-dividends-from-a-%2410000-investment-vz-psx-gild-2017-06-26", "https://www.nasdaq.com/articles/2-top-biotech-stocks-buy-sale-2017-06-24", "https://www.nasdaq.com/articles/proshares-ultrapro-qqq-experiences-big-inflow-2017-06-20", "https://www.nasdaq.com/articles/why-billionaire-just-bought-gilead-sciences-synergy-and-valeant-stock-2017-06-20", "https://www.nasdaq.com/articles/gileads-gild-hbv-drug-vemlidy-receives-approval-in-canada-2017-06-20", "https://www.nasdaq.com/articles/why-tesaro-inc-stock-briefly-dipped-today-2017-06-19", "https://www.nasdaq.com/articles/biotech-stock-roundup-clovis-soars-rubraca-data-seattle-hit-study-halt-2017-06-21", "https://www.nasdaq.com/articles/how-find-best-value-stocks-2017-06-21", "https://www.nasdaq.com/articles/3-beaten-down-stocks-ready-bounce-back-2017-06-16", "https://www.nasdaq.com/articles/will-these-cutting-edge-cancer-killers-reignite-biotech-rally-2017-06-15", "https://www.nasdaq.com/articles/3-stocks-better-dividends-cvs-health-corporation-2017-06-15", "https://www.nasdaq.com/articles/epizyme-provides-positive-interim-data-on-ezh2-inhibitor-2017-06-15", "https://www.nasdaq.com/articles/biotech-stock-roundup-management-changes-biogen-alexion-gild-files-hiv-drug-2017-06-15", "https://www.nasdaq.com/articles/notable-monday-option-activity-amg-trip-gild-2017-06-19", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-june-14-2017-2017-06-13", "https://www.nasdaq.com/articles/3-dividend-stocks-buy-sale-2017-06-13", "https://www.nasdaq.com/articles/gilead-gild-submits-nda-for-hiv-combination-therapy-regimen-2017-06-13", "https://www.nasdaq.com/articles/notable-monday-option-activity-ge-gild-adbe-2017-06-12", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-oef-ba-gild-usb-2017-06-12", "https://www.nasdaq.com/articles/ex-dividend-reminder-analogic-gilead-sciences-and-hill-rom-holdings-2017-06-12", "https://www.nasdaq.com/articles/3-beaten-biotech-stocks-are-they-bargains-2017-06-12", "https://www.nasdaq.com/articles/new-data-shows-tg-therapeutics-could-be-something-big-2017-06-15", "https://www.nasdaq.com/articles/3-best-value-stocks-you-can-buy-right-now-2017-06-09", "https://www.nasdaq.com/articles/gilead-sciences-inc-bear-case-bull-2017-06-09", "https://www.nasdaq.com/articles/why-glaxosmithkline-stock-had-breakout-may-2017-06-09", "https://www.nasdaq.com/articles/what-traders-can-learn-professional-horse-betting-2017-06-09", "https://www.nasdaq.com/articles/best-hep-c-drug-stock-buy-2017-2017-06-08", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-bp-dow-chemical-america-movil-and-metlife-2017", "https://www.nasdaq.com/articles/spring-bank-pharmaceuticals-hepatitis-b-results-context-2017-06-07", "https://www.nasdaq.com/articles/gild-named-top-socially-responsible-dividend-stock-2017-06-12", "https://www.nasdaq.com/articles/why-gilead-sciences-stock-slumped-may-2017-06-06", "https://www.nasdaq.com/articles/3-value-stocks-perfect-retirement-2017-06-06", "https://www.nasdaq.com/articles/3-stocks-baby-boomers-are-buying-that-millennials-arent-2017-06-05", "https://www.nasdaq.com/articles/3-great-dividend-stocks-buy-you-might-not-know-are-dividend-stocks-2017-06-04", "https://www.nasdaq.com/articles/3-dividend-stocks-daring-investors-2017-06-04", "https://www.nasdaq.com/articles/3-history-making-stocks-2017-06-03", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-ivw-sbux-qcom-gild-2017-06-02", "https://www.nasdaq.com/articles/top-stock-reports-gilead-bp-dow-chemical-2017-06-06", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-tup-rh-gild-2017-06-01", "https://www.nasdaq.com/articles/mercks-hiv-drug-isentress-gets-fda-approval-for-higher-dose-2017-05-31", "https://www.nasdaq.com/articles/gilead-single-tablet-regiment-for-hiv-good-in-phase-iii-2017-05-31", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-inc-2017-05-31", "https://www.nasdaq.com/articles/intercepts-icpt-liver-drug-ocaliva-approved-in-canada-2017-05-29", "https://www.nasdaq.com/articles/meet-cancer-therapy-could-become-second-best-selling-drug-world-years-end-2017-05-29", "https://www.nasdaq.com/articles/7-things-you-didnt-know-about-gilead-sciences-inc-2017-05-28", "https://www.nasdaq.com/articles/why-is-gilead-sciences-gild-down-3.5-since-the-last-earnings-report-2017-06-02", "https://www.nasdaq.com/articles/these-are-10-lowest-pe-stocks-today-2017-05-26", "https://www.nasdaq.com/articles/3-value-stocks-daring-investors-2017-05-26", "https://www.nasdaq.com/articles/federal-reserve-reluctant-let-go-2017-05-25", "https://www.nasdaq.com/articles/worst-behind-gilead-sciences-2017-05-24", "https://www.nasdaq.com/articles/3-reasons-gilead-sciences-inc-better-dividend-stock-amgen-inc-2017-05-24", "https://www.nasdaq.com/articles/inovio-pharmaceuticals-stock-soars-encouraging-hiv-vaccine-readout-2017-05-24", "https://www.nasdaq.com/articles/valeant-and-gilead-beaten-down-bargains-or-truly-terrible-2017-05-23", "https://www.nasdaq.com/articles/1-underdog-stock-im-watching-2017-05-26", "https://www.nasdaq.com/articles/mercks-hiv-drug-gets-positive-chmp-opinion-for-higher-dose-2017-05-22", "https://www.nasdaq.com/articles/woodford-investment-management-llp-buys-gilead-sciences-inc-bioverativ-inc-biogen-inc", "https://www.nasdaq.com/articles/zacks-value-investor-highlights%3A-avis-budget-group-general-motors-gilead-sciences-lgi", "https://www.nasdaq.com/articles/gilead-sciences-enters-oversold-territory-2017-05-18", "https://www.nasdaq.com/articles/doomed-trump-presidency-would-be-terrifying-development-pharmaceutical-stocks-2017-05-18", "https://www.nasdaq.com/articles/alcentra-capital-selling-stock-or-selling-out-2017-05-18", "https://www.nasdaq.com/articles/value-stock-or-value-trap-2017-05-17", "https://www.nasdaq.com/articles/investing-podcast-highlights-tech-stocks-trump-reits-retail-earnings-and-more-2017-05-22", "https://www.nasdaq.com/articles/vym-bmy-gild-qcom-etf-inflow-alert-2017-05-16", "https://www.nasdaq.com/articles/want-get-biotech-check-out-these-3-stocks-2017-05-16", "https://www.nasdaq.com/articles/3-best-dividend-stocks-biotech-2017-05-16", "https://www.nasdaq.com/articles/stocks-fell-3-year-lows-week-may-12-2017-05-14", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-amgen-inc-2017-05-14", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-may-15-2017-2017-05-12", "https://www.nasdaq.com/articles/why-gilead-sciences-top-dividend-stock-nasdaq-100-31-yield-gild-2017-05-12", "https://www.nasdaq.com/articles/3-dividend-stocks-you-havent-thought-2017-05-17", "https://www.nasdaq.com/articles/3-top-biotech-stocks-may-2017-05-11", "https://www.nasdaq.com/articles/better-buy-glaxosmithkline-vs-johnson-johnson-2017-05-10", "https://www.nasdaq.com/articles/why-gilead-sciences-stock-lagged-behind-other-biotechs-april-2017-05-10", "https://www.nasdaq.com/articles/i-still-cant-believe-gilead-sciences-inc-spent-148-billion-shareholder-rewards-2017-05-09", "https://www.nasdaq.com/articles/3-stocks-generate-tons-cash-2017-05-09", "https://www.nasdaq.com/articles/heres-why-diplomat-pharmacy-inc-rising-today-2017-05-09", "https://www.nasdaq.com/articles/proshares-ultrapro-sp500-experiences-big-outflow-2017-05-08", "https://www.nasdaq.com/articles/charles-brandes-invests-health-care-1st-quarter-2017-05-11", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-johnson-johnson-2017-05-05", "https://www.nasdaq.com/articles/intercept-icpt-q1-loss-narrower-than-expected-sales-beat-2017-05-05", "https://www.nasdaq.com/articles/top-research-reports-today-gild-dow-met-more-2017-05-05", "https://www.nasdaq.com/articles/big-new-threat-gilead-sciences-coming-2017-05-04", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-gra-aeri-gild-2017-05-03", "https://www.nasdaq.com/articles/how-to-trade-gilead-sciences-inc.-gild-stock-after-its-q1-miss-2017-05-03", "https://www.nasdaq.com/articles/gilead-gild-beats-on-q1-earnings-revenues-miss-estimates-2017-05-03", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-dow-chemical-metlife-tesla-and-emerson-electric", "https://www.nasdaq.com/articles/amazon-love-company-hate-stock-price-2017-05-03", "https://www.nasdaq.com/articles/gilead-sciences-posts-mixed-q1-results%3A-etfs-in-focus-2017-05-03", "https://www.nasdaq.com/articles/after-gilead-earnings-buy-these-biotech-stocks-2017-05-03", "https://www.nasdaq.com/articles/gilead-sciences-5-point-plan-turn-things-around-2017-05-03", "https://www.nasdaq.com/articles/daily-dividend-report-aapl-pep-expd-man-win-gild-syk-2017-05-03", "https://www.nasdaq.com/articles/walt-disney-co-dis-stock-cracks-and-it-could-get-worse-2017-05-03", "https://www.nasdaq.com/articles/gilead-sciences-incs-revenue-and-earnings-continue-fall-declining-hcv-sales-2017-05-02", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-gilead-celgene-q1-earnings-sunesis-down-vosaroxin-update-2017", "https://www.nasdaq.com/articles/gilead-gild-misses-q1-earnings-and-revenue-estimates-stock-drops-2017-05-02", "https://www.nasdaq.com/articles/weeks-must-see-earnings-charts-2017-05-02", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-727-follow-through-indicator-49-sensitive", "https://www.nasdaq.com/articles/after-hours-earnings-report-may-2-2017-aapl-gild-mdlz-apc-all-dvn-vrsk-dva-oke-oks-akam", "https://www.nasdaq.com/articles/geron-gern-q1-earnings%3A-whats-in-store-for-the-stock-2017-05-01", "https://www.nasdaq.com/articles/apple-facebook-and-gilead-sciences-are-part-of-zacks-earnings-preview-2017-05-01", "https://www.nasdaq.com/articles/3-big-drugmakers-could-make-billions-under-trumps-tax-plan-2017-05-01", "https://www.nasdaq.com/articles/apple-sells-fewer-iphones-gilead-misses-sales-2017-05-02", "https://www.nasdaq.com/articles/whats-in-store-for-zoetis-zts-stock-this-earnings-season-2017-05-01", "https://www.nasdaq.com/articles/what-to-expect-from-endocyte-ecyt-stock-for-q1-earnings-2017-05-01", "https://www.nasdaq.com/articles/spot-trading-llc-buys-walt-disney-co-johnson-johnson-mastercard-sells-spdr-sp-2017-05-01", "https://www.nasdaq.com/articles/gilead-sciences-inc.-gild-stock-still-looks-sick-2017-05-01", "https://www.nasdaq.com/articles/3-things-watch-gilead-sciences-inc-q1-results-2017-04-30", "https://www.nasdaq.com/articles/iusg-gild-qcom-twx-etf-inflow-alert-2017-04-28", "https://www.nasdaq.com/articles/sarepta-srpt-q1-loss-narrows-exondys-51-sales-pick-up-2017-04-28", "https://www.nasdaq.com/articles/radius-health-rdus-q1-earnings%3A-whats-in-store-2017-05-01", "https://www.nasdaq.com/articles/general-american-investors-co-inc-buys-ensco-plc-johnson-controls-international-plc", "https://www.nasdaq.com/articles/is-intercept-icpt-poised-for-a-beat-this-earnings-season-2017-04-28", "https://www.nasdaq.com/articles/what-to-expect-from-keryx-kerx-stock-this-earnings-season-2017-04-28", "https://www.nasdaq.com/articles/regeneron-regn-to-post-q1-earnings%3A-whats-in-the-cards-2017-04-28", "https://www.nasdaq.com/articles/tech-sectors-strong-earnings-power-2017-04-28", "https://www.nasdaq.com/articles/biomarin-bmrn-q1-earnings%3A-will-it-beat-estimates-again-2017-04-27", "https://www.nasdaq.com/articles/united-therapeutics-uthr-q1-earnings-beat-sales-miss-2017-04-27", "https://www.nasdaq.com/articles/why-gilead-gild-might-surprise-this-earnings-season-2017-04-28", "https://www.nasdaq.com/articles/whats-in-store-for-merck-mrk-this-earnings-season-2017-04-26", "https://www.nasdaq.com/articles/pfizer-pfe-q1-earnings%3A-will-it-pull-off-a-surprise-2017-04-26", "https://www.nasdaq.com/articles/what-awaits-aerie-pharmaceuticals-aeri-in-q1-earnings-2017-04-26", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-gains-strong-q1-nash-data-gilead-drug-2017-04-26", "https://www.nasdaq.com/articles/extreme-leverage-extreme-valuations-big-time-short-sellers-must-be-thinking-about-it-2017", "https://www.nasdaq.com/articles/after-hours-most-active-apr-26-2017-bac-qqq-nrg-mpw-ge-pfe-gm-mchi-gild-siri-mu-msft-2017", "https://www.nasdaq.com/articles/what-to-expect-from-prothena-prta-this-earnings-season-2017-04-26", "https://www.nasdaq.com/articles/1-dividend-stock-could-double-your-money-2017-04-27", "https://www.nasdaq.com/articles/jerome-dodson-keeps-buying-mckesson-axalta-pentair-2017-04-25", "https://www.nasdaq.com/articles/gilead-gild-q1-earnings%3A-stock-likely-to-beat-estimates-2017-04-25", "https://www.nasdaq.com/articles/exelixis-exel-q1-earnings%3A-will-the-stock-disappoint-2017-04-25", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-etsy-gild-ual-2017-04-25", "https://www.nasdaq.com/articles/bristol-myers-bmy-to-post-q1-earnings%3A-whats-in-store-2017-04-25", "https://www.nasdaq.com/articles/whats-in-store-for-agenus-agen-this-earnings-season-2017-04-24", "https://www.nasdaq.com/articles/celgene-celg-to-post-q1-earnings%3A-whats-in-the-cards-2017-04-24", "https://www.nasdaq.com/articles/3-stocks-could-double-their-dividends-shouldnt-2017-04-25", "https://www.nasdaq.com/articles/jerome-dodson-keeps-buying-mckesson-axalta-pentair-2017-04-25", "https://www.nasdaq.com/articles/gilead-gild-q1-earnings%3A-stock-likely-to-beat-estimates-2017-04-25", "https://www.nasdaq.com/articles/exelixis-exel-q1-earnings%3A-will-the-stock-disappoint-2017-04-25", "https://www.nasdaq.com/articles/whats-in-store-for-glaxosmithkline-gsk-in-q1-earnings-2017-04-21", "https://www.nasdaq.com/articles/amgen-amgn-to-report-q1-earnings%3A-will-it-beat-again-2017-04-21", "https://www.nasdaq.com/articles/alexion-alxn-q1-earnings%3A-can-the-stock-pull-a-surprise-2017-04-21", "https://www.nasdaq.com/articles/10-reasons-merck-could-be-worlds-most-perfect-stock-2017-04-21", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-vs-celgene-2017-04-24", "https://www.nasdaq.com/articles/should-gilead-sciences-be-worried-about-allergan-2017-04-23", "https://www.nasdaq.com/articles/novartis-nvs-q1-earnings%3A-will-the-stock-disappoint-2017-04-20", "https://www.nasdaq.com/articles/health-care-sector-update-04202017-gildimnpskln-2017-04-20", "https://www.nasdaq.com/articles/peek-under-hood-iyh-has-11-upside-2017-04-20", "https://www.nasdaq.com/articles/looking-smart-way-use-your-tax-refund-buy-these-3-stocks-2017-04-19", "https://www.nasdaq.com/articles/heres-real-reason-gilead-sciences-so-incredibly-cheap-2017-04-18", "https://www.nasdaq.com/articles/did-pharma-biotech-mas-pick-pace-q1-2017-04-18", "https://www.nasdaq.com/articles/3-reasons-gilead-sciences-better-dividend-stock-johnson-johnson-2017-04-21", "https://www.nasdaq.com/articles/health-care-sector-update-04212017-gildauphxbit-2017-04-21", "https://www.nasdaq.com/articles/novartis-nvs-q1-earnings%3A-will-the-stock-disappoint-2017-04-20", "https://www.nasdaq.com/articles/voo-bmy-gild-agn-large-inflows-detected-etf-2017-04-12", "https://www.nasdaq.com/articles/biotech-stock-roundup-geron-gains-interim-data-oncomed-slumps-pipeline-setback-2017-04-12", "https://www.nasdaq.com/articles/antipodes-partners-ltd-buys-united-states-natural-gas-fund-lp-gilead-sciences-baidu-2017", "https://www.nasdaq.com/articles/3-fire-sale-stocks-will-they-bounce-back-or-burn-you-2017-04-11", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-gild-agn-ba-2017-04-18", "https://www.nasdaq.com/articles/gilead-gild-hcv-drugs-gets-fda-nod-for-label-expansion-2017-04-10", "https://www.nasdaq.com/articles/3-best-hiv-drug-stocks-buy-2017-2017-04-09", "https://www.nasdaq.com/articles/would-gilead-sciences-make-staggeringly-audacious-move-2017-04-07", "https://www.nasdaq.com/articles/can-fallen-biotech-be-revived-2017-04-06", "https://www.nasdaq.com/articles/gilead-sciences-bull-bear-and-fence-sitter-2017-04-06", "https://www.nasdaq.com/articles/kmg-chemicals-gilead-sciences-stmicroelectronics-nv-lockheed-martin-and-aerovironment", "https://www.nasdaq.com/articles/bear-day-gilead-sciences-gild-2017-04-06", "https://www.nasdaq.com/articles/3-big-drugmakers-most-likely-buy-incyte-2017-04-11", "https://www.nasdaq.com/articles/gilead-gild-hcv-drugs-gets-fda-nod-for-label-expansion-2017-04-10", "https://www.nasdaq.com/articles/3-best-hiv-drug-stocks-buy-2017-2017-04-09", "https://www.nasdaq.com/articles/would-gilead-sciences-make-staggeringly-audacious-move-2017-04-07", "https://www.nasdaq.com/articles/can-fallen-biotech-be-revived-2017-04-06", "https://www.nasdaq.com/articles/gilead-sciences-bull-bear-and-fence-sitter-2017-04-06", "https://www.nasdaq.com/articles/kmg-chemicals-gilead-sciences-stmicroelectronics-nv-lockheed-martin-and-aerovironment", "https://www.nasdaq.com/articles/bear-day-gilead-sciences-gild-2017-04-06", "https://www.nasdaq.com/articles/3-big-drugmakers-most-likely-buy-incyte-2017-04-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-acorda-down-court-ruling-patent-challenge-celg-drug-2017-04-05", "https://www.nasdaq.com/articles/gilead-gild-up-4.3-since-earnings-report%3A-can-it-continue-2017-04-05", "https://www.nasdaq.com/articles/health-care-sector-update-04052017-srptgildneotunis-2017-04-05", "https://www.nasdaq.com/articles/biotech-stock-roundup-regeneron-tesaro-drugs-approved-vertex-scores-big-study-2017-03-29", "https://www.nasdaq.com/articles/3-drugmakers-boatloads-cash-spend-2017-03-29", "https://www.nasdaq.com/articles/3-least-risky-biotech-stocks-market-2017-03-28", "https://www.nasdaq.com/articles/6-reasons-gilead-sciences-could-be-worlds-most-perfect-stock-2017-04-03", "https://www.nasdaq.com/articles/ivw-hd-cmcsa-gild-large-inflows-detected-etf-2017-03-27", "https://www.nasdaq.com/articles/better-buy-celgene-corporation-vs-gilead-sciences-2017-03-27", "https://www.nasdaq.com/articles/3-top-dividend-stocks-selling-discount-spring-2017-03-27", "https://www.nasdaq.com/articles/best-case-scenario-gilead-sciences-inc-2017-03-24", "https://www.nasdaq.com/articles/why-teva-pharmaceutical-industries-ltd-adr-stock-has-staying-power-2017-03-23", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-nasdaq-biotechnology-index-gilead-valeant", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-down-repatha-data-nektar-surges-pain-results-2017-03-22", "https://www.nasdaq.com/articles/these-2-stocks-are-ridiculously-cheap-2017-03-28", "https://www.nasdaq.com/articles/is-valeant-pharmaceuticals-intl-inc-vrx-stock-worth-the-risk-2017-03-21", "https://www.nasdaq.com/articles/biotech-bull-making-comeback-2017-03-21", "https://www.nasdaq.com/articles/mylan-receives-tentative-approval-from-fda-for-hiv-therapy-2017-03-21", "https://www.nasdaq.com/articles/why-biotech-stock-gilead-gild-could-be-value-trap-2017-03-20", "https://www.nasdaq.com/articles/look-under-hood-bbh-has-12-upside-2017-03-20", "https://www.nasdaq.com/articles/3-stocks-are-ridiculously-cheap-right-now-2017-03-20", "https://www.nasdaq.com/articles/3-drug-stocks-some-highest-profit-margins-2017-03-17", "https://www.nasdaq.com/articles/my-3-worst-performing-stocks-and-why-i-still-own-them-2017-03-22", "https://www.nasdaq.com/articles/is-valeant-pharmaceuticals-intl-inc-vrx-stock-worth-the-risk-2017-03-21", "https://www.nasdaq.com/articles/biotech-bull-making-comeback-2017-03-21", "https://www.nasdaq.com/articles/mylan-receives-tentative-approval-from-fda-for-hiv-therapy-2017-03-21", "https://www.nasdaq.com/articles/3-reasons-why-gilead-sciences-will-buy-incyte-and-1-reason-why-it-wont-2017-03-15", "https://www.nasdaq.com/articles/forget-gilead-buy-these-small-cap-biotech-stocks-instead-2017-03-15", "https://www.nasdaq.com/articles/beginning-stock-portfolio-experiment-2017-03-15", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-vrtx-gild-hd-2017-03-17", "https://www.nasdaq.com/articles/sareptas-dmd-drug-launch-slow-whats-in-store-for-2017-2017-03-13", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-march-14-2017-2017-03-13", "https://www.nasdaq.com/articles/3-healthcare-stocks-are-looking-cheap-2017-03-12", "https://www.nasdaq.com/articles/which-biotech-best-dividend-stock-2017-03-11", "https://www.nasdaq.com/articles/ex-dividend-reminder-gilead-sciences-t-rowe-price-group-and-redwood-trust-2017-03-10", "https://www.nasdaq.com/articles/north-tide-capital-llc-buys-impax-laboratories-allergan-plc-accuray-sells-community-health", "https://www.nasdaq.com/articles/abbvie-stock-upgraded-what-you-need-know-2017-03-10", "https://www.nasdaq.com/articles/3-underdog-stocks-were-watching-closely-2017-03-13", "https://www.nasdaq.com/articles/will-gilead-sciences-net-270-million-windfall-2017-03-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-trump-tweet-hits-biotech-stocks-concert-gains-vertex-deal-2017-03-08", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-iyh-gild-agn-biib-2017-03-07", "https://www.nasdaq.com/articles/heres-why-best-yet-come-gilead-sciences-inc-2017-03-07", "https://www.nasdaq.com/articles/right-time-invest-biotech-stocks-2017-03-07", "https://www.nasdaq.com/articles/north-tide-capital-llc-buys-impax-laboratories-allergan-plc-accuray-sells-community-0", "https://www.nasdaq.com/articles/3-biotech-stocks-you-dont-have-babysit-2017-03-07", "https://www.nasdaq.com/articles/i-was-wrong-about-gilead-sciences-2017-03-09", "https://www.nasdaq.com/articles/should-you-buy-general-motors-company-gm-stock-3-pros-3-cons-2017-03-03", "https://www.nasdaq.com/articles/2-reasons-behind-sarepta-therapeutics-incs-69-february-jump-2017-03-03", "https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-sanofi-astrazeneca-novo-nordisk-gilead-sciences-and", "https://www.nasdaq.com/articles/biotech-etf-bbh-hits-new-52-week-high-2017-03-02", "https://www.nasdaq.com/articles/north-tide-capital-llc-buys-impax-laboratories-allergan-plc-accuray-sells-community-2", "https://www.nasdaq.com/articles/after-hours-most-active-mar-2-2017-ftr-v-ge-fig-xrx-hst-low-gild-disca-yhoo-qcom-cmcsa", "https://www.nasdaq.com/articles/sarepta-srpt-q4-loss-widens-sales-of-duchenne-drug-slow-2017-03-01", "https://www.nasdaq.com/articles/how-are-drug-prices-determined-2017-03-05", "https://www.nasdaq.com/articles/should-you-buy-general-motors-company-gm-stock-3-pros-3-cons-2017-03-03", "https://www.nasdaq.com/articles/jerome-dodson-adds-9-positions-4th-quarter-2017-03-01", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-inc-2017-02-27", "https://www.nasdaq.com/articles/north-tide-capital-llc-buys-impax-laboratories-allergan-plc-accuray-sells-community-1", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-now-2017-02-27", "https://www.nasdaq.com/articles/numeric-investors-llc-buys-gilead-sciences-microsoft-baxter-international-sells-facebook", "https://www.nasdaq.com/articles/carl-icahn-takes-aim-bristol-myers-squibb-2017-03-01", "https://www.nasdaq.com/articles/these-3-big-pharma-stocks-are-ridiculously-cheap-2017-02-26", "https://www.nasdaq.com/articles/voo-gild-hon-unp-large-inflows-detected-etf-2017-02-24", "https://www.nasdaq.com/articles/3-incredibly-cheap-biotech-stocks-2017-02-24", "https://www.nasdaq.com/articles/united-therapeutics-uthr-down-on-q4-earnings-sales-miss-2017-02-23", "https://www.nasdaq.com/articles/3-beaten-dividend-stocks-are-they-bargains-2017-02-22", "https://www.nasdaq.com/articles/biotech-stock-roundup-alexion-reports-4q-results-celgene-ms-drug-looks-promising-2017-02", "https://www.nasdaq.com/articles/north-tide-capital-llc-buys-impax-laboratories-allergan-plc-accuray-sells-community-3", "https://www.nasdaq.com/articles/3-stocks-are-ridiculously-cheap-right-now-2017-02-26", "https://www.nasdaq.com/articles/3-things-gilead-sciences-ceo-just-said-youll-want-know-2017-02-22", "https://www.nasdaq.com/articles/gilead-sciences-inc.-gild-stock-has-caught-a-cold-2017-02-21", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-tesla-volatility-index-and-gilead-2017-02-21", "https://www.nasdaq.com/articles/7-ultra-cheap-value-stocks-to-buy-now-2017-02-21", "https://www.nasdaq.com/articles/why-gilead-sciences-buy-2017-02-19", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-pfizer-inc-2017-02-18", "https://www.nasdaq.com/articles/thanks-martin-shkreli-dumbest-advice-ever-drug-pricing-2017-02-17", "https://www.nasdaq.com/articles/who-could-buy-bristol-myers-squibb-2017-02-22", "https://www.nasdaq.com/articles/3-things-gilead-sciences-ceo-just-said-youll-want-know-2017-02-22", "https://www.nasdaq.com/articles/gilead-sciences-inc.-gild-stock-has-caught-a-cold-2017-02-21", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-tesla-volatility-index-and-gilead-2017-02-21", "https://www.nasdaq.com/articles/7-ultra-cheap-value-stocks-to-buy-now-2017-02-21", "https://www.nasdaq.com/articles/why-gilead-sciences-buy-2017-02-19", "https://www.nasdaq.com/articles/drug-stocks-q4-earnings-slated-for-feb-16%3A-alxn-zts-more-2017-02-15", "https://www.nasdaq.com/articles/investors-are-betting-big-against-intercept-pharmaceuticals-are-they-wrong-2017-02-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-regenerons-praluent-remain-market-now-gild-presents-hiv-data-2017-02", "https://www.nasdaq.com/articles/could-blockbuster-cannabis-drug-be-way-gild-gwph-2017-02-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-celgene-fate-therapeutics-exelixis-and", "https://www.nasdaq.com/articles/tuesdays-vital-data%3A-tesla-inc-tsla-gilead-sciences-inc.-gild-and-microsoft-corporation", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-february-15-2017-2017-02-14", "https://www.nasdaq.com/articles/north-tide-capital-llc-buys-impax-laboratories-allergan-plc-accuray-sells-community-4", "https://www.nasdaq.com/articles/why-i-just-bought-more-shares-gilead-sciences-inc-2017-02-14", "https://www.nasdaq.com/articles/two-sigma-advisers-llc-buys-cisco-systems-medtronic-plc-oracle-sells-amazon-2017-02-15", "https://www.nasdaq.com/articles/gilead-gild-announces-data-on-combination-therapy-for-hiv-2017-02-14", "https://www.nasdaq.com/articles/drug-stocks-earnings-slated-for-feb-14%3A-incy-prta-more-2017-02-13", "https://www.nasdaq.com/articles/forget-gilead-buy-these-5-biotech-stocks-instead-2017-02-13", "https://www.nasdaq.com/articles/notable-monday-option-activity-gs-gild-de-2017-02-13", "https://www.nasdaq.com/articles/better-buy-illumina-or-gilead-sciences-2017-02-13", "https://www.nasdaq.com/articles/gilead-sciences-getting-ready-massive-acquisition-2017-02-12", "https://www.nasdaq.com/articles/gilead-sciences-fossil-reach-3-year-low-prices-2017-02-12", "https://www.nasdaq.com/articles/3-stocks-were-watching-first-quarter-2017-02-14", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-13-2017-2017-02-10", "https://www.nasdaq.com/articles/biotech-etfs-powered-q4-earnings-2017-02-10", "https://www.nasdaq.com/articles/dont-panic-gilead-sciences-really-isnt-value-trap-2017-02-09", "https://www.nasdaq.com/articles/thursdays-etf-unusual-volume-lrgf-2017-02-09", "https://www.nasdaq.com/articles/nasdaq-100-movers-mchp-viab-2017-02-09", "https://www.nasdaq.com/articles/zacks-market-edge-highlights%3A-health-care-spdr-etf-ishares-nasdaq-biotechnology-etf-acadia", "https://www.nasdaq.com/articles/thursdays-vital-data%3A-apple-inc.-aapl-gilead-sciences-inc.-gild-and-advanced-micro-devices", "https://www.nasdaq.com/articles/why-intercept-pharmaceuticals-latest-news-caused-stock-jump-2017-02-11", "https://www.nasdaq.com/articles/holowesko-partners-ltd-buys-wells-fargo-gilead-sciences-pultegroup-sells-citizens", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-stock-tumbles-dismal-guidance-2017-02-08", "https://www.nasdaq.com/articles/3-big-stock-charts-for-wednesday%3A-gilead-sciences-inc.-gild-ak-steel-holding-corporation", "https://www.nasdaq.com/articles/gilead-sciences-just-lost-9-billion-market-value-heres-why-2017-02-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-akam-mchp-2017-02-08", "https://www.nasdaq.com/articles/sp-500-movers-akam-mchp-2017-02-08", "https://www.nasdaq.com/articles/gilead-gild-beats-q4-earnings-sales-view-disappoints-2017-02-08", "https://www.nasdaq.com/articles/gilds-strong-dividend-history-helps-it-reach-top-dividend-stock-nasdaq-100-2017-02-09", "https://www.nasdaq.com/articles/pre-market-most-active-feb-8-2017-pe-gild-amc-twtr-fcau-bac-tvix-rio-qqq-ctsh-mchp-gmlp", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-gilead-report-4q-results-ariad-seeks-eu-nod-brigatinib-2017-02", "https://www.nasdaq.com/articles/why-gilead-sciences-zillow-group-and-parsley-energy-slumped-today-2017-02-08", "https://www.nasdaq.com/articles/why-gilead-sciences-inc.-gild-zillow-group-inc.-z-and-akamai-technologies-inc.-akam-are-3", "https://www.nasdaq.com/articles/5-things-gilead-sciences-management-said-its-stock-slumped-2017-02-08", "https://www.nasdaq.com/articles/why-gilead-sciences-stock-slumped-today-2017-02-08", "https://www.nasdaq.com/articles/daily-dividend-report-mmm-gild-alk-twx-syk-psx-ir-rcl-clx-2017-02-08", "https://www.nasdaq.com/articles/gilead-sciences-just-shocked-investors-and-it-wasnt-good-2017-02-08", "https://www.nasdaq.com/articles/3-attractive-income-stocks-whose-dividends-could-double-2017-02-07", "https://www.nasdaq.com/articles/gilead-sciences-inc-reports-q4-earnings-decline-and-worsening-outlook-2017-2017-02-07", "https://www.nasdaq.com/articles/gilead-sciences-posts-q4-earnings-beat-slumps-weak-guidance-2017-02-07", "https://www.nasdaq.com/articles/after-hours-most-active-feb-7-2017-bac-fcx-gild-scor-ge-msft-qqq-teva-hban-t-twlo-mtch", "https://www.nasdaq.com/articles/spot-trading-llc-buys-gilead-sciences-allergan-plc-bristol-myers-squibb-company-sells-spdr", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-7-2017-dis-gild-mdlz-pxd-orly-mchp-paa-akam-ato-cpt", "https://www.nasdaq.com/articles/vlue-gm-wmt-gild-etf-inflow-alert-2017-02-07", "https://www.nasdaq.com/articles/3-healthcare-tickers-that-will-return-profits-in-3-months-2017-02-06", "https://www.nasdaq.com/articles/drug-stocks-reporting-earnings-on-feb-7%3A-gild-mnk-more-2017-02-06", "https://www.nasdaq.com/articles/3-crucial-questions-gilead-sciences-should-answer-tuesday-2017-02-05", "https://www.nasdaq.com/articles/gilead-sciences-gild-q4-earnings%3A-whats-in-the-cards-2017-02-03", "https://www.nasdaq.com/articles/8-value-stocks-buy-sp-500-2017-02-02", "https://www.nasdaq.com/articles/3-dividend-stocks-biggest-revenue-growth-over-past-10-years-2017-02-02", "https://www.nasdaq.com/articles/these-3-biotech-stocks-are-ridiculously-cheap-2017-02-01", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-636-follow-through-indicator-40-sensitive", "https://www.nasdaq.com/articles/gilead-sciences-top-25-dividend-giant-263-yield-gild-2017-01-31", "https://www.nasdaq.com/articles/was-unquestionably-most-disappointing-drug-launch-2016-2017-01-31", "https://www.nasdaq.com/articles/3-critical-things-watch-gilead-sciences-q4-results-2017-01-31", "https://www.nasdaq.com/articles/key-takeaways-abbvies-q4-call-humira-and-pipeline-2017-01-30", "https://www.nasdaq.com/articles/why-youre-right-invest-gilead-sciences-stock-2017-01-30", "https://www.nasdaq.com/articles/single-most-important-number-gilead-sciences-2017-01-29", "https://www.nasdaq.com/articles/3-companies-putting-squeeze-bristol-myers-squibb-2017-01-27", "https://www.nasdaq.com/articles/15-best-short-term-stock-investments-2017-01-31", "https://www.nasdaq.com/articles/3-healthcare-stocks-to-buy-despite-trumps-bluster-2017-01-27", "https://www.nasdaq.com/articles/3-reasons-gilead-sciences-inc-stock-could-rise-2017-01-26", "https://www.nasdaq.com/articles/3-top-stocks-you-can-buy-sale-2017-01-25", "https://www.nasdaq.com/articles/forget-incyte-gilead-sciences-would-be-better-buying-company-2017-01-25", "https://www.nasdaq.com/articles/biotech-stock-roundup-synergy-drug-gets-fda-nod-abbvie-gild-hcv-drugs-under-eu-review-2017", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-now-2017-01-25", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-mtb-cma-gild-2017-01-25", "https://www.nasdaq.com/articles/3-most-unbelievably-undervalued-biotech-stocks-2017-01-27", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-inc-2017-01-24", "https://www.nasdaq.com/articles/gilead-sciences-stock-what-could-go-wrong-2017-01-24", "https://www.nasdaq.com/articles/can-q4-earnings-revitalize-healthcare-etfs-2017-01-23", "https://www.nasdaq.com/articles/has-gilead-sciences-cash-cow-finally-hit-bottom-2017-01-23", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-stock-great-value-investors-2017-01-23", "https://www.nasdaq.com/articles/gilead-gild-hcv-therapy-application-validated-in-europe-2017-01-23", "https://www.nasdaq.com/articles/incyte-has-insight-market-potential-blockbuster-drugs-2017-01-23", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-and-hold-stress-free-2017-01-24", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-inc-2017-01-24", "https://www.nasdaq.com/articles/gilead-sciences-stock-what-could-go-wrong-2017-01-24", "https://www.nasdaq.com/articles/is-gilead-sciences-gild-a-great-stock-for-value-investors-2017-01-20", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-las-vegas-sands-illinois-tool-works", "https://www.nasdaq.com/articles/are-you-undervaluing-these-3-biopharmas-pipelines-2017-01-20", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-vlue-gm-gild-f-2017-01-19", "https://www.nasdaq.com/articles/cabot-wellington-llc-buys-ishares-core-msci-eafe-vanguard-total-stock-market-sells-ishares", "https://www.nasdaq.com/articles/these-3-healthcare-stocks-are-ridiculously-cheap-2017-01-18", "https://www.nasdaq.com/articles/value-investing-2017-3-stocks-put-your-radar-2017-01-18", "https://www.nasdaq.com/articles/agree-buy-gilead-sciences-55-earn-44-using-options-2017-01-17", "https://www.nasdaq.com/articles/3-bargain-stocks-buy-now-2017-01-17", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-gild-q-axp-2017-01-17", "https://www.nasdaq.com/articles/donald-trump-big-pharmas-worst-nightmare-2017-01-15", "https://www.nasdaq.com/articles/should-investors-bet-gilead-sciences-version-30-2017-01-14", "https://www.nasdaq.com/articles/4-top-biotech-mutual-funds-for-2017-2017-01-18", "https://www.nasdaq.com/articles/stock-market-news-for-january-12-2017-2017-01-12", "https://www.nasdaq.com/articles/is-the-options-market-predicting-a-spike-in-gilead-sciences-gild-stock-2017-01-12", "https://www.nasdaq.com/articles/gilead-gild-hbv-drug-vemlidy-receives-european-approval-2017-01-12", "https://www.nasdaq.com/articles/waverton-investment-management-ltd-buys-wells-fargo-co-us-bancorp-baidu-inc-sells-2017-01", "https://www.nasdaq.com/articles/stumbling-biotech-stock-still-has-lot-promise-2017-01-11", "https://www.nasdaq.com/articles/should-you-buy-amgen-inc.-amgn-stock-3-pros-3-cons-2017-01-11", "https://www.nasdaq.com/articles/stock-market-roundup-jan-11-health-sector-lower-trump-murder-comment-2017-01-11", "https://www.nasdaq.com/articles/donald-trump-just-leveled-drug-companies-these-4-words-2017-01-14", "https://www.nasdaq.com/articles/why-ariad-pharmaceuticals-stock-soared-today-2017-01-09", "https://www.nasdaq.com/articles/top-biotech-resolutions-2017-2017-01-09", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-tqqq-amgn-khc-gild-2017-01-09", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-pepsi-united-parcel-services-twitter", "https://www.nasdaq.com/articles/2017-jp-morgan-healthcare-conference-roundup-2017-01-09", "https://www.nasdaq.com/articles/10-worst-stocks-nasdaq-2016-2017-01-09", "https://www.nasdaq.com/articles/4-things-gilead-sciences-ceo-says-expect-2017-2017-01-09", "https://www.nasdaq.com/articles/solution-gilead-sciences-woes-2017-01-10", "https://www.nasdaq.com/articles/what-if-you-considered-gilead-sciences-start-2017-01-07", "https://www.nasdaq.com/articles/biotech-investing-3-bold-predictions-2017-2017-01-06", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-apc-kite-gild-2017-01-06", "https://www.nasdaq.com/articles/5-stocks-to-buy-for-enterprise-investors-2017-01-05", "https://www.nasdaq.com/articles/why-gilead-sciences-lost-staggering-292-2016-2017-01-05", "https://www.nasdaq.com/articles/gilead-sciences-must-answer-investors-after-disappointing-2016-2017-01-05", "https://www.nasdaq.com/articles/gilead-sciences-incs-biggest-failure-2016-2017-01-05", "https://www.nasdaq.com/articles/kempner-capital-management-inc-buys-xl-group-ltd-teva-pharmaceutical-industries-ltd-gilead", "https://www.nasdaq.com/articles/biogen-playing-fire-2017-01-04", "https://www.nasdaq.com/articles/forget-gilead-sciences-inc-these-2-stocks-doubled-last-year-2017-01-02", "https://www.nasdaq.com/articles/biotech-stocks-what-watch-2017-2017-01-01", "https://www.nasdaq.com/articles/united-therapeutics-pah-suite-bodes-well-competition-rife-2016-12-29", "https://www.nasdaq.com/articles/2-incredibly-cheap-dividend-stocks-2016-12-28", "https://www.nasdaq.com/articles/will-2017-be-gilead-sciences-incs-worst-year-yet-2016-12-25", "https://www.nasdaq.com/articles/3-great-income-stocks-could-double-their-dividends-2016-12-24", "https://www.nasdaq.com/articles/stock-market-news-for-january-04-2017-2017-01-04", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-amgn-khc-gild-2016-12-22", "https://www.nasdaq.com/articles/will-2017-be-gilead-sciences-incs-worst-year-yet-2016-12-22", "https://www.nasdaq.com/articles/10-best-stocks-for-retirement-investors-2016-12-22", "https://www.nasdaq.com/articles/biotech-stock-roundup-conatus-soars-novartis-deal-early-fda-nod-clovis-drug-2016-12-21", "https://www.nasdaq.com/articles/5-steps-buying-biotech-stocks-2016-12-21", "https://www.nasdaq.com/articles/health-care-sector-update-12212016-alxngildmrusincymack-2016-12-21", "https://www.nasdaq.com/articles/forget-gilead-sciences-inc-these-3-stocks-are-better-buys-2016-12-21", "https://www.nasdaq.com/articles/most-likely-incyte-acquisition-deal-2017-2016-12-23", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-trip-2016-12-20", "https://www.nasdaq.com/articles/gilead-sciences-has-bought-back-10-billion-stock-2016-should-investors-be-happy-2016-12-20", "https://www.nasdaq.com/articles/3-incredibly-cheap-biotech-stocks-2016-12-20", "https://www.nasdaq.com/articles/could-gilead-sciences-game-changing-hiv-pill-solve-its-growth-problem-2016-12-19", "https://www.nasdaq.com/articles/12-greatest-medical-breakthroughs-2016-2016-12-18", "https://www.nasdaq.com/articles/most-expensive-drugs-2016-2016-12-18", "https://www.nasdaq.com/articles/3-small-biotech-stocks-big-biotechs-2016-12-18", "https://www.nasdaq.com/articles/2-great-stocks-you-can-buy-sale-2016-12-20", "https://www.nasdaq.com/articles/gilead-sciences-biggest-mistake-2016-2016-12-16", "https://www.nasdaq.com/articles/gilead-to-pay-merck-%242.5b-in-hcv-patent-dispute-stock-falls-2016-12-16", "https://www.nasdaq.com/articles/why-abbvie-inc-abbv-stock-is-still-a-long-term-winner-2016-12-16", "https://www.nasdaq.com/articles/gilead-sciences-year-officially-becomes-superbad-2016-12-16", "https://www.nasdaq.com/articles/gilead-sciences-incs-best-moves-2016-2016-12-15", "https://www.nasdaq.com/articles/how-risky-gilead-sciences-inc-2016-12-15", "https://www.nasdaq.com/articles/xlv-amgn-abbv-gild-etf-outflow-alert-2016-12-14", "https://www.nasdaq.com/articles/could-these-2-small-biotechs-beat-allergan-and-gilead-sciences-2016-12-17", "https://www.nasdaq.com/articles/gilead-sciences-biggest-mistake-2016-2016-12-16", "https://www.nasdaq.com/articles/gilead-to-pay-merck-%242.5b-in-hcv-patent-dispute-stock-falls-2016-12-16", "https://www.nasdaq.com/articles/3-beaten-cheap-stocks-are-they-bargains-2016-12-13", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-sale-2016-12-13", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-amgen-inc-2016-12-13", "https://www.nasdaq.com/articles/3-cheap-healthcare-stocks-you-can-buy-right-now-2016-12-12", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-medtronic-nvidia-accenture-and-simon", "https://www.nasdaq.com/articles/biotech-stock-roundup-ophthotech-slumps-fovista-results-achaogen-skyrockets-data-2016-12", "https://www.nasdaq.com/articles/3-most-profit-friendly-biotech-stocks-2016-12-12", "https://www.nasdaq.com/articles/how-gilead-sciences-inc-could-pay-you-30000-year-retirement-2016-12-11", "https://www.nasdaq.com/articles/after-hours-most-active-dec-9-2016-v-pbct-hpe-ifgl-fosl-pcar-cat-bac-mt-sxl-msft-gild-2016", "https://www.nasdaq.com/articles/top-research-reports-nvidia-medtronic-gilead-sciences-2016-12-09", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-xlv-mrk-amgn-gild-2016-12-06", "https://www.nasdaq.com/articles/gilead-sciences-incs-worst-moves-2016-2016-12-06", "https://www.nasdaq.com/articles/gilead-sciences-incs-10-billion-mistake-2016-12-01", "https://www.nasdaq.com/articles/3-biotech-buybacks-biggest-bang-buck-2016-12-12", "https://www.nasdaq.com/articles/trade-day-gilead-sciences-inc-gild-stock-looks-bargain-2016-11-30", "https://www.nasdaq.com/articles/5-things-gilead-sciences-ceo-just-said-you-need-know-2016-11-30", "https://www.nasdaq.com/articles/questions-gabriele-grego-2016-11-26", "https://www.nasdaq.com/articles/jj-jnj-reportedly-approaches-actelion-for-acquisition-2016-11-25", "https://www.nasdaq.com/articles/worst-growth-dividend-stocks-2016-2016-11-23", "https://www.nasdaq.com/articles/3-inexpensive-top-stocks-youve-overlooked-fall-2016-11-23", "https://www.nasdaq.com/articles/galapagos-glpg-filgotinib-in-phase-iii-for-crohns-disease-2016-11-23", "https://www.nasdaq.com/articles/the-10-best-healthcare-stocks-to-buy-for-2017-2016-12-01", "https://www.nasdaq.com/articles/trade-day-gilead-sciences-inc-gild-stock-looks-bargain-2016-11-30", "https://www.nasdaq.com/articles/5-things-gilead-sciences-ceo-just-said-you-need-know-2016-11-30", "https://www.nasdaq.com/articles/questions-gabriele-grego-2016-11-26", "https://www.nasdaq.com/articles/attention-biotech-investors-black-friday-already-here-2016-11-21", "https://www.nasdaq.com/articles/no-1-healthcare-concern-americans-want-donald-trump-fix-and-its-not-obamacare-2016-11-20", "https://www.nasdaq.com/articles/5-most-expensive-medicare-drugs-and-which-companies-are-getting-rich-them-2016-11-20", "https://www.nasdaq.com/articles/3-embarrassingly-cheap-dividend-stocks-2016-11-18", "https://www.nasdaq.com/articles/when-will-gilead-sciences-unlucky-streak-end-2016-11-23", "https://www.nasdaq.com/articles/gilead-reports-phase-iii-myelofibrosis-data-on-momelotinib-2016-11-17", "https://www.nasdaq.com/articles/3-beaten-down-biotech-stocks-to-buy-for-huge-gains-2016-11-17", "https://www.nasdaq.com/articles/bad-news-gilead-sciences-good-news-incyte-2016-11-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-biotech-stocks-soar-election-results-gilead-hbv-drug-approved-2016", "https://www.nasdaq.com/articles/3-potential-acquisition-targets-gilead-sciences-inc-2016-11-16", "https://www.nasdaq.com/articles/3-biotech-etfs-for-decades-of-big-returns-2016-11-15", "https://www.nasdaq.com/articles/4-biotech-stocks-to-buy-after-clintons-defeat-2016-11-14", "https://www.nasdaq.com/articles/does-gilead-sciences-pass-warren-buffetts-test-2016-11-17", "https://www.nasdaq.com/articles/mercks-triple-combination-hcv-therapy-positive-in-phase-iii-2016-11-14", "https://www.nasdaq.com/articles/gilead-gild-hbv-drug-vemlidy-gets-positive-chmp-opinion-2016-11-14", "https://www.nasdaq.com/articles/should-biopharma-companies-buy-innovation-2016-11-13", "https://www.nasdaq.com/articles/3-drugmakers-probably-have-lower-tax-rates-you-do-2016-11-13", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-november-14-2016-2016-11-11", "https://www.nasdaq.com/articles/drug-stocks-q3-earnings-to-watch-on-nov-14%3A-args-ast-2016-11-11", "https://www.nasdaq.com/articles/xlv-jnj-gild-biib-etf-inflow-alert-2016-11-10", "https://www.nasdaq.com/articles/these-3-stocks-are-undeniably-cheap-2016-11-14", "https://www.nasdaq.com/articles/peek-into-drug-stocks-q3-earnings-on-nov-11%3A-xbit-reph-2016-11-10", "https://www.nasdaq.com/articles/how-donald-trump-presidency-could-affect-biotech-stocks-2016-11-09", "https://www.nasdaq.com/articles/donald-trump-presidency-black-swan-event-pharma-stocks-2016-11-09", "https://www.nasdaq.com/articles/drug-stocks-q3-earnings-roster-for-nov-10%3A-avxs-gbt-bpmc-2016-11-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-ionis-soars-spinraza-data-regenerons-q3-results-mixed-2016-11-09", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-pfizer-inc-2016-11-09", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-exxonmobil-gilead-duke-energy-nvidia-and-monster", "https://www.nasdaq.com/articles/5-top-biotech-stocks-buy-trump-victory-2016-11-10", "https://www.nasdaq.com/articles/why-gilead-sciences-shares-fell-7-october-2016-11-08", "https://www.nasdaq.com/articles/biotech-etfs-slumping-on-q3-results-2016-11-08", "https://www.nasdaq.com/articles/top-research-reports-exxon-duke-gilead-2016-11-07", "https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-amgen-vertex-valeant-pharmaceuticals-international", "https://www.nasdaq.com/articles/3-best-healthcare-stocks-buy-now-2016-11-07", "https://www.nasdaq.com/articles/2-reasons-why-ishares-nasdaq-biotechnology-index-etf-tumbled-11-october-2016-11-07", "https://www.nasdaq.com/articles/3-best-biotech-stocks-21st-century-so-far-2016-11-06", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-november-09-2016-2016-11-08", "https://www.nasdaq.com/articles/drug-stocks-earnings-roster-for-nov-7%3A-hznp-acad-more-2016-11-04", "https://www.nasdaq.com/articles/after-hours-most-active-nov-4-2016-glw-bac-bhi-aks-evdy-ge-msft-ctsh-txn-aapl-qcom-gild", "https://www.nasdaq.com/articles/fridays-etf-unusual-volume-bbh-2016-11-04", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-vug-pm-orcl-gild-2016-11-03", "https://www.nasdaq.com/articles/company-news-for-november-03-2016-2016-11-03", "https://www.nasdaq.com/articles/drug-stocks-to-watch-for-earnings-on-nov-4-regn-more-2016-11-03", "https://www.nasdaq.com/articles/thursdays-vital-data%3A-facebook-inc-fb-alibaba-group-holdings-ltd-baba-and-gilead-sciences", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-allergan-gilead-sciences-pfizer-regeneron", "https://www.nasdaq.com/articles/5-things-gilead-sciences-management-said-after-its-earnings-plummet-2016-11-03", "https://www.nasdaq.com/articles/why-celgene-corp-better-buy-gilead-sciences-2016-11-03", "https://www.nasdaq.com/articles/gilead-gild-misses-q3-earnings-estimates-retains-view-2016-11-02", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-wednesday%3A-square-inc-sq-gilead-sciences-inc.-gild-and-electronic", "https://www.nasdaq.com/articles/gilead-sciences-inc-hepatitis-c-sales-sink-again-q3-2016-11-02", "https://www.nasdaq.com/articles/drug-stocks-q3-earnings-roster-for-nov-3-icpt-exel-akrx-2016-11-02", "https://www.nasdaq.com/articles/gileads-q3-bombshell-no-more-hepatitis-c-rd-2016-11-02", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-down-enbrel-sales-regenerons-sarilumab-faces-delay-2016-11-03", "https://www.nasdaq.com/articles/abbvies-stock-suffering-lack-diversification-2016-11-01", "https://www.nasdaq.com/articles/why-were-right-invest-gilead-sciences-stock-2016-11-01", "https://www.nasdaq.com/articles/gilead-gild-misses-q3-earnings-reiterates-2016-guidance-2016-11-01", "https://www.nasdaq.com/articles/after-hours-most-active-nov-1-2016-yumc-qcp-aa-ges-bac-csco-pfe-aapl-intc-ment-msft-gild", "https://www.nasdaq.com/articles/the-3-best-stocks-to-buy-before-nov.-8-2016-11-01", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-600-follow-through-indicator-42-sensitive", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-1-2016-gild-pxd-eix-ea-ilmn-dvn-cern-es-flt-nbl-sbac", "https://www.nasdaq.com/articles/daily-dividend-report-el-rok-hii-cdw-gild-2016-11-02", "https://www.nasdaq.com/articles/these-companies-make-millions-per-employee-and-yield-up-to-13-2016-10-31", "https://www.nasdaq.com/articles/40-billion-opportunity-3-biotechs-poised-dominate-2016-10-31", "https://www.nasdaq.com/articles/genetic-stocks-to-watch-for-earnings-on-nov-1%3A-gild-more-2016-10-31", "https://www.nasdaq.com/articles/your-two-minute-earnings-preview-gilead-gild-stock-2016-10-31", "https://www.nasdaq.com/articles/9-shiny-new-dividend-stocks-you-can-trust-in-the-long-run-2016-10-31", "https://www.nasdaq.com/articles/unfazed-fda-warning-gilead-sciences-stock-could-be-turning-corner-2016-10-29", "https://www.nasdaq.com/articles/3-things-abbvies-management-said-while-its-stock-got-hammered-2016-10-29", "https://www.nasdaq.com/articles/best-options-trade-gilead-sciences-gild-earnings-2016-10-31", "https://www.nasdaq.com/articles/these-companies-make-millions-per-employee-and-yield-up-to-13-2016-10-31", "https://www.nasdaq.com/articles/40-billion-opportunity-3-biotechs-poised-dominate-2016-10-31", "https://www.nasdaq.com/articles/genetic-stocks-to-watch-for-earnings-on-nov-1%3A-gild-more-2016-10-31", "https://www.nasdaq.com/articles/your-two-minute-earnings-preview-gilead-gild-stock-2016-10-31", "https://www.nasdaq.com/articles/global-blood-therapeutics-incredible-value-price-2016-10-26", "https://www.nasdaq.com/articles/biotech-stock-roundup-clinical-holds-hit-inovio-aduro-vertex-q3-results-miss-estimates", "https://www.nasdaq.com/articles/make-valeant-pharmaceuticals-intl-inc-vrx-stock-pay-you-2016-10-28", "https://www.nasdaq.com/articles/3-key-questions-gilead-sciences-inc-q3-2016-10-26", "https://www.nasdaq.com/articles/ivw-dis-ma-gild-etf-inflow-alert-2016-10-25", "https://www.nasdaq.com/articles/4-top-drug-stocks-can-be-purchased-cheap-fall-2016-10-25", "https://www.nasdaq.com/articles/healthcare-etfs-gain-or-pain-ahead-q3-earnings-2016-10-24", "https://www.nasdaq.com/articles/best-and-worst-biotech-etfs-2016-tell-tale-about-industry-2016-10-21", "https://www.nasdaq.com/articles/nothing-can-stop-merck-co.-inc.-mrk-stock-now-2016-10-20", "https://www.nasdaq.com/articles/better-buy-pfizer-inc-vs-glaxosmithkline-plc-2016-10-20", "https://www.nasdaq.com/articles/gilead-sciences-gild-q3-earnings%3A-stock-to-disappoint-2016-10-26", "https://www.nasdaq.com/articles/41-billion-reasons-why-gilead-sciences-might-need-new-management-2016-10-19", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-inc-2016-10-18", "https://www.nasdaq.com/articles/3-top-bargain-stocks-buy-today-2016-10-17", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-ivw-dis-gild-ma-2016-10-17", "https://www.nasdaq.com/articles/3-top-stocks-buy-your-grandchildrens-benefit-2016-10-17", "https://www.nasdaq.com/articles/any-bank-stocks-you-can-trust-2016-10-14", "https://www.nasdaq.com/articles/contravir-pharmaceuticals-stock-jumps-positive-results-hepatitis-b-drug-trial-2016-10-13", "https://www.nasdaq.com/articles/gilead-sciences-bar-set-low-enough-beat-2016-10-20", "https://www.nasdaq.com/articles/gilead-sciences-inc.-is-more-than-an-hcv-play-gild-2016-10-12", "https://www.nasdaq.com/articles/mercks-new-products-and-solid-pipeline-as-growth-drivers-2016-10-11", "https://www.nasdaq.com/articles/7-stocks-the-2016-presidential-candidates-have-called-out-by-name-2016-10-11", "https://www.nasdaq.com/articles/will-gilead-sciences-inc-set-its-sights-incyte-2016-10-10", "https://www.nasdaq.com/articles/after-hours-most-active-oct-10-2016-mu-pg-qqq-twtr-fb-yhoo-qcom-cpn-gild-ko-oln-mtg-2016", "https://www.nasdaq.com/articles/big-reason-you-shouldnt-give-big-cap-biotech-2016-10-08", "https://www.nasdaq.com/articles/steven-cohen-increases-position-dynavax-2016-10-07", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-wednesday%3A-barracuda-networks-inc-cuda-blackhawk-network-holdings-inc", "https://www.nasdaq.com/articles/biotech-stock-roundup-summit-soars-sarepta-deal-regeneron-presents-data-2016-10-05", "https://www.nasdaq.com/articles/fda-issues-warning-hepatitis-c-drugs-2016-10-05", "https://www.nasdaq.com/articles/how-yieldboost-gild-82-using-options-2016-10-04", "https://www.nasdaq.com/articles/nope-gilead-sciences-wont-get-bought-out-2016-10-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-ntap-ctsh-2016-10-03", "https://www.nasdaq.com/articles/gilead-sciences-pain-celgenes-gain-2016-10-03", "https://www.nasdaq.com/articles/7-stocks-that-could-be-bought-next-2016-10-03", "https://www.nasdaq.com/articles/gilead-sciences-should-absolutely-not-split-2016-10-06", "https://www.nasdaq.com/articles/hey-gilead-its-time-start-looking-over-your-shoulder-hepatitis-c-2016-09-30", "https://www.nasdaq.com/articles/nonalcoholic-steatohepatitis-whats-market-opportunity-and-who-are-major-players-2016-09-29", "https://www.nasdaq.com/articles/nonalcoholic-steatohepatitis-nash-whats-market-opportunity-and-who-are-major-players-2016", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgens-kyprolis-disappoints-array-cancer-data-2016-09-28", "https://www.nasdaq.com/articles/xlv-amgn-mdt-gild-etf-inflow-alert-2016-09-27", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-nclh-2016-09-27", "https://www.nasdaq.com/articles/5-safe-stocks-buy-today-2016-09-27", "https://www.nasdaq.com/articles/3-healthcare-stocks-could-raise-their-dividends-2016-10-01", "https://www.nasdaq.com/articles/why-cash-king-biotech-stocks-2016-09-27", "https://www.nasdaq.com/articles/tuesdays-etf-unusual-volume-iwy-2016-09-27", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-deutsche-bank-apple-therapeutics-allergan-and-gilead", "https://www.nasdaq.com/articles/tiny-company-best-pharmacy-stock-buy-2016-09-24", "https://www.nasdaq.com/articles/3-dirt-cheap-dividend-stocks-you-can-buy-right-now-2016-09-24", "https://www.nasdaq.com/articles/cheapest-stocks-biotech-2016-09-23", "https://www.nasdaq.com/articles/pros-and-cons-buying-gilead-sciences-stock-2016-09-22", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-530571-4822-points-2016-09-27", "https://www.nasdaq.com/articles/is-galectin-the-next-takeover-target-for-the-biotech-world-2016-09-22", "https://www.nasdaq.com/articles/gilead-sciences-incs-biggest-win-2016-so-far-2016-09-22", "https://www.nasdaq.com/articles/stock-market-news-for-september-21-2016-2016-09-21", "https://www.nasdaq.com/articles/trade-of-the-day%3A-ishares-nasdaq-biotechnology-index-etf-ibb-is-turning-things-around-2016", "https://www.nasdaq.com/articles/allergan-buys-nash-therapy-maker-tobira-at-huge-premium-2016-09-21", "https://www.nasdaq.com/articles/how-safe-gilead-sciences-inc-and-its-dividend-2016-09-20", "https://www.nasdaq.com/articles/after-hours-most-active-sep-20-2016-gild-hpq-qqq-csco-symc-intc-yhoo-vz-hes-evhc-bac-pot", "https://www.nasdaq.com/articles/gilead-to-stop-gs-5745-development-for-ulcerative-colitis-2016-09-22", "https://www.nasdaq.com/articles/after-hours-most-active-sep-20-2016-gild-hpq-qqq-csco-symc-intc-vz-yhoo-hes-evhc-pot-pg", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-mdt-gild-abbv-2016-09-19", "https://www.nasdaq.com/articles/how-risky-gilead-sciences-inc-2016-09-18", "https://www.nasdaq.com/articles/5-undervalued-stocks-to-buy-for-enterprising-value-investors-2016-09-16", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-total-oracle-and-gilead-sciences-2016-09-15", "https://www.nasdaq.com/articles/new-oracle-gilead-sciences-total-research-reports-2016-09-14", "https://www.nasdaq.com/articles/biotech-stock-roundup-horizon-raptor-acquisition-deal-geron-down-pipeline-news-2016-09-14", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-524135-632-points-2016-09-20", "https://www.nasdaq.com/articles/after-hours-most-active-sep-20-2016-gild-hpq-qqq-csco-symc-intc-vz-yhoo-hes-evhc-pot-pg", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-mdt-gild-abbv-2016-09-19", "https://www.nasdaq.com/articles/how-risky-gilead-sciences-inc-2016-09-18", "https://www.nasdaq.com/articles/5-undervalued-stocks-to-buy-for-enterprising-value-investors-2016-09-16", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-total-oracle-and-gilead-sciences-2016-09-15", "https://www.nasdaq.com/articles/new-oracle-gilead-sciences-total-research-reports-2016-09-14", "https://www.nasdaq.com/articles/buy-gilead-sciences-42-profit-what-you-need-know-2016-09-12", "https://www.nasdaq.com/articles/youll-never-guess-which-pharma-could-knock-gilead-sciences-its-hiv-throne-2016-09-14", "https://www.nasdaq.com/articles/two-things-you-must-understand-about-biotech-investing-2016-09-11", "https://www.nasdaq.com/articles/the-perfect-defensive-stock-for-this-joyless-bull-market-jnj-2016-09-09", "https://www.nasdaq.com/articles/hillary-clintons-new-prescription-drug-proposal-takes-aim-valeant-pharmaceuticals-and", "https://www.nasdaq.com/articles/7-good-stocks-buy-while-they-are-down-2016-09-08", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-2016-09-08", "https://www.nasdaq.com/articles/2-stocks-better-dividends-cvs-health-corporation-2016-09-08", "https://www.nasdaq.com/articles/zeke-ashton-invests-new-holdings-2016-09-08", "https://www.nasdaq.com/articles/could-save-medicare-least-16-billion-year-agency-barred-doing-it-2016-09-11", "https://www.nasdaq.com/articles/two-things-you-must-understand-about-biotech-investing-2016-09-11", "https://www.nasdaq.com/articles/the-perfect-defensive-stock-for-this-joyless-bull-market-jnj-2016-09-09", "https://www.nasdaq.com/articles/hillary-clintons-new-prescription-drug-proposal-takes-aim-valeant-pharmaceuticals-and", "https://www.nasdaq.com/articles/7-good-stocks-buy-while-they-are-down-2016-09-08", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-gilead-sciences-2016-09-08", "https://www.nasdaq.com/articles/2-stocks-better-dividends-cvs-health-corporation-2016-09-08", "https://www.nasdaq.com/articles/4-cheap-dividend-growth-stocks-to-buy-avb-cmi-gild-psa-2016-09-02", "https://www.nasdaq.com/articles/forget-gilead-sciences-inc-these-3-stocks-are-better-buys-2016-09-07", "https://www.nasdaq.com/articles/7-deeply-underloved-blue-chip-stocks-to-buy-now-2016-09-01", "https://www.nasdaq.com/articles/biotech-stock-roundup-gilead-patent-infringement-lawsuit-enbrel-biosimilar-approved-2016", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-mrk-gps-gild-2016-09-01", "https://www.nasdaq.com/articles/3-beaten-biotech-stocks-are-they-bargains-2016-08-31", "https://www.nasdaq.com/articles/theres-more-to-johnson-johnson-jnj-than-meets-the-eye-2016-08-30", "https://www.nasdaq.com/articles/2-clinical-stage-biotech-stocks-buy-2016-08-30", "https://www.nasdaq.com/articles/looking-beyond-hepatitis-c-heres-how-gilead-could-make-another-10-billion-annually-2016-08", "https://www.nasdaq.com/articles/gilead-sciences-becomes-oversold-2016-09-02", "https://www.nasdaq.com/articles/7-deeply-underloved-blue-chip-stocks-to-buy-now-2016-09-01", "https://www.nasdaq.com/articles/biotech-stock-roundup-gilead-patent-infringement-lawsuit-enbrel-biosimilar-approved-2016", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-mrk-gps-gild-2016-09-01", "https://www.nasdaq.com/articles/billionaire-george-soros-fund-dumped-these-3-biotech-holdings-should-you-2016-08-28", "https://www.nasdaq.com/articles/3-top-stocks-buy-your-children-2016-08-26", "https://www.nasdaq.com/articles/6-more-pharma-companies-selling-overpriced-drugs-2016-08-26", "https://www.nasdaq.com/articles/mylan-nv-myl%3A-stop-rewarding-big-pharma-greed-2016-08-25", "https://www.nasdaq.com/articles/mondays-etf-unusual-volume-pbe-2016-08-29", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-amgn-khc-gild-2016-08-29", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-tmus-2016-08-29", "https://www.nasdaq.com/articles/why-gilead-sciences-inc.-gild-valeant-pharmaceuticals-intl-inc-vrx-and-core-mark-holding", "https://www.nasdaq.com/articles/why-you-should-and-shouldnt-buy-gilead-sciences-inc-2016-08-24", "https://www.nasdaq.com/articles/biotech-stock-roundup-medivation-pfizer-clovis-priority-review-2016-08-24", "https://www.nasdaq.com/articles/gilead-gild-truvada-gets-eu-approval-for-label-expansion-2016-08-23", "https://www.nasdaq.com/articles/galapagos-glpg-advances-ra-drug-filgotinib-to-phase-iii-2016-08-23", "https://www.nasdaq.com/articles/stock-market-news-for-august-25-2016-2016-08-25", "https://www.nasdaq.com/articles/3-reasons-gilead-sciences-inc-stock-could-fall-2016-08-25", "https://www.nasdaq.com/articles/after-hours-most-active-aug-25-2016-ens-msft-bac-clf-lmt-wnc-qqq-wll-fitb-gild-urbn-ea", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-august-25-2016-2016-08-24", "https://www.nasdaq.com/articles/why-you-should-and-shouldnt-buy-gilead-sciences-inc-2016-08-24", "https://www.nasdaq.com/articles/top-undervalued-stocks-buy-2016-2016-08-21", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-gild-qcom-celg-2016-08-19", "https://www.nasdaq.com/articles/3-cheap-stocks-rookie-investors-start-2016-08-17", "https://www.nasdaq.com/articles/3-cheap-healthcare-stocks-paying-dividends-now-2016-08-23", "https://www.nasdaq.com/articles/4-top-biotech-stocks-can-be-purchased-cheap-summer-2016-08-16", "https://www.nasdaq.com/articles/7-battered-biotech-stocks-buy-2016-08-14", "https://www.nasdaq.com/articles/these-3-hated-dividend-stocks-look-buys-2016-08-14", "https://www.nasdaq.com/articles/could-gilead-sciences-face-unexpected-10-billion-tax-bill-2016-08-13", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-august-15-2016-2016-08-12", "https://www.nasdaq.com/articles/implied-analyst-12-month-target-qqxt-2016-08-11", "https://www.nasdaq.com/articles/gilead-sciences-inc-breakdown-looms-gild-stock-2016-08-10", "https://www.nasdaq.com/articles/biotech-stock-roundup-vertex-slips-study-halt-aurinia-plunges-lupus-data-2016-08-17", "https://www.nasdaq.com/articles/etfs-to-watch-as-nasdaq-hits-all-time-high-2016-08-09", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-oef-gild-agn-celg-2016-08-08", "https://www.nasdaq.com/articles/licensing-agreements-drive-ligand-pharmaceuticals-inc-13-higher-july-2016-08-08", "https://www.nasdaq.com/articles/are-gilead-sciences-best-days-behind-it-2016-08-07", "https://www.nasdaq.com/articles/ligand-lgnd-q2-earnings-decline-yy-maintains-view-2016-08-05", "https://www.nasdaq.com/articles/after-hours-most-active-aug-5-2016-aapl-bac-msft-qqq-gild-fcx-nvda-vz-aal-mrk-gm-pfe-2016", "https://www.nasdaq.com/articles/drug-stocks-earnings-to-watch-on-aug-5%3A-petx-dvax-more-2016-08-04", "https://www.nasdaq.com/articles/gilead-sciences-inc-stock-3-charts-2016-08-09", "https://www.nasdaq.com/articles/drug-stocks-to-watch-for-earnings-on-aug-3%3A-zts-exel-more-2016-08-02", "https://www.nasdaq.com/articles/celgene-corporation%3A-why-celg-stock-could-top-%24200-share-2016-08-01", "https://www.nasdaq.com/articles/rapidly-rising-prescription-drug-costs-could-put-medicare-life-support-2016-07-31", "https://www.nasdaq.com/articles/12-big-pharma-stats-will-blow-you-away-2016-07-31", "https://www.nasdaq.com/articles/what-awaits-acur-other-drug-stocks-this-earnings-season-2016-07-29", "https://www.nasdaq.com/articles/qual-gild-mmm-peg-etf-outflow-alert-2016-07-28", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-gilead-abbvie-amgen-and-celgene-2016-07-28", "https://www.nasdaq.com/articles/1-big-bright-spot-gilead-sciences-otherwise-dismal-quarter-2016-08-03", "https://www.nasdaq.com/articles/research-reports-facebook-dupont-gilead-others-2016-07-28", "https://www.nasdaq.com/articles/express-scripts-esrx-posts-in-line-earnings-lags-revenues-revised-2016-07-27", "https://www.nasdaq.com/articles/drug-price-war-just-took-big-new-twist-2016-07-27", "https://www.nasdaq.com/articles/wednesdays-vital-data%3A-apple-inc.-aapl-twitter-inc-twtr-and-gilead-sciences-inc.-gild-2016", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-q2-results-impress-gilead-hcv-franchise-under-pressure-2016", "https://www.nasdaq.com/articles/tuesdays-etf-unusual-volume-dln-2016-07-26", "https://www.nasdaq.com/articles/tuesdays-etf-movers-xme-bbh-2016-07-26", "https://www.nasdaq.com/articles/2-large-cap-drug-stocks-watch-earnings-abbv-mrk-2016-07-28", "https://www.nasdaq.com/articles/ishares-silver-trust-etf%3A-a-golden-opportunity-beckons-in-slv-2016-07-26", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-catch-falling-knife-now-2016-07-26", "https://www.nasdaq.com/articles/sp-500-movers-cnc-txn-2016-07-26", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-txn-2016-07-26", "https://www.nasdaq.com/articles/gilead-gild-beats-on-q2-earnings-cuts-2016-sales-view-2016-07-26", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-texas-instruments-gilead-sciences-and-las-vegas-sands", "https://www.nasdaq.com/articles/3-big-stock-charts-for-tuesday%3A-abbvie-inc-abbv-gilead-sciences-inc.-gild-and-sprint-corp", "https://www.nasdaq.com/articles/3-key-takeaways-following-gilead-sciences-second-quarter-conference-call-2016-07-26", "https://www.nasdaq.com/articles/pre-market-most-active-jul-26-2016-siri-rdsb-mbly-azn-fcx-nflx-mcd-s-gild-xiv-txn-aapl", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-tuesday%3A-express-scripts-holding-company-esrx-las-vegas-sands-corp.", "https://www.nasdaq.com/articles/jerome-dodson-comments-gilead-2016-07-26", "https://www.nasdaq.com/articles/after-gild-earnings-which-biomed-stock-best-right-now-2016-07-26", "https://www.nasdaq.com/articles/why-gilead-sciences-inc.-gild-mobileye-nv-mbly-and-under-armour-inc-ua-are-3-of-todays", "https://www.nasdaq.com/articles/harvoni-sales-declines-hurt-gilead-sciences-inc-q2-2016-07-26", "https://www.nasdaq.com/articles/daily-dividend-report-ibm-gild-cost-aep-exc-etn-fis-2016-07-26", "https://www.nasdaq.com/articles/express-scripts-esrx-tops-q2-earnings-lags-revenues-2016-07-26", "https://www.nasdaq.com/articles/roche-rhhby-misses-on-q2-revenues-new-launches-in-focus-2016-07-25", "https://www.nasdaq.com/articles/q2-earnings-after-bell-monday-txn-gild-lvs-2016-07-25", "https://www.nasdaq.com/articles/gilead-gild-stock-falls-sales-miss-and-lower-2016-revenues-guidance-2016-07-25", "https://www.nasdaq.com/articles/week-could-decide-whether-biotech-etfs-rally-sizzles-or-fizzles-2016-07-25", "https://www.nasdaq.com/articles/why-gilead-sciences-inc.-gild-netflix-inc.-nflx-and-sprint-corp-s-are-3-of-todays-best", "https://www.nasdaq.com/articles/after-hours-most-active-jul-25-2016-ge-gild-mdlz-aa-aapl-pfe-bac-msft-aer-qqq-foxa-xom", "https://www.nasdaq.com/articles/biotech-earnings-battle-gilead-gild-vs-amgen-amgn-2016-07-25", "https://www.nasdaq.com/articles/7-key-figures-gilead-sciences-q2-earnings-2016-07-25", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-600-follow-through-indicator-39-sensitive", "https://www.nasdaq.com/articles/3-stocks-turned-10000-1-million-2016-07-24", "https://www.nasdaq.com/articles/5-reasons-biotech-stocks-are-smart-investments-2016-07-24", "https://www.nasdaq.com/articles/i-just-bought-these-4-fast-growing-biotech-stocks-2016-07-23", "https://www.nasdaq.com/articles/medical-stocks-reporting-early-next-week%3A-gild-lly-more-2016-07-22", "https://www.nasdaq.com/articles/can-gopro-gpro-spring-a-surprise-this-earnings-season-2016-07-22", "https://www.nasdaq.com/articles/gilead-sciences-inc.%3A-2-gild-stock-trades-for-earnings-2016-07-21-0", "https://www.nasdaq.com/articles/after-hours-earnings-report-july-25-2016-gild-txn-cni-esrx-lvs-avb-ce-brx-cdns-re-wrb-acc", "https://www.nasdaq.com/articles/biogen-biib-stock-q2-earnings-beat-raised-outlook-2016-07-21", "https://www.nasdaq.com/articles/express-scripts-esrx-q2-earnings%3A-stock-to-disappoint-2016-07-21", "https://www.nasdaq.com/articles/eli-lilly-lly-may-beat-q2-earnings-will-stock-gain-2016-07-21", "https://www.nasdaq.com/articles/gilead-gild-stock-likely-to-beat-this-earnings-season-2016-07-21", "https://www.nasdaq.com/articles/whats-in-store-for-transunion-tru-this-earnings-season-2016-07-21", "https://www.nasdaq.com/articles/3-healthcare-etfs-to-buy-as-jnj-beats-q2-earnings-2016-07-21", "https://www.nasdaq.com/articles/will-honeywell-hon-pull-a-surprise-this-earnings-season-2016-07-20", "https://www.nasdaq.com/articles/3-enormously-important-things-you-wont-see-gilead-sciences-q2-results-2016-07-21", "https://www.nasdaq.com/articles/biogen-biib-stock-q2-earnings-beat-raised-outlook-2016-07-21", "https://www.nasdaq.com/articles/express-scripts-esrx-q2-earnings%3A-stock-to-disappoint-2016-07-21", "https://www.nasdaq.com/articles/eli-lilly-lly-may-beat-q2-earnings-will-stock-gain-2016-07-21", "https://www.nasdaq.com/articles/gilead-gild-stock-likely-to-beat-this-earnings-season-2016-07-21", "https://www.nasdaq.com/articles/whats-in-store-for-transunion-tru-this-earnings-season-2016-07-21", "https://www.nasdaq.com/articles/ishares-edge-msci-usa-quality-factor-etf-experiences-big-inflow-2016-07-19", "https://www.nasdaq.com/articles/5-stocks-with-high-roe-to-buy-as-earnings-bells-chime-2016-07-19", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-altria-group-priceline-group-zoetis-gilead-sciences-and", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-and-hold-2016-07-19", "https://www.nasdaq.com/articles/5-best-stocks-value-investors-week-2016-07-19", "https://www.nasdaq.com/articles/earnings-estimates-these-3-biotech-giants-should-be-heading-lower-heres-why-2016-07-19", "https://www.nasdaq.com/articles/gilead-sciences-most-underappreciated-drug-candidate-2016-07-18", "https://www.nasdaq.com/articles/abbott-labs-abt-q2-earnings%3A-will-the-stock-surprise-2016-07-18", "https://www.nasdaq.com/articles/te-connectivity-tel-q3-earnings%3A-whats-in-the-cards-2016-07-18", "https://www.nasdaq.com/articles/roches-gazyva-fails-in-phase-iii-b-cell-lymphoma-study-2016-07-18", "https://www.nasdaq.com/articles/4-top-stocks-sale-summer-2016-07-19", "https://www.nasdaq.com/articles/novartis-nvs-likely-to-beat-q2-earnings%3A-stock-to-gain-2016-07-15", "https://www.nasdaq.com/articles/will-unitedhealth-unh-continue-to-beat-on-earnings-in-q2-2016-07-15", "https://www.nasdaq.com/articles/gileads-hcv-drug-epclusa-gets-regulatory-nod-in-canada-2016-07-15", "https://www.nasdaq.com/articles/biogen-biib-q2-earnings-will-stock-disappoint-2016-07-15", "https://www.nasdaq.com/articles/jj-jnj-may-beat-q2-earnings-will-stock-gain-2016-07-15", "https://www.nasdaq.com/articles/how-much-do-stock-prices-matter-biotech-2016-07-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-juno-amgen-abbvie-gilead-and-cytrx-2016-07-14", "https://www.nasdaq.com/articles/4-rock-solid-cheap-biotech-stocks-2016-07-16", "https://www.nasdaq.com/articles/why-investors-are-underestimating-gilead-sciences-2016-07-13", "https://www.nasdaq.com/articles/biotech-stock-roundup-juno-and-out-clinical-hold-amgen-biosimilar-gets-panel-backing-2016", "https://www.nasdaq.com/articles/gilead-sciences-latest-approval-big-deal-2016-07-12", "https://www.nasdaq.com/articles/ligand-lgnd-signs-deal-with-gilead-for-omniab-technology-2016-07-11", "https://www.nasdaq.com/articles/gileads-pan-genotypic-hcv-drug-epclusa-gains-eu-approval-2016-07-11", "https://www.nasdaq.com/articles/3-stocks-with-50-more-post-brexit-upside-bp-gsk-rbs-2016-07-11", "https://www.nasdaq.com/articles/implied-rdvy-analyst-target-price-23-2016-07-11", "https://www.nasdaq.com/articles/3-dividend-aristocrats-avoid-2016-07-14", "https://www.nasdaq.com/articles/conscious-capitalism-youll-love-these-3-stocks-2016-07-10", "https://www.nasdaq.com/articles/attention-investors-pe-ratio-revisited-2016-07-08", "https://www.nasdaq.com/articles/health-care-select-sector-spdr-fund-experiences-big-outflow-2016-07-08", "https://www.nasdaq.com/articles/stock-market-news-for-july-07-2016-2016-07-07", "https://www.nasdaq.com/articles/non-gaap-earnings-arent-solution-2016-07-07", "https://www.nasdaq.com/articles/agree-purchase-gilead-sciences-4750-earn-44-using-options-2016-07-05", "https://www.nasdaq.com/articles/these-3-biotech-stocks-are-ridiculously-cheap-now-2016-07-05", "https://www.nasdaq.com/articles/top-7-research-reports-july-11-2016-2016-07-11", "https://www.nasdaq.com/articles/gilead-sciences-stock-stupid-cheap-2016-07-04", "https://www.nasdaq.com/articles/big-loser-after-gileads-latest-approval-may-not-be-who-you-think-hint-its-not-abbvie-inc", "https://www.nasdaq.com/articles/3-issues-every-healthcare-investor-should-consider-2016-07-02", "https://www.nasdaq.com/articles/10-biotech-and-specialty-pharma-bargains-do-you-have-guts-speculate-2016-07-01", "https://www.nasdaq.com/articles/health-insurers-surprising-key-drugmakers-sucess-2016-06-30", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-regulus-abbvie-the-medicines-and-gw-pharma-2016", "https://www.nasdaq.com/articles/3-dividend-growth-stocks-buy-july-2016-06-30", "https://www.nasdaq.com/articles/how-gileads-new-hepatitis-c-virus-combination-stacks-competition-2016-07-05", "https://www.nasdaq.com/articles/how-much-will-elections-affect-healthcare-stocks-2016-06-29", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-sale-right-now-2016-06-29", "https://www.nasdaq.com/articles/top-6-research-reports-june-29-2016-2016-06-29", "https://www.nasdaq.com/articles/biotech-stock-roundup-gilead-gets-fda-nod-hcv-drug-regulus-hit-clinical-hold-2016-06-29", "https://www.nasdaq.com/articles/why-gilead-sciences-gild-stock-gaining-today-2016-06-28", "https://www.nasdaq.com/articles/leading-indicator-suggests-stock-market-may-be-precipice-tumbling-2016-06-28", "https://www.nasdaq.com/articles/fda-unsurprisingly-approves-gileads-new-hepatitis-c-drug-now-what-2016-06-28", "https://www.nasdaq.com/articles/141-reasons-love-biotech-stocks-2016-06-30", "https://www.nasdaq.com/articles/gild-stock-fda-greenlights-gilead-sciences-inc-hep-c-drug-epclusa-2016-06-28", "https://www.nasdaq.com/articles/instant-analysis-gilead-sciences-wins-important-fda-approval-2016-06-28", "https://www.nasdaq.com/articles/regulus-therapeutics-inc-clinical-hold-should-investors-be-yellow-bellied-2016-06-27", "https://www.nasdaq.com/articles/when-will-gilead-sciences-celgene-and-cvs-health-hit-100-again-2016-06-27", "https://www.nasdaq.com/articles/can-gilead-sciences-rebound-second-half-2016-2016-06-25", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-now-long-haul-2016-06-25", "https://www.nasdaq.com/articles/the-ishares-nasdaq-biotechnology-index-ibb%3A-biotech-stocks-are-pushing-for-recovery-2016", "https://www.nasdaq.com/articles/why-gilead-sciences-inc.-gild-bank-of-america-corp-bac-and-facebook-inc-fb-are-3-of-todays", "https://www.nasdaq.com/articles/3-most-important-data-releases-and-fda-decisions-second-half-2016-2016-06-23", "https://www.nasdaq.com/articles/corporate-share-buybacks-rise-record-level-first-quarter-2016-06-22", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-unh-bmy-gild-2016-06-22", "https://www.nasdaq.com/articles/can-these-upstarts-knock-gilead-sciences-its-perch-2016-06-22", "https://www.nasdaq.com/articles/gilead-presents-favorable-preliminary-bictegravir-hiv-data-2016-06-21", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-june-21st-2016-06-21", "https://www.nasdaq.com/articles/these-5-biotech-stocks-are-ridiculously-cheap-2016-06-21", "https://www.nasdaq.com/articles/gileads-gild-hiv-treatment-odefsey-gains-approval-in-eu-2016-06-24", "https://www.nasdaq.com/articles/3-most-important-data-releases-and-fda-decisions-second-half-2016-2016-06-23", "https://www.nasdaq.com/articles/2-biotech-stocks-could-raise-their-dividends-and-1-wont-2016-06-18", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-june-17th-2016-06-17", "https://www.nasdaq.com/articles/abbv-named-top-socially-responsible-dividend-stock-2016-06-17", "https://www.nasdaq.com/articles/3-reasons-gilead-sciences-buy-2016-06-17", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-xlv-unh-bmy-gild-2016-06-14", "https://www.nasdaq.com/articles/why-achillion-pharmaceuticals-down-big-2016-2016-06-20", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-june-14-2016-2016-06-13", "https://www.nasdaq.com/articles/dividend-stocks-retirees-can-buy-2016-06-12", "https://www.nasdaq.com/articles/my-favorite-clinical-stage-biotech-stocks-buy-2016-06-11", "https://www.nasdaq.com/articles/3-stocks-are-ridiculously-cheap-right-now-2016-06-11", "https://www.nasdaq.com/articles/why-galapagos-nv-shares-soared-305-may-2016-06-09", "https://www.nasdaq.com/articles/acadia-pharmaceuticals-inc-7-companies-could-buy-acad-2016-06-08", "https://www.nasdaq.com/articles/legal-dispute-puts-ionis-pharmaceuticals-payday-hold-2016-06-07", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-if-market-crashes-2016-06-14", "https://www.nasdaq.com/articles/3-cheap-biotech-stocks-you-can-buy-now-2016-06-06", "https://www.nasdaq.com/articles/after-hours-most-active-jun-6-2016-bax-amat-wpx-spls-baba-s-csco-stj-gild-phm-tvix-cmcsa", "https://www.nasdaq.com/articles/7-stocks-buy-june-2016-06-05", "https://www.nasdaq.com/articles/forget-biogen-these-3-stocks-are-better-buys-2016-06-05", "https://www.nasdaq.com/articles/abbvies-stock-too-risky-2016-06-04", "https://www.nasdaq.com/articles/gurufocus-best-idea-contest-6-who-beating-market-2016-06-04", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-june-02-2016-2016-06-01", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-xlv-unh-bmy-gild-2016-06-06", "https://www.nasdaq.com/articles/3-perfect-stocks-baby-boomers-their-50s-consider-buying-2016-05-31", "https://www.nasdaq.com/articles/gileads-gild-new-hcv-drug-epclusa-wins-chmp-backing-2016-05-31", "https://www.nasdaq.com/articles/5-dividend-stocks-buy-june-2016-05-31", "https://www.nasdaq.com/articles/10-biotech-stocks-with-symptoms-of-strong-growth-2016-05-31", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-xlv-unh-bmy-gild-2016-05-27", "https://www.nasdaq.com/articles/interested-medivation-take-number-2016-05-27", "https://www.nasdaq.com/articles/3-retirement-stocks-buy-june-2016-05-27", "https://www.nasdaq.com/articles/biotech-stock-roundup-sarepta-shoots-fda-delay-ionis-falls-pipeline-news-2016-06-01", "https://www.nasdaq.com/articles/billionaires-are-bailing-gilead-sciences-should-you-too-2016-05-25", "https://www.nasdaq.com/articles/3-stocks-market-loves-hate-you-should-love-2016-05-25", "https://www.nasdaq.com/articles/after-hours-most-active-may-25-2016-fcx-yhoo-ete-qqq-jpm-symc-mcd-dow-wfc-intc-gild-aapl", "https://www.nasdaq.com/articles/galapagos-ra-drug-filgotinib-to-enter-phase-iii-in-3q16-2016-05-25", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-cytr-gild-ckec-2016-05-24", "https://www.nasdaq.com/articles/your-2016-guide-investing-gilead-sciences-stock-2016-05-23", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-grab-bargain-while-you-can-2016-05-23", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-johnson-johnson-2016-05-26", "https://www.nasdaq.com/articles/fridays-etf-unusual-volume-pbe-2016-05-20", "https://www.nasdaq.com/articles/these-4-value-stocks-are-collectively-generating-114-billion-free-cash-flow-year-2016-05", "https://www.nasdaq.com/articles/low-volatility-etfs-impatient-investor-are-latest-hot-trend-2016-05-20", "https://www.nasdaq.com/articles/biotech-stocks-show-signs-revival-beware-side-effects-2016-05-20", "https://www.nasdaq.com/articles/xlv-unh-gild-amgn-etf-outflow-alert-2016-05-19", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-may-13-2016-2016-05-12", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-unh-gild-amgn-2016-05-11", "https://www.nasdaq.com/articles/billionaire-george-soros-fund-bought-these-stocks-should-you-2016-05-21", "https://www.nasdaq.com/articles/biotech-giant-gilead-sciences-goes-sale-2016-05-10", "https://www.nasdaq.com/articles/drug-stocks-q1-earnings-slated-on-may-11%3A-acrs-ears-more-2016-05-10", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-may-11-2016-2016-05-10", "https://www.nasdaq.com/articles/walt-disney-co-dis-stock%3A-short-the-short-term-2016-05-09", "https://www.nasdaq.com/articles/should-you-buy-or-sell-gilead-gild-stock-3-pros-3-cons-2016-05-09", "https://www.nasdaq.com/articles/drug-stocks-earnings-previews%3A-fgen-irwd-enta-flml-2016-05-06", "https://www.nasdaq.com/articles/7-figures-sum-merck-cos-first-quarter-2016-05-05", "https://www.nasdaq.com/articles/drug-stocks-earnings-slated-for-this-week%3A-rdy-avxs-esaly-2016-05-11", "https://www.nasdaq.com/articles/drug-stocks-earnings-preview%3A-gern-rprx-icpt-agio-more-2016-05-04", "https://www.nasdaq.com/articles/health-care-select-sector-spdr-fund-experiences-big-inflow-2016-05-04", "https://www.nasdaq.com/articles/3-dirt-cheap-biotech-stocks-buy-2016-05-04", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-vs-biogen-2016-05-04", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-impresses-gilead-disappoints-q1-biogen-spin-hemophilia-2016-05", "https://www.nasdaq.com/articles/new-stock-market-trend-catching-investors-surprise-it-shouldnt-2016-05-03", "https://www.nasdaq.com/articles/mallinckrodt-mnk-tops-q2-earnings-and-sales-ups-view-2016-05-03", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-gilead-celgene-medivation-and-biogen-2016-05-05", "https://www.nasdaq.com/articles/drug-stocks-earnings-preview%3A-gern-rprx-icpt-agio-more-2016-05-04", "https://www.nasdaq.com/articles/health-care-select-sector-spdr-fund-experiences-big-inflow-2016-05-04", "https://www.nasdaq.com/articles/3-dirt-cheap-biotech-stocks-buy-2016-05-04", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-vs-biogen-2016-05-04", "https://www.nasdaq.com/articles/what-sent-medivation-incs-shares-soaring-251-april-2016-05-03", "https://www.nasdaq.com/articles/5-data-points-wall-street-anxiously-awaiting-mercks-q1-report-2016-05-03", "https://www.nasdaq.com/articles/surmodics-srdx-beats-q2-earnings-revenues-estimates-2016-05-03", "https://www.nasdaq.com/articles/alnylam-alny-reports-wider-than-expected-loss-in-q1-2016-05-03", "https://www.nasdaq.com/articles/novo-nordisk-nvo-beats-on-q1-earnings-retains-outlook-2016-05-02", "https://www.nasdaq.com/articles/immunogen-imgn-posts-wider-than-expected-q3-loss-2016-05-02", "https://www.nasdaq.com/articles/stock-market-news-for-may-02-2016-2016-05-02", "https://www.nasdaq.com/articles/biotech-etfs-sink-on-mixed-q1-results-2016-05-02", "https://www.nasdaq.com/articles/shire-shpg-tops-q1-earnings-baxalta-buyout-set-for-june-2016-05-02", "https://www.nasdaq.com/articles/trade-day-ibb-breaking-down-2016-05-02", "https://www.nasdaq.com/articles/good-news-gilead-sciences-discounted-its-drugs-again-2016-05-02", "https://www.nasdaq.com/articles/aduro-adro-q1-loss-wider-than-expected-revenues-fall-2016-05-03", "https://www.nasdaq.com/articles/3-key-pipeline-developments-gilead-investors-watch-2016-04-30", "https://www.nasdaq.com/articles/rpt-us-stocks-slump-led-healthcare-and-technology-2016-04-29", "https://www.nasdaq.com/articles/chevron-corporation-continues-chasing-a-moving-target-in-oil-cvx-2016-04-29", "https://www.nasdaq.com/articles/gilead-sciences-inc-reports-disappointing-q1-harvoni-sales-2016-04-29", "https://www.nasdaq.com/articles/3-drug-stocks-reporting-early-next-week%3A-pfe-myl-mnk-2016-04-29", "https://www.nasdaq.com/articles/2-bullish-bets-for-alibaba-group-holding-ltd-baba-2016-04-29", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-broadcom-kellogg-altria-group-gilead-sciences-and", "https://www.nasdaq.com/articles/does-healthcares-past-predict-its-future-2016-05-01", "https://www.nasdaq.com/articles/3-megatrends-powering-the-growth-machine-at-facebook-inc-fb-2016-04-29", "https://www.nasdaq.com/articles/motley-fools-10-best-stock-calls-last-10-years-2016-04-29", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-friday%3A-amgen-inc.-amgn-gilead-sciences-inc.-gild-and-tivo-inc.-tivo", "https://www.nasdaq.com/articles/why-gilead-sciences-inc.-gild-stericycle-inc-srcl-and-western-digital-corp-wdc-are-3-of", "https://www.nasdaq.com/articles/close-update-us-stocks-head-weekly-loss-amid-apples-woes-2016-04-29", "https://www.nasdaq.com/articles/us-stocks-head-weekly-loss-amid-apples-woes-2016-04-29", "https://www.nasdaq.com/articles/daily-dividend-report-gild-pfg-oxy-px-k-hcn-payx-2016-04-29", "https://www.nasdaq.com/articles/gilead-gild-lags-q1-earnings-revenues-16-view-intact-2016-04-29", "https://www.nasdaq.com/articles/3-megatrends-powering-the-growth-machine-at-facebook-inc-fb-2016-04-29", "https://www.nasdaq.com/articles/motley-fools-10-best-stock-calls-last-10-years-2016-04-29", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-friday%3A-amgen-inc.-amgn-gilead-sciences-inc.-gild-and-tivo-inc.-tivo", "https://www.nasdaq.com/articles/why-gilead-sciences-inc.-gild-stericycle-inc-srcl-and-western-digital-corp-wdc-are-3-of", "https://www.nasdaq.com/articles/close-update-us-stocks-head-weekly-loss-amid-apples-woes-2016-04-29", "https://www.nasdaq.com/articles/q1-earnings-reports-continue-deluge-amzn-gild-amgn-2016-04-28", "https://www.nasdaq.com/articles/gilead-sciences-gild-stock-slumps-q1-earnings-revenue-miss-2016-04-28", "https://www.nasdaq.com/articles/fridays-etf-movers-gdx-bbh-2016-04-29", "https://www.nasdaq.com/articles/rpt-mid-day-update-us-stocks-decline-led-technology-and-healthcare-sectors-after-weak", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-sarepta-catalyst-pharmaceuticals-abbvie-and", "https://www.nasdaq.com/articles/5-best-roe-stocks-to-beat-earnings-blues-2016-04-28", "https://www.nasdaq.com/articles/sanofis-bid-medivation-too-low-2016-04-28", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-500-follow-through-indicator-33-sensitive", "https://www.nasdaq.com/articles/after-hours-earnings-report-april-28-2016-amzn-gild-amgn-bidu-hig-rsg-expe-ess-bmrn-lnkd", "https://www.nasdaq.com/articles/4-biotech-stocks-reporting-apr-28-amgn-gild-alxn-celg-2016-04-27", "https://www.nasdaq.com/articles/amazon.com-inc.-amzn%3A-q1-earnings-answer-investors-prayers-2016-04-28", "https://www.nasdaq.com/articles/aegerion-aegr%3A-can-the-stock-surprise-in-q1-earnings-2016-04-27", "https://www.nasdaq.com/articles/aerie-aeri%3A-can-the-stock-pull-a-surprise-in-q1-earnings-2016-04-27", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-tops-q1-earnings-sarepta-catalyst-plunge-regulatory-news-2016", "https://www.nasdaq.com/articles/biotech-stock-gilead-gild-likely-to-beat-in-q1-earnings-2016-04-26", "https://www.nasdaq.com/articles/ucb-ucbjf-posts-q1-results-reiterates-2016-guidance-2016-04-26", "https://www.nasdaq.com/articles/health-care-select-sector-spdr-fund-experiences-big-inflow-2016-04-26", "https://www.nasdaq.com/articles/henry-schein-hsic-q1-earnings%3A-can-the-stock-surprise-2016-04-26", "https://www.nasdaq.com/articles/why-gilead-sciences-gild-might-surprise-this-earnings-season-2016-04-27", "https://www.nasdaq.com/articles/aegerion-aegr%3A-can-the-stock-surprise-in-q1-earnings-2016-04-27", "https://www.nasdaq.com/articles/aerie-aeri%3A-can-the-stock-pull-a-surprise-in-q1-earnings-2016-04-27", "https://www.nasdaq.com/articles/7-dividend-stocks-with-hidden-yields-2016-04-26", "https://www.nasdaq.com/articles/myriad-genetics-mygn-q3-earnings%3A-a-beat-in-the-cards-2016-04-26", "https://www.nasdaq.com/articles/perrigos-ceo-resigns-trims-2016-outlook-stock-tumbles-2016-04-26", "https://www.nasdaq.com/articles/healthcare-q1-earnings-look-solid-etfs-benefit-2016-04-25", "https://www.nasdaq.com/articles/will-ametek-ame-earnings-surpass-estimates-in-q1-2016-04-25", "https://www.nasdaq.com/articles/will-cvs-health-cvs-earnings-surprise-estimates-in-q1-2016-04-26", "https://www.nasdaq.com/articles/amgen-amgn-may-beat-q1-earnings-will-stock-gain-2016-04-25", "https://www.nasdaq.com/articles/can-arrowhead-do-hep-b-what-gilead-sciences-did-hep-c-2016-04-25", "https://www.nasdaq.com/articles/5-biotech-stocks-to-bet-on-this-earnings-season-2016-04-25", "https://www.nasdaq.com/articles/87-americans-want-medicare-have-power-federal-government-disagrees-2016-04-24", "https://www.nasdaq.com/articles/are-these-3-biotechs-destined-be-bought-out-2016-04-24", "https://www.nasdaq.com/articles/3-things-watch-gilead-sciences-incs-first-quarter-results-2016-04-23", "https://www.nasdaq.com/articles/whats-in-store-for-keryx-kerx-this-earnings-season-2016-04-25", "https://www.nasdaq.com/articles/texas-instruments-txn-q1-earnings%3A-what-lies-in-store-2016-04-25", "https://www.nasdaq.com/articles/will-thermo-fisher-tmo-exceed-q1-earnings-expectations-2016-04-22", "https://www.nasdaq.com/articles/will-gnc-holdings-gnc-q1-earnings-surprise-investors-2016-04-22", "https://www.nasdaq.com/articles/3-stocks-buy-crashing-market-2016-04-22", "https://www.nasdaq.com/articles/gild-makes-bullish-cross-above-critical-moving-average-2016-04-21", "https://www.nasdaq.com/articles/what-awaits-edwards-lifesciences-ew-in-q1-earnings-2016-04-21", "https://www.nasdaq.com/articles/zimmer-biomet-zbh-q1-earnings%3A-a-beat-in-the-cards-2016-04-22", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-medivation-synta-abbvie-gilead-and-orexigen-2016-04-21", "https://www.nasdaq.com/articles/express-scripts-esrx-q1-earnings%3A-stock-to-disappoint-2016-04-21", "https://www.nasdaq.com/articles/5-stocks-that-could-hike-their-dividends-20-2016-04-21", "https://www.nasdaq.com/articles/epizyme-epzm-q1-earnings%3A-can-the-stock-surprise-2016-04-21", "https://www.nasdaq.com/articles/healthcare-etfs-buy-blockbuster-jj-q1-results-2016-04-20", "https://www.nasdaq.com/articles/biotech-stock-roundup-medivation-buyout-rumors-resurface-synta-merger-deal-2016-04-20", "https://www.nasdaq.com/articles/3-biotech-stocks-that-could-endure-hillary-clinton-2016-04-19", "https://www.nasdaq.com/articles/biogen-biib-tops-q1-earnings-slight-revenue-miss-2016-04-21", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-medivation-synta-abbvie-gilead-and-orexigen-2016-04-21", "https://www.nasdaq.com/articles/express-scripts-esrx-q1-earnings%3A-stock-to-disappoint-2016-04-21", "https://www.nasdaq.com/articles/5-stocks-that-could-hike-their-dividends-20-2016-04-21", "https://www.nasdaq.com/articles/epizyme-epzm-q1-earnings%3A-can-the-stock-surprise-2016-04-21", "https://www.nasdaq.com/articles/gilead-presents-multiple-hcv-and-hbv-data-at-liver-congress-2016-04-18", "https://www.nasdaq.com/articles/top-4-sales-growth-stocks-2016-04-18", "https://www.nasdaq.com/articles/big-downside-better-medicine-higher-prices-2016-04-16", "https://www.nasdaq.com/articles/dont-let-days-news-drive-your-investing-2016-04-18", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-celgene-corporation-2016-04-15", "https://www.nasdaq.com/articles/why-regulus-therapeutics-slumping-14-today-2016-04-15", "https://www.nasdaq.com/articles/fridays-etf-unusual-volume-iyh-2016-04-15", "https://www.nasdaq.com/articles/abbvie-reveals-positive-data-on-combination-hcv-therapy-2016-04-14", "https://www.nasdaq.com/articles/merck-offers-positive-data-from-comparative-trial-on-zepatier-2016-04-14", "https://www.nasdaq.com/articles/spdr-sp-500-growth-etf-experiences-big-inflow-2016-04-14", "https://www.nasdaq.com/articles/better-buy-inovio-pharmaceuticals-or-arrowhead-research-corp-2016-04-14", "https://www.nasdaq.com/articles/1-stock-youve-been-overlooking-your-roth-ira-2016-04-16", "https://www.nasdaq.com/articles/horizon-pharma-plunges-on-bleak-q1-and-1h16-guidance-2016-04-13", "https://www.nasdaq.com/articles/nasdaq-100-movers-stx-jd-2016-04-13", "https://www.nasdaq.com/articles/cormedix-crmd-worth-watching%3A-stock-soars-19.9-2016-04-13", "https://www.nasdaq.com/articles/how-roe-can-ensure-big-gains-while-picking-cash-rich-stocks-2016-04-13", "https://www.nasdaq.com/articles/clovis-drops-fda-panel-seeks-more-data-on-rociletinib-2016-04-13", "https://www.nasdaq.com/articles/abbvies-venclexta-notches-fda-win-investors-might-want-temper-enthusiasm-2016-04-13", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-april-2016-04-12", "https://www.nasdaq.com/articles/3-momentum-stocks-buy-now-2016-04-14", "https://www.nasdaq.com/articles/weekly-ceo-sells-highlight-gilead-sciences-boston-scientific-sonic-healthequity-2016-04-11", "https://www.nasdaq.com/articles/after-nearly-39-million-deaths-cure-hiv-could-be-just-3-years-away-2016-04-10", "https://www.nasdaq.com/articles/edwards-lifesciences-corp-ew-stock-heart-innovation-2016-04-08", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-3m-canadian-pacific-railway-edison-international-cgi", "https://www.nasdaq.com/articles/after-hours-most-active-apr-8-2016-rig-cit-ge-symc-esrx-intc-glw-pfe-gild-csco-brcd-wmt", "https://www.nasdaq.com/articles/3m-mmm-likely-winner-among-losers-earnings-season-2016-04-07", "https://www.nasdaq.com/articles/3-big-pharma-stocks-to-buy-3-to-avoid-2016-04-12", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-regeneron-medivation-and-intercept-2016-04-07", "https://www.nasdaq.com/articles/gilead-gild-cheap-growth-stock-worth-buying-now-2016-04-06", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-iwb-gild-amgn-sbux-2016-04-06", "https://www.nasdaq.com/articles/5-dividend-stocks-starting-a-multi-decade-bull-market-2016-04-06", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-edwards-lifesciences-pra-health-sciences-gilead", "https://www.nasdaq.com/articles/biotech-stock-roundup-gileads-hiv-drug-approved-regeneron-positive-data-2016-04-06", "https://www.nasdaq.com/articles/4-great-stocks-ride-ibb-rebound-2016-04-05", "https://www.nasdaq.com/articles/ignore-exelixis-inc-here-are-3-better-stocks-2016-04-07", "https://www.nasdaq.com/articles/forget-regeneron-pharmaceuticals-inc-these-2-stocks-are-better-buys-2016-04-05", "https://www.nasdaq.com/articles/gilead-descovy-wins-fda-nod-to-buy-nimbus-liver-program-2016-04-05", "https://www.nasdaq.com/articles/why-gilead-sciences-gild-zacks-rank-1-stock-right-now-2016-04-05", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-buys-nimbus-therapeutics-subsidiary-12b-2016-04-04", "https://www.nasdaq.com/articles/commit-buy-gilead-sciences-4750-earn-36-using-options-2016-04-04", "https://www.nasdaq.com/articles/3-biotech-stocks-on-the-verge-of-an-overdue-run-amgn-gild-regn-2016-04-04", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-biogen-inc-2016-04-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-endp-ebay-2016-04-05", "https://www.nasdaq.com/articles/forget-regeneron-pharmaceuticals-inc-these-2-stocks-are-better-buys-2016-04-05", "https://www.nasdaq.com/articles/gilead-descovy-wins-fda-nod-to-buy-nimbus-liver-program-2016-04-05", "https://www.nasdaq.com/articles/why-gilead-sciences-gild-zacks-rank-1-stock-right-now-2016-04-05", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-buys-nimbus-therapeutics-subsidiary-12b-2016-04-04", "https://www.nasdaq.com/articles/commit-buy-gilead-sciences-4750-earn-36-using-options-2016-04-04", "https://www.nasdaq.com/articles/3-biotech-stocks-on-the-verge-of-an-overdue-run-amgn-gild-regn-2016-04-04", "https://www.nasdaq.com/articles/3-stocks-were-watching-second-quarter-2016-04-03", "https://www.nasdaq.com/articles/buying-these-2-drug-developers-would-make-lot-sense-johnson-johnson-2016-03-31", "https://www.nasdaq.com/articles/after-hours-most-active-mar-31-2016-bac-vg-ge-msft-gild-qqq-grub-fcx-pfe-aapl-csco-intc", "https://www.nasdaq.com/articles/health-care-sector-update-03312016-mdvnazngildamgnsnygnvalife-2016-03-31", "https://www.nasdaq.com/articles/3-biotech-stocks-that-make-the-grade-for-investors-2016-03-30", "https://www.nasdaq.com/articles/4-value-stocks-to-buy-now-2016-03-30", "https://www.nasdaq.com/articles/5-value-stocks-to-buy-now-2016-03-30", "https://www.nasdaq.com/articles/markets-reverse-earlier-declines-consumer-tech-stocks-lead-gains-falling-oil-price-yellen", "https://www.nasdaq.com/articles/5-large-cap-stocks-with-p-es-below-15%3A-a-must-buy-2016-03-31", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-accenture-broadcom-gilead-sciences-ulta-salon-cosmetics", "https://www.nasdaq.com/articles/3-biotech-stocks-you-dont-have-babysit-2016-03-29", "https://www.nasdaq.com/articles/close-update-wall-street-gives-yellens-speech-thumbs-2016-03-29", "https://www.nasdaq.com/articles/health-care-sector-update-03292016-nvtactrvbpmx-2016-03-29", "https://www.nasdaq.com/articles/health-care-sector-update-03292016-pbyictrvgildbpmx-2016-03-29", "https://www.nasdaq.com/articles/gilead-to-pay-%24200-million-to-merck-for-hcv-patent-dispute-2016-03-28", "https://www.nasdaq.com/articles/nasdaq-100-movers-mu-mar-2016-03-28", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-itot-aapl-cvx-gild-2016-03-29", "https://www.nasdaq.com/articles/snapshot-6-cheapest-megacap-stocks-2016-03-28", "https://www.nasdaq.com/articles/buy-these-5-large-caps-for-incredible-roi-potential-2016-03-28", "https://www.nasdaq.com/articles/patent-payoff-mercks-and-ionis-pharmaceuticals-take-could-be-tiny-2016-03-25", "https://www.nasdaq.com/articles/abbvie-incs-big-win-over-gilead-sciences-wasnt-hepatitis-c-2016-03-24", "https://www.nasdaq.com/articles/after-hours-most-active-mar-24-2016-bxlt-spn-ge-qqq-msft-san-aes-jd-pfe-qcom-atml-gild", "https://www.nasdaq.com/articles/gilead-biogens-patent-woes-amgen-scores-win-patent-litigation-2016-03-24", "https://www.nasdaq.com/articles/attempt-value-valeant-just-fun-2016-03-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-amgen-regeneron-ionis-and-biogen-2016-03-28", "https://www.nasdaq.com/articles/pre-market-most-active-mar-23-2016-mik-asx-hnt-vrx-cnc-nke-tvix-sdrl-hmin-ions-gild-qqq", "https://www.nasdaq.com/articles/gilead-sciences-cancer-folly-2016-03-23", "https://www.nasdaq.com/articles/why-freeport-mcmoran-inc-fcx-gilead-sciences-inc.-gild-and-tesla-motors-inc-tsla-are-3-of", "https://www.nasdaq.com/articles/eli-lilly-and-co%3A-can-lly-stock-get-healthy-again-2016-03-22", "https://www.nasdaq.com/articles/stock-market-news-for-march-22-2012-2016-03-22", "https://www.nasdaq.com/articles/gilead-and-4-other-buy-stocks-biotech-industry-2016-03-22", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-could-squeeze-bears-here-2016-03-22", "https://www.nasdaq.com/articles/surprising-winner-mercks-patent-war-gilead-sciences-2016-03-23", "https://www.nasdaq.com/articles/3-large-cap-stocks-highest-net-profit-margins-2016-03-21", "https://www.nasdaq.com/articles/forget-cvs-health-corp-here-are-2-better-dividend-stocks-2016-03-21", "https://www.nasdaq.com/articles/do-you-own-any-these-top-sector-funds-2016-03-18", "https://www.nasdaq.com/articles/gilead-expedia-are-greatly-undervalued-2016-03-18", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gw-pharma-orexigen-gilead-and-regeneron-2016-03-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-gw-pharma-soars-epidiolex-data-gileads-zydelig-trouble-2016-03-16", "https://www.nasdaq.com/articles/stock-market-news-for-march-16-2016-2016-03-16", "https://www.nasdaq.com/articles/xlv-gild-agn-abt-large-outflows-detected-etf-2016-03-21", "https://www.nasdaq.com/articles/why-investors-should-sell-these-biotech-stocks-buy-gilead-instead-2016-03-15", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-celgene-gilead-sciences-and-logitech-international-2016", "https://www.nasdaq.com/articles/better-short-biotech-etf-or-invest-inverse-counterpart-2016-03-15", "https://www.nasdaq.com/articles/4-large-caps-to-navigate-an-erratic-market-2016-03-15", "https://www.nasdaq.com/articles/gileads-zydelig-under-eu-review-amid-safety-concerns-2016-03-14", "https://www.nasdaq.com/articles/biotech-investing-guide-3-stocks-buy-and-3-avoid-2016-03-11", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-march-14-2016-2016-03-11", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-koninklijke-ahold-n.v.-gilead-sciences-hca-holdings-and", "https://www.nasdaq.com/articles/abbvie-inc-abbv-is-about-to-steamroll-the-competition-2016-03-10", "https://www.nasdaq.com/articles/sucampo-beats-earnings-revenues-on-strong-amitiza-sales-2016-03-09", "https://www.nasdaq.com/articles/merck-kgaas-q4-earnings-down-y-y-offers-2016-outlook-2016-03-09", "https://www.nasdaq.com/articles/us-demand-new-hepatitis-c-drugs-about-explode-2016-03-09", "https://www.nasdaq.com/articles/3-value-stocks-near-52-week-lows-worth-buying-2016-03-08", "https://www.nasdaq.com/articles/3-stocks-hold-forever-2016-03-08", "https://www.nasdaq.com/articles/celldex-advised-to-discontinue-phase-iii-study-on-rintega-2016-03-08", "https://www.nasdaq.com/articles/3-stocks-we-more-johnson-johnson-2016-03-11", "https://www.nasdaq.com/articles/can-conatus-cnat-surprise-estimates-in-q4-earnings-2016-03-07", "https://www.nasdaq.com/articles/better-buy-celgene-corporation-vs-gilead-sciences-2016-03-07", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-valeant-pharmaceuticals-international-gilead-sciences", "https://www.nasdaq.com/articles/after-hours-most-active-mar-7-2016-njr-sdrl-ftsm-clf-mos-hbi-v-amat-bjri-msft-gild-qqq", "https://www.nasdaq.com/articles/last-months-best-healthcare-etf-2016-03-05", "https://www.nasdaq.com/articles/what-does-trumps-healthcare-plan-mean-investors-2016-03-04", "https://www.nasdaq.com/articles/gilead-sciences-inc.%3A-short-the-looming-value-trap-in-gild-stock-2016-03-04", "https://www.nasdaq.com/articles/the-ishares-nasdaq-biotechnology-index-etf-ibb-is-a-buy-but-not-for-long-2016-03-08", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-amgen-baxalta-ptc-therapeutics-and-cara", "https://www.nasdaq.com/articles/biotech-stock-roundup-gilead-hiv-drug-approved-baxalta-immuno-oncology-deal-2016-03-02", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-petrobras-korea-electric-power-taiwans-chungwa-telecom", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-march-02-2016-2016-03-01", "https://www.nasdaq.com/articles/forget-eli-lilly-and-co-here-are-2-better-dividend-stocks-2016-03-01", "https://www.nasdaq.com/articles/worry-more-or-worry-less-global-week-ahead-2016-02-29", "https://www.nasdaq.com/articles/2-drug-stocks-to-buy-for-safe-dividends-and-20-gains-2016-02-29", "https://www.nasdaq.com/articles/after-hours-most-active-mar-4-2016-udr-hr-mu-aig-gild-ibn-qqq-jpm-cmi-aapl-vip-msft-2016", "https://www.nasdaq.com/articles/geron-q4-loss-line-estimates-imetelstat-focus-2016-02-26", "https://www.nasdaq.com/articles/united-therapeutics-tops-4q-revenues-earnings-yy-2016-02-26", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-xlv-pfe-gild-agn-2016-02-24", "https://www.nasdaq.com/articles/how-find-ethical-investments-pharmaceutical-industry-2016-02-24", "https://www.nasdaq.com/articles/look-back-2-successful-biotech-buyouts-2016-02-22", "https://www.nasdaq.com/articles/do-sky-high-drug-prices-turn-biotech-companies-bad-guys-2016-02-22", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-amgen-inc-2016-02-21", "https://www.nasdaq.com/articles/should-data-worry-gilead-sciences-incs-investors-2016-02-29", "https://www.nasdaq.com/articles/simple-way-i-search-next-hit-stock-2016-02-20", "https://www.nasdaq.com/articles/company-gilead-sciences-should-fear-most-hint-its-not-merck-or-abbvie-2016-02-20", "https://www.nasdaq.com/articles/5-ways-spot-awe-inspiring-growth-stocks-2016-02-20", "https://www.nasdaq.com/articles/agios-agio-q4-loss-wider-than-expected-pipeline-in-focus-2016-02-19", "https://www.nasdaq.com/articles/can-biotech-stocks-bounce-back-2016-02-19", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-incyte-intercept-pharma-gilead-aegerion-and-clovis-2016", "https://www.nasdaq.com/articles/forget-abbvie-inc-here-are-2-better-dividend-stocks-2016-02-18", "https://www.nasdaq.com/articles/big-pharma-evil-2016-02-21", "https://www.nasdaq.com/articles/simple-way-i-search-next-hit-stock-2016-02-20", "https://www.nasdaq.com/articles/company-gilead-sciences-should-fear-most-hint-its-not-merck-or-abbvie-2016-02-20", "https://www.nasdaq.com/articles/nasdaq-100-movers-cern-pcln-2016-02-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-incyte-down-jakafi-update-intercept-buyout-target-2016-02-17", "https://www.nasdaq.com/articles/express-scripts-tops-earnings-in-q4-misses-on-revenues-2016-02-17", "https://www.nasdaq.com/articles/pre-market-most-active-feb-17-2016-asx-bac-kmi-nj-grpn-rgls-mfg-nok-aapl-tvix-xiv-gild", "https://www.nasdaq.com/articles/3-quotes-show-gilead-sciences-new-ceo-ready-deal-2016-02-17", "https://www.nasdaq.com/articles/4-funds-to-buy-on-healthy-medical-sector-earnings-2016-02-18", "https://www.nasdaq.com/articles/gileads-hcv-drug-harvoni-approved-in-two-more-indications-2016-02-17", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-qual-msft-aapl-gild-2016-02-16", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-icpt-soars-on-buyout-rumors-2016-02-16", "https://www.nasdaq.com/articles/novartis-acquires-rights-to-biosimilar-of-remicade-from-pfizer-2016-02-16", "https://www.nasdaq.com/articles/7-words-could-have-biotech-and-big-pharma-very-worried-2016-02-16", "https://www.nasdaq.com/articles/zoetis-tops-q4-earnings-and-revenues-updates-guidance-2016-02-16", "https://www.nasdaq.com/articles/gilead-sciences-wants-make-being-shareholder-worth-it-2016-02-13", "https://www.nasdaq.com/articles/bouncing-biotech-here-are-3-stocks-buy-2016-02-17", "https://www.nasdaq.com/articles/acorda-q4-earnings-decline-yy-ampyra-pipeline-focus-2016-02-12", "https://www.nasdaq.com/articles/these-7-single-digit-pe-stocks-could-collectively-deliver-600-billion-free-cash-flow-2020", "https://www.nasdaq.com/articles/why-intercept-pharmaceuticals-inc-skyrocketing-today-2016-02-12", "https://www.nasdaq.com/articles/novartis-filing-for-neulasta-biosimilar-accepted-in-the-eu-2016-02-12", "https://www.nasdaq.com/articles/achillion-begins-study-on-first-complement-factor-d-inhibitor-2016-02-12", "https://www.nasdaq.com/articles/genomic-health-q4-loss-wider-than-expected-revenues-up-2016-02-11", "https://www.nasdaq.com/articles/gw-pharmaceuticals-up-on-narrower-than-expected-q1-loss-2016-02-11", "https://www.nasdaq.com/articles/shire-tops-q4-earnings-baxalta-buyout-lifitegrast-in-focus-2016-02-12", "https://www.nasdaq.com/articles/biotech-stock-roundup-alexion-regeneron-miss-estimates-setback-cti-biopharma-2016-02-10", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-11-2016-2016-02-10", "https://www.nasdaq.com/articles/pfizers-biosimilar-of-remicade-recommended-for-approval-2016-02-10", "https://www.nasdaq.com/articles/cti-biopharmas-myelofibrosis-drug-on-full-clinical-hold-2016-02-10", "https://www.nasdaq.com/articles/gilead-sciences-incs-outlook-2016-what-investors-need-know-2016-02-10", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-market-crash-2016-02-09", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-february-10-2016-2016-02-09", "https://www.nasdaq.com/articles/roche-to-stop-study-on-lung-cancer-drug-alecensa-early-2016-02-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-alexion-regeneron-miss-estimates-setback-cti-biopharma-2016-02-10", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-11-2016-2016-02-10", "https://www.nasdaq.com/articles/pfizers-biosimilar-of-remicade-recommended-for-approval-2016-02-10", "https://www.nasdaq.com/articles/cti-biopharmas-myelofibrosis-drug-on-full-clinical-hold-2016-02-10", "https://www.nasdaq.com/articles/gilead-sciences-incs-outlook-2016-what-investors-need-know-2016-02-10", "https://www.nasdaq.com/articles/grading-gilead-sciences-performance-2015-2016-02-06", "https://www.nasdaq.com/articles/1-company-gilead-sciences-should-consider-buying-right-now-2016-02-06", "https://www.nasdaq.com/articles/curing-hepatitis-c-how-gilead-sciences-plans-beat-merck-2016-02-09", "https://www.nasdaq.com/articles/5-stocks-were-buying-again-2016-02-05", "https://www.nasdaq.com/articles/gilead-sciences-2016-guidance-sandbagging-wall-street-again-2016-02-05", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-gilead-abbvie-intrexon-and-newlink-2016-02-04", "https://www.nasdaq.com/articles/why-did-biotech-fall-cliff-january-2016-02-04", "https://www.nasdaq.com/articles/4-cant-miss-numbers-glaxosmithklines-fourth-quarter-results-2016-02-04", "https://www.nasdaq.com/articles/why-achillion-pharmaceuticals-shares-crashed-37-january-2016-02-04", "https://www.nasdaq.com/articles/qiagen-q4-earnings-miss-molecular-diagnostics-disappoints-2016-02-03", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-gild-agn-mdt-2016-02-05", "https://www.nasdaq.com/articles/5-stocks-were-buying-again-2016-02-05", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-mylan-united-therapeutics-and-insys", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-darden-restaurants-kla-tencor-motorola-solutions-gilead", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-yahoo-chipotle-gilead-sciences-and-match-group-2016-02", "https://www.nasdaq.com/articles/gilead-gild-beats-q4-earnings-estimates-gives-2016-view-2016-02-03", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-450424-down-1271-points-2016-02-03", "https://www.nasdaq.com/articles/international-growth-propels-gilead-sciences-incs-solid-q4-results-2016-02-03", "https://www.nasdaq.com/articles/forget-gilead-sciences-these-stocks-doubled-last-year-2016-02-03", "https://www.nasdaq.com/articles/instant-analysis-gilead-sciences-raises-its-dividend-10-2016-02-03", "https://www.nasdaq.com/articles/myriad-genetics-tops-q2-earnings-myrisk-conversion-over-2016-02-03", "https://www.nasdaq.com/articles/why-gilead-sciences-shares-tumbled-18-january-2016-02-02", "https://www.nasdaq.com/articles/start-new-year-right-3-best-biotech-stocks-2016-02-02", "https://www.nasdaq.com/articles/4-top-ranked-biotech-stocks-sale-2016-02-02", "https://www.nasdaq.com/articles/5-top-rated-sp-500-dividend-stocks-to-buy-in-february-2016-02-02", "https://www.nasdaq.com/articles/gileads-stock-sale-should-you-buy-2016-02-03", "https://www.nasdaq.com/articles/gilead-sciences-gild-beats-earnings-and-revenue-estimates-2016-02-02", "https://www.nasdaq.com/articles/after-hours-most-active-feb-2-2016-fcau-qqq-mrvl-hpe-msft-gild-t-dft-aapl-fuel-akr-ge-2016", "https://www.nasdaq.com/articles/how-benefit-daily-trading-order-flow-2016-02-02", "https://www.nasdaq.com/articles/abbott-labs-to-boost-diagnostics-business-with-alere-buyout-2016-02-02", "https://www.nasdaq.com/articles/will-qorvo-qrvo-miss-q3-earnings-on-expected-low-sales-2016-02-02", "https://www.nasdaq.com/articles/whats-in-store-for-stericycle-srcl-this-earnings-2016-02-02", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-500-follow-through-indicator-31-sensitive", "https://www.nasdaq.com/articles/pfizer-beats-q4-earnings-revenues-outlook-disappoints-2016-02-02", "https://www.nasdaq.com/articles/gilead-sciences-gild-beats-earnings-and-revenue-estimates-2016-02-02", "https://www.nasdaq.com/articles/after-hours-most-active-feb-2-2016-fcau-qqq-mrvl-hpe-msft-gild-t-dft-aapl-fuel-akr-ge-2016", "https://www.nasdaq.com/articles/how-benefit-daily-trading-order-flow-2016-02-02", "https://www.nasdaq.com/articles/accuray-aray-q2-loss-wider-than-estimate-shares-fall-2016-02-01", "https://www.nasdaq.com/articles/3-biotech-stocks-you-dont-have-babysit-2016-02-01", "https://www.nasdaq.com/articles/will-mallinckrodt-mnk-earnings-disappoint-investors-in-q1-2016-02-01", "https://www.nasdaq.com/articles/can-microchip-mchp-keep-the-earnings-streak-alive-in-q3-2016-02-01", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-2-2016-gild-eqr-yhoo-ilmn-fisv-ew-cmg-kim-udr-chrw", "https://www.nasdaq.com/articles/is-alexion-alxn-likely-to-disappoint-this-earnings-season-2016-02-01", "https://www.nasdaq.com/articles/gw-pharmaceuticals-gwph%3A-what-awaits-in-q1-earnings-2016-02-01", "https://www.nasdaq.com/articles/is-illumina-ilmn-poised-to-beat-earnings-estimates-in-q4-2016-02-01", "https://www.nasdaq.com/articles/johnson-johnson-wants-investors-ignore-falling-hepatitis-c-drug-sales-2016-01-31", "https://www.nasdaq.com/articles/3-surprisingly-controversial-stocks-donald-trumps-portfolio-2016-01-31", "https://www.nasdaq.com/articles/heres-why-johnson-johnsons-sales-fell-last-year-2016-01-30", "https://www.nasdaq.com/articles/whats-in-store-for-nivalis-nvls-this-earnings-season-2016-01-29", "https://www.nasdaq.com/articles/can-glaxosmithkline-gsk-q4-earnings-surprise-estimates-2016-02-01", "https://www.nasdaq.com/articles/instant-analysis-can-merck-make-waves-crowded-hepatitis-c-space-2016-01-29", "https://www.nasdaq.com/articles/mercks-hepatitis-c-doublet-wins-fda-approval-and-unveils-its-secret-weapon-2016-01-29", "https://www.nasdaq.com/articles/should-you-buy-gilead-sciences-gild-ahead-of-earnings-2016-01-29", "https://www.nasdaq.com/articles/amgen-tops-q4-earnings-revenues-ups-2016-outlook-2016-01-29", "https://www.nasdaq.com/articles/pre-market-most-active-jan-29-2016-cbx-gild-tap-tvix-ubs-msft-ino-qqq-bac-fb-nok-xrx-2016", "https://www.nasdaq.com/articles/mercks-hcv-drug-zepatier-gets-fda-nod-sets-lower-price-2016-01-29", "https://www.nasdaq.com/articles/bristol-myers-daklinza-sovaldi-label-expanded-in-the-eu-2016-01-29", "https://www.nasdaq.com/articles/can-gilead-gild-keep-the-earnings-streak-alive-in-q4-2016-01-29", "https://www.nasdaq.com/articles/instant-analysis-can-merck-make-waves-crowded-hepatitis-c-space-2016-01-29", "https://www.nasdaq.com/articles/mercks-hepatitis-c-doublet-wins-fda-approval-and-unveils-its-secret-weapon-2016-01-29", "https://www.nasdaq.com/articles/should-you-buy-gilead-sciences-gild-ahead-of-earnings-2016-01-29", "https://www.nasdaq.com/articles/whats-in-the-cards-for-yahoo-yhoo-this-earnings-season-2016-01-29", "https://www.nasdaq.com/articles/roches-rhhby-earnings-miss-estimates-revenues-beat-2016-01-29", "https://www.nasdaq.com/articles/edwards-lifesciences-ew-likely-to-top-earnings-again-in-q4-2016-01-29", "https://www.nasdaq.com/articles/abbvie-posts-line-earnings-maintains-2016-outlook-2016-01-29", "https://www.nasdaq.com/articles/johnson-johnsons-results-include-healthy-dose-asterisks-2016-01-29", "https://www.nasdaq.com/articles/abbott-labs-abt-beats-on-q4-earnings-lags-on-revenues-2016-01-28", "https://www.nasdaq.com/articles/xlv-pfe-gild-agn-large-inflows-detected-etf-2016-01-28", "https://www.nasdaq.com/articles/celgene-misses-on-q4-earnings-reiterates-2016-guidance-2016-01-28", "https://www.nasdaq.com/articles/gilead-sciences-gild-looks-cheap-these-levels-2016-01-28", "https://www.nasdaq.com/articles/bristol-myers-beats-on-q4-earnings-provides-2016-guidance-2016-01-28", "https://www.nasdaq.com/articles/vertex-vrtx-posts-narrower-4q-loss-maintains-outlook-2016-01-28", "https://www.nasdaq.com/articles/3-things-watch-gilead-sciences-q4-results-2016-01-28", "https://www.nasdaq.com/articles/can-baxter-bax-pull-a-surprise-this-earnings-season-2016-01-29", "https://www.nasdaq.com/articles/immunogen-imgn-q2-earnings-preview%3A-what-to-expect-2016-01-27", "https://www.nasdaq.com/articles/will-alibaba-group-baba-beat-earnings-estimates-in-q3-2016-01-27", "https://www.nasdaq.com/articles/biogen-tops-q4-earnings-wide-margin-provides-view-2016-01-27", "https://www.nasdaq.com/articles/will-2016-be-biomarin-pharmaceuticals-best-year-yet-2016-01-27", "https://www.nasdaq.com/articles/will-abbvie-abbv-keep-earnings-streak-alive-q4-2016-01-27", "https://www.nasdaq.com/articles/will-currency-volatility-keep-hurting-abbotts-abt-earnings-2016-01-27", "https://www.nasdaq.com/articles/will-myriad-genetics-q2-earnings-mygn-surprise-investors-2016-01-27", "https://www.nasdaq.com/articles/5-mouthwatering-stocks-sale-now-2016-01-28", "https://www.nasdaq.com/articles/immunogen-imgn-q2-earnings-preview%3A-what-to-expect-2016-01-27", "https://www.nasdaq.com/articles/will-alibaba-group-baba-beat-earnings-estimates-in-q3-2016-01-27", "https://www.nasdaq.com/articles/biogen-tops-q4-earnings-wide-margin-provides-view-2016-01-27", "https://www.nasdaq.com/articles/can-qlogic-qlgc-keep-the-earnings-streak-alive-in-q3-2016-01-26", "https://www.nasdaq.com/articles/jjs-q4-results-mixed-earnings-beat-revenue-miss-2016-01-26", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-horizon-pharma-nxp-semiconductor-and", "https://www.nasdaq.com/articles/celgene-celg-to-report-q4-earnings%3A-what-to-expect-2016-01-26", "https://www.nasdaq.com/articles/will-thermo-fisher-tmo-surprise-q4-earnings-expectations-2016-01-26", "https://www.nasdaq.com/articles/will-currency-and-generics-hit-jjs-jnj-q4-earnings-2016-01-25", "https://www.nasdaq.com/articles/oil-short-covering-isnt-share-price-bottom-global-week-ahead-2016-01-25", "https://www.nasdaq.com/articles/forget-johnson-johnson-here-are-2-better-dividend-stocks-2016-01-25", "https://www.nasdaq.com/articles/stock-sell-what-should-you-do-now-2016-01-25", "https://www.nasdaq.com/articles/will-biogen-biib-beat-4q-earnings-ms-franchise-sales-2016-01-25", "https://www.nasdaq.com/articles/after-hours-most-active-jan-25-2016-bac-fcau-qqq-hlf-msft-schw-hpe-siri-aapl-hes-gild-csco", "https://www.nasdaq.com/articles/will-higher-expenses-hurt-vertexs-vrtx-4q-earnings-2016-01-25", "https://www.nasdaq.com/articles/will-mead-johnson-mjn-q4-earnings-let-down-investors-2016-01-26", "https://www.nasdaq.com/articles/see-which-latest-13f-filers-holds-gilead-sciences-2016-01-25", "https://www.nasdaq.com/articles/why-q4-earnings-beat-is-dicey-at-quest-diagnostics-dgx-2016-01-25", "https://www.nasdaq.com/articles/will-zimmer-biomet-zbh-beat-earnings-again-in-q4-2016-01-25", "https://www.nasdaq.com/articles/what-to-expect-from-lam-researchs-lrcx-q2-earnings-2016-01-25", "https://www.nasdaq.com/articles/whats-in-store-for-texas-instruments-txn-q4-earnings-2016-01-25", "https://www.nasdaq.com/articles/gilead-takes-page-out-celgenes-playbook-2016-01-23", "https://www.nasdaq.com/articles/whats-in-store-for-teradyne-ter-this-earnings-season-2016-01-22", "https://www.nasdaq.com/articles/will-bristol-myers-bmy-beat-q4-earnings-expectations-2016-01-25", "https://www.nasdaq.com/articles/whats-in-store-for-corning-glw-this-earnings-season-2016-01-21", "https://www.nasdaq.com/articles/5-dividend-stocks-buy-january-2016-01-21", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-gilead-sciences-qorvo-essex-property-trust-and", "https://www.nasdaq.com/articles/merrimack-reports-positive-onivyde-data-in-pancreatic-cancer-2016-01-20", "https://www.nasdaq.com/articles/dynavax-astrazeneca-amend-deal-for-asthma-candidate-2016-01-20", "https://www.nasdaq.com/articles/weekly-play-sell-calls-sector-ibb-2016-01-20", "https://www.nasdaq.com/articles/3-slides-perfectly-sum-where-abbvie-headed-next-2016-01-19", "https://www.nasdaq.com/articles/cleveland-biolabs-gets-orphan-status-for-entolimod-in-eu-2016-01-22", "https://www.nasdaq.com/articles/whats-in-store-for-corning-glw-this-earnings-season-2016-01-21", "https://www.nasdaq.com/articles/5-dividend-stocks-buy-january-2016-01-21", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-gilead-sciences-qorvo-essex-property-trust-and", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amazon.com-delta-air-lines-gilead-sciences-citrix", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-biogen-cytokinetics-and-bristol-myers", "https://www.nasdaq.com/articles/3-stocks-were-watching-first-quarter-2016-01-18", "https://www.nasdaq.com/articles/will-resmed-rmd-surprise-earnings-estimates-in-q2-2016-01-19", "https://www.nasdaq.com/articles/4-biotech-stocks-looking-good-this-earnings-season-2016-01-15", "https://www.nasdaq.com/articles/5-strong-growth-sp-500-stocks-to-buy-on-the-sell-off-2016-01-15", "https://www.nasdaq.com/articles/gilead-sciences-galapagos-deal-advances-it-toward-multibillion-dollar-market-2016-01-15", "https://www.nasdaq.com/articles/5-good-stocks-buy-while-they-are-cheap-2016-01-14", "https://www.nasdaq.com/articles/why-galapagos-nvs-shares-bolted-higher-2015-2016-01-14", "https://www.nasdaq.com/articles/pluristem-psti-gets-fda-approval-for-phase-i-plx-r18-trial-2016-01-14", "https://www.nasdaq.com/articles/gilead-sciences-takes-2-steps-forward-and-1-step-back-2016-01-13", "https://www.nasdaq.com/articles/abbvies-management-just-made-some-pretty-bold-predictions-2016-01-16", "https://www.nasdaq.com/articles/3-slides-suggesting-gilead-sciences-may-be-unstoppable-2016-01-12", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-pfe-gild-bmy-2016-01-12", "https://www.nasdaq.com/articles/3-things-you-absolutely-must-know-about-merck-2016-01-12", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-horizon-pharma-aveo-pharmaceuticals-achillion", "https://www.nasdaq.com/articles/invest-san-francisco-these-3-stocks-2016-01-12", "https://www.nasdaq.com/articles/aegerion-provides-preliminary-sales-view-pipeline-updates-2016-01-12", "https://www.nasdaq.com/articles/celldex-therapeutics-drops-10-biotech-heads-south-2016-01-11", "https://www.nasdaq.com/articles/gilead-seeks-approval-for-tenofovir-alafenamide-for-hbv-2016-01-13", "https://www.nasdaq.com/articles/3-slides-suggesting-gilead-sciences-may-be-unstoppable-2016-01-12", "https://www.nasdaq.com/articles/5-biotech-stocks-ready-to-crush-the-market-in-2016-2016-01-11", "https://www.nasdaq.com/articles/1-george-soros-quote-keep-mind-2016-2016-01-10", "https://www.nasdaq.com/articles/5-commonly-prescribed-drugs-six-digit-annual-price-tags-2016-01-09", "https://www.nasdaq.com/articles/3-healthcare-stocks-buy-sale-2016-01-09", "https://www.nasdaq.com/articles/abbvies-viekira-pak-snda-accepted-with-priority-review-2016-01-08", "https://www.nasdaq.com/articles/vertex-vrtx-gives-2016-view-orkambi-view-come-later-2016-01-11", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-mannkind-vivus-and-baxalta-2016-01-07", "https://www.nasdaq.com/articles/company-news-for-january-06-2016-2016-01-06", "https://www.nasdaq.com/articles/biotech-stock-roundup-mannkind-tanks-deal-termination-speedy-review-gilead-drug-2016-01-06", "https://www.nasdaq.com/articles/gilead-up-on-encouraging-data-on-tenofovir-alafenamide-2016-01-06", "https://www.nasdaq.com/articles/gileads-gild-hcv-drug-gets-priority-review-status-in-u.s.-2016-01-05", "https://www.nasdaq.com/articles/how-pick-undervalued-stock-it-picks-steam-2016-01-05", "https://www.nasdaq.com/articles/why-dow-jones-industrial-average-falling-today-2016-01-05", "https://www.nasdaq.com/articles/buy-gilead-gild-deep-rooted-growth-2016-2016-01-08", "https://www.nasdaq.com/articles/3-stocks-buy-market-crash-2016-01-04", "https://www.nasdaq.com/articles/what-does-2016-hold-biotech-stocks-2016-01-03", "https://www.nasdaq.com/articles/what-makes-stock-cheap-2016-01-02", "https://www.nasdaq.com/articles/why-did-gilead-sciences-inc-take-mountain-debt-2016-01-01", "https://www.nasdaq.com/articles/can-gilead-sciences-score-abbvies-dropped-ball-2015-12-31", "https://www.nasdaq.com/articles/drugmaker-returns-rd-are-shrinking-2015-12-30", "https://www.nasdaq.com/articles/irony-ironies-gilead-sciences-licensing-abbvies-rejected-drug-2015-12-29", "https://www.nasdaq.com/articles/xlv-pfe-gild-bmy-large-outflows-detected-etf-2016-01-04", "https://www.nasdaq.com/articles/enzon-pharmaceuticals-inc-enzn-ex-dividend-date-scheduled-december-30-2015-2015-12-29", "https://www.nasdaq.com/articles/5-play-it-safe-stocks-2016-2015-12-28", "https://www.nasdaq.com/articles/what-happened-biotech-2015-2015-12-28", "https://www.nasdaq.com/articles/worst-johnson-johnson-headlines-2015-2015-12-28", "https://www.nasdaq.com/articles/3-new-drugs-ready-explode-2016-2015-12-26", "https://www.nasdaq.com/articles/biotech-industry-could-offer-early-profit-2016-2015-12-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-actelion-amgen-gilead-abbvie-and-biomarin-2015-12-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-ofs-capital-carnival-navios-maritime-acquisition", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-xlv-jnj-gild-bmy-2015-12-23", "https://www.nasdaq.com/articles/dont-sell-gilead-sciences-try-instead-2015-12-23", "https://www.nasdaq.com/articles/biotech-stock-roundup-kalobios-removes-ceo-shkreli-actelion-pah-drug-approved-2015-12-23", "https://www.nasdaq.com/articles/after-hours-most-active-dec-22-2015-bk-pfe-ete-mu-aapl-gild-abev-nke-qqq-yhoo-hpe-ubnt", "https://www.nasdaq.com/articles/merck-co-about-derail-gilead-sciences-2015-12-22", "https://www.nasdaq.com/articles/after-hours-most-active-dec-21-2015-hst-gm-aapl-emc-c-csco-kr-pfe-qcom-fb-xiv-gild-2015-12", "https://www.nasdaq.com/articles/revolutionary-fda-approval-showcases-important-trend-2015-12-20", "https://www.nasdaq.com/articles/best-merck-co-inc-headlines-2015-2015-12-24", "https://www.nasdaq.com/articles/ackman-sequoia-stock-valeant-changes-course-2015-12-18", "https://www.nasdaq.com/articles/gilead-gild-collaborates-with-galapagos-for-filgotinib-2015-12-18", "https://www.nasdaq.com/articles/us-stock-futures-extend-post-fed-gains-2015-12-17", "https://www.nasdaq.com/articles/instant-analysis-amgen-cranks-dividend-27-higher-2015-12-17", "https://www.nasdaq.com/articles/there-any-value-left-healthcare-top-investing-firm-seems-think-not-2015-12-16", "https://www.nasdaq.com/articles/amgen-returns-more-to-shareholders-hikes-dividend-by-27-2015-12-16", "https://www.nasdaq.com/articles/iusg-gild-bmy-mcd-etf-inflow-alert-2015-12-15", "https://www.nasdaq.com/articles/7-best-cheap-stocks-buy-2016-2015-12-18", "https://www.nasdaq.com/articles/ackman-sequoia-stock-valeant-changes-course-2015-12-18", "https://www.nasdaq.com/articles/gilead-gild-collaborates-with-galapagos-for-filgotinib-2015-12-18", "https://www.nasdaq.com/articles/3-small-cap-biotech-stocks-big-news-coming-2016-2015-12-12", "https://www.nasdaq.com/articles/average-american-spends-much-prescription-drugs-each-year-2015-12-12", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-december-14-2015-2015-12-11", "https://www.nasdaq.com/articles/balance-sheet-brawl-pfizer-vs-bristol-myers-squibb-2015-12-11", "https://www.nasdaq.com/articles/will-study-finally-catapult-gilead-sciences-cancer-powerhouse-2015-12-10", "https://www.nasdaq.com/articles/glaxosmithkline-plcs-best-drug-2015-2015-12-15", "https://www.nasdaq.com/articles/3-most-important-drugs-gilead-sciences-pipeline-2015-12-07", "https://www.nasdaq.com/articles/gileads-hcv-drugs-regulatory-application-validated-in-eu-2015-12-07", "https://www.nasdaq.com/articles/bristol-myers-abbvie-report-long-term-data-on-empliciti-2015-12-07", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-repros-therapeutics-abbvie-amgen-xoma-and-gilead-2015", "https://www.nasdaq.com/articles/abbvies-nda-for-once-daily-viekira-pak-accepted-by-fda-2015-12-03", "https://www.nasdaq.com/articles/after-hours-most-active-dec-3-2015-pah-qqq-mdlz-hpe-pfe-fcx-aapl-wen-bac-orcl-gild-csco", "https://www.nasdaq.com/articles/why-achillion-pharmaceuticals-shot-30-higher-november-2015-12-03", "https://www.nasdaq.com/articles/gilead-reveals-encouraging-data-on-leukemia-drug-zydelig-2015-12-10", "https://www.nasdaq.com/articles/3-most-important-drugs-gilead-sciences-pipeline-2015-12-07", "https://www.nasdaq.com/articles/gileads-hcv-drugs-regulatory-application-validated-in-eu-2015-12-07", "https://www.nasdaq.com/articles/bristol-myers-abbvie-report-long-term-data-on-empliciti-2015-12-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-repros-tanks-crl-abbvie-multiple-myeloma-drug-approved-2015-12-02", "https://www.nasdaq.com/articles/stock-market-news-for-december-01-2015-2015-12-01", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-december-02-2015-2015-12-01", "https://www.nasdaq.com/articles/curing-world-shout-out-healthcare-innovators-2015-12-01", "https://www.nasdaq.com/articles/john-rogers-comments-gilead-sciences-inc-2015-12-02", "https://www.nasdaq.com/articles/theres-00000000000028-chance-drug-doesnt-work-2015-11-30", "https://www.nasdaq.com/articles/most-important-message-charlie-sheens-recent-hiv-admission-2015-11-28", "https://www.nasdaq.com/articles/3-healthcare-stocks-massive-buyback-programs-2015-11-28", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biomarin-amgen-vertex-gilead-biogen-and-repros-2015-11", "https://www.nasdaq.com/articles/5-dividend-stocks-buy-december-2015-11-27", "https://www.nasdaq.com/articles/giving-thanks-healthcare-style-2015-11-27", "https://www.nasdaq.com/articles/gilead-sciences-grabs-4-regulatory-wins-does-it-matter-2015-11-26", "https://www.nasdaq.com/articles/where-will-gilead-sciences-be-10-years-2015-11-30", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-mylan-indivior-omnicomm-systems-and-air", "https://www.nasdaq.com/articles/gileads-gild-cocktail-hiv-drug-genvoya-approved-in-eu-2015-11-24", "https://www.nasdaq.com/articles/5-cheap-health-care-stocks-that-promise-healthy-returns-2015-11-24", "https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-valeant-pfizer-allergan-abbvie-and-gilead-2015-11-24", "https://www.nasdaq.com/articles/healthcares-greatest-dividend-stocks-2015-11-24", "https://www.nasdaq.com/articles/biogens-biib-biosimilar-of-pfizers-enbrel-gets-chmp-nod-2015-11-23", "https://www.nasdaq.com/articles/can-merck-co-take-down-gilead-sciences-2015-11-23", "https://www.nasdaq.com/articles/biotech-stock-roundup-kalobios-soars-shkreli-steps-fda-panel-not-convinced-about-biomarin", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-mylan-indivior-omnicomm-systems-and-air", "https://www.nasdaq.com/articles/gileads-gild-cocktail-hiv-drug-genvoya-approved-in-eu-2015-11-24", "https://www.nasdaq.com/articles/5-cheap-health-care-stocks-that-promise-healthy-returns-2015-11-24", "https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-valeant-pfizer-allergan-abbvie-and-gilead-2015-11-24", "https://www.nasdaq.com/articles/just-upgrades-and-downgrades-2015-11-18", "https://www.nasdaq.com/articles/gild-makes-bullish-cross-above-critical-moving-average-2015-11-18", "https://www.nasdaq.com/articles/vertexs-vrtx-orkambi-approved-in-eu-for-cystic-fibrosis-2015-11-23", "https://www.nasdaq.com/articles/3-biotech-stocks-you-dont-have-babysit-2015-11-17", "https://www.nasdaq.com/articles/gileads-leukemia-study-unblinded-early-on-positive-data-2015-11-17", "https://www.nasdaq.com/articles/bristol-myers-opdivo-gets-priority-review-from-the-fda-2015-11-17", "https://www.nasdaq.com/articles/better-dividend-stock-gilead-sciences-inc-vs-teva-pharmaceutical-industries-2015-11-16", "https://www.nasdaq.com/articles/abbvie-reports-encouraging-data-on-hcv-drug-viekira-pak-2015-11-16", "https://www.nasdaq.com/articles/5-drugs-are-face-prescription-drug-reform-2015-11-15", "https://www.nasdaq.com/articles/tyco-q4-earnings-in-line-with-estimates-revenues-lag-2015-11-13", "https://www.nasdaq.com/articles/biotech-stock-roundup-clovis-plunges-label-expansion-gileads-harvoni-2015-11-18", "https://www.nasdaq.com/articles/hepatitis-c-treatment-2016-will-gilead-sciences-or-abbvie-win-2015-11-13", "https://www.nasdaq.com/articles/gileads-gild-hcv-drug-harvonis-label-expanded-in-u.s.-2015-11-13", "https://www.nasdaq.com/articles/iwf-aapl-gild-cmcsa-etf-inflow-alert-2015-11-11", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-retrophin-exelixis-actelion-and-enzo", "https://www.nasdaq.com/articles/trio-catalysts-lift-merck-higher-october-2015-11-11", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-november-12-2015-2015-11-11", "https://www.nasdaq.com/articles/5-biotech-stocks-good-growth-prospects-2015-11-10", "https://www.nasdaq.com/articles/5-stocks-generating-incredible-return-on-assets-2015-11-13", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-november-10-2015-2015-11-09", "https://www.nasdaq.com/articles/three-rules-options-trading-success-2015-11-09", "https://www.nasdaq.com/articles/what-does-2016-hold-closely-watched-biotech-etf-2015-11-09", "https://www.nasdaq.com/articles/5-picks-on-strongest-jobs-gains-of-2015-2015-11-09", "https://www.nasdaq.com/articles/biotech-sees-better-than-expected-earnings%3A-etfs-in-focus-2015-11-06", "https://www.nasdaq.com/articles/marijuana-and-hepatitis-c-what-watch-2016-2015-11-06", "https://www.nasdaq.com/articles/gileads-gild-cocktail-hiv-drug-genvoya-gets-fda-nod-2015-11-06", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-fiserv-gilead-sciences-american-eagle-outfitters-bjs", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbvie-amgen-dyax-repros-and-gilead-2015-11-05", "https://www.nasdaq.com/articles/does-abbvies-viekira-pak-warning-land-express-scripts-penalty-box-2015-11-05", "https://www.nasdaq.com/articles/gileads-sovaldi-in-focus-on-bradyarrhythmia-concerns-2015-11-05", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvies-humira-remains-strong-shire-buy-dyax-2015-11-04", "https://www.nasdaq.com/articles/5-exciting-biotech-stocks-to-buy-on-november-upswing-2015-11-03", "https://www.nasdaq.com/articles/vanguard-growth-etf-experiences-big-inflow-2015-11-03", "https://www.nasdaq.com/articles/viiv-healthcare-attacking-gilead-prepares-strike-back-2015-11-03", "https://www.nasdaq.com/articles/gilead-and-2-biotech-picks-value-investors-will-love-2015-11-06", "https://www.nasdaq.com/articles/make-gilead-part-your-biotech-portfolio-2015-11-02", "https://www.nasdaq.com/articles/which-dividends-would-be-safest-if-drug-prices-were-slashed-tomorrow-2015-11-02", "https://www.nasdaq.com/articles/whats-in-store-for-conatus-cnat-this-earnings-season-2015-11-02", "https://www.nasdaq.com/articles/5-best-dividend-stocks-buy-november-2015-11-02", "https://www.nasdaq.com/articles/10-stocks-with-10-plus-gains-in-october-2015-11-02", "https://www.nasdaq.com/articles/gilead-sciences-shrugging-its-competitors-2015-10-31", "https://www.nasdaq.com/articles/health-care-sector-update-10302015-gild-sgen-2015-10-30", "https://www.nasdaq.com/articles/zoetis-tops-q3-earnings-ups-2015-bottom-line-guidance-2015-11-03", "https://www.nasdaq.com/articles/will-abbvie-abbv-surprise-earnings-again-q3-2015-10-29", "https://www.nasdaq.com/articles/daily-dividend-report-afl-sxi-aapl-wfc-gild-met-ice-gww-chd-2015-10-28", "https://www.nasdaq.com/articles/commit-purchase-gilead-sciences-60-earn-51-using-options-2015-10-28", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-tops-estimates-fda-approves-alexions-strensiq-2015-10-28", "https://www.nasdaq.com/articles/gilead-gild-beats-on-q3-earnings-hcv-drugs-lose-shine-2015-10-28", "https://www.nasdaq.com/articles/companys-31-year-adjusted-eps-growth-streak-will-likely-end-2015-2015-10-28", "https://www.nasdaq.com/articles/top-rated-stock-picks-and-most-read-stories-nasdaqcom-october-18-24-2015-10-27", "https://www.nasdaq.com/articles/another-strong-quarter-gilead-sciences-inc-2015-10-29", "https://www.nasdaq.com/articles/heres-why-wall-street-may-be-dead-wrong-about-abbvie-2015-10-27", "https://www.nasdaq.com/articles/gilead-sciences-gild-stock-rising-q3-earnings-and-revenue-estimates-2015-10-27", "https://www.nasdaq.com/articles/after-hours-most-active-oct-27-2015-twtr-aapl-ge-abx-qqq-msft-csco-pps-nrg-hcc-gild-fb", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-444-follow-through-indicator-32-sensitive", "https://www.nasdaq.com/articles/after-hours-earnings-report-october-27-2015-aapl-gild-esrx-cni-apc-afl-fisv-eix-twtr-vrsk", "https://www.nasdaq.com/articles/specialty-drug-classes-are-costing-consumers-arm-and-leg-2015-10-24", "https://www.nasdaq.com/articles/abbvie-slumps-fda-issues-warning-related-to-2-hcv-drugs-2015-10-23", "https://www.nasdaq.com/articles/vug-aapl-gild-dhr-etf-inflow-alert-2015-10-27", "https://www.nasdaq.com/articles/gilead-sciences-gild-jumps%3A-stock-adds-5.8-in-session-2015-10-23", "https://www.nasdaq.com/articles/whats-in-store-for-gilead-gild-this-earnings-season-2015-10-23", "https://www.nasdaq.com/articles/shares-abbvie-inc-plummeted-today-heres-why-2015-10-22", "https://www.nasdaq.com/articles/achillion-jjs-hcv-combo-drug-phase-iia-study-started-2015-10-22", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-gild-2015-10-22", "https://www.nasdaq.com/articles/stock-market-news-for-october-21-2015-2015-10-21", "https://www.nasdaq.com/articles/battle-royale-gilead-sciences-inc-vs-celgene-corporation-2015-10-21", "https://www.nasdaq.com/articles/see-which-latest-13f-filers-holds-gilead-sciences-2015-10-23", "https://www.nasdaq.com/articles/gilead-sciences-gild-jumps%3A-stock-adds-5.8-in-session-2015-10-23", "https://www.nasdaq.com/articles/whats-in-store-for-gilead-gild-this-earnings-season-2015-10-23", "https://www.nasdaq.com/articles/gilead-sciences-stagnation-directly-ahead-2015-10-18", "https://www.nasdaq.com/articles/5-best-bargains-stock-market-2015-10-18", "https://www.nasdaq.com/articles/bristol-myers-bmy-daklinza-gets-nice-recommendation-2015-10-16", "https://www.nasdaq.com/articles/breaking-down-biotechs-bloodbath-which-companies-buy-2015-10-15", "https://www.nasdaq.com/articles/3-big-questions-gilead-sciences-inc-q3-2015-10-20", "https://www.nasdaq.com/articles/stock-market-news-for-october-20-2015-2015-10-20", "https://www.nasdaq.com/articles/johnson-johnson-tells-gilead-sciences-game-2015-10-20", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-qual-aapl-gild-cost-2015-10-19", "https://www.nasdaq.com/articles/gilead-sciences-stagnation-directly-ahead-2015-10-18", "https://www.nasdaq.com/articles/5-best-bargains-stock-market-2015-10-18", "https://www.nasdaq.com/articles/bristol-myers-bmy-daklinza-gets-nice-recommendation-2015-10-16", "https://www.nasdaq.com/articles/4-biotech-stocks-now-bargain-prices-2015-10-09", "https://www.nasdaq.com/articles/3-beaten-down-biotech-stocks-buy-now-2015-10-14", "https://www.nasdaq.com/articles/build-your-long-term-investment-portfolio-2015-10-09", "https://www.nasdaq.com/articles/stock-market-news-for-october-08-2015-2015-10-08", "https://www.nasdaq.com/articles/gilead-about-disappoint-investors-all-right-reasons-2015-10-08", "https://www.nasdaq.com/articles/3-pharma-stocks-big-margins-safety-2015-10-08", "https://www.nasdaq.com/articles/stock-market-news-for-october-07-2015-2015-10-07", "https://www.nasdaq.com/articles/biotechs-bloodbath-ridiculous-heres-why-2015-10-07", "https://www.nasdaq.com/articles/bristol-myers-gets-priority-review-for-hcv-drug-daklinza-2015-10-07", "https://www.nasdaq.com/articles/2-reasons-gilead-sciences-suffered-through-rough-september-2015-10-09", "https://www.nasdaq.com/articles/3-biotech-stocks-have-been-unfairly-beaten-down-2015-10-06", "https://www.nasdaq.com/articles/mercks-mrk-all-oral-ribavirin-free-hcv-data-published-2015-10-06", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-gild-hp-t-2015-10-06", "https://www.nasdaq.com/articles/why-abbvie-incs-shares-slumped-13-september-2015-10-06", "https://www.nasdaq.com/articles/contravir-soars-150-new-hbv-drug-60x-more-active-gileads-viread-2015-10-05", "https://www.nasdaq.com/articles/3-biotech-bargains-buy-2015-10-05", "https://www.nasdaq.com/articles/tweet-hillary-pros-see-biotech-etfs-buy-2015-10-05", "https://www.nasdaq.com/articles/health-care-sector-update-10072015-ctrvavxladpt-2015-10-07", "https://www.nasdaq.com/articles/health-care-sector-update-10052015-oncectrvsien-2015-10-05", "https://www.nasdaq.com/articles/health-care-sector-update-10052015-atrcctrvgildsien-2015-10-05", "https://www.nasdaq.com/articles/5-stocks-we-bought-recently-2015-10-04", "https://www.nasdaq.com/articles/ishares-msci-usa-quality-factor-etf-experiences-big-inflow-2015-10-01", "https://www.nasdaq.com/articles/stock-market-news-for-october-01-2015-2015-10-01", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-vertex-gilead-biogen-and-celgene-2015-10-01", "https://www.nasdaq.com/articles/3-companies-could-beat-apple-1-trillion-valuation-2015-10-01", "https://www.nasdaq.com/articles/gileads-letairis-gets-fda-nod-in-combination-with-adcirca-2015-10-05", "https://www.nasdaq.com/articles/biotech-stock-roundup-pricing-concerns-hit-biotech-stocks-eu-nod-regenerons-praluent-2015", "https://www.nasdaq.com/articles/buy-3-compelling-biotech-stocks-at-bargain-prices-2015-09-29", "https://www.nasdaq.com/articles/gilead-sciences-dominance-hepatitis-c-unstoppable-2015-09-29", "https://www.nasdaq.com/articles/john-buckinghams-interview-barrons-2015-09-29", "https://www.nasdaq.com/articles/charlie-mungers-six-filters-investing-successfully-2015-09-28", "https://www.nasdaq.com/articles/regeneron-sanofis-pcsk9-inhibitor-praluent-approved-in-eu-2015-09-28", "https://www.nasdaq.com/articles/genomic-health-posts-positive-breast-cancer-trial-results-2015-09-28", "https://www.nasdaq.com/articles/stock-market-news-for-september-30-2015-2015-09-30", "https://www.nasdaq.com/articles/stock-market-news-for-september-25-2015-2015-09-25", "https://www.nasdaq.com/articles/kempharm-kmph-updates-on-abuse-deterrent-opioid-drug-2015-09-25", "https://www.nasdaq.com/articles/aduro-adro-to-acquire-bionovion-in-cash-and-stock-deal-2015-09-25", "https://www.nasdaq.com/articles/bellerophon-presents-positive-interim-data-on-inopulse-2015-09-25", "https://www.nasdaq.com/articles/fridays-etf-unusual-volume-xbi-2015-09-25", "https://www.nasdaq.com/articles/myriad-genetics-posts-positive-data-on-oncology-tests-2015-09-25", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-juno-amgen-gilead-intra-cellular-and-traconthe-zacks", "https://www.nasdaq.com/articles/best-selling-drugs-world-2020-2015-09-26", "https://www.nasdaq.com/articles/conatus-reports-promising-phase-ii-data-on-emricasan-2015-09-24", "https://www.nasdaq.com/articles/amgen-allergans-biosimilar-of-avastin-tops-phase-iii-study-2015-09-24", "https://www.nasdaq.com/articles/pdl-biopharma-concludes-financing-agreement-with-avinger-2015-09-24", "https://www.nasdaq.com/articles/myriad-genetics%3A-study-results-impress-currency-woes-stay-2015-09-24", "https://www.nasdaq.com/articles/biotech-stock-roundup-clintons-tweet-shakes-biotech-stocks-amgen-pipeline-boosting-deals", "https://www.nasdaq.com/articles/zacks.com-featured-expert-kevin-matras-highlights%3A-cal-maine-foods-express-tesoro-build-a", "https://www.nasdaq.com/articles/247-billion-says-gilead-something-2015-09-23", "https://www.nasdaq.com/articles/orexigen-receives-%2422m-milestone-payment-for-contrave-2015-09-24", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-falls%3A-stock-goes-down-15.8-2015-09-23", "https://www.nasdaq.com/articles/strength-seen-in-vascular-biogenics-vblt%3A-stock-up-22-2015-09-23", "https://www.nasdaq.com/articles/kythera-files-ind-application-for-male-hair-loss-treatment-2015-09-23", "https://www.nasdaq.com/articles/herons-hrtx-post-operative-pain-candidate-encourages-2015-09-23", "https://www.nasdaq.com/articles/acelrxs-pain-treatment-drug-zalviso-approved-in-europe-2015-09-23", "https://www.nasdaq.com/articles/weekly-insider-sells-highlight-flowers-foods-gilead-sciences-cigna-hanesbrands-2015-09-22", "https://www.nasdaq.com/articles/pfizers-xeljanz-tops-phase-iii-ulcerative-colitis-studies-2015-09-22", "https://www.nasdaq.com/articles/horizon-pharma-hznp-in-focus%3A-stock-plunges-12-2015-09-23", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-falls%3A-stock-goes-down-15.8-2015-09-23", "https://www.nasdaq.com/articles/5-biotech-stocks-hit-hard-hillary-clintons-tweet-2015-09-22", "https://www.nasdaq.com/articles/peg-ratio-vs-pe-ratio-2015-09-22", "https://www.nasdaq.com/articles/10-super-high-growth-stocks-buy-now-2015-09-21", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-drna-rises%3A-stock-gains-7.8-2015-09-21", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-medivation-gilead-sciences-regeneron-pharmaceuticals", "https://www.nasdaq.com/articles/organovo-holdings-onvo-in-focus%3A-stock-jumps-6.7-2015-09-21", "https://www.nasdaq.com/articles/inovio-gets-grant-for-ebola-drugs-regeneron-inks-deal-2015-09-22", "https://www.nasdaq.com/articles/flex-pharma-flks-in-focus-stock-tumbles-8.9-2015-09-21", "https://www.nasdaq.com/articles/heres-why-gilead-sciences-buy-hint-its-not-hepatitis-c-2015-09-21", "https://www.nasdaq.com/articles/test-or-retest-2015-09-21", "https://www.nasdaq.com/articles/amgens-kyprolis-label-expansion-under-priority-review-2015-09-21", "https://www.nasdaq.com/articles/trevena-hits-a-52-week-high-on-positive-phase-ii-data-2015-09-21", "https://www.nasdaq.com/articles/gild-crosses-below-key-moving-average-level-2015-09-21", "https://www.nasdaq.com/articles/tracon-skyrockets-on-positive-choriocarcinoma-study-data-2015-09-21", "https://www.nasdaq.com/articles/genvec-gnvc-shows-strength%3A-stock-moves-up-18.7-2015-09-21", "https://www.nasdaq.com/articles/neogenomics-hits-a-52-week-high-on-cancer-testing-deal-2015-09-21", "https://www.nasdaq.com/articles/3-triple-digit-biotech-stocks-are-worth-every-penny-2015-09-19", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-xlv-jnj-gild-mrk-2015-09-18", "https://www.nasdaq.com/articles/yellen-doesnt-raise-rates%3A-4-biotech-stocks-to-buy-2015-09-18", "https://www.nasdaq.com/articles/allergan-gedeons-vraylar-gets-fda-nod-for-mental-disorders-2015-09-18", "https://www.nasdaq.com/articles/fridays-etf-unusual-volume-xbi-2015-09-18", "https://www.nasdaq.com/articles/3-biotech-stocks-can-upgrade-your-portfolio-2015-09-18", "https://www.nasdaq.com/articles/biodelivery-up-opioid-dependence-treatments-in-focus-2015-09-21", "https://www.nasdaq.com/articles/neogenomics-hits-a-52-week-high-on-cancer-testing-deal-2015-09-21", "https://www.nasdaq.com/articles/3-triple-digit-biotech-stocks-are-worth-every-penny-2015-09-19", "https://www.nasdaq.com/articles/aerie-reported-positive-phase-iii-data-on-rhopressa-2015-09-17", "https://www.nasdaq.com/articles/novo-nordisks-victoza-fares-better-than-sanofis-lyxumia-2015-09-17", "https://www.nasdaq.com/articles/intra-cellular-up-on-positive-data-from-schizophrenia-study-2015-09-17", "https://www.nasdaq.com/articles/xenoport-hits-52-week-low-on-preliminary-psoriasis-data-2015-09-17", "https://www.nasdaq.com/articles/bristol-myers-up-opdivo-gets-breakthrough-therapy-status-2015-09-17", "https://www.nasdaq.com/articles/inovio-presents-positive-data-on-cervical-neoplasia-drug-2015-09-18", "https://www.nasdaq.com/articles/intra-cellular-therapies-itci-jumps%3A-stock-rises-86.9-2015-09-17", "https://www.nasdaq.com/articles/could-these-2-biopharmas-be-real-apples-gilead-sciences-eye-2015-09-17", "https://www.nasdaq.com/articles/aerie-reported-positive-phase-iii-data-on-rhopressa-2015-09-17", "https://www.nasdaq.com/articles/novo-nordisks-victoza-fares-better-than-sanofis-lyxumia-2015-09-17", "https://www.nasdaq.com/articles/insite-vision-terminates-qlt-deal-in-favor-of-sun-pharma-2015-09-16", "https://www.nasdaq.com/articles/baxalta-seeks-fda-nod-for-primary-immunodeficiency-disorder-2015-09-16", "https://www.nasdaq.com/articles/top-weekly-insider-sells-highlights-2015-09-15", "https://www.nasdaq.com/articles/illumina-in-partnership-with-memorial-sloan-to-develop-ctdna-2015-09-17", "https://www.nasdaq.com/articles/trevena-trvn-catches-eye%3A-stock-adds-15.5-in-session-2015-09-15", "https://www.nasdaq.com/articles/raptor-pharmaceuticals-rptp-in-focus%3A-stock-plunges-37.5-2015-09-15", "https://www.nasdaq.com/articles/did-gilead-sciences-just-commit-cardinal-sin-2015-09-15", "https://www.nasdaq.com/articles/medivation-upgraded-to-strong-buy-perfect-for-your-portfolio-2015-09-15", "https://www.nasdaq.com/articles/abbvie-seeks-fda-approval-for-imbruvicas-label-expansion-2015-09-15", "https://www.nasdaq.com/articles/raptor-crushed-by-liver-disease-data-hits-52-week-low-2015-09-15", "https://www.nasdaq.com/articles/company-news-for-september-14-2015-2015-09-14", "https://www.nasdaq.com/articles/biotech-poised-rebound-5-growth-picks-2015-09-15", "https://www.nasdaq.com/articles/which-biotech-blue-chip-stock-best-buy-2015-09-14", "https://www.nasdaq.com/articles/collegiums-xtampza-supported-for-approval-by-fda-panels-2015-09-14", "https://www.nasdaq.com/articles/sanofis-sny-lixilan-positive-in-phase-iii-diabetes-study-2015-09-14", "https://www.nasdaq.com/articles/better-buy-biogen-vs-gilead-sciences-2015-09-14", "https://www.nasdaq.com/articles/will-kite-kite-get-orphan-status-again-eu-kte-c19-2015-09-14", "https://www.nasdaq.com/articles/4-ways-protect-yourself-biotech-meltdown-2015-09-13", "https://www.nasdaq.com/articles/weekly-cfo-sells-highlight-gilead-sciences-dexcom-and-palo-alto-networks-2015-09-13", "https://www.nasdaq.com/articles/seattle-genetics-sgen-catches-eye%3A-stock-moves-up-8.3-2015-09-14", "https://www.nasdaq.com/articles/which-biotech-blue-chip-stock-best-buy-2015-09-14", "https://www.nasdaq.com/articles/why-is-gilead-gild-raising-a-whopping-%2410-billion-2015-09-11", "https://www.nasdaq.com/articles/health-care-sector-update-09112015-akbabiibgildarwrnwbo-2015-09-11", "https://www.nasdaq.com/articles/revances-botulinum-toxin-type-a-gel-in-phase-ii-study-2015-09-11", "https://www.nasdaq.com/articles/aduro-incyte-in-clinical-trial-agreement-for-ovarian-cancer-2015-09-11", "https://www.nasdaq.com/articles/genomic-health%3A-test-volume-impresses-margin-woes-persist-2015-09-11", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xlv-jnj-gild-mrk-2015-09-10", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-september-14-2015-2015-09-11", "https://www.nasdaq.com/articles/vbi-vaccines-vbiv-worth-a-look%3A-stock-adds-8-in-session-2015-09-10", "https://www.nasdaq.com/articles/clovis-oncology-clvs-jumps%3A-stock-adds-13.8-in-session-2015-09-10", "https://www.nasdaq.com/articles/vivus-vvus-in-focus%3A-stock-moves-12.5-higher-in-session-2015-09-10", "https://www.nasdaq.com/articles/marinus-end-of-phase-ii-meeting-positive-for-ganaxolone-2015-09-10", "https://www.nasdaq.com/articles/protalixs-phase-i-ii-fabry-disease-study-interim-data-positive-2015-09-10", "https://www.nasdaq.com/articles/integra-faces-multiple-headwinds-seaspine-spin-off-strong-2015-09-10", "https://www.nasdaq.com/articles/notable-thursday-option-activity-brcm-cvc-gild-2015-09-10", "https://www.nasdaq.com/articles/biogen-biib-autoimmune-disease-deal-worth-544m-2015-09-10", "https://www.nasdaq.com/articles/vbi-vaccines-vbiv-worth-a-look%3A-stock-adds-8-in-session-2015-09-10", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-regeneron-pharmaceuticals-thermo-fisher", "https://www.nasdaq.com/articles/immunomedics-immu-worth-watching%3A-stock-rises-8.4-2015-09-09", "https://www.nasdaq.com/articles/does-achillions-13-slump-august-make-it-bargain-2015-09-09", "https://www.nasdaq.com/articles/impax-hayward-facility-gets-fda-clearance-shares-rise-2015-09-09", "https://www.nasdaq.com/articles/biodelivery-up-on-striking-deal-with-tenncare-for-bunavail-2015-09-09", "https://www.nasdaq.com/articles/theravance-glaxo-summit-study-misses-primary-endpoint-2015-09-09", "https://www.nasdaq.com/articles/epi-syg-big-etf-inflows-2015-09-09", "https://www.nasdaq.com/articles/bursting-biotechs-are-these-stocks-buys-2015-09-08", "https://www.nasdaq.com/articles/healthcare-boom-a-bubble-4-stocks-to-buy-anyway-2015-09-08", "https://www.nasdaq.com/articles/perigon-wealth-managements-largest-buys-second-quarter-2015-09-08", "https://www.nasdaq.com/articles/bristol-myers-opdivo-encourages-in-lung-cancer-study-2015-09-08", "https://www.nasdaq.com/articles/is-another-amendment-of-qlt-insite-vision-deal-coming-up-2015-09-08", "https://www.nasdaq.com/articles/whipsaw-market-right-back-these-three-tech-investing-plays-2015-09-08", "https://www.nasdaq.com/articles/alexions-kanuma-fda-action-date-delayed-by-three-months-2015-09-07", "https://www.nasdaq.com/articles/alnylam-to-speed-up-development-for-primary-hyperoxaluria-2015-09-09", "https://www.nasdaq.com/articles/astrazeneca-starpharma-ink-drug-delivery-technology-deal-2015-09-07", "https://www.nasdaq.com/articles/4-low-volatility-stocks-to-sail-through-market-mayhem-2015-09-04", "https://www.nasdaq.com/articles/value-stocks-2-buy-1-avoid-2015-09-04", "https://www.nasdaq.com/articles/roches-hemophilia-a-drug-gets-breakthrough-status-in-u.s.-2015-09-04", "https://www.nasdaq.com/articles/allergan-agn-to-buy-eye-care-device-company-aquesys-2015-09-04", "https://www.nasdaq.com/articles/astrazenecas-brilinta-gains-fda-nod-for-label-expansion-2015-09-04", "https://www.nasdaq.com/articles/dicerna-files-ind-application-for-primary-hyperoxaluria-drug-2015-09-04", "https://www.nasdaq.com/articles/5-low-risk-stocks-dividend-investors-2015-09-07", "https://www.nasdaq.com/articles/astrazeneca-ties-up-for-flumist-caz-avi-scores-shares-up-2015-09-03", "https://www.nasdaq.com/articles/nektar-receives-%2440m-milestone-payment-from-astrazeneca-2015-09-03", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-google-gilead-sciences-regeneron-pharmaceuticals", "https://www.nasdaq.com/articles/gilead-sciences-11-drop-august-could-make-it-steal-2015-09-03", "https://www.nasdaq.com/articles/incyte-hengrui-to-develop-anti-pd-1-monoclonal-antibody-2015-09-03", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-xlv-gild-agn-amgn-2015-09-02", "https://www.nasdaq.com/articles/4-google-beating-stocks-that-still-hold-promise-2015-09-02", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-middle-turbulent-market-2015-09-03", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-news-ariad-takeover-target-2015-09-02", "https://www.nasdaq.com/articles/meet-manager-top-performing-mutual-fund-2015-09-02", "https://www.nasdaq.com/articles/astrazeneca-strikes-deal-with-valeant-for-psoriasis-drug-2015-09-02", "https://www.nasdaq.com/articles/illumina-acquires-genologics-boosts-genomic-sequencing-2015-09-02", "https://www.nasdaq.com/articles/stock-market-news-for-september-01-2015-2015-09-01", "https://www.nasdaq.com/articles/cytori-therapeutics-cytx-in-focus%3A-stock-rises-15-2015-09-01", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-september-02-2015-2015-09-01", "https://www.nasdaq.com/articles/strength-seen-in-trevena-trvn%3A-stock-surges-51.5-2015-09-02", "https://www.nasdaq.com/articles/5-top-stocks-buy-september-2015-09-01", "https://www.nasdaq.com/articles/intercepts-icpt-oca-under-priority-review-in-the-u.s.-2015-09-01", "https://www.nasdaq.com/articles/amicus-fold-signs-agreement-to-acquire-scioderm-2015-09-01", "https://www.nasdaq.com/articles/trevenas-postoperative-pain-drug-positive-in-phase-iib-study-2015-09-01", "https://www.nasdaq.com/articles/sanofi-teams-up-with-google-life-sciences-for-diabetes-2015-09-01", "https://www.nasdaq.com/articles/allergan-buys-naurex-boosts-mental-health-portfolio-2015-09-01", "https://www.nasdaq.com/articles/ariad-skyrockets-more-than-40-following-buyout-rumors-2015-08-31", "https://www.nasdaq.com/articles/bind-therapeutics-bind-rises%3A-stock-adds-5.4-in-session-2015-09-01", "https://www.nasdaq.com/articles/alnylam-presents-positive-data-on-pcsk9-synthesis-inhibitor-2015-08-31", "https://www.nasdaq.com/articles/4-not-too-scary-ways-make-money-biotech-stocks-2015-08-30", "https://www.nasdaq.com/articles/pfizer-pfe-gains-on-label-expansion-efforts-for-ibrance-2015-08-28", "https://www.nasdaq.com/articles/exelixis-up-on-swiss-approval-of-advanced-melanoma-drug-2015-08-28", "https://www.nasdaq.com/articles/eli-lillys-lly-diabetes-drug-synjardy-gets-u.s.-approval-2015-08-28", "https://www.nasdaq.com/articles/12-attractive-fast-growing-dividend-growth-stocks-high-total-return-2015-08-27", "https://www.nasdaq.com/articles/celldex-cldx-shows-strength%3A-stock-adds-8.2-in-session-2015-08-26", "https://www.nasdaq.com/articles/applied-genetic-meets-enrolment-milestone-in-xlrs-study-2015-08-31", "https://www.nasdaq.com/articles/what-makes-colucid-pharmaceuticals-clcd-a-strong-sell-2015-08-26", "https://www.nasdaq.com/articles/jj-to-sell-sugar-substitute-splenda-to-heartland-food-2015-08-26", "https://www.nasdaq.com/articles/novartis-nvs-promacta-label-further-expanded-in-u.s.-2015-08-26", "https://www.nasdaq.com/articles/eli-lillys-alimta-patent-upheld-by-u.s.-district-court-2015-08-26", "https://www.nasdaq.com/articles/sareptas-dmd-drug-eteplirsen-gains-fda-priority-review-2015-08-26", "https://www.nasdaq.com/articles/bouncing-biotech-3-stocks-buy-2015-08-25", "https://www.nasdaq.com/articles/xlv-gild-agn-amgn-large-outflows-detected-etf-2015-08-25", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-jumps%3A-stock-moves-8.3-higher-2015-08-26", "https://www.nasdaq.com/articles/epizyme-epzm-shows-strength%3A-stock-adds-9.6-in-session-2015-08-25", "https://www.nasdaq.com/articles/4-notable-stocks-still-green-after-late-tuesday-sell-2015-08-25", "https://www.nasdaq.com/articles/nasdaq-slips-into-correction%3A-4-stocks-stand-tall-2015-08-25", "https://www.nasdaq.com/articles/medivation-to-gain-global-rights-to-biomarins-talazoparib-2015-08-25", "https://www.nasdaq.com/articles/astrazeneca-peregrine-team-up-for-immuno-oncology-study-2015-08-25", "https://www.nasdaq.com/articles/stock-futures-plunge%3A-4-value-stocks-brokers-love-right-now-2015-08-24", "https://www.nasdaq.com/articles/6-things-you-should-know-about-stock-market-correction-2015-08-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-dsw-cardtronics-and-ceco-environmental", "https://www.nasdaq.com/articles/raptor-pharmaceuticals-rptp-in-focus%3A-stock-adds-5.8-2015-08-24", "https://www.nasdaq.com/articles/seres-mcrb-up-on-orphan-drug-status-for-lead-candidate-2015-08-24", "https://www.nasdaq.com/articles/alkermes-alks-aristada-review-date-postponed-by-fda-2015-08-24", "https://www.nasdaq.com/articles/bad-news-hepatitis-c-patients-your-treatment-costs-may-be-higher-expected-2015-08-22", "https://www.nasdaq.com/articles/fridays-etf-unusual-volume-pjp-2015-08-21", "https://www.nasdaq.com/articles/argos-therapeutics-args-jumps%3A-stock-moves-up-12-2015-08-21", "https://www.nasdaq.com/articles/falling-earnings-estimates-signal-weakness-ahead-for-alexion-pharmaceuticals-alxn-2015-08", "https://www.nasdaq.com/articles/arena-pharmaceuticals-arna-rises%3A-stock-adds-5.7-in-session-2015-08-24", "https://www.nasdaq.com/articles/vascular-vblt-starts-patient-dosing-in-glioblastoma-study-2015-08-21", "https://www.nasdaq.com/articles/raptor-rptp-to-buy-quinsair-boost-rare-disease-portfolio-2015-08-21", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-gild-2015-08-21", "https://www.nasdaq.com/articles/is-valeants-vrx-%241b-buy-of-addyi-maker-a-prudent-move-2015-08-21", "https://www.nasdaq.com/articles/gileads-eu-regulatory-application-for-hiv-drug-validated-2015-08-21", "https://www.nasdaq.com/articles/why-eli-lilly-lly-was-bright-spot-market-thursday-2015-08-21", "https://www.nasdaq.com/articles/weakness-seen-in-trovagene-trov-estimates%3A-should-you-stay-away-2015-08-20", "https://www.nasdaq.com/articles/did-abbvie-just-make-incredibly-brilliant-decision-2015-08-21", "https://www.nasdaq.com/articles/vascular-vblt-starts-patient-dosing-in-glioblastoma-study-2015-08-21", "https://www.nasdaq.com/articles/raptor-rptp-to-buy-quinsair-boost-rare-disease-portfolio-2015-08-21", "https://www.nasdaq.com/articles/vicals-antifungal-candidate-vl-2397-receives-qidp-status-2015-08-20", "https://www.nasdaq.com/articles/biomarins-drisapersen-gets-rare-pediatric-disease-status-2015-08-20", "https://www.nasdaq.com/articles/illumina-ilmn-creates-helix-to-encourage-genomics-startups-2015-08-20", "https://www.nasdaq.com/articles/insys-files-cp-dronabinol-oral-solution-under-fda-review-2015-08-19", "https://www.nasdaq.com/articles/mercks-keytruda-under-fda-review-for-first-line-melanoma-2015-08-19", "https://www.nasdaq.com/articles/bellerophon-therapeutics-blph-jumps%3A-stock-rises-15.8-2015-08-20", "https://www.nasdaq.com/articles/3-dividend-paying-healthcare-stocks-buy-and-hold-forever-2015-08-18", "https://www.nasdaq.com/articles/achillion-pharmaceuticals-achn-jumps%3A-stock-gains-16.7-2015-08-18", "https://www.nasdaq.com/articles/kite-pharma-provides-update-death-not-related-kte-c19-2015-08-18", "https://www.nasdaq.com/articles/biolinerx-up-on-phase-iib-study-initiation-on-leukemia-drug-2015-08-18", "https://www.nasdaq.com/articles/myriad-genetics%3A-myrisk-offers-strength-currency-woes-linger-2015-08-18", "https://www.nasdaq.com/articles/genomic-health-prostate-cancer-test-wins-medicare-coverage-2015-08-18", "https://www.nasdaq.com/articles/ishares-core-sp-500-etf-experiences-big-inflow-2015-08-17", "https://www.nasdaq.com/articles/walgreens-boots-plans-to-eliminate-370-employees-to-cut-cost-2015-08-19", "https://www.nasdaq.com/articles/3-numbers-show-why-gilead-sciences-inc-great-position-today-2015-08-15", "https://www.nasdaq.com/articles/what-falling-estimates-price-mean-for-bluebird-bio-blue-2015-08-14", "https://www.nasdaq.com/articles/why-acadia-pharmaceuticals-acad-could-be-positioned-for-a-slump-2015-08-14", "https://www.nasdaq.com/articles/john-buckingham-buys-10-new-stakes-second-quarter-2015-08-14", "https://www.nasdaq.com/articles/emergent-biosolutions-gets-%2444m-cdc-contract-for-vigiv-2015-08-14", "https://www.nasdaq.com/articles/amgn-vs-gild-battle-large-cap-biotech-stock-2015-08-14", "https://www.nasdaq.com/articles/better-dividend-stock-gilead-sciences-inc-vs-amgen-inc-2015-08-17", "https://www.nasdaq.com/articles/myriad%3A-medicare-coverage-for-prolaris-prostrate-cancer-test-2015-08-14", "https://www.nasdaq.com/articles/integras-acquisitions-to-buoy-growth-in-15-currency-woes-stay-2015-08-14", "https://www.nasdaq.com/articles/biodeliverys-new-onsolis-formulation-gains-fda-approval-2015-08-14", "https://www.nasdaq.com/articles/juno-therapeutics-posts-line-2q-loss-pipeline-focus-2015-08-13", "https://www.nasdaq.com/articles/myriad-genetics-mygn-jumps%3A-stock-moves-6.8-higher-2015-08-13", "https://www.nasdaq.com/articles/should-you-get-rid-of-five-prime-therapeutics-fprx-now-2015-08-13", "https://www.nasdaq.com/articles/gilead-sciences-biotechs-biggest-bargain-2015-08-13", "https://www.nasdaq.com/articles/integra-closes-tei-buyout-to-grow-in-regenerative-wound-care-2015-08-14", "https://www.nasdaq.com/articles/tevas-chorea-in-huntington-disease-treatment-under-review-2015-08-13", "https://www.nasdaq.com/articles/myriad-genetics-posts-in-line-earnings-in-q4-margins-suffer-2015-08-12", "https://www.nasdaq.com/articles/enzon-pharmaceuticals-inc-enzn-ex-dividend-date-scheduled-august-13-2015-2015-08-12", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-august-13-2015-2015-08-12", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-august-13-2015-2015-08-12", "https://www.nasdaq.com/articles/should-you-get-rid-of-ani-pharmaceuticals-anip-now-2015-08-12", "https://www.nasdaq.com/articles/clovis-oncology-strikes-deal-with-roche-for-rociletinib-2015-08-12", "https://www.nasdaq.com/articles/abbvie-roches-leukemia-drug-hits-phase-ii-primary-endpoint-2015-08-13", "https://www.nasdaq.com/articles/pluristem-psti-provides-update-on-plx-pad-cells-in-japan-2015-08-12", "https://www.nasdaq.com/articles/bioscrips-strategic-plans-offer-hope-margin-concerns-stay-2015-08-12", "https://www.nasdaq.com/articles/kite-pharma-2q-loss-wider-expected-pipeline-focus-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/repros-incurs-narrower-y-y-loss-in-q2-pipeline-in-focus-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/celldex-q2-loss-narrower-than-expected-pipeline-in-focus-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/biodelivery-incurs-wider-loss-in-q2-revenues-fall-y-y-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/trovagene-q2-loss-widens-on-higher-expenses-shares-fall-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/stocks-etfs-to-reflect-top-sales-growth-2015-08-12", "https://www.nasdaq.com/articles/sanofi-inks-deals-diabetes-and-immuno-oncology-in-focus-analyst-blog-2015-08-10", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-august-2015-08-09", "https://www.nasdaq.com/articles/did-gilead-sciences-just-give-wall-street-huge-head-fake-2015-08-08", "https://www.nasdaq.com/articles/ishares-core-sp-500-etf-experiences-big-inflow-2015-08-07", "https://www.nasdaq.com/articles/top-biotech-stocks-buy-sale-2015-08-07", "https://www.nasdaq.com/articles/what-does-the-social-media-crowd-think-about-gilead-sciences-gild-stock-tale-of-the-tape", "https://www.nasdaq.com/articles/sarepta-posts-narrower-than-expected-loss-in-q2-shares-up-analyst-blog-2015-08-07", "https://www.nasdaq.com/articles/gilead-sciences-stock%3A-3-reasons-why-it-is-a-top-choice-for-growth-investors-tale-of-the", "https://www.nasdaq.com/articles/geron-q2-loss-narrower-expected-imetelstat-focus-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/arena-pharmaceuticals-2q-loss-narrower-expected-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/ronald-muhlenkamp-makes-small-changes-composition-his-top-10-stakes-2015-08-06", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-misses-on-q2-earnings-affirms-view-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/osiris-therapeutics-q2-earnings-revenues-grow-yy-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/allergans-agn-2q-earnings-revenues-shoot-yy-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/what-company-will-be-fastest-growing-big-cap-biotech-2015-08-05", "https://www.nasdaq.com/articles/genomic-health-q2-loss-wider-than-expected-tests-ramp-up-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-bjs-restaurants-gilead-sciences-scorpio-tankers-and", "https://www.nasdaq.com/articles/mixed-biotech-earnings-put-these-etfs-in-focus-etf-news-and-commentary-2015-08-04", "https://www.nasdaq.com/articles/integra-tops-earnings-revenues-guides-low-on-spine-sale-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/4-stocks-set-to-crush-their-52-week-highs-soon-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/whats-in-store-for-conatus-cnat-this-earnings-season-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/5-cant-miss-quotes-gilead-sciences-management-2015-08-01", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-xlv-gild-agn-bmy-2015-07-30", "https://www.nasdaq.com/articles/top-rated-stock-picks-and-most-read-stories-nasdaqcom-july-26-august-1-2015-08-04", "https://www.nasdaq.com/articles/gileads-hepatitis-c-dominance-unchecked-abbvie-2015-07-30", "https://www.nasdaq.com/articles/pharma-etf-focused-quality-fast-growing-stocks-2015-07-30", "https://www.nasdaq.com/articles/even-recent-declines-investors-still-love-biotech-etfs-2015-07-30", "https://www.nasdaq.com/articles/yieldboost-gilead-sciences-04-54-using-options-2015-07-29", "https://www.nasdaq.com/articles/stock-market-news-for-july-29-2015-market-news-2015-07-29", "https://www.nasdaq.com/articles/amp-your-portfolio-these-biotech-stocks-2015-07-29", "https://www.nasdaq.com/articles/gilead-gild-beats-on-q2-earnings-raises-2015-outlook-analyst-blog-2015-07-29", "https://www.nasdaq.com/articles/stock-market-news-for-july-30-2015-market-news-2015-07-30", "https://www.nasdaq.com/articles/gileads-hepatitis-c-dominance-unchecked-abbvie-2015-07-30", "https://www.nasdaq.com/articles/daily-dividend-report-mpc-hlt-cg-xom-wfc-gild-amgn-syk-px-bdx-2015-07-29", "https://www.nasdaq.com/articles/great-stocks-baby-boomers-2015-07-28", "https://www.nasdaq.com/articles/ewg-dwaq-big-etf-inflows-2015-07-28", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-abbvie-merck-achillion-pharmaceuticals", "https://www.nasdaq.com/articles/are-these-2-big-pharmas-really-buyout-candidates-2015-07-28", "https://www.nasdaq.com/articles/3-big-biotech-buybacks-investors-should-love-2015-07-28", "https://www.nasdaq.com/articles/lithia-motors-qualcomm-twitter-gilead-and-facebook-highlighted-as-zacks-bull-and-bear-of", "https://www.nasdaq.com/articles/gilead-sciences-inc-posts-q2-results-able-beat-earnings-revenue-estimates-stocks-news-2015", "https://www.nasdaq.com/articles/gilead-sciences-inc-q2-earnings-harvoni-delivers-again-2015-07-28", "https://www.nasdaq.com/articles/after-hours-most-active-jul-28-2015-twtr-sig-jd-prxl-acwi-t-abev-mrk-bac-gild-utiw-fb-2015", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-556-follow-through-indicator-35-sensitive", "https://www.nasdaq.com/articles/after-hours-earnings-report-july-28-2015-gild-esrx-apc-eqr-afl-twtr-ew-akam-vrsk-ctxs-kim", "https://www.nasdaq.com/articles/stock-market-news-for-july-27-2015-market-news-2015-07-27", "https://www.nasdaq.com/articles/3-stocks-retirees-buy-2015-07-27", "https://www.nasdaq.com/articles/twitter-q2-earnings-turns-after-hours-rollercoaster-analyst-blog-2015-07-28", "https://www.nasdaq.com/articles/gilead-sciences-inc-posts-q2-results-able-beat-earnings-revenue-estimates-stocks-news-2015", "https://www.nasdaq.com/articles/gilead-sciences-inc-q2-earnings-harvoni-delivers-again-2015-07-28", "https://www.nasdaq.com/articles/after-hours-most-active-jul-28-2015-twtr-sig-jd-prxl-acwi-t-abev-mrk-bac-gild-utiw-fb-2015", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-556-follow-through-indicator-35-sensitive", "https://www.nasdaq.com/articles/after-hours-earnings-report-july-28-2015-gild-esrx-apc-eqr-afl-twtr-ew-akam-vrsk-ctxs-kim", "https://www.nasdaq.com/articles/gilead-sciences-next-big-move-may-not-be-what-youre-thinking-2015-07-22", "https://www.nasdaq.com/articles/gilead-gild-presents-encouraging-data-on-hiv-candidate-analyst-blog-2015-07-22", "https://www.nasdaq.com/articles/4-stocks-to-fight-the-virus-on-world-hepatitis-day-analyst-blog-2015-07-27", "https://www.nasdaq.com/articles/best-deals-value-stocks-2015-07-21", "https://www.nasdaq.com/articles/bristol-myers-hiv-1-drug-evotaz-gets-european-approval-analyst-blog-2015-07-17", "https://www.nasdaq.com/articles/8-biotech-stocks-buy-2015-07-16", "https://www.nasdaq.com/articles/manager-hot-new-biotech-etfs-explains-strategy-2015-07-16", "https://www.nasdaq.com/articles/are-gilead-sciences-incs-expectations-too-high-drug-2015-07-15", "https://www.nasdaq.com/articles/stock-market-news-for-july-14-2015-market-news-2015-07-14", "https://www.nasdaq.com/articles/3-biotech-stocks-could-soon-rocket-higher-2015-07-14", "https://www.nasdaq.com/articles/top-rated-stock-picks-and-most-read-stories-nasdaqcom-july-12-18-2015-07-21", "https://www.nasdaq.com/articles/best-deals-value-stocks-2015-07-21", "https://www.nasdaq.com/articles/bristol-myers-hiv-1-drug-evotaz-gets-european-approval-analyst-blog-2015-07-17", "https://www.nasdaq.com/articles/8-biotech-stocks-buy-2015-07-16", "https://www.nasdaq.com/articles/manager-hot-new-biotech-etfs-explains-strategy-2015-07-16", "https://www.nasdaq.com/articles/are-gilead-sciences-incs-expectations-too-high-drug-2015-07-15", "https://www.nasdaq.com/articles/3-stocks-buy-market-crash-2015-07-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-vertex-cf-drug-approved-biogen-strikes-deal-gene-therapy-analyst", "https://www.nasdaq.com/articles/midyear-report-card-grading-my-biotech-predictions-2015-2015-07-14", "https://www.nasdaq.com/articles/ishares-russell-1000-etf-experiences-big-inflow-2015-07-13", "https://www.nasdaq.com/articles/5-drugs-investors-may-be-undervaluing-2015-07-13", "https://www.nasdaq.com/articles/after-hours-most-active-jul-6-2015-abbv-infy-rad-cag-gild-intc-sfm-sfun-bndx-ppc-mbi-mu", "https://www.nasdaq.com/articles/gileads-gild-hcv-drug-harvoni-gets-approval-in-japan-analyst-blog-2015-07-06", "https://www.nasdaq.com/articles/gilead-sciences-spent-125-million-get-drug-market-4-months-early-2015-07-06", "https://www.nasdaq.com/articles/competitive-advantage-best-biotech-stocks-2015-07-05", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-iwb-dis-gild-amzn-2015-07-02", "https://www.nasdaq.com/articles/are-biotechs-bubble-2015-07-07", "https://www.nasdaq.com/articles/express-scripts-reports-public-exchange-pharmacy-trends-analyst-blog-2015-07-02", "https://www.nasdaq.com/articles/stock-market-news-for-july-01-2015-market-news-2015-07-01", "https://www.nasdaq.com/articles/what-beyond-vision-loss-blockbuster-regeneron-2015-07-01", "https://www.nasdaq.com/articles/stock-market-news-for-june-30-2015-market-news-2015-06-30", "https://www.nasdaq.com/articles/juno-celgene-immunotherapy-deal-initial-deal-value-1b-analyst-blog-2015-06-30", "https://www.nasdaq.com/articles/gilead-sciences-gild-ideal-buy-dip-candidate-2015-06-30", "https://www.nasdaq.com/articles/celldexs-rintega-phase-iii-study-recommended-to-continue-analyst-blog-2015-06-30", "https://www.nasdaq.com/articles/gilead-submits-marketing-application-for-hiv-drug-to-fda-analyst-blog-2015-07-02", "https://www.nasdaq.com/articles/biomarins-nda-for-dmd-drug-drisapersen-accepted-by-fda-analyst-blog-2015-06-30", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-files-for-oca-in-u.s.-and-europe-analyst-blog-2015-06-30", "https://www.nasdaq.com/articles/integra-to-acquire-tei-expand-in-regenerative-wound-care-analyst-blog-2015-06-30", "https://www.nasdaq.com/articles/3-stocks-buy-if-biotech-crashes-2015-06-29", "https://www.nasdaq.com/articles/better-dividend-stock-abbvie-or-johnson-johnson-2015-06-29", "https://www.nasdaq.com/articles/biogen-sobis-hemophilia-b-drug-alprolix-under-eu-review-analyst-blog-2015-06-29", "https://www.nasdaq.com/articles/biomarin-dmd-drug-drisapersen-validated-for-eu-review-analyst-blog-2015-06-26", "https://www.nasdaq.com/articles/sarepta-files-eteplirsen-nda-secures-%2440m-debt-financing-analyst-blog-2015-06-30", "https://www.nasdaq.com/articles/eli-lilly-wins-alimta-patent-lawsuit-in-the-uk-shares-up-analyst-blog-2015-06-26", "https://www.nasdaq.com/articles/glaxo-pfizer-meningitis-b-vaccines-get-acips-category-b-analyst-blog-2015-06-25", "https://www.nasdaq.com/articles/agios-doses-first-patient-with-ag-881-in-early-stage-study-analyst-blog-2015-06-25", "https://www.nasdaq.com/articles/transition-therapeutics-tanks-on-alzheimers-disease-data-analyst-blog-2015-06-25", "https://www.nasdaq.com/articles/genomics-oncotype-dcis-score-betters-treatment-guidance-analyst-blog-2015-06-25", "https://www.nasdaq.com/articles/macrocure-mcur-falls%3A-stock-goes-down-10-tale-of-the-tape-2015-06-24", "https://www.nasdaq.com/articles/alnylam-reports-encouraging-new-data-on-hemophilia-drug-analyst-blog-2015-06-24", "https://www.nasdaq.com/articles/can-cambrex-keep-profits-healthy-gilead-pact-2015-06-26", "https://www.nasdaq.com/articles/eli-lilly-wins-alimta-patent-lawsuit-in-the-uk-shares-up-analyst-blog-2015-06-26", "https://www.nasdaq.com/articles/stock-market-news-for-june-23-2015-market-news-2015-06-23", "https://www.nasdaq.com/articles/kite-pharma-and-bluebird-tie-hpv-cancer-targets-analyst-blog-2015-06-23", "https://www.nasdaq.com/articles/can-growth-stock-also-be-value-stock-2015-06-23", "https://www.nasdaq.com/articles/pfizer-to-buy-two-meningitis-vaccines-from-glaxo-for-%24130m-analyst-blog-2015-06-23", "https://www.nasdaq.com/articles/the-medicines-co.-antiplatelet-drug-kengreal-wins-fda-nod-analyst-blog-2015-06-23", "https://www.nasdaq.com/articles/synergy-pharmaceuticals-plecanatide-in-2nd-ibs-c-study-analyst-blog-2015-06-24", "https://www.nasdaq.com/articles/isis-pharmaceuticals-up-on-spinal-muscular-atrophy-data-analyst-blog-2015-06-23", "https://www.nasdaq.com/articles/proshares-releases-2-new-leveraged-biotech-etfs-2015-06-23", "https://www.nasdaq.com/articles/epizyme-lead-candidate-effective-in-ongoing-cancer-study-analyst-blog-2015-06-22", "https://www.nasdaq.com/articles/bristol-myers-bmy-melanoma-drug-opdivo-gets-eu-nod-analyst-blog-2015-06-22", "https://www.nasdaq.com/articles/gilead-patent-for-sovaldi-rejected-in-china-shares-down-analyst-blog-2015-06-22", "https://www.nasdaq.com/articles/where-can-mega-drug-stock-gilead-sciences-go-now-2015-06-22", "https://www.nasdaq.com/articles/did-china-just-crush-gilead-sciences-dreams-2015-06-21", "https://www.nasdaq.com/articles/vicals-genital-herpes-vaccine-fails-in-phase-i-ii-study-analyst-blog-2015-06-23", "https://www.nasdaq.com/articles/stock-market-news-for-june-19-2015-market-news-2015-06-19", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-surges-on-price-target-increase-analyst-blog-2015-06-19", "https://www.nasdaq.com/articles/qiagen-hitachi-high-technologies-ink-molecular-testing-deal-analyst-blog-2015-06-19", "https://www.nasdaq.com/articles/nasdaq-composites-new-high-built-solid-growth-2015-06-19", "https://www.nasdaq.com/articles/masimo-masi-upped-to-strong-buy-on-a-slew-of-positives-analyst-blog-2015-06-18", "https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-or-celgene-corporation-2015-06-18", "https://www.nasdaq.com/articles/lion-biotechnologies-lbio-falls%3A-stock-goes-down-9.1-tale-of-the-tape-2015-06-18", "https://www.nasdaq.com/articles/best-return-equity-biotech-2015-06-20", "https://www.nasdaq.com/articles/eli-lilly-reports-data-on-migraine-drug-inks-oncology-deals-analyst-blog-2015-06-18", "https://www.nasdaq.com/articles/synergy-pharmaceuticals-soars-on-constipation-drug-data-analyst-blog-2015-06-18", "https://www.nasdaq.com/articles/qiagens-new-genetic-fingerprint-kits-to-aid-dna-analysis-analyst-blog-2015-06-18", "https://www.nasdaq.com/articles/biotech-etfs-hit-new-2015-highs-2015-06-18", "https://www.nasdaq.com/articles/the-ensign-group-hits-52-week-high-acquisitions-hold-key-analyst-blog-2015-06-17", "https://www.nasdaq.com/articles/3-good-stocks-buy-their-earnings-growth-2015-06-17", "https://www.nasdaq.com/articles/5-healthcare-stocks-dividend-lovers-2015-06-17", "https://www.nasdaq.com/articles/kythera-soars-on-%242.1-billion-buyout-offer-from-allergan-analyst-blog-2015-06-18", "https://www.nasdaq.com/articles/acorda-gains-on-positive-parkinsons-disease-study-data-analyst-blog-2015-06-17", "https://www.nasdaq.com/articles/genomic-health-liquid-biopsy-test-fit-for-bladder-cancer-analyst-blog-2015-06-17", "https://www.nasdaq.com/articles/shire-to-make-milestone-payment-to-armagen-for-agt-182-analyst-blog-2015-06-16", "https://www.nasdaq.com/articles/redhill-biopharma-surges-on-encouraging-data-on-rhb-105-analyst-blog-2015-06-16", "https://www.nasdaq.com/articles/united-therapeutics-faces-patent-challenge-for-tyvaso-analyst-blog-2015-06-16", "https://www.nasdaq.com/articles/sanofi-starts-dosing-in-phase-i-ii-study-on-olipudase-alfa-analyst-blog-2015-06-16", "https://www.nasdaq.com/articles/bluebird-bio-reports-encouraging-data-on-thalassemia-drug-analyst-blog-2015-06-16", "https://www.nasdaq.com/articles/teva-announces-positive-results-on-tardive-dyskinesia-drug-analyst-blog-2015-06-17", "https://www.nasdaq.com/articles/avalanche-biotechnologies-slips-on-weak-ava-101-data-analyst-blog-2015-06-16", "https://www.nasdaq.com/articles/ishares-us-healthcare-etf-experiences-big-outflow-2015-06-15", "https://www.nasdaq.com/articles/stock-market-news-for-june-15-2015-market-news-2015-06-15", "https://www.nasdaq.com/articles/agios-reports-new-data-on-hematologic-malignancy-drugs-analyst-blog-2015-06-15", "https://www.nasdaq.com/articles/astrazeneca-presents-phase-iii-data-on-gout-drug-lesinurad-analyst-blog-2015-06-15", "https://www.nasdaq.com/articles/celgene-presents-positive-sprint-study-data-on-revlimid-analyst-blog-2015-06-15", "https://www.nasdaq.com/articles/alnylam-reveals-positive-initial-data-on-rnai-drug-aln-cc5-analyst-blog-2015-06-15", "https://www.nasdaq.com/articles/roches-diagnostic-test-with-pfizer-approved-by-fda-analyst-blog-2015-06-16", "https://www.nasdaq.com/articles/novartis-presents-data-on-leukemia-dermatology-drugs-analyst-blog-2015-06-15", "https://www.nasdaq.com/articles/gilead-sciences-next-growth-market-2015-06-14", "https://www.nasdaq.com/articles/novartis-nvs-promactas-label-expansion-approved-in-u.s.-analyst-blog-2015-06-12", "https://www.nasdaq.com/articles/pfizers-pristiq-fails-in-first-phase-iii-pediatric-study-analyst-blog-2015-06-12", "https://www.nasdaq.com/articles/isis-pharmaceuticals-up-on-positive-data-on-isis-smnrx-analyst-blog-2015-06-12", "https://www.nasdaq.com/articles/3-things-abbvie-incs-management-wants-you-know-2015-06-11", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-ex-dividend-date-scheduled-june-12-2015-2015-06-11", "https://www.nasdaq.com/articles/ariad-aria-presents-favorable-long-term-data-on-iclusig-analyst-blog-2015-06-15", "https://www.nasdaq.com/articles/after-hours-most-active-jun-11-2015-qrvo-twtr-wetf-qcom-lo-gm-foxa-gild-aa-rai-qqq-amh", "https://www.nasdaq.com/articles/bayer-bayry-up-on-deal-to-sell-diabetes-care-business-analyst-blog-2015-06-11", "https://www.nasdaq.com/articles/agios-gets-orphan-drug-designation-from-fda-for-ag-120-analyst-blog-2015-06-11", "https://www.nasdaq.com/articles/illumina-partners-in-china-to-develop-ngs-diagnostic-solution-analyst-blog-2015-06-11", "https://www.nasdaq.com/articles/7-things-know-about-gilead-sciences-stocks-news-2015-06-10", "https://www.nasdaq.com/articles/trovagene-hits-52-week-high-pcm-continues-to-impress-analyst-blog-2015-06-10", "https://www.nasdaq.com/articles/roches-actemra-gets-breakthrough-therapy-designation-analyst-blog-2015-06-10", "https://www.nasdaq.com/articles/novartis-reports-data-on-cosentyx-for-ankylosing-spondylitis-analyst-blog-2015-06-11", "https://www.nasdaq.com/articles/celgene-and-lycera-collaborate-acquisition-option-included-analyst-blog-2015-06-10", "https://www.nasdaq.com/articles/seattle-genetics-unum-therapeutics-tie-up-for-cancer-drugs-analyst-blog-2015-06-09", "https://www.nasdaq.com/articles/roche-to-develop-diagnostic-test-for-cardiovascular-disease-analyst-blog-2015-06-09", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-sleep-disorder-drug-enters-phase-iii-analyst-blog-2015-06-09", "https://www.nasdaq.com/articles/renaissance-technologies-heres-what-huge-hedge-fund-company-has-been-buying-2015-06-09", "https://www.nasdaq.com/articles/10-most-profitable-businesses-san-francisco-2015-06-09", "https://www.nasdaq.com/articles/intrexon-fibrocell-announce-positive-pre-clinical-data-analyst-blog-2015-06-09", "https://www.nasdaq.com/articles/regeneron-sanofis-praluent-gets-positive-fda-panel-vote-analyst-blog-2015-06-10", "https://www.nasdaq.com/articles/chimerix-enrolls-for-trial-on-cytomegalovirus-infection-drug-analyst-blog-2015-06-09", "https://www.nasdaq.com/articles/repros-enclomiphene-to-face-fda-advisory-panel-in-november-analyst-blog-2015-06-09", "https://www.nasdaq.com/articles/biomarin-seeks-eu-approval-for-dmd-drug-drisapersen-analyst-blog-2015-06-09", "https://www.nasdaq.com/articles/horizon-pharma-hnzp-starts-phase-iii-study-on-actimmune-analyst-blog-2015-06-08", "https://www.nasdaq.com/articles/regeneron-sanofis-pcsk9-drug-praluent-set-for-fda-panel-analyst-blog-2015-06-08", "https://www.nasdaq.com/articles/gilead-sciences-gild-stock%3A-moving-average-crossover-alert-tale-of-the-tape-2015-06-08", "https://www.nasdaq.com/articles/eli-lilly-lly-presents-encouraging-data-on-diabetes-drugs-analyst-blog-2015-06-08", "https://www.nasdaq.com/articles/amgens-repatha-briefing-document-gives-mixed-review-analyst-blog-2015-06-09", "https://www.nasdaq.com/articles/after-hours-most-active-jun-8-2015-pfe-cmcsa-ftr-bac-htz-cx-vsh-qqq-gnw-hban-gild-qvca", "https://www.nasdaq.com/articles/bio-techne-to-buy-cliniqa-boost-clinical-controls-portfolio-analyst-blog-2015-06-08", "https://www.nasdaq.com/articles/are-biotech-stocks-really-overvalued-2015-06-07", "https://www.nasdaq.com/articles/problems-obamacare-could-prove-difficult-fix-2015-06-07", "https://www.nasdaq.com/articles/bad-news-obamacare-insurance-rates-could-rise-double-digits-2016-2015-06-06", "https://www.nasdaq.com/articles/gilead-sciences-incs-moat-filling-sand-2015-06-06", "https://www.nasdaq.com/articles/5-stocks-buy-june-2015-06-05", "https://www.nasdaq.com/articles/sanofi-sny-presents-data-from-extension-studies-on-toujeo-analyst-blog-2015-06-08", "https://www.nasdaq.com/articles/retrophins-neurodegenerative-drug-gets-fast-track-status-analyst-blog-2015-06-05", "https://www.nasdaq.com/articles/ardelyx-regains-product-portfolio-rights-from-astrazeneca-analyst-blog-2015-06-04", "https://www.nasdaq.com/articles/bluebird-amends-collaboration-agreement-with-celgene-analyst-blog-2015-06-04", "https://www.nasdaq.com/articles/cvs-health-hhs-to-endorse-preventive-health-services-online-analyst-blog-2015-06-04", "https://www.nasdaq.com/articles/merges-new-cloud-based-mobile-app-to-aid-clinical-research-analyst-blog-2015-06-04", "https://www.nasdaq.com/articles/biotech-stock-roundup-immunogen-soars-asco-data-amgen-collaborates-roche-analyst-blog-2015", "https://www.nasdaq.com/articles/zacks.com-featured-expert-kevin-matras-highlights%3A-gilead-sciences-goodyear-tire-kraton", "https://www.nasdaq.com/articles/abbvie-reports-positive-results-on-oncology-drug-imbruvica-analyst-blog-2015-06-05", "https://www.nasdaq.com/articles/ultragenyx-krn23-positive-in-children-to-be-studied-in-adults-analyst-blog-2015-06-03", "https://www.nasdaq.com/articles/3-bargain-stocks-beat-market-2015-06-02", "https://www.nasdaq.com/articles/why-gilead-sciences-inc-catapulted-higher-may-2015-06-02", "https://www.nasdaq.com/articles/mercks-keytruda-under-priority-review-lung-cancer-analyst-blog-2015-06-02", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-june-03-2015-2015-06-02", "https://www.nasdaq.com/articles/celldex-glioblastoma-vaccine-hits-phase-ii-primary-endpoint-analyst-blog-2015-06-02", "https://www.nasdaq.com/articles/roche-collaborates-with-amgen-for-immuno-oncology-analyst-blog-2015-06-02", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-updates-viking-ipo-ups-2015-view-analyst-blog-2015-06-03", "https://www.nasdaq.com/articles/bristol-myers-slumps%3A-bmy-falls-6.6-in-session-tale-of-the-tape-2015-06-01", "https://www.nasdaq.com/articles/are-celgene-corps-shares-about-get-hammered-2015-06-01", "https://www.nasdaq.com/articles/why-im-buying-gilead-sciences-stock-2015-06-01", "https://www.nasdaq.com/articles/your-best-investing-questions-2015-06-01", "https://www.nasdaq.com/articles/gilead-reveals-encouraging-data-from-leukemia-study-analyst-blog-2015-06-01", "https://www.nasdaq.com/articles/bristol-myers-opdivo-superior-to-standard-of-care-therapies-analyst-blog-2015-06-01", "https://www.nasdaq.com/articles/abbvie-presents-positive-data-from-multiple-studies-at-asco-analyst-blog-2015-06-01", "https://www.nasdaq.com/articles/novartis-presents-data-on-leukemia-lung-cancer-drugs-analyst-blog-2015-06-02", "https://www.nasdaq.com/articles/why-abbvie-inc-better-long-term-buy-gilead-sciences-inc-2015-05-31", "https://www.nasdaq.com/articles/stocks-watch-biotech-2015-05-31", "https://www.nasdaq.com/articles/investing-beginners-how-start-biotech-2015-05-30", "https://www.nasdaq.com/articles/leading-health-insurers-these-4-states-just-proposed-25-52-premium-price-hikes-2015-05-30", "https://www.nasdaq.com/articles/3-best-breed-biotech-stocks-2015-05-30", "https://www.nasdaq.com/articles/time-take-profits-gilead-sciences-inc-stock-2015-05-30", "https://www.nasdaq.com/articles/teva-settles-provigil-drug-delay-charge-with-ftc-for-%241.2b-analyst-blog-2015-05-29", "https://www.nasdaq.com/articles/stock-market-bubble-healthcare-stocks-2015-05-31", "https://www.nasdaq.com/articles/is-cvs-health-cvs-worth-adding-to-your-portfolio-now-analyst-blog-2015-05-29", "https://www.nasdaq.com/articles/gileads-new-hiv-combination-drug-under-review-in-the-eu-analyst-blog-2015-05-29", "https://www.nasdaq.com/articles/gileads-sustainable-competitive-advantage-2015-05-28", "https://www.nasdaq.com/articles/iwf-gild-v-cmcsa-large-inflows-detected-etf-2015-05-28", "https://www.nasdaq.com/articles/undervalued-stocks-biotech-worth-buying-2015-05-28", "https://www.nasdaq.com/articles/actavis-viberzi-gets-fda-nod-for-irritable-bowel-syndrome-analyst-blog-2015-05-28", "https://www.nasdaq.com/articles/qiagen-launches-clinical-insight-bioinformatics-platform-analyst-blog-2015-05-28", "https://www.nasdaq.com/articles/pacira-fda-meet-for-exparels-nerve-block-label-expansion-analyst-blog-2015-05-29", "https://www.nasdaq.com/articles/globeimmune-gileads-hepatitis-b-drug-fails-in-phase-ii-analyst-blog-2015-05-28", "https://www.nasdaq.com/articles/retrophin-soars-on-%24245m-priority-review-voucher-sale-analyst-blog-2015-05-28", "https://www.nasdaq.com/articles/synageva-biopharma-files-for-kanumas-approval-in-japan-analyst-blog-2015-05-27", "https://www.nasdaq.com/articles/genomics-prostate-cancer-test-recommended-by-palmetto-analyst-blog-2015-05-27", "https://www.nasdaq.com/articles/7-best-etfs-buy-june-2015-05-27", "https://www.nasdaq.com/articles/merck-jj-get-chmp-backing-for-simponis-expanded-use-analyst-blog-2015-05-27", "https://www.nasdaq.com/articles/health-care-sector-update-05272015-gbimgildgbsnnuro-2015-05-27", "https://www.nasdaq.com/articles/valeant-pharmaceuticals-gets-fda-nod-for-xifaxan-for-ibs-d-analyst-blog-2015-05-28", "https://www.nasdaq.com/articles/globeimmune-gileads-hepatitis-b-drug-fails-in-phase-ii-analyst-blog-2015-05-28", "https://www.nasdaq.com/articles/retrophin-soars-on-%24245m-priority-review-voucher-sale-analyst-blog-2015-05-28", "https://www.nasdaq.com/articles/pop-3-buy-if-biotech-stocks-burst-2015-05-26", "https://www.nasdaq.com/articles/pharmacyclics-imbruvica-gets-chmps-nod-for-full-approval-analyst-blog-2015-05-26-0", "https://www.nasdaq.com/articles/mercks-mrk-keytruda-a-step-closer-to-european-approval-analyst-blog-2015-05-26-0", "https://www.nasdaq.com/articles/amgens-pcsk9-inhibitor-step-closer-eu-approval-analyst-blog-2015-05-25", "https://www.nasdaq.com/articles/best-business-model-biotech-2015-05-25", "https://www.nasdaq.com/articles/alnylam-alny-begins-phase-i-study-on-liver-disease-drug-analyst-blog-2015-05-27", "https://www.nasdaq.com/articles/aegerions-juxtapid-successful-in-phase-iii-japanese-study-analyst-blog-2015-05-27", "https://www.nasdaq.com/articles/actavis-continue-selling-namenda-ir-under-court-ruling-analyst-blog-2015-05-26", "https://www.nasdaq.com/articles/healthcare-investment-opportunities-long-term-2015-05-23", "https://www.nasdaq.com/articles/novartis-announces-positive-data-on-oncology-drug-afinitor-analyst-blog-2015-05-22", "https://www.nasdaq.com/articles/kite-pharma-starts-dosing-in-phase-i-ii-study-on-kte-c19-analyst-blog-2015-05-22", "https://www.nasdaq.com/articles/should-you-get-rid-of-cytrx-corporation-cytr-now-tale-of-the-tape-2015-05-22", "https://www.nasdaq.com/articles/mannkind-front-and-center-best-product-doesnt-always-equal-best-stock-2015-05-21", "https://www.nasdaq.com/articles/bristol-myers-opdivo-gets-positive-opinion-from-chmp-analyst-blog-2015-05-25", "https://www.nasdaq.com/articles/astrazeneca-amgen-end-psoriasis-drug-brodalumab-deal-analyst-blog-2015-05-25", "https://www.nasdaq.com/articles/warren-buffetts-portfolio-3-biotech-stocks-oracle-omaha-could-love-2015-05-24", "https://www.nasdaq.com/articles/bristol-myers-hcv-combination-designation-amended-by-fda-analyst-blog-2015-05-21", "https://www.nasdaq.com/articles/why-achillion-pharmaceuticals-inc-shares-are-collapsing-2015-05-20", "https://www.nasdaq.com/articles/iwf-gild-v-slb-large-inflows-detected-etf-2015-05-20", "https://www.nasdaq.com/articles/swot-analysis-gilead-sciences-inc-stock-2015-05-20", "https://www.nasdaq.com/articles/zacks.com-featured-expert-kevin-matras-highlights%3A-outerwall-gilead-sciences-lionbridge", "https://www.nasdaq.com/articles/following-hepatitis-c-could-be-next-disease-researchers-cure-2015-05-21", "https://www.nasdaq.com/articles/how-celgene-stock-breaking-all-rules-2015-05-20", "https://www.nasdaq.com/articles/johnson-johnson-takes-gilead-sciences-hep-c-again-2015-05-20", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-reveals-phase-iii-oca-study-plan-analyst-blog-2015-05-20", "https://www.nasdaq.com/articles/achillion-and-johnson-johnson-in-%241.1b-hcv-tie-up-analyst-blog-2015-05-20", "https://www.nasdaq.com/articles/stock-market-news-for-may-19-2015-market-news-2015-05-19", "https://www.nasdaq.com/articles/merck-kgaa-q1-earnings-fall-y-y-2015-sales-view-retained-analyst-blog-2015-05-19", "https://www.nasdaq.com/articles/eleven-biotherapeutics-ebio-in-focus%3A-stock-tanks-69.2-tale-of-the-tape-2015-05-19", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-icpt-in-focus%3A-stock-tanks-16.1-tale-of-the-tape-2015-05-20", "https://www.nasdaq.com/articles/how-celgene-stock-breaking-all-rules-2015-05-20", "https://www.nasdaq.com/articles/regeneron-sanofi-announce-positive-data-on-dupilumab-analyst-blog-2015-05-19", "https://www.nasdaq.com/articles/theravance-biopharma-posts-positive-data-on-velusetrag-analyst-blog-2015-05-19", "https://www.nasdaq.com/articles/genomic-healths-loss-lingers-profits-expected-in-4q15-analyst-blog-2015-05-19", "https://www.nasdaq.com/articles/xbiotechs-xilonix-recommended-for-colorectal-cancer-study-analyst-blog-2015-05-19", "https://www.nasdaq.com/articles/lannett-lci-signs-deal-to-acquire-silarx-pharmaceuticals-analyst-blog-2015-05-19", "https://www.nasdaq.com/articles/celgene-accelreons-luspatercept-granted-fast-track-status-analyst-blog-2015-05-19", "https://www.nasdaq.com/articles/endo-to-acquire-par-pharma-for-%248.05b-shares-down-analyst-blog-2015-05-19", "https://www.nasdaq.com/articles/kite-pharma-narrows-q1-loss-misses-estimates-gives-view-analyst-blog-2015-05-18", "https://www.nasdaq.com/articles/experimental-drug-could-finally-cure-hiv-2015-05-18", "https://www.nasdaq.com/articles/gilead-sciences-gild-stock%3A-3-reasons-why-it-is-a-top-choice-for-growth-investors-tale-of", "https://www.nasdaq.com/articles/3-types-risks-facing-biotech-stocks-2015-05-18", "https://www.nasdaq.com/articles/best-blue-chips-own-forever-2015-05-18", "https://www.nasdaq.com/articles/alnylam-files-clinical-trial-application-for-aln-aat-analyst-blog-2015-05-18", "https://www.nasdaq.com/articles/why-achillion-pharmaceuticals-inc-shares-soared-today-2015-05-18", "https://www.nasdaq.com/articles/abbvies-humira-gets-fda-orphan-status-for-skin-disease-analyst-blog-2015-05-18", "https://www.nasdaq.com/articles/gilead-sciences-its-own-worst-enemy-2015-05-17", "https://www.nasdaq.com/articles/could-hivaids-vaccine-be-reality-end-decade-2015-05-16", "https://www.nasdaq.com/articles/could-tiny-biotech-be-gilead-sciences-ma-radar-2015-05-16", "https://www.nasdaq.com/articles/prestige-brands-holdings-beats-on-q4-earnings-revenues-analyst-blog-2015-05-15", "https://www.nasdaq.com/articles/amgen-announces-positive-results-on-migraine-candidate-analyst-blog-2015-05-15", "https://www.nasdaq.com/articles/endo-biodelivery-reveal-encouraging-data-on-pain-drug-analyst-blog-2015-05-15", "https://www.nasdaq.com/articles/agenus-agen-provides-update-on-its-brain-cancer-vaccine-analyst-blog-2015-05-15", "https://www.nasdaq.com/articles/3-safe-investments-biotech-relatively-speaking-2015-05-17", "https://www.nasdaq.com/articles/teva-presents-encouraging-data-from-chronic-migraine-study-analyst-blog-2015-05-15", "https://www.nasdaq.com/articles/eli-lilly-sanford-burnham-ink-deal-for-immunotherapies-analyst-blog-2015-05-15", "https://www.nasdaq.com/articles/emergent-biosolutions-glaxo-initiate-ebola-vaccine-study-analyst-blog-2015-05-14", "https://www.nasdaq.com/articles/sanofi-sny-exercises-celiac-disease-program-option-analyst-blog-2015-05-14", "https://www.nasdaq.com/articles/roche-reports-encouraging-data-on-lung-cancer-drugs-analyst-blog-2015-05-14", "https://www.nasdaq.com/articles/rxi-rxii-q1-loss-wider-than-expected-pipeline-in-focus-analyst-blog-2015-05-14", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-orkambi-wins-fda-panel-backing-analyst-blog-2015-05-13", "https://www.nasdaq.com/articles/corcept-therapeutics-korlym-positive-in-breast-cancer-study-analyst-blog-2015-05-15", "https://www.nasdaq.com/articles/biotech-stock-roundup-alexion-buy-synageva-fda-panel-backs-vertexs-orkambi-analyst-blog", "https://www.nasdaq.com/articles/zacks.com-featured-expert-kevin-matras-highlights%3A-gilead-sciences-citigroup-and-barclays", "https://www.nasdaq.com/articles/mckesson-beats-on-q4-earnings-revenues-guides-strong-analyst-blog-2015-05-13", "https://www.nasdaq.com/articles/why-ani-pharmaceuticals-anip-could-be-positioned-for-a-slump-tale-of-the-tape-2015-05-13", "https://www.nasdaq.com/articles/falling-earnings-estimates-signal-weakness-ahead-for-compugen-cgen-tale-of-the-tape-2015", "https://www.nasdaq.com/articles/retail-sector-spotlight-earnings-outlook-2015-05-13", "https://www.nasdaq.com/articles/retail-sector-spotlight-earnings-trends-2015-05-13", "https://www.nasdaq.com/articles/perrigo-prgo-buys-patheons-mexican-business-for-%2434m-analyst-blog-2015-05-13", "https://www.nasdaq.com/articles/biotech-stock-roundup-alexion-buy-synageva-fda-panel-backs-vertexs-orkambi-analyst-blog", "https://www.nasdaq.com/articles/trovagene-trov-in-focus%3A-stock-rises-7.1-tale-of-the-tape-2015-05-12", "https://www.nasdaq.com/articles/inovio-narrows-q1-loss-y-y-misses-earnings-estimates-analyst-blog-2015-05-12", "https://www.nasdaq.com/articles/arena-pharmaceuticals-1q-loss-narrower-expected-analyst-blog-2015-05-12", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-may-13-2015-2015-05-12", "https://www.nasdaq.com/articles/forget-gilead-sciences-inc-tiny-biotech-offers-much-richer-opportunity-2015-05-12", "https://www.nasdaq.com/articles/orexigen-slumps-as-new-contrave-data-comes-to-light-analyst-blog-2015-05-13", "https://www.nasdaq.com/articles/fluidigm-q1-revenues-lower-than-expected-stock-down-analyst-blog-2015-05-12", "https://www.nasdaq.com/articles/etfs-in-focus-on-impressive-q1-biotech-earnings-etf-news-and-commentary-2015-05-11", "https://www.nasdaq.com/articles/iwb-mrk-gild-v-large-inflows-detected-etf-2015-05-11", "https://www.nasdaq.com/articles/actavis-tops-1q-earnings-wide-margin-provides-outlook-analyst-blog-2015-05-11", "https://www.nasdaq.com/articles/osiris-therapeutics-q1-earnings-revenues-grow-yy-analyst-blog-2015-05-11", "https://www.nasdaq.com/articles/bio-techne-lags-on-q3-earnings-revenues-expenses-rise-analyst-blog-2015-05-11", "https://www.nasdaq.com/articles/seattle-genetics-sgen-in-focus%3A-stock-up-8.1-tale-of-the-tape-2015-05-11", "https://www.nasdaq.com/articles/johnson-johnsons-invega-sustenna-snda-suffers-setback-analyst-blog-2015-05-12", "https://www.nasdaq.com/articles/novartis-zykadia-approved-in-the-eu-for-lung-cancer-analyst-blog-2015-05-11", "https://www.nasdaq.com/articles/endo-endp-beats-on-q1-earnings-2015-guidance-upped-analyst-blog-2015-05-11", "https://www.nasdaq.com/articles/myriad-genetics-q3-test-growth-impresses-yet-revenues-fall-analyst-blog-2015-05-11", "https://www.nasdaq.com/articles/nxstage-medical-loss-narrower-than-expected-revenues-up-analyst-blog-2015-05-11", "https://www.nasdaq.com/articles/best-and-worst-etfs-week-amid-biotech-rebound-2015-05-09", "https://www.nasdaq.com/articles/stock-market-bubble-biotech-stocks-2015-05-09", "https://www.nasdaq.com/articles/mannkinds-mnkd-q1-loss-in-line-with-expectation-analyst-blog-2015-05-08", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-may-12-2015-2015-05-11", "https://www.nasdaq.com/articles/novartis-zykadia-approved-in-the-eu-for-lung-cancer-analyst-blog-2015-05-11", "https://www.nasdaq.com/articles/endo-endp-beats-on-q1-earnings-2015-guidance-upped-analyst-blog-2015-05-11", "https://www.nasdaq.com/articles/emergent-biosolutions-ebs-loss-wider-than-expectations-analyst-blog-2015-05-08", "https://www.nasdaq.com/articles/sarepta-posts-wider-than-expected-loss-eteplirsen-in-focus-analyst-blog-2015-05-08", "https://www.nasdaq.com/articles/medivation-mdvn-misses-q1-earnings-revenues-analyst-blog-2015-05-08", "https://www.nasdaq.com/articles/corcept-therapeutics-reports-wider-q1-loss-revenue-miss-analyst-blog-2015-05-08", "https://www.nasdaq.com/articles/alnylams-q1-loss-narrower-than-expected-confirms-guidance-analyst-blog-2015-05-08", "https://www.nasdaq.com/articles/big-pharma-giant-abbvie-inc-took-april-heres-why-2015-05-07", "https://www.nasdaq.com/articles/10-most-profitable-companies-healthcare-2015-05-07", "https://www.nasdaq.com/articles/after-hours-most-active-may-7-2015-valep-vale-rig-emc-gild-msft-aapl-pfe-cx-odp-mrvl-qqq", "https://www.nasdaq.com/articles/alexion-to-buy-synageva-for-%248.4b%3A-alexion-down-synageva-up-analyst-blog-2015-05-07", "https://www.nasdaq.com/articles/glaxos-gsk-q1-earnings-fall-y-y-gives-five-year-view-analyst-blog-2015-05-07", "https://www.nasdaq.com/articles/standout-sectors-q1-earnings-season-earnings-trends-2015-05-07", "https://www.nasdaq.com/articles/standout-sectors-q1-earnings-season-earnings-outlook-2015-05-07", "https://www.nasdaq.com/articles/qiagen-q1-earnings-in-line-revenues-miss-the-mark-analyst-blog-2015-05-07", "https://www.nasdaq.com/articles/top-rated-stock-picks-and-most-read-stories-nasdaqcom-april-26-may-2-2015-2015-05-05", "https://www.nasdaq.com/articles/beyond-pharma-3-healthcare-choices-analyst-blog-2015-05-05", "https://www.nasdaq.com/articles/why-street-keeps-doubting-gilead-sciences-inc-2015-05-05", "https://www.nasdaq.com/articles/conatus-pharmaceuticals-cnat%3A-whats-up-this-earnings-analyst-blog-2015-05-05", "https://www.nasdaq.com/articles/stock-market-news-for-may-04-2015-market-news-2015-05-04", "https://www.nasdaq.com/articles/how-these-2-industries-helped-save-stock-market-earnings-season-2015-05-04", "https://www.nasdaq.com/articles/biotechs-blue-chip-stocks-2015-05-04", "https://www.nasdaq.com/articles/sucampo-posts-in-line-first-quarter-earnings-revenue-miss-analyst-blog-2015-05-07", "https://www.nasdaq.com/articles/midday-update-wall-street-mostly-ignores-weak-manufacturing-data-starts-may-buying-mood", "https://www.nasdaq.com/articles/qual-gild-v-ma-etf-outflow-alert-2015-05-01", "https://www.nasdaq.com/articles/gilead-tops-q1-earnings-estimates-2015-outlook-revised-analyst-blog-2015-05-01", "https://www.nasdaq.com/articles/gilead-sciences-inc-earnings-hepatitis-c-market-numbers-2015-05-01", "https://www.nasdaq.com/articles/daily-dividend-report-lm-ko-gild-aig-vfc-payx-2015-05-01", "https://www.nasdaq.com/articles/agree-buy-gilead-sciences-70-earn-54-using-options-2015-04-30", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-celladon-biogen-celgene-and-gilead-press-releases", "https://www.nasdaq.com/articles/bristol-myers-squibb-outpaces-abbvie-hepatitis-c-2015-05-02", "https://www.nasdaq.com/articles/q1-earnings-scorecard-dollar-impact-earnings-outlook-2015-04-30", "https://www.nasdaq.com/articles/after-hours-most-active-apr-30-2015-lnkd-qqq-msft-gild-aapl-low-hd-nvax-cy-nrz-bac-ge-2015", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-556-follow-through-indicator-37-sensitive", "https://www.nasdaq.com/articles/after-hours-earnings-report-april-30-2015-gild-v-aig-psa-lnkd-bmrn-swks-flt-emn-expe-wu", "https://www.nasdaq.com/articles/whats-behind-vertex-pharmaceuticals-incorporateds-disappointing-q1-2015-04-29", "https://www.nasdaq.com/articles/bristol-myers-squibb-crushes-first-quarter-earnings-heres-why-2015-04-28", "https://www.nasdaq.com/articles/3-things-watch-gilead-sciences-incs-q1-earnings-2015-04-28", "https://www.nasdaq.com/articles/gilead-sciences-inc-reaps-big-q1-harvest-harvoni-2015-04-30", "https://www.nasdaq.com/articles/5-biotech-stocks-to-avoid-after-mondays-slump-analyst-blog-2015-04-28", "https://www.nasdaq.com/articles/10-most-profitable-businesses-biotech-2015-04-28", "https://www.nasdaq.com/articles/gilead-and-bristol-myers-reveal-positive-data-on-hcv-drugs-analyst-blog-2015-04-27", "https://www.nasdaq.com/articles/will-express-scripts-esrx-disappoint-earnings-in-q1-analyst-blog-2015-04-27", "https://www.nasdaq.com/articles/biotech-bubble-bursting-3-stocks-i-want-buy-2015-04-27", "https://www.nasdaq.com/articles/why-healthcare-best-sector-your-money-2015-04-26", "https://www.nasdaq.com/articles/can-you-guess-which-state-wont-pay-hepatitis-c-drugs-2015-04-26", "https://www.nasdaq.com/articles/will-gilead-gild-miss-q1-earnings-on-weak-hcv-sales-analyst-blog-2015-04-28", "https://www.nasdaq.com/articles/merck-reports-encouraging-data-on-hcv-combo-candidate-analyst-blog-2015-04-24", "https://www.nasdaq.com/articles/abbvies-hcv-cocktail-treatment-under-fda-priority-review-analyst-blog-2015-04-24", "https://www.nasdaq.com/articles/amgen-incs-dividend-sustainable-2015-04-23", "https://www.nasdaq.com/articles/gilead-gild-announces-encouraging-data-on-its-hcv-drugs-analyst-blog-2015-04-23", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-xlv-gild-unh-esrx-2015-04-22", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-biogen-geron-johnson-johnson-and", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-starts-earnings-season-strong-note-setbacks-ampio-athersys", "https://www.nasdaq.com/articles/4-nasdaq-stocks-all-time-highs-analyst-blog-2015-04-24", "https://www.nasdaq.com/articles/3-biotech-stocks-could-be-developing-billion-dollar-drugs-2015-04-19", "https://www.nasdaq.com/articles/how-invest-money-biotech-2015-04-19", "https://www.nasdaq.com/articles/what-could-possibly-go-wrong-gilead-sciences-inc-stock-2015-04-18", "https://www.nasdaq.com/articles/3-drug-stocks-leading-charge-against-infectious-diseases-2015-04-18", "https://www.nasdaq.com/articles/gilead-sciences-gild-shares-cross-below-200-dma-2015-04-17", "https://www.nasdaq.com/articles/johnson-johnsons-earnings-good-bad-and-ugly-2015-04-16", "https://www.nasdaq.com/articles/best-stock-invest-hep-c-2015-04-16", "https://www.nasdaq.com/articles/forget-gilead-gild-buy-these-impressive-biotech-stocks-instead-analyst-blog-2015-04-21", "https://www.nasdaq.com/articles/3-biotech-stocks-under-%2410-with-amazing-growth-prospects-analyst-blog-2015-04-15", "https://www.nasdaq.com/articles/xlv-mrk-gild-unh-etf-outflow-alert-2015-04-14", "https://www.nasdaq.com/articles/j.p.-morgan-bank-of-america-gilead-sciences-and-actavis-are-part-of-zacks-earnings-preview", "https://www.nasdaq.com/articles/q1-earnings-season-ramps-earnings-preview-2015-04-13", "https://www.nasdaq.com/articles/3-stocks-you-absolutely-must-watch-earnings-season-2015-04-13", "https://www.nasdaq.com/articles/3-best-stocks-invest-biotechnology-2015-04-11", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-alkermes-regulus-juno-therapeutics-targacept-and-gilead", "https://www.nasdaq.com/articles/abbvies-hcv-treatment-granted-priority-review-in-japan-analyst-blog-2015-04-16", "https://www.nasdaq.com/articles/mercks-hcv-combo-drug-gets-two-breakthrough-status-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/gilead-submits-regulatory-application-for-hiv-drug-in-u.s.-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-alkermes-drug-fares-well-targacept-slides-deal-termination-analyst", "https://www.nasdaq.com/articles/one-biotech-stock-looks-bargain-these-days-2015-04-06", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-xlv-mrk-gild-unh-2015-04-06", "https://www.nasdaq.com/articles/actavis-in-patent-infringement-lawsuit-for-gileads-letairis-analyst-blog-2015-04-06", "https://www.nasdaq.com/articles/after-hours-most-active-apr-6-2015-win-o-igt-dei-cno-siri-kkr-ko-qqq-csco-foxa-gild-2015", "https://www.nasdaq.com/articles/after-hours-most-active-apr-9-2015-mu-epd-pbr-cx-sfun-qqq-win-mdco-scty-gild-sxl-aa-2015", "https://www.nasdaq.com/articles/why-smart-money-loves-biotech-stock-2015-04-05", "https://www.nasdaq.com/articles/5-big-losers-if-supreme-court-strikes-down-federal-obamacare-subsidies-2015-04-05", "https://www.nasdaq.com/articles/following-gilead-sciences-inc-which-biotech-will-pay-dividend-next-2015-04-04", "https://www.nasdaq.com/articles/safest-biotech-bet-market-2015-04-04", "https://www.nasdaq.com/articles/abbvie-inc-stock-about-crash-2015-04-02", "https://www.nasdaq.com/articles/q1-earnings-season-spotlight-alcoa-aa-reports-results-earnings-preview-2015-04-02", "https://www.nasdaq.com/articles/zacks-earnings-trends-highlights%3A-bank-of-america-gilead-sciences-and-apple-press-releases", "https://www.nasdaq.com/articles/3-events-could-sink-biotech-sector-year-2015-04-05", "https://www.nasdaq.com/articles/after-hours-most-active-apr-1-2015-aa-mu-pfe-acwi-myl-jnj-mrk-aviv-qqq-pagp-thrm-gild-2015", "https://www.nasdaq.com/articles/post-unh-deal-spotlight-on-pharmacy-benefit-stocks-analyst-blog-2015-03-31", "https://www.nasdaq.com/articles/what-look-earnings-season-earnings-outlook-2015-03-31", "https://www.nasdaq.com/articles/what-look-earnings-season-earnings-trends-2015-03-31", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-bristol-myers-squibb-achillion", "https://www.nasdaq.com/articles/3-triple-digit-stocks-upside-potential-least-40-2015-03-30", "https://www.nasdaq.com/articles/3-best-dividend-stocks-2015-2015-03-29", "https://www.nasdaq.com/articles/should-gilead-sciences-inc-be-worried-achillion-pharmaceuticals-2015-04-01", "https://www.nasdaq.com/articles/best-dividend-paying-healthcare-stocks-2015-03-29", "https://www.nasdaq.com/articles/biggest-red-flag-biotech-investors-2015-03-28", "https://www.nasdaq.com/articles/could-these-experimental-drugs-eclipse-harvonis-historic-launch-2015-03-28", "https://www.nasdaq.com/articles/investors-might-want-stay-away-biotech-etf-2015-03-27", "https://www.nasdaq.com/articles/gileads-hepatitis-c-drug-sovaldi-gets-approval-in-japan-analyst-blog-2015-03-27", "https://www.nasdaq.com/articles/ishares-sp-100-etf-experiences-big-outflow-2015-03-26", "https://www.nasdaq.com/articles/stock-market-news-for-march-26-2015-market-news-2015-03-26", "https://www.nasdaq.com/articles/gilead-sciences-inc-about-crater-our-very-eyes-2015-03-29", "https://www.nasdaq.com/articles/best-dividend-paying-healthcare-stocks-2015-03-29", "https://www.nasdaq.com/articles/bubble-bursting-3-top-stock-biotech-stocks-buy-2015-03-25", "https://www.nasdaq.com/articles/company-news-for-march-24-2015-corporate-summary-2015-03-24", "https://www.nasdaq.com/articles/pre-market-most-active-mar-23-2015-sto-gsk-gild-aapl-vrtx-imgn-rdsb-qqq-fb-rdsa-sdrl-nvs", "https://www.nasdaq.com/articles/better-dividend-stock-abbvie-or-gilead-sciences-inc-2015-03-23", "https://www.nasdaq.com/articles/after-hours-most-active-mar-23-2015-bac-opk-csco-ge-qqq-zts-ocn-msft-gild-mdlz-aapl-wfc", "https://www.nasdaq.com/articles/previewing-q1-earnings-season-video-blog-2015-03-23", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-prothena-vertex-gilead-and-amgen-press-releases", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-soars-alzheimers-data-gilead-hcv-drugs-label-update-analyst", "https://www.nasdaq.com/articles/drug-spending-soaring-3-takeaways-you-cant-miss-2015-03-21", "https://www.nasdaq.com/articles/1-biotech-stock-you-can-buy-and-hold-next-20-years-2015-03-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-regeneron-shine-acc-nektar-drug-disappoints-analyst-blog-2015", "https://www.nasdaq.com/articles/why-im-not-giving-tiny-biotech-stock-yet-2015-03-18", "https://www.nasdaq.com/articles/bristol-myers-squibb-co-back-hepatitis-c-race-2015-03-17", "https://www.nasdaq.com/articles/3-stocks-benefiting-jaw-dropping-growth-specialty-drug-spending-2015-03-17", "https://www.nasdaq.com/articles/3-things-you-need-know-about-achillion-pharmaceuticals-inc-2015-03-22", "https://www.nasdaq.com/articles/3-biotech-stocks-wall-street-loves-2015-03-16", "https://www.nasdaq.com/articles/should-gilead-sciences-incs-slowing-growth-concern-investors-2015-03-15", "https://www.nasdaq.com/articles/number-scariest-healthcare-statistic-out-there-2015-03-15", "https://www.nasdaq.com/articles/bristol-myers-seeks-daclatasvir-approval-in-the-u.s.-analyst-blog-2015-03-13", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvie-buy-pharmacyclics-fda-approves-first-biosimilar-analyst-blog", "https://www.nasdaq.com/articles/express-scripts-issues-report-on-prescription-drug-spending-analyst-blog-2015-03-11", "https://www.nasdaq.com/articles/case-you-missed-it-gilead-sciences-incs-bad-news-actually-great-2015-03-10", "https://www.nasdaq.com/articles/sp-500-analyst-moves-gild-2015-03-17", "https://www.nasdaq.com/articles/forget-gilead-sciences-gild-buy-these-biotech-stocks-instead-stocks-news-2015-03-06", "https://www.nasdaq.com/articles/after-hours-most-active-mar-5-2015-emc-bac-grmn-rio-ge-qqq-klac-mu-dnr-ms-gild-aapl-2015", "https://www.nasdaq.com/articles/bristol-myers-drug-shows-impressive-data-inks-deal-analyst-blog-2015-03-05", "https://www.nasdaq.com/articles/top-rated-stock-picks-and-most-read-stories-nasdaqcom-feb-22-28-2015-2015-03-04", "https://www.nasdaq.com/articles/pioneer-fundamental-growth-fund-why-it-revving-2015-03-03", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-march-03-2015-2015-03-02", "https://www.nasdaq.com/articles/gileads-gild-hiv-drug-positive-in-2-phase-iii-studies-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/iyh-pfe-mrk-gild-etf-inflow-alert-2015-03-09", "https://www.nasdaq.com/articles/3-big-cap-biotechs-could-trounce-gilead-sciences-year-2015-03-01", "https://www.nasdaq.com/articles/why-dont-these-winning-stocks-pay-dividends-2015-03-01", "https://www.nasdaq.com/articles/breakthrough-study-may-allow-researchers-tackle-root-cause-heart-disease-2015-02-28", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-iyh-mrk-gild-amgn-2015-02-27", "https://www.nasdaq.com/articles/biotech-head-head-gilead-vs-celgene-2015-02-26", "https://www.nasdaq.com/articles/these-pharmaceutical-stocks-let-you-tap-402-billion-trend-2015-02-25", "https://www.nasdaq.com/articles/why-pharmacyclics-inc-soared-higher-today-2015-02-25", "https://www.nasdaq.com/articles/billionaire-george-soros-just-dumped-these-3-dividend-stocks-2015-03-01", "https://www.nasdaq.com/articles/3-big-cap-biotechs-could-trounce-gilead-sciences-year-2015-03-01", "https://www.nasdaq.com/articles/nasdaq-100-turns-30%3A-tracking-innovation-large-cap-growth-2015-02-23", "https://www.nasdaq.com/articles/3-stocks-pre-retirees-can-buy-and-hold-next-20-years-2015-02-23", "https://www.nasdaq.com/articles/3-biotech-stocks-id-love-stash-away-my-portfolio-forever-2015-02-22", "https://www.nasdaq.com/articles/did-researchers-just-discover-cure-hivaids-2015-02-22", "https://www.nasdaq.com/articles/3-tiny-biotech-stocks-im-paying-attention-2015-2015-02-22", "https://www.nasdaq.com/articles/gilead-insider-buys-10000-shares-2015-02-20", "https://www.nasdaq.com/articles/billions-line-next-drug-pricing-war-2015-02-24", "https://www.nasdaq.com/articles/xlv-pfe-mrk-gild-large-inflows-detected-etf-2015-02-19", "https://www.nasdaq.com/articles/117-billion-reasons-gilead-sciences-inc-should-keep-winning-2015-02-19", "https://www.nasdaq.com/articles/gilead-sciences-inc-stock-cheap-now-2015-02-18", "https://www.nasdaq.com/articles/not-too-late-to-ride-on-q4-earnings%3A-3-biotech-picks-earnings-esp-2015-02-17", "https://www.nasdaq.com/articles/surprise-we-still-need-drugmakers-develop-revolutionary-hepatitis-c-drugs-2015-02-17", "https://www.nasdaq.com/articles/tiger-managements-julian-robertson-buys-apple-netflix-illumina-sells-alibaba-ebay-mastec", "https://www.nasdaq.com/articles/could-be-biggest-advance-hepatitis-c-gilead-sciences-sovaldi-2015-02-16", "https://www.nasdaq.com/articles/will-express-scripts-esrx-beat-q4-earnings-estimates-analyst-blog-2015-02-20", "https://www.nasdaq.com/articles/obamacare-could-soon-make-these-stocks-soar-2015-02-15", "https://www.nasdaq.com/articles/was-gilead-sciences-incs-dividend-good-idea-2015-02-15", "https://www.nasdaq.com/articles/3-biotech-stocks-i-love-2015-02-14", "https://www.nasdaq.com/articles/1-number-shows-why-gilead-sciences-inc-shareholders-should-be-thrilled-right-now-2015-02", "https://www.nasdaq.com/articles/case-you-missed-it-theres-new-fastest-growing-drug-world-2015-02-14", "https://www.nasdaq.com/articles/1-sentence-tells-you-everything-you-need-know-about-each-these-10-big-pharma-earnings-rep", "https://www.nasdaq.com/articles/5-things-cvs-healths-management-wants-you-know-2015-02-13", "https://www.nasdaq.com/articles/1-george-soros-quote-every-investor-should-read-right-now-2015-02-15", "https://www.nasdaq.com/articles/obamacare-could-soon-make-these-stocks-soar-2015-02-15", "https://www.nasdaq.com/articles/was-gilead-sciences-incs-dividend-good-idea-2015-02-15", "https://www.nasdaq.com/articles/oef-gild-c-dis-etf-outflow-alert-2015-02-11", "https://www.nasdaq.com/articles/gilead-sciences-shares-rise-amid-insider-buy-conference-presentation-broadcast-stocks-news", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-february-11-2015-2015-02-10", "https://www.nasdaq.com/articles/why-shares-regulus-therapeutics-inc-crashed-2015-02-09", "https://www.nasdaq.com/articles/forget-gilead-sciences-here-are-3-better-biotech-stocks-2015-02-12", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-10-2015-2015-02-09", "https://www.nasdaq.com/articles/achillion-soars-6-week-hcv-cure-when-used-gileads-sofosbuvir-stocks-news-2015-02-09", "https://www.nasdaq.com/articles/dividend-investing-news-gm-gild-and-29-more-increases-2015-02-09", "https://www.nasdaq.com/articles/whats-bad-gilead-sciences-and-merck-good-sign-patients-2015-02-07", "https://www.nasdaq.com/articles/5-key-findings-after-1-full-year-obamacare-2015-02-07", "https://www.nasdaq.com/articles/can-you-guess-stock-putting-gilead-sciences-shame-hint-its-not-abbvie-2015-02-07", "https://www.nasdaq.com/articles/3-things-you-ought-know-about-gileads-tumble-2015-02-06", "https://www.nasdaq.com/articles/why-shares-achillion-pharmaceuticals-inc-soared-2015-02-09", "https://www.nasdaq.com/articles/gilead-amgen-q4-earnings-weak-outlook-affect-biotech-etfs-etf-news-and-commentary-2015-02", "https://www.nasdaq.com/articles/why-achillion-pharmaceuticals-inc-stock-crashing-today-2015-02-04", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-impresses-4q-results-gilead-abbvie-hcv-drugs-focus-analyst", "https://www.nasdaq.com/articles/why-gilead-sciences-shares-crashed-today-2015-02-04", "https://www.nasdaq.com/articles/abbvie-inc-earnings-after-strong-year-eyes-shift-2015-2015-02-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-ctsh-2015-02-04", "https://www.nasdaq.com/articles/sp-500-movers-rl-sjm-2015-02-04", "https://www.nasdaq.com/articles/can-gilead-boost-hcv-sales-with-health-service-deals-analyst-blog-2015-02-06", "https://www.nasdaq.com/articles/pre-market-most-active-feb-4-2015-odp-spls-pbr-viv-gild-gm-gsk-phg-azn-tvix-pegi-qqq-2015", "https://www.nasdaq.com/articles/gilead-tops-q4-earnings-estimates-2015-outlook-disappoints-analyst-blog-2015-02-04", "https://www.nasdaq.com/articles/dow-jones-ends-choppy-trading-session-6-point-gain-2015-02-04", "https://www.nasdaq.com/articles/merck-co-inc-earnings-1-sentence-changed-everything-2015-02-04", "https://www.nasdaq.com/articles/iyh-gild-amgn-abbv-etf-outflow-alert-2015-02-03", "https://www.nasdaq.com/articles/gilead-sciences-inc-earnings-well-make-it-volume-2015-02-03", "https://www.nasdaq.com/articles/gilead-sciences-beats-q4-earnings-estimates-gild-falls-revenue-outlook-stocks-news-2015-02", "https://www.nasdaq.com/articles/surprise-gilead-sciences-inc-pay-dividend-2015-02-04", "https://www.nasdaq.com/articles/whats-behind-gilead-sciences-strong-q4-weak-2015-outlook-2015-02-03", "https://www.nasdaq.com/articles/after-hours-most-active-feb-3-2015-fnfg-cost-gild-qqq-bk-aaxj-dis-cop-bac-esrx-stt-allya", "https://www.nasdaq.com/articles/earnings-reaction-history-gilead-sciences-inc-444-follow-through-indicator-30-sensitive", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-3-2015-gild-dis-eqr-afl-cmg-fisv-wynn-ew-itub-chrw", "https://www.nasdaq.com/articles/3-things-watch-gilead-sciences-inc-q4-results-2015-02-02", "https://www.nasdaq.com/articles/why-gilead-sciences-inc-shares-roared-higher-11-january-2015-02-02", "https://www.nasdaq.com/articles/will-gilead-gild-miss-q4-earnings-on-low-hcv-drug-sales-analyst-blog-2015-02-02", "https://www.nasdaq.com/articles/should-you-buy-abbvie-inc-stock-dip-2015-02-03", "https://www.nasdaq.com/articles/can-biotech-duplicate-its-2014-performance-or-it-time-jump-ship-2015-02-01", "https://www.nasdaq.com/articles/gilead-sciences-future-3-simple-slides-2015-01-31", "https://www.nasdaq.com/articles/3-biotech-giants-shouldnt-pay-dividend-2015-01-31", "https://www.nasdaq.com/articles/abbvie-abbv-tops-4q-earnings-estimates-affirms-view-tale-of-the-tape-2015-01-30", "https://www.nasdaq.com/articles/abbvie-abbv-set-beat-4q-earnings-humira-sales-analyst-blog-2015-01-28", "https://www.nasdaq.com/articles/cancer-biotech-kolltan-pharmaceuticals-withdraws-86-million-ipo-2015-01-28", "https://www.nasdaq.com/articles/telling-figure-insinuates-big-pharma-could-be-big-trouble-2015-01-27", "https://www.nasdaq.com/articles/should-you-buy-gilead-sciences-gild-stock-ahead-earnings-stocks-news-2015-02-02", "https://www.nasdaq.com/articles/heres-why-years-flu-vaccine-isnt-working-2015-01-24", "https://www.nasdaq.com/articles/iwf-gild-pep-orcl-large-outflows-detected-etf-2015-01-23", "https://www.nasdaq.com/articles/why-johnson-johnsons-stock-could-crater-2015-2015-01-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-eu-approvals-abbvie-celgene-drugs-cytrx-partial-clinical-hold-lifted", "https://www.nasdaq.com/articles/healthcare-etfs-focus-mixed-jnj-results-etf-news-and-commentary-2015-01-21", "https://www.nasdaq.com/articles/after-hours-most-active-jan-20-2015-bac-pfe-emc-aapl-qqq-nflx-fcx-intc-jpm-ibm-gild-mack", "https://www.nasdaq.com/articles/johnson-johnson-overcomes-threats-competitors-delivers-solid-quarterly-results-2015-01-20", "https://www.nasdaq.com/articles/gilead-includes-pan-genotypic-agent-in-hcv-licensing-deals-analyst-blog-2015-01-27", "https://www.nasdaq.com/articles/1-drug-really-outselling-legalized-marijuana-2015-01-19", "https://www.nasdaq.com/articles/3-big-pharma-stocks-more-free-cash-flow-gilead-sciences-inc-2015-01-18", "https://www.nasdaq.com/articles/understanding-stock-dilution-and-why-you-should-care-about-it-2015-01-16", "https://www.nasdaq.com/articles/will-organovo-holdings-inc-be-bought-out-2015-2015-01-16", "https://www.nasdaq.com/articles/qual-gild-hd-orcl-etf-inflow-alert-2015-01-15", "https://www.nasdaq.com/articles/3-stocks-buy-when-market-crashes-2015-01-14", "https://www.nasdaq.com/articles/how-much-could-abbvie-inc-make-selling-its-hepatitis-c-drug-year-2015-01-14", "https://www.nasdaq.com/articles/abbvie-gains-eu-approval-hepatitis-c-virus-treatment-analyst-blog-2015-01-19", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-celg-2015-01-13", "https://www.nasdaq.com/articles/did-gilead-sciences-sales-soar-q4-2015-01-13", "https://www.nasdaq.com/articles/why-pharmacyclics-inc-skyrocketed-higher-today-2015-01-13", "https://www.nasdaq.com/articles/1-big-loser-slugfest-between-abbvie-and-gilead-sciences-2015-01-12", "https://www.nasdaq.com/articles/which-big-biotech-will-soar-2015-2015-01-12", "https://www.nasdaq.com/articles/celgene-corporation-takeover-target-2015-2015-01-12", "https://www.nasdaq.com/articles/better-healthcare-buy-big-or-little-biotechs-2015-01-11", "https://www.nasdaq.com/articles/gilead-sciences-inc-no-longer-just-hiv-company-2015-01-14", "https://www.nasdaq.com/articles/3-ways-gilead-sciences-inc-could-still-be-big-trouble-2015-01-11", "https://www.nasdaq.com/articles/should-abbvie-inc-or-gilead-sciences-buy-these-tiny-biotech-stocks-2015-01-11", "https://www.nasdaq.com/articles/dark-secret-abbvie-gilead-sciences-hepatitis-c-drug-war-2015-01-10", "https://www.nasdaq.com/articles/did-gilead-sciences-just-buy-its-next-blockbuster-drug-2015-01-10", "https://www.nasdaq.com/articles/gilead-sciences-inc-now-takeover-target-2015-01-09", "https://www.nasdaq.com/articles/why-medivation-inc-stock-sank-14-december-2015-01-08", "https://www.nasdaq.com/articles/1-amazing-chart-shows-why-gilead-sciences-incs-stock-still-belongs-your-portfolio-2015-01", "https://www.nasdaq.com/articles/5-predictions-biotechnology-stocks-2015-2015-01-11", "https://www.nasdaq.com/articles/vv-c-gild-pep-etf-inflow-alert-2015-01-07", "https://www.nasdaq.com/articles/3-biotech-stocks-could-trounce-gilead-sciences-inc-2015-2015-01-07", "https://www.nasdaq.com/articles/enzon-pharmaceuticals-inc-enzn-ex-dividend-date-scheduled-january-08-2015-2015-01-07", "https://www.nasdaq.com/articles/biggest-surprise-battle-between-abbvie-and-gilead-sciences-2015-01-07", "https://www.nasdaq.com/articles/gilead-to-purchase-liver-disease-program-from-phenex-analyst-blog-2015-01-07", "https://www.nasdaq.com/articles/prospects-2014s-best-and-worst-performing-sectors-2015-01-05", "https://www.nasdaq.com/articles/why-gilead-sciences-inc-stock-plunged-much-14-december-2015-01-05", "https://www.nasdaq.com/articles/gilead-sciences-inc-fires-back-abbvie-inc-2015-01-07", "https://www.nasdaq.com/articles/vv-c-gild-pep-etf-inflow-alert-2015-01-07", "https://www.nasdaq.com/articles/3-underlying-reasons-why-gilead-sciences-inc-could-remain-wildly-successful-2015-01-03", "https://www.nasdaq.com/articles/how-1-tiny-hepatitis-c-drug-developer-trounced-gilead-sciences-inc-2014-2015-01-02", "https://www.nasdaq.com/articles/interesting-gild-put-and-call-options-february-2015-2014-12-31", "https://www.nasdaq.com/articles/these-3-biotechs-are-looking-happy-new-year-2014-12-31", "https://www.nasdaq.com/articles/3-biotech-stocks-soared-past-gilead-2014-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/start-new-year-right-3-best-biotech-stocks-2014-12-30", "https://www.nasdaq.com/articles/growth-stocks-2015-3-companies-room-run-2015-01-04", "https://www.nasdaq.com/articles/doctorx-positions-2015-i-have-cut-back-my-exposure-all-biotech-substantially-2014-12-30", "https://www.nasdaq.com/articles/gilead-jj-expand-taf-based-hiv-drugs-related-agreement-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-gild-2014-12-29", "https://www.nasdaq.com/articles/ibb-gild-regn-bmrn-large-inflows-detected-etf-2014-12-29", "https://www.nasdaq.com/articles/health-care-sector-update-12292014-pozn-aezs-gild-2014-12-29", "https://www.nasdaq.com/articles/pre-market-most-active-dec-29-2014-rio-tvix-alu-fcau-gild-xiv-juno-aapl-pbr-bac-gpro-mtw", "https://www.nasdaq.com/articles/gilead-sciences-inc-value-stock-following-its-tumble-2014-12-29", "https://www.nasdaq.com/articles/3-cheap-dividend-stocks-you-can-buy-right-now-2014-12-30", "https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-slides-3-gilead-sciences-shares-spike-higher-2014-12", "https://www.nasdaq.com/articles/should-abbvie-inc-and-gilead-sciences-inc-fear-biotech-instead-each-other-2014-12-28", "https://www.nasdaq.com/articles/pharma-stocks-could-be-deep-trouble-2015-heres-why-2014-12-28", "https://www.nasdaq.com/articles/3-stocks-poised-eye-popping-gains-2015-2014-12-27", "https://www.nasdaq.com/articles/sp-500-movers-eqt-gild-2014-12-26", "https://www.nasdaq.com/articles/nasdaq-100-movers-vip-gild-2014-12-26", "https://www.nasdaq.com/articles/stock-market-news-for-december-26-2014-market-news-2014-12-26", "https://www.nasdaq.com/articles/gilead-sciences-inc-cant-do-it-alone-2014-12-29", "https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-slides-3-gilead-sciences-shares-spike-higher-2014-12", "https://www.nasdaq.com/articles/nasdaq-100-movers-vip-celg-2014-12-24", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvies-hcv-treatment-approved-immunogen-plunges-data-analyst-blog", "https://www.nasdaq.com/articles/hepatitis-c-drug-developer-crushed-gilead-sciences-inc-2014-hint-its-not-abbvie-2014-12-24", "https://www.nasdaq.com/articles/pre-market-most-active-dec-24-2014-rig-gpro-snn-arcp-fb-smfg-achn-bac-fcau-tvix-crh-gild", "https://www.nasdaq.com/articles/biotech-booms-amid-pre-christmas-snoozefest-2014-12-24", "https://www.nasdaq.com/articles/could-express-scripts-holding-companys-gilead-gamble-backfire-2014-12-24", "https://www.nasdaq.com/articles/after-gilead-sciences-is-it-time-to-sell-biotech-stocks-analyst-blog-2014-12-26", "https://www.nasdaq.com/articles/gild-makes-notable-cross-below-critical-moving-average-2014-12-23", "https://www.nasdaq.com/articles/gilead-falls-on-abbvie-and-express-scripts-deal%3A-3-biotech-etfs-to-watch-etf-news-and", "https://www.nasdaq.com/articles/what-worlds-biggest-hedge-fund-has-been-selling-2014-12-23", "https://www.nasdaq.com/articles/express-scripts-hates-gilead-sciences-loves-abbvie-2014-12-23", "https://www.nasdaq.com/articles/top-rated-stock-picks-and-most-read-stories-week-december-15-nasdaqcom-2014-12-23", "https://www.nasdaq.com/articles/abbvie-inc-throws-first-punch-hep-c-price-war-gilead-sciences-inc-2014-12-23", "https://www.nasdaq.com/articles/gilead-sciences-slumps%3A-gild-tumbles-14.3-in-session-tale-of-the-tape-2014-12-23", "https://www.nasdaq.com/articles/midday-update-stocks-extending-winning-streak-fifth-day-following-strong-gdp-consumer", "https://www.nasdaq.com/articles/pre-market-most-active-dec-23-2014-alu-valep-nq-rad-rig-gpro-aria-bac-jrjc-qqq-gild-tvix", "https://www.nasdaq.com/articles/achillion-gains-on-positive-results-from-its-hcv-candidates-analyst-blog-2014-12-23", "https://www.nasdaq.com/articles/express-scripts-esrx-picks-abbvies-hepatitis-c-drug-analyst-blog-2014-12-23", "https://www.nasdaq.com/articles/why-achillion-pharmaceuticals-shares-collapsed-25-today-2014-12-23", "https://www.nasdaq.com/articles/sp-500-movers-gild-lm-2014-12-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-vip-2014-12-22", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-caesars-entertainment-buy-caesars", "https://www.nasdaq.com/articles/gilead-sciences-vs-abbvie-surprise-sovaldi-still-matters-2014-12-23", "https://www.nasdaq.com/articles/us-stocks-set-mostly-continue-post-fed-rally-light-holiday-trading-chicago-fed-activity", "https://www.nasdaq.com/articles/pre-market-most-active-dec-22-2014-achn-gild-chl-tvix-abbv-fb-rad-alu-pbr-ally-xiv-qqq", "https://www.nasdaq.com/articles/us-stock-futures-gain-pre-christmas-rally-2014-12-22", "https://www.nasdaq.com/articles/could-gilead-sciences-inc-be-top-stock-2015-2014-12-22", "https://www.nasdaq.com/articles/abbvies-all-oral-interferon-free-hcv-treatment-approved-analyst-blog-2014-12-22", "https://www.nasdaq.com/articles/why-gilead-sciences-shares-tumbled-today-2014-12-22", "https://www.nasdaq.com/articles/gilead-ono-pharmaceutical-ink-deal-for-blood-cancer-drug-analyst-blog-2014-12-22", "https://www.nasdaq.com/articles/price-still-right-gilead-sciences-2014-12-22", "https://www.nasdaq.com/articles/mondays-etf-movers-eem-bbh-2014-12-22", "https://www.nasdaq.com/articles/these-biotech-stocks-are-growing-even-faster-gilead-sciences-2014-12-21", "https://www.nasdaq.com/articles/gilead-sciences-inc-gets-some-competition-not-really-2014-12-21", "https://www.nasdaq.com/articles/3-pharma-giants-growing-significantly-faster-pfizer-inc-2014-12-19", "https://www.nasdaq.com/articles/united-therapeutics-lung-drug-keeps-going-and-going-2014-12-19", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-oef-gild-goog-pm-2014-12-17", "https://www.nasdaq.com/articles/pfizer-inc-invests-growth-literally-2014-12-17", "https://www.nasdaq.com/articles/week-ahead-market-report-december-22-2014-2014-12-22", "https://www.nasdaq.com/articles/3-most-exceptional-ceos-2014-2014-12-16", "https://www.nasdaq.com/articles/3-healthcare-stocks-watch-2015-2014-12-15", "https://www.nasdaq.com/articles/could-worlds-top-selling-drug-be-toppled-2014-12-15", "https://www.nasdaq.com/articles/why-im-not-short-gilead-sciences-inc-2014-12-13", "https://www.nasdaq.com/articles/can-these-top-dividend-paying-stocks-soar-2015-2014-12-13", "https://www.nasdaq.com/articles/why-gilead-sciences-and-abbvie-care-about-tiny-company-2014-12-11", "https://www.nasdaq.com/articles/cheap-stocks-2015-best-buys-healthcare-2014-12-10", "https://www.nasdaq.com/articles/which-biotech-will-become-next-gilead-sciences-inc-2014-12-16", "https://www.nasdaq.com/articles/3-most-exceptional-ceos-2014-2014-12-16", "https://www.nasdaq.com/articles/3-healthcare-stocks-watch-2015-2014-12-15", "https://www.nasdaq.com/articles/could-worlds-top-selling-drug-be-toppled-2014-12-15", "https://www.nasdaq.com/articles/why-im-not-short-gilead-sciences-inc-2014-12-13", "https://www.nasdaq.com/articles/george-soros-dumping-these-3-dividend-stocks-should-you-2014-12-07", "https://www.nasdaq.com/articles/3-top-large-cap-biotech-stocks-2015-2014-12-06", "https://www.nasdaq.com/articles/3-reasons-gilead-sciences-could-soar-2015-2014-12-06", "https://www.nasdaq.com/articles/smartest-financial-decision-i-ever-made-2014-12-10", "https://www.nasdaq.com/articles/25-best-stocks-2015-2014-12-04", "https://www.nasdaq.com/articles/3-cheap-growth-stocks-you-can-buy-right-now-2014-12-04", "https://www.nasdaq.com/articles/1-big-fda-decision-im-watching-month-2014-12-04", "https://www.nasdaq.com/articles/why-biotech-stocks-dont-pay-dividends-2014-12-04", "https://www.nasdaq.com/articles/johnson-johnson-bought-alios-hepatitis-c-2014-12-04", "https://www.nasdaq.com/articles/most-important-fda-decision-were-watching-month-2014-12-02", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-december-03-2014-2014-12-02", "https://www.nasdaq.com/articles/gilead-sciences-inc-beats-another-threat-2014-12-05", "https://www.nasdaq.com/articles/mylan-gilead-ink-deal-for-taf-based-hiv-drugs-analyst-blog-2014-12-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-vip-gild-2014-12-01", "https://www.nasdaq.com/articles/3-healthcare-stocks-hold-forever-2014-12-01", "https://www.nasdaq.com/articles/bristol-myers-squibb-cos-hep-c-drug-denied-gilead-sciences-inc-smiling-now-2014-11-29", "https://www.nasdaq.com/articles/5-drug-classes-where-prescription-spending-could-grow-quickest-2014-11-29", "https://www.nasdaq.com/articles/johnson-johnsons-rezolsta-approved-in-the-eu-for-hiv-1-analyst-blog-2014-11-27", "https://www.nasdaq.com/articles/should-gilead-sciences-inc-pay-dividend-2014-11-26", "https://www.nasdaq.com/articles/why-gilead-sciences-inc-stock-lost-10-november-2014-12-02", "https://www.nasdaq.com/articles/why-you-shouldnt-bet-against-gilead-sciences-gild-stock-tale-of-the-tape-2014-11-25", "https://www.nasdaq.com/articles/3-biotech-growth-stocks-you-can-buy-right-now-2014-11-25", "https://www.nasdaq.com/articles/abbvie-takes-aim-gilead-sciences-2014-11-25", "https://www.nasdaq.com/articles/gilead-sciences-inc-just-paid-125-million-something-it-cant-use-year-2014-11-24", "https://www.nasdaq.com/articles/abbvies-hcv-cocktail-treatment-closer-eu-approval-analyst-blog-2014-11-24", "https://www.nasdaq.com/articles/can-partnering-fight-hepatitis-c-pay-enanta-2014-11-24", "https://www.nasdaq.com/articles/3-biotech-stocks-could-soar-even-higher-2014-11-24", "https://www.nasdaq.com/articles/3-simple-reasons-doctors-may-stick-gilead-sciences-instead-abbvie-2014-11-25", "https://www.nasdaq.com/articles/why-you-shouldnt-bet-against-gilead-sciences-gild-stock-tale-of-the-tape-2014-11-25", "https://www.nasdaq.com/articles/3-biotech-growth-stocks-you-can-buy-right-now-2014-11-25", "https://www.nasdaq.com/articles/biotechs-3-most-influential-ceos-2014-11-20", "https://www.nasdaq.com/articles/gilead-to-buy-knight-therapeutics-priority-review-voucher-analyst-blog-2014-11-20", "https://www.nasdaq.com/articles/biotech-stock-roundup-geron-soars-935m-jj-deal-gileads-harvoni-approved-eu-analyst-blog", "https://www.nasdaq.com/articles/stock-market-news-for-november-19-2014-market-news-2014-11-19", "https://www.nasdaq.com/articles/nasdaq-100-movers-tsla-spls-2014-11-19", "https://www.nasdaq.com/articles/get-your-wallet-out-global-drug-spending-about-hit-dubious-milestone-2014-11-23", "https://www.nasdaq.com/articles/may-be-fastest-growing-big-biotech-stock-next-year-hint-its-not-gilead-sciences-2014-11-22", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-vti-bac-gild-intc-2014-11-20", "https://www.nasdaq.com/articles/biotechs-3-most-influential-ceos-2014-11-20", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-ntap-2014-11-14", "https://www.nasdaq.com/articles/biotech-and-yet-weve-just-begun-2014-11-14", "https://www.nasdaq.com/articles/tiger-managements-julian-robertson-buys-alibaba-ebay-mastec-sells-tableau-software-2014-11", "https://www.nasdaq.com/articles/nasdaq-100-movers-ntap-viab-2014-11-13", "https://www.nasdaq.com/articles/why-top-dividend-stock-johnson-johnson-could-plunge-2015-2014-11-17", "https://www.nasdaq.com/articles/3-stocks-smartest-investors-are-buying-right-now-2014-11-17", "https://www.nasdaq.com/articles/tiny-biotech-piggybacking-gilead-sciences-incs-success-2014-11-12", "https://www.nasdaq.com/articles/gilead-reports-promising-data-on-its-hcv-drug-harvoni-analyst-blog-2014-11-12", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-xlv-mrk-gild-unh-2014-11-11", "https://www.nasdaq.com/articles/stock-market-news-for-november-11-2014-market-news-2014-11-11", "https://www.nasdaq.com/articles/gilead-sciences-inc-breathes-sigh-relief-hepatitis-c-patients-not-so-much-2014-11-11", "https://www.nasdaq.com/articles/bristol-myers-gives-updates-on-hcv-candidate-daclatasvir-analyst-blog-2014-11-11", "https://www.nasdaq.com/articles/why-gilead-sciences-gild-isnt-done-growing-earnings-yet-tale-of-the-tape-2014-11-13", "https://www.nasdaq.com/articles/biotech-stock-roundup-gilead-abbvie-score-liver-meeting-dendreon-files-bankruptcy-analyst", "https://www.nasdaq.com/articles/tiny-biotech-piggybacking-gilead-sciences-incs-success-2014-11-12", "https://www.nasdaq.com/articles/pre-market-most-active-nov-10-2014-baba-alu-mtu-gild-gpro-pbr-qqq-nvo-achn-tvix-nmr-aapl", "https://www.nasdaq.com/articles/3-drugs-make-gilead-sciences-harvoni-look-cheap-2014-11-10", "https://www.nasdaq.com/articles/merck-reports-interim-data-on-hepatitis-c-virus-drug-analyst-blog-2014-11-10", "https://www.nasdaq.com/articles/5-prescription-drugs-selling-hot-cakes-2014-11-09", "https://www.nasdaq.com/articles/3-biotech-stocks-watch-november-2014-11-08", "https://www.nasdaq.com/articles/achillion-jumps-on-encouraging-data-on-its-hcv-candidate-analyst-blog-2014-11-11", "https://www.nasdaq.com/articles/why-abbvie-incs-game-changing-new-drug-could-be-serious-threat-gilead-sciences-inc-2014-11", "https://www.nasdaq.com/articles/gilead-gild-submits-hiv-combination-drug-for-fda-review-analyst-blog-2014-11-07", "https://www.nasdaq.com/articles/pharmacyclics-incs-imbruvica-holds-its-own-against-gilead-sciences-incs-zydelig-2014-11-07", "https://www.nasdaq.com/articles/5-things-abbvie-incs-management-wants-you-know-2014-11-06", "https://www.nasdaq.com/articles/why-achillion-pharmaceuticals-inc-stock-launched-18-higher-october-2014-11-06", "https://www.nasdaq.com/articles/etf-outlook-first-trust-amex-biotech-index-fund-etf-fbt-2014-11-06", "https://www.nasdaq.com/articles/trend-making-gilead-sciences-inc-worry-2014-11-05", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-november-10-2014-2014-11-07", "https://www.nasdaq.com/articles/seattle-genetics-gains-on-narrower-than-expected-q3-loss-analyst-blog-2014-11-03", "https://www.nasdaq.com/articles/novo-nordisks-earnings-rise-in-q3-2014-outlook-narrowed-analyst-blog-2014-11-03", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-xlv-gild-mrk-unh-2014-11-03", "https://www.nasdaq.com/articles/2-more-gilead-sciences-inc-blockbusters-you-ought-know-about-2014-11-03", "https://www.nasdaq.com/articles/5-staggering-statistics-about-fastest-growing-drug-world-2014-11-01", "https://www.nasdaq.com/articles/5-things-bristol-myers-squibb-cos-management-wants-you-know-2014-10-30", "https://www.nasdaq.com/articles/why-you-shouldnt-worry-about-gilead-sciences-inc-2014-10-30", "https://www.nasdaq.com/articles/bio-techne-corp-tech-ex-dividend-date-scheduled-november-06-2014-2014-11-05", "https://www.nasdaq.com/articles/gilead-beats-on-q3-earnings-sovaldi-sales-fall-sequentially-analyst-blog-2014-10-29", "https://www.nasdaq.com/articles/news-facebook-earnings-att-facing-lawsuit-over-throttling-and-more-2014-10-29", "https://www.nasdaq.com/articles/amgen-beats-earnings-estimates-whats-next-amgn-stocks-news-2014-10-28", "https://www.nasdaq.com/articles/gilead-gild-posts-weak-earnings-stock-falls-4-after-hours-stocks-news-2014-10-28", "https://www.nasdaq.com/articles/3-ways-youll-know-gilead-sciences-inc-stock-still-track-2014-10-28", "https://www.nasdaq.com/articles/what-make-gilead-sciences-incs-third-quarter-earnings-miss-2014-10-28", "https://www.nasdaq.com/articles/after-hours-most-active-oct-28-2014-fb-qqq-bac-jnj-bsbr-emc-aapl-san-kmi-gpor-yhoo-gild", "https://www.nasdaq.com/articles/5-things-mckesson-corporations-management-wants-you-know-2014-10-30", "https://www.nasdaq.com/articles/will-marijuana-based-pharmaceuticals-make-drugs-more-affordable-2014-10-27", "https://www.nasdaq.com/articles/iyh-gild-abt-agn-large-inflows-detected-etf-2014-10-27", "https://www.nasdaq.com/articles/safe-route-biotech-sector-2014-10-27", "https://www.nasdaq.com/articles/stock-week-gilead-sciences-gild-2014-10-27", "https://www.nasdaq.com/articles/3-biotech-stocks-growing-faster-gilead-sciences-inc-2014-10-27", "https://www.nasdaq.com/articles/merck-co-inc-earnings-patent-losses-and-competition-weigh-sales-2014-10-27", "https://www.nasdaq.com/articles/how-gilead-sciences-inc-isnt-gouging-hepatitis-c-patients-1-simple-infographic-2014-10-26", "https://www.nasdaq.com/articles/after-hours-earnings-report-october-28-2014-fb-gild-esrx-mck-apc-afl-vrtx-eqr-amp-wdc-mar", "https://www.nasdaq.com/articles/bristol-myers-squibb-cos-third-quarter-earnings-beat-street-2014-10-24", "https://www.nasdaq.com/articles/stocks-trade-higher-ahead-news-heavy-weekend-2014-10-24", "https://www.nasdaq.com/articles/fridays-etf-unusual-volume-bbh-2014-10-24", "https://www.nasdaq.com/articles/will-gilead-gild-miss-earnings-on-high-operating-costs-analyst-blog-2014-10-24", "https://www.nasdaq.com/articles/johnson-johnsons-worst-nightmare-becoming-reality-2014-10-22", "https://www.nasdaq.com/articles/gileads-hep-c-dream-drug-faces-demanding-investors-2014-10-22", "https://www.nasdaq.com/articles/why-regulus-therapeutics-inc-stock-more-doubled-2014-10-22", "https://www.nasdaq.com/articles/5-things-johnson-johnsons-management-wants-you-know-2014-10-24", "https://www.nasdaq.com/articles/3-drugs-critical-johnson-johnsons-future-2014-10-21", "https://www.nasdaq.com/articles/what-johnson-johnson-can-tell-us-about-gilead-sciences-inc-stock-2014-10-20", "https://www.nasdaq.com/articles/3-stocks-ill-buy-if-market-crashes-2014-10-20", "https://www.nasdaq.com/articles/drug-could-outsell-medical-marijuana-2014-10-19", "https://www.nasdaq.com/articles/180-million-people-have-disease-yet-few-are-aware-it-2014-10-19", "https://www.nasdaq.com/articles/could-game-changing-drug-deliver-10-billion-sales-within-its-first-year-2014-10-18", "https://www.nasdaq.com/articles/iyh-gild-tmo-cov-large-outflows-detected-etf-2014-10-17", "https://www.nasdaq.com/articles/5-best-biotech-stocks-buy-now-2014-10-21", "https://www.nasdaq.com/articles/3-drugs-critical-johnson-johnsons-future-2014-10-21", "https://www.nasdaq.com/articles/what-johnson-johnson-can-tell-us-about-gilead-sciences-inc-stock-2014-10-20", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gilead-nabs-fda-nod-for-combo-hcv-drug-auxilium-accepts-endo-offer", "https://www.nasdaq.com/articles/should-gilead-sciences-inc-fear-incoming-competition-2014-10-15", "https://www.nasdaq.com/articles/healthcare-etfs-focus-jnj-earnings-beat-etf-news-and-commentary-2014-10-15", "https://www.nasdaq.com/articles/sp-500-movers-gild-cci-2014-10-14", "https://www.nasdaq.com/articles/will-sagging-scripts-dent-gilead-sciences-inc-earnings-2014-10-17", "https://www.nasdaq.com/articles/gilead-sciences-president-and-coo-sells-146895-shares-2014-10-14", "https://www.nasdaq.com/articles/gilead-sciences-inc-stocks-green-light-sparks-offensive-2014-10-13", "https://www.nasdaq.com/articles/gileads-all-oral-combo-hcv-drug-harvoni-cleared-by-fda-analyst-blog-2014-10-13", "https://www.nasdaq.com/articles/gilead-sciences-inc-gets-first-hepatitis-c-cocktail-drug-approved-2014-10-10", "https://www.nasdaq.com/articles/bristol-myers-co-regroups-hepatitis-c-fight-gilead-sciences-not-over-2014-10-09", "https://www.nasdaq.com/articles/ishares-us-healthcare-etf-experiences-big-inflow-2014-10-09", "https://www.nasdaq.com/articles/3-stocks-buy-if-market-crashes-2014-10-09", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-symc-2014-10-14", "https://www.nasdaq.com/articles/after-hours-most-active-oct-9-2014-siri-svu-bndx-brkb-bac-syf-cog-cs-qqq-aapl-msft-gild", "https://www.nasdaq.com/articles/bristol-myers-tells-gilead-sciences-inc-you-win-2014-10-08", "https://www.nasdaq.com/articles/etf-outlook-health-care-select-sector-spdr-etf-xlv-2014-10-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-sunesis-tanks-study-results-chimerix-ebola-update-analyst-blog-2014", "https://www.nasdaq.com/articles/bristol-myers-gives-up-on-us-approval-of-2-drug-hcv-combo-analyst-blog-2014-10-08", "https://www.nasdaq.com/articles/after-hours-most-active-oct-8-2014-aa-rexx-qqq-cs-gps-cx-abb-kmi-znga-gild-siri-msft-2014", "https://www.nasdaq.com/articles/most-important-number-you-need-know-buying-gilead-sciences-inc-stock-2014-10-07", "https://www.nasdaq.com/articles/can-arrowhead-research-corp-stock-recover-its-horrendous-drop-2014-10-09", "https://www.nasdaq.com/articles/after-hours-most-active-oct-6-2014-itub-bac-cx-puk-hsbc-ftr-jdsu-hban-bid-gild-symc-fitb", "https://www.nasdaq.com/articles/gilead-sciences-other-important-new-drug-2014-10-05", "https://www.nasdaq.com/articles/gilead-sciences-inc-got-2-drugs-approved-and-didnt-bother-tell-anyone-2014-10-04", "https://www.nasdaq.com/articles/better-dividend-stock-merck-co-inc-or-bristol-myers-squibb-co-2014-10-04", "https://www.nasdaq.com/articles/biggest-threat-facing-johnson-johnson-2014-10-04", "https://www.nasdaq.com/articles/mannkind-receives-%24150-million-upfront-payment-from-sanofi-analyst-blog-2014-10-03", "https://www.nasdaq.com/articles/regeneron-sanofis-dupilumab-meets-all-endpoints-analyst-blog-2014-10-03", "https://www.nasdaq.com/articles/johnson-johnson-takes-aim-gilead-sciences-inc-2014-10-06", "https://www.nasdaq.com/articles/progenics-salixs-relistor-label-expanded-in-the-u.s.-analyst-blog-2014-10-02", "https://www.nasdaq.com/articles/abbvies-abbv-humira-gains-yet-another-fda-approval-analyst-blog-2014-10-02", "https://www.nasdaq.com/articles/aveo-biodesix-reveal-lung-cancer-study-exploratory-data-analyst-blog-2014-10-02", "https://www.nasdaq.com/articles/did-achillion-pharmaceuticals-inc-get-left-out-ma-cold-2014-10-01", "https://www.nasdaq.com/articles/round-2-gilead-sciences-incs-offensive-begins-2014-10-01", "https://www.nasdaq.com/articles/premarket-primer-wednesday-october-1-first-case-ebola-us-confirmed-2014-10-01", "https://www.nasdaq.com/articles/seattle-genetics-takeda-reveal-impressive-adcetris-data-analyst-blog-2014-10-01", "https://www.nasdaq.com/articles/top-fund-buys-chipotle-allergan-jazz-gilead-2014-10-02", "https://www.nasdaq.com/articles/ambit-biosciences-ambi-soars%3A-stock-adds-87.1-tale-of-the-tape-2014-09-30", "https://www.nasdaq.com/articles/immunomedics-immu-jumps%3A-stock-adds-9.1-is-session-tale-of-the-tape-2014-09-30", "https://www.nasdaq.com/articles/gilead-sciences-inc-stocks-stunning-new-opportunity-2014-09-30", "https://www.nasdaq.com/articles/raptor-pharmaceuticals-rptp-crumbles%3A-stock-falls-by-7.2-tale-of-the-tape-2014-09-30", "https://www.nasdaq.com/articles/cormedix-files-ind-application-for-neutrolin-in-the-us-analyst-blog-2014-09-30", "https://www.nasdaq.com/articles/amag-up-on-roughly-%241b-deal-with-lumara-to-widen-portfolio-analyst-blog-2014-09-30", "https://www.nasdaq.com/articles/regado-trims-workforce-revamps-strategy-on-trial-halt-analyst-blog-2014-09-30", "https://www.nasdaq.com/articles/machines-rule-bears-drool-video-blog-2014-10-01", "https://www.nasdaq.com/articles/gilead-sciences-inc-takes-aim-bristol-myers-squibb-2014-09-29", "https://www.nasdaq.com/articles/bristol-myers-opdivo-under-review-in-us-eu-for-cancer-treatment-analyst-blog-2014-09-29", "https://www.nasdaq.com/articles/alimera-psividas-iluvien-receives-fda-approval-for-dme-analyst-blog-2014-09-29", "https://www.nasdaq.com/articles/agios-to-present-data-on-ag-120-in-november-shares-rises-analyst-blog-2014-09-29", "https://www.nasdaq.com/articles/gileads-hcv-combo-drug-harvoni-secures-chmp-backing-analyst-blog-2014-09-29", "https://www.nasdaq.com/articles/nektar-astrazenecas-moventig-a-step-closer-to-eu-approval-analyst-blog-2014-09-29", "https://www.nasdaq.com/articles/what-huge-george-soros-mistake-can-teach-you-2014-09-27", "https://www.nasdaq.com/articles/repros-therapeutics-rprx-worth-watching%3A-stock-up-17-tale-of-the-tape-2014-09-29", "https://www.nasdaq.com/articles/rexahn-pharmaceuticals-rnn-jumps%3A-stock-gains-10.2-tale-of-the-tape-2014-09-26", "https://www.nasdaq.com/articles/5-best-biotech-stocks-2014so-far-2014-09-26", "https://www.nasdaq.com/articles/celldex-cldx-up-on-pilot-study-initiation-on-cdx-301-analyst-blog-2014-09-26", "https://www.nasdaq.com/articles/alnylam-starts-new-study-on-cardiac-amyloidosis-patients-analyst-blog-2014-09-26", "https://www.nasdaq.com/articles/mannkind-and-sanofi-complete-afrezza-collaboration-deal-analyst-blog-2014-09-26", "https://www.nasdaq.com/articles/gileads-hiv-drugs-tybost-and-vitekta-get-fda-clearance-analyst-blog-2014-09-26", "https://www.nasdaq.com/articles/myriad-genetics-poised-on-strong-myrisk-overseas-results-analyst-blog-2014-09-26", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-mack-soars%3A-stock-adds-7.4-is-session-tale-of-the-tape-2014-09", "https://www.nasdaq.com/articles/etf-outlook-sp-health-care-select-spdr-etf-xlv-2014-09-25", "https://www.nasdaq.com/articles/switch-could-make-gilead-sciences-inc-stock-billions-2014-09-25", "https://www.nasdaq.com/articles/best-biotech-stock-your-growth-portfolio-2014-09-25", "https://www.nasdaq.com/articles/seattle-genetics-adcetris-positive-in-durability-analysis-analyst-blog-2014-09-25", "https://www.nasdaq.com/articles/acorda-skyrockets-on-%24525m-civitas-therapeutics-deal-analyst-blog-2014-09-25", "https://www.nasdaq.com/articles/gilead-scores-with-taf-based-hiv-regimen-shares-up-analyst-blog-2014-09-25", "https://www.nasdaq.com/articles/genomic-health-upbeat-on-strong-international-performance-analyst-blog-2014-09-25", "https://www.nasdaq.com/articles/qiagens-molecular-diagnostics-global-market-show-strength-analyst-blog-2014-09-26", "https://www.nasdaq.com/articles/etf-outlook-sp-health-care-select-spdr-etf-xlv-2014-09-25", "https://www.nasdaq.com/articles/next-blue-chip-stocks-gilead-sciences-inc-2014-09-24", "https://www.nasdaq.com/articles/novavaxs-influenza-vaccine-study-shows-adjuvant-efficiency-analyst-blog-2014-09-24", "https://www.nasdaq.com/articles/gilead-gild-seeks-japanese-approval-for-hcv-combo-drug-analyst-blog-2014-09-24", "https://www.nasdaq.com/articles/celgenes-otezla-label-expanded-to-include-plaque-psoriasis-analyst-blog-2014-09-24", "https://www.nasdaq.com/articles/emergent-biosolutions-initiates-pivotal-study-on-biothrax-analyst-blog-2014-09-24", "https://www.nasdaq.com/articles/iwf-ibm-vz-gild-large-inflows-detected-etf-2014-09-23", "https://www.nasdaq.com/articles/acceleron-pharma-xlrn-jumps%3A-stock-rises-12.8-tale-of-the-tape-2014-09-24", "https://www.nasdaq.com/articles/amgen-files-blinatumomab-marketing-application-in-u.s.-analyst-blog-2014-09-23", "https://www.nasdaq.com/articles/astrazeneca-posts-positive-data-on-its-type-ii-diabetes-drug-analyst-blog-2014-09-23", "https://www.nasdaq.com/articles/bayer-regeneron-successfully-expand-eylea-label-in-japan-analyst-blog-2014-09-23", "https://www.nasdaq.com/articles/integra-freedom-wrists-commercial-availability-falls-flat-analyst-blog-2014-09-23", "https://www.nasdaq.com/articles/dynavax-dvax-jumps%3A-stock-moves-6.7-higher-tale-of-the-tape-2014-09-22", "https://www.nasdaq.com/articles/cytori-therapeutics-cytx-jumps%3A-stock-rises-6.4-tale-of-the-tape-2014-09-22", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-vrtx-jumps%3A-stock-rises-6.6-tale-of-the-tape-2014-09-22", "https://www.nasdaq.com/articles/oncomed-pharmaceuticals-omed-jumps%3A-stock-up-5.4-tale-of-the-tape-2014-09-23", "https://www.nasdaq.com/articles/isis-pharmaceuticals-up-on-%244m-milestone-payment-analyst-blog-2014-09-22", "https://www.nasdaq.com/articles/gileads-gild-zydelig-gets-eu-clearance-for-blood-cancer-analyst-blog-2014-09-22", "https://www.nasdaq.com/articles/flexion-continues-to-fall-post-clinical-hold-on-fx006-analyst-blog-2014-09-22", "https://www.nasdaq.com/articles/surprising-silver-lining-gilead-sciences-inc-stock-2014-09-22", "https://www.nasdaq.com/articles/dividend-aristocrats-time-buy-abbvie-inc-stock-2014-09-19", "https://www.nasdaq.com/articles/5-things-gilead-sciences-inc-management-wants-you-know-2014-09-19", "https://www.nasdaq.com/articles/vivus-inc.-vvus-rises%3A-stock-adds-12.4-in-session-tale-of-the-tape-2014-09-19", "https://www.nasdaq.com/articles/glaxo-fined-roughly-%24484m-in-china-bribery-probe-analyst-blog-2014-09-22", "https://www.nasdaq.com/articles/vivus-and-auxilium-announce-stendra-label-expansion-analyst-blog-2014-09-19", "https://www.nasdaq.com/articles/bristol-myers-bmy-yervoy-label-expanded-in-canada-analyst-blog-2014-09-19", "https://www.nasdaq.com/articles/spectrum-pharmaceuticals-out-licenses-products-in-china-analyst-blog-2014-09-19", "https://www.nasdaq.com/articles/bayer-to-shed-materialscience-business-shares-rise-analyst-blog-2014-09-19", "https://www.nasdaq.com/articles/eli-lillys-trulicity-approved-by-fda-for-type-ii-diabetes-analyst-blog-2014-09-19", "https://www.nasdaq.com/articles/is-merck-kgaa-on-track-with-its-fit-for-2018-program-analyst-blog-2014-09-19", "https://www.nasdaq.com/articles/sector-update-health-care-shares-lower-pre-market-trade-2014-09-19", "https://www.nasdaq.com/articles/it-time-buy-dividend-stock-bristol-myers-squibb-co-2014-09-18", "https://www.nasdaq.com/articles/immunocellular-therapeutics-imuc-jumps%3A-stock-up-9-tale-of-the-tape-2014-09-18", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-jumps%3A-stock-up-9.3-tale-of-the-tape-2014-09-18", "https://www.nasdaq.com/articles/repros-therapeutics-rprx-crumbles%3A-stock-falls-by-10.5-tale-of-the-tape-2014-09-18", "https://www.nasdaq.com/articles/gilead-sciences-inc-stocks-incoming-game-changer-2014-09-18", "https://www.nasdaq.com/articles/3-best-stocks-investing-biotech-2014-09-18", "https://www.nasdaq.com/articles/sanofi-myokardia-ink-deal-to-develop-cardiomyopathies-analyst-blog-2014-09-18", "https://www.nasdaq.com/articles/gilead-science-stumbles-stays-its-feet-2014-09-18", "https://www.nasdaq.com/articles/alnylam-alny-to-file-clinical-trial-application-for-aln-cc5-analyst-blog-2014-09-18", "https://www.nasdaq.com/articles/gilead-down-on-weak-simtuzumab-data-and-sovaldi-news-analyst-blog-2014-09-18", "https://www.nasdaq.com/articles/3-hot-ways-play-biotechnology-bonanza-2014-09-17", "https://www.nasdaq.com/articles/sector-update-health-care-shares-mixed-pre-market-2014-09-17", "https://www.nasdaq.com/articles/sector-update-health-care-2014-09-17-0", "https://www.nasdaq.com/articles/merck-posts-positive-data-on-osteoporosis-drug-odanacatib-analyst-blog-2014-09-17", "https://www.nasdaq.com/articles/shires-vyvanse-accepted-for-fda-review-for-binge-eating-analyst-blog-2014-09-17", "https://www.nasdaq.com/articles/bayer-orion-progress-with-prostate-cancer-drug-odm-201-analyst-blog-2014-09-18", "https://www.nasdaq.com/articles/regeneron-gets-breakthrough-therapy-status-for-eylea-analyst-blog-2014-09-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-avanir-soars-phase-ii-data-orexigens-contrave-approved-analyst-blog", "https://www.nasdaq.com/articles/astrazeneca-and-eli-lilly-collaborate-for-alzheimers-drug-analyst-blog-2014-09-16", "https://www.nasdaq.com/articles/synthetic-biologics-syn-005-gets-orphan-drug-designation-analyst-blog-2014-09-16", "https://www.nasdaq.com/articles/gilead-gild-slips-on-generic-sovaldi-licensing-deals-analyst-blog-2014-09-16", "https://www.nasdaq.com/articles/is-illumina-ilmn-a-buy-on-solid-q2-strategic-road-map-analyst-blog-2014-09-16", "https://www.nasdaq.com/articles/ucb-amgen-reveals-positive-data-on-romosozumab-for-pmo-analyst-blog-2014-09-17", "https://www.nasdaq.com/articles/astrazenecas-constipation-drug-movantik-gets-fda-nod-analyst-blog-2014-09-17", "https://www.nasdaq.com/articles/sector-update-health-care-2014-09-15-1", "https://www.nasdaq.com/articles/nps-pharmaceuticals-natpara-gets-positive-fda-panel-vote-analyst-blog-2014-09-15", "https://www.nasdaq.com/articles/alnylam-expands-pipeline-with-preeclampsia-drug-aln-agt-analyst-blog-2014-09-15", "https://www.nasdaq.com/articles/novartis-presents-positive-data-on-lucentis-and-jetrea-analyst-blog-2014-09-15", "https://www.nasdaq.com/articles/abbott-labs-presents-positive-one-year-data-on-absorb-analyst-blog-2014-09-15", "https://www.nasdaq.com/articles/sp-500-movers-gild-tap-2014-09-15", "https://www.nasdaq.com/articles/eli-lillys-cyramza-scores-in-colorectal-cancer-study-analyst-blog-2014-09-15", "https://www.nasdaq.com/articles/genomic-health-reveals-positive-oncotype-dx-test-results-analyst-blog-2014-09-15", "https://www.nasdaq.com/articles/3-reasons-mckesson-corporations-stock-could-rise-2014-09-15", "https://www.nasdaq.com/articles/premarket-primer-friday-september-12-us-allies-vague-about-participation-syrian-airstrikes", "https://www.nasdaq.com/articles/will-allergans-board-be-revamped-to-aid-valeant-buyout-analyst-blog-2014-09-12", "https://www.nasdaq.com/articles/abbott-labs-abt-to-repurchase-shares-for-%243b-analyst-blog-2014-09-12", "https://www.nasdaq.com/articles/biogen-reports-positive-two-year-data-on-ms-drug-plegridy-analyst-blog-2014-09-12", "https://www.nasdaq.com/articles/amarin-plunges-after-the-fda-denies-vascepa-spa-appeal-analyst-blog-2014-09-15", "https://www.nasdaq.com/articles/novartis-presents-data-on-multiple-sclerosis-drug-gilenya-analyst-blog-2014-09-11", "https://www.nasdaq.com/articles/momenta-gains-on-purchase-of-autoimmune-antibodies-analyst-blog-2014-09-11", "https://www.nasdaq.com/articles/medivation-eyes-blockbuster-cancer-drug-gets-ok-2014-09-11", "https://www.nasdaq.com/articles/mylan-to-acquire-u.s.-rights-to-arixtra-for-up-to-%24300m-analyst-blog-2014-09-11", "https://www.nasdaq.com/articles/why-gilead-sciences-stock-40-2014-2014-09-11", "https://www.nasdaq.com/articles/biotech-etfs-slip-on-gilead-weakness-buying-opportunity-now-etf-news-and-commentary-2014", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvie-ties-infinity-keryx-slips-fda-approval-analyst-blog-2014-09", "https://www.nasdaq.com/articles/medivation-astellas-xtandis-label-expanded-fda-analyst-blog-2014-09-11", "https://www.nasdaq.com/articles/peregrine-pharmaceuticals-q1-loss-wider-than-expected-analyst-blog-2014-09-10", "https://www.nasdaq.com/articles/stemline-therapeutics-stml-in-focus%3A-stock-up-12.3-tale-of-the-tape-2014-09-10", "https://www.nasdaq.com/articles/pdl-biopharma-sees-higher-than-expected-revenues-in-q3-analyst-blog-2014-09-10", "https://www.nasdaq.com/articles/spectrum-pharmaceuticals-to-advance-neutropenia-drug-analyst-blog-2014-09-10", "https://www.nasdaq.com/articles/auxilium-pharmaceuticals-to-restructure-cut-jobs-by-30-analyst-blog-2014-09-10", "https://www.nasdaq.com/articles/emergent-biosolutions-wins-29m-anthrax-vaccine-deal-analyst-blog-2014-09-10", "https://www.nasdaq.com/articles/myriad-genetics-posts-encouraging-mypath-melanoma-data-analyst-blog-2014-09-10", "https://www.nasdaq.com/articles/erba-diagnostics-erb-in-focus%3A-stock-up-7-tale-of-the-tape-2014-09-10", "https://www.nasdaq.com/articles/glaxo-gsk-updates-on-asthma-candidate-mepolizumab-analyst-blog-2014-09-09", "https://www.nasdaq.com/articles/pluristem-united-therapeutics-progress-with-phase-i-study-analyst-blog-2014-09-09", "https://www.nasdaq.com/articles/hospira-down-on-legal-blow-court-allows-generic-precedex-analyst-blog-2014-09-09", "https://www.nasdaq.com/articles/ziopharm-oncology-ziop-in-focus%3A-stock-rises-10.4-tale-of-the-tape-2014-09-08", "https://www.nasdaq.com/articles/keryx-biopharmaceuticals-kerx-crumbles%3A-stock-falls-by-5.5-tale-of-the-tape-2014-09-08", "https://www.nasdaq.com/articles/biodelivery-sciences-bdsi-jumps%3A-stock-rises-8.9-tale-of-the-tape-2014-09-08", "https://www.nasdaq.com/articles/stock-week-express-scripts-esrx-2014-09-08", "https://www.nasdaq.com/articles/astrazeneca-presents-unfavorable-benralizumab-study-data-analyst-blog-2014-09-09", "https://www.nasdaq.com/articles/oncomeds-shares-gain-on-lifting-of-partial-clinical-hold-analyst-blog-2014-09-08", "https://www.nasdaq.com/articles/prana-biotechnology-up-on-orphan-drug-status-for-pbt2-analyst-blog-2014-09-08", "https://www.nasdaq.com/articles/novartis-nvs-presents-positive-data-on-ultibro-breezhaler-analyst-blog-2014-09-08", "https://www.nasdaq.com/articles/bayer-regeneron-looking-for-eylea-label-expansion-in-japan-analyst-blog-2014-09-08", "https://www.nasdaq.com/articles/bristol-myers-sues-merck-of-patent-infringement-on-keytruda-analyst-blog-2014-09-08", "https://www.nasdaq.com/articles/gilead-down-on-likely-sovaldi-generic-deal-in-poor-nations-analyst-blog-2014-09-08", "https://www.nasdaq.com/articles/cheap-hepatitis-c-cure-about-go-global-2014-09-07", "https://www.nasdaq.com/articles/keryx-falls-after-ferric-citrates-approval-with-warnings-analyst-blog-2014-09-08", "https://www.nasdaq.com/articles/oncomeds-shares-gain-on-lifting-of-partial-clinical-hold-analyst-blog-2014-09-08", "https://www.nasdaq.com/articles/markets-edge-lower-zumiez-issues-weak-outlook-2014-09-05", "https://www.nasdaq.com/articles/xoma-corporation-xoma-jumps%3A-stock-rises-6.2-tale-of-the-tape-2014-09-05", "https://www.nasdaq.com/articles/mallinckrodts-pain-therapy-hits-phase-iii-primary-endpoint-analyst-blog-2014-09-05", "https://www.nasdaq.com/articles/celgenes-revlimid-impresses-in-phase-iii-ndmm-study-analyst-blog-2014-09-05", "https://www.nasdaq.com/articles/abbott-labs-freestyle-libre-flash-glucose-gets-ce-mark-analyst-blog-2014-09-05", "https://www.nasdaq.com/articles/rexahn-pharmaceuticals-rnn-jumps%3A-stock-rises-9.6-tale-of-the-tape-2014-09-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-vrtx-2014-09-05", "https://www.nasdaq.com/articles/ishares-russell-1000-growth-etf-experiences-big-inflow-2014-09-05", "https://www.nasdaq.com/articles/3-reasons-bristol-myers-squibbs-stock-could-fall-2014-09-04", "https://www.nasdaq.com/articles/jj-ebola-vaccine-gets-funding-development-to-pick-pace-analyst-blog-2014-09-04", "https://www.nasdaq.com/articles/bristol-myers-returns-clazakizumab-rights-alder-sinks-analyst-blog-2014-09-03", "https://www.nasdaq.com/articles/biotech-stock-roundup-united-therapeutics-court-ruling-amgen-files-pcsk9-inhibitor-analyst", "https://www.nasdaq.com/articles/alder-biopharmaceuticals-slumps%3A-aldr-tanks-13.2-in-session-tale-of-the-tape-2014-09-03", "https://www.nasdaq.com/articles/exact-sciences-corp.-exas-in-focus%3A-stock-rises-6.3-tale-of-the-tape-2014-09-04", "https://www.nasdaq.com/articles/infinity-pharma-infi-shares-skyrocket-cancer-drug-partnership-stocks-news-2014-09-03", "https://www.nasdaq.com/articles/sanofi-reports-positive-phase-iii-data-on-dengue-vaccine-analyst-blog-2014-09-03", "https://www.nasdaq.com/articles/three-stocks-top-performing-funds-facebook-baidu-gilead-2014-09-03", "https://www.nasdaq.com/articles/new-managers-revive-thrivent-large-cap-growth-fund-2014-09-03", "https://www.nasdaq.com/articles/arena-pharmaceuticals-apd811-gets-orphan-drug-status-analyst-blog-2014-09-03", "https://www.nasdaq.com/articles/bayer-discloses-encouraging-data-on-anticoagulant-xarelto-analyst-blog-2014-09-03", "https://www.nasdaq.com/articles/etf-insider-qa-kevin-kelly-recon-capital-partners-2014-09-03", "https://www.nasdaq.com/articles/roches-cobas-6800-8800-testing-systems-launched-analyst-blog-2014-09-03", "https://www.nasdaq.com/articles/ambit-biosciences-ambi-jumps%3A-stock-up-6.6-tale-of-the-tape-2014-09-02", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-september-03-2014-2014-09-02", "https://www.nasdaq.com/articles/bristol-myers-pfizers-eliquis-encourages-in-vte-analysis-analyst-blog-2014-09-02", "https://www.nasdaq.com/articles/astrazeneca-reports-data-on-brilinta-from-atlantic-study-analyst-blog-2014-09-02", "https://www.nasdaq.com/articles/bayer-johnson-johnson-to-expand-xarelto-label-further-analyst-blog-2014-09-02", "https://www.nasdaq.com/articles/united-therapeutics-soars-on-remodulin-patent-case-win-analyst-blog-2014-09-02", "https://www.nasdaq.com/articles/novartis-releases-positive-data-on-lcz696-for-heart-failure-analyst-blog-2014-09-02", "https://www.nasdaq.com/articles/biotechnology-oil-and-brazil-etfs-watch-week-2014-09-02", "https://www.nasdaq.com/articles/biocrysts-ebola-candidate-moving-to-efficacy-study-soon-analyst-blog-2014-09-02", "https://www.nasdaq.com/articles/3-simple-ways-invest-george-soros-2014-08-30", "https://www.nasdaq.com/articles/protalix-biotherapeutics-inc.-plx-jumps%3A-stock-adds-8.3-in-session-tale-of-the-tape-2014", "https://www.nasdaq.com/articles/why-gilead-sciences-gild-could-be-positioned-for-a-surge-tale-of-the-tape-2014-08-29", "https://www.nasdaq.com/articles/oncomed-pharmaceuticals-omed-in-focus%3A-stock-up-9.9-tale-of-the-tape-2014-08-29", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-pipeline-progress-raises-costs-analyst-blog-2014-08-29", "https://www.nasdaq.com/articles/pfizers-c.-difficile-vaccine-gets-fast-track-status-analyst-blog-2014-08-29", "https://www.nasdaq.com/articles/prestige-brands-to-sell-bonine-for-insight-acquisition-analyst-blog-2014-09-02", "https://www.nasdaq.com/articles/isis-pharmaceuticals-starts-phase-iii-study-on-isis-apociiirx-analyst-blog-2014-08-29", "https://www.nasdaq.com/articles/momenta-sandozs-generic-copaxone-accepted-for-review-by-fda-analyst-blog-2014-08-29", "https://www.nasdaq.com/articles/guggenheim-sp-500-equal-weight-etf-experiences-big-inflow-2014-08-28", "https://www.nasdaq.com/articles/bristol-myers-squibbs-daklinza-threatens-johnson-johnson-more-gilead-sciences-2014-08-28", "https://www.nasdaq.com/articles/has-gilead-sciences-incs-star-drug-already-peaked-2014-08-28", "https://www.nasdaq.com/articles/bristol-myers-oral-hcv-treatment-daklinza-gets-eu-clearance-analyst-blog-2014-08-28", "https://www.nasdaq.com/articles/intellipharmaceutics-oxycodone-program-to-prevent-overdose-analyst-blog-2014-08-29", "https://www.nasdaq.com/articles/amgens-chronic-heart-failure-drug-gets-priority-review-analyst-blog-2014-08-28", "https://www.nasdaq.com/articles/aegerion-resolves-fdas-warning-on-juxtapid-lifts-overhang-analyst-blog-2014-08-28", "https://www.nasdaq.com/articles/medicinova-rises-on-fdas-nod-on-mn-166-study-initiation-analyst-blog-2014-08-28", "https://www.nasdaq.com/articles/allergan-seeks-court-order-to-stop-valeant-affiliates-analyst-blog-2014-08-28", "https://www.nasdaq.com/articles/q2-earnings-season-rearview-mirror-earnings-trends-2014-08-28", "https://www.nasdaq.com/articles/q2-earnings-season-rearview-mirror-earnings-outlook-2014-08-28", "https://www.nasdaq.com/articles/biotimes-ast-opc1-cleared-by-fda-for-phase-i-iia-study-analyst-blog-2014-08-28", "https://www.nasdaq.com/articles/redhill-expands-eradicate-study-on-rhb-105-for-h.-pylori-analyst-blog-2014-08-28", "https://www.nasdaq.com/articles/it-time-buy-abbvie-stock-2014-08-27", "https://www.nasdaq.com/articles/amicus-therapeutics-hits-52-week-high-on-migalastat-data-analyst-blog-2014-08-27", "https://www.nasdaq.com/articles/3-reasons-pfizer-incs-stock-could-fall-2014-08-27", "https://www.nasdaq.com/articles/isis-pharmaceuticals-inc.-isis-surges%3A-stock-moves-10.8-higher-tale-of-the-tape-2014-08-27", "https://www.nasdaq.com/articles/celldex-therapeutics-cldx-worth-watching%3A-stock-rises-9.1-tale-of-the-tape-2014-08-27", "https://www.nasdaq.com/articles/premarket-primer-wednesday-august-27-israel-and-hamas-resume-peace-talks-cairo-2014-08-27", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-tsco-2014-08-26", "https://www.nasdaq.com/articles/repros-reports-encouraging-late-stage-data-on-androxal-analyst-blog-2014-08-28", "https://www.nasdaq.com/articles/gilead-gild-shares-march-higher-can-it-continue-tale-of-the-tape-2014-08-26", "https://www.nasdaq.com/articles/trovagene-trov-jumps%3A-stock-rises-9.2-tale-of-the-tape-2014-08-26", "https://www.nasdaq.com/articles/intermune-itmn-worth-watching%3A-stock-rises-35.4-tale-of-the-tape-2014-08-26", "https://www.nasdaq.com/articles/alkermes-gains-on-aripiprazole-lauroxil-nda-submission-analyst-blog-2014-08-26", "https://www.nasdaq.com/articles/kite-pharma-drug-fares-well-in-non-hodgkins-lymphoma-study-analyst-blog-2014-08-26", "https://www.nasdaq.com/articles/premarket-primer-tuesday-august-26-us-gathers-intelligence-syria-2014-08-26", "https://www.nasdaq.com/articles/cardiome-pharma-signs-agreement-with-eurolab-for-brinavess-analyst-blog-2014-08-26", "https://www.nasdaq.com/articles/should-gilead-sciences-inc-fear-new-competitor-drug-2014-08-26", "https://www.nasdaq.com/articles/sp-500-movers-stz-gild-2014-08-25", "https://www.nasdaq.com/articles/nasdaq-100-movers-intu-gild-2014-08-25", "https://www.nasdaq.com/articles/oncomed-pharmaceuticals-omed-in-focus%3A-stock-rises-5.1-tale-of-the-tape-2014-08-25", "https://www.nasdaq.com/articles/cubist-pharmaceuticals-antibiotic-accepted-for-eu-review-analyst-blog-2014-08-25", "https://www.nasdaq.com/articles/more-biotech-mergers-roche-acquire-intermune-itmn-stocks-news-2014-08-25", "https://www.nasdaq.com/articles/3-reasons-johnson-johnsons-stock-could-fall-2014-08-25", "https://www.nasdaq.com/articles/regado-slumps-on-permanent-termination-of-revolixys-study-analyst-blog-2014-08-26", "https://www.nasdaq.com/articles/vivus-acquires-certain-topamax-related-patents-from-jj-analyst-blog-2014-08-26", "https://www.nasdaq.com/articles/sp-500-movers-stz-gild-2014-08-25", "https://www.nasdaq.com/articles/nasdaq-100-movers-intu-gild-2014-08-25", "https://www.nasdaq.com/articles/oncomed-pharmaceuticals-omed-in-focus%3A-stock-rises-5.1-tale-of-the-tape-2014-08-25", "https://www.nasdaq.com/articles/cubist-pharmaceuticals-antibiotic-accepted-for-eu-review-analyst-blog-2014-08-25", "https://www.nasdaq.com/articles/more-biotech-mergers-roche-acquire-intermune-itmn-stocks-news-2014-08-25", "https://www.nasdaq.com/articles/vti-mrk-ko-gild-large-inflows-detected-etf-2014-08-21", "https://www.nasdaq.com/articles/repros-therapeutics-rprx-shows-strength%3A-stock-rises-5-tale-of-the-tape-2014-08-22", "https://www.nasdaq.com/articles/amicus-therapeutics-fold-worth-watching%3A-stock-rises-20.4-tale-of-the-tape-2014-08-21", "https://www.nasdaq.com/articles/discovery-laboratories-dsco-worth-watching%3A-stock-up-6.9-tale-of-the-tape-2014-08-21", "https://www.nasdaq.com/articles/bristol-myers-celgene-pair-up-for-oncology-combo-treatments-analyst-blog-2014-08-21", "https://www.nasdaq.com/articles/achillion-attains-52-week-high-on-ach-3102-patent-protection-analyst-blog-2014-08-21", "https://www.nasdaq.com/articles/amicus-therapeutics-fold-soars-on-fabry-drug-trial-results-analyst-blog-2014-08-21", "https://www.nasdaq.com/articles/emergent-biosolutions-morphosys-tie-up-on-cancer-candidate-analyst-blog-2014-08-20", "https://www.nasdaq.com/articles/3-reasons-gilead-science-incs-stock-could-rise-2014-08-20", "https://www.nasdaq.com/articles/gilead-gild-hits-52-week-high-thanks-to-sovaldi-analyst-blog-2014-08-21", "https://www.nasdaq.com/articles/healthcare-enjoys-growth-trends%3A-3-medical-stocks-to-buy-analyst-blog-2014-08-20", "https://www.nasdaq.com/articles/record-earnings-stronger-growth-q2-earnings-trends-2014-08-20", "https://www.nasdaq.com/articles/record-earnings-stronger-growth-q2-earnings-outlook-2014-08-20", "https://www.nasdaq.com/articles/oncothyreon-onty-slumps-tecemotide-fails-phase-i-ii-study-analyst-blog-2014-08-20", "https://www.nasdaq.com/articles/pdl-biopharma-misses-on-q2-earnings-due-to-higher-expenses-analyst-blog-2014-08-19", "https://www.nasdaq.com/articles/celladon-corp.-cldn-jumps%3A-stock-adds-11.3-in-session-tale-of-the-tape-2014-08-19", "https://www.nasdaq.com/articles/will-roche-rhhby-buy-the-remaining-stake-in-chugai-analyst-blog-2014-08-19", "https://www.nasdaq.com/articles/hospira-sues-fda-on-generic-precedex-approval-shares-down-analyst-blog-2014-08-20", "https://www.nasdaq.com/articles/after-hours-most-active-aug-19-2014-bac-xom-aapl-qqq-met-msft-nok-cat-bbd-mdlz-gild-achn", "https://www.nasdaq.com/articles/pfizer-submits-palbociclib-marketing-application-to-the-fda-analyst-blog-2014-08-19", "https://www.nasdaq.com/articles/biogen-strengthens-ms-portfolio-plegridy-fda-approval-analyst-blog-2014-08-19", "https://www.nasdaq.com/articles/techne-corporation-tech-ex-dividend-date-scheduled-august-19-2014-2014-08-18", "https://www.nasdaq.com/articles/premarket-primer-monday-august-18-jackson-hole-draws-market-attention-2014-08-18", "https://www.nasdaq.com/articles/achillion-pharmaceuticals-soars-on-mid-stage-hcv-study-data-analyst-blog-2014-08-18", "https://www.nasdaq.com/articles/should-achillion-pharma-achn-be-your-portfolio-now-stocks-news-2014-08-18", "https://www.nasdaq.com/articles/amgen-amgn-reports-encouraging-top-line-data-on-amg-416-analyst-blog-2014-08-19", "https://www.nasdaq.com/articles/array-biopharma-falls-despite-narrower-than-expected-q4-loss-analyst-blog-2014-08-15", "https://www.nasdaq.com/articles/closing-update-nasdaq-closes-higher-afternoon-rebound-dow-sp-500-finish-red-russia-ukraine", "https://www.nasdaq.com/articles/double-dose-good-news-gilead-sciences-inc-2014-08-15", "https://www.nasdaq.com/articles/sector-update-health-care-stocks-turn-mixed-close-achillion-pharma-spikes-after-hep-c-drug", "https://www.nasdaq.com/articles/sector-update-health-care-2014-08-15", "https://www.nasdaq.com/articles/why-achillion-pharmaceuticals-inc-stock-soared-2014-08-15", "https://www.nasdaq.com/articles/gilead-sciences-gild-plenty-room-run-2014-08-14", "https://www.nasdaq.com/articles/gilead-scores-legal-victory-over-roche-for-sovaldi-shares-up-analyst-blog-2014-08-18", "https://www.nasdaq.com/articles/after-hours-most-active-aug-14-2014-jcp-cie-kmi-qqq-gfi-ulti-siri-king-cat-pten-gild-gluu", "https://www.nasdaq.com/articles/strong-earnings-season-winding-down-earnings-trends-2014-08-14", "https://www.nasdaq.com/articles/strong-earnings-season-winding-down-earnings-outlook-2014-08-14", "https://www.nasdaq.com/articles/should-gilead-sciences-gild-be-your-portfolio-stocks-news-2014-08-14", "https://www.nasdaq.com/articles/iwf-ko-gild-orcl-large-inflows-detected-etf-2014-08-13", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-posts-earnings-pipeline-in-focus-analyst-blog-2014-08-13", "https://www.nasdaq.com/articles/etf-outlook-spdr-sp-biotech-etf-xbi-2014-08-13", "https://www.nasdaq.com/articles/amgens-focus-study-on-multiple-myeloma-drug-kyprolis-fails-analyst-blog-2014-08-14", "https://www.nasdaq.com/articles/dendreon-down-on-default-risk-reports-narrower-q2-loss-analyst-blog-2014-08-13", "https://www.nasdaq.com/articles/biodelivery-sciences-q2-loss-narrows-up-on-solid-revenues-analyst-blog-2014-08-13", "https://www.nasdaq.com/articles/spectrum-pharmaceuticals-sppi-posts-strong-earnings-in-q2-analyst-blog-2014-08-12", "https://www.nasdaq.com/articles/mannkind-posts-wider-q2-loss-up-on-sanofi-deal-for-afrezza-analyst-blog-2014-08-12", "https://www.nasdaq.com/articles/anacors-q2-loss-narrower-than-expected-kerydin-in-focus-analyst-blog-2014-08-12", "https://www.nasdaq.com/articles/ovascience-ovas-shows-strength%3A-stock-up-7-tale-of-the-tape-2014-08-12", "https://www.nasdaq.com/articles/five-prime-therapeutics-fprx-jumps%3A-stock-adds-10.3-in-session-tale-of-the-tape-2014-08-12", "https://www.nasdaq.com/articles/bull-day-gilead-sciences-gild-bull-day-2014-08-13", "https://www.nasdaq.com/articles/after-hours-most-active-aug-12-2014-king-qqq-rad-xrx-nvda-td-kmi-cat-ea-gild-msft-mrvl", "https://www.nasdaq.com/articles/tekmira-shares-continue-to-rise-in-the-search-for-ebola-cure-analyst-blog-2014-08-12", "https://www.nasdaq.com/articles/what-your-stocks-earnings-yield-screen-week-2014-08-12", "https://www.nasdaq.com/articles/sarepta-therapeutics-reports-wider-y-y-loss-revenues-miss-analyst-blog-2014-08-12", "https://www.nasdaq.com/articles/alnylams-q2-loss-wider-than-expected-pipeline-in-focus-analyst-blog-2014-08-11", "https://www.nasdaq.com/articles/medivation-jumps-on-q2-earnings-beat-outlook-encourages-analyst-blog-2014-08-11", "https://www.nasdaq.com/articles/emergent-biosolutions-misses-on-earnings-ups-revenue-view-analyst-blog-2014-08-11", "https://www.nasdaq.com/articles/regenerons-eye-drug-eylea-cleared-in-the-eu-for-dme-analyst-blog-2014-08-12", "https://www.nasdaq.com/articles/mannkind-enters-into-a-global-deal-with-sanofi-for-afrezza-analyst-blog-2014-08-11", "https://www.nasdaq.com/articles/after-hours-most-active-aug-11-2014-kmi-qqq-mu-sqnm-gild-nuan-amkr-2014-08-11", "https://www.nasdaq.com/articles/tekmira-pharma-soars-fda-announcement-over-ebola-drug-analyst-blog-2014-08-11", "https://www.nasdaq.com/articles/market-strategy-play-energy-it-analyst-blog-2014-08-08", "https://www.nasdaq.com/articles/premarket-primer-thursday-august-7-russia-set-release-list-banned-goods-2014-08-07", "https://www.nasdaq.com/articles/q3-earnings-estimates-not-falling-much-earnings-trends-2014-08-06", "https://www.nasdaq.com/articles/achillion-pharmaceuticals-up-on-narrower-than-expected-loss-analyst-blog-2014-08-11", "https://www.nasdaq.com/articles/xlv-mrk-gild-unh-large-outflows-detected-etf-2014-08-04", "https://www.nasdaq.com/articles/can-earnings-rebound-be-sustained-earnings-trends-2014-07-31", "https://www.nasdaq.com/articles/can-earnings-rebound-be-sustained-earnings-outlook-2014-07-31", "https://www.nasdaq.com/articles/biotech-stock-roundup-gileads-sovaldi-biogens-tecfidera-impressive-run-continues-analyst", "https://www.nasdaq.com/articles/merck-jj-baxter-provide-healthy-dividend-stream-2014-07-30", "https://www.nasdaq.com/articles/premarket-primer-monday-july-28-tension-between-us-and-israel-rise-2014-07-28", "https://www.nasdaq.com/articles/biotech-etf-price-swings-may-signal-need-caution-2014-07-28", "https://www.nasdaq.com/articles/q3-earnings-estimates-not-falling-much-earnings-outlook-2014-08-06", "https://www.nasdaq.com/articles/xlv-mrk-gild-unh-large-outflows-detected-etf-2014-08-04", "https://www.nasdaq.com/articles/can-earnings-rebound-be-sustained-earnings-trends-2014-07-31", "https://www.nasdaq.com/articles/can-earnings-rebound-be-sustained-earnings-outlook-2014-07-31", "https://www.nasdaq.com/articles/biotech-stock-roundup-gileads-sovaldi-biogens-tecfidera-impressive-run-continues-analyst", "https://www.nasdaq.com/articles/merck-jj-baxter-provide-healthy-dividend-stream-2014-07-30", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvies-tax-inversion-amgen-drug-scores-phase-3-analyst-blog-2014-07", "https://www.nasdaq.com/articles/gileads-oncology-drug-recommended-for-approval-in-the-eu-analyst-blog-2014-07-28", "https://www.nasdaq.com/articles/will-gilead-gild-earnings-disappoint-in-q2-as-costs-rise-analyst-blog-2014-07-22", "https://www.nasdaq.com/articles/biogen-shares-rebound-street-has-change-heart-2014-07-21", "https://www.nasdaq.com/articles/nasdaq-100-movers-nvda-avgo-2014-07-18", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvie-woos-shire-revised-offer-sarepta-slips-eteplirsen-data", "https://www.nasdaq.com/articles/hefty-price-tag-of-gileads-sovaldi-questioned-again-analyst-blog-2014-07-14", "https://www.nasdaq.com/articles/sector-update-health-care-stocks-ending-mixed-achillion-pharmaceutical-easing-ma-fueled", "https://www.nasdaq.com/articles/sector-update-health-care-2014-07-11", "https://www.nasdaq.com/articles/after-hours-earnings-report-july-23-2014-t-fb-qcom-gild-cci-ilmn-avb-wft-nxpi-orly-trip-ca", "https://www.nasdaq.com/articles/bristol-myers-gains-japanese-approval-for-hcv-combo-drug-analyst-blog-2014-07-08", "https://www.nasdaq.com/articles/alexion-pharma-looks-life-beyond-its-blockbuster-2014-07-08", "https://www.nasdaq.com/articles/merck-gilead-lead-race-eradicate-hepatitis-c-2014-07-03", "https://www.nasdaq.com/articles/nasdaq-100-movers-payx-lmca-2014-07-02", "https://www.nasdaq.com/articles/biotech-stock-roundup-vertex-jumps-phase-iii-data-mannkind-scores-fda-approval-analyst", "https://www.nasdaq.com/articles/iyh-pfe-gild-abt-large-inflows-detected-etf-2014-06-30", "https://www.nasdaq.com/articles/gilead-seeks-japanese-approval-for-sovaldi-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/gilead-sciences-august-29th-options-begin-trading-2014-07-10", "https://www.nasdaq.com/articles/regenerx-and-lees-pharmaceutical-dry-eye-drug-progresses-analyst-blog-2014-06-23", "https://www.nasdaq.com/articles/cubist-gains-fda-approval-for-sivextro-analyst-blog-2014-06-23", "https://www.nasdaq.com/articles/novo-nordisk-reveals-positive-data-on-victoza-3-mg-analyst-blog-2014-06-23", "https://www.nasdaq.com/articles/alkermes-plc-alks-jumps%3A-stock-rises-5.7-tale-of-the-tape-2014-06-23", "https://www.nasdaq.com/articles/strength-seen-in-cara-therapeutics-inc.-cara-as-stock-rallies-19.60-tale-of-the-tape-2014", "https://www.nasdaq.com/articles/merrimack-falls-steeply-as-sanofi-returns-oncology-drug-rights-analyst-blog-2014-06-23", "https://www.nasdaq.com/articles/celgene-rises-on-yet-another-stock-split-analyst-blog-2014-06-20", "https://www.nasdaq.com/articles/strength-seen-in-vertex-pharmaceuticals-incorporated-vrtx-as-stock-shoots-40.41-tale-of", "https://www.nasdaq.com/articles/astrazenecas-naloxegol-data-published-analyst-blog-2014-06-20", "https://www.nasdaq.com/articles/oncomeds-omp-54f28-on-partial-clinical-hold-analyst-blog-2014-06-20", "https://www.nasdaq.com/articles/merge-healthcare%3A-updated-research-report-analyst-blog-2014-06-20", "https://www.nasdaq.com/articles/illumina%3A-updated-research-report-analyst-blog-2014-06-20", "https://www.nasdaq.com/articles/alkermes-aripiprazole-lauroxil-looks-promising-analyst-blog-2014-06-19", "https://www.nasdaq.com/articles/ultragenyx-pharmaceutical-rare-jumps%3A-stock-up-6.5-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/insmed-incorporated-insm-catches-eye%3A-stock-surges-42.6-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/cubist-gets-priority-review-from-fda-for-antibiotic-candidate-analyst-blog-2014-06-20", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-in-focus%3A-stock-moves-7.8-higher-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/applied-genetic-technologies-agtc-jumps%3A-stock-up-6.1-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/intra-cellular-therapies-inc.-itci-in-focus%3A-stock-rises-8.74-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/protalix-drug-in-phase-iia-study-for-gaucher-disease-analyst-blog-2014-06-19", "https://www.nasdaq.com/articles/biolinerx-to-commence-bl-8040-study-analyst-blog-2014-06-19", "https://www.nasdaq.com/articles/valeant-launches-hostile-bid-for-allergan-analyst-blog-2014-06-19", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-johnson-johnson-collaborate-on-flu-drug-analyst-blog-2014-06-19", "https://www.nasdaq.com/articles/protalix-plx-in-focus%3A-stock-adds-6.5-in-session-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-in-focus%3A-stock-moves-7.8-higher-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/applied-genetic-technologies-agtc-jumps%3A-stock-up-6.1-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/pfizer-ties-up-with-cellectis-for-cancer-immunotherapy-analyst-blog-2014-06-18", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-catches-eye%3A-stock-up-11.4-tale-of-the-tape-2014-06-18", "https://www.nasdaq.com/articles/merck-kgaa-ono-pharma-deal-ends-analyst-blog-2014-06-18", "https://www.nasdaq.com/articles/orexigen-orex-in-focus%3A-stock-moves-7.5-higher-tale-of-the-tape-2014-06-17", "https://www.nasdaq.com/articles/sequenom-inc.-sqnm-soars%3A-stock-rises-9.2-tale-of-the-tape-2014-06-17", "https://www.nasdaq.com/articles/insmed-soars-on-arikayces-breakthrough-designation-analyst-blog-2014-06-19", "https://www.nasdaq.com/articles/strength-seen-in-bluebird-bio-inc.-blue-as-stock-shoots-up-32.08-tale-of-the-tape-2014-06", "https://www.nasdaq.com/articles/jjs-velcade-in-focus-at-the-european-hematology-association-analyst-blog-2014-06-17", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-crumbles-on-analyst-worries-analyst-blog-2014-06-17", "https://www.nasdaq.com/articles/novartis-submits-bexsero-to-fda-for-marketing-approval-analyst-blog-2014-06-17", "https://www.nasdaq.com/articles/glaxos-promacta-holds-promise-analyst-blog-2014-06-17", "https://www.nasdaq.com/articles/ligand-pharmas-lgd-6972-positive-in-phase-i-study-analyst-blog-2014-06-17", "https://www.nasdaq.com/articles/valeant-receives-fdas-clearance-for-restylane-analyst-blog-2014-06-17", "https://www.nasdaq.com/articles/achillion-pharmaceuticals-achn-jumps%3A-stock-up-20.9-tale-of-the-tape-2014-06-17", "https://www.nasdaq.com/articles/gileads-hcv-combination-therapy-data-looks-promising-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/what-falling-estimates-price-mean-for-rexahn-pharmaceuticals-rnn-tale-of-the-tape-2014-06", "https://www.nasdaq.com/articles/sector-update-shares-mixed-pre-market-gilead-lifts-phase-3-results-hepatitis-c-treatment", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-06-16-1", "https://www.nasdaq.com/articles/actelions-selexipag-meets-primary-endpoint-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/celgenes-vidaza-disappoints-in-phase-iii-study-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/oncomeds-omp-18r5-on-clinical-hold-shares-down-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/celgenes-pomalyst-data-at-european-hematology-association-shows-promise-analyst-blog-2014", "https://www.nasdaq.com/articles/karyopharm-therapeutics-skyrockets-on-drug-trial-news-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/novo-nordisks-victoza-3-mg-positive-in-phase-iii-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/sanofis-diabetes-portfolio-in-focus-at-american-diabetes-association-sessions-analyst-blog", "https://www.nasdaq.com/articles/integra-lifesciences-premier-ink-3-year-purchase-deal-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/abbvie-gets-priority-review-from-fda-for-hcv-treatment-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/bristol-myers-suffers-a-legal-setback-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/bind-therapeutics-bind-soars%3A-stock-up-6.8-tale-of-the-tape-2014-06-13", "https://www.nasdaq.com/articles/agios-presents-data-on-ag-221-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/karyopharm-therapeutics-skyrockets-on-drug-trial-news-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/astrazeneca-boosts-pipeline-with-%24232-million-synairgen-deal-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/relief-for-nektar-after-aadpac-voting-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/sanofi-regeneron-present-postive-data-on-sarilumab-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/jj-viiv-healthcare-tie-up-for-single-tablet-hiv-treatment-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-new-kalydeco-data-out-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/sunesis-pharmaceuticals-snss-soars%3A-stock-adds-8-in-session-tale-of-the-tape-2014-06-13", "https://www.nasdaq.com/articles/avanir-gains-avp-825-hits-phase-iii-primary-endpoint-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/auxilium-pharma-launches-authorized-generic-testim-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/roches-hpv-test-approved-in-canada-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/encouraging-long-term-data-on-celgenes-otezla-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/geron-corp.-gern-soars%3A-stock-up-10.6-tale-of-the-tape-2014-06-12", "https://www.nasdaq.com/articles/vital-therapies-vtl-catches-eye%3A-stock-surges-20.7-tale-of-the-tape-2014-06-12", "https://www.nasdaq.com/articles/orexigen-therapeutics-orex-in-focus%3A-stock-tumbles-14.7-tale-of-the-tape-2014-06-12", "https://www.nasdaq.com/articles/geron-gains-as-fda-lifts-partial-hold-on-imetelstat-study-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/avanir-gains-avp-825-hits-phase-iii-primary-endpoint-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/auxilium-pharma-launches-authorized-generic-testim-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/orexigen-slumps-as-obesity-drug-approval-delayed-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/eli-lillys-cyramza-misses-primary-goal-liver-cancer-study-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/amgen-astrazeneca-psoriatic-arthritis-drug-shows-improvement-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/genomic-healths-oncotype-dx-redefines-breast-cancer-therapy-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/allergan-rejects-valeants-proposal-yet-again-analyst-blog-2014-06-11", "https://www.nasdaq.com/articles/biodelivery-sciences-international-bdsi-jumps%3A-stock-up-14.1-tale-of-the-tape-2014-06-12", "https://www.nasdaq.com/articles/achillion-pharmaceuticals-achn-in-focus%3A-stock-falls-6.4-tale-of-the-tape-2014-06-12", "https://www.nasdaq.com/articles/achillion-surges-two-days-in-a-row-hcv-in-focus-analyst-blog-2014-06-11", "https://www.nasdaq.com/articles/alkermes-progresses-with-its-late-stage-candidate-analyst-blog-2014-06-11", "https://www.nasdaq.com/articles/centene-dodges-bullets-changing-medicaid-landscape-2014-06-11", "https://www.nasdaq.com/articles/merck-kgaa-auxogyns-eeva-system-gets-fda-clearance-analyst-blog-2014-06-11", "https://www.nasdaq.com/articles/nps-pharmas-natpara-likely-to-be-reviewed-in-september-analyst-blog-2014-06-11", "https://www.nasdaq.com/articles/oragenics-ogen-in-focus%3A-stock-adds-6-in-session-tale-of-the-tape-2014-06-11", "https://www.nasdaq.com/articles/strength-seen-in-receptos-inc.-rcpt-as-stock-shoots-up-36.78-tale-of-the-tape-2014-06-11", "https://www.nasdaq.com/articles/why-puma-biotechnology-pbyi-could-be-positioned-for-a-slump-tale-of-the-tape-2014-06-10", "https://www.nasdaq.com/articles/idenix-pharmaceuticals-idix-soars%3A-stock-rises-229.1-tale-of-the-tape-2014-06-10", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-inc.-aveo-in-focus%3A-stock-rises-7.8-tale-of-the-tape-2014-06-10", "https://www.nasdaq.com/articles/pharmacyclics-imbruvica-under-fda-priority-review-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/immunomedics-immu-132-gets-orphan-drug-status-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/isis-pharma-earns-milestone-payment-on-study-initiation-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/strength-seen-in-inovio-ino%3A-stock-rises-9.4-tale-of-the-tape-2014-06-10", "https://www.nasdaq.com/articles/achillion-pharmaceuticals-achn-in-focus%3A-stock-rises-47.6-tale-of-the-tape-2014-06-10", "https://www.nasdaq.com/articles/closing-books-q1-earnings-season-earnings-trends-2014-06-10", "https://www.nasdaq.com/articles/integra-lifesciences-down-to-sell-on-poor-q1-segment-show-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/idenix-skyrockets-on-merck-acquisition-deal-focus-on-hcv-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-higher-tyson-wins-bidding-battle-buy-hillshire", "https://www.nasdaq.com/articles/dendreons-ceo-departs-at-critical-juncture-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/novavax-nvax-crumbles%3A-stock-tumbles-by-7.7-tale-of-the-tape-2014-06-09", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-inc.-aeri-in-focus%3A-stock-rises-5.71-tale-of-the-tape-2014-06-09", "https://www.nasdaq.com/articles/pre-market-most-active-jun-9-2014-hsh-idix-wu-achn-aapl-fdo-rio-yelp-dg-fb-mnkd-gild-2014", "https://www.nasdaq.com/articles/pipeline-progress-at-momenta-analyst-blog-2014-06-09", "https://www.nasdaq.com/articles/gw-pharma-gets-fast-track-designation-for-epidiolex-analyst-blog-2014-06-09", "https://www.nasdaq.com/articles/biodelivery-sciences-bunavail-gets-fda-nod-analyst-blog-2014-06-09", "https://www.nasdaq.com/articles/orexigens-upcoming-pipeline-catalyst-analyst-blog-2014-06-09", "https://www.nasdaq.com/articles/fibrocell-science-fcsc-in-focus%3A-stock-rises-14.4-tale-of-the-tape-2014-06-09", "https://www.nasdaq.com/articles/pipeline-progress-at-glaxosmithkline-analyst-blog-2014-06-06", "https://www.nasdaq.com/articles/celldex-therapeutics-cldx-soars%3A-stock-adds-12.6-in-session-tale-of-the-tape-2014-06-06", "https://www.nasdaq.com/articles/clovis-oncology-clvs-jumps%3A-stock-rises-6.2-tale-of-the-tape-2014-06-06", "https://www.nasdaq.com/articles/mannkind-hits-52-week-high-analyst-blog-2014-06-06", "https://www.nasdaq.com/articles/curis-re-initiates-dosing-for-cudc-427-analyst-blog-2014-06-06", "https://www.nasdaq.com/articles/alkermes-pipeline-holds-promise-analyst-blog-2014-06-06", "https://www.nasdaq.com/articles/affymetrix-biodiscovery-launch-cancer-research-software-analyst-blog-2014-06-06", "https://www.nasdaq.com/articles/biogens-eloctate-approved-in-the-u.s.-analyst-blog-2014-06-09", "https://www.nasdaq.com/articles/mannkind-corp.-mnkd-soars%3A-stock-adds-10.8-in-session-tale-of-the-tape-2014-06-05", "https://www.nasdaq.com/articles/vanda-up-on-eu-news-analyst-blog-2014-06-05", "https://www.nasdaq.com/articles/roches-ventana-collaborates-with-astrazenecas-medimmune-analyst-blog-2014-06-05", "https://www.nasdaq.com/articles/halozyme-study-clinical-hold-lifted-by-fda-analyst-blog-2014-06-05", "https://www.nasdaq.com/articles/bristol-myers-focuses-on-india-analyst-blog-2014-06-05", "https://www.nasdaq.com/articles/positive-data-on-vertex-pharmas-kalydeco-analyst-blog-2014-06-05", "https://www.nasdaq.com/articles/biotech-stock-roundup-gilead-pharmacyclics-impress-asco-analyst-blog-2014-06-04", "https://www.nasdaq.com/articles/stock-market-news-for-june-05-2014-market-news-2014-06-05", "https://www.nasdaq.com/articles/mannkind-corp.-mnkd-soars%3A-stock-adds-10.8-in-session-tale-of-the-tape-2014-06-05", "https://www.nasdaq.com/articles/data-on-incytes-jakafi-analyst-blog-2014-06-03", "https://www.nasdaq.com/articles/data-on-bristol-myers-yervoy-analyst-blog-2014-06-03", "https://www.nasdaq.com/articles/puma-biotech-crashes-on-pb272-study-news-analyst-blog-2014-06-03", "https://www.nasdaq.com/articles/myriad-genetics-posts-key-mypath-melanoma-data-analyst-blog-2014-06-03", "https://www.nasdaq.com/articles/valeant-relentless-on-acquiring-allergan-analyst-blog-2014-06-03", "https://www.nasdaq.com/articles/encouraging-data-on-pharmacyclics-jj-drug-analyst-blog-2014-06-02", "https://www.nasdaq.com/articles/incyte-gains-on-positive-jakafi-data-analyst-blog-2014-06-04", "https://www.nasdaq.com/articles/stock-market-news-for-june-02-2014-market-news-2014-06-02", "https://www.nasdaq.com/articles/retrophin-rtrx-jumps%3A-stock-adds-13.5-in-session-tale-of-the-tape-2014-06-02", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-june-03-2014-2014-06-02", "https://www.nasdaq.com/articles/allergan-inc.-agn-in-focus%3A-stock-rises-5.65-tale-of-the-tape-2014-06-02", "https://www.nasdaq.com/articles/merck-presents-positive-trial-results-cancer-drug-2014-06-02", "https://www.nasdaq.com/articles/roche-acquires-genia-technologies-analyst-blog-2014-06-02", "https://www.nasdaq.com/articles/myriad-genetics-to-unveil-bracanalysis-hrd-data-analyst-blog-2014-06-02", "https://www.nasdaq.com/articles/nps-pharma-on-shires-radar-analyst-blog-2014-06-02", "https://www.nasdaq.com/articles/update-on-bayers-xarelto-analyst-blog-2014-05-30", "https://www.nasdaq.com/articles/oncothyreon-collaborates-with-celldex-analyst-blog-2014-05-30", "https://www.nasdaq.com/articles/valeant-ups-offer-for-allergan-analyst-blog-2014-05-29", "https://www.nasdaq.com/articles/intercepts-obeticholic-acid-gets-fast-track-status-analyst-blog-2014-05-29", "https://www.nasdaq.com/articles/biomarins-pipeline-advances-analyst-blog-2014-05-29", "https://www.nasdaq.com/articles/orexigen-orex-in-focus%3A-stock-moves-6.1-higher-tale-of-the-tape-2014-05-29", "https://www.nasdaq.com/articles/xenoport-inc.-xnpt-soars%3A-stock-up-5.9-tale-of-the-tape-2014-05-29", "https://www.nasdaq.com/articles/amicus-therapeutics-fold-soars%3A-stock-up-10-tale-of-the-tape-2014-05-30", "https://www.nasdaq.com/articles/gtx-inc.-gtxi-soars%3A-stock-up-9.7-tale-of-the-tape-2014-05-29", "https://www.nasdaq.com/articles/array-biopharma-collaborates-with-biogen-analyst-blog-2014-05-29", "https://www.nasdaq.com/articles/verastem-vstm-in-focus%3A-stock-adds-14-in-session-tale-of-the-tape-2014-05-28", "https://www.nasdaq.com/articles/isis-pharmaceuticals-inc.-isis-in-focus%3A-stock-rises-9.21-tale-of-the-tape-2014-05-28", "https://www.nasdaq.com/articles/intermune-resubmits-esbriet-nda-analyst-blog-2014-05-28", "https://www.nasdaq.com/articles/incyte-joins-forces-with-bristol-myers-analyst-blog-2014-05-28", "https://www.nasdaq.com/articles/valeant-selling-product-rights-to-nestle-analyst-blog-2014-05-28", "https://www.nasdaq.com/articles/kalobios-pharmaceuticals-kbio-worth-watching%3A-stock-up-5.3-tale-of-the-tape-2014-05-29", "https://www.nasdaq.com/articles/pfizer-pulls-out-of-astrazeneca-deal-analyst-blog-2014-05-27", "https://www.nasdaq.com/articles/ambit-biosciences-ambi-in-focus%3A-stock-jumps-10.0-tale-of-the-tape-2014-05-27", "https://www.nasdaq.com/articles/amgens-vectibix-label-expanded-analyst-blog-2014-05-27", "https://www.nasdaq.com/articles/chmp-negative-on-novartis-rlx030-analyst-blog-2014-05-27", "https://www.nasdaq.com/articles/chmp-positive-on-roches-gazyvaro-analyst-blog-2014-05-27", "https://www.nasdaq.com/articles/durata-therapeutics-skin-drug-gets-fda-nod-analyst-blog-2014-05-27", "https://www.nasdaq.com/articles/ptc-therapeutics-up-on-positive-chmp-opinion-analyst-blog-2014-05-27", "https://www.nasdaq.com/articles/abbvie-up-on-hcv-filing-in-canada-analyst-blog-2014-05-28", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-vip-2014-05-23", "https://www.nasdaq.com/articles/stock-market-news-for-may-23-2014-market-news-2014-05-23", "https://www.nasdaq.com/articles/pipeline-progress-at-redhill-biopharma-analyst-blog-2014-05-23", "https://www.nasdaq.com/articles/ziopharm-presents-encouraging-data-analyst-blog-2014-05-23", "https://www.nasdaq.com/articles/update-on-celsions-thermodox-analyst-blog-2014-05-23", "https://www.nasdaq.com/articles/sarepta-to-acquire-manufacturing-facility-analyst-blog-2014-05-23", "https://www.nasdaq.com/articles/celgene-gains-slightly-on-management-changes-analyst-blog-2014-05-23", "https://www.nasdaq.com/articles/sp-500-movers-gild-hpq-2014-05-23", "https://www.nasdaq.com/articles/clovis-gets-breakthrough-therapy-designation-analyst-blog-2014-05-22", "https://www.nasdaq.com/articles/data-on-insmeds-arikayce-analyst-blog-2014-05-22", "https://www.nasdaq.com/articles/another-weak-earnings-season-coming-end-earnings-outlook-2014-05-22", "https://www.nasdaq.com/articles/another-weak-earnings-season-coming-end-earnings-trends-2014-05-22", "https://www.nasdaq.com/articles/gileads-gs-5806-encourages-analyst-blog-2014-05-21", "https://www.nasdaq.com/articles/celgene-inks-licensing-deal-with-aadi-analyst-blog-2014-05-21", "https://www.nasdaq.com/articles/insmed-insm-in-focus%3A-stock-moves-6.7-higher-tale-of-the-tape-2014-05-21", "https://www.nasdaq.com/articles/isis-pharma-gains-on-mid-stage-data-analyst-blog-2014-05-23", "https://www.nasdaq.com/articles/clovis-gets-breakthrough-therapy-designation-analyst-blog-2014-05-22", "https://www.nasdaq.com/articles/data-on-insmeds-arikayce-analyst-blog-2014-05-22", "https://www.nasdaq.com/articles/another-weak-earnings-season-coming-end-earnings-outlook-2014-05-22", "https://www.nasdaq.com/articles/dendreon-up-on-provenge-data-analyst-blog-2014-05-21", "https://www.nasdaq.com/articles/abbvies-humira-gets-orphan-drug-designation-analyst-blog-2014-05-21", "https://www.nasdaq.com/articles/myriad-genetics-unveils-positive-prolaris-data-analyst-blog-2014-05-21", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-05-21-1", "https://www.nasdaq.com/articles/glaxo-genmabs-arzerra-disappoints-analyst-blog-2014-05-20", "https://www.nasdaq.com/articles/intermune-up-on-esbriet-data-presentation-analyst-blog-2014-05-20", "https://www.nasdaq.com/articles/astrazeneca-rejects-pfizers-final-offer-analyst-blog-2014-05-19", "https://www.nasdaq.com/articles/ligand-astrazeneca-collaborate-analyst-blog-2014-05-19", "https://www.nasdaq.com/articles/shire-meets-fda-for-lifitegrast-analyst-blog-2014-05-19", "https://www.nasdaq.com/articles/after-hours-most-active-may-19-2014-mtcn-cam-msft-mo-nxpi-jnj-arcp-fitb-dtv-gild-2014-05", "https://www.nasdaq.com/articles/xenoport-reckitt-benckiser-pharma-collaborate-analyst-blog-2014-05-16", "https://www.nasdaq.com/articles/intermune-itmn-jumps%3A-stock-moves-13.4-higher-tale-of-the-tape-2014-05-20", "https://www.nasdaq.com/articles/clovis-oncology-inc.-clvs-in-focus%3A-stock-surges-16-tale-of-the-tape-2014-05-16", "https://www.nasdaq.com/articles/data-on-novo-nordisks-novoeight-analyst-blog-2014-05-16", "https://www.nasdaq.com/articles/update-on-glaxos-darapladib-analyst-blog-2014-05-16", "https://www.nasdaq.com/articles/novartis-settles-gleevec-patent-litigation-analyst-blog-2014-05-15", "https://www.nasdaq.com/articles/progenics-q1-loss-narrows-analyst-blog-2014-05-15", "https://www.nasdaq.com/articles/arena-slides-on-wider-q1-loss-misses-ests-analyst-blog-2014-05-15", "https://www.nasdaq.com/articles/incyte-to-collaborate-with-astrazeneca-analyst-blog-2014-05-15", "https://www.nasdaq.com/articles/rexahn-pharmaceuticals-rnn-jumps%3A-stock-surges-19.2-tale-of-the-tape-2014-05-16", "https://www.nasdaq.com/articles/q1-earnings-season-coming-end-earnings-outlook-2014-05-15", "https://www.nasdaq.com/articles/q1-earnings-season-coming-end-earnings-trends-2014-05-15", "https://www.nasdaq.com/articles/athersys-reports-wider-than-expected-q1-loss-analyst-blog-2014-05-14", "https://www.nasdaq.com/articles/oragenics-ogen-catches-eye%3A-stock-rises-9.7-tale-of-the-tape-2014-05-14", "https://www.nasdaq.com/articles/halozyme-therapeutics-inc.-halo-in-focus%3A-stock-up-6.9-tale-of-the-tape-2014-05-14", "https://www.nasdaq.com/articles/xenoports-q1-loss-narrows-analyst-blog-2014-05-14", "https://www.nasdaq.com/articles/pdl-biopharma-misses-on-q1-earnings-analyst-blog-2014-05-13", "https://www.nasdaq.com/articles/celldex-gains-on-bristol-myers-squibb-deal-analyst-blog-2014-05-15", "https://www.nasdaq.com/articles/halozymes-q1-loss-widens-analyst-blog-2014-05-13", "https://www.nasdaq.com/articles/osiris-therapeutics-q1-loss-narrower-than-expected-analyst-blog-2014-05-13", "https://www.nasdaq.com/articles/tesaro-inc.-tsro-looks-strong-as-stock-rallies-21-tale-of-the-tape-2014-05-13", "https://www.nasdaq.com/articles/shire-to-acquire-lumena-analyst-blog-2014-05-13", "https://www.nasdaq.com/articles/insys-in-focus-on-subsys-worries-analyst-blog-2014-05-13", "https://www.nasdaq.com/articles/gilead-shows-more-pipeline-progress-analyst-blog-2014-05-13", "https://www.nasdaq.com/articles/loss-widens-at-achillion-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/repros-q1-loss-in-line-with-expectations-analyst-blog-2014-05-13", "https://www.nasdaq.com/articles/radnet-touches-new-52-week-high-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/dendreon-falls-on-q1-loss-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/strength-seen-in-medivation-mdvn%3A-stock-up-8.5-tale-of-the-tape-2014-05-12", "https://www.nasdaq.com/articles/spectrum-pharma-up-on-q1-earnings-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/illumina-upgraded-to-strong-buy-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/amgen-astrazeneca-psoriasis-drug-scores-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/mallinckrodt-earnings-beat-shares-dip-on-low-revs-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/medivation-q1-loss-wider-than-expected-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/earnings-up-at-jazz-pharma-guidance-reiterated-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/xoma-posts-wider-q1-loss-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/anacor-reports-wider-than-expected-q1-loss-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/salix-q1-earnings-boosted-santarus-acquisition-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/avanir-loss-in-line-with-ests-revs-up-analyst-blog-2014-05-08", "https://www.nasdaq.com/articles/jj-gilead-hcv-combo-drug-filed-analyst-blog-2014-05-08", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-nps-pharma-shares-down-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/medivation-q1-loss-wider-than-expected-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-momenta-analyst-blog-2014-05-07", "https://www.nasdaq.com/articles/split-update-overshadows-wider-q1-loss-at-theravance-analyst-blog-2014-05-07", "https://www.nasdaq.com/articles/iyh-gild-bmy-abbv-etf-outflow-alert-2014-05-07", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-aegerion-analyst-blog-2014-05-07", "https://www.nasdaq.com/articles/dynavax-reports-in-line-q1-results-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/myriad-genetics-drops-despite-earnings-revs-beat-ups-view-analyst-blog-2014-05-08", "https://www.nasdaq.com/articles/marginal-earnings-beat-at-zoetis-view-maintained-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/techne-corporation-tech-ex-dividend-date-scheduled-may-07-2014-2014-05-06", "https://www.nasdaq.com/articles/endocyte-inc.-ecyt-in-focus%3A-stock-rises-5.6-tale-of-the-tape-2014-05-06", "https://www.nasdaq.com/articles/regeneron-inks-ophthalmology-deal-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/vical-narrows-q1-loss-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/nasdaq-100-movers-wynn-gild-2014-05-05", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-seattle-genetics-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-pacira-revs-up-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/vertex-down-on-wider-than-expected-loss-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/intermune-up-on-narrower-than-expected-q1-loss-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/celldexs-q1-loss-widens-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/pfizer-tops-q1-earnings-generics-hit-revs-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/idenixs-q1-loss-widens-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/geron-reports-in-line-q1-loss-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/astrazeneca-rejects-pfizers-latest-offer-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/earnings-beat-at-pharmacyclics-guidance-pulls-down-stock-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/bull-day-gilead-sciences-gild-bull-day-2014-05-05", "https://www.nasdaq.com/articles/novo-nordisk-beats-earnings-ests-misses-revs-analyst-blog-2014-05-02", "https://www.nasdaq.com/articles/wider-than-expected-q1-loss-at-incyte-analyst-blog-2014-05-02", "https://www.nasdaq.com/articles/can-the-rally-in-gilead-gild-shares-continue-tale-of-the-tape-2014-05-02", "https://www.nasdaq.com/articles/earnings-estimates-moving-higher-for-gilead-gild%3A-time-to-buy-tale-of-the-tape-2014-05-02", "https://www.nasdaq.com/articles/loss-at-biomarin-narrower-than-expected-analyst-blog-2014-05-02", "https://www.nasdaq.com/articles/shire-beats-on-earnings-in-q1-analyst-blog-2014-05-02", "https://www.nasdaq.com/articles/endocyte-shares-sink-on-dsmb-recommendation-analyst-blog-2014-05-05", "https://www.nasdaq.com/articles/3-biotech-beats-this-earnings-season-earnings-esp-2014-05-01", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-alkermes-revenues-slip-analyst-blog-2014-05-01", "https://www.nasdaq.com/articles/oncogenex-posts-wider-loss-beats-revenues-analyst-blog-2014-05-01", "https://www.nasdaq.com/articles/synagevas-q1-loss-narrower-than-expected-analyst-blog-2014-05-01", "https://www.nasdaq.com/articles/merck-mrk-earnings-beat-puts-healthcare-etfs-in-focus-etf-news-and-commentary-2014-05-01", "https://www.nasdaq.com/articles/united-therapeutics-gains-on-q1-earnings-analyst-blog-2014-05-01", "https://www.nasdaq.com/articles/q2-earnings-estimates-coming-down-earnings-outlook-2014-04-30", "https://www.nasdaq.com/articles/affymetrix-q1-earnings-beat-ests-by-a-penny-analyst-blog-2014-05-02", "https://www.nasdaq.com/articles/3-biotech-beats-this-earnings-season-earnings-esp-2014-05-01", "https://www.nasdaq.com/articles/vug-qcom-hd-gild-large-outflows-detected-etf-2014-04-29", "https://www.nasdaq.com/articles/oncogenexs-custirsen-misses-primary-endpoint-analyst-blog-2014-04-29", "https://www.nasdaq.com/articles/can-affymetrix-affx-surprise-this-earnings-season-analyst-blog-2014-04-29", "https://www.nasdaq.com/articles/hyperion-set-to-acquire-andromeda-analyst-blog-2014-04-29", "https://www.nasdaq.com/articles/3-pharma-mutual-funds-beating-the-sp-500-best-of-funds-2014-04-28", "https://www.nasdaq.com/articles/abbvie-beats-on-q1-earnings-humira-soars-analyst-blog-2014-04-25", "https://www.nasdaq.com/articles/q2-earnings-estimates-coming-down-earnings-trends-2014-04-30", "https://www.nasdaq.com/articles/alexion-posts-strong-earnings-in-q1-analyst-blog-2014-04-24", "https://www.nasdaq.com/articles/strong-q1-earnings-at-gilead-on-stellar-sovaldi-sales-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/nasdaq-100-movers-isrg-gild-2014-04-23", "https://www.nasdaq.com/articles/cubist-pharma-posts-weak-earnings-on-soft-cubicin-sales-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/stock-market-news-for-april-23-2014-market-news-2014-04-23", "https://www.nasdaq.com/articles/amgens-q1-earnings-decline-y-y-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/us-futures-mixed-amid-earnings-deluge-apple-facebook-set-report-after-close-2014-04-23", "https://www.nasdaq.com/articles/earnings-from-gilead-and-amgen-put-these-etfs-in-focus-etf-news-and-commentary-2014-04-24", "https://www.nasdaq.com/articles/us-futures-edge-lower-amid-mixed-earnings-bag-markets-eye-apple-facebook-after-close-2014", "https://www.nasdaq.com/articles/improving-still-weak-earnings-picture-earnings-trends-2014-04-23", "https://www.nasdaq.com/articles/improving-still-weak-earnings-picture-earnings-outlook-2014-04-23", "https://www.nasdaq.com/articles/abbvie-files-for-hcv-combination-therapy-in-u.s.-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/biogens-q1-earnings-soar-y-y-on-tecfidera-sales-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/keep-an-eye-on-these-3-biotech-stocks-earnings-esp-2014-04-22", "https://www.nasdaq.com/articles/synageva-heading-big-disappointment-2014-04-22", "https://www.nasdaq.com/articles/pre-market-most-active-apr-23-2014-vz-mdlz-dow-gild-ing-fb-t-emc-jnpr-ebay-vod-akam-2014", "https://www.nasdaq.com/articles/after-hours-earnings-report-april-22-2014-t-gild-amgn-cni-yum-dfs-ilmn-isrg-vmw-fti-jnpr", "https://www.nasdaq.com/articles/will-gilead-gild-beat-q1-earnings-analyst-blog-2014-04-21", "https://www.nasdaq.com/articles/after-hours-most-active-apr-21-2014-bac-c-nflx-gsi-agn-fb-amd-pt-qqq-msft-gild-wen-2014-04", "https://www.nasdaq.com/articles/weekly-cfo-sells-highlight-athenahealth-inc-gilead-sciences-inc-jpmorgan-chase-co-2014-04", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-vht-gild-mdt-esrx-2014-04-17", "https://www.nasdaq.com/articles/has-streamlined-fda-raised-value-drug-stocks-2014-04-17", "https://www.nasdaq.com/articles/sp-500-movers-nem-trip-2014-04-15", "https://www.nasdaq.com/articles/after-hours-most-active-apr-22-2014-cx-btu-qqq-cmcsa-t-gild-amx-intc-c-agn-hban-cree-2014", "https://www.nasdaq.com/articles/gilead-bucks-biotech-trend-thanks-to-sovaldi-news-analyst-blog-2014-04-14", "https://www.nasdaq.com/articles/pre-market-most-active-apr-14-2014-c-ing-bac-fb-qqq-alu-tvix-bcs-nbg-xiv-asml-gild-2014-04", "https://www.nasdaq.com/articles/hard-to-cure-patients-may-benefit-from-mercks-hcv-drug-analyst-blog-2014-04-14", "https://www.nasdaq.com/articles/positive-data-on-abbvies-hcv-program-analyst-blog-2014-04-14", "https://www.nasdaq.com/articles/encouraging-data-from-bristol-myers-analyst-blog-2014-04-11", "https://www.nasdaq.com/articles/gilead-sciences-gild-falls%3A-stock-goes-down-7.3-tale-of-the-tape-2014-04-11", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-lower-pre-market-trade-2014-04-11", "https://www.nasdaq.com/articles/bristol-myers-seeks-approval-for-hiv-combo-drug-analyst-blog-2014-04-15", "https://www.nasdaq.com/articles/encouraging-results-on-gileads-sovaldi-analyst-blog-2014-04-11", "https://www.nasdaq.com/articles/3-pharma-mutual-funds-beating-the-sp-500-best-of-funds-2014-04-11", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-04-11-1", "https://www.nasdaq.com/articles/sector-update-healthcare-mixed-late-session-gilead-sciences-turns-higher-2014-04-11", "https://www.nasdaq.com/articles/3-top-ranked-biotech-stocks-rebound-analyst-blog-2014-04-10", "https://www.nasdaq.com/articles/after-hours-most-active-apr-10-2014-cwhd-hban-qqq-msft-ge-vz-emc-mo-d-lrcx-fb-gild-2014-04", "https://www.nasdaq.com/articles/gilead-announces-encouraging-sovaldi-data-analyst-blog-2014-04-10", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-04-11-0", "https://www.nasdaq.com/articles/vug-gild-hd-axp-large-inflows-detected-etf-2014-04-09", "https://www.nasdaq.com/articles/nasdaq-100-movers-myl-bidu-2014-04-08", "https://www.nasdaq.com/articles/fda-target-date-for-gileads-hcv-candidate-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/encouraging-results-from-pfizers-palbociclib-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/pipeline-update-from-idenix-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/fda-news-lifts-dyax-slightly-analyst-blog-2014-04-07", "https://www.nasdaq.com/articles/amgens-oncology-candidate-disappoints-analyst-blog-2014-04-07", "https://www.nasdaq.com/articles/merck-up-on-encouraging-hcv-data-analyst-blog-2014-04-10", "https://www.nasdaq.com/articles/vug-gild-hd-axp-large-inflows-detected-etf-2014-04-09", "https://www.nasdaq.com/articles/ishares-russell-1000-growth-etf-experiences-big-outflow-2014-04-01", "https://www.nasdaq.com/articles/stock-market-news-for-april-01-2014-market-news-2014-04-01", "https://www.nasdaq.com/articles/ultragenyx-rare-jumps%3A-stock-rises-7.0-tale-of-the-tape-2014-04-01", "https://www.nasdaq.com/articles/momenta-pharmaceuticals-slumps%3A-mnta-falls-16.9-in-session-tale-of-the-tape-2014-04-01", "https://www.nasdaq.com/articles/biotechnology-shares-rebound-24-monday-still-track-end-march-lower-2014-03-31", "https://www.nasdaq.com/articles/pre-market-most-active-mar-31-2014-rio-bbry-qqq-bac-nok-fb-gild-tvix-twtr-mnkd-mt-alsn", "https://www.nasdaq.com/articles/the-medicines-cos-fibrocaps-under-u.s.-review-analyst-blog-2014-04-04", "https://www.nasdaq.com/articles/gilead-sciences-now-33-largest-company-surpassing-visa-2014-03-31", "https://www.nasdaq.com/articles/any-survivors-from-the-biotech-etf-meltdown-etf-news-and-commentary-2014-03-31", "https://www.nasdaq.com/articles/fda-nod-for-biogens-alprolix-analyst-blog-2014-03-31", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-03-28-0", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-ctsh-2014-03-28", "https://www.nasdaq.com/articles/gileads-hcv-candidate-under-review-in-the-eu-analyst-blog-2014-03-28", "https://www.nasdaq.com/articles/glaxo-presents-darapladib-data-analyst-blog-2014-03-31", "https://www.nasdaq.com/articles/gilead-sciences-breaks-below-200-day-moving-average-notable-gild-2014-03-28", "https://www.nasdaq.com/articles/update-on-glaxos-mekinist-tafinlar-analyst-blog-2014-03-28", "https://www.nasdaq.com/articles/moderate-gains-healthcare-stocks-gilead-sciences-slips-after-reported-sales-dip-hcv-drug", "https://www.nasdaq.com/articles/glaxos-eperzan-approved-in-eu-analyst-blog-2014-03-27", "https://www.nasdaq.com/articles/insmed-down-on-disappointing-arikayce-results-analyst-blog-2014-03-27", "https://www.nasdaq.com/articles/retrophin-rtrx-catches-eye%3A-stock-moves-7.9-higher-tale-of-the-tape-2014-03-26", "https://www.nasdaq.com/articles/positive-data-on-halozyme-candidate-analyst-blog-2014-03-26", "https://www.nasdaq.com/articles/dow-30-stock-roundup-pfizer-gains-crimea-biotech-stocks-drag-markets-analyst-blog-2014-03", "https://www.nasdaq.com/articles/gilead-sciences-breaks-below-200-day-moving-average-notable-gild-2014-03-28", "https://www.nasdaq.com/articles/update-on-glaxos-mekinist-tafinlar-analyst-blog-2014-03-28", "https://www.nasdaq.com/articles/gilead-gild-is-now-in-oversold-territory-tale-of-the-tape-2014-03-24", "https://www.nasdaq.com/articles/gilead-down-on-sovaldi-price-issue-analyst-blog-2014-03-24", "https://www.nasdaq.com/articles/are-biotech-stocks-oversold-analyst-blog-2014-03-24", "https://www.nasdaq.com/articles/closing-update-stocks-decline-below-consensus-manufacturing-index-biotech-selling-blitz", "https://www.nasdaq.com/articles/pfizer-gains-slightly-on-xalkori-data-analyst-blog-2014-03-26", "https://www.nasdaq.com/articles/update-on-celgenes-product-portfolio-analyst-blog-2014-03-25", "https://www.nasdaq.com/articles/biotech-continues-friday-sell-drug-pricing-concerns-2014-03-24", "https://www.nasdaq.com/articles/healthcare-stocks-undercut-earlier-market-advance-gilead-sciences-sinks-after-congress", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-03-21", "https://www.nasdaq.com/articles/favorable-data-for-myriad-genetics-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-akam-2014-03-20", "https://www.nasdaq.com/articles/sp-500-movers-symc-exc-2014-03-21", "https://www.nasdaq.com/articles/health-care-select-sector-spdr-fund-experiences-big-inflow-2014-03-20", "https://www.nasdaq.com/articles/palatin-technologies-ptn-worth-watching%3A-stock-soars-15.6-tale-of-the-tape-2014-03-20", "https://www.nasdaq.com/articles/why-ani-pharmaceuticals-anip-has-a-bright-short-term-future-tale-of-the-tape-2014-03-20", "https://www.nasdaq.com/articles/stock-market-news-for-march-19-2014-market-news-2014-03-19", "https://www.nasdaq.com/articles/strength-seen-in-gtx-gtxi%3A-stock-moves-8.8-higher-tale-of-the-tape-2014-03-19", "https://www.nasdaq.com/articles/idenix-files-lawsuit-vs.-gilead-again-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/after-hours-most-active-mar-19-2014-btu-jpm-qqq-wfc-bpo-stag-met-gild-hznp-adsk-csco-msft", "https://www.nasdaq.com/articles/prothena-surges-on-clinical-data-hopes-analyst-blog-2014-03-20", "https://www.nasdaq.com/articles/biogen-faces-delay-in-fda-action-date-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-relypsa-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/actelions-tracleer-misses-primary-endpoint-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/repros-provides-proellex-update-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/intercept-sees-weakness-in-earnings-result-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/amgen-scores-again-with-pcsk9-inhibitor-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/biogen-to-be-added-to-sp100-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/medivation-astellas-seek-xtandi-label-expansion-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/novartis-bexsero-recommended-in-australia-analyst-blog-2014-03-17", "https://www.nasdaq.com/articles/sp-500-movers-celg-coh-2014-03-14", "https://www.nasdaq.com/articles/raptor-pharma-posts-wider-than-expected-q4-loss-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/anacor-reports-narrower-q4-loss-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/narrower-than-expected-q4-loss-at-repros-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/vanda-pharmaceuticals-vnda-soars%3A-stock-adds-9.6-in-session-tale-of-the-tape-2014-03-14", "https://www.nasdaq.com/articles/sector-update-health-care-2014-03-14", "https://www.nasdaq.com/articles/actelions-update-on-asahi-litigation-analyst-blog-2014-03-17", "https://www.nasdaq.com/articles/astrazeneca-to-sell-cheshire-research-site-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/bright-outlook-at-bayer-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/unfavorable-ruling-for-pfizer-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/wider-q4-loss-at-keryx-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/geron-plunges-on-fda-clinical-hold-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/sanofi-ucb-ink-deal-analyst-blog-2014-03-12", "https://www.nasdaq.com/articles/phase-i-data-on-rexahns-supinoxin-analyst-blog-2014-03-12", "https://www.nasdaq.com/articles/sector-update-health-care-shares-mixed-pre-market-idenix-file-patent-infringement-suit-vs", "https://www.nasdaq.com/articles/is-gilead-sciences-gild-a-great-growth-stock-tale-of-the-tape-2014-03-11", "https://www.nasdaq.com/articles/focus-on-regulus-pipeline-analyst-blog-2014-03-11", "https://www.nasdaq.com/articles/alexion-lifts-2014-view-shares-up-analyst-blog-2014-03-11", "https://www.nasdaq.com/articles/oef-gild-hd-utx-etf-inflow-alert-2014-03-10", "https://www.nasdaq.com/articles/salesforce-crm-macrogenics-mgnx-relative-value-potential-2014-03-10", "https://www.nasdaq.com/articles/additional-positive-data-on-omeros-treatment-analyst-blog-2014-03-10", "https://www.nasdaq.com/articles/newlink-genetics-shares-sink-analyst-blog-2014-03-10", "https://www.nasdaq.com/articles/chelsea-therapeutics-posts-wider-q4-loss-analyst-blog-2014-03-12", "https://www.nasdaq.com/articles/alcobra-gains-ind-clearance-for-mdx-analyst-blog-2014-03-07", "https://www.nasdaq.com/articles/fridays-etf-unusual-volume-ibb-2014-03-07", "https://www.nasdaq.com/articles/pipeline-progress-at-bristol-myers-analyst-blog-2014-03-06", "https://www.nasdaq.com/articles/oncothyreon-onty-jumps%3A-stock-moves-9.9-higher-tale-of-the-tape-2014-03-06", "https://www.nasdaq.com/articles/rigel-rises-on-narrower-q4-loss-analyst-blog-2014-03-06", "https://www.nasdaq.com/articles/osiris-misses-on-q4-earnings-analyst-blog-2014-03-06", "https://www.nasdaq.com/articles/biogen-eisai-ink-alzheimers-deal-analyst-blog-2014-03-06", "https://www.nasdaq.com/articles/sangamo-biosciences-sgmo-worth-watching%3A-stock-surges-17.1-tale-of-the-tape-2014-03-07", "https://www.nasdaq.com/articles/dynavax-receives-milestone-payments-from-astrazeneca-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/pipeline-setback-overshadows-xomas-q4-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/narrower-than-expected-q4-loss-at-gtx-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/sunesis-snss-jumps%3A-stock-moves-6.8-higher-tale-of-the-tape-2014-03-05", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-jumps%3A-stock-rises-7.5-tale-of-the-tape-2014-03-05", "https://www.nasdaq.com/articles/theravance-to-split-in-q2-analyst-blog-2014-03-04", "https://www.nasdaq.com/articles/celldex-posts-narrower-than-expected-loss-in-q4-analyst-blog-2014-03-04", "https://www.nasdaq.com/articles/update-on-alexions-soliris-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-dendreon-drives-shares-up-analyst-blog-2014-03-04", "https://www.nasdaq.com/articles/abbvie-hcv-combination-therapy-data-looks-good-analyst-blog-2014-03-04", "https://www.nasdaq.com/articles/isis-pharma-slips-on-wider-than-expected-q4-loss-analyst-blog-2014-03-04", "https://www.nasdaq.com/articles/are-these-biotechs-part-of-your-portfolio-analyst-blog-2014-03-03", "https://www.nasdaq.com/articles/eu-review-for-the-medicines-co.s-oritavancin-analyst-blog-2014-03-03", "https://www.nasdaq.com/articles/actelion-gains-on-qidp-and-fast-track-status-analyst-blog-2014-03-03", "https://www.nasdaq.com/articles/update-on-anacors-an2728-analyst-blog-2014-03-03", "https://www.nasdaq.com/articles/synageva-4q-loss-narrower-than-expected-loss-analyst-blog-2014-03-04", "https://www.nasdaq.com/articles/earnings-decline-yoy-at-alkermes-analyst-blog-2014-02-28", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-ibb-biib-gild-amgn-2014-02-28", "https://www.nasdaq.com/articles/cara-therapeutics-cara-zooms%3A-stock-up-12.4-tale-of-the-tape-2014-02-28", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-march-03-2014-2014-02-28", "https://www.nasdaq.com/articles/bluebird-bio-blue-zooms%3A-stock-up-7.2-tale-of-the-tape-2014-02-28", "https://www.nasdaq.com/articles/mylan-beats-on-q4-earnings-revenues-analyst-blog-2014-02-27", "https://www.nasdaq.com/articles/no-looking-back-for-regenerons-eylea-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/biogen-keeps-momentum-going-ms-drug-tecfidera-2014-03-03", "https://www.nasdaq.com/articles/earnings-decline-yoy-at-alkermes-analyst-blog-2014-02-28", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-ibb-biib-gild-amgn-2014-02-28", "https://www.nasdaq.com/articles/cara-therapeutics-cara-zooms%3A-stock-up-12.4-tale-of-the-tape-2014-02-28", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-march-03-2014-2014-02-28", "https://www.nasdaq.com/articles/stock-market-news-for-february-12-2014-market-news-2014-02-12", "https://www.nasdaq.com/articles/ibb-gild-biib-amgn-large-inflows-detected-etf-2014-02-11", "https://www.nasdaq.com/articles/gilead-seeks-u.s.-approval-analyst-blog-2014-02-11", "https://www.nasdaq.com/articles/fda-designation-for-bristol-myers-candidate-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/pharmacyclics-attains-52-week-high-analyst-blog-2014-02-24", "https://www.nasdaq.com/articles/sp-500-analyst-moves-gild-2014-02-24", "https://www.nasdaq.com/articles/biomarin-rises-on-favorable-chmp-opinion-analyst-blog-2014-02-21", "https://www.nasdaq.com/articles/will-gilead-gild-disappoint-this-earnings-season-analyst-blog-2014-02-03", "https://www.nasdaq.com/articles/3-reasons-biotech-stock-advance-continue-2014-02-03", "https://www.nasdaq.com/articles/weekly-cfo-sells-highlight-google-inc-forest-laboratories-inc-facebook-inc-gilead-sciences", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-11-2014-2014-02-10", "https://www.nasdaq.com/articles/chmp-positive-on-bayers-riociguat-analyst-blog-2014-01-27", "https://www.nasdaq.com/articles/pre-market-most-active-jan-22-2014-pbra-vale-amd-bbd-cx-coh-nuan-bbry-fb-gild-grpn-tsla", "https://www.nasdaq.com/articles/after-hours-most-active-jan-22-2014-ebay-qqq-nflx-bac-exel-avp-aa-fcx-cole-msft-xom-gild", "https://www.nasdaq.com/articles/european-approval-for-gilead-drug-analyst-blog-2014-01-20", "https://www.nasdaq.com/articles/weekly-cfo-sells-highlight-gilead-sciences-inc-micron-technology-inc-adobe-systems-inc", "https://www.nasdaq.com/articles/bayers-adempas-gets-japanese-approval-analyst-blog-2014-01-20", "https://www.nasdaq.com/articles/stocks-2014-investing-growth-power-and-protection-high-compounding-earnings-growth-part-2", "https://www.nasdaq.com/articles/idenix-to-raise-funds-shares-up-analyst-blog-2014-01-29", "https://www.nasdaq.com/articles/can-biotech-repeat-2014-2014-01-14", "https://www.nasdaq.com/articles/stock-market-news-for-january-10-2014-corporate-summary-2014-01-10", "https://www.nasdaq.com/articles/bullish-on-gilead-analyst-blog-2014-01-02", "https://www.nasdaq.com/articles/gilead-sciences-inc-gild-new-analyst-report-zacks-equity-research-zacks-equity-research", "https://www.nasdaq.com/articles/weekly-cfo-sells-highlight-facebook-inc-google-inc-verisk-analytics-inc-gilead-sciences", "https://www.nasdaq.com/articles/update-on-redhill-biopharmas-pipeline-analyst-blog-2013-12-30", "https://www.nasdaq.com/articles/genomic-health-remains-neutral-analyst-blog-2013-12-27", "https://www.nasdaq.com/articles/standard-review-for-gileads-oncology-candidate-analyst-blog-2014-01-14", "https://www.nasdaq.com/articles/enzon-pharmaceuticals-inc-enzn-ex-dividend-date-scheduled-december-24-2013-2013-12-23", "https://www.nasdaq.com/articles/stock-market-news-for-december-19-2013-market-news-2013-12-19", "https://www.nasdaq.com/articles/positive-data-on-gileads-sovaldi-analyst-blog-2013-12-19", "https://www.nasdaq.com/articles/gileads-sovaldi-holds-promise-analyst-blog-2013-12-18", "https://www.nasdaq.com/articles/label-of-gileads-complera-expanded-analyst-blog-2013-12-16", "https://www.nasdaq.com/articles/after-hours-most-active-dec-16-2013-jpm-bac-bry-qqq-msft-gild-pfe-gm-emc-intc-csco-mu-2013", "https://www.nasdaq.com/articles/buzz-street-naughty-bears-may-keep-santa-away-2013-12-13", "https://www.nasdaq.com/articles/dynavax-submits-response-to-ema-analyst-blog-2013-12-24", "https://www.nasdaq.com/articles/enzon-pharmaceuticals-inc-enzn-ex-dividend-date-scheduled-december-24-2013-2013-12-23", "https://www.nasdaq.com/articles/fda-clears-gileads-sovaldi-analyst-blog-2013-12-09", "https://www.nasdaq.com/articles/are-biotech-etfs-back-on-track-etf-news-and-commentary-2013-12-04", "https://www.nasdaq.com/articles/update-on-gileads-legal-troubles-analyst-blog-2013-12-04", "https://www.nasdaq.com/articles/biotech-stock-roundup-cbst-hits-52-week-high-orex-lights-analyst-blog-2013-12-04", "https://www.nasdaq.com/articles/medidata-caesarstone-among-new-buys-top-funds-2013-12-03", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-december-03-2013-2013-12-02", "https://www.nasdaq.com/articles/gileads-pipeline-encourages-analyst-blog-2013-12-11", "https://www.nasdaq.com/articles/pre-market-most-active-dec-9-2013-givn-syy-infi-nok-alu-jcp-gild-aaxj-fb-bac-crnt-nj-2013", "https://www.nasdaq.com/articles/fda-clears-gileads-sovaldi-analyst-blog-2013-12-09", "https://www.nasdaq.com/articles/sector-update-biotech-select-index-achieves-all-time-high-ubs-reportedly-positive-2013-11", "https://www.nasdaq.com/articles/gilead-soars-on-positive-chmp-opinion-analyst-blog-2013-11-25", "https://www.nasdaq.com/articles/stock-market-news-for-november-25-2013-market-news-2013-11-25", "https://www.nasdaq.com/articles/glaxo-shares-rise-on-tivicay-news-analyst-blog-2013-11-25", "https://www.nasdaq.com/articles/recent-cloud-ipo-veeva-systems-scores-health-biz-2013-11-22", "https://www.nasdaq.com/articles/safe-way-win-biotech-growth-2013-12-02", "https://www.nasdaq.com/articles/gilead-sciences-can-fix-whats-ailing-your-portfolio-2013-12-02", "https://www.nasdaq.com/articles/3-invesco-funds-delivering-great-returns-revised-analyst-blog-2013-11-29", "https://www.nasdaq.com/articles/sector-update-biotech-select-index-achieves-all-time-high-ubs-reportedly-positive-2013-11", "https://www.nasdaq.com/articles/u.s.-launch-of-actelions-opsumit-analyst-blog-2013-11-05", "https://www.nasdaq.com/articles/bristol-myers-seeks-japanese-approval-analyst-blog-2013-11-04", "https://www.nasdaq.com/articles/antiviral-franchise-powers-earnings-beat-at-gilead-analyst-blog-2013-10-30", "https://www.nasdaq.com/articles/after-hours-earnings-report-october-29-2013-gild-bidu-afl-lnkd-amp-vrtx-bxp-eix-fisv-rrc", "https://www.nasdaq.com/articles/dendreon-dndn-in-focus%3A-stock-moves-9.7-higher-tale-of-the-tape-2013-11-20", "https://www.nasdaq.com/articles/glaxo-seeks-eu-approval-for-hiv-drug-analyst-blog-2013-10-28", "https://www.nasdaq.com/articles/positive-chmp-opinion-for-actelions-opsumit-analyst-blog-2013-10-28", "https://www.nasdaq.com/articles/top-ranked-biotech-etf-in-focus%3A-bbh-etf-news-and-commentary-2013-10-24", "https://www.nasdaq.com/articles/after-hours-most-active-oct-24-2013-znga-msft-csco-abv-amzn-gild-bac-qqq-ko-crm-tsm-ozm", "https://www.nasdaq.com/articles/inside-biotech-etfs%3A-can-the-run-continue-etf-news-and-commentary-2013-10-22", "https://www.nasdaq.com/articles/united-therapeutics-aims-cardiovascular-drug-ok-2013-10-22", "https://www.nasdaq.com/articles/actelions-opsumit-cleared-in-the-u.s.-analyst-blog-2013-10-21", "https://www.nasdaq.com/articles/will-gilead-gild-disappoint-in-q3-analyst-blog-2013-10-28", "https://www.nasdaq.com/articles/glaxo-seeks-eu-approval-for-hiv-drug-analyst-blog-2013-10-28", "https://www.nasdaq.com/articles/bayers-adempas-cleared-in-the-u.s.-analyst-blog-2013-10-10", "https://www.nasdaq.com/articles/jj-gains-marginally-on-hcv-deal-analyst-blog-2013-10-10", "https://www.nasdaq.com/articles/weekly-cfo-sells-highlight-fwlt-door-nke-mgam-gild-2013-10-07", "https://www.nasdaq.com/articles/after-hours-most-active-oct-7-2013-aat-mu-qcom-amd-gild-qqq-aaxj-renn-foxa-xom-pbra-mlu", "https://www.nasdaq.com/articles/playing-momentum-etfs-pdp-pie-mtum-2013-10-07", "https://www.nasdaq.com/articles/after-hours-most-active-oct-18-2013-qqq-rvbd-bac-sid-eln-msft-rf-ge-cbsh-kmi-csco-gild", "https://www.nasdaq.com/articles/gilead-back-to-neutral-analyst-blog-2013-09-30", "https://www.nasdaq.com/articles/health-care-stocks-gurus-investors-are-buying-ahead-obamacare-2013-09-27", "https://www.nasdaq.com/articles/update-on-gileads-portfolio-analyst-blog-2013-09-27", "https://www.nasdaq.com/articles/threats-government-shutdown-weigh-dow-sp-500-2013-09-27", "https://www.nasdaq.com/articles/pipeline-progress-at-agios-pharma-analyst-blog-2013-09-24", "https://www.nasdaq.com/articles/pipeline-progress-at-biomarin-analyst-blog-2013-09-24", "https://www.nasdaq.com/articles/good-news-for-perrigos-generic-unit-analyst-blog-2013-09-24", "https://www.nasdaq.com/articles/bayer-cardiovascular-suite-progresses-analyst-blog-2013-10-03", "https://www.nasdaq.com/articles/sativex-pricing-agreement-for-gw-pharma-analyst-blog-2013-09-24", "https://www.nasdaq.com/articles/japanese-approval-for-theravance-glaxo-drug-analyst-blog-2013-09-23", "https://www.nasdaq.com/articles/pipeline-progress-at-alexion-analyst-blog-2013-09-23", "https://www.nasdaq.com/articles/sarepta-therapeutics-srpt-worth-considering%3A-stock-surges-18.0-analyst-blog-2013-09-23", "https://www.nasdaq.com/articles/data-on-cytoris-cell-therapy-analyst-blog-2013-09-23", "https://www.nasdaq.com/articles/pipeline-progress-at-omeros-analyst-blog-2013-09-20", "https://www.nasdaq.com/articles/chmp-positive-on-gsk-thrx-candidate-analyst-blog-2013-09-20", "https://www.nasdaq.com/articles/iart-accomplishes-shoulder-implant-analyst-blog-2013-09-24", "https://www.nasdaq.com/articles/data-on-kalobios-kb001-published-analyst-blog-2013-09-20", "https://www.nasdaq.com/articles/positive-data-on-paciras-exparel-analyst-blog-2013-09-20", "https://www.nasdaq.com/articles/actelion-acquires-ceptaris-analyst-blog-2013-09-20", "https://www.nasdaq.com/articles/sangamo-prices-shares-analyst-blog-2013-09-19", "https://www.nasdaq.com/articles/biogen-upped-to-outperform-analyst-blog-2013-09-19", "https://www.nasdaq.com/articles/biocryst-niaid-collaborate-for-bcx4430-analyst-blog-2013-09-19", "https://www.nasdaq.com/articles/protalix-raises-funds-analyst-blog-2013-09-19", "https://www.nasdaq.com/articles/strength-seen-in-isis-pharmaceuticals-isis%3A-stock-soars-14.1-analyst-blog-2013-09-20", "https://www.nasdaq.com/articles/still-neutral-on-perrigo-analyst-blog-2013-09-19", "https://www.nasdaq.com/articles/u.s.-patent-allowance-for-biolinerx-bl-8020-analyst-blog-2013-09-19", "https://www.nasdaq.com/articles/pipeline-update-from-biomarin-analyst-blog-2013-09-18", "https://www.nasdaq.com/articles/kythera-biopharmaceuticals-kyth-in-focus%3A-stock-surges-25.1-analyst-blog-2013-09-18", "https://www.nasdaq.com/articles/clovis-oncology-clvs-surges%3A-stock-gains-7.3-in-session-analyst-blog-2013-09-18", "https://www.nasdaq.com/articles/encouraging-data-on-kytheras-atx-101-analyst-blog-2013-09-17", "https://www.nasdaq.com/articles/eu-approval-for-raptor-pharmas-procysbi-analyst-blog-2013-09-17", "https://www.nasdaq.com/articles/coronado-biosciences-tso-in-phase-ii-study-analyst-blog-2013-09-19", "https://www.nasdaq.com/articles/pipeline-progress-at-gilead-analyst-blog-2013-09-16", "https://www.nasdaq.com/articles/new-patents-for-insmeds-arikace-analyst-blog-2013-09-16", "https://www.nasdaq.com/articles/new-phase-i-data-on-omeros-oms824-analyst-blog-2013-09-13", "https://www.nasdaq.com/articles/united-therapeutics-nda-accepted-analyst-blog-2013-09-13", "https://www.nasdaq.com/articles/good-news-for-perrigo-analyst-blog-2013-09-13", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-friday-tale-of-the-tape-2013-09-13", "https://www.nasdaq.com/articles/protalix-prices-notes-analyst-blog-2013-09-13", "https://www.nasdaq.com/articles/encouraging-news-for-alexion-analyst-blog-2013-09-16", "https://www.nasdaq.com/articles/biotech-alexion-giant-tiny-orphan-market-2013-09-13", "https://www.nasdaq.com/articles/gilead-seeks-fda-approval-for-idelalisib-analyst-blog-2013-09-12", "https://www.nasdaq.com/articles/positive-results-on-ventrus-candidate-shares-up-analyst-blog-2013-09-12", "https://www.nasdaq.com/articles/data-on-actelions-opsumit-analyst-blog-2013-09-12", "https://www.nasdaq.com/articles/some-new-etfs-impressive-starts-2013-09-12", "https://www.nasdaq.com/articles/biogen-amicus-in-parkinsons-deal-analyst-blog-2013-09-11", "https://www.nasdaq.com/articles/lannett-beats-q4-earnings-estimates-analyst-blog-2013-09-11", "https://www.nasdaq.com/articles/data-from-alexions-soliris-study-analyst-blog-2013-09-13", "https://www.nasdaq.com/articles/catalyst-pharma-raises-funds-analyst-blog-2013-09-11", "https://www.nasdaq.com/articles/biogen-isis-team-up-again-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/rigel-pharma-trims-workforce-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/cubist-pharma-prices-senior-notes-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/data-on-biodels-biod-123-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/encouraging-data-on-oncolytics-reolysin-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/orphan-status-for-biolinerx-candidate-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/encouraging-data-on-xenoports-xp23829-analyst-blog-2013-09-11", "https://www.nasdaq.com/articles/target-date-for-endo-healths-aveed-analyst-blog-2013-09-09", "https://www.nasdaq.com/articles/illumina-inks-supply-deal-in-nipt-analyst-blog-2013-09-09", "https://www.nasdaq.com/articles/fda-expands-celgenes-abraxane-label-analyst-blog-2013-09-09", "https://www.nasdaq.com/articles/pipeline-progress-at-astrazeneca-analyst-blog-2013-09-09", "https://www.nasdaq.com/articles/bayer-looking-to-expand-in-russia-analyst-blog-2013-09-09", "https://www.nasdaq.com/articles/data-on-pomalyst-published-analyst-blog-2013-09-06", "https://www.nasdaq.com/articles/fda-licensure-for-merck-facility-analyst-blog-2013-09-06", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-monday-tale-of-the-tape-2013-09-09", "https://www.nasdaq.com/articles/amgen-cytokinetics-drug-misses-primary-endpoint-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/encouraging-news-from-thrxs-td-4208-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/data-on-mdcos-cangrelor-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/new-u.s.-patent-for-biolinerxs-bl-8040-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/pipeline-progress-at-tetraphase-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/good-news-for-chelsea-therapeutics-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/priority-review-for-takeda-candidate-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/bull-day-gilead-sciences-gild-bull-day-2013-09-06", "https://www.nasdaq.com/articles/gilead-sciences-biotech-powerhouse-2013-09-04", "https://www.nasdaq.com/articles/sanofi-unveils-bond-issue-pricing-analyst-blog-2013-09-04", "https://www.nasdaq.com/articles/spectrum-pharma-launches-marqibo-analyst-blog-2013-09-04", "https://www.nasdaq.com/articles/data-presented-on-eliquis-analyst-blog-2013-09-03", "https://www.nasdaq.com/articles/interim-phase-ii-data-on-isis-candidate-analyst-blog-2013-09-03", "https://www.nasdaq.com/articles/additional-funds-for-galectin-analyst-blog-2013-09-03", "https://www.nasdaq.com/articles/aradigm-grifols-collaborate-analyst-blog-2013-09-03", "https://www.nasdaq.com/articles/european-approval-for-glaxos-tafinlar-analyst-blog-2013-09-04", "https://www.nasdaq.com/articles/affymetrix-upped-to-outperform-analyst-blog-2013-08-30", "https://www.nasdaq.com/articles/pcycs-ibrutinib-under-fda-review-analyst-blog-2013-08-30", "https://www.nasdaq.com/articles/voluntary-recall-at-cubist-pharma-analyst-blog-2013-08-30", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-september-03-2013-2013-08-30", "https://www.nasdaq.com/articles/data-on-actelions-opsumit-published-analyst-blog-2013-08-30", "https://www.nasdaq.com/articles/swissmedic-negative-on-apricus-vitaros-analyst-blog-2013-08-30", "https://www.nasdaq.com/articles/opko-acquires-prolor-biotech-analyst-blog-2013-08-30", "https://www.nasdaq.com/articles/sanofis-aubagio-gets-eu-nod-analyst-blog-2013-09-03", "https://www.nasdaq.com/articles/merrimack-progresses-with-mm-398-analyst-blog-2013-08-29", "https://www.nasdaq.com/articles/topline-data-on-astex-candidate-analyst-blog-2013-08-29", "https://www.nasdaq.com/articles/sanofi-reports-positive-vaccine-data-analyst-blog-2013-08-29", "https://www.nasdaq.com/articles/good-news-for-regeneron-on-eylea-analyst-blog-2013-08-29", "https://www.nasdaq.com/articles/orexigen-provides-contrave-update-analyst-blog-2013-08-28", "https://www.nasdaq.com/articles/pharmacyclics-ibrutinib-data-published-analyst-blog-2013-08-28", "https://www.nasdaq.com/articles/akorn-to-buy-hi-tech-pharma-analyst-blog-2013-08-28", "https://www.nasdaq.com/articles/endo-health-eyeing-generic-company-shares-up-analyst-blog-2013-08-29", "https://www.nasdaq.com/articles/rigel-down-on-phase-ii-setback-analyst-blog-2013-08-27", "https://www.nasdaq.com/articles/actelion-inches-close-to-ceptaris-analyst-blog-2013-08-26", "https://www.nasdaq.com/articles/amgen-to-acquire-onyx-pharma-analyst-blog-2013-08-26", "https://www.nasdaq.com/articles/xoma-raises-funds-analyst-blog-2013-08-26", "https://www.nasdaq.com/articles/horizon-pharma-settles-with-par-pharma-analyst-blog-2013-08-26", "https://www.nasdaq.com/articles/pipeline-setback-for-glaxo-analyst-blog-2013-08-26", "https://www.nasdaq.com/articles/after-hours-most-active-aug-26-2013-jcp-ftk-qqq-hcbk-gild-onxx-bac-msft-cdns-rf-cat-amd", "https://www.nasdaq.com/articles/sanofi-initiates-vaccine-study-in-canada-analyst-blog-2013-08-27", "https://www.nasdaq.com/articles/cytokinetics-tirasemtiv-data-published-analyst-blog-2013-08-23", "https://www.nasdaq.com/articles/pound-pound-are-biotechs-still-worth-their-salt-2013-08-23", "https://www.nasdaq.com/articles/merrimack-study-data-published-analyst-blog-2013-08-23", "https://www.nasdaq.com/articles/omnicell-held-at-neutral-analyst-blog-2013-08-23", "https://www.nasdaq.com/articles/good-news-for-redhill-biopharma-analyst-blog-2013-08-23", "https://www.nasdaq.com/articles/positive-results-from-fibrocell-science-analyst-blog-2013-08-22", "https://www.nasdaq.com/articles/epizyme-wins-orphan-drug-status-analyst-blog-2013-08-22", "https://www.nasdaq.com/articles/vical-cuts-jobs-shifts-focus-analyst-blog-2013-08-23", "https://www.nasdaq.com/articles/voluntary-recall-at-alexion-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/xoma-prices-offering-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/pipeline-setback-for-gtx-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/after-hours-most-active-aug-21-2013-hpq-life-msft-gmcr-gild-ge-twc-phm-qqq-xom-vnda-emc", "https://www.nasdaq.com/articles/boston-scientific-upgraded-to-buy-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/medtronic-posts-in-line-q1-earnings-misses-revs-analyst-blog-2013-08-20", "https://www.nasdaq.com/articles/japanese-reimbursement-for-ew-valve-analyst-blog-2013-08-22", "https://www.nasdaq.com/articles/life-remains-at-neutral-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/voluntary-recall-at-alexion-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/still-neutral-on-cubist-pharma-analyst-blog-2013-08-20", "https://www.nasdaq.com/articles/new-reagent-kits-from-illumina-analyst-blog-2013-08-20", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-athersys-analyst-blog-2013-08-19", "https://www.nasdaq.com/articles/update-on-chelseas-northera-analyst-blog-2013-08-19", "https://www.nasdaq.com/articles/glaxos-tyverb-gets-eu-approval-analyst-blog-2013-08-19", "https://www.nasdaq.com/articles/gilead%3A-a-buying-opportunity-analyst-blog-2013-08-20", "https://www.nasdaq.com/articles/apricus-loss-narrows-y-y-analyst-blog-2013-08-16", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-biodel-analyst-blog-2013-08-16", "https://www.nasdaq.com/articles/glaxos-tivicay-gets-approval-analyst-blog-2013-08-16", "https://www.nasdaq.com/articles/after-hours-most-active-aug-16-2013-bac-snv-qqq-qcom-pgr-se-rsg-fe-vrtx-dell-gild-ca-2013", "https://www.nasdaq.com/articles/integra-receives-go-ahead-in-n.j.-analyst-blog-2013-08-16", "https://www.nasdaq.com/articles/progenics-loss-narrows-y-y-analyst-blog-2013-08-15", "https://www.nasdaq.com/articles/earnings-beat-at-perrigo-in-q4-sales-dip-analyst-blog-2013-08-15", "https://www.nasdaq.com/articles/sizing-jackson-hole-analyst-blog-2013-08-19", "https://www.nasdaq.com/articles/endp-to-offload-anatomical-pathology-unit-analyst-blog-2013-08-14", "https://www.nasdaq.com/articles/myriad-outstrips-q4-and-fy-earnings-estimates-analyst-blog-2013-08-14", "https://www.nasdaq.com/articles/wider-y-y-loss-at-ariad-analyst-blog-2013-08-13", "https://www.nasdaq.com/articles/major-setback-for-vical-analyst-blog-2013-08-13", "https://www.nasdaq.com/articles/impax-surpasses-earnings-estimates-analyst-blog-2013-08-13", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-august-14-2013-2013-08-13", "https://www.nasdaq.com/articles/techne-corporation-tech-ex-dividend-date-scheduled-august-14-2013-2013-08-13", "https://www.nasdaq.com/articles/biodelivery-sciences-posts-loss-y-y-analyst-blog-2013-08-14", "https://www.nasdaq.com/articles/glaxo-seeks-vaccine-approval-analyst-blog-2013-08-12", "https://www.nasdaq.com/articles/bristol-myers-downgraded-to-underperform-analyst-blog-2013-08-09", "https://www.nasdaq.com/articles/fda-panel-to-review-thrx-gsk-candidate-analyst-blog-2013-08-09", "https://www.nasdaq.com/articles/glaxo-seeks-votrient-label-expansion-in-eu-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/jazz-pharma-posts-higher-earnings-revs-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-spectrum-pharma-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/after-hours-most-active-aug-8-2013-bac-qqq-mack-onnn-ctl-gild-dndn-fig-tsm-wmgi-rax-key", "https://www.nasdaq.com/articles/narrower-q2-loss-at-geron-analyst-blog-2013-08-12", "https://www.nasdaq.com/articles/affymetrix-rise-on-turnaround-2q-earnings-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/rigel-pharma-narrows-q2-loss-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/endo-health-beats-on-earnings-revs.-in-q2-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/sanofis-vaccine-progresses-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/earnings-beat-at-regeneron-in-q2-analyst-blog-2013-08-06", "https://www.nasdaq.com/articles/zoetis-reports-in-line-earnings-in-q2-analyst-blog-2013-08-06", "https://www.nasdaq.com/articles/anika-soars-on-strong-q2-results-analyst-blog-2013-08-05", "https://www.nasdaq.com/articles/affymetrix-rolls-out-advanced-assay-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/earnings-beat-at-astrazeneca-in-2q-analyst-blog-2013-08-02", "https://www.nasdaq.com/articles/earnings-increase-at-bayer-in-2q-analyst-blog-2013-08-01", "https://www.nasdaq.com/articles/pcyc-reports-earnings-in-q2-revs-surge-analyst-blog-2013-08-01", "https://www.nasdaq.com/articles/earnings-beat-at-hospira-in-2q-sales-in-line-analyst-blog-2013-07-31", "https://www.nasdaq.com/articles/amgen-beats-on-earnings-revs-in-q2-analyst-blog-2013-07-31", "https://www.nasdaq.com/articles/cubist-pharma-announces-acquisition-deals-analyst-blog-2013-07-31", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-tuesday-tale-of-the-tape-2013-07-30", "https://www.nasdaq.com/articles/affymetrix-sees-earnings-after-two-years-analyst-blog-2013-08-05", "https://www.nasdaq.com/articles/can-the-recent-uptrend-continue-for-gilead-sciences-inc.-gild-tale-of-the-tape-2013-07-29", "https://www.nasdaq.com/articles/after-hours-most-active-jul-29-2013-eln-pfe-hlf-qqq-hal-zts-cat-mu-fb-gild-agnc-pdli-2013", "https://www.nasdaq.com/articles/after-hours-earnings-report-july-25-2013-amzn-gild-sbux-mck-cb-cern-nem-rsg-pfg-klac-bmrn", "https://www.nasdaq.com/articles/biogen-idec-inc-biib-todays-most-compelling-stock-buy-2013-07-11", "https://www.nasdaq.com/articles/after-hours-most-active-jul-8-2013-s-nlsn-intc-fb-orcl-nok-aa-csco-msft-gild-igt-jnpr-2013", "https://www.nasdaq.com/articles/gilead-retained-at-neutral-analyst-blog-2013-06-25", "https://www.nasdaq.com/articles/gilead-presents-idelalisib-data-analyst-blog-2013-06-19", "https://www.nasdaq.com/articles/best-stocks-isis-gilead-celgene-and-regeneron-take-over-top-ranks-2013-07-29", "https://www.nasdaq.com/articles/3-impressive-biotech-etfs-crushing-market-etf-news-and-commentary-2013-06-11", "https://www.nasdaq.com/articles/priority-review-for-gilead-drug-analyst-blog-2013-06-10", "https://www.nasdaq.com/articles/enzon-pharmaceuticals-inc-enzn-ex-dividend-date-scheduled-june-05-2013-2013-06-04", "https://www.nasdaq.com/articles/stock-market-news-for-june-3-2013-market-news-2013-06-03", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-june-03-2013-2013-05-31", "https://www.nasdaq.com/articles/pre-market-most-active-may-22-2013-ntap-pfe-nmr-rdsa-rdsb-nok-sne-pgti-irwd-gild-vod-znga", "https://www.nasdaq.com/articles/gileads-sofosbuvir-under-european-review-analyst-blog-2013-05-22", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-345213-2857-points-2013-06-17", "https://www.nasdaq.com/articles/3-impressive-biotech-etfs-crushing-market-etf-news-and-commentary-2013-06-11", "https://www.nasdaq.com/articles/priority-review-for-gilead-drug-analyst-blog-2013-06-10", "https://www.nasdaq.com/articles/enzon-pharmaceuticals-inc-enzn-ex-dividend-date-scheduled-june-05-2013-2013-06-04", "https://www.nasdaq.com/articles/danish-laboratories-hope-looms-large-permanent-hiv-cure-2013-05-08", "https://www.nasdaq.com/articles/techne-corporation-tech-ex-dividend-date-scheduled-may-08-2013-2013-05-07", "https://www.nasdaq.com/articles/markets-now-dow-sp-hit-new-highs-employment-report-2013-05-03", "https://www.nasdaq.com/articles/gilead-misses-on-earnings-sales-in-1q-analyst-blog-2013-05-03", "https://www.nasdaq.com/articles/pre-market-most-active-may-20-2013-wcrx-rdsb-yhoo-act-bac-bp-au-nbg-gild-asml-wbsn-znga", "https://www.nasdaq.com/articles/after-hours-earnings-report-may-2-2013-gild-aig-cnq-lnkd-myl-wft-flr-xl-tdc-mhk-mchp-cpt", "https://www.nasdaq.com/articles/markets-now-stocks-climb-higher-after-ecb-rate-cut-jobless-claims-report-2013-05-02", "https://www.nasdaq.com/articles/double-setback-for-gilead-analyst-blog-2013-04-30", "https://www.nasdaq.com/articles/look-ahead-weeks-etfs-watch-2013-04-28", "https://www.nasdaq.com/articles/after-hours-most-active-apr-26-2013-stx-cmcsa-bac-ntap-vz-qqq-gild-intc-apc-ge-axp-pfe", "https://www.nasdaq.com/articles/buzz-street-apple-earnings-hijacked-ap-and-telltale-vix-make-one-wacky-week-2013-04-26", "https://www.nasdaq.com/articles/biotech-sector-still-market-leader-real-time-insight-2013-04-25", "https://www.nasdaq.com/articles/benzinga-market-primer-thursday-may-2-2013-05-02", "https://www.nasdaq.com/articles/will-eli-lilly-beat-earnings-in-1q-analyst-blog-2013-04-23", "https://www.nasdaq.com/articles/forest-labs-likely-to-miss-4q-earnings-analyst-blog-2013-04-22", "https://www.nasdaq.com/articles/biogen%3A-will-it-miss-earnings-again-analyst-blog-2013-04-22", "https://www.nasdaq.com/articles/will-amgen-beat-earnings-analyst-blog-2013-04-22", "https://www.nasdaq.com/articles/bristol-myers-likely-to-report-in-line-earnings-analyst-blog-2013-04-22", "https://www.nasdaq.com/articles/vertex-news-lifts-biotech-etfs-2013-04-19", "https://www.nasdaq.com/articles/waters-1q-earnings-expected-to-miss-analyst-blog-2013-04-19", "https://www.nasdaq.com/articles/gilead-reports-encouraging-hcv-data-analyst-blog-2013-04-24", "https://www.nasdaq.com/articles/will-eli-lilly-beat-earnings-in-1q-analyst-blog-2013-04-23", "https://www.nasdaq.com/articles/forest-labs-likely-to-miss-4q-earnings-analyst-blog-2013-04-22", "https://www.nasdaq.com/articles/biogen%3A-will-it-miss-earnings-again-analyst-blog-2013-04-22", "https://www.nasdaq.com/articles/will-amgen-beat-earnings-analyst-blog-2013-04-22", "https://www.nasdaq.com/articles/data-on-arqules-arq-092-analyst-blog-2013-04-10", "https://www.nasdaq.com/articles/gilead-seeks-fda-approval-analyst-blog-2013-04-09", "https://www.nasdaq.com/articles/priority-review-for-bayers-riociguat-analyst-blog-2013-04-09", "https://www.nasdaq.com/articles/after-hours-most-active-apr-19-2013-pbra-crm-ppl-dow-gild-ms-qqq-emc-dtv-dndn-sqnm-yhoo", "https://www.nasdaq.com/articles/generics%3A-the-way-forward-in-india-analyst-blog-2013-04-05", "https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-apr-2013-zacks-analyst-interviews-2013-04-04", "https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-apr-2013-industry-outlook-2013-04-04", "https://www.nasdaq.com/articles/gileads-hcv-study-to-continue-analyst-blog-2013-04-01", "https://www.nasdaq.com/articles/after-hours-most-active-apr-1-2013-bac-fcx-qqq-cpno-png-intc-vcsh-hum-gild-ms-vcit-aer", "https://www.nasdaq.com/articles/weekly-cfo-sells-highlight-anik-gild-petm-nke-adbe-2013-03-31", "https://www.nasdaq.com/articles/balanced-view-on-gilead-sciences-analyst-blog-2013-03-28", "https://www.nasdaq.com/articles/weekly-ceo-sells-highlight-activision-blizzard-nielsen-holdings-nv-gilead-sciences", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-325652-404-points-2013-03-27", "https://www.nasdaq.com/articles/after-hours-most-active-mar-26-2013-twx-hal-rf-wfc-hpq-nem-mdlz-qcom-intc-orcl-qqq-gild", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-rise-cyprus-deal-dollar-general-posts-higher-profit-2013", "https://www.nasdaq.com/articles/gileads-stribild-backed-by-chmp-analyst-blog-2013-03-25", "https://www.nasdaq.com/articles/mid-afternoon-market-update-vrinetx-falls-veeco-continues-boost-2013-03-25", "https://www.nasdaq.com/articles/mid-day-market-update-markets-turn-red-apollo-group-surges-upbeat-results-2013-03-25", "https://www.nasdaq.com/articles/pre-market-most-active-mar-14-2013-bbry-vod-slca-bac-etfc-gild-nok-qqq-tsm-sd-eric-mt-2013", "https://www.nasdaq.com/articles/setback-for-idenix-pharma-analyst-blog-2013-03-28", "https://www.nasdaq.com/articles/gilead-hits-52-week-high-analyst-blog-2013-03-13", "https://www.nasdaq.com/articles/encouraging-data-presented-by-gilead-analyst-blog-2013-03-12", "https://www.nasdaq.com/articles/gilead-puts-biotech-etfs-in-focus-etf-news-and-commentary-2013-03-11", "https://www.nasdaq.com/articles/good-news-for-gileads-hiv-pipeline-analyst-blog-2013-03-07", "https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-march-01-2013-2013-02-27", "https://www.nasdaq.com/articles/gilead-and-teva-bury-the-hatchet-analyst-blog-2013-02-21", "https://www.nasdaq.com/articles/march-action-date-for-uthr-candidate-analyst-blog-2013-02-20", "https://www.nasdaq.com/articles/after-hours-most-active-mar-14-2013-bac-qqq-rcl-v-jpm-ulta-ge-c-csco-msft-gild-intc-2013", "https://www.nasdaq.com/articles/gilead-hits-52-week-high-analyst-blog-2013-03-13", "https://www.nasdaq.com/articles/techne-corporation-tech-ex-dividend-date-scheduled-february-13-2013-2013-02-11", "https://www.nasdaq.com/articles/gilead-closes-ym-biosciences-buyout-analyst-blog-2013-02-11", "https://www.nasdaq.com/articles/after-hours-most-active-feb-11-2013-bac-fb-gild-ual-ttwo-fe-wfr-amgn-tlm-atvi-kors-sqnm", "https://www.nasdaq.com/articles/amgen-inc-amgn-ex-dividend-date-scheduled-february-11-2013-2013-02-07", "https://www.nasdaq.com/articles/gilead-beats-estimates-in-4q-analyst-blog-2013-02-05", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-4-2013-gild-apc-yum-bidu-ggp-bap-life-hig-ew-axs-leg", "https://www.nasdaq.com/articles/gilead-presents-positive-hcv-data-analyst-blog-2013-02-20", "https://www.nasdaq.com/articles/medtech-industry-stock-outlook-jan-2013-industry-outlook-2013-01-29-0", "https://www.nasdaq.com/articles/medtech-industry-stock-outlook-jan-2013-zacks-analyst-interviews-2013-01-29", "https://www.nasdaq.com/articles/safest-way-play-biotech-cooks-kitchen-2013-01-25", "https://www.nasdaq.com/articles/gileads-hiv-candidate-advances-analyst-blog-2013-01-25", "https://www.nasdaq.com/articles/one-biotech-stock-investors-are-unfairly-ignoring-2013-01-15", "https://www.nasdaq.com/articles/smart-money-loves-these-10-stocks-2013-01-14", "https://www.nasdaq.com/articles/update-on-hcv-pipeline-from-gilead-analyst-blog-2013-01-14", "https://www.nasdaq.com/articles/medtech-industry-stock-outlook-jan-2013-industry-outlook-2013-01-29", "https://www.nasdaq.com/articles/stock-could-be-perfect-dividend-decade-2013-01-08", "https://www.nasdaq.com/articles/roches-tamiflu-label-expanded-analyst-blog-2012-12-24", "https://www.nasdaq.com/articles/actelion-drug-accepted-for-review-analyst-blog-2012-12-18", "https://www.nasdaq.com/articles/gilead-to-buy-ym-biosciences-analyst-blog-2012-12-13", "https://www.nasdaq.com/articles/gilead-plans-to-split-stock-2-for-1-analyst-blog-2012-12-11", "https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-dec-2012-industry-outlook-2012-12-06-0", "https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-dec-2012-zacks-analyst-interviews-2012-12-06", "https://www.nasdaq.com/articles/after-hours-most-active-jan-9-2013-qqq-bac-hpq-siri-nly-nok-arct-key-gild-ppg-trow-fb-2013", "https://www.nasdaq.com/articles/stock-could-be-perfect-dividend-decade-2013-01-08", "https://www.nasdaq.com/articles/roches-tamiflu-label-expanded-analyst-blog-2012-12-24", "https://www.nasdaq.com/articles/actelion-drug-accepted-for-review-analyst-blog-2012-12-18", "https://www.nasdaq.com/articles/gilead-to-buy-ym-biosciences-analyst-blog-2012-12-13", "https://www.nasdaq.com/articles/actelion-drug-to-be-reviewed-in-eu-analyst-blog-2012-11-26", "https://www.nasdaq.com/articles/weekly-top-insider-sells-aapl-gild-bmrn-and-pcln-2012-11-19", "https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-dec-2012-industry-outlook-2012-12-06", "https://www.nasdaq.com/articles/biotech-etfs-fiscal-cliff-safe-haven-etf-news-and-commentary-2012-11-16", "https://www.nasdaq.com/articles/gilead-presents-encouraging-data-analyst-blog-2012-11-16", "https://www.nasdaq.com/articles/abbotts-phase-iii-plans-for-hcv-analyst-blog-2012-11-14", "https://www.nasdaq.com/articles/mid-day-market-update-markets-slow-their-rally-jc-penney-spikes-lower-2012-11-12", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-continue-cautious-rally-jefferies-acquired-leucadia-2012", "https://www.nasdaq.com/articles/pre-market-most-active-nov-12-2012-tie-un-bac-gild-mt-clvs-fb-jef-grpn-dcm-nktr-qqq-2012", "https://www.nasdaq.com/articles/gilead-sciences-and-celgene-liven-biotech-etfs-2012-11-12", "https://www.nasdaq.com/articles/steven-cohens-sac-capital-advisors-q3-updates-buys-fossil-fastenal-company-and-cr-bard", "https://www.nasdaq.com/articles/after-hours-most-active-nov-12-2012-met-pgr-qqq-pru-gild-ever-cim-msft-c-qcom-nvda-intc", "https://www.nasdaq.com/articles/mid-afternoon-market-update-markets-near-flat-jc-penney-falling-further-2012-11-12", "https://www.nasdaq.com/articles/after-hours-most-active-nov-8-2012-pdli-qqq-avp-etp-pfe-grpn-mrk-bac-sd-nvda-gild-msft", "https://www.nasdaq.com/articles/edward-owens-vanguard-health-care-fund-does-more-shedding-adding-third-quarter-2012-11-01", "https://www.nasdaq.com/articles/actelion-files-nda-for-macitentan-analyst-blog-2012-10-29", "https://www.nasdaq.com/articles/pre-market-most-active-oct-24-2012-fb-siri-emc-bac-qqq-gild-dow-znga-mm-bp-seh-amrn-2012", "https://www.nasdaq.com/articles/sp-likes-trio-biotech-etfs-2012-10-24", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-290426-down-61-points-2012-11-12", "https://www.nasdaq.com/articles/actelion-beats-maintains-view-analyst-blog-2012-10-19", "https://www.nasdaq.com/articles/arena-pharma-initiates-pah-study-analyst-blog-2012-10-15", "https://www.nasdaq.com/articles/after-hours-most-active-oct-11-2012-qqq-amd-bac-etp-lope-clwr-s-wcrx-san-gild-ppl-msft", "https://www.nasdaq.com/articles/three-biotech-stocks-analysts-are-keen-aria-mack-geva-2012-10-03", "https://www.nasdaq.com/articles/mixed-results-from-vertex-studies-analyst-blog-2012-09-26", "https://www.nasdaq.com/articles/weekly-cfo-sells-highlight-asgn-cof-akrx-mcrs-gild-rop-pll-2012-09-24", "https://www.nasdaq.com/articles/cost-cutting-at-actelion-analyst-blog-2012-09-11", "https://www.nasdaq.com/articles/gilead-beats-zacks-estimates-analyst-blog-2012-10-24", "https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-aug.-2012-industry-outlook-2012-08-09", "https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-aug.-2012-industry-outlook-2012-08-09-0", "https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-aug.-2012-zacks-analyst-interviews-2012-08-09", "https://www.nasdaq.com/articles/pre-market-most-active-aug-2-2012-kcg-nok-bac-gild-siri-caj-gmcr-fslr-nav-qqq-idix-bmy", "https://www.nasdaq.com/articles/top-performing-funds-latch-biotech-and-discount-retail-stocks-2012-08-02", "https://www.nasdaq.com/articles/gilead-beats-zacks-estimates-analyst-blog-2012-07-27", "https://www.nasdaq.com/articles/balanced-view-on-gilead-analyst-blog-2012-09-07", "https://www.nasdaq.com/articles/gileads-stribild-gets-fda-nod-analyst-blog-2012-08-29", "https://www.nasdaq.com/articles/earnings-preview%3A-celgene-analyst-blog-2012-07-24", "https://www.nasdaq.com/articles/fda-nod-for-gileads-truvada-analyst-blog-2012-07-23", "https://www.nasdaq.com/articles/fda-nod-for-gileads-truvada-analyst-blog-2012-07-23-0", "https://www.nasdaq.com/articles/gilead-seeks-fda-ok-for-cobicistat-analyst-blog-2012-07-02", "https://www.nasdaq.com/articles/gilead-seeks-fda-approval-analyst-blog-2012-06-28", "https://www.nasdaq.com/articles/ema-validates-gileads-drug-analyst-blog-2012-06-20", "https://www.nasdaq.com/articles/biotechs-motion-new-drug-pipeline-brims-2012-07-27", "https://www.nasdaq.com/articles/fda-nod-for-merck-drug-label-update-analyst-blog-2012-05-24", "https://www.nasdaq.com/articles/gilead-drug-up-for-european-review-analyst-blog-2012-05-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-abbott-labs-alliance-data-systems", "https://www.nasdaq.com/articles/good-news-for-gilead-analyst-blog-2012-05-14", "https://www.nasdaq.com/articles/after-hours-most-active-may-4-2012-qqq-bac-std-stj-nem-gild-ggc-tot-sppi-msft-fnfg-intc", "https://www.nasdaq.com/articles/higher-costs-hurt-gilead-analyst-blog-2012-04-27", "https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-april-2012-industry-outlook-2012-04-26", "https://www.nasdaq.com/articles/weekly-ceo-sells-highlight-widepoint-corp-gilead-sciences-primoris-services-and-riverbed", "https://www.nasdaq.com/articles/fda-nod-for-merck-drug-label-update-analyst-blog-2012-05-24", "https://www.nasdaq.com/articles/gilead-drug-up-for-european-review-analyst-blog-2012-05-24", "https://www.nasdaq.com/articles/pre-market-most-active-apr-19-2012-bac-hgsi-gild-ms-cvi-qqq-nok-ebay-tot-emc-vod-aapl-2012", "https://www.nasdaq.com/articles/after-hours-most-active-apr-5-2012-qqq-ftr-ddd-std-bac-exc-gild-csco-tleo-mdas-syk-msft", "https://www.nasdaq.com/articles/vertex-hcv-hiv-treatment-impresses-analyst-blog-2012-03-21", "https://www.nasdaq.com/articles/3-nasdaq-stocks-active-investors-2012-03-07", "https://www.nasdaq.com/articles/largest-option-buying-equities-so-far-2012-02-28", "https://www.nasdaq.com/articles/celgene-misses-reaffirms-analyst-blog-2012-04-26", "https://www.nasdaq.com/articles/action-date-for-uthr-candidate-analyst-blog-2012-02-24", "https://www.nasdaq.com/articles/gileads-hcv-drug-suffers-setback-analyst-blog-2012-02-21", "https://www.nasdaq.com/articles/gilead-remains-neutral-analyst-blog-2012-02-17", "https://www.nasdaq.com/articles/weak-revenues-pull-down-actelion-analyst-blog-2012-02-15", "https://www.nasdaq.com/articles/generic-challenge-for-uthrs-remodulin-analyst-blog-2012-02-08", "https://www.nasdaq.com/articles/company-news-for-february-6-2012-corporate-summary-2012-02-06", "https://www.nasdaq.com/articles/gilead-misses-eps-ests-sales-up-analyst-blog-2012-02-03", "https://www.nasdaq.com/articles/actelion-gets-auxilium-drug-rights-analyst-blog-2012-02-27", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-bristol-myers-squibb-inhibitex-vertex", "https://www.nasdaq.com/articles/gilead-clinches-pharmasset-buy-analyst-blog-2012-01-19", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-bristol-myers-squibb-sanofi-inhibitex-gilead-sciences", "https://www.nasdaq.com/articles/bmy-kicks-off-2012-pharma-deals-analyst-blog-2012-01-09", "https://www.nasdaq.com/articles/take-look-my-cheat-sheet-undervalued-stocks-2012-01-05", "https://www.nasdaq.com/articles/pharma-biotech-stock-review-outlook-zacks-analyst-interviews-2011-12-28", "https://www.nasdaq.com/articles/pharma-biotech-stock-review-outlook-industry-outlook-2011-12-28-0", "https://www.nasdaq.com/articles/best-way-invest-biotech-stocks-2012-01-26", "https://www.nasdaq.com/articles/fate-on-gilead-quad-set-for-aug-12-analyst-blog-2011-12-28", "https://www.nasdaq.com/articles/pharma-biotech-stock-review-outlook-industry-outlook-2011-12-28", "https://www.nasdaq.com/articles/gileads-candidate-under-ema-review-analyst-blog-2011-12-21", "https://www.nasdaq.com/articles/gilead-presents-elvitegravir-data-analyst-blog-2011-12-12", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-autozone-johnson-johnson-bristol-myers-squibb-gilead", "https://www.nasdaq.com/articles/spotlight-hepatitis-c-market-analyst-blog-2011-12-06", "https://www.nasdaq.com/articles/gilead-delivers-once-again-analyst-blog-2011-12-06", "https://www.nasdaq.com/articles/eu-nod-for-uthrs-remodulin-iv-analyst-blog-2011-12-28", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-pharmasset-nasdaq-biotechnology-etf", "https://www.nasdaq.com/articles/gilead-to-buy-pharmasset-for-%2411b-analyst-blog-2011-11-22", "https://www.nasdaq.com/articles/mid-day-update-stocks-plunge-expected-super-committee-failure-home-sales-rise-2011-11-21", "https://www.nasdaq.com/articles/biotech-investing-lessons-gild-buys-vrus-tactical-trading-2011-11-21", "https://www.nasdaq.com/articles/super-committee-anything-analyst-blog-2011-11-21", "https://www.nasdaq.com/articles/ahead-wall-street-november-21-2011-ahead-wall-street-2011-11-21", "https://www.nasdaq.com/articles/gileads-eviplera-cleared-in-eu-analyst-blog-2011-11-29", "https://www.nasdaq.com/articles/debt-supercycle-are-these-leveraged-companies-trouble-2011-11-02", "https://www.nasdaq.com/articles/5-more-forever-stocks-sale-2011-09-29", "https://www.nasdaq.com/articles/stocks-rally-mid-day-lower-jobless-claims-ciscos-upbeat-earnings-guidance-2011-08-11", "https://www.nasdaq.com/articles/mid-day-update-stocks-rally-weekly-jobless-claims-drop-gold-backs-record-2011-08-11", "https://www.nasdaq.com/articles/25-undervalued-stocks-great-management-teams-2011-01-21", "https://www.nasdaq.com/articles/european-market-may-open-its-doors-biotech-2011-01-13", "https://www.nasdaq.com/articles/stocks-near-flat-ahead-christmas-holiday-weekend-deal-news-provides-some-support-2010-12", "https://www.nasdaq.com/articles/gilead-steady-at-neutral-analyst-blog-2011-11-17", "https://www.nasdaq.com/articles/three-sectors-and-four-stocks-consider-despite-macro-uncertainty-2010-10-26", "https://www.nasdaq.com/articles/perfect-technical-trade-market-2010-10-18", "https://www.nasdaq.com/articles/using-etfs-mimic-mutual-fund-ideas-2010-09-13", "https://www.nasdaq.com/articles/6-hazardous-stocks-sell-now-2010-08-06", "https://www.nasdaq.com/articles/11-health-care-stocks-sell-2010-08-02", "https://www.nasdaq.com/articles/opening-view-can-spx-hold-above-1100-2010-07-26", "https://www.nasdaq.com/articles/11-famous-health-care-stocks-sell-2010-07-20", "https://www.nasdaq.com/articles/mid-day-update-stocks-mixed-economic-data-begets-choppy-holiday-trading-2010-12-23", "https://www.nasdaq.com/articles/bullish-roll-out-us-steel-nyse-x-call-spread-seller-gilead-nasdaq-gild-2010-02-16", "https://www.nasdaq.com/articles/40-million-people-need-life-saving-drug-2010-01-10", "https://www.nasdaq.com/articles/easy-way-find-winning-stocks-2009-10-14", "https://www.nasdaq.com/articles/indicators-show-market-dangerously-overbought-2010-04-22"], "Content": []}